https://bio-research.ai/ https://bio-research.ai/pricing/ https://bio-research.ai/news-main/ https://bio-research.ai/section/clinical-trials/ https://bio-research.ai/section/deals/ https://bio-research.ai/section/regulatory/ https://bio-research.ai/section/funding/ https://bio-research.ai/subscribe/ https://bio-research.ai/sk-biopharmaceuticals-secures-rights-to-biohaven-s-epilepsy-drug-in-795-million-deal/ 2026-08-26 https://bio-research.ai/spyre-therapeutics-tl1a-antibody-shows-das28-crp-improvement-in-phase-2-rheumatoid-arthritis-trial/ 2026-08-25 https://bio-research.ai/akeso-s-phase-3-trial-shows-statistically-significant-improvement-in-overall-survival-for-biliary-tract-cancer/ 2026-08-25 https://bio-research.ai/mahzi-therapeutics-aav9-tcf4-gene-replacement-therapy-receives-fda-rare-pediatric-disease-designation/ 2026-08-25 https://bio-research.ai/fda-approves-ziihera-plus-tevimbra-and-chemotherapy-for-first-line-her2-gastroesophageal-carcinoma/ 2026-08-25 https://bio-research.ai/haisco-licenses-type-2-inflammatory-disease-asset-to-php-and-arch-backed-sentivera-in-1-5b-deal/ 2026-08-25 https://bio-research.ai/fda-grants-fast-track-to-dualitybio-s-adam9-targeting-adc-for-pancreatic-ductal-adenocarcinoma/ 2026-08-25 https://bio-research.ai/fda-approves-j-j-s-imaavy-for-warm-autoimmune-hemolytic-anemia-following-phase-2-3-energy-study/ 2026-08-24 https://bio-research.ai/fda-grants-orphan-drug-designation-to-lakefront-biotherapeutics-bcmaxcd3-bispecific-t-cell-engager-for-pemphigus/ 2026-08-24 https://bio-research.ai/fda-accepts-application-for-oral-prostacyclin-receptor-agonist-to-treat-pulmonary-hypertension/ 2026-08-24 https://bio-research.ai/fda-grants-fast-track-designation-to-sirna-therapy-inhibiting-prekallikrein-for-hae/ 2026-08-24 https://bio-research.ai/fda-grants-fast-track-designation-to-erasca-s-pan-ras-molecular-glue-for-metastatic-pancreatic-adenocarcinoma/ 2026-08-24 https://bio-research.ai/valerio-therapeutics-acquires-etherna-for-30m-and-secures-40-25m-pipe-financing/ 2026-08-24 https://bio-research.ai/hanmi-pharmaceutical-licenses-ucn2-analog-to-genentech-and-roche-in-deal-worth-up-to-2-3b/ 2026-08-24 https://bio-research.ai/european-commission-approves-tecvayli-plus-daratumumab-for-relapsed-or-refractory-multiple-myeloma/ 2026-08-21 https://bio-research.ai/werewolf-therapeutics-and-ambros-therapeutics-enter-merger-agreement-with-150m-private-placement/ 2026-08-21 https://bio-research.ai/aston-sci-raises-39-6-billion-krw-for-therapeutic-cancer-vaccine-clinical-trials/ 2026-08-20 https://bio-research.ai/bristol-myers-squibb-and-chai-discovery-collaborate-on-ai-powered-antibody-discovery/ 2026-08-20 https://bio-research.ai/nuvation-bio-s-mutant-idh1-inhibitor-receives-fda-fast-track-designation-for-idh1-mutant-glioma/ 2026-08-20 https://bio-research.ai/fda-grants-fast-track-designation-to-rein-therapeutics-inhaled-peptide-for-idiopathic-pulmonary-fibrosis/ 2026-08-20 https://bio-research.ai/simcere-pharmaceutical-group-and-ruiyang-biopharmaceutical-partner-to-commercialize-rsv-monoclonal-antibody/ 2026-08-20 https://bio-research.ai/fda-approves-regeneron-s-pasatru-to-reduce-heterotopic-ossification-lesions-and-flare-ups-in-adults-with-fop/ 2026-08-19 https://bio-research.ai/fda-grants-accelerated-approval-for-ultragenyx-s-genglycos-to-treat-glycogen-storage-disease-type-ia/ 2026-08-19 https://bio-research.ai/merck-and-moderna-s-mrna-cancer-vaccine-plus-keytruda-improves-rfs-and-dmfs-in-phase-3-melanoma-trial/ 2026-08-19 https://bio-research.ai/fda-accepts-teva-s-nda-for-selective-d1-receptor-antagonist-in-pediatric-tourette-syndrome/ 2026-08-19 https://bio-research.ai/kalivir-immunotherapeutics-raises-14-million-to-advance-oncolytic-virus-clinical-trial/ 2026-08-19 https://bio-research.ai/neoimmunetech-licenses-long-acting-il-7-to-tolerance-bio-in-deal-worth-up-to-260m/ 2026-08-19 https://bio-research.ai/xspray-pharma-receives-fda-complete-response-letter-for-its-amorphous-formulation-of-dasatinib/ 2026-08-19 https://bio-research.ai/biomarin-to-acquire-alesta-therapeutics-for-275m-to-gain-an-oral-small-molecule-for-hpp/ 2026-08-18 https://bio-research.ai/tanabe-pharma-transfers-melanocortin-1-receptor-agonist-rights-to-leo-pharma-for-435m/ 2026-08-18 https://bio-research.ai/fda-grants-fast-track-to-oral-dual-v-8-v-1-integrin-inhibitor-plus-pembrolizumab-for-ici-resistant-solid-tumors/ 2026-08-18 https://bio-research.ai/fda-grants-fast-track-to-blossomhill-therapeutics-egfr-inhibitor-for-c797s-positive-nsclc/ 2026-08-18 https://bio-research.ai/abcuro-raises-66-million-for-clinical-study-of-monoclonal-antibody-targeting-klrg1-in-ibm/ 2026-08-18 https://bio-research.ai/amylyx-pharmaceuticals-glp-1-receptor-antagonist-reduces-hypoglycemic-events-by-55-in-phase-3-pbh-trial/ 2026-08-18 https://bio-research.ai/chugai-and-gsk-sign-exclusive-license-agreement-for-anti-dengue-virus-antibody-aid351/ 2026-08-18 https://bio-research.ai/leal-therapeutics-initiates-phase-1b-2a-trial-of-oral-gls1-inhibitor-in-adults-with-schizophrenia/ 2026-08-17 https://bio-research.ai/omniab-inc-and-eli-lilly-and-company-enter-collaboration-and-license-agreement-for-up-to-370-m/ 2026-08-17 https://bio-research.ai/fulcrum-and-slate-enter-merger-agreement-to-develop-anti-pacap-vip-monoclonal-antibody-with-245m/ 2026-08-17 https://bio-research.ai/argenx-s-phase-3-trial-of-vyvgart-hytrulo-shows-15-4-point-tis-improvement-in-autoimmune-myositis/ 2026-08-17 https://bio-research.ai/sandoz-and-henlius-sign-322m-agreement-for-egfr-targeted-therapy-and-nine-biosimilar-assets/ 2026-08-17 https://bio-research.ai/aizen-therapeutics-and-a-san-diego-based-public-biotech-partner-for-oral-peptide-therapeutics-for-100m/ 2026-08-15 https://bio-research.ai/fda-grants-fast-track-designation-to-anti-cldn18-2-cd47-bispecific-antibody-for-biliary-tract-cancer/ 2026-08-14 https://bio-research.ai/skye-and-redx-enter-transaction-agreement-and-125m-financing-for-gi-restricted-pan-rock-inhibitor/ 2026-08-14 https://bio-research.ai/fda-approves-tauklarify-for-brain-pet-imaging-to-identify-tau-pathology-in-alzheimer-s-disease/ 2026-08-14 https://bio-research.ai/vcare-pharmatech-s-jak1-inhibitor-phase-2-trial-shows-43-f-vasi-improvement-in-vitiligo/ 2026-08-13 https://bio-research.ai/khartis-therapeutics-raises-50-million-for-oral-igf-1r-inhibitor-in-thyroid-eye-disease/ 2026-08-13 https://bio-research.ai/fda-approves-bristol-myers-squibb-s-zenbexus-as-first-celmod-for-multiple-myeloma/ 2026-08-13 https://bio-research.ai/allist-and-arrivent-sign-agreement-for-muc16-napi2b-dual-targeting-adc-in-china/ 2026-08-13 https://bio-research.ai/taiho-pharmaceutical-s-phase-3-trial-of-irreversible-egfr-inhibitor-meets-pfs-primary-endpoint/ 2026-08-13 https://bio-research.ai/amplifica-closes-26-million-financing-to-advance-hair-follicle-regeneration-candidates/ 2026-08-12 https://bio-research.ai/fda-grants-fast-track-designation-to-attralus-pan-amyloid-removal-therapeutic-for-al-amyloidosis/ 2026-08-12 https://bio-research.ai/definium-therapeutics-5-ht2a-receptor-partial-agonist-achieves-5-4-point-placebo-adjusted-ham-a-improvement-in-phase-3/ 2026-08-12 https://bio-research.ai/indupro-raises-77m-series-b-and-initiates-phase-1-trial-of-egfr-targeting-bispecific-adc/ 2026-08-12 https://bio-research.ai/infinimmune-secures-75-million-for-monoclonal-antibodies-targeting-il-22-and-il-13/ 2026-08-11 https://bio-research.ai/vaderis-therapeutics-raises-152m-series-b-and-initiates-phase-3-trial-of-oral-akt-inhibitor-in-hht/ 2026-08-11 https://bio-research.ai/macrogenics-earns-10m-milestone-as-gilead-exercises-option-for-preclinical-bispecific-program/ 2026-08-11 https://bio-research.ai/epicrispr-biotechnologies-raises-90-million-to-advance-epigenetic-therapy-for-fshd/ 2026-08-11 https://bio-research.ai/mereo-biopharma-and-sentynl-sign-option-and-license-deal-for-neutrophil-elastase-inhibitor/ 2026-08-11 https://bio-research.ai/gan-lee-and-menarini-enter-726m-license-agreement-for-biweekly-glp-1ra-in-obesity-and-overweight-treatment/ 2026-08-11 https://bio-research.ai/silence-therapeutics-phase-2-trial-of-sirna-shows-88-response-rate-in-polycythemia-vera/ 2026-08-10 https://bio-research.ai/bios-life-secures-25-million-for-ai-based-cancer-surveillance-and-survivorship-care-platforms/ 2026-08-10 https://bio-research.ai/novo-nordisk-and-aws-form-strategic-partnership-to-accelerate-drug-discovery-using-ai-and-cloud/ 2026-08-10 https://bio-research.ai/tenax-therapeutics-k-atp-channel-activator-calcium-sensitizer-reduces-nt-probnp-by-49-in-phase-3/ 2026-08-10 https://bio-research.ai/jazz-pharmaceuticals-to-acquire-actio-biosciences-for-820m-upfront-to-develop-kcnt1-ion-inhibitor/ 2026-08-10 https://bio-research.ai/oculis-to-acquire-peptoid-small-molecule-from-accure-in-3-8m-asset-purchase-agreement/ 2026-08-10 https://bio-research.ai/innovent-biologics-and-daiichi-sankyo-enter-agreement-to-commercialize-vanflyta-in-china/ 2026-08-10 https://bio-research.ai/nmpa-approves-yochanra-for-fgfr2-positive-cholangiocarcinoma-following-fgfr-inhibitor-therapy/ 2026-08-07 https://bio-research.ai/fda-grants-fast-track-designation-to-anti-tnfr2-antibody-for-ovarian-cancer-with-keytruda/ 2026-08-07 https://bio-research.ai/fda-grants-accelerated-approval-to-replimune-s-oncolytic-immunotherapy-tudriqev-plus-nivolumab-for-advanced-melanoma/ 2026-08-06 https://bio-research.ai/aclaris-therapeutics-receives-fda-fast-track-designation-for-itk-jak3-inhibitor-in-moderate-to-severe-lichen-planus/ 2026-08-06 https://bio-research.ai/tarsus-pharmaceuticals-to-acquire-alkeus-adding-phase-3-stargardt-disease-therapy/ 2026-08-06 https://bio-research.ai/mediar-therapeutics-and-ono-enter-collaboration-and-option-agreement-to-develop-antibody-therapies-for-fibro-inflammatory-diseases/ 2026-08-06 https://bio-research.ai/harrow-to-acquire-dry-eye-nasal-spray-tyrvaya-from-viatris-for-up-to-100m/ 2026-08-06 https://bio-research.ai/fda-approves-moderna-s-mrna-flu-vaccine-mflusiva-for-adults-aged-50-and-older/ 2026-08-06 https://bio-research.ai/fda-approves-takeda-s-first-in-class-ox2r-agonist-orzeyful-for-narcolepsy-type-1/ 2026-08-05 https://bio-research.ai/adneuris-licenses-dual-nmr-agonist-to-maruishi-in-japan-and-south-korea-for-35m-upfront/ 2026-08-05 https://bio-research.ai/expedition-therapeutics-raises-115m-series-b-to-advance-dpp1-inhibitor-in-phase-2-copd-trial/ 2026-08-05 https://bio-research.ai/lexeo-therapeutics-receives-fda-rmat-designation-for-aav-based-gene-therapy-in-pkp2-acm/ 2026-08-05 https://bio-research.ai/hengrui-s-glp-1-gip-dual-agonist-achieves-2-78-hba1c-reduction-in-phase-3-diabetes-trial/ 2026-08-05 https://bio-research.ai/mironid-raises-46-million-to-advance-a-small-molecule-targeting-cyclic-amp-for-adpkd/ 2026-08-05 https://bio-research.ai/phylo-and-chugai-collaborate-to-deploy-an-agentic-ai-platform-for-drug-discovery/ 2026-08-04 https://bio-research.ai/amplia-and-eli-lilly-enter-ctcsa-to-evaluate-fak-inhibitor-and-kras-g12c-inhibitor-in-nsclc/ 2026-08-04 https://bio-research.ai/arrowhead-pharmaceuticals-signs-agreement-with-undisclosed-third-party-to-acquire-prv-for-redemplo/ 2026-08-04 https://bio-research.ai/evexta-bio-and-roche-partner-on-phase-1b-trial-of-an-oral-dual-node-pam-pathway-inhibitor-plus-a-serd/ 2026-08-04 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-muc18-directed-adc-for-advanced-melanoma/ 2026-08-04 https://bio-research.ai/pathos-ai-and-astrazeneca-sign-licensing-agreement-for-protac-using-an-ai-platform/ 2026-08-04 https://bio-research.ai/dash-bio-raises-30-million-for-an-automated-bioanalysis-platform-to-support-drug-development/ 2026-08-03 https://bio-research.ai/fda-grants-orphan-drug-designation-to-dll3-antibody-drug-conjugate-for-neuroendocrine-carcinomas/ 2026-08-03 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-kras-g12c-inhibitor-for-advanced-pancreatic-cancer/ 2026-08-03 https://bio-research.ai/novo-nordisk-phase-3-trial-of-il-6-ligand-antibody-shows-0-99-hazard-ratio-for-mace-reduction/ 2026-07-31 https://bio-research.ai/ratio-therapeutics-raises-70-million-to-advance-fap-targeted-therapeutic-for-advanced-sarcomas/ 2026-07-31 https://bio-research.ai/prg-s-tech-s-oral-therapy-targeting-t-r1-and-rkip-interaction-receives-fda-rpdd-for-nf2-related-schwannomatosis/ 2026-07-31 https://bio-research.ai/alexion-enzyme-replacement-therapy-shows-1-67-median-rgi-c-score-in-phase-3-pediatric-hpp-trial/ 2026-07-31 https://bio-research.ai/taisho-pharmaceutical-and-kaigene-enter-exclusive-license-agreement-for-fcrn-inhibitor-in-japan/ 2026-07-31 https://bio-research.ai/karyopharm-therapeutics-xpovio-shows-12-75-month-median-pfs-but-misses-phase-3-primary-endpoint/ 2026-07-30 https://bio-research.ai/j-j-s-rybrevant-faspro-gains-fda-priority-review-in-advanced-head-and-neck-cancer/ 2026-07-30 https://bio-research.ai/pfizer-s-litfulo-meets-co-primary-endpoints-in-two-phase-3-trials-for-nonsegmental-vitiligo/ 2026-07-30 https://bio-research.ai/johnson-johnson-partners-with-sail-on-in-vivo-car-t-with-exclusive-2-58b-acquisition-option/ 2026-07-29 https://bio-research.ai/abcellera-and-vertex-pharmaceuticals-sign-28-m-agreement-for-multispecific-t-cell-engagers/ 2026-07-29 https://bio-research.ai/ocugen-s-aav5-based-gene-therapy-receives-fda-rmat-designation-for-geographic-atrophy/ 2026-07-29 https://bio-research.ai/qureight-raises-20-million-to-expand-ai-powered-quantitative-imaging-platform-for-clinical-trials/ 2026-07-29 https://bio-research.ai/haya-therapeutics-antisense-oligonucleotide-receives-fast-track-designation-for-nhcm-treatment/ 2026-07-29 https://bio-research.ai/claris-biotherapeutics-raises-118m-to-advance-recombinant-human-deleted-hgf-therapy-for-lscd/ 2026-07-28 https://bio-research.ai/altimmune-s-glucagon-glp-1-dual-receptor-agonist-reduces-heavy-drinking-days-in-phase-2-alcohol-use-disorder-trial/ 2026-07-28 https://bio-research.ai/core-biomedicine-signs-licensing-agreement-with-eisai-for-preclinical-oncology-programs/ 2026-07-28 https://bio-research.ai/atea-s-nucleotide-polymerase-inhibitor-ns5a-inhibitor-combination-meets-primary-endpoint-in-phase-3-hcv-trial/ 2026-07-28 https://bio-research.ai/hansoh-pharma-s-b7-h3-targeting-adc-significantly-improves-pfs-in-phase-3-osteosarcoma-trial/ 2026-07-28 https://bio-research.ai/dualitybio-and-biontech-s-b7-h3-targeting-adc-receives-nmpa-breakthrough-therapy-designation-for-mcrpc/ 2026-07-28 https://bio-research.ai/innocare-pharma-s-tyk2-allosteric-inhibitor-meets-phase-iii-primary-endpoint-in-psoriasis-study/ 2026-07-27 https://bio-research.ai/astrazeneca-s-c5-complement-inhibitor-misses-primary-endpoint-in-adult-adolescent-hsct-tma-phase-iii-trial/ 2026-07-27 https://bio-research.ai/astrazeneca-s-anti-cldn18-2-adc-improves-overall-survival-in-phase-iii-gastric-cancer-trial/ 2026-07-27 https://bio-research.ai/argenx-to-acquire-forte-biosciences-for-2-2b-to-advance-anti-cd122-antibody-in-autoimmune-diseases/ 2026-07-27 https://bio-research.ai/pfizer-and-eisai-to-begin-co-promotion-of-nartique-for-migraine-treatment-and-prevention-in-japan/ 2026-07-27 https://bio-research.ai/fda-approves-otsuka-s-simtriyo-as-first-ndsri-treatment-for-adhd/ 2026-07-24 https://bio-research.ai/almirall-and-certest-biotec-sign-licensing-agreement-for-mrna-and-lipid-nanoparticle-platform/ 2026-07-24 https://bio-research.ai/fda-approves-outlook-therapeutics-lytenava-as-first-ophthalmic-bevacizumab-for-wet-amd/ 2026-07-24 https://bio-research.ai/meiji-seika-pharma-s-epigenetic-immunomodulator-plus-nivolumab-meets-phase-3-pfs-endpoint-in-advanced-melanoma/ 2026-07-24 https://bio-research.ai/ipsen-s-ibat-inhibitor-fails-to-improve-native-liver-survival-in-phase-3-biliary-atresia-trial/ 2026-07-24 https://bio-research.ai/ema-grants-orphan-designation-to-atsena-therapeutics-gene-therapies-for-lca1-and-xlrs/ 2026-07-23 https://bio-research.ai/scancell-and-neuphoria-therapeutics-sign-merger-and-89m-financing-for-dna-active-immunotherapy/ 2026-07-23 https://bio-research.ai/lilly-s-triple-agonist-retatrutide-delivers-up-to-22-6-weight-loss-in-two-additional-phase-3-obesity-trials/ 2026-07-23 https://bio-research.ai/astrazeneca-s-etcamah-approved-in-eu-for-esr1-mutated-er-her2-advanced-breast-cancer-based-on-phase-3-serena-6-trial/ 2026-07-23 https://bio-research.ai/lundbeck-s-orexin-2-receptor-agonist-receives-fda-fast-track-designation-for-narcolepsy/ 2026-07-23 https://bio-research.ai/fda-approves-gsk-s-ros1-inhibitor-jideytro-for-previously-treated-ros1-positive-nsclc/ 2026-07-22 https://bio-research.ai/tikva-raises-8-million-series-a-to-advance-off-the-shelf-b7-h3-car-t-toward-ind-submission/ 2026-07-22 https://bio-research.ai/crystalys-therapeutics-raises-130-million-series-b-to-advance-oral-urat1-inhibitor-through-global-phase-3-gout-trials/ 2026-07-22 https://bio-research.ai/fda-grants-orphan-drug-designation-to-affinia-s-one-time-aav-gene-therapy-for-bag3-associated-dcm/ 2026-07-22 https://bio-research.ai/arrowhead-s-plozasiran-cuts-triglycerides-by-up-to-81-and-acute-pancreatitis-events-in-phase-3-trials/ 2026-07-22 https://bio-research.ai/royalty-pharma-acquires-royalty-interest-in-neurimmune-s-attr-cm-antibody-for-up-to-425-million/ 2026-07-22 https://bio-research.ai/n-zyme-biomedical-closes-4-6-million-series-a-financing-to-advance-pepsin-inhibitor-platform/ 2026-07-21 https://bio-research.ai/celldex-halts-anti-kit-antibody-development-in-prurigo-nodularis-after-phase-2-misses-primary-and-key-secondary-endpoints/ 2026-07-21 https://bio-research.ai/estrigenix-therapeutics-closes-2m-seed-financing-for-selective-estrogen-receptor-beta-platform/ 2026-07-21 https://bio-research.ai/gilead-and-merck-s-once-weekly-oral-hiv-regimen-demonstrates-noninferior-viral-suppression-at-week-48-in-two-phase-3-switch-trials/ 2026-07-21 https://bio-research.ai/polypid-and-azurity-enter-320m-commercial-agreement-for-a-prolonged-release-antibiotic/ 2026-07-21 https://bio-research.ai/tempest-and-senlang-partner-to-develop-an-in-vivo-dual-target-cd19-bcma-car-t-therapy/ 2026-07-21 https://bio-research.ai/jupiter-neurosciences-and-pharmala-biotech-holdings-sign-100m-license-for-non-racemic-mdma/ 2026-07-21 https://bio-research.ai/agios-discontinues-pyruvate-kinase-activator-development-in-sickle-cell-disease-after-phase-2-fails-to-show-differentiation/ 2026-07-21 https://bio-research.ai/fda-grants-orphan-drug-designation-to-carna-biosciences-cdc7-inhibitor-for-acute-myeloid-leukemia/ 2026-07-21 https://bio-research.ai/jacobio-pharma-s-bet-inhibitor-included-in-cde-rare-disease-drug-development-pilot-program/ 2026-07-21 https://bio-research.ai/kolon-tissuegene-cell-therapy-did-not-meet-co-primary-endpoints-in-phase-3-trial-of-tg-c/ 2026-07-20 https://bio-research.ai/tempus-ai-to-acquire-personalis-for-1-5b-to-advance-tumor-informed-mrd-technology-for-cancer-care/ 2026-07-20 https://bio-research.ai/abelzeta-receives-ema-prime-designation-for-autologous-anti-cd20-bcma-car-t-in-refractory-sle/ 2026-07-20 https://bio-research.ai/acadia-receives-fda-fast-track-for-5-ht2a-receptor-inverse-agonist-in-alzheimer-s-disease-psychosis/ 2026-07-20 https://bio-research.ai/belite-bio-reports-positive-secondary-endpoint-update-from-phase-3-trial-of-oral-rbp4-inhibitor-in-stargardt-disease/ 2026-07-20 https://bio-research.ai/halozyme-and-incyte-sign-license-agreement-for-mutcalr-targeted-monoclonal-antibody-development/ 2026-07-20 https://bio-research.ai/samsung-biologics-expands-into-peptides-with-chf-1-46b-polypeptide-acquisition/ 2026-07-20 https://bio-research.ai/gsk-halts-p2x3-receptor-antagonist-development-for-chronic-cough-after-poor-phase-iii-results/ 2026-07-17 https://bio-research.ai/mission-therapeutics-divests-usp30-inhibitor-to-dimerix-limited-for-up-to-292m-in-payments/ 2026-07-17 https://bio-research.ai/fda-approves-novartis-first-and-only-complement-inhibitor-to-slow-kidney-function-decline-in-primary-igan/ 2026-07-17 https://bio-research.ai/trellis-bioscience-closes-financing-for-phase-2-trial-of-biofilm-disrupting-mab-for-pji/ 2026-07-16 https://bio-research.ai/merck-s-lipfendra-becomes-the-first-fda-approved-once-daily-oral-pcsk9-inhibitor-for-adults-with-hypercholesterolemia/ 2026-07-16 https://bio-research.ai/fda-grants-fast-track-designation-to-monoclonal-antibody-targeting-cdpp3-for-cardiogenic-shock/ 2026-07-16 https://bio-research.ai/eli-lilly-to-acquire-ataibeckley-for-up-to-3-8b-to-advance-neuroplastogen-pipeline-for-depression/ 2026-07-16 https://bio-research.ai/biomed-industries-small-molecule-shows-promising-efficacy-and-tolerability-in-phase-2-3-rett-syndrome-trial/ 2026-07-16 https://bio-research.ai/innocare-pharma-s-phase-iii-trial-of-tyk2-inhibitor-meets-primary-endpoint-in-atopic-dermatitis/ 2026-07-15 https://bio-research.ai/advancell-raises-315-million-to-advance-lead-212-psma-targeted-alpha-therapy-to-phase-3-development/ 2026-07-15 https://bio-research.ai/veradermics-extended-release-oral-minoxidil-improves-hair-coverage-in-90-of-women-in-phase-2-trial/ 2026-07-15 https://bio-research.ai/kelun-biotech-s-adc-plus-pembrolizumab-meets-phase-3-pfs-endpoint-in-first-line-pd-l1-negative-nsclc/ 2026-07-15 https://bio-research.ai/fda-approves-revtorpyk-for-pik3ca-wild-type-hr-her2-advanced-breast-cancer/ 2026-07-14 https://bio-research.ai/biogen-s-phase-2-study-of-tau-targeting-aso-shows-clinical-benefit-and-robust-tau-reduction-in-early-alzheimer-s-disease/ 2026-07-14 https://bio-research.ai/fda-grants-fast-track-designation-to-cdh17-targeting-adc-for-advanced-colorectal-cancer/ 2026-07-14 https://bio-research.ai/spero-and-innovent-enter-1-1b-agreement-for-anti-cd40l-antibody-in-immune-mediated-diseases/ 2026-07-14 https://bio-research.ai/hansoh-out-licenses-oral-il-23-receptor-antagonist-to-avere-in-deal-worth-up-to-2-3b/ 2026-07-14 https://bio-research.ai/summit-sells-phase-iii-antibiotic-ridinilazole-to-biossil-for-up-to-105m/ 2026-07-14 https://bio-research.ai/nextcure-and-avere-merge-to-advance-once-weekly-oral-il-23-receptor-antagonist-with-320m-financing/ 2026-07-14 https://bio-research.ai/astrazeneca-and-dizal-enter-license-agreement-for-zegfrovy-with-600m-upfront-and-900m-milestones/ 2026-07-14 https://bio-research.ai/niagen-bioscience-receives-fda-rpd-and-ema-ompd-for-oral-small-molecule-therapy-in-ataxia-telangiectasia/ 2026-07-13 https://bio-research.ai/ardigen-and-veraxa-biotech-collaborate-on-ai-for-t-cell-engagers-and-antibody-drug-conjugates/ 2026-07-13 https://bio-research.ai/q32-bio-anti-il-7ra-antibody-reduces-salt-score-by-35-3-in-phase-2a-alopecia-areata-trial/ 2026-07-13 https://bio-research.ai/gsk-s-jemperli-achieves-meaningful-12-month-clinical-complete-response-rate-in-phase-ii-rectal-cancer-trial/ 2026-07-13 https://bio-research.ai/velogene-biotechnology-completes-series-a-financing-for-tetraploid-complementation-technology-platform/ 2026-07-13 https://bio-research.ai/insilico-medicine-and-cms-partner-for-ai-driven-cns-drug-discovery-in-cny-1-2-b-deal/ 2026-07-13 https://bio-research.ai/hansoh-pharma-s-phase-3-trial-of-b7-h3-directed-adc-shows-overall-survival-improvement-in-sclc/ 2026-07-10 https://bio-research.ai/simcere-and-schr-dinger-enter-drug-discovery-and-development-collaboration-via-computational-platform/ 2026-07-10 https://bio-research.ai/bausch-lomb-discontinues-small-molecule-eye-drops-program-for-glaucoma-after-phase-2-misses-primary-endpoint/ 2026-07-09 https://bio-research.ai/fda-grants-fast-track-to-monovalent-monoclonal-antibody-for-anti-nmda-receptor-encephalitis/ 2026-07-09 https://bio-research.ai/ionis-and-astrazeneca-phase-3-trial-of-rna-targeted-silencer-fails-to-meet-primary-endpoint/ 2026-07-09 https://bio-research.ai/allotera-therapeutics-raises-funds-for-pivotal-trial-of-off-the-shelf-cd7-targeted-car-t-therapy/ 2026-07-08 https://bio-research.ai/keenova-therapeutics-phase-3-trial-of-xiaflex-met-its-primary-pain-endpoint-in-plantar-fibromatosis/ 2026-07-08 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-oral-selective-tlr-7-8-inhibitor-for-lupus/ 2026-07-08 https://bio-research.ai/chemomab-therapeutics-and-scipher-medicine-merge-for-anti-ccl24-antibody-phase-2-trial-in-ra/ 2026-07-08 https://bio-research.ai/astrazeneca-licenses-chia-tai-tianqing-s-inhaled-pde3-4-inhibitor-in-up-to-2-1b-deal/ 2026-07-08 https://bio-research.ai/vanda-pharmaceuticals-antisense-oligonucleotide-receives-fda-rare-pediatric-disease-designation/ 2026-07-07 https://bio-research.ai/meiragtx-secures-up-to-400m-strategic-investment-from-oberland-capital-for-aav-gene-therapy-programs/ 2026-07-07 https://bio-research.ai/kailera-oral-small-molecule-glp-1-receptor-agonist-reduces-weight-by-10-9-and-hba1c-by-1-68/ 2026-07-07 https://bio-research.ai/healome-therapeutics-raises-2-million-to-advance-eye-drop-matrix-technology-for-ocular-diseases/ 2026-07-07 https://bio-research.ai/cyllene-therapeutics-raises-33-million-for-dna-medicine-targeting-type-c-sensory-neurons/ 2026-07-07 https://bio-research.ai/fda-grants-rare-pediatric-disease-designation-to-prg-s-tech-small-molecule-treatment-for-nf2/ 2026-07-07 https://bio-research.ai/vertex-to-acquire-crinetics-for-10-0b-to-add-palsonify-and-acth-receptor-antagonist-to-portfolio/ 2026-07-06 https://bio-research.ai/health-canada-authorizes-besremi-for-the-treatment-of-adults-with-polycythemia-vera/ 2026-07-06 https://bio-research.ai/astex-genentech-ink-490m-breast-cancer-research-collaboration-and-license-agreement/ 2026-07-06 https://bio-research.ai/novartis-to-acquire-myricx-bio-for-1-5b-to-advance-nmt-inhibitor-adc-payload-platform/ 2026-07-06 https://bio-research.ai/pyrotech-biotechnology-completes-financing-for-pyroptosis-and-small-molecule-immunomodulator-platforms/ 2026-07-03 https://bio-research.ai/fosun-pharma-and-aribio-sign-27-5m-strategic-equity-investment-agreement-for-oral-dmt/ 2026-07-03 https://bio-research.ai/cspc-s-b7-h3-targeting-antibody-drug-conjugate-granted-breakthrough-therapy-designation/ 2026-07-02 https://bio-research.ai/united-therapeutics-acquires-thymmune-therapeutics-for-300m-to-advance-thymic-cell-therapy/ 2026-07-02 https://bio-research.ai/cspc-pharmaceutical-group-limited-and-astrazeneca-sign-sirna-drug-agreement-worth-up-to-1-77b/ 2026-07-02 https://bio-research.ai/roche-s-kras-g12c-inhibitor-improves-pfs-and-os-in-phase-iii-trial-for-pretreated-nsclc/ 2026-07-02 https://bio-research.ai/otsuka-s-voyxact-stabilizes-egfr-over-two-years-in-phase-3-iga-nephropathy-study/ 2026-07-02 https://bio-research.ai/insilico-medicine-and-takeda-sign-600m-agreement-to-discover-drugs-using-generative-ai-platform/ 2026-07-01 https://bio-research.ai/ipsen-to-acquire-memo-therapeutics-adding-bk-polyomavirus-antibody-to-rare-disease-pipeline/ 2026-07-01 https://bio-research.ai/alzecure-and-quantumcell-sign-2-2b-agreement-for-trk-pam-project-and-cns-disease-platform/ 2026-07-01 https://bio-research.ai/fda-approves-orca-bio-s-tregzi-as-first-precision-engineered-cell-therapy-for-use-in-allogeneic-hsct/ 2026-06-30 https://bio-research.ai/metis-techbio-licenses-ai-designed-trispecific-t-cell-engager-mts-128-to-boulevard-bio-in-up-to-1-62b-deal/ 2026-06-30 https://bio-research.ai/fda-grants-rare-pediatric-disease-designation-to-monopar-s-albumin-tripartite-complex-activator/ 2026-06-30 https://bio-research.ai/flare-therapeutics-raises-85-million-to-advance-aron-degrader-and-appoints-anna-protopapas-as-ceo/ 2026-06-30 https://bio-research.ai/beone-medicines-brukinsa-plus-rituximab-reduces-risk-of-progression-or-death-by-43-in-frontline-mcl/ 2026-06-30 https://bio-research.ai/sanofi-s-nexviazyme-meets-phase-3-primary-endpoint-in-infantile-onset-pompe-disease-at-52-weeks/ 2026-06-30 https://bio-research.ai/abbvie-s-phase-3-trial-shows-epkinly-and-lenalidomide-reduced-progression-risk-by-60-in-dlbcl/ 2026-06-29 https://bio-research.ai/evommune-oral-mrgprx2-antagonist-phase-2b-trial-did-not-meet-primary-endpoint-at-12-weeks/ 2026-06-29 https://bio-research.ai/fda-grants-fast-track-designation-to-an-aak1-inhibitor-for-duchenne-muscular-dystrophy/ 2026-06-29 https://bio-research.ai/zymeworks-inc-to-acquire-theravance-biopharma-for-929m-in-cash-plus-a-contingent-value-right/ 2026-06-29 https://bio-research.ai/ipsen-to-acquire-kartos-therapeutics-for-up-to-1-3b-plus-450m-upfront-for-mdm2-inhibitor-therapy/ 2026-06-29 https://bio-research.ai/astrazeneca-s-enzyme-replacement-therapy-shows-1-67-median-rgi-c-difference-in-phase-3-hpp-trial/ 2026-06-28 https://bio-research.ai/fda-approves-lumvoa-for-the-treatment-of-active-and-chronic-thyroid-eye-disease/ 2026-06-26 https://bio-research.ai/nippon-shinyaku-elixirgen-and-ns-pharma-enter-agreement-for-mrna-therapeutic-in-dmd/ 2026-06-26 https://bio-research.ai/abbisko-therapeutics-phase-2-trial-of-fgfr2-3-and-pd-l1-inhibitors-shows-90-orr-in-gastric-cancer/ 2026-06-26 https://bio-research.ai/ligachem-biosciences-inc-receives-500-billion-krw-for-antibody-drug-conjugate-platform-development/ 2026-06-26 https://bio-research.ai/merck-enters-definitive-agreement-to-acquire-bio-techne-for-11-3b-to-expand-in-life-sciences-markets/ 2026-06-25 https://bio-research.ai/ec-grants-orphan-drug-designation-to-gene-editing-therapy-for-primary-hyperoxaluria-type-1/ 2026-06-25 https://bio-research.ai/artivila-biopharma-raises-12-8-million-usd-to-advance-ai-drug-discovery-and-irak4-1-inhibitor/ 2026-06-25 https://bio-research.ai/fda-approves-keytruda-and-keytruda-qlex-plus-trodelvy-for-first-line-treatment-of-advanced-tnbc/ 2026-06-25 https://bio-research.ai/oblenio-bio-closes-62-million-series-b-for-cd19-bcma-cd3-tri-specific-t-cell-engager/ 2026-06-25 https://bio-research.ai/ionis-and-recordati-enter-30m-license-agreement-for-antisense-oligonucleotide-medicine/ 2026-06-25 https://bio-research.ai/hutchmed-fgfr-inhibitor-shows-42-5-objective-response-rate-in-phase-ii-cholangiocarcinoma-study/ 2026-06-25 https://bio-research.ai/fda-approves-trodelvy-as-the-only-adc-for-first-line-mtnbc-across-pd-l1-status/ 2026-06-24 https://bio-research.ai/passage-bio-and-remix-therapeutics-enter-merger-agreement-to-advance-mrna-degrader-with-100m/ 2026-06-24 https://bio-research.ai/fda-approves-tryngolza-the-first-and-only-therapy-to-reduce-triglycerides-and-acute-pancreatitis-risk-in-shtg/ 2026-06-24 https://bio-research.ai/anodyne-nanotech-raises-12-6-million-to-advance-glp-1-patch-for-obesity-into-phase-1-trial/ 2026-06-24 https://bio-research.ai/ollin-biosciences-raises-330-million-for-phase-3-trials-of-a-vegf-ang2-bispecific-antibody/ 2026-06-24 https://bio-research.ai/antares-and-novartis-partner-to-develop-small-molecule-medicines-for-105m-upfront-and-1-8b-milestones/ 2026-06-24 https://bio-research.ai/rq-bio-completes-115-million-financing-for-long-acting-antibody-therapeutic-for-influenza/ 2026-06-24 https://bio-research.ai/lyncbio-therapeutics-secures-financing-to-advance-adc-for-ibd-and-bispecific-oncology-adc-platform/ 2026-06-24 https://bio-research.ai/abbisko-therapeutics-and-lilly-partner-on-multi-target-drug-discovery-in-up-to-1-9b-deal/ 2026-06-24 https://bio-research.ai/osanni-bio-closes-190-million-series-b-financing-for-therapeutics-platform-and-pipeline/ 2026-06-23 https://bio-research.ai/combotope-therapeutics-and-boehringer-ingelheim-partner-for-tumor-selective-antibody-discovery/ 2026-06-23 https://bio-research.ai/corxel-pharmaceuticals-limited-phase-2-trial-of-oral-glp-1-ra-shows-11-5-weight-loss-at-36-weeks/ 2026-06-23 https://bio-research.ai/pfizer-phase-3-trial-of-integrin-beta-6-directed-adc-shows-no-improvement-in-overall-survival/ 2026-06-22 https://bio-research.ai/dropgenie-closes-seed-financing-to-support-launch-of-miniaturized-gene-editing-platform/ 2026-06-22 https://bio-research.ai/truelab-and-bionyra-pharma-ink-985m-deal-for-anti-tl1a-mab-and-tl1a-x-il-23p19-bispecific-antibody/ 2026-06-22 https://bio-research.ai/nuvectis-and-haisco-license-cfb-and-paradox-breaker-braf-inhibitors-in-deal-worth-up-to-1-461b/ 2026-06-22 https://bio-research.ai/nura-bio-doses-first-patient-in-phase-1b-2a-als-study-of-oral-brain-penetrant-sarm1-inhibitor/ 2026-06-22 https://bio-research.ai/merck-anti-tl1a-monoclonal-antibody-reaches-clinical-remission-at-12-weeks-in-phase-3-uc-trial/ 2026-06-22 https://bio-research.ai/definium-therapeutics-phase-3-trial-of-5-ht2a-receptor-partial-agonist-shows-8-1-point-madrs-change/ 2026-06-22 https://bio-research.ai/abbvie-to-acquire-apogee-therapeutics-for-10-9b-to-advance-il-13-targeting-monoclonal-antibodies/ 2026-06-22 https://bio-research.ai/bioarctic-and-eli-lilly-sign-800m-agreement-for-blood-brain-barrier-transport-technology/ 2026-06-22 https://bio-research.ai/insilico-medicine-and-sk-biopharmaceuticals-sign-2-5b-ai-driven-neuroimmune-cns-drug-agreement/ 2026-06-21 https://bio-research.ai/greenstone-biosciences-and-intel-corp-collaborate-to-advance-drug-discovery-using-an-ipsc-platform/ 2026-06-20 https://bio-research.ai/fda-grants-fast-track-designation-to-sophrosyne-pharmaceuticals-aldh2-inhibitor-for-alcohol-use-disorder/ 2026-06-18 https://bio-research.ai/memento-medicines-raises-93m-for-bispecific-antibody-activating-tie2-and-inhibiting-vegf-for-namd/ 2026-06-18 https://bio-research.ai/gri-bio-receives-fda-orphan-drug-designation-for-oral-rar-selective-agonist-in-ipf/ 2026-06-18 https://bio-research.ai/cour-pharma-closes-50-million-funding-for-phase-2-trial-of-nanoparticle-therapy-in-type-1-diabetes/ 2026-06-18 https://bio-research.ai/denali-therapeutics-enters-agreement-to-sell-prv-for-195m-following-avlayah-approval/ 2026-06-18 https://bio-research.ai/f2g-and-shionogi-report-positive-phase-3-topline-results-for-a-novel-dhodh-inhibitor-in-invasive-aspergillosis/ 2026-06-18 https://bio-research.ai/biogen-to-acquire-raythera-for-up-to-1b-to-add-immunology-assets-to-its-portfolio/ 2026-06-17 https://bio-research.ai/vedana-therapeutics-secures-46-million-for-anti-pacap-and-bispecific-antibody-migraine-programs/ 2026-06-17 https://bio-research.ai/jazz-pharmaceuticals-and-abcellera-ink-56m-deal-for-t-cell-engaging-multispecific-antibodies/ 2026-06-17 https://bio-research.ai/triveni-bio-raises-65-million-for-phase-2-trial-of-il-13-and-klk5-7-dual-targeting-antibody/ 2026-06-17 https://bio-research.ai/multivalent-biotherapies-raises-27-million-for-phase-1b-2a-psma-x-fr-targeted-drug-conjugate-trial/ 2026-06-16 https://bio-research.ai/eli-lilly-and-company-acquires-4e-therapeutics-and-its-mnk-inhibitor-for-chronic-pain/ 2026-06-16 https://bio-research.ai/luye-pharma-group-s-vmat2-inhibitor-and-sigma-1r-activator-reaches-76-5-response-rate-in-td-trial/ 2026-06-16 https://bio-research.ai/henlius-anti-vegf-monoclonal-antibody-is-non-inferior-to-ranibizumab-at-week-36-in-phase-3-trial/ 2026-06-16 https://bio-research.ai/protillion-biosciences-and-merck-sign-discovery-agreement-using-protein-design-ai-platform/ 2026-06-16 https://bio-research.ai/everest-medicines-and-dimerix-sign-exclusive-licensing-agreement-for-ccr2-inhibitor-for-up-to-340m/ 2026-06-16 https://bio-research.ai/radical-numerics-launches-with-50-million-dollars-seed-funding-for-genomic-language-models/ 2026-06-15 https://bio-research.ai/spyre-therapeutics-phase-2-trial-of-anti-tl1a-antibody-shows-10-7-point-reduction-in-rhi-score/ 2026-06-15 https://bio-research.ai/fda-grants-orphan-drug-exclusivity-to-papzimeos-for-recurrent-respiratory-papillomatosis/ 2026-06-15 https://bio-research.ai/fda-grants-fast-track-designation-to-oral-nek7-allosteric-modulator-for-lower-risk-mds-treatment/ 2026-06-15 https://bio-research.ai/hmnc-raises-50-million-dollars-for-oral-ketamine-and-oral-vasopressin-v1b-receptor-antagonist-trials/ 2026-06-15 https://bio-research.ai/synact-pharma-s-selective-melanocortin-agonist-reaches-76-4-acr20-response-in-phase-2b-trial/ 2026-06-15 https://bio-research.ai/fda-and-ema-grant-orphan-drug-designation-to-ojjaara-for-vexas-syndrome/ 2026-06-12 https://bio-research.ai/human-continuum-inc-closes-5-13-million-seed-financing-for-exosome-based-therapeutics-platform/ 2026-06-11 https://bio-research.ai/neion-bio-closes-23-million-series-a-to-advance-its-genetic-engineering-manufacturing-platform/ 2026-06-11 https://bio-research.ai/takeda-s-oral-tyk2-inhibitor-outperforms-deucravacitinib-in-phase-3-plaque-psoriasis-study/ 2026-06-11 https://bio-research.ai/johnson-johnson-s-fcrn-blocker-delivers-durable-hemoglobin-response-in-phase-2-3-waiha-trial/ 2026-06-11 https://bio-research.ai/novartis-antibody-oligonucleotide-conjugate-meets-primary-biomarker-endpoint-in-phase-i-ii-fshd-study/ 2026-06-11 https://bio-research.ai/alphamab-oncology-s-anbenitamab-plus-docetaxel-albumin-bound-meet-phase-iii-breast-cancer-endpoint/ 2026-06-11 https://bio-research.ai/laekna-and-vasque-bio-enter-exclusive-licensing-agreement-for-pi3k-pan-mutant-selective-inhibitor/ 2026-06-10 https://bio-research.ai/sonothera-raises-125-million-to-advance-ultrasound-mediated-genetic-medicines-for-dmd-and-adpkd/ 2026-06-10 https://bio-research.ai/genesis-pharma-and-alnylam-pharmaceuticals-expand-agreement-for-rnai-therapeutics-in-nordic-markets/ 2026-06-10 https://bio-research.ai/fda-grants-orphan-drug-designation-to-tris-pharma-s-once-nightly-oxybate-for-idiopathic-hypersomnia/ 2026-06-10 https://bio-research.ai/orionis-biosciences-and-novartis-partner-for-molecular-glue-drugs-in-a-deal-worth-up-to-1-4b/ 2026-06-10 https://bio-research.ai/sanofi-s-phase-3-trial-of-humanized-igg4-monoclonal-antibody-in-cidp-discontinued-for-lack-of-efficacy/ 2026-06-10 https://bio-research.ai/parabilis-medicines-prices-upsized-670-million-initial-public-offering/ 2026-06-10 https://bio-research.ai/medexus-excellthera-and-cordex-sign-license-and-supply-deal-for-hematopoietic-stem-cell-therapy/ 2026-06-09 https://bio-research.ai/fda-grants-rmat-designation-to-cd22-targeting-allogeneic-car-t-cell-therapy-for-r-r-b-all/ 2026-06-09 https://bio-research.ai/ammax-and-lonza-sign-licensing-agreement-for-linker-payload-technologies-to-develop-oncology-adc/ 2026-06-09 https://bio-research.ai/cartesian-and-westgene-enter-strategic-licensing-agreement-for-mrna-car-t-via-lnp-platform/ 2026-06-09 https://bio-research.ai/bial-s-phase-2b-trial-of-allosteric-activator-of-beta-glucocerebrosidase-fails-to-meet-endpoints/ 2026-06-09 https://bio-research.ai/alzecure-pharma-and-eli-lilly-and-company-sign-1b-deal-for-a-gamma-secretase-modulator/ 2026-06-09 https://bio-research.ai/city-therapeutics-completes-series-b-financing-to-advance-rnai-platform-and-phase-1-clinical-trial/ 2026-06-08 https://bio-research.ai/engitix-and-gsk-sign-liver-fibrosis-deal-including-up-to-44-5m-in-upfront-and-near-term-payments/ 2026-06-08 https://bio-research.ai/johnson-johnson-to-acquire-firefly-bio-inc-and-degrader-antibody-conjugate-platform-for-1b/ 2026-06-08 https://bio-research.ai/eu-approves-sanofi-s-sarclisa-subcutaneous-for-multiple-myeloma-via-on-body-injector/ 2026-06-08 https://bio-research.ai/nurix-and-roche-collaborate-to-develop-btk-targeted-protein-degrader-for-700m-upfront-and-2-3b/ 2026-06-08 https://bio-research.ai/everest-medicines-and-corxel-pharmaceuticals-sign-vizz-asset-purchase-agreement/ 2026-06-08 https://bio-research.ai/amgen-s-repatha-reduces-risk-of-first-major-cardiovascular-events-by-29-in-high-risk-diabetes-patients/ 2026-06-07 https://bio-research.ai/fda-grants-fast-track-designation-to-genfleet-s-oral-kras-g12d-inhibitor-for-nsclc-treatment/ 2026-06-06 https://bio-research.ai/innocare-pharma-phase-iib-trial-of-orelabrutinib-shows-57-1-sri-4-response-rate-in-sle-patients/ 2026-06-05 https://bio-research.ai/pfizer-and-chai-discovery-sign-license-agreement-for-ai-platform-to-accelerate-drug-discovery/ 2026-06-04 https://bio-research.ai/lonza-and-stipple-bio-sign-multi-target-licensing-agreement-to-develop-next-generation-adc-therapies/ 2026-06-04 https://bio-research.ai/japan-s-mhlw-grants-orphan-drug-designation-to-quoin-s-topical-lotion-for-netherton-syndrome/ 2026-06-04 https://bio-research.ai/fda-grants-orphan-drug-designation-to-attralus-pan-amyloid-removal-therapeutic-for-al-amyloidosis/ 2026-06-04 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-antisense-oligonucleotide-for-spinal-muscular-atrophy/ 2026-06-04 https://bio-research.ai/everest-medicines-and-mabworks-sign-license-agreement-for-bejescin-for-up-to-rmb-209m/ 2026-06-04 https://bio-research.ai/ona-therapeutics-raises-86-6-million-in-series-b-to-advance-adcs-in-breast-and-colorectal-cancer/ 2026-06-04 https://bio-research.ai/alnylam-pharmaceuticals-and-inceptive-nucleics-partner-in-2b-ai-based-rnai-therapeutics-alliance/ 2026-06-03 https://bio-research.ai/verastem-oncology-s-oral-kras-g12d-inhibitor-receives-fda-fast-track-designation-for-nsclc/ 2026-06-03 https://bio-research.ai/adc-therapeutics-reports-positive-phase-3-lotis-5-results-for-zynlonta-in-r-r-dlbcl/ 2026-06-03 https://bio-research.ai/lilly-and-ascidian-therapeutics-sign-1-9b-agreement-for-rna-exon-editing-in-kidney-diseases/ 2026-06-03 https://bio-research.ai/cytomx-and-regeneron-expand-bispecific-therapy-collaboration-with-37m-payment-and-up-to-4b-in-milestones/ 2026-06-03 https://bio-research.ai/mineralys-repurchases-aldosterone-synthase-inhibitor-royalty-obligations-from-tanabe/ 2026-06-03 https://bio-research.ai/johnson-johnson-s-fcrn-blocker-reduces-sle-disease-activity-in-53-5-of-patients-at-24-weeks/ 2026-06-03 https://bio-research.ai/os-therapies-immunotherapy-shows-75-2-5-year-overall-survival-in-metastatic-osteosarcoma-trial/ 2026-06-02 https://bio-research.ai/newlimit-raises-435m-to-initiate-human-trials-for-an-epigenetic-reprogramming-medicine-next-year/ 2026-06-02 https://bio-research.ai/causaly-and-microsoft-collaborate-to-combine-an-ai-platform-with-an-analytics-platform-for-r-d/ 2026-06-02 https://bio-research.ai/ilant-health-raises-15-million-in-series-a-funding-for-ai-enabled-obesity-care-services/ 2026-06-02 https://bio-research.ai/celcuity-inc-pan-pi3k-mtorc1-2-inhibitor-reduces-disease-progression-risk-by-50-in-phase-3-trial/ 2026-06-02 https://bio-research.ai/gilead-sciences-phase-3-trial-shows-livdelzi-achieves-alp-normalization-at-52-weeks-in-pbc-patients/ 2026-06-02 https://bio-research.ai/tavo-biotherapeutics-raises-17-million-for-glaucoma-and-retinal-disease-programs/ 2026-06-02 https://bio-research.ai/fda-issues-complete-response-letter-for-cingulate-s-adhd-treatment-candidate/ 2026-06-02 https://bio-research.ai/travere-therapeutics-licenses-reversible-covalent-btk-inhibitor-from-everest-medicines-in-up-to-1-14b-deal/ 2026-06-02 https://bio-research.ai/fda-accepts-nda-for-the-first-oral-serd-with-positive-phase-3-results-in-early-breast-cancer/ 2026-06-02 https://bio-research.ai/shanghai-juncell-therapeutics-til-therapy-achieves-4-3-months-pfs-in-melanoma/ 2026-06-02 https://bio-research.ai/periotherapia-raises-jpy-575-million-and-receives-amed-grant-for-antibody-clinical-trials/ 2026-06-02 https://bio-research.ai/servier-acquires-edgewise-therapeutics-muscular-dystrophy-business-and-fast-skeletal-myosin-inhibitor-for-up-to-2-65b/ 2026-06-01 https://bio-research.ai/astrazeneca-s-emerald-3-phase-iii-trial-shows-30-reduction-in-disease-progression-risk/ 2026-06-01 https://bio-research.ai/rallybio-and-avenzo-announce-merger-alongside-215m-private-placement-financing/ 2026-06-01 https://bio-research.ai/oak-hill-bio-closes-series-a-financing-to-advance-an-aso-therapy-for-angelman-syndrome/ 2026-06-01 https://bio-research.ai/therappi-closes-pre-seed-round-advances-erk-myd88-protein-interaction-program/ 2026-06-01 https://bio-research.ai/circio-and-genassist-announce-research-collaboration-to-develop-aav-gene-therapy-candidates/ 2026-06-01 https://bio-research.ai/us-fda-approves-xocova-for-post-exposure-prophylaxis-of-covid-19/ 2026-06-01 https://bio-research.ai/hanmi-pharmaceutical-licenses-glp-2-analog-to-eli-lilly-in-1-26b-agreement/ 2026-06-01 https://bio-research.ai/oculis-phase-3-trials-of-ocs-01-eye-drops-in-dme-did-not-meet-primary-endpoint/ 2026-05-29 https://bio-research.ai/breakthrough-therapy-designation-for-a-kras-g12c-inhibitor-with-keytruda-in-nsclc/ 2026-05-29 https://bio-research.ai/mabgeek-phase-iii-trial-of-anti-il-4r-mab-for-prurigo-nodularis-meets-primary-endpoint/ 2026-05-29 https://bio-research.ai/pfizer-and-innovent-enter-licensing-and-collaboration-agreement-for-cancer-medicines-worth-10-5b/ 2026-05-28 https://bio-research.ai/fda-extends-review-of-cyclodextrin-based-therapy-nda-for-infantile-onset-niemann-pick-disease/ 2026-05-28 https://bio-research.ai/fda-approves-imfinzi-based-first-and-only-immunotherapy-combination-for-bcg-na-ve-high-risk-nmibc/ 2026-05-28 https://bio-research.ai/fda-accepts-nda-for-kit-inhibitor-and-sunitinib-combination-for-patients-with-gist/ 2026-05-28 https://bio-research.ai/psilera-secures-seed-funding-extension-to-advance-neuroplastogen-towards-trials/ 2026-05-28 https://bio-research.ai/fda-grants-priority-review-to-sanofi-s-oral-gcsi-nda-for-type-3-gaucher-disease/ 2026-05-28 https://bio-research.ai/fda-approves-abbvie-s-decnupaz-for-patients-with-blastic-plasmacytoid-dendritic-cell-neoplasm/ 2026-05-27 https://bio-research.ai/ono-s-s1p5-receptor-agonist-demonstrates-placebo-comparable-safety-in-msa-phase-2-trial/ 2026-05-27 https://bio-research.ai/protuoso-biosciences-raises-9-5-million-seed-financing-for-ai-enabled-protein-engineering-platform/ 2026-05-27 https://bio-research.ai/junshi-biosciences-achieves-positive-final-phase-3-results-for-perioperative-anti-pd-1-therapy-in-stage-ii-iii-nsclc/ 2026-05-26 https://bio-research.ai/lilly-to-acquire-curevo-vaccine-to-advance-adjuvanted-subunit-vaccine-for-up-to-1-5b/ 2026-05-26 https://bio-research.ai/lilly-to-acquire-vaccine-company-for-up-to-1-55b-to-advance-ebv-vaccine-candidate/ 2026-05-26 https://bio-research.ai/fda-grants-fast-track-designation-to-cns-thyroid-hormone-receptor-agonist-for-bipolar-depression/ 2026-05-26 https://bio-research.ai/eli-lilly-and-company-to-acquire-limmatech-biologics-ag-in-deal-worth-up-to-780m-for-bacterial-vaccine-programs/ 2026-05-26 https://bio-research.ai/zbd-pharmaceutical-signs-distribution-contract-with-zhejiang-teruisi-for-cd20-targeting-adc/ 2026-05-26 https://bio-research.ai/merz-therapeutics-and-kvvit-sign-exclusive-license-and-collaboration-agreement-for-inbrija/ 2026-05-26 https://bio-research.ai/sk-bioscience-and-vecol-sign-agreement-for-260m-vaccine-localization-initiative-in-colombia/ 2026-05-26 https://bio-research.ai/nmpa-approves-lilin-for-multiple-myeloma-and-mantle-cell-lymphoma-treatment/ 2026-05-25 https://bio-research.ai/fda-approves-datroway-for-first-line-metastatic-triple-negative-breast-cancer/ 2026-05-22 https://bio-research.ai/european-commission-grants-marketing-authorization-for-pyrukynd-in-adults-with-thalassemia/ 2026-05-22 https://bio-research.ai/chmp-recommends-approval-of-wegovy-7-2-mg-single-dose-pen-in-the-eu-for-obesity/ 2026-05-22 https://bio-research.ai/ec-grants-marketing-authorization-for-joenja-to-treat-activated-pi3k-delta-syndrome-in-the-eu/ 2026-05-22 https://bio-research.ai/fda-grants-accelerated-approval-to-hepcludex-for-chronic-hepatitis-delta-virus-infection/ 2026-05-22 https://bio-research.ai/eli-lilly-and-company-reports-foundayo-associated-with-13-weight-reduction-in-older-adults/ 2026-05-22 https://bio-research.ai/ose-immunotherapeutics-trial-shows-tedopi-and-pembrolizumab-improve-pfs-to-4-1-months-in-ovarian-cancer/ 2026-05-22 https://bio-research.ai/biogen-and-denali-lrrk2-inhibitor-fails-to-meet-endpoints-in-phase-2b-parkinson-s-study/ 2026-05-22 https://bio-research.ai/sobi-s-urat1-inhibitor-achieves-significant-serum-uric-acid-reduction-in-phase-3-reduce-2-trial/ 2026-05-21 https://bio-research.ai/calico-and-nexo-collaborate-to-develop-small-molecule-therapeutics-utilizing-a-covalent-platform/ 2026-05-21 https://bio-research.ai/degron-therapeutics-and-msd-enter-joint-development-collaboration-agreement-in-oncology/ 2026-05-21 https://bio-research.ai/lilly-acquires-engage-biologics-and-its-non-viral-dna-delivery-platform-for-up-to-202m/ 2026-05-20 https://bio-research.ai/incyte-and-genesis-expand-ai-platform-collaboration-with-120m-upfront-consideration/ 2026-05-20 https://bio-research.ai/century-health-secures-5-million-in-seed-funding-to-scale-its-clinical-data-platform/ 2026-05-19 https://bio-research.ai/blank-bio-secures-7-2-million-to-develop-ai-foundation-models-for-rna-in-oncology/ 2026-05-19 https://bio-research.ai/oorja-bio-launches-with-30m-series-a-to-advance-peptide-therapeutic-for-idiopathic-pulmonary-fibrosis/ 2026-05-19 https://bio-research.ai/forlong-biotechnology-raises-120-million-rmb-to-advance-il-15-superagonist-and-pd-1-il-18-bispecific-antibody/ 2026-05-19 https://bio-research.ai/inmed-pharmaceuticals-merges-with-mentari-therapeutics-to-develop-pacap-targeting-migraine-therapies/ 2026-05-19 https://bio-research.ai/fda-grants-orphan-drug-designation-to-flt3xcd3-t-cell-engager-for-relapsed-refractory-aml/ 2026-05-19 https://bio-research.ai/fda-grants-priority-review-for-bayer-s-oral-fxia-inhibitor-for-secondary-stroke-prevention/ 2026-05-19 https://bio-research.ai/hansa-biopharma-and-serb-pharmaceuticals-enter-115m-licensing-agreement-for-idefirix/ 2026-05-19 https://bio-research.ai/accro-bioscience-closes-50-million-dollar-financing-to-advance-ripk2-inhibitor-for-ulcerative-colitis/ 2026-05-19 https://bio-research.ai/toregem-biopharma-raises-usd-5-3-million-for-phase-ii-trials-of-anti-usag-1-antibody/ 2026-05-19 https://bio-research.ai/regeneron-and-parabilis-partner-to-develop-novel-antibody-helicon-conjugates-in-a-deal-worth-up-to-2-3b/ 2026-05-18 https://bio-research.ai/merck-phase-3-trial-of-trop2-directed-adc-improves-os-and-pfs-in-advanced-endometrial-cancer/ 2026-05-18 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-non-opioid-investigational-treatment-for-back-pain/ 2026-05-18 https://bio-research.ai/lundbeck-receives-orphan-drug-designation-in-japan-for-anti-acth-monoclonal-antibody-for-cah-and-cd/ 2026-05-18 https://bio-research.ai/inhibrx-s-phase-2-trial-of-hexavalent-ox40-agonist-and-pembrolizumab-shows-44-0-corr-in-hnscc/ 2026-05-18 https://bio-research.ai/yoltech-therapeutics-in-vivo-gene-editing-therapy-for-aatd-receives-fda-rmat-designation/ 2026-05-14 https://bio-research.ai/fda-grants-fast-track-designation-to-selective-soluble-tnf-inhibitor-for-early-alzheimer-s-disease/ 2026-05-14 https://bio-research.ai/degron-therapeutics-raises-40-million-to-advance-hur-molecular-glue-degrader-phase-1-trial/ 2026-05-14 https://bio-research.ai/create-medicines-closes-122-million-series-b-to-advance-in-vivo-car-therapies/ 2026-05-14 https://bio-research.ai/biogen-s-tau-targeting-aso-shows-benefit-at-60-mg-but-fails-to-meet-phase-2-primary-endpoint/ 2026-05-14 https://bio-research.ai/astrazeneca-s-imfinzi-and-enfortumab-vedotin-improve-event-free-and-overall-survival-in-mibc/ 2026-05-14 https://bio-research.ai/shanghai-yiminokang-biotechnology-raises-250-million-yuan-for-antibody-discovery-platforms/ 2026-05-13 https://bio-research.ai/alloplex-biotherapeutics-receives-fda-fast-track-designation-for-autologous-cellular-therapy-in-crc/ 2026-05-13 https://bio-research.ai/fosun-pharma-and-aribio-sign-global-option-deal-for-oral-pde-5-inhibitor-for-alzheimer-s-disease/ 2026-05-13 https://bio-research.ai/fda-approves-first-and-only-bcl2-inhibitor-beqalzi-for-r-r-mantle-cell-lymphoma/ 2026-05-13 https://bio-research.ai/eli-lilly-and-company-reports-weight-maintenance-with-foundayo-and-lower-dose-zepbound-following-high-dose-incretin-therapy/ 2026-05-12 https://bio-research.ai/servier-s-b7-h4-directed-adc-receives-fda-breakthrough-designation-for-adenoid-cystic-carcinoma/ 2026-05-12 https://bio-research.ai/isomorphic-labs-raises-2-1-billion-to-scale-its-ai-drug-design-engine-and-pipeline/ 2026-05-12 https://bio-research.ai/alkermes-reports-positive-phase-3-data-for-lumryz-in-idiopathic-hypersomnia/ 2026-05-12 https://bio-research.ai/boehringer-ingelheim-licenses-preclinical-antibody-program-from-immunitas-therapeutics-for-up-to-407-5m/ 2026-05-12 https://bio-research.ai/rigel-pharmaceuticals-licenses-fda-approved-oral-protac-veppanu-from-arvinas-and-pfizer-in-up-to-405m-deal/ 2026-05-12 https://bio-research.ai/ribo-life-science-and-insilico-medicine-sign-strategic-cooperation-agreement-for-ai-driven-sirna/ 2026-05-12 https://bio-research.ai/bristol-myers-squibb-and-hengrui-pharma-enter-15-2b-license-agreements-for-13-early-stage-programs/ 2026-05-12 https://bio-research.ai/fda-grants-fast-track-designation-to-zai-lab-s-dll3-targeting-adc-for-epnecs/ 2026-05-11 https://bio-research.ai/fda-approves-bizengri-for-advanced-nrg1-fusion-positive-cholangiocarcinoma/ 2026-05-11 https://bio-research.ai/fda-grants-fast-track-designation-to-sarm1-inhibitor-for-chemotherapy-induced-peripheral-neuropathy/ 2026-05-11 https://bio-research.ai/nxera-pharma-founded-spin-out-closes-series-a-financing-to-advance-gpcr-targeting-drug-candidate-toward-global-clinical-trials/ 2026-05-11 https://bio-research.ai/breakthrough-therapy-designation-for-pd-1-il-2-bias-bispecific-fusion-protein-and-avastin-in-crc/ 2026-05-11 https://bio-research.ai/curacle-mabtics-and-memento-medicines-sign-1-08b-dual-antibody-technology-transfer-agreement/ 2026-05-11 https://bio-research.ai/raynovent-phase-iib-trial-of-pan-pde-inhibitor-shows-64-9-response-rate-in-mash-patients/ 2026-05-08 https://bio-research.ai/fda-grants-rmat-designation-to-rznomics-rna-based-gene-therapy-for-hepatocellular-carcinoma/ 2026-05-08 https://bio-research.ai/halozyme-and-gsk-enter-agreement-to-develop-oncology-adcs-using-drug-delivery-technology/ 2026-05-07 https://bio-research.ai/aim-immunotech-reports-50-objective-response-rate-in-phase-2-ovarian-cancer-trial/ 2026-05-07 https://bio-research.ai/bristol-myers-squibb-licenses-adc-platform-from-lonza-for-single-target-development/ 2026-05-07 https://bio-research.ai/parcelbio-raises-13-million-to-advance-mrna-platform-and-in-vivo-car-t-for-autoimmune-disease/ 2026-05-07 https://bio-research.ai/angelini-pharma-to-acquire-catalyst-pharmaceuticals-for-4-1b-to-expand-in-rare-diseases/ 2026-05-07 https://bio-research.ai/fda-grants-fast-track-designation-to-dendritic-cell-therapy-for-cutaneous-melanoma/ 2026-05-06 https://bio-research.ai/ltz-therapeutics-raises-38-million-to-advance-myeloid-cell-engager-immunotherapy-pipeline/ 2026-05-06 https://bio-research.ai/brano-therapeutics-secures-seed-funding-for-small-molecule-compound-development-in-heart-failure/ 2026-05-06 https://bio-research.ai/kanvas-biosciences-raises-48-million-to-conduct-clinical-trials-for-live-biotherapeutic-product/ 2026-05-06 https://bio-research.ai/cellcentric-raises-220-million-to-advance-p300-cbp-inhibitor-into-pivotal-multiple-myeloma-trials/ 2026-05-06 https://bio-research.ai/halozyme-and-oruka-enter-agreement-for-microparticle-technology-with-il-23p19-antibody/ 2026-05-06 https://bio-research.ai/bayer-to-acquire-perfuse-therapeutics-for-up-to-2-45b-to-expand-ophthalmology-pipeline/ 2026-05-06 https://bio-research.ai/gsk-and-siranbio-enter-1-005b-license-agreement-for-phase-i-long-acting-sirna-oligonucleotide/ 2026-05-06 https://bio-research.ai/avalo-therapeutics-anti-il-1-mab-shows-42-9-hiscr75-response-rate-in-phase-2-trial-for-hidradenitis-suppurativa/ 2026-05-05 https://bio-research.ai/fda-grants-fast-track-designation-to-synaptic-regenerative-therapy-for-als-treatment/ 2026-05-05 https://bio-research.ai/dandelion-health-raises-14-million-to-scale-clinical-intelligence-platform-for-drug-development/ 2026-05-05 https://bio-research.ai/cytokinetics-phase-3-cardiac-myosin-inhibitor-aficamten-trial-meets-dual-primary-endpoints-in-non-obstructive-hcm/ 2026-05-05 https://bio-research.ai/viridian-therapeutics-anti-igf-1r-mab-achieves-54-proptosis-responder-rate-in-chronic-ted-trial/ 2026-05-05 https://bio-research.ai/johnson-johnson-co-antibody-therapy-shows-positive-phase-2b-results-in-crohn-s-disease-and-ulcerative-colitis/ 2026-05-05 https://bio-research.ai/cytospire-therapeutics-closes-series-a-financing-to-advance-pan-gamma-delta-t-cell-engagers/ 2026-05-05 https://bio-research.ai/oncolytics-biotech-reports-19-5-month-response-duration-for-rna-immunotherapeutic-in-mcrc-study/ 2026-05-04 https://bio-research.ai/spur-therapeutics-gene-therapy-improves-bone-marrow-burden-score-from-11-to-7-in-gaucher-disease/ 2026-05-04 https://bio-research.ai/dr-falk-pharma-and-renexxion-5-ht4-agonist-and-d2-antagonist-shows-0-405-symptom-score-improvement/ 2026-05-04 https://bio-research.ai/lineage-cell-therapeutics-rpe-cell-therapy-shows-9-letter-bcva-gain-at-36-months-in-ga-patients/ 2026-05-04 https://bio-research.ai/biocryst-and-neopharmed-gentili-sign-345m-license-for-plasma-kallikrein-inhibitor-in-europe/ 2026-05-04 https://bio-research.ai/ucb-to-acquire-candid-therapeutics-for-up-to-2-2b-to-advance-t-cell-engager-therapies-in-immunology/ 2026-05-03 https://bio-research.ai/celcuity-phase-3-trial-of-pam-inhibitor-shows-significant-pfs-improvement-in-pik3ca-mutant-breast-cancer/ 2026-05-01 https://bio-research.ai/fda-approves-veppanu-for-esr1-mutated-er-her2-advanced-or-metastatic-breast-cancer/ 2026-05-01 https://bio-research.ai/stoked-bio-inc-closes-seed-round-to-advance-anti-infectives-and-cancer-therapeutics/ 2026-05-01 https://bio-research.ai/archimed-to-acquire-esperion-for-up-to-1-1-b-including-milestone-payments-for-nexletol-and-nexlizet/ 2026-05-01 https://bio-research.ai/kissei-signs-sub-licensing-deal-with-oep-for-idh1-inhibitor-in-taiwan/ 2026-05-01 https://bio-research.ai/restore-vision-gene-therapy-shows-all-high-dose-patients-reached-light-perception-in-phase-1-2-trial/ 2026-05-01 https://bio-research.ai/fda-grants-fast-track-designation-to-live-biotherapeutic-product-for-ulcerative-colitis-treatment/ 2026-04-30 https://bio-research.ai/contineum-therapeutics-phase-1b-trial-of-lpa1-receptor-antagonist-shows-1-60-point-pain-reduction/ 2026-04-30 https://bio-research.ai/cue-biopharma-and-ascendant-health-sign-691-5m-license-for-anti-ige-mab/ 2026-04-30 https://bio-research.ai/fda-approves-auvelity-for-agitation-associated-with-dementia-due-to-alzheimer-s-disease/ 2026-04-30 https://bio-research.ai/leo-pharma-to-acquire-replay-for-50m-upfront-to-advance-hsv-gene-therapy-platform-for-skin-diseases/ 2026-04-30 https://bio-research.ai/iterative-health-secures-77-million-to-expand-multispecialty-clinical-research-network/ 2026-04-30 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-pegylated-carboxyhemoglobin-bovine-for-stroke/ 2026-04-30 https://bio-research.ai/ascendo-biotechnology-completes-series-a-funding-to-advance-innate-immune-checkpoint-therapies/ 2026-04-30 https://bio-research.ai/fda-grants-orphan-drug-designation-to-fgfr2b-targeted-adc-for-gastric-cancer/ 2026-04-30 https://bio-research.ai/astrazeneca-pays-pinetree-25m-to-license-bispecific-antibody-degrader-targeting-egfr/ 2026-04-30 https://bio-research.ai/osr-holdings-and-bcme-enter-license-agreement-for-oral-immunotherapy-for-up-to-815m-milestones/ 2026-04-29 https://bio-research.ai/vivacta-bio-completes-financing-to-advance-clinical-trials-for-in-vivo-car-t-therapy/ 2026-04-29 https://bio-research.ai/teva-to-acquire-emalex-for-700m-to-advance-dopamine-d1-receptor-antagonist-for-tourette-syndrome/ 2026-04-29 https://bio-research.ai/chiesi-to-acquire-kalvista-pharmaceuticals-for-1-9b-to-expand-rare-disease-portfolio-with-ekterly/ 2026-04-29 https://bio-research.ai/pfizer-reports-elrexfio-improves-progression-free-survival-in-phase-3-multiple-myeloma-trial/ 2026-04-29 https://bio-research.ai/fda-grants-rmat-designation-to-orca-bio-allogeneic-t-cell-immunotherapy-for-hematologic-malignancies/ 2026-04-28 https://bio-research.ai/ec-grants-orphan-drug-designation-to-aav-based-gene-therapy-for-duchenne-muscular-dystrophy/ 2026-04-28 https://bio-research.ai/coultreon-biopharma-raises-125-million-to-advance-oral-sik3-inhibitor-in-autoimmune-diseases/ 2026-04-28 https://bio-research.ai/lighthouse-pharmaceuticals-secures-financing-to-advance-small-molecule-therapy-in-phase-2-trial/ 2026-04-28 https://bio-research.ai/remepy-and-merck-kgaa-collaborate-to-develop-hybrid-drugs-using-a-digital-intervention-platform/ 2026-04-28 https://bio-research.ai/profluent-and-lilly-partner-to-develop-ai-designed-recombinases-in-a-2-25b-genetic-medicine-deal/ 2026-04-28 https://bio-research.ai/rocket-pharmaceuticals-sells-kresladi-prv-for-180m-to-support-cardiovascular-pipeline/ 2026-04-28 https://bio-research.ai/zealand-pharma-reports-boehringer-ingelheim-s-glucagon-glp-1-receptor-dual-agonist-achieved-16-6-weight-loss-in-phase-3-obesity-trial/ 2026-04-28 https://bio-research.ai/keythera-pharmaceuticals-oral-ep4-receptor-antagonist-reduces-womac-pain-scores-by-86-7-in-koa-study/ 2026-04-27 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-oral-allosteric-bcr-abl1-inhibitor-for-ph-cml/ 2026-04-27 https://bio-research.ai/fda-grants-fast-track-designation-to-amyloid-depleter-antibody-for-attr-amyloidosis-treatment/ 2026-04-27 https://bio-research.ai/fathom-therapeutics-raises-47-million-dollars-to-advance-small-molecule-design-platform/ 2026-04-27 https://bio-research.ai/ligand-pharmaceuticals-to-acquire-xoma-royalty-for-739m-to-expand-biopharmaceutical-portfolio/ 2026-04-27 https://bio-research.ai/eli-lilly-and-company-to-acquire-ajax-therapeutics-and-its-type-ii-jak2-inhibitor-for-2-3b/ 2026-04-27 https://bio-research.ai/teikoku-seiyaku-and-curedisc-enter-license-agreement-for-recombinant-human-matrix-metalloproteinase-7/ 2026-04-27 https://bio-research.ai/fda-grants-orphan-drug-designation-to-monoclonal-monovalent-antibody-fragment-for-heart-transplant/ 2026-04-27 https://bio-research.ai/hk-inno-n-and-atomatrix-sign-agreement-to-develop-small-molecule-non-incretin-obesity-treatments/ 2026-04-27 https://bio-research.ai/sun-pharma-to-acquire-organon-in-a-definitive-agreement-valued-at-ev-of-us-11-75-b/ 2026-04-26 https://bio-research.ai/astellas-and-msn-amend-settlement-and-license-agreement-for-myrbetriq-with-75m-payment/ 2026-04-24 https://bio-research.ai/ema-grants-orphan-drug-designation-to-recombinant-human-hgf-protein-for-acute-spinal-cord-injury/ 2026-04-24 https://bio-research.ai/fda-grants-fast-track-designation-to-oncolys-biopharma-s-oncolytic-virus-for-unresectable-gastroesophageal-cancer/ 2026-04-23 https://bio-research.ai/fda-grants-accelerated-approval-for-otarmeni-in-otof-related-hearing-loss-based-on-chord-trial-results/ 2026-04-23 https://bio-research.ai/dogwood-therapeutics-and-pridcor-therapeutics-enter-partnership-for-anti-viral-assets-up-to-100m/ 2026-04-23 https://bio-research.ai/novo-nordisk-oral-glp-1-cuts-hba1c-by-0-83-vs-placebo-in-kids-with-type-2-diabetes/ 2026-04-23 https://bio-research.ai/fda-grants-orphan-drug-designation-to-pegylated-monoclonal-antibody-fragment-for-heart-transplant/ 2026-04-22 https://bio-research.ai/10x-science-closes-seed-round-for-ai-protein-characterization-platform-for-drug-development/ 2026-04-22 https://bio-research.ai/orega-biotech-cd39-blocking-antibody-with-durvalumab-shows-50-pcr-in-pd-l1-high-nsclc-patients/ 2026-04-22 https://bio-research.ai/gc-biopharma-and-galux-enter-agreement-to-develop-antibody-therapeutics-via-ai-design-platform/ 2026-04-21 https://bio-research.ai/dayspring-pharma-phase-ii-trial-of-minoxidil-and-finasteride-foam-improves-efficacy-by-50-in-aga/ 2026-04-21 https://bio-research.ai/fda-approves-idvynso-for-adults-with-virologically-suppressed-hiv-1-infection/ 2026-04-21 https://bio-research.ai/tortugas-neuroscience-launches-with-106-million-to-advance-small-molecule-clinical-stage-pipeline/ 2026-04-21 https://bio-research.ai/ray-therapeutics-secures-125-million-dollars-to-advance-optogenetic-gene-therapies-for-vision-loss/ 2026-04-21 https://bio-research.ai/fda-grants-designations-to-monoclonal-antibody-targeting-protein-s-for-von-willebrand-disease/ 2026-04-21 https://bio-research.ai/astrazeneca-trial-of-ultomiris-shows-statistically-significant-proteinuria-reduction-at-week-34/ 2026-04-21 https://bio-research.ai/lytix-biopharma-phase-ii-trial-of-oncolytic-peptide-with-pembrolizumab-shows-13-6-response-rate/ 2026-04-20 https://bio-research.ai/fda-grants-fast-track-designation-to-anti-gd2-monoclonal-antibody-for-high-risk-neuroblastoma/ 2026-04-20 https://bio-research.ai/biogen-to-acquire-cd38-targeting-mab-from-i-mab-for-up-to-850m-plus-royalties/ 2026-04-20 https://bio-research.ai/lilly-to-acquire-kelonia-for-up-to-7b-to-advance-in-vivo-car-t-therapy-for-multiple-myeloma/ 2026-04-20 https://bio-research.ai/synsmart-and-amporin-collaborate-to-develop-small-molecule-drugs-for-degenerative-diseases/ 2026-04-20 https://bio-research.ai/astrazeneca-anti-il-33-mab-reduces-moderate-to-severe-copd-exacerbations-in-phase-iii-miranda-trial/ 2026-04-20 https://bio-research.ai/ucb-to-acquire-neurona-therapeutics-for-up-to-1-15b-to-develop-a-neuronal-cell-therapy-for-epilepsy/ 2026-04-17 https://bio-research.ai/meiragtx-enters-asset-purchase-agreement-with-j-j-to-acquire-aav5-gene-therapy-for-25m-upfront/ 2026-04-16 https://bio-research.ai/interna-therapeutics-and-daiichi-sankyo-sign-research-agreement-for-intracellular-delivery-platform/ 2026-04-16 https://bio-research.ai/aligos-and-amoytop-sign-license-agreement-for-capsid-assembly-modulator-in-chronic-hbv-for-445m/ 2026-04-16 https://bio-research.ai/eli-lilly-and-company-s-glp-1-pill-shows-57-lower-risk-of-death-in-achieve-4-trial/ 2026-04-16 https://bio-research.ai/storm-therapeutics-raises-56m-to-advance-mettl3-inhibitor-in-phase-2-trial/ 2026-04-16 https://bio-research.ai/opna-bio-receives-fda-fast-track-designation-for-dual-ep300-cbp-inhibitor-to-treat-multiple-myeloma/ 2026-04-15 https://bio-research.ai/fda-grants-fast-track-designation-to-rnai-therapeutic-for-chronic-hepatitis-b-treatment/ 2026-04-15 https://bio-research.ai/boehringer-ingelheim-and-zai-lab-collaborate-on-dual-dll3-targeting-combination-for-sclc-and-necs/ 2026-04-15 https://bio-research.ai/terremoto-biosciences-closes-108-million-financing-to-advance-akt1-selective-inhibitors/ 2026-04-15 https://bio-research.ai/alloy-therapeutics-secures-40-million-series-e-financing-for-ai-driven-discovery-platforms/ 2026-04-15 https://bio-research.ai/restore-vision-secures-jpy-1-3-billion-to-advance-gene-therapy-for-retinal-disorders/ 2026-04-15 https://bio-research.ai/galera-and-obsidian-enter-merger-agreement-and-secure-350m-to-advance-autologous-til-cell-therapy/ 2026-04-14 https://bio-research.ai/spiral-therapeutics-closes-series-b-financing-for-drug-delivery-platform-and-inner-ear-programs/ 2026-04-14 https://bio-research.ai/lilly-to-acquire-crossbridge-bio-for-up-to-300m-to-advance-dual-payload-adc-platform/ 2026-04-14 https://bio-research.ai/adcendo-raises-75-million-dollars-to-advance-antibody-drug-conjugate-programs-in-clinical-trials/ 2026-04-14 https://bio-research.ai/fda-grants-fast-track-and-ind-clearance-for-anti-gd2-monoclonal-antibody-in-neuroblastoma/ 2026-04-14 https://bio-research.ai/kazia-therapeutics-in-licenses-setdb1-targeted-epigenetic-drug-platform-from-qimr-berghofer-for-1-39m/ 2026-04-13 https://bio-research.ai/neomorph-closes-100-million-dollar-financing-to-advance-molecular-glue-degrader-phase-1-2-trial/ 2026-04-13 https://bio-research.ai/ideaya-biosciences-and-servier-combination-therapy-for-metastatic-uveal-melanoma-improves-median-pfs-to-6-9-months/ 2026-04-13 https://bio-research.ai/fda-grants-fast-track-designation-to-oral-stat6-degrader-for-eosinophilic-asthma/ 2026-04-13 https://bio-research.ai/protierbiotech-secures-2-45m-for-molecular-glue-platform-and-multiple-myeloma-programs/ 2026-04-13 https://bio-research.ai/telix-and-regeneron-to-co-develop-radiopharmaceutical-therapies-in-deal-worth-up-to-2-1b/ 2026-04-13 https://bio-research.ai/haisco-and-abbvie-enter-licensing-agreement-for-pain-compounds-in-deal-worth-up-to-745m/ 2026-04-13 https://bio-research.ai/synox-therapeutics-csf-1r-inhibitor-meets-primary-endpoint-in-phase-3-trial-for-tgct-at-6-months/ 2026-04-13 https://bio-research.ai/oricell-therapeutics-raises-110-million-dollars-to-advance-gpc3-targeted-autologous-car-t-therapy/ 2026-04-10 https://bio-research.ai/gilead-exercises-option-for-kymera-cdk2-molecular-glue-degrader-in-45m-milestone-agreement/ 2026-04-09 https://bio-research.ai/c4-therapeutics-and-roche-partner-to-develop-dacs-for-oncology-in-a-deal-worth-over-1b/ 2026-04-09 https://bio-research.ai/oxford-biotherapeutics-and-bristol-myers-squibb-partner-to-develop-t-cell-engager-therapies/ 2026-04-09 https://bio-research.ai/oral-kras-g12d-inhibitor-receives-breakthrough-therapy-designation-for-pancreatic-cancer-in-china/ 2026-04-09 https://bio-research.ai/jw-pharmaceutical-signs-81-1m-license-in-agreement-with-gan-lee-for-glp-1-receptor-agonist/ 2026-04-08 https://bio-research.ai/life-biosciences-initiates-phase-1-trial-of-transcription-factor-therapy-for-optic-neuropathies/ 2026-04-08 https://bio-research.ai/sidewinder-therapeutics-raises-137-million-dollars-to-develop-bispecific-antibody-drug-conjugates/ 2026-04-08 https://bio-research.ai/nmpa-approves-exdensur-for-chronic-rhinosinusitis-with-nasal-polyps-in-china/ 2026-04-08 https://bio-research.ai/fda-grants-orphan-drug-designation-to-dll4-and-vegf-a-bispecific-antibody-for-biliary-tract-cancer/ 2026-04-08 https://bio-research.ai/insmed-phase-2b-trial-misses-endpoints-with-40-3-reduction-in-inflammatory-nodule-count/ 2026-04-07 https://bio-research.ai/gilead-sciences-to-acquire-tubulis-for-3-15b-to-advance-napi2b-directed-topo1i-adc-platform/ 2026-04-07 https://bio-research.ai/vertex-and-halozyme-sign-license-agreement-for-microparticle-technology-in-15m-upfront-deal/ 2026-04-07 https://bio-research.ai/alloy-therapeutics-and-biogen-sign-agreement-for-antisense-oligonucleotide-discovery-platform/ 2026-04-06 https://bio-research.ai/amgen-phase-3-trial-of-subcutaneous-tepezza-shows-77-proptosis-response-in-thyroid-eye-disease/ 2026-04-06 https://bio-research.ai/stipple-bio-secures-100-million-dollars-to-advance-antibody-drug-conjugate-into-clinical-studies/ 2026-04-06 https://bio-research.ai/neurocrine-biosciences-enters-agreement-to-acquire-soleno-therapeutics-for-2-9b/ 2026-04-06 https://bio-research.ai/praxis-precision-medicines-aso-shows-77-seizure-reduction-in-scn2a-developmental-encephalopathy/ 2026-04-06 https://bio-research.ai/anthropic-acquires-coefficient-bio-for-400m-to-expand-its-drug-r-d-and-clinical-planning-platform/ 2026-04-03 https://bio-research.ai/syneron-bio-closes-series-b-financing-to-advance-macrocyclic-peptide-discovery-platform/ 2026-04-03 https://bio-research.ai/vericel-and-barda-sign-197m-agreement-for-nexobrid-procurement-and-advanced-development/ 2026-04-02 https://bio-research.ai/regeneron-to-invest-200m-in-trinetx-to-expand-genomic-and-proteomic-electronic-health-record-data/ 2026-04-02 https://bio-research.ai/lipocine-inc-oral-brexanolone-misses-primary-endpoint-with-1-3-point-ham-d-reduction-at-hour-60/ 2026-04-02 https://bio-research.ai/immunovant-phase-3-studies-of-fcrn-blocker-fail-to-meet-primary-endpoint-in-thyroid-eye-disease/ 2026-04-02 https://bio-research.ai/fda-grants-fast-track-designation-to-a-cldn6-x-cd3-t-cell-engaging-bispecific-antibody-for-proc/ 2026-04-02 https://bio-research.ai/fda-grants-fast-track-designation-to-oral-protease-inhibitor-for-norovirus-infection-treatment/ 2026-04-02 https://bio-research.ai/fda-grants-orphan-drug-designation-to-retinoic-acid-receptor-agonist-for-adpkd-treatment/ 2026-04-02 https://bio-research.ai/celldex-therapeutics-prices-300-million-dollar-offering-to-fund-antibody-based-therapeutics/ 2026-04-01 https://bio-research.ai/alphamab-oncology-her2-bispecific-antibody-phase-iii-trial-meets-primary-endpoint-in-breast-cancer/ 2026-04-01 https://bio-research.ai/fda-approves-foundayo-for-weight-management-in-adults-with-obesity-or-overweight/ 2026-04-01 https://bio-research.ai/fda-grants-rmat-designation-to-optogenetic-gene-therapy-for-retinitis-pigmentosa-treatment/ 2026-04-01 https://bio-research.ai/axsome-enters-asset-purchase-agreement-with-takeda-for-selective-pde10a-inhibitor-rights/ 2026-04-01 https://bio-research.ai/apollomics-secures-2-0-million-dollars-to-support-clinical-development-of-a-c-met-inhibitor/ 2026-04-01 https://bio-research.ai/sk-biopharmaceuticals-submits-nda-for-xcopri-oral-suspension-to-fda-for-partial-onset-seizures/ 2026-04-01 https://bio-research.ai/ambrosia-biosciences-raises-100-million-dollars-to-advance-oral-small-molecule-glp-1-into-phase-1/ 2026-03-31 https://bio-research.ai/eli-lilly-to-acquire-centessa-for-6-3b-to-advance-ox2r-agonist-portfolio-in-neuroscience/ 2026-03-31 https://bio-research.ai/scala-biodesign-secures-16-million-dollars-to-expand-ai-driven-protein-design-software-platform/ 2026-03-31 https://bio-research.ai/biogen-to-acquire-apellis-for-5-6b-to-expand-immunology-portfolio-with-empaveli-and-syfovre/ 2026-03-31 https://bio-research.ai/ema-grants-prime-designation-to-peptoid-small-molecule-for-treatment-of-optic-neuritis/ 2026-03-31 https://bio-research.ai/european-commission-approves-kygevvi-for-thymidine-kinase-2-deficiency-treatment/ 2026-03-31 https://bio-research.ai/galapagos-gilead-ouro-and-keymed-agree-to-develop-bcmaxcd3-t-cell-engager-for-1-675b-upfront/ 2026-03-31 https://bio-research.ai/sam-chun-dang-pharm-signs-100m-license-agreement-with-undisclosed-partner-for-semaglutide-generics/ 2026-03-30 https://bio-research.ai/palisade-bio-s-phase-1b-trial-of-oral-pde4-inhibitor-prodrug-shows-47-5-ses-cd-reduction-in-fscd/ 2026-03-30 https://bio-research.ai/hengrui-pharma-cardiac-myosin-inhibitor-reduces-lvot-g-in-42-obstructive-hcm-patients/ 2026-03-30 https://bio-research.ai/fda-grants-fast-track-designation-to-fr-targeting-adc-for-platinum-resistant-ovarian-cancer/ 2026-03-30 https://bio-research.ai/viridian-therapeutics-igf-1r-monoclonal-antibody-shows-63-proptosis-responder-rate-in-phase-3-trial/ 2026-03-30 https://bio-research.ai/simcere-s-monoclonal-antibody-shows-96-6-easi-75-response-at-52-weeks-in-atopic-dermatitis-trial/ 2026-03-30 https://bio-research.ai/abclon-and-chong-kun-dang-expand-partnership-to-develop-bispecific-antibodies-for-solid-tumors/ 2026-03-30 https://bio-research.ai/merck-s-activin-signaling-inhibitor-reduces-pulmonary-vascular-resistance-by-1-02-wood-units/ 2026-03-29 https://bio-research.ai/bristol-myers-squibb-cardiac-myosin-inhibitor-reduces-lvot-gradient-by-48-0-mm-hg-in-adolescents/ 2026-03-29 https://bio-research.ai/biogen-igg1-monoclonal-antibody-targeting-bdca2-reduces-cle-disease-activity-by-11-8-in-phase-2-trial/ 2026-03-28 https://bio-research.ai/otsuka-pharmaceutical-to-acquire-transcend-via-otsuka-america-in-a-1-225b-deal-for-neuroplastogen/ 2026-03-27 https://bio-research.ai/astrazeneca-monoclonal-antibody-targeting-il-33-reduces-copd-exacerbation-rates-in-phase-iii-trials/ 2026-03-27 https://bio-research.ai/novartis-to-acquire-excellergy-for-up-to-2b-to-develop-anti-ige-antibody-for-ige-driven-diseases/ 2026-03-27 https://bio-research.ai/terrestrial-bio-establishes-boston-headquarters-and-manufacturing-for-microarray-patch-platform/ 2026-03-26 https://bio-research.ai/fda-grants-orphan-drug-designation-to-alpk1-inhibitor-for-rosah-syndrome-treatment/ 2026-03-26 https://bio-research.ai/pinnacle-medicines-raises-89-million-dollars-to-advance-oral-peptide-pipeline-through-clinical-trials/ 2026-03-26 https://bio-research.ai/european-commission-grants-orphan-drug-designation-to-innate-defense-regulator-for-behcet-s-disease/ 2026-03-26 https://bio-research.ai/insilico-and-tenacia-expand-ai-driven-r-d-deal-for-cns-small-molecule-inhibitors-worth-94-75m/ 2026-03-25 https://bio-research.ai/fda-approves-lifyorli-with-nab-paclitaxel-for-platinum-resistant-epithelial-ovarian-cancer/ 2026-03-25 https://bio-research.ai/fda-grants-fast-track-designation-to-molecular-glue-degrader-for-alk-positive-lung-cancer/ 2026-03-25 https://bio-research.ai/alteogen-and-biogen-sign-agreement-for-sc-formulations-using-human-hyaluronidase-for-up-to-579m/ 2026-03-25 https://bio-research.ai/maze-therapeutics-dual-mechanism-apol1-inhibitor-reduces-uacr-by-35-6-in-phase-2-amkd-trial/ 2026-03-25 https://bio-research.ai/merck-to-acquire-terns-pharmaceuticals-for-6-7-b-to-advance-allosteric-bcr-abl1-inhibitor-for-cml/ 2026-03-25 https://bio-research.ai/tul-and-novo-nordisk-triple-agonist-reduces-hba1c-by-2-16-and-weight-by-9-8-in-phase-2-trial/ 2026-03-25 https://bio-research.ai/gilgamesh-pharma-closes-60-million-dollar-financing-and-reports-nmda-receptor-antagonist-results/ 2026-03-24 https://bio-research.ai/rybodyn-closes-10-million-dollar-seed-financing-to-advance-oncology-discovery-platform/ 2026-03-24 https://bio-research.ai/karyopharm-reports-oral-xpo1-inhibitor-plus-ruxolitinib-achieved-50-svr35-in-phase-3-sentry-trial/ 2026-03-24 https://bio-research.ai/ocugen-s-aav5-based-gene-therapy-shows-31-reduction-in-lesion-growth-in-phase-2-trial/ 2026-03-24 https://bio-research.ai/quotient-and-merck-sign-2-2b-research-agreement-for-ibd-using-somatic-genomics-platform-technology/ 2026-03-24 https://bio-research.ai/immutrin-raises-87-million-dollars-to-advance-antibody-therapy-for-attr-cardiomyopathy/ 2026-03-24 https://bio-research.ai/japan-approves-dupixent-for-adults-with-moderate-to-severe-bullous-pemphigoid/ 2026-03-24 https://bio-research.ai/oryon-cell-therapies-autologous-neuron-replacement-therapy-shows-motor-improvements-in-parkinson-s/ 2026-03-23 https://bio-research.ai/gilead-to-acquire-ouro-medicines-for-1-675m-and-intends-to-collaborate-with-galapagos/ 2026-03-23 https://bio-research.ai/prestige-biopharma-biosimilar-to-avastin-meets-primary-endpoint-with-48-7-response-rate-in-nsclc/ 2026-03-23 https://bio-research.ai/innovent-biologics-vegfr-cr1-fusion-protein-shows-10-37-letter-vision-gain-in-phase-3-namd-study/ 2026-03-23 https://bio-research.ai/sanofi-and-kali-therapeutics-enter-agreement-for-tri-specific-t-cell-engager-for-1-05b/ 2026-03-23 https://bio-research.ai/haizexin-receives-mhlw-approval-for-pik3ca-mutated-ovarian-clear-cell-carcinoma-in-japan/ 2026-03-23 https://bio-research.ai/gsk-b7-h3-targeted-antibody-drug-conjugate-receives-orphan-drug-designation-in-japan-for-sclc/ 2026-03-23 https://bio-research.ai/everest-medicines-acquires-cardamyst-from-corxel-for-30m-upfront-and-20m-in-milestone-payments/ 2026-03-23 https://bio-research.ai/earendil-labs-raises-787-million-dollars-to-advance-ai-driven-biologics-and-anti-tl1a-antibody/ 2026-03-20 https://bio-research.ai/novartis-to-acquire-pikavation-from-synnovation-for-2b-to-develop-a-pan-mutant-selective-pi3k-inhibitor/ 2026-03-20 https://bio-research.ai/fda-approves-wegovy-hd-for-weight-management-based-on-step-up-trial-results/ 2026-03-19 https://bio-research.ai/fda-approves-lynavoy-for-cholestatic-pruritus-in-adult-patients-with-pbc/ 2026-03-19 https://bio-research.ai/fda-grants-fast-track-designation-to-small-molecule-myb-mrna-degrader-for-adenoid-cystic-carcinoma/ 2026-03-19 https://bio-research.ai/eli-lilly-triple-hormone-receptor-agonist-reduces-a1c-by-2-0-and-weight-by-16-8-in-phase-3-trial/ 2026-03-19 https://bio-research.ai/collegium-pharmaceutical-to-acquire-azstarys-from-corium-therapeutics-for-650m-in-cash/ 2026-03-19 https://bio-research.ai/fda-grants-rmat-designation-to-autologous-cell-therapy-for-secondary-progressive-multiple-sclerosis/ 2026-03-18 https://bio-research.ai/crossbow-therapeutics-raises-77-million-to-advance-t-cell-engager-therapies-for-cancer-treatment/ 2026-03-18 https://bio-research.ai/elaris-and-valneva-enter-license-agreement-for-clostridioides-difficile-antigen-technology/ 2026-03-18 https://bio-research.ai/fda-approves-johnson-johnson-s-icotyde-for-moderate-to-severe-plaque-psoriasis-treatment/ 2026-03-18 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-oral-gcs-inhibitor-for-type-3-gaucher-disease/ 2026-03-18 https://bio-research.ai/ascendis-pharma-lonapegsomatropin-shows-9-05-cm-year-height-velocity-in-phase-2-turner-syndrome-trial/ 2026-03-17 https://bio-research.ai/r1-therapeutics-launches-to-advance-pan-phosphate-transporter-inhibitor-in-hyperphosphatemia/ 2026-03-17 https://bio-research.ai/idel-therapeutics-closes-eur-9-million-seed-financing-to-advance-intracellular-shuttling-technology/ 2026-03-17 https://bio-research.ai/pfizer-s-phase-2-trial-of-cdk4-inhibitor-shows-40-reduction-in-risk-of-disease-progression/ 2026-03-17 https://bio-research.ai/vst-bio-closes-series-a-financing-to-advance-monoclonal-antibody-for-stroke-into-clinical-trials/ 2026-03-17 https://bio-research.ai/unnatural-products-secures-45-million-dollars-to-advance-macrocyclic-peptide-discovery-platform/ 2026-03-16 https://bio-research.ai/structure-therapeutics-oral-glp-1-receptor-agonist-shows-16-3-mean-weight-loss-at-44-weeks/ 2026-03-16 https://bio-research.ai/commave-to-purchase-zevra-sdx-portfolio-including-azstarys-and-sdx-prodrug-for-50m/ 2026-03-16 https://bio-research.ai/fda-grants-fast-track-designation-to-argo-biopharma-sirna-therapy-for-hereditary-angioedema-treatment/ 2026-03-16 https://bio-research.ai/nerviano-medical-sciences-discontinues-phase-2-trial-of-mps1-inhibitor-for-hepatocellular-cancer/ 2026-03-16 https://bio-research.ai/bayer-study-shows-kerendia-reduces-kidney-function-decline-in-non-diabetic-chronic-kidney-disease/ 2026-03-16 https://bio-research.ai/connext-secures-krw-15-billion-for-recombinant-protein-treatment-for-dupuytren-s-contracture/ 2026-03-16 https://bio-research.ai/merck-shows-91-8-virologic-suppression-for-its-hiv-1-reverse-transcriptase-inhibitor-combination/ 2026-03-13 https://bio-research.ai/enodia-acquires-sec61-assets-from-kezar-life-sciences-for-up-to-127m-under-purchase-agreement/ 2026-03-12 https://bio-research.ai/fda-grants-orphan-drug-designation-to-polyamine-transport-inhibitor-for-malignant-glioma/ 2026-03-12 https://bio-research.ai/capricor-therapeutics-cardiac-derived-cell-therapy-slows-dmd-progression-by-83-in-dva-assessment/ 2026-03-12 https://bio-research.ai/ultragenyx-aav8-gene-therapy-shows-18-percent-reduction-in-ammonia-in-phase-3-study-results/ 2026-03-12 https://bio-research.ai/solid-biosciences-reports-gene-therapy-91-mean-microdystrophin-expression-at-day-360-in-40-patients/ 2026-03-11 https://bio-research.ai/bridgebio-pharma-phase-3-trial-shows-oral-bbp-418-reduced-creatine-kinase-in-59-6-of-patients-in-interim-analysis/ 2026-03-11 https://bio-research.ai/vertex-dual-baff-and-april-inhibitor-reduces-proteinuria-by-49-8-in-phase-3-iga-nephropathy-trial/ 2026-03-11 https://bio-research.ai/excellthera-reports-zemcelpro-24-month-overall-survival-of-63-7-in-high-risk-blood-cancer-trials/ 2026-03-10 https://bio-research.ai/ascletis-pharma-glp-1r-agonist-shows-7-5-mean-weight-loss-at-week-16-in-phase-ii-obesity-study/ 2026-03-10 https://bio-research.ai/samsung-biologics-and-lilly-sign-agreement-to-establish-innovation-hub-for-biotech-companies/ 2026-03-10 https://bio-research.ai/fda-grants-orphan-drug-designation-for-nitazoxanide-for-acute-on-chronic-liver-failure/ 2026-03-09 https://bio-research.ai/pfizer-s-trispecific-antibody-shows-positive-phase-2-results-in-atopic-dermatitis/ 2026-03-09 https://bio-research.ai/european-commission-approves-parp-inhibitor-and-abiraterone-acetate-with-adt-for-mhspc/ 2026-03-09 https://bio-research.ai/rapport-therapeutics-grants-tenacia-biotechnology-greater-china-rights-for-an-investigational-small-molecule-for-20m-upfront/ 2026-03-09 https://bio-research.ai/relmada-therapeutics-secures-160-0-million-in-pipe-financing-for-working-capital-and-r-d/ 2026-03-09 https://bio-research.ai/bristol-myers-squibb-s-oral-immunomodulatory-drug-improves-progression-free-survival-in-phase-3-study/ 2026-03-09 https://bio-research.ai/gsk-licenses-global-rights-for-a-cholestatic-pruritus-treatment-to-alfasigma-for-300m-upfront/ 2026-03-09 https://bio-research.ai/roche-s-phase-iii-persevera-study-did-not-meet-primary-endpoint-in-breast-cancer/ 2026-03-09 https://bio-research.ai/hansoh-pharmaceutical-s-glp-1-gip-receptor-dual-agonist-shows-up-to-19-3-weight-loss/ 2026-03-07 https://bio-research.ai/european-commission-approves-zynyz-with-chemotherapy-for-scac-based-on-pod1um-303-study/ 2026-03-06 https://bio-research.ai/fda-approves-sotyktu-for-active-psoriatic-arthritis-treatment/ 2026-03-06 https://bio-research.ai/fda-approves-tecvayli-plus-darzalex-faspro-for-relapsed-or-refractory-multiple-myeloma/ 2026-03-05 https://bio-research.ai/tenaya-therapeutics-and-alnylam-pharmaceuticals-collaborate-on-cardiovascular-disease-targets-for-10m-upfront-1-13b-milestones/ 2026-03-05 https://bio-research.ai/zealand-pharma-s-amylin-analog-shows-10-7-mean-body-weight-reduction-at-week-42/ 2026-03-05 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-for-sutacimig-for-glanzmann-thrombasthenia/ 2026-03-05 https://bio-research.ai/fda-grants-orphan-drug-designation-to-a-small-molecule-for-desmoid-tumors/ 2026-03-04 https://bio-research.ai/sanofi-licenses-jak-rock-inhibitor-from-chia-tai-tianqing-pharmaceutical-group-co-ltd-for-135m-upfront-and-up-to-1-395b-in-milestones/ 2026-03-04 https://bio-research.ai/fda-grants-fast-track-designation-for-genetic-medicine-in-bag3-associated-dilated-cardiomyopathy/ 2026-03-04 https://bio-research.ai/can-fite-biopharma-s-phase-iia-study-of-an-a3-adenosine-receptor-agonist-meets-primary-safety-endpoint-in-pancreatic-cancer/ 2026-03-04 https://bio-research.ai/blackstone-life-sciences-invests-400-million-in-teva-for-the-development-of-an-anti-tl1a-monoclonal-antibody/ 2026-03-03 https://bio-research.ai/ucb-and-antengene-partner-on-bispecific-antibody-for-autoimmune-diseases-antengene-receives-80m-upfront-and-over-1-1b-in-milestones-and-royalties/ 2026-03-03 https://bio-research.ai/moderna-to-pay-genevant-and-arbutus-950m-upfront-plus-1-3b-for-lnp-technology-license/ 2026-03-03 https://bio-research.ai/persevere-therapeutics-launches-with-seed-funding-and-plans-for-a-phase-1b-2a-trial-of-a-dual-c-myc-and-nf-b-inhibitor-in-ovarian-cancer/ 2026-03-03 https://bio-research.ai/insilico-medicine-and-liquid-ai-partner-to-create-a-new-ai-model-for-drug-discovery/ 2026-03-03 https://bio-research.ai/fda-approves-juxtapid-for-pediatric-hofh-patients-aged-2-and-older/ 2026-03-03 https://bio-research.ai/fda-grants-rare-hearing-on-vanda-s-hetlioz-jet-lag-application-first-in-over-40-years/ 2026-03-03 https://bio-research.ai/abbvie-s-skyrizi-sc-phase-3-study-shows-superiority-at-week-12-in-crohn-s-disease/ 2026-03-02 https://bio-research.ai/longbio-pharma-s-anti-ige-antibody-shows-superior-efficacy-in-comparison-to-omalizumab-in-202-patients-trial/ 2026-03-02 https://bio-research.ai/gyre-therapeutics-acquires-cullgen-inc-for-300m-in-all-stock-deal-creating-a-new-biopharma-company/ 2026-03-02 https://bio-research.ai/rallybio-candid-merger-backed-by-505m-financing-to-advance-t-cell-engager-therapies-for-autoimmune-diseases/ 2026-03-02 https://bio-research.ai/lynk-s-zemprocitinib-meets-all-phase-iii-endpoints-in-atopic-dermatitis-achieving-up-to-46-4-easi-75-improvement-vs-placebo/ 2026-03-02 https://bio-research.ai/deucrictibant-demonstrates-1-28-hour-median-onset-and-90-4-relief-by-12-hours-in-phase-3-hae-study/ 2026-03-02 https://bio-research.ai/roche-s-phase-iii-study-of-fenebrutinib-in-rms-reduced-annualized-relapse-rate-by-51/ 2026-03-02 https://bio-research.ai/innovent-biologics-announces-chinese-approval-for-jaypirca-to-treat-adult-cll-sll-patients/ 2026-03-01 https://bio-research.ai/rhythm-pharmaceuticals-phase-3-transcend-mc4r-agonist-trial-shows-18-8-bmi-reduction/ 2026-03-01 https://bio-research.ai/upstream-bio-s-anti-tslp-mab-phase-2-trial-shows-nps-reduction-of-1-95-in-crswnp/ 2026-03-01 https://bio-research.ai/blueprint-medicines-ayvakit-achieves-65-6-median-reduction-in-diarrhea-frequency-and-sustained-symptom-improvement-at-4-years-in-ism/ 2026-02-28 https://bio-research.ai/fda-approves-yuviwel-for-children-with-achondroplasia-and-open-epiphyses/ 2026-02-27 https://bio-research.ai/fda-approves-once-weekly-somapacitan-beco-injection-for-pediatric-growth-disorders/ 2026-02-27 https://bio-research.ai/wuxi-xdc-licenses-payload-linker-technology-to-earendil-labs-for-885m-deal/ 2026-02-27 https://bio-research.ai/onconic-therapeutics-parp-and-tankyrase-inhibitor-receives-orphan-drug-designation-for-sclc/ 2026-02-27 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-investigational-gene-therapy-for-rett-syndrome/ 2026-02-26 https://bio-research.ai/bayer-s-phase-iii-peace-3-trial-xofigo-with-enzalutamide-cut-death-risk-by-24/ 2026-02-26 https://bio-research.ai/systimmune-and-bristol-myers-squibb-announce-positive-phase-3-results-for-iza-bren-in-tnbc/ 2026-02-26 https://bio-research.ai/boehringer-ingelheim-licenses-exclusive-global-preclinical-small-molecule-program-from-sitryx-for-over-500m/ 2026-02-26 https://bio-research.ai/metagen-therapeutics-secures-3-52-billion-in-series-b-funding-for-microbiota-drug-development/ 2026-02-26 https://bio-research.ai/asahi-kasei-acquires-aicuris-anti-infective-cures-ag-for-780m-expanding-veloxis-pharmaceuticals-platform/ 2026-02-26 https://bio-research.ai/breezebio-secures-60-million-in-series-b-financing-to-advance-therapeutic-programs-and-expand-its-delivery-platform/ 2026-02-25 https://bio-research.ai/merck-s-dor-isl-phase-3-trials-show-non-inferiority-at-week-48-in-hiv-1-patients/ 2026-02-25 https://bio-research.ai/novo-nordisk-and-vivtex-corporation-partner-for-oral-drug-delivery-technologies-in-a-2-1b-deal/ 2026-02-25 https://bio-research.ai/gsk-acquires-35pharma-and-its-activin-signalling-inhibitor-for-950m/ 2026-02-25 https://bio-research.ai/slate-medicines-secures-130-million-to-advance-anti-pacap-monoclonal-antibody-for-migraine/ 2026-02-24 https://bio-research.ai/turbine-secures-25-million-series-b-financing-expands-virtual-cell-platform-and-immunology-partnership/ 2026-02-24 https://bio-research.ai/cambrian-bio-secures-30-8-million-arpa-h-funding-for-next-generation-mtorc1-inhibitors/ 2026-02-24 https://bio-research.ai/fda-grants-fast-track-designation-to-miniprotein-radioconjugate-for-urothelial-cancer/ 2026-02-24 https://bio-research.ai/linnaeus-therapeutics-secures-up-to-22m-from-arpa-h-to-advance-small-molecule-for-healthspan-preservation/ 2026-02-24 https://bio-research.ai/cadrenal-therapeutics-cad-1005-phase-2-trial-shows-25-reduction-in-thrombosis-in-hit-strengthening-phase-3-path/ 2026-02-24 https://bio-research.ai/palvella-therapeutics-phase-3-study-of-rapamycin-gel-for-microcystic-lymphatic-malformations-met-primary-endpoint-p-0-001/ 2026-02-24 https://bio-research.ai/protara-therapeutics-reports-phase-2-65-7-complete-response-rates-in-bladder-cancer/ 2026-02-23 https://bio-research.ai/fda-grants-accelerated-approval-to-loargys-for-hyperargininemia-in-arg1-d-patients/ 2026-02-23 https://bio-research.ai/gossamer-bio-s-phase-3-prosera-study-of-seralutinib-in-pah-misses-prespecified-0-025-threshold-despite-13-3m-6mwd-gain/ 2026-02-23 https://bio-research.ai/novo-nordisk-s-cagrisema-phase-3-trial-shows-23-0-weight-loss/ 2026-02-23 https://bio-research.ai/frontier-biotechnologies-licenses-two-sirna-products-to-gsk-for-40m-upfront-up-to-963m-in-milestones/ 2026-02-23 https://bio-research.ai/gilead-acquires-arcellx-for-7-8b-gaining-full-control-of-an-anti-bcma-car-t-cell-therapy/ 2026-02-23 https://bio-research.ai/harbour-biomed-licenses-bispecific-antibody-to-solstice-oncology-for-105m-upfront-1-1b-in-milestones/ 2026-02-23 https://bio-research.ai/johnson-johnson-tremfya-study-shows-80-8-clinical-remission-at-week-140/ 2026-02-21 https://bio-research.ai/cdt-equity-inc-invests-115m-in-sarborg-limited-acquiring-20-stake-to-deepen-ai-collaboration/ 2026-02-20 https://bio-research.ai/fda-approves-calquence-plus-venetoclax-as-first-all-oral-fixed-duration-regimen-for-first-line-cll/ 2026-02-20 https://bio-research.ai/takeda-s-vedolizumab-iv-phase-3-kepler-trial-47-3-pediatric-ulcerative-colitis-patients-achieve-remission-at-54-weeks/ 2026-02-19 https://bio-research.ai/fda-grants-fast-track-designation-for-anti-cd36-monoclonal-antibody-in-hepatocellular-carcinoma/ 2026-02-19 https://bio-research.ai/altesa-biosciences-secures-75-million-for-phase-2b-trial-of-rhinovirus-therapeutic-in-copd-patients/ 2026-02-19 https://bio-research.ai/merck-s-enflonsia-shows-consistent-safety-in-children-under-two-during-second-rsv-season/ 2026-02-19 https://bio-research.ai/starget-pharma-secures-18m-series-a-to-advance-sstr3-targeted-theranostic-pipeline/ 2026-02-18 https://bio-research.ai/moleculin-biotech-s-phase-2b-3-trial-for-aml-shows-40-complete-remission-rate/ 2026-02-18 https://bio-research.ai/sensei-biotherapeutics-acquires-faeth-therapeutics-for-piktor-secures-200m-financing/ 2026-02-18 https://bio-research.ai/novartis-and-unnatural-products-partner-on-an-ai-enhanced-macrocycle-platform-program-for-up-to-1-8b/ 2026-02-18 https://bio-research.ai/korsana-biosciences-launches-with-175-million-to-develop-neurodegenerative-disease-therapies/ 2026-02-18 https://bio-research.ai/eli-lilly-s-taltz-and-zepbound-combination-achieves-40-higher-pasi-100-at-36-weeks/ 2026-02-18 https://bio-research.ai/novartis-oral-btk-inhibitor-phase-iii-remind-trial-met-primary-endpoint-at-week-12/ 2026-02-18 https://bio-research.ai/accrufer-is-the-first-prescription-oral-iron-treatment-approved-by-the-fda-for-iron-deficiency-in-children/ 2026-02-17 https://bio-research.ai/european-commission-approves-myqorzo-for-symptomatic-obstructive-hypertrophic-cardiomyopathy/ 2026-02-17 https://bio-research.ai/european-commission-approves-wegovy-7-2-mg-once-weekly-maintenance-dose-for-obesity/ 2026-02-17 https://bio-research.ai/fda-approves-wakix-for-cataplexy-in-pediatric-narcolepsy-patients-6-years-and-older/ 2026-02-17 https://bio-research.ai/bostongene-and-daiichi-sankyo-collaborate-on-ai-driven-analytics-for-antibody-drug-conjugate-development/ 2026-02-17 https://bio-research.ai/ocular-therapeutix-s-axpaxli-phase-3-trial-shows-74-1-vision-maintenance-in-wet-amd/ 2026-02-17 https://bio-research.ai/twist-bioscience-and-invenra-inc-sign-a-licensing-agreement-for-a-bispecific-antibody-platform-service/ 2026-02-17 https://bio-research.ai/european-commission-approves-exdensur-for-severe-asthma-and-severe-chronic-rhinosinusitis/ 2026-02-17 https://bio-research.ai/alchemedicine-and-asahi-kasei-pharma-enter-exclusive-global-license-agreement-for-hisap-compounds/ 2026-02-17 https://bio-research.ai/eli-lilly-s-ret-kinase-inhibitor-met-primary-endpoint-for-event-free-survival-in-phase-3-nsclc-adjuvant-trial/ 2026-02-16 https://bio-research.ai/clarity-pharmaceuticals-cu-sar-bispsma-identified-significantly-more-lesions-than-ga-psma-11/ 2026-02-16 https://bio-research.ai/genentech-s-phase-iii-majesty-study-of-gazyva-met-primary-endpoint-at-two-years/ 2026-02-15 https://bio-research.ai/fda-issues-complete-response-letter-for-bitopertin-nda-for-erythropoietic-protoporphyria/ 2026-02-13 https://bio-research.ai/european-commission-approves-uplizna-for-generalized-myasthenia-gravis/ 2026-02-13 https://bio-research.ai/immunic-secures-400-million-to-complete-phase-3-ensure-trials-for-vidofludimus-calcium/ 2026-02-13 https://bio-research.ai/novartis-vanrafia-shows-2-39-ml-min-1-73m-egfr-difference-in-igan-phase-3-study/ 2026-02-13 https://bio-research.ai/hanchorbio-received-orphan-drug-designation-for-sirp-igg4-fc-fusion-protein-in-gastric-cancer/ 2026-02-13 https://bio-research.ai/bridgebio-pharma-s-oral-fgfr1-3-inhibitor-met-primary-endpoint-in-phase-3-achondroplasia-study/ 2026-02-12 https://bio-research.ai/nektar-therapeutics-announces-pricing-of-400-million-public-offering-for-drug-candidate-support/ 2026-02-11 https://bio-research.ai/upstream-bio-s-verekitug-phase-2-trial-shows-reduced-asthma-exacerbation-rate-in-adults/ 2026-02-11 https://bio-research.ai/fda-approves-keytruda-and-keytruda-qlex-for-pd-l1-platinum-resistant-ovarian-carcinoma/ 2026-02-11 https://bio-research.ai/madrigal-pharmaceuticals-licenses-six-preclinical-sirna-programs-from-ribo-life-science-and-ribocure-pharmaceuticals-for-60m-upfront-and-up-to-4-4b-in-milestones/ 2026-02-11 https://bio-research.ai/olix-and-key2brain-collaborate-on-cns-sirna-conjugates-using-a-bbb-shuttle-technology/ 2026-02-10 https://bio-research.ai/biocodex-acquires-global-rights-for-batten-1-and-north-american-rights-for-tx01-from-thx-pharma/ 2026-02-10 https://bio-research.ai/evommune-s-phase-2a-trial-of-an-oral-small-molecule-shows-easi-reductions-at-weeks-4-8-and-12/ 2026-02-10 https://bio-research.ai/iliad-biotechnologies-secures-115-million-in-series-b-financing-for-pertussis-vaccine-phase-3-development/ 2026-02-10 https://bio-research.ai/hengrui-pharma-s-oral-ribupatide-shows-12-1-weight-reduction-at-26-weeks-in-phase-2-obesity-trial/ 2026-02-10 https://bio-research.ai/abbisko-therapeutics-fgf19-inhibitor-received-fda-fast-track-designation-for-hcc/ 2026-02-10 https://bio-research.ai/biofrontera-s-phase-3-trial-of-ameluz-pdt-shows-superior-lesion-clearance/ 2026-02-09 https://bio-research.ai/iambic-and-takeda-ink-ai-drug-discovery-collaboration-for-small-molecule-programs-worth-over-1-7b/ 2026-02-09 https://bio-research.ai/fda-grants-rmat-designation-to-krystal-biotech-s-gene-therapy-for-advanced-nsclc/ 2026-02-09 https://bio-research.ai/aerska-secures-39-million-in-series-a-financing-to-advance-antibody-oligo-conjugate-platform/ 2026-02-09 https://bio-research.ai/quantx-biosciences-raises-85-million-in-series-b-financing-to-advance-oral-small-molecule-inhibitors/ 2026-02-09 https://bio-research.ai/eli-lilly-and-company-acquires-orna-therapeutics-inc-for-up-to-2-4b-for-a-circular-rna-platform/ 2026-02-09 https://bio-research.ai/memo-therapeutics-partners-with-csl-for-recombinant-polyclonal-igg-technology-328m-plus-royalties/ 2026-02-09 https://bio-research.ai/sanofi-s-rilzabrutinib-receives-breakthrough-therapy-and-orphan-drug-designations-for-waiha/ 2026-02-09 https://bio-research.ai/claris-biotherapeutics-secures-93-5-million-for-recombinant-human-hgf-protein-in-lscd-trials/ 2026-02-09 https://bio-research.ai/innovent-biologics-and-eli-lilly-form-oncology-and-immunology-collaboration-with-350m-upfront/ 2026-02-08 https://bio-research.ai/genentech-s-fenebrutinib-meets-primary-endpoint-in-ppms-12-risk-reduction-versus-ocrevus/ 2026-02-07 https://bio-research.ai/akeso-s-bispecific-antibody-receives-breakthrough-therapy-designation-for-advanced-biliary-tract-cancer/ 2026-02-05 https://bio-research.ai/bayer-50mg-factor-xia-inhibitor-reduced-ischemic-stroke-by-26-percent-in-phase-3-trial/ 2026-02-05 https://bio-research.ai/angitia-biopharmaceuticals-secures-130-million-in-series-d-financing-for-clinical-development/ 2026-02-05 https://bio-research.ai/aicuris-phase-3-trial-of-pritelivir-shows-62-7-lesion-healing-rate/ 2026-02-05 https://bio-research.ai/eisai-and-henlius-partner-for-pd-1-inhibitor-in-japan-with-75m-upfront-and-313m-in-milestones/ 2026-02-05 https://bio-research.ai/alvotech-s-avt80-biosimilar-candidate-meets-all-primary-endpoints-in-pharmacokinetic-study/ 2026-02-05 https://bio-research.ai/hanmi-pharmaceutical-s-glucagon-analog-receives-u-s-fda-breakthrough-therapy-designation-for-chi/ 2026-02-05 https://bio-research.ai/everest-medicines-licenses-dual-targeting-polypeptide-from-shaanxi-micot-for-200m-upfront-1-04b-milestones/ 2026-02-05 https://bio-research.ai/pharmazz-s-tycamzzi-phase-iv-study-92-3-achieved-mrs-score-of-0-2-at-day-90/ 2026-02-04 https://bio-research.ai/biomica-licenses-microbiome-therapeutic-to-lishan-biotech-for-global-development/ 2026-02-04 https://bio-research.ai/cumberland-pharmaceuticals-oral-therapy-receives-fda-fast-track-designation-for-fatal-heart-condition-in-dmd/ 2026-02-04 https://bio-research.ai/third-arc-bio-inc-secures-52-million-series-a-extension-to-advance-immunology-inflammation-and-oncology-programs/ 2026-02-04 https://bio-research.ai/ucb-s-bimzelx-three-year-data-shows-40-1-resolution-of-inflammatory-lesions-in-hs/ 2026-02-04 https://bio-research.ai/pfizer-s-injectable-glp-1-receptor-agonist-shows-12-3-weight-loss-at-week-28/ 2026-02-03 https://bio-research.ai/zovegalisib-combined-with-fulvestrant-receives-fda-breakthrough-therapy-designation/ 2026-02-03 https://bio-research.ai/fda-issues-complete-response-letter-for-anifrolumab-s-bla-for-subcutaneous-sle-treatment/ 2026-02-03 https://bio-research.ai/accuredit-therapeutics-secures-75-million-in-series-a-financing-for-its-gene-editing-programs/ 2026-02-03 https://bio-research.ai/ultragenyx-announces-long-term-data-for-gene-therapy-in-sanfilippo-syndrome-type-a/ 2026-02-03 https://bio-research.ai/zonsen-peplib-biotech-inc-and-eli-lilly-and-company-partner-to-develop-novel-peptide-based-drug-candidates/ 2026-02-03 https://bio-research.ai/arcutis-biotherapeutics-zoryve-cream-0-05-shows-58-easi-75-at-week-4-in-infants-with-atopic-dermatitis/ 2026-02-02 https://bio-research.ai/skye-bioscience-s-phase-2a-trial-of-nimacimab-plus-semaglutide-shows-22-3-weight-loss/ 2026-02-02 https://bio-research.ai/aquestive-therapeutics-receives-fda-complete-response-letter-for-epinephrine-sublingual-film/ 2026-02-02 https://bio-research.ai/sanegenebio-licenses-rnai-program-to-genentech-for-200m-upfront-1-5b-in-milestones/ 2026-02-02 https://bio-research.ai/biorce-secures-43-8-million-in-series-a-funding-to-expand-ai-platform-for-clinical-trial-preparation/ 2026-02-02 https://bio-research.ai/yoltech-therapeutics-gene-editing-therapy-received-fda-rmat-designation-for-primary-hyperoxaluria-type-1/ 2026-02-02 https://bio-research.ai/sanofi-s-venglustat-met-all-primary-endpoints-in-type-3-gaucher-disease-phase-3-study/ 2026-02-02 https://bio-research.ai/ipsen-and-origami-therapeutics-enter-global-collaboration-and-option-agreement-for-protein-degrader-program/ 2026-01-30 https://bio-research.ai/promis-neurosciences-announces-private-placement-financing-to-fund-alzheimer-s-disease-study/ 2026-01-30 https://bio-research.ai/hebei-senlang-s-cd7-car-t-receives-cde-breakthrough-designation-for-t-lymphoblastic-lymphoma-leukemia/ 2026-01-30 https://bio-research.ai/astrazeneca-and-cspc-pharmaceuticals-form-a-strategic-collaboration-for-1-2b-for-eight-obesity-and-type-2-diabetes-therapies/ 2026-01-30 https://bio-research.ai/vaxcyte-announces-pricing-of-public-offering-of-common-stock/ 2026-01-29 https://bio-research.ai/quince-therapeutics-phase-3-ataxia-telangiectasia-trial-did-not-achieve-statistical-significance/ 2026-01-29 https://bio-research.ai/formation-bio-acquires-global-rights-to-mir-124-activator-from-jiangsu-chia-tai-feng-hai-for-up-to-500m/ 2026-01-29 https://bio-research.ai/breakthru-medicine-completes-series-a-financing-round-to-develop-therapeutic-modalities-for-cancer/ 2026-01-29 https://bio-research.ai/ascletis-pharma-announces-phase-3-results-for-denifanstat-in-240-patients-with-acne-vulgaris/ 2026-01-29 https://bio-research.ai/repertoire-immune-medicines-and-eli-lilly-collaborate-on-autoimmune-therapies-repertoire-receives-85m-upfront/ 2026-01-29 https://bio-research.ai/tenpoint-therapeutics-raises-85-million-in-series-b-preferred-stock-financing/ 2026-01-28 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-biib059-for-cutaneous-lupus-erythematosus/ 2026-01-28 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-car-t-cell-therapy-for-relapsed-refractory-al-amyloidosis/ 2026-01-28 https://bio-research.ai/seamless-therapeutics-and-eli-lilly-partner-for-hearing-loss-treatments-in-a-deal-valued-over-1-12b/ 2026-01-28 https://bio-research.ai/sensorion-secures-60-million-in-reserved-offering-sanofi-contributes-20-million/ 2026-01-28 https://bio-research.ai/boehringer-ingelheim-s-phase-ii-trial-of-a-trpc6-inhibitor-shows-40-proteinuria-reduction/ 2026-01-28 https://bio-research.ai/trex-bio-raises-50-million-to-advance-tnfr2-agonist-in-phase-1a-b-trial-for-inflammatory-diseases/ 2026-01-27 https://bio-research.ai/simcere-pharmaceutical-and-boehringer-ingelheim-partner-on-bispecific-antibody-for-inflammatory-bowel-disease/ 2026-01-27 https://bio-research.ai/insilico-medicine-and-qilu-pharmaceutical-collaborate-on-small-molecule-inhibitors-for-cardiovascular-and-metabolic-diseases-with-the-deal-valued-over-hk-931m/ 2026-01-27 https://bio-research.ai/roche-s-phase-2-trial-of-ct-388-achieved-22-5-weight-loss-at-48-weeks/ 2026-01-27 https://bio-research.ai/russia-s-ministry-of-health-approves-a-domestically-developed-hpv-vaccine-for-children-aged-9-17-based-on-phase-iii-trial-results/ 2026-01-26 https://bio-research.ai/innovent-biologics-tri-specific-antibody-receives-fast-track-designation-for-multiple-myeloma/ 2026-01-26 https://bio-research.ai/sarepta-therapeutics-embark-study-shows-three-year-results-for-elevidys-in-dmd-patients/ 2026-01-26 https://bio-research.ai/1stbio-therapeutics-secures-series-d-financing-for-hpk1-inhibitor-clinical-development/ 2026-01-26 https://bio-research.ai/gsk-s-arexvy-receives-european-commission-approval-for-adults-aged-18-and-older/ 2026-01-26 https://bio-research.ai/huahui-health-receives-conditional-nmpa-approval-for-libevitug-injection-an-adult-chronic-hepatitis-d-virus-treatment/ 2026-01-24 https://bio-research.ai/bausch-health-global-phase-3-red-c-program-did-not-meet-primary-endpoint/ 2026-01-23 https://bio-research.ai/bavarian-nordic-and-eurofarma-sign-exclusive-distribution-agreement-for-chikungunya-vaccine-in-brazil/ 2026-01-23 https://bio-research.ai/sanofi-s-amlitelimab-phase-3-atopic-dermatitis-trial-meets-endpoints/ 2026-01-23 https://bio-research.ai/aribio-licenses-its-pde-5-inhibitor-technology-to-restari-llc-for-230m-plus-royalties/ 2026-01-23 https://bio-research.ai/mendra-launches-with-82-million-in-series-a-financing-to-acquire-and-develop-rare-disease-therapeutics/ 2026-01-22 https://bio-research.ai/corcept-therapeutics-phase-3-rosella-trial-shows-35-death-risk-reduction-in-ovarian-cancer/ 2026-01-22 https://bio-research.ai/corxel-pharmaceuticals-secures-287-million-for-oral-glp-1-agonist-phase-2-trials/ 2026-01-22 https://bio-research.ai/janux-therapeutics-and-bristol-myers-squibb-enter-exclusive-global-license-agreement-worth-up-to-850m/ 2026-01-22 https://bio-research.ai/bayer-and-bluerock-s-ipsc-derived-cell-therapy-receives-orphan-drug-designation-for-retinitis-pigmentosa/ 2026-01-22 https://bio-research.ai/bioage-prices-115-million-offering-to-advance-bge-102-and-metabolic-aging-programs/ 2026-01-21 https://bio-research.ai/corvus-prices-175-million-offering-to-fund-phase-3-t-cell-lymphoma-trial/ 2026-01-21 https://bio-research.ai/intrabio-s-levacetylleucine-significantly-improves-neurological-function-in-phase-iii-a-t-trial/ 2026-01-21 https://bio-research.ai/european-commission-authorizes-aqneursa-for-niemann-pick-type-c-disease-in-eu-adults-and-children/ 2026-01-21 https://bio-research.ai/scynexis-s-triterpenoid-antifungal-received-fda-qidp-and-fast-track-designations-for-invasive-candidiasis/ 2026-01-21 https://bio-research.ai/isomorphic-labs-and-johnson-johnson-s-janssen-biotech-enter-ai-first-drug-design-collaboration/ 2026-01-20 https://bio-research.ai/tanabe-pharma-america-s-phase-3-inspire-study-meets-primary-endpoint-in-epp-and-xlp/ 2026-01-20 https://bio-research.ai/think-bioscience-secures-55-million-in-series-a-funding-for-small-molecule-pipeline-and-synthetic-biology-platform/ 2026-01-20 https://bio-research.ai/reunion-neuroscience-s-phase-2-trial-met-primary-endpoint-with-23-0-point-madrs-reduction/ 2026-01-20 https://bio-research.ai/novavax-licenses-matrix-m-adjuvant-to-pfizer-for-30m-upfront-with-potential-for-500m-in-milestones/ 2026-01-20 https://bio-research.ai/moderna-s-adjuvant-neoantigen-mrna-vaccine-combination-with-keytruda-reduces-melanoma-recurrence-by-49/ 2026-01-20 https://bio-research.ai/corvus-pharmaceuticals-s-soquelitinib-phase-1-trial-in-atopic-dermatitis-shows-consistent-easi-reduction-at-day-56/ 2026-01-20 https://bio-research.ai/eqt-life-sciences-co-leads-series-b-financing-for-exciva-s-alzheimer-s-agitation-therapy-phase-2-trial/ 2026-01-20 https://bio-research.ai/gsk-acquires-rapt-therapeutics-for-2-2b-gaining-global-rights-to-an-anti-ige-antibody/ 2026-01-20 https://bio-research.ai/alteogen-licenses-hybrozyme-technology-to-tesaro-a-gsk-subsidiary-for-20m-upfront-265m-in-milestones/ 2026-01-20 https://bio-research.ai/iregene-therapeutics-cell-therapy-receives-rmat-designation-for-parkinson-s-disease-treatment/ 2026-01-19 https://bio-research.ai/nxera-pharma-s-daridorexant-50-mg-phase-3-study-meets-sleep-endpoints-in-korea/ 2026-01-19 https://bio-research.ai/astrazeneca-acquires-abelzeta-pharma-s-50-share-of-china-rights-for-autologous-gpc3-targeting-car-t-therapy-for-up-to-630m/ 2026-01-18 https://bio-research.ai/dbv-technologies-secures-166-7-million-to-fund-operations-and-support-the-launch-of-viaskin-peanut/ 2026-01-16 https://bio-research.ai/fda-grants-orphan-drug-designation-to-z-endoxifen-for-duchenne-muscular-dystrophy/ 2026-01-16 https://bio-research.ai/johnson-johnson-caplyta-shows-65-remission-in-mdd-at-six-weeks/ 2026-01-16 https://bio-research.ai/interax-biotech-and-alveus-therapeutics-partner-on-small-molecule-for-metabolic-disease/ 2026-01-15 https://bio-research.ai/unloxcyt-cosibelimab-ipdl-available-in-the-u-s-for-adults-with-metastatic-or-locally-advanced-cscc/ 2026-01-15 https://bio-research.ai/ocugen-s-gene-therapy-phase-2-trial-shows-46-lesion-growth-reduction-in-geographic-atrophy/ 2026-01-15 https://bio-research.ai/china-approves-sanofi-s-myqorzo-for-ohcm-and-redemplo-for-familial-chylomicronemia-syndrome/ 2026-01-15 https://bio-research.ai/santhera-pharmaceuticals-receives-swissmedic-approval-for-agamree-to-treat-duchenne-muscular-dystrophy/ 2026-01-15 https://bio-research.ai/johnson-johnson-tecvayli-shows-71-reduction-in-disease-progression-or-death/ 2026-01-14 https://bio-research.ai/alfasigma-partners-with-innovative-molecules-for-exclusive-global-rights-to-adibelivir-s-parenteral-formulation/ 2026-01-14 https://bio-research.ai/caldera-therapeutics-launches-backed-by-112-5-million-begins-phase-1-trial-of-first-in-class-ibd-bispecific-cld-423/ 2026-01-14 https://bio-research.ai/gan-lee-pharmaceuticals-insulin-glargine-injection-approved-for-diabetes-treatment-in-europe/ 2026-01-14 https://bio-research.ai/genethon-licenses-aav-based-gene-therapy-component-to-askbio-a-subsidiary-of-bayer-ag/ 2026-01-14 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-for-bcl-2-inhibitor-in-aml/ 2026-01-13 https://bio-research.ai/fda-approves-zycubo-for-pediatric-menkes-disease-improving-survival/ 2026-01-13 https://bio-research.ai/immunitybio-s-anktiva-plus-checkpoint-inhibitor-therapy-shows-immune-restoration-in-151-nsclc-patients/ 2026-01-13 https://bio-research.ai/fda-extends-review-for-travere-therapeutics-snda-for-filspariin-fsgs/ 2026-01-13 https://bio-research.ai/xtl-biopharmaceuticals-acquires-85-of-beyond-air-s-neuronos-subsidiary-for-1m-cash-and-up-to-32-5m-milestones/ 2026-01-13 https://bio-research.ai/bayer-acquires-two-investigational-pet-and-spect-agents-from-attralus-inc/ 2026-01-13 https://bio-research.ai/oricell-therapeutics-secures-70m-for-car-t-cell-therapy-clinical-development-and-expansion/ 2026-01-12 https://bio-research.ai/nuvation-bio-and-eisai-partner-for-ros1-inhibitor-eisai-gets-ex-us-rights/ 2026-01-12 https://bio-research.ai/abbvie-and-remegen-form-licensing-agreement-for-pd-1-vegf-bispecific-antibody-for-650m-upfront/ 2026-01-12 https://bio-research.ai/encoded-therapeutics-aav9-based-gene-regulation-therapy-granted-breakthrough-therapy-designation-for-scn1a-dravet-syndrome/ 2026-01-12 https://bio-research.ai/fda-grants-rmat-designation-to-car-t-cell-therapy-for-advanced-hepatocellular-carcinoma/ 2026-01-12 https://bio-research.ai/lynk-pharmaceuticals-phase-iii-trial-of-zemprocitinib-in-ra-meets-primary-secondary-endpoints/ 2026-01-12 https://bio-research.ai/bristol-myers-squibb-camzyos-reduces-valsalva-left-ventricular-outflow-tract-gradient-at-week-28/ 2026-01-12 https://bio-research.ai/european-commission-approves-teizeild-for-delaying-stage-3-type-1-diabetes-onset/ 2026-01-12 https://bio-research.ai/royalty-pharma-to-invest-up-to-500m-in-teva-s-anti-il-15-antibody-for-vitiligo-and-celiac-disease/ 2026-01-11 https://bio-research.ai/kinaset-therapeutics-secures-103-million-series-b-financing-to-advance-inhaled-pan-jak-inhibitor-into-phase-2-studies/ 2026-01-10 https://bio-research.ai/madrigal-pharmaceuticals-licenses-oral-dgat-2-inhibitor-and-mash-assets-from-pfizer-for-50m/ 2026-01-09 https://bio-research.ai/medilink-and-roche-partner-on-a-b7h3-targeting-adc-with-medilink-receiving-570m-upfront/ 2026-01-09 https://bio-research.ai/ollin-biosciences-oln324-4mg-results-in-90-absence-of-dme-at-12-weeks/ 2026-01-08 https://bio-research.ai/noetik-and-gsk-collaborate-on-virtual-cell-models-for-nsclc-and-colorectal-cancer-with-a-50m-upfront-payment/ 2026-01-08 https://bio-research.ai/sustained-therapeutics-phase-2-trial-of-sustained-release-drug-shows-pain-reduction/ 2026-01-08 https://bio-research.ai/eli-lilly-s-together-psa-trial-achieved-50-acr50-and-10-weight-reduction/ 2026-01-08 https://bio-research.ai/beacon-therapeutics-raises-over-75-million-in-series-c-financing-to-advance-gene-therapy-for-x-linked-retinitis-pigmentosa/ 2026-01-08 https://bio-research.ai/parabilis-medicines-secures-305-million-to-advance-clinical-development-of-zolucatetide/ 2026-01-08 https://bio-research.ai/foresee-pharmaceuticals-licenses-mmp-12-inhibitor-programs-to-primevera-therapeutics-for-10m-upfront/ 2026-01-08 https://bio-research.ai/vanda-pharmaceuticals-supplemental-new-drug-application-for-hetlioz-for-jet-lag-disorder-not-approved-by-fda/ 2026-01-08 https://bio-research.ai/eli-lilly-and-company-to-acquire-ventyx-biosciences-inc-for-1-2b-in-all-cash-transaction/ 2026-01-07 https://bio-research.ai/octapharma-usa-receives-fda-approval-for-2-gram-presentation-of-fibryga-for-acquired-fibrinogen-deficiency/ 2026-01-07 https://bio-research.ai/indupro-and-eli-lilly-partner-for-up-to-950m-to-discover-oncology-bispecific-and-multispecific-antibodies/ 2026-01-07 https://bio-research.ai/poplar-therapeutics-launches-with-50-million-series-a-to-develop-anti-ige-therapy-for-food-allergy/ 2026-01-07 https://bio-research.ai/rakuten-medical-secures-funding-for-global-phase-3-trial-of-photoimmunotherapy-in-head-and-neck-cancer/ 2026-01-07 https://bio-research.ai/disco-pharmaceuticals-licenses-novel-cancer-therapeutic-candidates-to-amgen-in-a-deal-worth-up-to-618m/ 2026-01-07 https://bio-research.ai/rezolute-s-phase-3-sunrize-study-for-congenital-hyperinsulinism-missed-primary-and-key-secondary-endpoints/ 2026-01-07 https://bio-research.ai/european-commission-approves-shingrix-in-prefilled-syringe/ 2026-01-07 https://bio-research.ai/gsk-announces-bepirovirsen-meets-primary-endpoint-in-two-phase-iii-trials/ 2026-01-07 https://bio-research.ai/alumis-tyk2-inhibitor-meets-all-primary-and-secondary-endpoints-in-phase-iii-plaque-psoriasis-trials/ 2026-01-07 https://bio-research.ai/eli-lilly-and-nimbus-therapeutics-collaborate-on-an-oral-obesity-therapeutic-for-up-to-1-3b/ 2026-01-06 https://bio-research.ai/amgen-acquires-dark-blue-therapeutics-for-global-rights-to-an-mllt1-3-inhibitor-valued-up-to-840m/ 2026-01-06 https://bio-research.ai/gilgamesh-pharma-s-oral-nmda-receptor-antagonist-shows-6-3-point-madrs-reduction/ 2026-01-06 https://bio-research.ai/cartography-biosciences-and-pfizer-collaborate-to-discover-tumor-selective-antigens-for-65m-upfront-and-over-850m-total/ 2026-01-06 https://bio-research.ai/china-s-nmpa-approves-augtyro-for-ntrk-gene-fusion-positive-solid-tumors/ 2026-01-06 https://bio-research.ai/lupin-secures-exclusive-license-from-gan-lee-pharmaceuticals-for-a-bi-weekly-glp-1ra-in-india/ 2026-01-06 https://bio-research.ai/astrazeneca-s-saphnelo-reduces-sle-disease-activity-by-56-2-in-phase-iii-tulip-sc-trial/ 2026-01-06 https://bio-research.ai/china-approves-azstarys-for-adhd-treatment-in-patients-aged-6-years-and-older/ 2026-01-06 https://bio-research.ai/aribio-fosun-pharma-and-newcopharma-partner-for-alzheimer-s-treatment-in-asean-countries/ 2026-01-06 https://bio-research.ai/crinetics-atumelnant-achieves-67-androstenedione-reduction-in-phase-2-cohort-4-cah-study/ 2026-01-05 https://bio-research.ai/incyte-s-tafasitamab-plus-lenalidomide-and-r-chop-meets-primary-pfs-endpoint-in-phase-3-frontmind-trial-for-first-line-dlbcl/ 2026-01-05 https://bio-research.ai/neumora-therapeutics-phase-1b-study-shows-15-7-reduction-on-mean-cmai-total-score/ 2026-01-05 https://bio-research.ai/sanofi-and-earendil-labs-collaborate-on-bispecific-candidates-for-autoimmune-and-inflammatory-diseases-for-up-to-2-56b/ 2026-01-05 https://bio-research.ai/china-s-nmpa-approves-nucala-for-copd-in-adults-with-elevated-eosinophils/ 2026-01-05 https://bio-research.ai/bioinvent-international-s-phase-2a-study-of-anti-tnfr2-antibody-plus-pembrolizumab-shows-24-orr-in-ovarian-cancer/ 2026-01-05 https://bio-research.ai/fda-accepts-tzield-for-priority-review-to-expand-age-indication-for-delaying-stage-3-type-1-diabetes-onset/ 2026-01-05 https://bio-research.ai/insilico-medicine-and-servier-collaborate-on-oncology-therapies-a-deal-worth-up-to-888m/ 2026-01-04 https://bio-research.ai/suzhou-xueji-biotechnology-secures-b1-round-financing-to-advance-in-vitro-platelet-lineage-regeneration-and-drug-development/ 2026-01-01 https://bio-research.ai/fda-issues-complete-response-letter-for-ons-5010-s-bla-resubmission/ 2025-12-31 https://bio-research.ai/fda-issues-complete-response-letter-for-corcept-s-gr-modulator-for-hypercortisolism-related-hypertension/ 2025-12-31 https://bio-research.ai/bioatla-and-inversagen-ai-llc-secure-a-40m-spv-transaction-for-an-antibody-drug-conjugate/ 2025-12-31 https://bio-research.ai/vanda-pharmaceuticals-announces-fda-approval-of-nereus-for-prevention-of-vomiting-induced-by-motion/ 2025-12-30 https://bio-research.ai/vilobelimab-demonstrates-significant-ulcer-volume-and-area-reduction-in-post-hoc-phase-3-analyses/ 2025-12-30 https://bio-research.ai/royalty-pharma-acquires-final-portion-of-ptc-therapeutics-evrysdi-royalty-from-roche-for-240m-upfront/ 2025-12-29 https://bio-research.ai/mereo-biopharma-group-s-phase-3-setrusumab-studies-did-not-meet-primary-endpoint/ 2025-12-29 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-for-ulixacaltamide-for-essential-tremor/ 2025-12-29 https://bio-research.ai/aosaikang-pharmaceutical-and-adlai-nortye-collaborate-on-pan-ras-on-molecular-glue-inhibitor/ 2025-12-29 https://bio-research.ai/harbour-biomed-and-yantai-lannacheng-biotechnology-collaborate-on-next-generation-rdcs/ 2025-12-29 https://bio-research.ai/surv-biopharma-raises-670-million-more-in-series-b-supports-oncolytic-adenovirus-program/ 2025-12-28 https://bio-research.ai/shenzhen-beimei-pharmaceutical-and-deva-holding-a-s-secure-nmpa-approval-for-posaconazole-oral-suspension/ 2025-12-26 https://bio-research.ai/hengrui-s-cldn18-2-targeting-adc-receives-breakthrough-therapy-designation-in-china/ 2025-12-26 https://bio-research.ai/alteogen-signs-option-agreement-with-global-pharma-for-subcutaneous-formulation-product-including-option-fee-and-technology-transfer/ 2025-12-26 https://bio-research.ai/maxvax-biotechnology-secures-d-round-funding-for-recombinant-herpes-zoster-and-rsv-vaccines/ 2025-12-25 https://bio-research.ai/omeros-yartemlea-wins-fda-approval-backed-by-strong-survival-and-response-data-in-ta-tma/ 2025-12-24 https://bio-research.ai/biohaven-s-phase-2-study-of-an-investigational-agent-for-major-depressive-disorder-did-not-meet-its-primary-endpoint/ 2025-12-24 https://bio-research.ai/foresee-pharmaceuticals-phase-3-trial-shows-94-of-patients-achieved-lh-suppression-at-week-24/ 2025-12-24 https://bio-research.ai/gilead-sciences-acquires-repare-therapeutics-polymerase-theta-atpase-inhibitor-for-up-to-30m/ 2025-12-24 https://bio-research.ai/sanofi-acquires-dynavax-technologies-for-2-2b-expanding-adult-immunization-with-heplisav-b/ 2025-12-24 https://bio-research.ai/fda-issues-complete-response-letter-for-bruton-s-tyrosine-kinase-inhibitor-in-multiple-sclerosis/ 2025-12-24 https://bio-research.ai/fda-approves-aqvesme-for-anemia-in-adults-with-alpha-or-beta-thalassemia/ 2025-12-23 https://bio-research.ai/vyriad-secures-85m-to-advance-clinical-development-of-an-in-vivo-car-t-cell-therapy-candidate/ 2025-12-23 https://bio-research.ai/seismic-pharmaceutical-holdings-acquires-windtree-therapeutics-cardiovascular-drug-candidates/ 2025-12-23 https://bio-research.ai/lexaria-phase-1b-oral-semaglutide-study-shows-55-fewer-gi-side-effects-than-rybelsus/ 2025-12-23 https://bio-research.ai/european-commission-approves-btk-inhibitor-wayrilz-for-immune-thrombocytopenia-in-adults/ 2025-12-23 https://bio-research.ai/hengrui-pharmaceuticals-jak-inhibitor-ointment-0-5-and-1-phase-iii-results-for-atopic-dermatitis/ 2025-12-23 https://bio-research.ai/fda-approves-wegovy-oral-semaglutide-25-mg-for-weight-management-and-cardiovascular-risk-reduction/ 2025-12-22 https://bio-research.ai/neurocrine-biosciences-valbenazine-phase-3-study-in-dyskinetic-cerebral-palsy-did-not-meet-endpoints/ 2025-12-22 https://bio-research.ai/fda-approves-two-denosumab-biosimilars-referencing-prolia-and-xgeva/ 2025-12-22 https://bio-research.ai/rectify-pharmaceuticals-and-boehringer-ingelheim-partner-on-oral-small-molecules-for-chronic-kidney-disease/ 2025-12-22 https://bio-research.ai/independent-unblinded-review-identifies-separation-from-placebo-in-halneuron-phase-2b-pain-study/ 2025-12-22 https://bio-research.ai/gilead-sciences-licenses-hsv-helicase-primase-inhibitor-programs-from-assembly-bio-for-35m-upfront/ 2025-12-22 https://bio-research.ai/promontory-therapeutics-phase-2-study-of-pt-112-for-recurrent-thymoma-shows-30-recist-partial-responses/ 2025-12-22 https://bio-research.ai/enhertu-receives-breakthrough-therapy-designation-for-her2-positive-early-breast-cancer/ 2025-12-22 https://bio-research.ai/astrazeneca-s-latify-phase-iii-trial-for-nsclc-did-not-meet-primary-overall-survival-endpoint/ 2025-12-22 https://bio-research.ai/chugai-pharmaceutical-obtains-approval-for-tecentriq-for-unresectable-thymic-carcinoma/ 2025-12-22 https://bio-research.ai/senju-pharmaceutical-receives-approval-for-trpv1-antagonist-ophthalmic-suspension-for-dry-eye-treatment/ 2025-12-22 https://bio-research.ai/ipsen-acquires-ex-china-rights-to-simcere-zaiming-s-adc-for-up-to-1-06b/ 2025-12-22 https://bio-research.ai/windward-bio-and-qyuns-therapeutics-ink-licensing-agreement-for-bispecific-antibody-worth-up-to-700m/ 2025-12-21 https://bio-research.ai/jacobio-pharma-and-astrazeneca-partner-on-pan-kras-inhibitor-jacobio-receives-100m-upfront-1-915b-milestones/ 2025-12-21 https://bio-research.ai/obi-pharma-licenses-global-rights-for-a-glycoprotein-targeting-adc-to-tegmine-therapeutics/ 2025-12-19 https://bio-research.ai/takeda-s-zasocitinib-phase-3-studies-met-all-primary-and-secondary-endpoints/ 2025-12-18 https://bio-research.ai/eli-lilly-s-orforglipron-achieves-primary-endpoint-for-weight-maintenance-in-phase-3-trial/ 2025-12-18 https://bio-research.ai/cepi-invests-up-to-54-3m-in-moderna-for-mrna-based-h5-influenza-vaccine-phase-3-trial/ 2025-12-18 https://bio-research.ai/syremis-therapeutics-launches-with-165-million-series-a-financing-to-advance-pipeline/ 2025-12-18 https://bio-research.ai/fda-grants-fast-track-designation-to-crc-t-cell-engager-phase-1-trial-planned-for-2026/ 2025-12-18 https://bio-research.ai/camp4-therapeutics-and-gsk-partner-for-aso-drug-candidates-in-neurodegenerative-and-kidney-diseases/ 2025-12-18 https://bio-research.ai/athira-pharma-acquires-global-rights-to-lasofoxifene-from-sermonix-pharmaceuticals-for-up-to-100m/ 2025-12-18 https://bio-research.ai/her3-targeting-antibody-drug-conjugate-receives-fda-fast-track-designation/ 2025-12-18 https://bio-research.ai/atavistik-bio-raises-120-million-in-series-b-funding-to-advance-two-clinical-programs/ 2025-12-18 https://bio-research.ai/rybrevant-faspro-receives-fda-approval-for-egfr-mutated-nsclc/ 2025-12-17 https://bio-research.ai/johnson-johnson-s-phase-iii-study-teclistamab-plus-daratumumab-sc-reduced-disease-progression-by-83-4/ 2025-12-17 https://bio-research.ai/valink-therapeutics-and-nona-biosciences-form-bispecific-antibody-and-adc-discovery-alliance/ 2025-12-17 https://bio-research.ai/vistagen-s-phase-3-study-of-intranasal-fasedienol-for-social-anxiety-disorder-failed-to-meet-primary-endpoint/ 2025-12-17 https://bio-research.ai/astellas-and-pfizer-ev-304-trial-results-for-padcev-plus-keytruda-in-bladder-cancer/ 2025-12-17 https://bio-research.ai/cascade-raises-300-million-rmb-in-series-b-financing-for-phase-iii-trials-and-pipeline-development/ 2025-12-17 https://bio-research.ai/european-medicines-agency-grants-orphan-designation-to-a-recombinant-human-aat-fc-fusion-protein-for-aatd-related-emphysema/ 2025-12-17 https://bio-research.ai/harbour-biomed-and-bristol-myers-squibb-form-multi-year-collaboration-for-multi-specific-antibodies/ 2025-12-17 https://bio-research.ai/fda-approves-exdensur-for-severe-eosinophilic-asthma-in-patients-aged-12-and-older/ 2025-12-16 https://bio-research.ai/dbv-technologies-phase-3-trial-of-peanut-patch-in-children-4-7-years-shows-46-6-response/ 2025-12-16 https://bio-research.ai/hansa-biopharma-s-phase-3-trial-for-anti-glomerular-basement-membrane-disease-did-not-meet-primary-endpoint/ 2025-12-16 https://bio-research.ai/ambros-therapeutics-launches-with-series-a-financing-to-advance-late-stage-therapies/ 2025-12-16 https://bio-research.ai/vir-biotechnology-licenses-hepatitis-delta-combination-to-norgine-pharma-uk-for-eur-55m-upfront/ 2025-12-16 https://bio-research.ai/targed-biopharmaceuticals-secures-21-5-million-series-a-extension-for-thrombolytic-clinical-development/ 2025-12-16 https://bio-research.ai/tsc-alliance-endowment-fund-invests-in-aeovian-pharmaceuticals-phase-2-trial-of-a-cns-penetrant-selective-mtorc1-inhibitor-for-tuberous-sclerosis-complex/ 2025-12-16 https://bio-research.ai/royalty-pharma-acquires-royalty-interest-in-nuvalent-s-tyrosine-kinase-inhibitors-for-up-to-315m/ 2025-12-16 https://bio-research.ai/xoma-royalty-corporation-acquires-generation-bio-co-for-4-29-per-share-plus-cvr/ 2025-12-15 https://bio-research.ai/adel-grants-sanofi-exclusive-worldwide-rights-for-acetylated-tau-targeting-antibody/ 2025-12-15 https://bio-research.ai/sanofi-and-dren-bio-collaborate-on-next-generation-b-cell-depleting-therapy-100m-upfront-1-7b-milestones/ 2025-12-15 https://bio-research.ai/chai-discovery-secures-130-million-in-series-b-financing-for-ai-driven-molecule-design/ 2025-12-15 https://bio-research.ai/immunome-s-phase-3-ringside-trial-of-varegacestat-significantly-improve-progression-free-survival-in-desmoid-tumors/ 2025-12-15 https://bio-research.ai/radiopharm-theranostics-phase-2b-trial-of-rad-101-shows-92-concordance-with-mri/ 2025-12-15 https://bio-research.ai/fda-approves-lerochol-injection-for-adults-with-hypercholesterolemia/ 2025-12-15 https://bio-research.ai/greenwich-lifesciences-flamingo-01-phase-3-trial-shows-80-recurrence-rate-reduction/ 2025-12-15 https://bio-research.ai/kyverna-therapeutics-phase-2-trial-shows-miv-cel-reverses-disability-in-stiff-person-syndrome/ 2025-12-15 https://bio-research.ai/sanofi-s-phase-3-study-of-bruton-s-tyrosine-kinase-inhibitor-in-primary-progressive-multiple-sclerosis-did-not-meet-primary-endpoint/ 2025-12-15 https://bio-research.ai/hk-inno-n-acquires-japanese-rights-for-k-cab-from-raqualia-pharma-expanding-global-reach/ 2025-12-15 https://bio-research.ai/sobi-acquires-arthrosi-therapeutics-for-up-to-1-5b-gaining-a-phase-3-asset-for-gout-treatment/ 2025-12-13 https://bio-research.ai/taiho-pharmaceutical-discontinues-star-221-phase-3-study-due-to-futility/ 2025-12-13 https://bio-research.ai/fda-approves-akeega-plus-prednisone-for-brca2-mutated-mcspc-based-on-amplitude-study-results/ 2025-12-12 https://bio-research.ai/fda-approves-bacterial-type-ii-topoisomerase-inhibitor-for-uncomplicated-urogenital-gonorrhea/ 2025-12-12 https://bio-research.ai/fda-approves-calcium-channel-blocker-nasal-spray-for-acute-symptomatic-episodes-of-psvt/ 2025-12-12 https://bio-research.ai/fda-approves-uplizna-for-generalized-myasthenia-gravis-in-anti-achr-and-anti-musk-antibody-positive-adults/ 2025-12-11 https://bio-research.ai/fda-approves-gepotidacin-for-uncomplicated-urogenital-gonorrhoea-in-patients-aged-12-and-older/ 2025-12-11 https://bio-research.ai/fda-approves-extended-release-antibiotic-for-community-acquired-pneumonia-and-acute-bacterial-sinusitis/ 2025-12-11 https://bio-research.ai/everest-medicines-and-hasten-biopharmaceutical-sign-two-agreements-for-6-approved-products-and-a-pcsk9-inhibitor-including-a-us-29m-payment/ 2025-12-11 https://bio-research.ai/allegria-therapeutics-secures-seed-extension-financing-to-advance-preclinical-candidates/ 2025-12-11 https://bio-research.ai/prolynx-secures-70-million-in-series-a-financing-to-advance-its-portfolio-of-ultra-long-acting-obesity-drugs/ 2025-12-11 https://bio-research.ai/eli-lilly-s-phase-3-trial-12-mg-retatrutide-reduces-body-weight-by-28-7-at-68-weeks/ 2025-12-11 https://bio-research.ai/zealand-pharma-and-otr-therapeutics-in-multi-program-collaboration-for-up-to-30m-upfront-2-5b-milestones/ 2025-12-11 https://bio-research.ai/nanexa-and-moderna-sign-license-and-option-agreement-for-drug-delivery-platform-worth-up-to-503m/ 2025-12-10 https://bio-research.ai/gri-bio-s-phase-2a-data-for-an-investigational-small-molecule-shows-good-tolerability-over-12-weeks/ 2025-12-10 https://bio-research.ai/sanofi-and-indupro-collaborate-on-a-bispecific-pd-1-agonist-program-for-autoimmune-and-inflammatory-disorders/ 2025-12-10 https://bio-research.ai/epilepsygtx-raises-33-million-to-advance-aav-gene-therapy-for-focal-refractory-epilepsy/ 2025-12-10 https://bio-research.ai/formation-bio-and-bleecker-bio-acquire-tyk2-inhibitor-rights-from-lynk-pharmaceuticals-for-605m/ 2025-12-10 https://bio-research.ai/genentech-giredestrant-reduced-invasive-disease-recurrence-or-death-by-30-in-breast-cancer/ 2025-12-10 https://bio-research.ai/psithera-secures-47-5-million-series-a-financing-to-advance-tnf-superfamily-programs/ 2025-12-10 https://bio-research.ai/china-s-nmpa-approved-nerandomilast-for-progressive-pulmonary-fibrosis/ 2025-12-10 https://bio-research.ai/blossomhill-therapeutics-secures-84-million-series-b-extension-for-egfr-inhibitor-and-clk-inhibitor/ 2025-12-10 https://bio-research.ai/sanegenebio-secures-over-110-million-in-series-b-financing-to-advance-rnai-therapeutics/ 2025-12-10 https://bio-research.ai/oxford-biotherapeutics-and-gsk-form-collaboration-for-antibody-based-cancer-therapeutics/ 2025-12-10 https://bio-research.ai/bioxodes-raises-5-5-million-in-series-a-extension-funding-for-a-phase-2b-trial-of-a-small-molecule-for-ich/ 2025-12-10 https://bio-research.ai/gsk-s-antibody-drug-conjugate-received-fda-orphan-drug-designation-for-small-cell-lung-cancer/ 2025-12-10 https://bio-research.ai/structure-therapeutics-raises-650-million-following-positive-mid-stage-trial-results-for-oral-obesity-drug-aleniglipron/ 2025-12-09 https://bio-research.ai/mandos-adrabetadex-for-infantile-onset-niemann-pick-disease-type-c-receives-breakthrough-therapy-designation/ 2025-12-09 https://bio-research.ai/d3-bio-raises-108-million-to-advance-kras-g12c-inhibitor-into-global-phase-iii-trials/ 2025-12-09 https://bio-research.ai/johnson-johnson-s-teclistamab-plus-daratumumab-sc-reduces-disease-progression-by-83-4/ 2025-12-09 https://bio-research.ai/novartis-phase-iii-vayhit2-trial-ianalumab-plus-eltrombopag-extends-disease-control-by-45/ 2025-12-09 https://bio-research.ai/pfizer-and-yaopharma-partner-for-global-glp-1-receptor-agonist-development-150m-upfront-up-to-1-935b-milestones/ 2025-12-09 https://bio-research.ai/car-nk-cell-therapy-receives-fda-rmat-designation-for-relapsed-refractory-aml/ 2025-12-09 https://bio-research.ai/relation-and-novartis-partner-for-ai-drug-discovery-relation-receives-55m-upfront-and-up-to-1-7b/ 2025-12-09 https://bio-research.ai/japan-s-mhlw-grants-sakigake-designation-to-two-aav-gene-therapies-for-parkinson-s-and-non-ischemic-heart-failure/ 2025-12-09 https://bio-research.ai/european-commission-approves-gazyva-with-mycophenolate-mofetil-for-lupus-nephritis/ 2025-12-09 https://bio-research.ai/exicure-s-phase-2-trial-17-of-19-patients-achieve-cd34-cell-collection-endpoint/ 2025-12-08 https://bio-research.ai/convergen-secures-10-million-in-seed-financing-for-targeted-protein-degradation-platform/ 2025-12-08 https://bio-research.ai/cogent-biosciences-bezuclastinib-shows-57-orr-in-systemic-mastocytosis/ 2025-12-08 https://bio-research.ai/mirum-pharmaceuticals-to-acquire-bluejay-therapeutics-and-hdv-antibody-for-up-to-820m/ 2025-12-08 https://bio-research.ai/immutep-and-dr-reddy-s-sign-exclusive-licensing-agreement-for-lag-3-protein-immutep-receives-20m-upfront/ 2025-12-08 https://bio-research.ai/pan-cancer-t-b-v-raises-eur-5-million-for-a-first-in-human-clinical-trial-of-ropn1-targeting-tcr-t-cell-therapy-in-tnbc/ 2025-12-08 https://bio-research.ai/kallyope-s-oral-trpm8-antagonist-shows-competitive-phase-2b-migraine-results/ 2025-12-08 https://bio-research.ai/ucb-s-phase-3-study-of-fenfluramine-shows-reduced-motor-seizure-frequency/ 2025-12-08 https://bio-research.ai/eli-lilly-s-btk-inhibitor-achieved-76-risk-reduction-in-cll-sll-patients/ 2025-12-07 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-a-mutcalr-targeted-mab-for-essential-thrombocythemia/ 2025-12-07 https://bio-research.ai/ayrmid-receives-fda-approval-for-omisirge-for-the-treatment-of-severe-aplastic-anemia/ 2025-12-05 https://bio-research.ai/trop2-targeted-antibody-drug-conjugate-receives-second-orphan-drug-designation-for-gastric-cancer/ 2025-12-05 https://bio-research.ai/dasan-pharmaceutical-secures-13-billion-won-for-ipo-and-global-cdmo-expansion/ 2025-12-04 https://bio-research.ai/otr-therapeutics-secures-100-million-in-series-a-funding-to-advance-its-pipeline-and-r-d/ 2025-12-04 https://bio-research.ai/fda-approves-breyanzi-for-relapsed-or-refractory-marginal-zone-lymphoma/ 2025-12-04 https://bio-research.ai/royalty-pharma-to-fund-denali-therapeutics-for-an-enzyme-replacement-therapy-with-200m-upon-fda-approval/ 2025-12-04 https://bio-research.ai/replicate-bioscience-and-instituto-butantan-collaborate-on-srrna-rabies-vaccine/ 2025-12-04 https://bio-research.ai/hmi-115-receives-fda-fast-track-designation-for-endometriosis-pain-treatment/ 2025-12-04 https://bio-research.ai/neurimmune-and-alexion-expand-collaboration-for-al-amyloidosis-antibody-with-neurimmune-receiving-up-to-780m/ 2025-12-04 https://bio-research.ai/crescent-biopharma-and-kelun-biotech-form-oncology-therapeutics-partnership-worth-up-to-1-38b/ 2025-12-04 https://bio-research.ai/scineuro-pharmaceuticals-secures-53-million-in-equity-financing-for-advancing-its-neurodegenerative-disease-pipeline/ 2025-12-04 https://bio-research.ai/laigo-bio-secures-11-5-million-in-seed-financing-for-targeted-protein-degradation-therapeutics/ 2025-12-04 https://bio-research.ai/labgenius-therapeutics-and-sanofi-enter-second-collaboration-for-ai-ml-antibody-design/ 2025-12-04 https://bio-research.ai/sobi-phase-3-study-of-pegcetacoplan-shows-68-proteinuria-reduction-in-c3g-and-ic-mpgn/ 2025-12-04 https://bio-research.ai/lupin-and-valorum-biologics-ink-exclusive-licensing-agreement-for-biosimilar-pegfilgrastim-unne-in-u-s/ 2025-12-04 https://bio-research.ai/simcere-pharmaceutical-group-licenses-nucleoside-analogue-from-vigonvita-life-science-for-rsv-hmpv-in-greater-china/ 2025-12-03 https://bio-research.ai/lipigon-pharmaceuticals-phase-ii-study-of-aso-shows-no-significant-lipid-reduction/ 2025-12-03 https://bio-research.ai/excelsior-sciences-secures-95-million-in-funding-for-ai-driven-chemistry/ 2025-12-03 https://bio-research.ai/junevity-secures-10-million-to-advance-sirna-program-for-type-2-diabetes-and-obesity-into-clinic/ 2025-12-03 https://bio-research.ai/iolyx-therapeutics-and-laboratoires-th-a-partner-for-ocular-surface-disease-treatment-iolyx-receives-up-to-280m/ 2025-12-03 https://bio-research.ai/capricor-therapeutics-phase-3-hope-3-study-met-primary-and-key-secondary-endpoints/ 2025-12-03 https://bio-research.ai/fda-approves-jaypirca-for-adults-with-relapsed-or-refractory-cll-sll-following-btk-inhibitor-treatment/ 2025-12-03 https://bio-research.ai/triana-biomedicines-completes-120-million-series-b-financing-round-for-alk-targeted-molecular-glue-degrader/ 2025-12-03 https://bio-research.ai/pharvaris-deucrictibant-shows-median-symptom-relief-in-1-28-hours-in-phase-3-study/ 2025-12-03 https://bio-research.ai/cosmo-pharmaceuticals-reports-539-and-168-hair-count-improvements-in-male-androgenetic-alopecia-trials/ 2025-12-03 https://bio-research.ai/the-fda-granted-orphan-drug-rare-pediatric-disease-and-fast-track-designations-for-latus-bio-s-aav-therapy-for-cln2-disease/ 2025-12-02 https://bio-research.ai/rna-interference-therapeutic-receives-fda-breakthrough-therapy-designation-for-severe-hypertriglyceridemia/ 2025-12-02 https://bio-research.ai/axoltis-pharma-secures-18-million-in-series-a-funding-for-als-drug-candidate-in-phase-2-trials/ 2025-12-02 https://bio-research.ai/imvax-phase-2b-trial-shows-6-3-month-overall-survival-benefit-in-newly-diagnosed-gbm/ 2025-12-02 https://bio-research.ai/fda-grants-oligonucleotide-breakthrough-therapy-designation-for-alexander-disease/ 2025-12-02 https://bio-research.ai/hightide-therapeutics-phase-iii-trial-of-htd1801-shows-superior-hba1c-reduction-1-12/ 2025-12-01 https://bio-research.ai/fcrn-blocker-nipocalimab-receives-european-marketing-authorization-for-generalized-myasthenia-gravis/ 2025-12-01 https://bio-research.ai/fda-grants-oral-anti-inflammatory-breakthrough-therapy-designation-for-meniere-s-disease/ 2025-12-01 https://bio-research.ai/solid-biosciences-investigational-gene-therapy-for-friedreich-s-ataxia-receives-rare-pediatric-disease-designation/ 2025-12-01 https://bio-research.ai/juniper-biosciences-secures-40-million-seed-financing-to-advance-radiopharmaceutical-drug-development/ 2025-12-01 https://bio-research.ai/protego-biopharma-completes-130-million-series-b-financing-to-advance-lead-candidate-into-pivotal-trial/ 2025-12-01 https://bio-research.ai/morphocell-technologies-completes-us-50-million-series-a-financing-for-reliver-program-and-manufacturing-expansion/ 2025-12-01 https://bio-research.ai/belite-bio-s-phase-3-trial-of-tinlarebant-shows-36-reduction-in-retinal-lesion-growth/ 2025-12-01 https://bio-research.ai/regeneron-and-tessera-therapeutics-collaborate-on-gene-writing-program-for-aat-deficiency-tessera-receives-150m-upfront/ 2025-12-01 https://bio-research.ai/akebia-acquires-global-rights-to-c3d-factor-h-fusion-protein-from-q32-bio-for-10m/ 2025-12-01 https://bio-research.ai/orphalan-acquires-orphelia-pharma-gaining-kigabeq-and-kizfizo-bolstering-rare-disease-portfolio/ 2025-12-01 https://bio-research.ai/perseus-proteomics-and-eurus-therapeutics-form-a-joint-research-agreement-for-new-therapeutic-drugs/ 2025-12-01 https://bio-research.ai/lupin-receives-u-s-fda-approval-for-armlupeg-a-pegfilgrastim-biosimilar/ 2025-12-01 https://bio-research.ai/pecondle-receives-nmpa-approval-in-china-for-moderate-to-severe-plaque-psoriasis/ 2025-11-28 https://bio-research.ai/health-canada-approves-eydenzelt-a-biosimilar-referencing-eylea-for-all-approved-indications/ 2025-11-27 https://bio-research.ai/imugene-and-jw-therapeutics-partner-to-investigate-oncolytic-virus-and-car-t-cell-therapy-for-solid-tumors/ 2025-11-27 https://bio-research.ai/cathepsin-k-inhibitor-for-osteogenesis-imperfecta-receives-orphan-drug-designation/ 2025-11-27 https://bio-research.ai/kedrion-s-investigational-treatment-for-congenital-aceruloplasminemia-receives-orphan-drug-designation/ 2025-11-27 https://bio-research.ai/u-s-fda-grants-orphan-drug-designation-to-leukogene-therapeutics-cd33-targeting-car-t-for-aml/ 2025-11-27 https://bio-research.ai/sk-biopharmaceuticals-secures-exclusive-global-rights-from-warf-for-a-preclinical-radiopharmaceutical-therapy/ 2025-11-27 https://bio-research.ai/fda-grants-fast-track-designation-to-oral-multi-kinase-inhibitor-for-recurrent-high-grade-gliomas/ 2025-11-26 https://bio-research.ai/fda-grants-priority-review-to-a-bcl-2-inhibitor-for-relapsed-or-refractory-mantle-cell-lymphoma/ 2025-11-26 https://bio-research.ai/otsuka-receives-fda-accelerated-approval-for-voyxact-to-reduce-proteinuria-in-adults-with-igan/ 2025-11-26 https://bio-research.ai/zetagen-therapeutics-secures-12-9m-for-breast-cancer-therapies-and-clinical-development/ 2025-11-25 https://bio-research.ai/astrazeneca-s-imfinzi-combined-with-flot-chemotherapy-gained-us-approval-for-gastric-gej-cancers/ 2025-11-25 https://bio-research.ai/european-commission-grants-marketing-authorizations-for-teva-s-denosumab-biosimilars/ 2025-11-25 https://bio-research.ai/novo-nordisk-s-phase-2-trial-shows-up-to-14-5-weight-loss-with-amycretin/ 2025-11-25 https://bio-research.ai/european-commission-approves-sugemalimab-for-unresectable-stage-iii-nsclc/ 2025-11-25 https://bio-research.ai/human-life-cord-inc-secures-1-9-billion-in-series-c-funding-for-phase-iii-trials/ 2025-11-25 https://bio-research.ai/junshi-biosciences-phase-3-study-of-toripalimab-injection-met-primary-endpoints-in-nsclc/ 2025-11-24 https://bio-research.ai/novartis-itvisma-a-gene-therapy-receives-fda-approval-for-sma-patients/ 2025-11-24 https://bio-research.ai/fda-grants-fast-track-designation-to-a-bispecific-antibody-drug-conjugate-for-advanced-urothelial-cancer/ 2025-11-24 https://bio-research.ai/mindimmune-therapeutics-secures-series-a-extension-funding-advances-monoclonal-antibody-into-phase-1-clinical-studies/ 2025-11-24 https://bio-research.ai/european-commission-approves-breyanzi-for-relapsed-or-refractory-mantle-cell-lymphoma/ 2025-11-24 https://bio-research.ai/dayra-therapeutics-secures-over-70m-including-a-collaboration-with-biogen-for-oral-macrocyclic-peptides/ 2025-11-24 https://bio-research.ai/novo-nordisk-s-evoke-and-evoke-phase-3-trials-of-oral-semaglutide-miss-primary-endpoint/ 2025-11-24 https://bio-research.ai/sichuan-kelun-biotech-s-phase-iii-study-of-sacituzumab-tirumotecan-meets-pfs-endpoint/ 2025-11-24 https://bio-research.ai/swissmedic-approves-zepzelca-plus-atezolizumab-for-es-sclc-maintenance/ 2025-11-24 https://bio-research.ai/biokin-pharmaceutical-s-iza-bren-met-pfs-and-os-in-a-pre-specified-interim-analysis-in-advanced-escc/ 2025-11-24 https://bio-research.ai/sprint-bioscience-sells-trex1-cancer-program-to-gilead-sciences-for-14m-upfront-up-to-400m-milestones/ 2025-11-24 https://bio-research.ai/bayer-s-oral-fxia-inhibitor-reduces-ischemic-stroke-risk-in-phase-iii-oceanic-stroke-study/ 2025-11-23 https://bio-research.ai/fda-approves-pembrolizumab-and-pembrolizumab-qlex-with-padcev-for-bladder-cancer/ 2025-11-21 https://bio-research.ai/contineum-therapeutics-phase-2-vista-trial-of-pipe-307-did-not-meet-efficacy-endpoints/ 2025-11-20 https://bio-research.ai/scineuro-pharmaceuticals-secures-5m-grant-from-mjff-for-aso-targeting-lrrk2-preclinical-development/ 2025-11-20 https://bio-research.ai/aspen-neuroscience-secures-115-million-in-series-c-financing-for-autologous-ipsc-derived-therapy/ 2025-11-20 https://bio-research.ai/valo-health-and-merck-kgaa-collaborate-on-parkinson-s-disease-therapeutics-valo-to-receive-over-3b/ 2025-11-20 https://bio-research.ai/ec-approves-gobivaz-alvotech-s-biosimilar-to-simponi-golimumab-for-marketing-in-eea/ 2025-11-20 https://bio-research.ai/fda-grants-accelerated-approval-for-hyrnuo-in-her2-mutated-nsclc-based-on-soho-01-trial/ 2025-11-20 https://bio-research.ai/trioar-signs-license-agreement-and-co-development-option-with-celltrion-for-356m/ 2025-11-19 https://bio-research.ai/fda-approves-imdelltra-for-es-sclc-after-platinum-based-chemotherapy/ 2025-11-19 https://bio-research.ai/profluent-secures-106-million-in-financing-to-accelerate-work-in-designing-genome-editors-antibodies-and-enzymes/ 2025-11-19 https://bio-research.ai/ai-proteins-secures-41-5-million-in-series-a-funding-to-advance-its-ai-driven-miniprotein-medicine-platform/ 2025-11-19 https://bio-research.ai/pfizer-licenses-nona-biosciences-hcab-platform-for-preclinical-antibody-discovery/ 2025-11-19 https://bio-research.ai/agios-pharmaceuticals-mitapivat-phase-3-trial-meets-hemoglobin-endpoint-but-misses-scpc-endpoint-in-sickle-cell-disease/ 2025-11-19 https://bio-research.ai/merck-s-phase-3-trial-of-dor-isl-shows-non-inferiority-to-bic-ftc-taf-at-week-48/ 2025-11-19 https://bio-research.ai/european-commission-approves-subcutaneous-keytruda-for-all-adult-indications-in-the-eu/ 2025-11-19 https://bio-research.ai/european-commission-grants-marketing-authorization-for-lynkuet-in-the-eu/ 2025-11-19 https://bio-research.ai/gsk-and-ltz-therapeutics-form-strategic-research-collaboration-for-myeloid-cell-engagers-50m-upfront/ 2025-11-19 https://bio-research.ai/hanmi-pharmaceutical-acquires-aptose-biosciences-for-c-2-41-per-share-continuing-aml-drug-development/ 2025-11-19 https://bio-research.ai/rafa-laboratories-secures-186m-barda-contract-for-developing-a-novel-txa-formulation-and-autoinjector-for-uncontrolled-bleeding/ 2025-11-19 https://bio-research.ai/lifordi-immunotherapeutics-secures-112-million-for-a-phase-1-study-of-an-immunotherapeutic-adc-in-rheumatoid-arthritis/ 2025-11-18 https://bio-research.ai/european-commission-approves-brinsupri-for-non-cystic-fibrosis-bronchiectasis/ 2025-11-18 https://bio-research.ai/fda-approves-redemplo-for-familial-chylomicronemia-syndrome-based-on-phase-3-palisade-study/ 2025-11-18 https://bio-research.ai/mvm-partners-invests-32-million-in-avanzanite-bioscience-to-expand-european-infrastructure/ 2025-11-18 https://bio-research.ai/tulex-and-artisan-therapeutics-phase-2a-trial-of-ard-501-in-autism-shows-clinical-benefit-in-4-of-6-participants/ 2025-11-18 https://bio-research.ai/imbria-pharmaceuticals-secures-series-b-financing-to-advance-ninerafaxstat-in-phase-2b-trial/ 2025-11-17 https://bio-research.ai/johnson-johnson-acquires-halda-therapeutics-for-3-05b-cash-gaining-riptac-therapeutic-and-platform/ 2025-11-17 https://bio-research.ai/fda-grants-fast-track-designation-to-condensate-modulator-for-gastric-cancer/ 2025-11-17 https://bio-research.ai/artios-pharma-secures-115-million-to-expand-clinical-evaluation-of-alnodesertib-and-initiate-a-phase-2-trial-of-its-dna-pol-inhibitor/ 2025-11-17 https://bio-research.ai/beone-medicines-her2-targeted-bispecific-antibody-phase-3-trial-shows-improved-progression-free-survival/ 2025-11-17 https://bio-research.ai/solve-therapeutics-raises-120-million-for-its-clinical-adc-pipeline-and-linker-platform-development/ 2025-11-17 https://bio-research.ai/merus-licenses-halozyme-s-drug-delivery-technology-for-egfr-x-lgr5-bispecific-antibody/ 2025-11-17 https://bio-research.ai/nuvalent-s-alkove-1-phase-1-2-trial-shows-31-objective-response-rate-in-alk-positive-nsclc/ 2025-11-17 https://bio-research.ai/leo-pharma-s-tralokinumab-phase-3b-adhand-trial-meets-all-primary-and-secondary-endpoints/ 2025-11-17 https://bio-research.ai/captain-t-cell-secures-eur-20-million-to-advance-autologous-tcr-t-cell-program-into-phase-i-trial/ 2025-11-17 https://bio-research.ai/trop2-targeting-antibody-drug-conjugate-receives-orphan-drug-designation-for-cholangiocarcinoma/ 2025-11-16 https://bio-research.ai/sarepta-therapeutics-updates-elevidys-label-with-boxed-warning-for-acute-liver-injury/ 2025-11-14 https://bio-research.ai/merck-acquires-cidara-therapeutics-for-9-2b-in-cash-to-gain-an-antiviral-agent/ 2025-11-14 https://bio-research.ai/chmp-recommends-teizeild-for-eu-approval-in-stage-2-type-1-diabetes-based-on-tn-10-study/ 2025-11-14 https://bio-research.ai/egetis-therapeutics-announces-retriact-study-shows-significant-serum-t3-change/ 2025-11-14 https://bio-research.ai/abl-bio-secures-krw-22-billion-strategic-investment-from-eli-lilly-and-company/ 2025-11-14 https://bio-research.ai/gate-bioscience-secures-65-million-in-series-b-financing-for-small-molecule-therapies/ 2025-11-13 https://bio-research.ai/gilead-sciences-phase-3-artistry-1-trial-finds-bic-len-efficacy-non-inferior/ 2025-11-13 https://bio-research.ai/fda-grants-full-approval-of-komzifti-for-adult-patients-with-relapsed-or-refractory-aml/ 2025-11-13 https://bio-research.ai/scripta-therapeutics-raises-12-million-seed-funding-to-develop-transcription-factor-modulators/ 2025-11-13 https://bio-research.ai/4teen4-pharmaceuticals-secures-55-million-for-monoclonal-antibody-in-cardiogenic-shock-phase-2a-trial/ 2025-11-13 https://bio-research.ai/day-one-biopharmaceuticals-to-acquire-mersana-therapeutics-for-up-to-285m-in-adc-deal/ 2025-11-13 https://bio-research.ai/adagene-licenses-its-bispecific-antibody-platform-to-third-arc-bio-for-5m-upfront-up-to-840m-milestones-and-royalties/ 2025-11-13 https://bio-research.ai/t-therapeutics-secures-32-million-in-series-a-extension-to-advance-tcr-cd3-bispecifics/ 2025-11-13 https://bio-research.ai/novartis-phase-iii-kaluma-study-for-malaria-treatment-achieved-a-97-4-cure-rate/ 2025-11-12 https://bio-research.ai/neurogene-inc-ngn-401-gene-therapy-shows-functional-gains-in-all-eight-rett-syndrome-participants/ 2025-11-12 https://bio-research.ai/octant-and-bristol-myers-squibb-collaborate-to-discover-and-develop-small-molecule-therapeutics/ 2025-11-12 https://bio-research.ai/chiesi-group-licenses-aliada-therapeutics-blood-brain-barrier-crossing-platform-for-enzyme-replacement-therapies/ 2025-11-12 https://bio-research.ai/alkermes-announces-alixorexton-phase-2-study-meets-dual-primary-endpoints-in-narcolepsy-type-2/ 2025-11-12 https://bio-research.ai/fda-grants-fast-track-designation-to-catenin-tcf-interaction-inhibitor-for-desmoid-tumors/ 2025-11-12 https://bio-research.ai/laekna-licenses-its-akt-inhibitor-to-qilu-pharma-for-china-in-a-deal-worth-up-to-rmb-2-045m/ 2025-11-12 https://bio-research.ai/abl-bio-and-eli-lilly-partner-on-abl-bio-s-blood-brain-barrier-platform-for-40m-upfront-and-up-to-2-562b-in-milestones/ 2025-11-12 https://bio-research.ai/engene-holdings-phase-2-trial-of-gene-therapy-shows-62-complete-response-at-6-months/ 2025-11-11 https://bio-research.ai/surv-biopharma-co-ltd-secures-1-5-billion-in-series-b-first-close-to-advance-oncolytic-virus-series/ 2025-11-11 https://bio-research.ai/precision-biosciences-announces-common-stock-and-warrant-offering-to-fund-research-and-development/ 2025-11-10 https://bio-research.ai/atai-beckley-n-v-phase-2b-trial-of-mebufotenin-benzoate-nasal-spray-shows-sustained-antidepressant-effects/ 2025-11-10 https://bio-research.ai/insilico-medicine-and-eli-lilly-expand-ai-software-licensing-agreement-insilico-to-receive-over-100m/ 2025-11-10 https://bio-research.ai/purdue-pharma-s-investigational-alkylating-agent-receives-orphan-drug-designation-for-malignant-gliomas/ 2025-11-10 https://bio-research.ai/lyell-immunopharma-acquires-gcc-targeted-car-t-cell-candidate-from-innovative-cellular-therapeutics-for-40m-upfront-and-up-to-820m-in-milestones/ 2025-11-10 https://bio-research.ai/camurus-phase-1b-study-of-semaglutide-formulation-shows-9-3-weight-reduction/ 2025-11-10 https://bio-research.ai/meiragtx-and-eli-lilly-partner-on-ophthalmology-aav-based-gene-therapy-collaboration-for-75m-upfront/ 2025-11-10 https://bio-research.ai/cogent-biosciences-phase-3-trial-of-bezuclastinib-in-gist-reports-16-5-month-median-pfs/ 2025-11-10 https://bio-research.ai/fda-grants-fast-track-designation-to-egfr-her3-bispecific-antibody-drug-conjugate-for-nsclc/ 2025-11-10 https://bio-research.ai/merck-s-oral-pcsk9-inhibitor-reduces-ldl-c-by-55-8-in-phase-3-trial/ 2025-11-08 https://bio-research.ai/crispr-therapeutics-gene-editing-therapy-shows-dose-dependent-angptl3-triglyceride-and-ldl-reductions/ 2025-11-08 https://bio-research.ai/vor-bio-s-b-cell-activating-factor-and-a-proliferation-inducing-ligand-inhibitor-reduces-urine-protein-by-55/ 2025-11-08 https://bio-research.ai/sanegenebio-and-eli-lilly-collaborate-on-rnai-candidates-for-metabolic-diseases-with-sanegenebio-receiving-up-to-1-2b/ 2025-11-08 https://bio-research.ai/pfizer-to-acquire-metsera-for-over-10b-after-metsera-rejected-novo-nordisk-s-bid/ 2025-11-07 https://bio-research.ai/rivus-pharmaceuticals-phase-2-m-accel-trial-of-hu6-shows-significant-liver-fat-reduction/ 2025-11-07 https://bio-research.ai/sanofi-and-regeneron-announce-dupixent-meets-all-endpoints-in-phase-3-afrs-trial-fda-grants-priority-review/ 2025-11-07 https://bio-research.ai/nmpa-approves-car-t-cell-therapy-for-pediatric-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia/ 2025-11-07 https://bio-research.ai/fda-approves-darzalex-faspro-for-high-risk-smoldering-multiple-myeloma/ 2025-11-06 https://bio-research.ai/eledon-pharmaceuticals-phase-2-trial-of-tegoprubart-in-kidney-transplant-patients-shows-12-month-egfr-of-69-ml-min-1-73-m/ 2025-11-06 https://bio-research.ai/accipiter-biosciences-secures-12-7-million-in-seed-financing-establishes-research-collaborations/ 2025-11-06 https://bio-research.ai/mavrix-bio-received-fda-orphan-drug-designation-for-its-aav-based-gene-therapy-for-angelman-syndrome/ 2025-11-06 https://bio-research.ai/bayer-s-phase-3-fine-one-study-shows-finerenone-reduced-uacr-by-25/ 2025-11-06 https://bio-research.ai/prokidney-corp-phase-2-trial-of-cell-therapy-shows-4-6-ml-min-1-73m-egfr-improvement/ 2025-11-06 https://bio-research.ai/urogen-pharma-s-phase-3-trial-of-ugn-103-shows-77-8-three-month-complete-response-rate-in-recurrent-low-grade-intermediate-risk-nmibc/ 2025-11-06 https://bio-research.ai/fda-approves-caplyta-for-major-depressive-disorder-trials-show-efficacy-and-safety/ 2025-11-06 https://bio-research.ai/viking-therapeutics-phase-2-venture-trial-for-vk2735-reduces-prediabetes-by-78/ 2025-11-06 https://bio-research.ai/eli-lilly-s-eloralintide-phase-2-trial-shows-9-5-to-20-1-weight-reduction/ 2025-11-06 https://bio-research.ai/renasant-bio-launches-to-develop-treatments-for-adpkd-with-oral-small-molecule-therapies/ 2025-11-06 https://bio-research.ai/novo-nordisk-s-oasis-4-trial-oral-semaglutide-25-mg-improved-blood-sugar/ 2025-11-05 https://bio-research.ai/neurona-therapeutics-cell-therapy-for-drug-resistant-focal-epilepsy-receives-ema-prime-designation/ 2025-11-05 https://bio-research.ai/calico-life-sciences-llc-s-anti-papp-a-monoclonal-antibody-receives-orphan-drug-and-fast-track-designations/ 2025-11-05 https://bio-research.ai/dynavax-and-vaxart-form-exclusive-global-licensing-and-collaboration-for-oral-covid-19-vaccine-candidate/ 2025-11-05 https://bio-research.ai/ailux-and-eli-lilly-partner-for-bispecific-antibody-discovery-deal-up-to-345m/ 2025-11-05 https://bio-research.ai/braveheart-bio-launches-with-185-million-to-advance-cardiac-myosin-inhibitor-for-hypertrophic-cardiomyopathy/ 2025-11-05 https://bio-research.ai/mhra-grants-marketing-authorization-for-xoanacyl-for-chronic-kidney-disease-complications/ 2025-11-05 https://bio-research.ai/astrazeneca-s-phase-iii-matterhorn-trial-imfinzi-reduces-risk-of-death-by-22/ 2025-11-05 https://bio-research.ai/biohaven-receives-complete-response-letter-from-fda-for-troriluzole-nda-for-spinocerebellar-ataxia/ 2025-11-04 https://bio-research.ai/fda-approves-contepo-fosfomycin-injection-for-complicated-urinary-tract-infections/ 2025-11-04 https://bio-research.ai/hengrui-pharma-s-phase-3-trial-for-once-weekly-glp-1-receptor-agonist-in-obesity-met-co-primary-endpoints/ 2025-11-04 https://bio-research.ai/azalea-therapeutics-launches-with-82-million-to-advance-its-enveloped-delivery-vehicle-technology/ 2025-11-04 https://bio-research.ai/spinogenix-s-phase-2a-study-in-23-als-patients-showed-a-drug-effect-on-brain-areas/ 2025-11-04 https://bio-research.ai/neok-bio-secures-75-million-for-bispecific-antibody-drug-conjugate-programs-phase-1-trials-planned/ 2025-11-04 https://bio-research.ai/boehringer-ingelheim-and-cdr-life-ink-global-licensing-agreement-for-antibody-worth-up-to-570m/ 2025-11-04 https://bio-research.ai/amacathera-and-pacira-biosciences-partner-on-a-long-acting-non-opioid-anesthetic-for-5m-upfront-up-to-225m-in-milestones-and-royalties/ 2025-11-04 https://bio-research.ai/merck-and-blackstone-life-sciences-partner-for-700m-antibody-drug-conjugate-development-funding/ 2025-11-04 https://bio-research.ai/incyte-acquires-exclusive-option-for-prelude-s-jak2v617f-jh2-inhibitor-program-for-60m-upfront/ 2025-11-04 https://bio-research.ai/celltrion-and-kaigene-sign-exclusive-global-licensing-agreement-for-antibody-assets-for-up-to-744m/ 2025-11-03 https://bio-research.ai/hlb-group-secures-145-million-investment-for-clinical-development-and-global-commercialization/ 2025-11-03 https://bio-research.ai/servier-announces-phase-3-indigo-trial-data-for-idh1-2-inhibitor-in-grade-2-glioma/ 2025-11-03 https://bio-research.ai/fda-approves-kygevvi-for-thymidine-kinase-2-deficiency-in-adults-and-pediatric-patients/ 2025-11-03 https://bio-research.ai/benitec-biopharma-received-fda-fast-track-designation-for-its-aav-based-gene-therapy/ 2025-11-03 https://bio-research.ai/manifold-bio-and-roche-collaborate-on-brain-targeted-therapies-for-55m-upfront-2b-milestones/ 2025-11-03 https://bio-research.ai/courage-therapeutics-secures-funding-develops-treatments-for-genetic-and-dietary-obesity/ 2025-11-03 https://bio-research.ai/aavantgarde-bio-secures-141-million-series-b-financing-for-aav-based-gene-therapies-in-inherited-retinal-diseases/ 2025-11-03 https://bio-research.ai/arctic-therapeutics-small-molecule-receives-ema-authorization-for-phase-iia-study-in-alzheimer-s-disease/ 2025-11-03 https://bio-research.ai/boost-pharma-secures-sek-34-million-investment-for-stem-cell-based-therapy-in-osteogenesis-imperfecta/ 2025-11-03 https://bio-research.ai/akeso-biopharma-s-bispecific-antibody-receives-breakthrough-therapy-designation-for-tnbc/ 2025-11-03 https://bio-research.ai/neuraclegenetics-secures-10-8-billion-krw-to-advance-global-clinical-trials-for-aav-based-gene-therapy/ 2025-11-03 https://bio-research.ai/genentech-s-phase-iii-allegory-study-of-gazyva-meets-primary-and-all-key-secondary-endpoints-in-sle/ 2025-11-02 https://bio-research.ai/lepu-biopharma-s-egfr-targeted-adc-received-nmpa-approval-for-nasopharyngeal-carcinoma/ 2025-10-31 https://bio-research.ai/maxvax-biotechnology-secures-rmb-400-million-in-series-d-financing-to-advance-vaccine-clinical-trials/ 2025-10-31 https://bio-research.ai/4d-molecular-therapeutics-and-otsuka-pharmaceutical-partner-for-an-85m-gene-therapy-deal/ 2025-10-30 https://bio-research.ai/alexion-astrazeneca-rare-disease-s-gefurulimab-meets-primary-endpoint-in-gmg-phase-iii-trial/ 2025-10-30 https://bio-research.ai/fda-approves-stoboclo-and-osenvelt-as-interchangeable-denosumab-biosimilars/ 2025-10-30 https://bio-research.ai/cytocares-tri-specific-tce-drug-platform-receives-investment-lead-drug-shows-b-cell-clearance-in-sle/ 2025-10-30 https://bio-research.ai/dongna-medical-health-fund-and-aier-eye-hospital-s-fund-invest-in-cell-therapy-for-tumors-and-fibrosis/ 2025-10-30 https://bio-research.ai/kyowa-kirin-licenses-small-molecule-program-to-boehringer-ingelheim-for-up-to-640m/ 2025-10-30 https://bio-research.ai/everest-medicines-licenses-bispecific-biologic-from-visara-for-7m-upfront-89m-milestones-and-royalties/ 2025-10-30 https://bio-research.ai/abbvie-s-rinvoq-phase-3-studies-show-50-t-vasi-and-75-f-vasi-reduction-in-vitiligo/ 2025-10-29 https://bio-research.ai/novartis-ianalumab-phase-3-trials-show-reduction-in-sj-gren-s-disease-activity/ 2025-10-29 https://bio-research.ai/fda-grants-orphan-drug-designation-to-condensate-modulator-for-gastric-cancer/ 2025-10-29 https://bio-research.ai/bridgebio-pharma-s-encaleret-phase-3-study-shows-76-of-participants-achieve-target-calcium-levels/ 2025-10-29 https://bio-research.ai/european-commission-approves-keytruda-for-resectable-la-hnscc-expressing-pd-l1/ 2025-10-29 https://bio-research.ai/modex-therapeutics-and-regeneron-partner-for-multispecific-antibodies-in-a-deal-worth-over-1b/ 2025-10-29 https://bio-research.ai/iaso-biotherapeutics-and-gc-cell-partner-to-promote-car-t-cell-therapy-fucaso-in-south-korea/ 2025-10-29 https://bio-research.ai/zag-bio-launches-with-80-million-financing-appoints-jason-f-cole-as-ceo-advances-systemic-therapeutic-for-type-1-diabetes/ 2025-10-28 https://bio-research.ai/neurenati-therapeutics-combination-therapy-for-hirschsprung-disease-receives-ema-orphan-drug-designation/ 2025-10-28 https://bio-research.ai/cns-penetrant-tyk2-inhibitor-sudo-550-demonstrates-90-target-inhibition-in-both-central-and-peripheral-systems/ 2025-10-28 https://bio-research.ai/aldeyra-therapeutics-rasp-modulator-shows-significant-improvement-in-liver-function-in-alcohol-associated-hepatitis/ 2025-10-28 https://bio-research.ai/edesa-biotech-announces-phase-3-results-for-paridiprubart-in-ards-25-mortality-reduction/ 2025-10-28 https://bio-research.ai/gsk-and-empirico-partner-for-a-respiratory-sirna-candidate-in-a-deal-worth-up-to-745m/ 2025-10-28 https://bio-research.ai/ex-vivo-autologous-hematopoietic-stem-cell-gene-therapy-for-mld-receives-orphan-regenerative-medicine-product-designation-in-japan/ 2025-10-28 https://bio-research.ai/genentech-s-gazyva-phase-iii-inshore-study-meets-primary-endpoint-in-idiopathic-nephrotic-syndrome/ 2025-10-27 https://bio-research.ai/johnson-johnson-s-il-23r-blocker-phase-2b-anthem-uc-study-shows-sustained-results-at-week-28/ 2025-10-27 https://bio-research.ai/fda-approves-once-monthly-omvoh-for-adults-with-ulcerative-colitis/ 2025-10-27 https://bio-research.ai/bridgebio-pharma-s-fortify-phase-3-study-meets-all-endpoints-in-lgmd2i-r9/ 2025-10-27 https://bio-research.ai/hemab-therapeutics-raises-157-million-in-series-c-to-advance-sutacimig-and-hmb-002/ 2025-10-27 https://bio-research.ai/gsk-gains-exclusive-global-rights-to-syndivia-s-adc-for-mcrpc-up-to-268m-milestones/ 2025-10-27 https://bio-research.ai/askgene-pharma-inc-reports-12-45-months-mpfs-for-anti-cldn18-2-antibody-in-advanced-gastric-cancer/ 2025-10-27 https://bio-research.ai/novartis-acquires-avidity-biosciences-and-spinco-for-12b-strengthening-neuroscience-and-xrna-strategy/ 2025-10-26 https://bio-research.ai/guard-therapeutics-phase-2b-pointer-study-of-investigational-kidney-protective-treatment-misses-endpoints/ 2025-10-26 https://bio-research.ai/incyte-presents-updated-true-ad4-results-demonstrating-early-itch-nrs4-response-and-sustained-symptom-control-with-opzelura-in-adults-with-moderate-ad/ 2025-10-25 https://bio-research.ai/lu-edotreotide-delivers-superior-efficacy-across-patient-subgroups-in-phase-3-compete-trial/ 2025-10-25 https://bio-research.ai/starna-therapeutics-secures-funding-for-targeted-delivery-platform-and-car-t-pipeline-advancement/ 2025-10-24 https://bio-research.ai/medimabbio-raises-krw-25-6-billion-in-series-b-financing-to-advance-fusion-antibody-platform-programs/ 2025-10-24 https://bio-research.ai/eli-lilly-and-cipla-partner-to-distribute-and-promote-mounjaro-in-india/ 2025-10-24 https://bio-research.ai/fda-issues-complete-response-letter-for-low-dose-atropine-nda-in-pediatric-myopia/ 2025-10-23 https://bio-research.ai/fda-approves-blenrep-in-combination-with-bortezomib-and-dexamethasone-for-relapsed-or-refractory-multiple-myeloma/ 2025-10-23 https://bio-research.ai/inhibrx-biosciences-ozekibart-meets-primary-endpoint-in-advanced-chondrosarcoma/ 2025-10-23 https://bio-research.ai/zenocutuzumab-zbco-receives-fda-breakthrough-therapy-designation-for-nrg1-cholangiocarcinoma/ 2025-10-23 https://bio-research.ai/halia-therapeutics-nek7-modulator-receives-fda-orphan-drug-designation-for-myelodysplastic-syndromes/ 2025-10-23 https://bio-research.ai/george-medicines-single-pill-combination-therapy-reduces-recurrent-stroke-risk-in-trident-trial/ 2025-10-23 https://bio-research.ai/kure-cells-secures-10-million-in-pre-series-a-funding-for-car-t-cell-manufacturing-platform/ 2025-10-23 https://bio-research.ai/silver-creek-pharmaceuticals-announces-phase-ii-trial-results-for-scp776-in-acute-ischemic-stroke/ 2025-10-23 https://bio-research.ai/mitsubishi-tanabe-pharma-corporation-receives-complete-response-letter-for-investigational-parkinson-s-disease-treatment/ 2025-10-23 https://bio-research.ai/harbour-biomed-reports-34-8-objective-response-rate-for-porustobart-plus-tislelizumab-in-mss-metastatic-colorectal-cancer/ 2025-10-23 https://bio-research.ai/sanofi-s-investigational-enzyme-replacement-therapy-increases-aat-levels-in-phase-ii-study/ 2025-10-22 https://bio-research.ai/electra-therapeutics-raises-183-million-for-global-pivotal-trial-of-an-anti-cd8-antibody/ 2025-10-22 https://bio-research.ai/summit-therapeutics-raises-500-million-to-advance-clinical-development-of-an-anti-pd-1-vegf-bispecific-antibody/ 2025-10-22 https://bio-research.ai/china-s-nmpa-approves-boehringer-ingelheim-s-jascayd-nerandomilast-for-adult-idiopathic-pulmonary-fibrosis/ 2025-10-22 https://bio-research.ai/novartis-cosentyx-phase-iii-replenish-trial-meets-all-endpoints-in-polymyalgia-rheumatica/ 2025-10-22 https://bio-research.ai/tezspire-receives-eu-approval-for-severe-chronic-rhinosinusitis-with-nasal-polyps/ 2025-10-22 https://bio-research.ai/ipsen-to-acquire-imcheck-therapeutics-for-up-to-1b-including-350m-upfront-for-ict01-rights/ 2025-10-22 https://bio-research.ai/alkermes-to-acquire-avadel-pharmaceuticals-for-up-to-2-1b-including-cvr-for-lumryz-approval/ 2025-10-22 https://bio-research.ai/elevara-medicines-secures-70m-for-oral-cdk4-6-inhibitor-phase-2-trial-in-rheumatoid-arthritis/ 2025-10-22 https://bio-research.ai/chemify-raises-over-50-million-in-series-b-funding-to-scale-its-digital-chemistry-platform/ 2025-10-21 https://bio-research.ai/takeda-and-innovent-biologics-partner-for-1-2b-oncology-drug-co-development-and-commercialization/ 2025-10-21 https://bio-research.ai/terns-pharmaceuticals-reports-4-6-maximum-placebo-adjusted-weight-loss-for-obesity-drug-halts-development/ 2025-10-21 https://bio-research.ai/alector-s-phase-3-infront-3-trial-for-an-anti-progranulin-monoclonal-antibody-in-ftd-grn-did-not-meet-its-primary-endpoint/ 2025-10-21 https://bio-research.ai/quoin-pharmaceuticals-topical-lotion-for-netherton-syndrome-received-fda-orphan-drug-designation/ 2025-10-21 https://bio-research.ai/ventus-therapeutics-and-genentech-agreement-for-small-molecule-candidates-worth-over-460m/ 2025-10-21 https://bio-research.ai/iambic-therapeutics-and-jazz-pharmaceuticals-collaborate-to-evaluate-iam1363-and-zanidatamab-in-her2-positive-breast-cancer/ 2025-10-21 https://bio-research.ai/the-fda-has-granted-orphan-drug-and-fast-track-designations-toan-oral-small-molecule-abcg2-inhibitor-for-epp-and-xlp/ 2025-10-21 https://bio-research.ai/minerva-neurosciences-secures-200-million-for-confirmatory-phase-3-trial-of-roluperidone/ 2025-10-21 https://bio-research.ai/european-commission-approves-winlevi-clascoterone-1-cream-for-acne-vulgaris/ 2025-10-21 https://bio-research.ai/spero-therapeutics-and-gsk-s-phase-3-pivot-po-trial-shows-non-inferiority-of-oral-antibacterial-in-cuti/ 2025-10-21 https://bio-research.ai/stella-pharma-s-boron-drug-achieved-a-50-objective-response-rate-in-10-angiosarcoma-patients/ 2025-10-21 https://bio-research.ai/valink-therapeutics-closes-11-8-million-funding-round-to-advance-oncology-pipeline/ 2025-10-20 https://bio-research.ai/faeth-therapeutics-raises-25-million-to-advance-pi3k-program/ 2025-10-20 https://bio-research.ai/newlimit-secures-45m-for-epigenetic-reprogramming-programs-plans-first-clinical-study/ 2025-10-20 https://bio-research.ai/rapt-therapeutics-and-shanghai-jeyou-pharmaceutical-s-phase-2-trial-of-rpt904-shows-comparable-efficacy-and-safety-to-omalizumab/ 2025-10-20 https://bio-research.ai/viridian-therapeutics-secures-up-to-300m-in-royalty-financing-agreement-with-dri-healthcare-acquisitions-and-amends-credit-facility-with-hercules-capital/ 2025-10-20 https://bio-research.ai/bezuclastinib-receives-fda-breakthrough-therapy-designation-for-nonadvanced-systemic-mastocytosis/ 2025-10-20 https://bio-research.ai/fda-accepts-bla-resubmission-for-oncolytic-immunotherapy-and-opdivo-in-advanced-melanoma/ 2025-10-20 https://bio-research.ai/riltide-medicines-secures-seed-funding-to-advance-oral-drugs-for-autoimmune-diseases-and-develop-its-ai-molecular-design-platform/ 2025-10-20 https://bio-research.ai/exelixis-phase-3-trial-of-zanzalintinib-plus-atezolizumab-reduced-risk-of-death-by-20/ 2025-10-20 https://bio-research.ai/tokiwa-bio-secures-390-million-jpy-for-rna-vector-technology-applicable-in-regenerative-medicine/ 2025-10-20 https://bio-research.ai/henlius-pd-l1-antibody-drug-conjugate-receives-fda-orphan-drug-designation-for-thymic-epithelial-tumors/ 2025-10-20 https://bio-research.ai/kelun-biotech-s-trastuzumab-botidotin-phase-3-results-show-11-1-months-median-pfs-in-breast-cancer/ 2025-10-20 https://bio-research.ai/fda-approves-obinutuzumab-for-lupus-nephritis-based-on-phase-2-nobility-and-phase-3-regency-studies/ 2025-10-20 https://bio-research.ai/genentech-s-tecentriq-reduces-risk-of-death-by-41-in-muscle-invasive-bladder-cancer/ 2025-10-20 https://bio-research.ai/daiichi-sankyo-phase-2-data-50-5-objective-response-rate-for-antibody-drug-conjugate/ 2025-10-20 https://bio-research.ai/taiho-pharmaceutical-and-arcus-biosciences-agreement-for-exclusive-hif-2-inhibitor-development-in-asia/ 2025-10-19 https://bio-research.ai/fda-issues-complete-response-letter-for-ranibizumab-biosimilar-bla-due-to-manufacturing-observations/ 2025-10-19 https://bio-research.ai/hansoh-pharma-and-roche-ink-licensing-deal-for-cdh17-targeting-adc-worth-80m-upfront/ 2025-10-17 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-for-nasal-spray-in-treatment-resistant-depression/ 2025-10-16 https://bio-research.ai/veradermics-secures-150-million-series-c-financing-for-extended-release-oral-minoxidil-development/ 2025-10-16 https://bio-research.ai/evoq-and-sanofi-enter-collaboration-and-license-agreement-for-nanodisc-technology-worth-over-500m/ 2025-10-16 https://bio-research.ai/bridgene-biosciences-raises-28-million-to-advance-covalent-tead-inhibitor-in-solid-tumors/ 2025-10-16 https://bio-research.ai/aicuris-phase-3-trial-of-helicase-primase-inhibitor-for-hsv-met-primary-endpoint/ 2025-10-16 https://bio-research.ai/dianthus-therapeutics-licenses-bifunctional-bdca2-and-baff-april-inhibitor-from-nanjing-leads-biolabs-for-up-to-1b/ 2025-10-16 https://bio-research.ai/fda-approves-1-otic-clotrimazole-for-otomycosis-treatment/ 2025-10-16 https://bio-research.ai/fda-grants-fast-track-designation-for-enterome-s-immunotherapy-for-follicular-lymphoma/ 2025-10-16 https://bio-research.ai/haihe-biopharma-licenses-a-pi3k-inhibitor-to-taiho-pharmaceutical-for-japan-rights/ 2025-10-16 https://bio-research.ai/novartis-fabhalta-phase-iii-study-shows-superiority-in-slowing-igan-progression-over-two-years/ 2025-10-16 https://bio-research.ai/pelage-pharmaceuticals-secures-120-million-to-advance-topical-therapy-for-hair-growth/ 2025-10-15 https://bio-research.ai/novo-nordisk-acquires-exclusive-global-rights-to-anti-masp-2-mab-from-omeros-for-up-to-2-1b/ 2025-10-15 https://bio-research.ai/tubulis-raises-308-million-series-c-to-advance-antibody-drug-conjugate-candidate-and-expand-adc-platform/ 2025-10-15 https://bio-research.ai/minovia-therapeutics-mitochondrial-cell-therapy-received-fda-orphan-drug-designation-for-myelodysplastic-syndrome/ 2025-10-15 https://bio-research.ai/transpire-bio-s-inhaled-phosphodiesterase-4-inhibitor-and-inhaled-cannabidiol-receive-orphan-drug-designation/ 2025-10-15 https://bio-research.ai/eli-lilly-and-company-s-orforglipron-lowers-a1c-by-up-to-1-7-in-achieve-2-and-2-1-in-achieve-5/ 2025-10-15 https://bio-research.ai/step-pharma-completes-38m-series-c-for-clinical-development-of-oral-ctps1-inhibitor/ 2025-10-15 https://bio-research.ai/adocia-and-tonghua-dongbao-s-phase-3-trial-shows-non-inferior-hba1c-reduction-at-26-weeks/ 2025-10-15 https://bio-research.ai/nabla-bio-and-takeda-announce-multi-year-research-collaboration-for-de-novo-antibody-design/ 2025-10-14 https://bio-research.ai/insitro-and-bristol-myers-squibb-extend-als-molecule-discovery-collaboration-for-20m-upfront-and-over-2b-in-milestones/ 2025-10-14 https://bio-research.ai/kardigan-secures-254-million-in-series-b-financing-to-advance-three-lead-programs/ 2025-10-14 https://bio-research.ai/mabwell-s-b7-h3-targeting-adc-shows-19-responses-in-54-patients-with-advanced-solid-tumors/ 2025-10-14 https://bio-research.ai/fda-grants-platform-technology-designation-to-hsv-1-vector-platform-of-krystal-biotech/ 2025-10-14 https://bio-research.ai/everzom-raises-10-million-for-exosome-biotherapies-and-evergel-development-reviving-the-exosome-field/ 2025-10-14 https://bio-research.ai/kailera-therapeutics-secures-600-million-for-glp-1-gip-dual-agonist-phase-3-trials-in-obesity/ 2025-10-14 https://bio-research.ai/sumitomo-pharma-and-novo-nordisk-pharma-to-co-promote-wegovy-in-japan/ 2025-10-14 https://bio-research.ai/remegen-s-blys-and-april-inhibitor-phase-iii-study-in-sj-gren-s-syndrome-meets-primary-and-all-key-secondary-endpoints/ 2025-10-14 https://bio-research.ai/clarity-pharmaceuticals-co-psma-trial-detected-more-psma-positive-prostate-cancer-lesions/ 2025-10-14 https://bio-research.ai/excellergy-launches-with-70-million-series-a-financing-to-advance-allergic-effector-cell-response-inhibitors/ 2025-10-13 https://bio-research.ai/iregene-therapeutics-reports-52-8-improvement-in-motor-scores-in-parkinson-s-disease-phase-i-trial-of-ipsc-based-progenitor-cell-therapy/ 2025-10-13 https://bio-research.ai/adc-therapeutics-raises-60-million-in-pipe-financing-for-zynlonta-commercial-expansion/ 2025-10-13 https://bio-research.ai/lundbeck-s-bexicaserin-receives-china-btd-for-seizures-in-dees/ 2025-10-13 https://bio-research.ai/nouscom-s-phase-2-trial-of-investigational-vaccine-with-pembrolizumab-shows-15-orr-in-msi-h-mcrc/ 2025-10-13 https://bio-research.ai/taiho-oncology-and-cullinan-therapeutics-zipalertinib-achieves-31-3-intracranial-orr-in-nsclc/ 2025-10-12 https://bio-research.ai/arcus-biosciences-announces-overall-survival-results-from-arm-a1-of-phase-2-edge-gastric-study/ 2025-10-12 https://bio-research.ai/satellos-bioscience-s-muscle-stem-cell-regulator-increases-grip-strength-by-118-6-in-duchenne-muscular-dystrophy/ 2025-10-10 https://bio-research.ai/quoin-pharmaceuticals-secures-104-5-million-in-financing-advancing-netherton-syndrome-treatment/ 2025-10-10 https://bio-research.ai/bristol-myers-squibb-acquires-orbital-therapeutics-for-1-5b-gaining-rna-immunotherapy-and-rna-platform/ 2025-10-10 https://bio-research.ai/assembly-biosciences-helicase-primase-inhibitor-shows-shedding-rate-reductions-in-phase-1b-trial/ 2025-10-10 https://bio-research.ai/f-hoffmann-la-roche-licenses-glp-1-gip-receptor-agonist-to-chugai-pharmaceutical-co-for-japan/ 2025-10-10 https://bio-research.ai/expedition-therapeutics-secures-165-million-series-a-financing-to-advance-oral-dpp1-inhibitor-into-phase-2-study/ 2025-10-09 https://bio-research.ai/fda-approves-eydenzelt-for-wet-age-related-macular-degeneration-and-diabetic-retinopathy/ 2025-10-09 https://bio-research.ai/henlius-pd-1-inhibitor-meets-primary-endpoint-of-event-free-survival-in-phase-iii-gastric-cancer-study/ 2025-10-09 https://bio-research.ai/genethon-s-gene-therapy-for-duchenne-muscular-dystrophy-shows-motor-function-gain-in-3-patients/ 2025-10-09 https://bio-research.ai/cidara-therapeutics-antiviral-drug-fc-conjugate-received-fda-breakthrough-therapy-designation-for-influenza-a-and-b/ 2025-10-09 https://bio-research.ai/novo-nordisk-to-acquire-akero-therapeutics-for-up-to-5-2b-for-a-mash-treatment/ 2025-10-09 https://bio-research.ai/fda-approves-jascayd-for-idiopathic-pulmonary-fibrosis-based-on-fvc-decline-reduction/ 2025-10-09 https://bio-research.ai/abli-therapeutics-risvodetinib-phase-2-trial-meets-primary-safety-endpoint-in-parkinson-s-disease/ 2025-10-09 https://bio-research.ai/fda-grants-fast-track-designation-to-antibody-drug-conjugate-for-soft-tissue-sarcoma/ 2025-10-09 https://bio-research.ai/chengdu-new-radiomedicine-technology-secures-800-million-rmb-in-series-d-financing/ 2025-10-09 https://bio-research.ai/aviadobio-and-ugenex-therapeutics-sign-an-exclusive-option-and-license-agreement-for-aav-based-gene-therapy/ 2025-10-09 https://bio-research.ai/ono-pharmaceutical-s-ep4-antagonist-plus-opdivo-and-chemotherapy-prolonged-pfs-in-phase-2-gastric-cancer-study/ 2025-10-09 https://bio-research.ai/ono-pharmaceutical-s-s1p5-receptor-agonist-phase-2-trial-shows-slower-msa-progression/ 2025-10-09 https://bio-research.ai/fda-approves-libtayo-for-adjuvant-treatment-of-high-risk-cscc/ 2025-10-08 https://bio-research.ai/nilo-therapeutics-launches-with-101-million-in-series-a-financing-appoints-kim-seth-as-ceo/ 2025-10-08 https://bio-research.ai/arthrosi-raises-153m-in-series-e-to-advance-late-stage-trials-of-next-generation-urat1-inhibitor/ 2025-10-08 https://bio-research.ai/zenas-biopharma-and-innocare-pharma-ink-licensing-deal-for-btk-il-17aa-af-and-tyk2-inhibitors-worth-over-2b/ 2025-10-08 https://bio-research.ai/fda-grants-fast-track-designation-to-vivace-therapeutics-tead-autopalmitoylation-inhibitor-for-mesothelioma/ 2025-10-08 https://bio-research.ai/accent-therapeutics-sells-preclinical-small-molecule-program-to-boehringer-ingelheim/ 2025-10-08 https://bio-research.ai/transcode-therapeutics-acquires-polynoma-llc-and-its-late-stage-melanoma-vaccine-backed-by-25m-from-ck-life-sciences/ 2025-10-08 https://bio-research.ai/sanofi-s-sstr-targeted-alpha-therapy-meets-all-primary-efficacy-endpoints-in-phase-2-study/ 2025-10-08 https://bio-research.ai/u-s-fda-approves-simponi-for-pediatric-ulcerative-colitis/ 2025-10-07 https://bio-research.ai/precision-neuromed-glioblastoma-therapy-receives-fda-orphan-drug-designation/ 2025-10-07 https://bio-research.ai/kazia-and-qimr-berghofer-enter-exclusive-collaboration-and-in-licensing-agreement-for-pd-l1-degrader/ 2025-10-07 https://bio-research.ai/herantis-pharma-s-cdnf-derived-peptidomimetic-meets-all-endpoints-in-phase-1b-parkinson-s-disease-trial-at-200-mg-and-300-mg/ 2025-10-07 https://bio-research.ai/johnson-johnson-astro-study-of-tremfya-shows-clinical-and-endoscopic-remission-at-48-weeks/ 2025-10-07 https://bio-research.ai/johnson-johnson-oral-il-23-receptor-antagonist-shows-63-5-clinical-response-in-phase-2b-ulcerative-colitis-trial/ 2025-10-07 https://bio-research.ai/aerorx-therapeutics-secures-21-million-series-a-financing-to-advance-nebulized-laba-lama-therapy-for-copd/ 2025-10-07 https://bio-research.ai/torl-biotherapeutics-raises-96-million-in-series-c-funding-to-advance-claudin-6-targeting-adc/ 2025-10-07 https://bio-research.ai/affinia-therapeutics-secures-40-million-for-aav-based-gene-therapy-in-bag3-dilated-cardiomyopathy/ 2025-10-07 https://bio-research.ai/celaid-therapeutics-raises-jpy-1-055-billion-for-ex-vivo-expanded-hematopoietic-stem-cell-therapy/ 2025-10-07 https://bio-research.ai/molcure-and-boehringer-ingelheim-ink-multi-year-research-agreement-for-antibody-therapeutics-with-llm-platform/ 2025-10-07 https://bio-research.ai/winlevi-clascoterone-cream-1-approved-in-korea-for-acne-vulgaris-treatment/ 2025-10-07 https://bio-research.ai/astrazeneca-s-baxdrostat-phase-iii-trial-shows-statistically-significant-24-hour-ambulatory-systolic-blood-pressure-reduction/ 2025-10-07 https://bio-research.ai/algen-biotechnologies-and-astrazeneca-form-multi-target-immunology-drug-discovery-platform-partnership-up-to-555m/ 2025-10-06 https://bio-research.ai/biomea-fusion-s-phase-ii-covalent-111-study-shows-1-8-hba1c-reduction-at-week-52-in-type-2-diabetes/ 2025-10-06 https://bio-research.ai/skye-bioscience-s-nimacimab-monotherapy-does-not-meet-weight-loss-endpoint-in-phase-2a-study/ 2025-10-06 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-enzyme-replacement-therapy-for-sanfilippo-syndrome-type-b/ 2025-10-06 https://bio-research.ai/chiesi-group-and-arbor-biotechnologies-partner-for-a-gene-editing-program-in-ph1-for-up-to-115m-upfront-2b-in-milestones-and-royalties/ 2025-10-06 https://bio-research.ai/astrazeneca-and-daiichi-sankyo-s-tropion-breast02-phase-iii-trial-results-show-significantly-improved-survival/ 2025-10-06 https://bio-research.ai/trogenix-secures-70-million-to-advance-cancer-therapies-and-develop-its-odysseus-platform/ 2025-10-06 https://bio-research.ai/arvinas-inc-phase-1-data-shows-lrrk2-targeting-protac-reduces-parkinson-s-biomarkers-after-14-days/ 2025-10-05 https://bio-research.ai/guard-therapeutics-phase-2a-akita-study-shows-renoprotective-effect-and-reduced-kidney-injury-biomarkers/ 2025-10-05 https://bio-research.ai/european-commission-s-hera-and-hipra-sign-procurement-contract-for-bimervax-covid-19-vaccine-4-million-doses/ 2025-10-03 https://bio-research.ai/ovid-therapeutics-gaba-aminotransferase-inhibitor-shows-brain-penetration-and-target-engagement/ 2025-10-03 https://bio-research.ai/fda-approves-zepzelca-plus-atezolizumab-for-es-sclc-maintenance-treatment/ 2025-10-02 https://bio-research.ai/cartography-biosciences-secures-67-million-to-advance-lead-oncology-program-into-phase-1-trial/ 2025-10-02 https://bio-research.ai/cirrus-therapeutics-secures-11-million-to-advance-aav-gene-therapy-for-dry-amd/ 2025-10-02 https://bio-research.ai/nacuity-pharmaceuticals-naca-tablet-receives-fda-breakthrough-therapy-designation-for-retinitis-pigmentosa/ 2025-10-02 https://bio-research.ai/amgen-s-phase-3-vesalius-cv-trial-of-repatha-met-dual-primary-endpoints/ 2025-10-02 https://bio-research.ai/george-medicines-and-biolab-farmac-utica-partner-for-single-pill-hypertension-treatment-in-brazil/ 2025-10-02 https://bio-research.ai/calico-life-sciences-anti-papp-a-mab-granted-fda-fast-track-designation-for-autosomal-dominant-polycystic-kidney-disease/ 2025-10-02 https://bio-research.ai/anavex-life-sciences-corp-phase-2-study-of-anavex3-71-achieves-primary-endpoint/ 2025-10-02 https://bio-research.ai/taysha-gene-therapies-secures-fda-breakthrough-therapy-designation-for-aav-based-gene-therapy-in-rett-syndrome/ 2025-10-02 https://bio-research.ai/formycon-klinge-biopharma-and-valorum-biologics-settle-eylea-biosimilar-patent-disputes-with-regeneron/ 2025-10-02 https://bio-research.ai/aminex-therapeutics-investigational-drug-receives-orphan-drug-designation-for-neuroblastoma/ 2025-10-02 https://bio-research.ai/pi3k-inhibitor-receives-fda-fast-track-designation-for-pik3ca-mutant-advanced-breast-cancer/ 2025-10-01 https://bio-research.ai/seabelife-secures-2-million-funding-to-advance-small-molecule-drug-candidates/ 2025-10-01 https://bio-research.ai/vertanical-s-phase-3-studies-show-ver-01-reduces-chronic-low-back-pain-compared-to-placebo/ 2025-10-01 https://bio-research.ai/cellphire-therapeutics-phase-2-3-study-of-investigational-hemostatic-agent-meets-primary-efficacy-endpoint/ 2025-10-01 https://bio-research.ai/athernal-bio-secures-3-5-million-funding-to-develop-targeted-immunotherapies-for-clonal-haematopoiesis/ 2025-10-01 https://bio-research.ai/aerska-secures-21-million-to-develop-rnai-medicines-for-brain-diseases/ 2025-10-01 https://bio-research.ai/fda-grants-fast-track-designation-to-anti-mtbr-tau-antibody-for-early-alzheimer-s-disease/ 2025-10-01 https://bio-research.ai/niaid-awards-appili-therapeutics-and-vitalex-biosciences-a-40m-contract-for-a-vaccine-for-invasive-fungal-infections/ 2025-10-01 https://bio-research.ai/halozyme-therapeutics-acquires-elektrofi-for-its-microparticle-technology-for-up-to-900m/ 2025-10-01 https://bio-research.ai/hinge-bio-and-kyorin-pharmaceutical-collaborate-on-an-antibody-therapeutic-for-autoimmune-diseases/ 2025-09-30 https://bio-research.ai/fda-approves-rhapsido-for-chronic-spontaneous-urticaria/ 2025-09-30 https://bio-research.ai/crystalys-therapeutics-launches-with-205-million-to-advance-urat1-inhibitor-for-gout-treatment/ 2025-09-30 https://bio-research.ai/barinthus-biotherapeutics-merges-with-clywedog-therapeutics-to-advance-treatments-in-metabolic-and-autoimmune-diseases/ 2025-09-30 https://bio-research.ai/orion-corporation-s-2a-adrenoceptor-agonist-phase-2-study-for-insomnia-did-not-meet-primary-goal/ 2025-09-30 https://bio-research.ai/star-therapeutics-secures-125-million-in-series-d-financing-to-advance-monoclonal-antibody-for-bleeding-disorders/ 2025-09-30 https://bio-research.ai/clear-scientific-s-injectable-small-molecule-receives-fda-fast-track-designation-for-acute-methamphetamine-intoxication/ 2025-09-30 https://bio-research.ai/abbvie-submits-bla-for-cd123-targeting-adc-in-blastic-plasmacytoid-dendritic-cell-neoplasm/ 2025-09-30 https://bio-research.ai/fda-grants-fast-track-designation-to-cd19-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-lymphoma-and-chronic-lymphocytic-leukemia/ 2025-09-30 https://bio-research.ai/merck-s-phase-3-hyperion-trial-showed-winrevair-reduced-clinical-worsening-by-76-in-pah-adults/ 2025-09-30 https://bio-research.ai/boryung-corporation-acquires-global-rights-for-taxotere-from-sanofi-for-up-to-175m-euros/ 2025-09-30 https://bio-research.ai/full-life-technologies-secures-77-million-to-advance-radiopharmaceutical-pipeline-and-manufacturing/ 2025-09-29 https://bio-research.ai/aarvik-therapeutics-secures-series-seed-2-financing-to-advance-antibody-drug-conjugate-pipeline/ 2025-09-29 https://bio-research.ai/metsera-glp-1ra-shows-up-to-14-1-weight-loss-in-phase-2b-trials/ 2025-09-29 https://bio-research.ai/mindrank-ai-announces-8-9-body-weight-reduction-with-oral-small-molecule-glp-1ra/ 2025-09-29 https://bio-research.ai/fda-approves-tremfya-for-pediatric-plaque-psoriasis-and-active-psoriatic-arthritis/ 2025-09-29 https://bio-research.ai/fda-approves-qivigy-for-primary-humoral-immunodeficiency-in-adults/ 2025-09-29 https://bio-research.ai/enanta-s-oral-n-protein-inhibitor-misses-primary-endpoint-but-shows-strong-secondary-benefits-in-phase-2b-rsv-trial/ 2025-09-29 https://bio-research.ai/kala-bio-s-phase-2b-trial-of-topical-mesenchymal-stem-cell-secretome-therapy-for-pced-did-not-meet-primary-endpoint/ 2025-09-29 https://bio-research.ai/hanmi-hhp-and-gilead-sign-exclusive-global-deal-for-oral-p-gp-inhibitor/ 2025-09-29 https://bio-research.ai/boehringer-ingelheim-s-pde4b-inhibitor-shows-59-reduction-in-death-risk-in-ipf-and-ild-trials/ 2025-09-29 https://bio-research.ai/astrazeneca-and-daiichi-sankyo-s-enhertu-improves-invasive-disease-free-survival-in-her2-positive-early-breast-cancer/ 2025-09-29 https://bio-research.ai/genmab-acquires-merus-for-8-0b-in-cash-for-late-stage-bispecific-antibody/ 2025-09-29 https://bio-research.ai/novatim-immune-therapeutics-licenses-parallel-dual-target-car-t-therapy-to-vrise-therapeutics-for-india/ 2025-09-28 https://bio-research.ai/moonlake-immunotherapeutics-nanobody-shows-statistically-significant-improvement-in-phase-3-hidradenitis-suppurativa-trials/ 2025-09-28 https://bio-research.ai/abbvie-submits-nda-to-fda-for-dopamine-d1-d5-receptor-partial-agonist-for-parkinson-s-disease/ 2025-09-26 https://bio-research.ai/china-medical-system-reports-phase-3-results-of-topical-jak-inhibitor-with-63-iga-0-1-in-atopic-dermatitis/ 2025-09-26 https://bio-research.ai/fda-extends-evkeeza-approval-for-homozygous-familial-hypercholesterolemia-in-children-aged-1-to-5/ 2025-09-26 https://bio-research.ai/fda-approves-palsonify-for-acromegaly-based-on-two-phase-3-trials/ 2025-09-25 https://bio-research.ai/european-commission-approves-kisunla-for-early-symptomatic-alzheimer-s-disease/ 2025-09-25 https://bio-research.ai/arialys-therapeutics-receives-rare-pediatric-disease-designation-for-an-monoclonal-antibody-for-anti-nmda-receptor-encephalitis/ 2025-09-25 https://bio-research.ai/fda-approves-inluriyo-for-er-her2-esr1-mutated-advanced-or-metastatic-breast-cancer/ 2025-09-25 https://bio-research.ai/msd-licenses-evaxion-s-vaccine-candidate-for-7-5m-upfront-with-potential-milestones-up-to-592m/ 2025-09-25 https://bio-research.ai/gossamer-bio-secures-option-to-acquire-respira-therapeutics-for-an-inhaled-drug-issues-2-5m-shares/ 2025-09-25 https://bio-research.ai/biostar-pharma-s-microtubule-inhibitor-receives-orphan-drug-designation-for-pancreatic-cancer/ 2025-09-25 https://bio-research.ai/fda-grants-orphan-drug-designation-to-aav-therapy-for-limb-girdle-muscular-dystrophy-type-r9/ 2025-09-24 https://bio-research.ai/uniqure-s-aav-based-gene-therapy-phase-i-ii-results-show-slowing-of-huntington-s-disease-progression-at-36-months/ 2025-09-24 https://bio-research.ai/sparrow-pharmaceuticals-secures-95-million-in-series-b-to-advance-hsd-1-inhibitor-into-phase-2b-development/ 2025-09-24 https://bio-research.ai/glenmark-subsidiary-secures-rights-to-hengrui-s-her2-targeting-adc-in-1-1b-deal/ 2025-09-24 https://bio-research.ai/fda-grants-fast-track-designation-to-oral-art-inhibitor-for-atm-negative-metastatic-colorectal-cancer/ 2025-09-24 https://bio-research.ai/acadia-pharmaceuticals-phase-3-compass-pws-trial-of-intranasal-carbetocin-shows-no-significant-improvement/ 2025-09-24 https://bio-research.ai/harmony-biosciences-phase-3-reconnect-study-of-transdermal-cannabidiol-gel-did-not-meet-its-primary-endpoint/ 2025-09-24 https://bio-research.ai/variational-ai-and-merck-partner-for-small-molecule-therapeutics-variational-ai-receives-up-to-349m/ 2025-09-23 https://bio-research.ai/neurocentrx-pharma-secures-5m-from-wellcome-for-bipolar-depression-trial/ 2025-09-23 https://bio-research.ai/manas-ai-completes-26m-seed-extension-to-advance-its-drug-discovery-models-and-therapeutic-campaigns/ 2025-09-23 https://bio-research.ai/prellis-biologics-and-eli-lilly-partner-to-discover-and-develop-human-antibody-therapeutics/ 2025-09-23 https://bio-research.ai/tegmine-therapeutics-and-boehringer-ingelheim-collaborate-on-adc-development-for-up-to-three-cancer-targets/ 2025-09-23 https://bio-research.ai/daltontx-raises-4-million-in-seed-financing-for-ai-enabled-drug-discovery-platforms/ 2025-09-23 https://bio-research.ai/seed-therapeutics-raised-a-30-million-series-a-3-financing-and-receives-fda-ind-clearance-for-rbm39-targeting-molecular-glue-degrader/ 2025-09-23 https://bio-research.ai/bms-phase-3-excaliber-rrmm-trial-shows-celmod-agent-combo-achieves-significant-mrd-negativity-in-relapsed-refractory-multiple-myeloma/ 2025-09-23 https://bio-research.ai/atai-life-sciences-and-beckley-psytech-s-intranasal-5-meo-dmt-therapy-shows-durable-3-month-antidepressant-benefit/ 2025-09-23 https://bio-research.ai/fda-issues-complete-response-letter-for-anti-promyostatin-mab-bla-citing-facility-observations/ 2025-09-23 https://bio-research.ai/sanofi-s-aav-gene-therapy-receives-fda-fast-track-designation-for-myotonic-dystrophy-type-1/ 2025-09-23 https://bio-research.ai/mavrix-bio-s-aav-gene-therapy-receives-fda-fast-track-designation-for-angelman-syndrome/ 2025-09-22 https://bio-research.ai/avenzo-therapeutics-secures-60-million-in-series-b-financing-to-advance-oncology-drug-candidates/ 2025-09-22 https://bio-research.ai/angelini-pharma-and-sovargen-ink-mtor-targeting-aso-deal-for-brain-health-550m-in-milestones/ 2025-09-22 https://bio-research.ai/j-j-s-ox2r-antagonist-misses-phase-3-primary-endpoint-in-mdd-but-shows-better-tolerability-than-quetiapine-xr/ 2025-09-22 https://bio-research.ai/european-commission-approves-voranigo-for-idh-mutated-grade-2-astrocytoma-or-oligodendroglioma/ 2025-09-22 https://bio-research.ai/starpharma-and-genentech-partner-for-dep-drug-delivery-technology-worth-up-to-569-5m/ 2025-09-22 https://bio-research.ai/mbx-biosciences-parathyroid-hormone-peptide-prodrug-achieved-primary-endpoint-at-week-12-in-phase-2-avail-trial/ 2025-09-22 https://bio-research.ai/ionis-gfap-targeting-aso-hits-pivotal-phase-3-primary-endpoint-in-alexander-disease-nda-filing-planned-for-q1-2026/ 2025-09-22 https://bio-research.ai/fda-extends-review-of-oral-btk-inhibitor-for-non-relapsing-secondary-progressive-multiple-sclerosis/ 2025-09-22 https://bio-research.ai/roche-s-phase-iii-evera-study-of-oral-selective-estrogen-receptor-degrader-plus-everolimus-met-co-primary-endpoints/ 2025-09-22 https://bio-research.ai/ausperbio-therapeutics-closes-63-million-series-b2-financing-round-to-advance-aso-clinical-development/ 2025-09-21 https://bio-research.ai/otsuka-and-lundbeck-receive-complete-response-letter-from-fda-for-rexulti-snda-in-ptsd/ 2025-09-20 https://bio-research.ai/fda-approves-merck-s-keytruda-qlex-subcutaneous-injection-for-adult-solid-tumor-indications/ 2025-09-19 https://bio-research.ai/fda-grants-accelerated-approval-to-forzinity-for-muscle-strength-in-barth-syndrome-patients/ 2025-09-19 https://bio-research.ai/fda-approves-subcutaneous-tremfya-induction-for-ulcerative-colitis-following-phase-3-astro-trial/ 2025-09-19 https://bio-research.ai/affibody-s-il-17a-inhibitor-achieves-hiscr75-in-phase-3-hidradenitis-suppurativa-trial-at-week-12/ 2025-09-19 https://bio-research.ai/fda-grants-orphan-drug-designation-to-an-antisense-oligonucleotide-drug-candidate-for-duchenne-muscular-dystrophy/ 2025-09-19 https://bio-research.ai/abclon-s-car-t-cell-therapy-candidate-receives-orphan-drug-designation/ 2025-09-19 https://bio-research.ai/immuto-scientific-closes-8-million-financing-collaborates-with-daiichi-sankyo-on-drug-discovery/ 2025-09-18 https://bio-research.ai/beijing-ql-biopharmaceutical-s-glp-1-receptor-agonist-candidate-phase-2-results-show-weight-reduction-with-a-160-mg-dose/ 2025-09-18 https://bio-research.ai/nektar-therapeutics-rezolve-ad-phase-2b-study-met-primary-and-secondary-endpoints-at-week-16/ 2025-09-18 https://bio-research.ai/biogen-acquires-alcyone-therapeutics-for-85m-and-expands-intrathecal-drug-delivery-portfolio-with-thecaflex-drx/ 2025-09-18 https://bio-research.ai/biovance-capital-partners-orbimed-and-torrey-pines-investment-fund-mondego-bio-for-ptpn2-inhibitors/ 2025-09-18 https://bio-research.ai/ucb-s-trispecific-antibody-achieves-64-9-easi75-and-46-6-easi90-in-phase-1-2a-atopic-dermatitis-trial/ 2025-09-18 https://bio-research.ai/roche-acquires-89bio-for-2-4b-cash-with-up-to-1-1b-contingent-value-right-for-mash-treatment/ 2025-09-18 https://bio-research.ai/ascletis-pharma-s-oral-fasn-inhibitor-met-all-primary-and-secondary-endpoints-in-phase-iii-acne-study/ 2025-09-17 https://bio-research.ai/eli-lilly-and-company-s-mounjaro-shows-a1c-and-bmi-improvements-at-30-weeks/ 2025-09-17 https://bio-research.ai/ollin-biosciences-launches-with-100-million-in-financing-to-develop-therapies-for-vision-threatening-diseases/ 2025-09-17 https://bio-research.ai/european-commission-grants-marketing-authorization-for-zurzuvae-to-treat-postpartum-depression/ 2025-09-17 https://bio-research.ai/leo-pharma-s-phase-2b-trial-of-anti-il22ra1-antibody-met-primary-endpoint-for-three-highest-doses/ 2025-09-17 https://bio-research.ai/lilly-s-oral-glp-1-outperforms-oral-semaglutide-in-phase-3-achieve-3-trial-for-type-2-diabetes/ 2025-09-17 https://bio-research.ai/mabwell-and-aditum-bio-form-kalexo-bio-licensing-dual-target-sirna-for-up-to-1b-12m-upfront/ 2025-09-17 https://bio-research.ai/roivant-and-priovant-s-oral-tyk2-jak1-inhibitor-meets-primary-and-all-secondary-endpoints-in-phase-3-valor-dermatomyositis-trial/ 2025-09-17 https://bio-research.ai/regeneron-pharmaceuticals-anti-activin-a-mab-met-primary-endpoint-in-phase-3-optima-trial-with-90-reduction-in-new-ho-lesions/ 2025-09-17 https://bio-research.ai/arthex-biotech-secures-87-million-in-series-b-funding-to-advance-antimir-oligonucleotide-for-myotonic-dystrophy-type-1/ 2025-09-17 https://bio-research.ai/astrazeneca-s-phase-iii-tulip-sc-trial-of-saphnelo-reduces-disease-activity-in-sle-patients/ 2025-09-17 https://bio-research.ai/mindrank-s-phase-iib-oral-glp-1-ra-achieves-10-3-weight-reduction-at-24-weeks/ 2025-09-17 https://bio-research.ai/astrazeneca-s-resolute-phase-iii-trial-for-fasenra-in-copd-did-not-achieve-statistical-significance/ 2025-09-17 https://bio-research.ai/sanofi-s-anti-tnf-ox40l-nanobody-achieves-positive-phase-2a-results-in-hidradenitis-suppurativa-at-week-16/ 2025-09-17 https://bio-research.ai/hightide-therapeutics-anti-inflammatory-metabolic-modulator-met-primary-endpoint-in-phase-3-symphony-2-trial-for-type-2-diabetes/ 2025-09-16 https://bio-research.ai/eli-lilly-s-oral-glp-1-phase-3-attain-1-trial-shows-12-4-weight-loss-at-72-weeks/ 2025-09-16 https://bio-research.ai/apollo-s-anti-il-18-mab-achieves-significant-easi-reduction-at-week-16-in-phase-2a-chameleon-trial/ 2025-09-16 https://bio-research.ai/dualitas-therapeutics-launches-with-65-million-series-a-financing-to-advance-bispecific-antibodies/ 2025-09-16 https://bio-research.ai/allrock-bio-inc-secures-50-million-in-series-a-funding-to-advance-pan-rock-inhibitor-into-phase-2-development/ 2025-09-16 https://bio-research.ai/reunion-neuroscience-secures-133-million-in-series-a-funding-supports-rekindle-phase-2-trial/ 2025-09-16 https://bio-research.ai/areteia-therapeutics-phase-iii-exhale-4-study-of-dexpramipexole-improves-lung-function-and-reduces-blood-absolute-eosinophil-count/ 2025-09-16 https://bio-research.ai/varmx-partners-with-csl-in-strategic-option-and-collaboration-agreement-targeting-coagulation-disorders/ 2025-09-16 https://bio-research.ai/sk-biopharmaceuticals-reports-phase-3-trial-shows-71-9-seizure-reduction-with-xcopri/ 2025-09-16 https://bio-research.ai/drug-hunter-receives-seed-investment-from-teamworthy-ventures-to-aid-research-and-development-teams/ 2025-09-15 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-cdh6-targeting-adc-for-platinum-resistant-ovarian-and-fallopian-tube-cancers/ 2025-09-15 https://bio-research.ai/oral-semaglutide-receives-eu-approval-for-type-2-diabetes-with-cardiovascular-benefits-in-soul-trial/ 2025-09-15 https://bio-research.ai/atyr-pharma-s-phase-3-trial-of-trna-synthetase-derived-therapy-in-sarcoidosis-patients-misses-primary-endpoint-at-week-48/ 2025-09-15 https://bio-research.ai/novartis-secures-exclusive-license-from-monte-rosa-for-immunology-degraders-in-deal-worth-up-to-5-7b/ 2025-09-15 https://bio-research.ai/shenzhen-rui-therapeutics-completes-series-a-funding-to-advance-clinical-trials-and-international-strategy/ 2025-09-15 https://bio-research.ai/alterity-therapeutics-phase-2-trial-of-ath434-shows-improved-disease-progression-in-multiple-system-atrophy/ 2025-09-15 https://bio-research.ai/fore-biotherapeutics-reports-braf-inhibitor-delivers-63-9-month-mpfs-and-85-7-cbr-in-braf-v600-papillary-thyroid-cancer/ 2025-09-12 https://bio-research.ai/uni-bio-science-partners-with-kexing-biopharm-for-bogutai-commercialization-in-six-international-markets/ 2025-09-12 https://bio-research.ai/galimedix-therapeutics-phase-1-study-of-oral-a-aggregation-modulator-shows-safety-and-blood-brain-barrier-penetration/ 2025-09-12 https://bio-research.ai/dianthus-therapeutics-closes-public-offering-raising-288-million-for-development-and-corporate-activities/ 2025-09-11 https://bio-research.ai/advent-sells-zentiva-to-gtcr-aiming-for-early-2026-closure-pending-regulatory-approvals/ 2025-09-11 https://bio-research.ai/zelgen-biopharmaceuticals-trispecific-antibody-and-bispecific-antibody-candidates-show-efficacy-and-safety-in-cancer-studies/ 2025-09-11 https://bio-research.ai/maze-therapeutics-secures-150-million-to-advance-an-apol1-inhibitor-candidate-and-an-slc6a19-inhibitor-candidate-for-kidney-and-metabolic-diseases/ 2025-09-11 https://bio-research.ai/affibody-reports-positive-phase-3-week-16-results-of-il-17a-inhibitor-in-hidradenitis-suppurativa-with-deepening-responses/ 2025-09-11 https://bio-research.ai/bioxodes-sa-phase-2a-trial-of-factor-xia-xiia-inhibitor-shows-reduced-hematoma-volume-in-intracerebral-hemorrhage/ 2025-09-11 https://bio-research.ai/us-fda-grants-fast-track-designation-to-sanofi-s-gene-therapy-for-neovascular-age-related-macular-degeneration/ 2025-09-11 https://bio-research.ai/yoltech-therapeutics-raises-300-million-rmb-to-advance-mrna-lnp-delivery-technology-and-clinical-pipelines/ 2025-09-10 https://bio-research.ai/kriya-therapeutics-secures-320-million-to-advance-gene-therapy-trials-and-product-development/ 2025-09-10 https://bio-research.ai/dewpoint-therapeutics-secures-series-d-financing-to-advance-oral-condensate-modulator-into-clinical-trials-by-2025/ 2025-09-10 https://bio-research.ai/odyssey-therapeutics-raises-213-million-in-series-d-financing-to-advance-autoimmune-disease-treatments/ 2025-09-10 https://bio-research.ai/ridge-biotechnologies-launches-with-25-million-and-partners-to-enhance-adc-therapeutic-discovery/ 2025-09-09 https://bio-research.ai/insitro-and-eli-lilly-partner-to-advance-machine-learning-models-for-small-molecule-pharmacology/ 2025-09-09 https://bio-research.ai/fda-approves-inlexzo-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer/ 2025-09-09 https://bio-research.ai/iregene-therapeutics-raises-funds-for-global-clinical-development-of-therapies-for-parkinson-s-and-retinal-diseases/ 2025-09-09 https://bio-research.ai/janssen-cilag-phase-3-mariposa-study-shows-reduced-resistance-mutations-in-advanced-lung-cancer/ 2025-09-09 https://bio-research.ai/teva-s-alpha-synuclein-oligomerization-inhibitor-granted-fast-track-by-fda-for-multiple-system-atrophy-treatment/ 2025-09-09 https://bio-research.ai/circle-pharma-partners-with-eli-lilly-to-apply-tunelab-ai-ml-to-mxmo-platform-and-advance-macrocycle-cancer-therapies/ 2025-09-09 https://bio-research.ai/ionis-pharmaceuticals-receives-fda-breakthrough-therapy-designation-for-antisense-oligonucleotide-therapy-to-treat-angelman-syndrome/ 2025-09-09 https://bio-research.ai/ns-pharma-s-jak1-inhibitor-receives-fda-fast-track-designation-for-treating-eosinophilic-granulomatosis-with-polyangiitis/ 2025-09-09 https://bio-research.ai/novartis-to-acquire-tourmaline-bio-for-48-per-share-in-1-4b-deal-for-anti-il6-mab-development/ 2025-09-09 https://bio-research.ai/atom-therapeutics-oral-urat1-inhibitor-meets-all-endpoints-in-global-phase-2b-3-gout-trial/ 2025-09-08 https://bio-research.ai/saol-therapeutics-receives-fda-crl-for-sl1009-in-pyruvate-dehydrogenase-deficiency/ 2025-09-08 https://bio-research.ai/remedium-bio-and-eli-lilly-collaborate-on-gene-therapies-for-type-2-diabetes-and-obesity/ 2025-09-08 https://bio-research.ai/biontech-and-bms-report-76-3-response-rate-in-phase-2-trial-of-pd-l1xvegf-a-bispecific-antibody-in-es-sclc/ 2025-09-08 https://bio-research.ai/alchemab-raises-32m-in-series-a-extension-to-support-muscle-atrophy-immune-and-neurological-programs/ 2025-09-08 https://bio-research.ai/eli-lilly-s-noncovalent-btk-inhibitor-pirtobrutinib-shows-pfs-benefit-in-phase-3-cll-sll-trial/ 2025-09-08 https://bio-research.ai/rapport-s-phase-2a-trial-of-tarp-8-nam-shows-30-seizure-reduction-in-85-2-of-patients-with-drug-resistant-focal-onset-seizures/ 2025-09-08 https://bio-research.ai/dianthus-therapeutics-phase-2-trial-of-anti-c1s-mab-shows-significant-improvement-in-mg-adl-and-qmg-scores/ 2025-09-08 https://bio-research.ai/alkermes-plc-s-phase-2-study-shows-its-ox2r-agonist-improves-wakefulness-and-cognition-in-narcolepsy-type-1/ 2025-09-08 https://bio-research.ai/takeda-s-phase-3-trial-of-ox2r-selective-agonist-meets-all-endpoints-in-treating-narcolepsy-type-1/ 2025-09-08 https://bio-research.ai/nrg-therapeutics-secures-50m-for-als-mnd-and-parkinson-s-treatment-development/ 2025-09-08 https://bio-research.ai/servier-to-acquire-bk-channel-modulator-from-kaerus-bioscience-in-deal-worth-up-to-450m/ 2025-09-08 https://bio-research.ai/epigenic-therapeutics-secures-60-million-to-advance-clinical-development-of-therapies-for-chronic-hepatitis-b-and-hypercholesterolemia/ 2025-09-08 https://bio-research.ai/shanghai-junshi-biosciences-anti-il-17a-mab-meets-endpoints-in-phase-3-psoriasis-trial/ 2025-09-07 https://bio-research.ai/daiichi-sankyo-and-merck-s-b7-h3-targeted-adc-shows-48-2-response-rate-in-phase-2-ideate-lung01-trial-for-es-sclc/ 2025-09-07 https://bio-research.ai/astrazeneca-s-phase-iii-flaura2-trial-shows-tagrisso-combo-cuts-death-risk-by-23-in-egfr-mutated-lung-cancer/ 2025-09-07 https://bio-research.ai/hengrui-pharma-licenses-phase-3-cardiac-myosin-inhibitor-to-braveheart-bio-in-deal-worth-up-to-1-013b/ 2025-09-05 https://bio-research.ai/biontech-and-dualitybio-phase-3-trial-meets-progression-free-survival-endpoint-in-her2-positive-cancer/ 2025-09-05 https://bio-research.ai/simcere-pharmaceutical-group-s-phase-iii-trial-of-quviviq-shows-improvements-in-insomnia-symptoms/ 2025-09-05 https://bio-research.ai/cage-bio-s-phase-2b-trial-of-cgb-500-shows-59-treatment-success-in-atopic-dermatitis/ 2025-09-04 https://bio-research.ai/enveda-enrolls-first-patient-in-phase-1b-trial-of-env-294-targeting-atopic-dermatitis/ 2025-09-04 https://bio-research.ai/release-therapeutics-and-geneva-university-partner-to-advance-mvx-onco-autologous-vaccination-program/ 2025-09-04 https://bio-research.ai/rapafusyn-pharmaceuticals-raises-44-million-to-advance-molecular-glue-therapeutics-in-oncology/ 2025-09-04 https://bio-research.ai/lactiga-us-and-baylor-college-collaborate-on-nih-funded-project-to-develop-human-breastmilk-siga-therapy/ 2025-09-04 https://bio-research.ai/ashvattha-therapeutics-phase-2-trial-of-hydroxyl-dendrimer-vegfr-tyrosine-kinase-inhibitor-shows-reduced-need-for-anti-vegf-injections/ 2025-09-04 https://bio-research.ai/al-s-pharma-s-phase-2-study-of-its-anti-sod1-drug-candidate-in-als-shows-safety-survival-improvements-and-biomarker-stabilization/ 2025-09-04 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-olomorasib-with-pembrolizumab-for-non-small-cell-lung-cancer/ 2025-09-04 https://bio-research.ai/mrm-health-raises-55m-for-phase-2b-trial-of-live-microbial-consortium-therapy-in-ulcerative-colitis/ 2025-09-04 https://bio-research.ai/biocytogen-and-merck-kgaa-collaborate-to-develop-antibody-conjugated-lnp-drug-delivery-solutions/ 2025-09-04 https://bio-research.ai/sanofi-s-phase-3-trial-of-anti-ox40l-mab-meets-all-endpoints-in-atopic-dermatitis-study/ 2025-09-04 https://bio-research.ai/boehringer-ingelheim-s-hernexeos-gets-breakthrough-therapy-designation-for-first-line-treatment-in-her2-mutant-metastatic-nsclc/ 2025-09-03 https://bio-research.ai/amgen-s-phase-3-trial-of-anti-fgfr2b-antibody-shows-diminished-survival-benefit-in-gastric-cancer/ 2025-09-03 https://bio-research.ai/treeline-biosciences-raises-200m-in-series-a-extension-to-advance-pipeline-and-initiate-phase-1-trials/ 2025-09-03 https://bio-research.ai/argo-and-novartis-strike-160m-upfront-5-2b-milestone-deal-covering-angptl3-and-additional-sirna-candidates/ 2025-09-03 https://bio-research.ai/novatim-partners-with-radiance-to-advance-ky-0301-globally-securing-15m-upfront-and-up-to-1b-in-milestones/ 2025-09-03 https://bio-research.ai/enlaza-therapeutics-and-vertex-pharmaceuticals-partner-on-drug-conjugates-with-45m-upfront-payment/ 2025-09-02 https://bio-research.ai/encoded-therapeutics-receives-rmat-designation-for-scn1a-gene-aav-drug-candidate-targeting-scn1a-dravet-syndrome/ 2025-09-02 https://bio-research.ai/upstream-bio-s-phase-2-trial-of-verekitug-reduces-nasal-polyp-scores-in-chronic-rhinosinusitis/ 2025-09-02 https://bio-research.ai/merck-phase-3-trial-of-enlicitide-shows-ldl-c-reduction-in-hypercholesterolemia-after-24-weeks/ 2025-09-02 https://bio-research.ai/arrowhead-and-novartis-sign-200m-deal-for-aro-snca-sirna-therapy-in-synucleinopathies/ 2025-09-02 https://bio-research.ai/charm-therapeutics-raises-80-million-in-series-b-funding-to-advance-menin-inhibitor-for-leukemia/ 2025-09-02 https://bio-research.ai/phase-2-trial-shows-ami-pharm-s-ayp-101-achieves-clinically-meaningful-smf-reduction-in-69-7-of-patients/ 2025-09-01 https://bio-research.ai/fda-approves-subcutaneous-form-of-lecanemab-for-weekly-maintenance-after-18-month-iv-initiation/ 2025-09-01 https://bio-research.ai/abl-bio-s-synuclein-targeting-bispecific-antibody-demonstrates-safety-in-phase-1-u-s-study/ 2025-09-01 https://bio-research.ai/astrazeneca-s-baxhtn-phase-iii-trial-meets-all-endpoints-with-aldosterone-synthase-inhibitor-in-hard-to-control-hypertension/ 2025-08-30 https://bio-research.ai/novartis-phase-iv-study-shows-85-on-leqvio-hit-ldl-c-targets-vs-31-on-placebo-after-90-days/ 2025-08-30 https://bio-research.ai/maple-hcm-phase-iii-trial-demonstrates-cardiac-myosin-inhibitor-reduces-nt-probnp-and-improves-cardiac-function-measures/ 2025-08-30 https://bio-research.ai/oral-sgc-stimulator-misses-endpoint-in-bayer-and-msd-s-victor-trial-but-pooled-analysis-shows-benefit/ 2025-08-30 https://bio-research.ai/fda-approves-wayrilz-for-adults-with-chronic-immune-thrombocytopenia-after-luna-3-phase-3-study/ 2025-08-29 https://bio-research.ai/zydus-therapeutics-reports-epics-iii-trial-shows-its-ppar-agonist-improves-biochemical-response-in-pbc/ 2025-08-29 https://bio-research.ai/accro-bioscience-grants-fosun-pharma-rights-to-develop-tyk2-jak1-inhibitor-ac-201-in-greater-china/ 2025-08-29 https://bio-research.ai/beone-medicines-phase-1-2-study-of-oral-bcl-2-inhibitor-in-mantle-cell-lymphoma-achieves-overall-response-rate/ 2025-08-29 https://bio-research.ai/meiji-seika-pharma-gains-approval-to-manufacture-and-market-costaibe-vaccine-for-covid-19-prevention/ 2025-08-29 https://bio-research.ai/medipal-holdings-and-jcr-pharmaceuticals-agree-on-jr-479-s-international-development-for-gm2-gangliosidosis/ 2025-08-29 https://bio-research.ai/microbiotix-completes-series-b-fundraising-to-support-bacteriophage-therapeutics-development/ 2025-08-29 https://bio-research.ai/fda-grants-breakthrough-therapy-and-orphan-drug-designations-to-d3-bio-s-kras-g12c-inhibitor-candidate-for-kras-g12c-mutated-cancers/ 2025-08-28 https://bio-research.ai/replicate-bioscience-and-novo-nordisk-partner-on-srrna-technology-for-cardiometabolic-therapies-up-to-550m/ 2025-08-28 https://bio-research.ai/teva-pharmaceuticals-launches-generic-saxenda-for-weight-loss-after-fda-approval/ 2025-08-28 https://bio-research.ai/ascletis-pharma-s-phase-ib-study-shows-glp-1r-biased-agonist-drug-candidate-with-2-3-to-3-3-fold-higher-drug-exposure-in-obesity/ 2025-08-27 https://bio-research.ai/hope-biosciences-receives-fda-rmat-designation-for-hb-admscs-in-multiple-sclerosis-treatment/ 2025-08-27 https://bio-research.ai/antiva-biosciences-trial-shows-46-achieving-hrhpv-negativity-at-week-12-with-abi-2280-vaginal-insert/ 2025-08-27 https://bio-research.ai/eli-lilly-phase-3-trial-shows-verzenio-improves-overall-survival-in-high-risk-early-breast-cancer/ 2025-08-27 https://bio-research.ai/leal-therapeutics-secures-30-million-to-advance-clinical-trials-for-schizophrenia-and-als-treatments/ 2025-08-27 https://bio-research.ai/remegen-s-phase-3-trial-in-china-shows-taci-fc-fusion-protein-achieves-55-reduction-in-upcr-for-iga-nephropathy/ 2025-08-27 https://bio-research.ai/amylyx-pharmaceuticals-discontinues-orion-program-for-its-neuroprotective-fdc-therapy-due-to-lack-of-efficacy-at-week-24/ 2025-08-27 https://bio-research.ai/mannkind-and-united-therapeutics-expand-collaboration-for-dry-powder-inhalation-therapy/ 2025-08-27 https://bio-research.ai/wugen-secures-115-million-to-advance-t-rrex-trial-of-cd7-targeted-car-t-therapy-for-t-all-and-t-lbl/ 2025-08-27 https://bio-research.ai/fda-accepts-bayer-s-nda-for-gadoquatrane-low-dose-gadolinium-contrast-agent-for-mri/ 2025-08-27 https://bio-research.ai/shanghai-fosun-and-sitala-ink-675m-licensing-deal-for-small-molecule-inhibitor-ex-china-rights/ 2025-08-27 https://bio-research.ai/fda-grants-fast-track-designation-to-parp-inhibitor-for-advanced-ovarian-cancer-treatment/ 2025-08-26 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-fr-directed-adc-for-recurrent-endometrial-cancer-treatment/ 2025-08-26 https://bio-research.ai/regeneron-s-phase-3-nimble-trial-of-sirna-therapy-targeting-c5-meets-key-endpoints-in-myasthenia-gravis-shows-2-3-point-mg-adl-benefit/ 2025-08-26 https://bio-research.ai/eli-lilly-s-phase-3-attain-2-trial-of-oral-glp-1ra-shows-significant-weight-loss-and-a1c-reduction/ 2025-08-26 https://bio-research.ai/european-commission-approves-yeytuo-for-hiv-1-prevention-after-phase-3-trials-demonstrate-efficacy/ 2025-08-26 https://bio-research.ai/bioarctic-partners-with-novartis-for-neurodegeneration-treatment-gains-30m-upfront-payment/ 2025-08-26 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-protagonist-s-hepcidin-mimetic-peptide-for-polycythemia-vera/ 2025-08-25 https://bio-research.ai/pds-biotechnology-s-phase-2-trial-shows-39-3-months-median-survival-in-hpv16-positive-hnscc/ 2025-08-25 https://bio-research.ai/abbvie-acquires-5-ht2a-agonist-from-gilgamesh-pharma-inc-in-a-deal-worth-up-to-1-2-b/ 2025-08-25 https://bio-research.ai/arnatar-therapeutics-aso-receives-fda-orphan-drug-and-rare-pediatric-disease-designations-for-alagille-syndrome/ 2025-08-25 https://bio-research.ai/incyclix-bio-raises-11-25m-series-b-extension-to-support-phase-1-2-trial-of-cdk2-inhibitor/ 2025-08-25 https://bio-research.ai/royalty-pharma-acquires-beone-royalties-on-amgen-s-dll3-targeting-bite-therapy-sales-outside-china-for-up-to-950m/ 2025-08-25 https://bio-research.ai/mannkind-acquires-scpharmaceuticals-for-360m-with-175m-support-from-blackstone-to-expand-portfolio/ 2025-08-25 https://bio-research.ai/vaxxas-raises-90-million-to-advance-hd-map-needle-free-vaccine-technology-and-expand-manufacturing/ 2025-08-25 https://bio-research.ai/h-lundbeck-a-s-phase-1b-2a-trial-shows-seizure-reduction-in-55-of-epilepsy-patients/ 2025-08-25 https://bio-research.ai/argenx-s-adapt-seron-study-shows-significant-mg-adl-improvement-in-seronegative-mg-patients/ 2025-08-25 https://bio-research.ai/akeso-inc-s-phase-3-trials-meet-endpoints-for-anti-il-17a-mab-in-ankylosing-spondylitis-and-anti-il-4r-mab-in-dermatitis/ 2025-08-25 https://bio-research.ai/imbiologics-and-genequantum-partner-to-co-develop-adcs-using-multivalent-antibody-backbone-technology-platform/ 2025-08-22 https://bio-research.ai/veongen-therapeutics-aav-based-abca4-gene-therapy-candidate-receives-rmat-designation-for-stargardt-disease-and-related-dystrophies/ 2025-08-21 https://bio-research.ai/abbvie-phase-3-trial-shows-oral-jak-inhibitor-achieves-endpoints-with-increased-scalp-hair-coverage-in-alopecia-areata/ 2025-08-21 https://bio-research.ai/gilead-s-kite-to-acquire-interius-biotherapeutics-for-350m-to-advance-in-vivo-car-therapeutics/ 2025-08-21 https://bio-research.ai/fda-approves-dawnzera-first-rna-targeted-medicine-for-hereditary-angioedema-in-patients-aged-12/ 2025-08-21 https://bio-research.ai/immuneering-prices-25-million-private-placement/ 2025-08-21 https://bio-research.ai/nicox-s-no-donating-bimatoprost-non-inferior-to-latanoprost-in-phase-3-reducing-iop-by-7-9-to-10-0-mmhg/ 2025-08-21 https://bio-research.ai/bio-thera-and-stada-enter-136m-actemra-biosimilar-deal-later-broadened-to-simponi-biosimilar/ 2025-08-21 https://bio-research.ai/keros-therapeutics-fc-fusion-protein-receives-fda-orphan-drug-designation-for-dmd-therapy/ 2025-08-20 https://bio-research.ai/bioaegis-therapeutics-gains-fda-fast-track-for-rhu-pgsn-in-decompression-sickness-treatment/ 2025-08-20 https://bio-research.ai/xoma-royalty-corporation-to-acquire-mural-oncology-plc-for-approximately-36-2m/ 2025-08-20 https://bio-research.ai/jazz-pharmaceuticals-and-saniona-form-global-agreement-for-kv7-2-kv7-3-potassium-channel-activator-in-epilepsy-valued-up-to-1-04b/ 2025-08-20 https://bio-research.ai/celldex-therapeutics-phase-2-trial-shows-anti-kit-antibody-depletes-mast-cells-but-fails-to-improve-eoe-symptoms/ 2025-08-19 https://bio-research.ai/rezdiffra-receives-eu-approval-as-first-therapy-for-mash-with-moderate-to-advanced-liver-fibrosis/ 2025-08-19 https://bio-research.ai/vantai-and-halda-therapeutics-partner-to-create-next-gen-riptac-medicines-in-1b-agreement/ 2025-08-19 https://bio-research.ai/fda-issues-complete-response-letter-to-ptc-therapeutics-for-15-lo-inhibitor-in-friedreich-s-ataxia/ 2025-08-19 https://bio-research.ai/viking-therapeutics-phase-2-trial-of-oral-glp-1-gip-dual-agonist-shows-up-to-12-2-mean-weight-loss-over-13-weeks/ 2025-08-19 https://bio-research.ai/remegen-partners-with-santen-granting-exclusive-rights-for-vegf-fgf-dual-target-fusion-protein-in-asia-for-rmb-250m-upfront/ 2025-08-18 https://bio-research.ai/fda-extends-review-timeline-for-regenxbio-s-mps-ii-aav-therapy-bla-to-february-2026-after-additional-data-submission/ 2025-08-18 https://bio-research.ai/boehringer-ingelheim-and-palatin-technologies-collaborate-on-retinal-disease-therapies-for-280m/ 2025-08-18 https://bio-research.ai/skyhawk-therapeutics-partners-with-merck-kgaa-in-2b-deal-for-rna-targeting-neurological-therapies/ 2025-08-18 https://bio-research.ai/reunion-neuroscience-phase-2-trial-shows-re104-30mg-reduces-depression-scores-in-postpartum-depression/ 2025-08-18 https://bio-research.ai/stealth-biotherapeutics-resubmits-new-drug-application-for-mitochondrial-targeted-therapeutic-to-treat-barth-syndrome/ 2025-08-18 https://bio-research.ai/enlivex-therapeutics-ltd-phase-iia-trial-reports-72-knee-pain-reduction-in-osteoarthritis/ 2025-08-18 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-b7-h3-directed-adc-for-extensive-stage-small-cell-lung-cancer/ 2025-08-18 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-egfrxher3-adc-for-advanced-nsclc-with-egfr-mutations/ 2025-08-18 https://bio-research.ai/anocca-secures-funding-for-gene-edited-tcr-t-cell-therapy-phase-i-trial-targeting-kras-mutations-in-pancreatic-cancer/ 2025-08-18 https://bio-research.ai/khondrion-and-medvisis-finalize-exclusive-licensing-for-oral-redox-modulator-in-switzerland-and-liechtenstein/ 2025-08-18 https://bio-research.ai/avixgen-signs-500b-krw-agreement-with-u-s-biotech-for-peptide-based-drug-delivery-technology/ 2025-08-18 https://bio-research.ai/the-european-medicines-agency-accepts-senaparib-application-for-advanced-ovarian-cancer-therapy/ 2025-08-18 https://bio-research.ai/pfizer-s-phase-3-trial-of-anti-p-selectin-antibody-fails-to-reduce-vaso-occlusive-crises-in-sickle-cell-disease/ 2025-08-15 https://bio-research.ai/fda-approves-wegovy-for-treating-mash-with-liver-fibrosis-based-on-essence-trial-results/ 2025-08-15 https://bio-research.ai/fda-approves-tonmya-first-non-opioid-sublingual-tablet-for-fibromyalgia-treatment-in-over-15-years/ 2025-08-15 https://bio-research.ai/papzimeos-gains-fda-approval-as-first-therapy-for-recurrent-respiratory-papillomatosis-in-adults/ 2025-08-15 https://bio-research.ai/visen-pharmaceuticals-phase-2-china-trial-shows-sustained-release-of-cnp-increases-growth-velocity-in-achondroplasia/ 2025-08-15 https://bio-research.ai/superluminal-medicines-and-eli-lilly-collaborate-on-gpcr-targeting-therapeutics-for-cardiometabolic-diseases/ 2025-08-14 https://bio-research.ai/shilpa-medicare-gets-approval-for-norudca-effective-against-non-alcoholic-fatty-liver-disease/ 2025-08-14 https://bio-research.ai/rtw-signs-75m-royalty-based-funding-deal-with-aquestive-for-anaphylm-contingent-on-fda-approval/ 2025-08-14 https://bio-research.ai/halda-therapeutics-ar-targeting-riptac-drug-candidate-receives-fast-track-status-for-treating-metastatic-prostate-cancer/ 2025-08-14 https://bio-research.ai/beam-therapeutics-gene-edited-cell-therapy-candidate-receives-fda-designation-and-increases-fetal-hemoglobin-levels-in-sickle-cell-disease/ 2025-08-14 https://bio-research.ai/tyk-medicines-phase-ii-trial-shows-higher-response-rate-for-asandeutertinib-in-egfr-mutant-nsclc/ 2025-08-14 https://bio-research.ai/basilea-pharmaceutica-secures-global-rights-to-phase-3-ready-oral-antibiotic-for-complicated-utis-from-venatorx/ 2025-08-14 https://bio-research.ai/sanofi-s-oral-btk-inhibitor-receives-orphan-designation-from-ema-for-igg4-related-disease/ 2025-08-14 https://bio-research.ai/roche-and-pilatus-biosciences-collaborate-for-phase-1-trial-of-anti-cd36-mab-plus-tecentriq-in-hcc/ 2025-08-13 https://bio-research.ai/response-pharmaceuticals-phase-2-trial-shows-reduced-postprandial-triglycerides-and-weight-regain-with-gut-specific-mtp-inhibitor/ 2025-08-13 https://bio-research.ai/creative-medical-technology-holdings-gets-fda-fast-track-for-allogeneic-perinatal-cell-therapy-in-degenerative-disc-disease/ 2025-08-13 https://bio-research.ai/remegen-s-phase-3-study-of-dual-baff-april-inhibitor-achieves-primary-endpoint-for-primary-sj-gren-s-disease-in-china/ 2025-08-13 https://bio-research.ai/vedanta-biosciences-live-biotherapeutic-product-fails-primary-endpoint-in-phase-2-ulcerative-colitis-study/ 2025-08-13 https://bio-research.ai/jocasta-neuroscience-secures-35-million-for-phase-1-development-of-a-klotho-protein-therapeutic-jn-0413/ 2025-08-12 https://bio-research.ai/gameto-secures-44-million-to-advance-phase-3-trial-for-fertility-treatment-using-stem-cells/ 2025-08-12 https://bio-research.ai/fda-approves-first-dpp1-inhibitor-brinsupri-for-non-cystic-fibrosis-bronchiectasis/ 2025-08-12 https://bio-research.ai/aavantgarde-bio-s-aav-gene-therapy-candidate-receives-fda-fast-track-designation-for-stargardt-disease/ 2025-08-12 https://bio-research.ai/amphastar-licenses-peptides-from-nanjing-anji-for-u-s-and-canada-in-6m-upfront-deal/ 2025-08-12 https://bio-research.ai/merck-s-phase-3-trial-shows-keytruda-padcev-combo-boosts-survival-and-pathologic-response-in-muscle-invasive-bladder-cancer/ 2025-08-12 https://bio-research.ai/bayer-and-kumquat-biosciences-enter-1-3b-global-agreement-for-kras-g12d-inhibitor-development/ 2025-08-12 https://bio-research.ai/novartis-phase-iii-trial-shows-delayed-treatment-failure-and-improved-platelet-count-in-primary-immune-thrombocytopenia/ 2025-08-12 https://bio-research.ai/fosun-pharma-licenses-expedition-therapeutics-for-645m-deal-to-develop-oral-dpp-1-inhibitor/ 2025-08-11 https://bio-research.ai/bridgebio-oncology-merges-with-helix-acquisition-nets-382m-to-fund-ras-targeted-drug-pipeline/ 2025-08-11 https://bio-research.ai/fda-grants-fast-track-designation-to-iv-ketamine-formulation-for-suicidal-ideation-in-depression/ 2025-08-11 https://bio-research.ai/io-biotech-s-phase-3-trial-of-cancer-vaccine-plus-pembrolizumab-shows-19-4-month-pfs-in-advanced-melanoma-narrowly-missing-statistical-significance/ 2025-08-11 https://bio-research.ai/fda-accepts-supplemental-application-for-blujepa-treating-uncomplicated-gonorrhoea-in-patients-12/ 2025-08-11 https://bio-research.ai/novartis-reports-phase-iii-trials-of-baff-r-targeting-mab-show-significant-improvement-in-sj-gren-s-disease-activity/ 2025-08-11 https://bio-research.ai/k36-therapeutics-starts-phase-1-trial-of-nsd2-inhibitor-ktx-2001-plus-ari-in-collaboration-with-bayer-and-pcctc-for-prostate-cancer/ 2025-08-08 https://bio-research.ai/fda-grants-accelerated-approval-to-hernexeos-her2-tki-for-non-squamous-nsclc-with-specific-her2-mutations/ 2025-08-08 https://bio-research.ai/assembly-biosciences-reports-94-reduction-in-hsv-2-lesion-rates-with-helicase-primase-inhibitor-in-phase-1b-trial/ 2025-08-08 https://bio-research.ai/biontech-resolves-mrna-patent-litigation-with-curevac-and-gsk-in-740m-deal/ 2025-08-08 https://bio-research.ai/us-fda-awards-orphan-drug-designation-to-kedrion-for-treatment-targeting-congenital-aceruloplasminemia/ 2025-08-07 https://bio-research.ai/proteinqure-s-ai-designed-pq203-receives-fda-fast-track-designation-for-triple-negative-breast-cancer/ 2025-08-07 https://bio-research.ai/cormedix-inc-to-acquire-melinta-therapeutics-llc-for-300m-upfront-with-potential-milestone-payments/ 2025-08-07 https://bio-research.ai/genmab-a-s-phase-3-trial-shows-improved-response-and-survival-in-the-treatment-of-relapsed-refractory-follicular-lymphoma/ 2025-08-07 https://bio-research.ai/minghui-pharmaceutical-secures-usd-131-million-in-pre-ipo-financing-to-advance-clinical-programs/ 2025-08-07 https://bio-research.ai/strand-therapeutics-secures-153m-in-series-b-funding-to-advance-mrna-therapy-pipeline/ 2025-08-07 https://bio-research.ai/eli-lilly-s-phase-3-trial-shows-significant-weight-loss-with-oral-glp-1-receptor-agonist-after-72-weeks/ 2025-08-07 https://bio-research.ai/snipr-biome-raises-eur-35-million-to-advance-bacterial-targeting-crispr-cas-therapies-for-cystic-fibrosis-and-cancer/ 2025-08-07 https://bio-research.ai/luxna-biotech-secures-additional-150-million-yen-in-series-c-funding-for-aso-drug-discovery-and-global-expansion/ 2025-08-07 https://bio-research.ai/xtalpi-and-dovetree-medicines-collaborate-on-ai-and-robot-driven-drug-discovery-in-deal-worth-up-to-5-99b/ 2025-08-06 https://bio-research.ai/chai-discovery-raises-70-million-in-series-a-to-advance-ai-driven-drug-discovery-with-chai-2-model/ 2025-08-06 https://bio-research.ai/fda-grants-accelerated-approval-to-modeyso-for-treating-h3-k27m-mutant-diffuse-midline-glioma/ 2025-08-06 https://bio-research.ai/cardiol-therapeutics-cannabidiol-therapy-shows-ecv-improvement-trend-no-gls-difference-in-phase-ii-myocarditis-study/ 2025-08-06 https://bio-research.ai/astria-therapeutics-grants-kaken-rights-to-develop-and-commercialize-plasma-kallikrein-inhibitor-in-japan/ 2025-08-06 https://bio-research.ai/fda-grants-fast-track-designation-to-dizal-s-lyn-btk-dual-inhibitor-for-relapsed-or-refractory-cll-sll-treatment/ 2025-08-06 https://bio-research.ai/galapagos-nv-s-cd19-car-t-cell-therapy-receives-rmat-designation-from-fda-for-relapsed-mantle-cell-lymphoma-treatment/ 2025-08-06 https://bio-research.ai/faron-pharmaceuticals-reports-43-complete-remission-in-bexmab-trial-for-high-risk-myelodysplastic-syndrome/ 2025-08-06 https://bio-research.ai/hmnc-brain-health-s-v1b-receptor-antagonist-shows-benefit-in-genetic-subgroup-but-misses-primary-endpoint-in-phase-2b-mdd-trial/ 2025-08-05 https://bio-research.ai/serb-pharmaceuticals-to-acquire-y-mabs-therapeutics-in-a-412m-all-cash-deal/ 2025-08-05 https://bio-research.ai/urogen-s-phase-3-trial-shows-72-2-24-month-response-durability-in-bladder-cancer/ 2025-08-05 https://bio-research.ai/elevar-therapeutics-phase-2-trial-of-oral-fgfr2-inhibitor-shows-superior-response-rate-in-cholangiocarcinoma/ 2025-08-05 https://bio-research.ai/surv-biopharma-grants-nippon-zoki-exclusive-rights-to-market-oncolytic-virus-therapy-in-japan-for-up-to-10-5-b-yen/ 2025-08-05 https://bio-research.ai/metis-technologies-raises-rmb-400-million-in-series-d-financing-to-enhance-automation-and-expand-partnerships/ 2025-08-05 https://bio-research.ai/fda-accepts-application-for-breyanzi-to-treat-relapsed-or-refractory-marginal-zone-lymphoma/ 2025-08-04 https://bio-research.ai/vertex-pharmaceuticals-phase-2-trial-of-nav1-8-inhibitor-shows-no-significant-pain-relief-in-post-bunionectomy-surgery/ 2025-08-04 https://bio-research.ai/xoma-royalty-corporation-to-acquire-lava-therapeutics-n-v-with-milestone-and-royalty-benefits/ 2025-08-04 https://bio-research.ai/xoma-royalty-corporation-to-acquire-hillevax-with-1-95-per-share-offer-and-future-earnings-rights/ 2025-08-04 https://bio-research.ai/praxis-precision-medicines-phase-2-radiant-trial-shows-56-3-median-reduction-in-seizure-frequency/ 2025-08-04 https://bio-research.ai/topline-results-from-hansa-biopharma-show-imlifidase-lowers-anti-aav-antibodies-before-elevidys-in-dmd-patients/ 2025-08-01 https://bio-research.ai/spine-biopharma-s-phase-3-trial-of-a-tgf-antagonist-peptide-fails-to-meet-its-primary-endpoint-in-chronic-low-back-pain/ 2025-08-01 https://bio-research.ai/sanofi-obtains-exclusive-license-from-visirna-for-apoc3-rnai-in-china-with-130m-upfront-payment/ 2025-08-01 https://bio-research.ai/chordia-therapeutics-and-senju-pharmaceutical-explore-eye-disease-treatments-using-gcn2-kinase-inhibitor/ 2025-08-01 https://bio-research.ai/fda-approves-alhemo-for-once-daily-bleeding-prevention-in-hemophilia-a-and-b-patients-aged-12-and-up/ 2025-07-31 https://bio-research.ai/fda-approves-vizz-from-lenz-therapeutics-as-first-presbyopia-treatment-after-phase-3-trials/ 2025-07-31 https://bio-research.ai/maxcyte-partners-with-anocca-granting-access-to-flow-electroporation-technology-for-t-cell-therapies/ 2025-07-31 https://bio-research.ai/soligenix-phase-2a-study-of-therapeutic-peptide-candidate-for-beh-et-s-disease-shows-reduced-oral-ulcers-and-pain/ 2025-07-31 https://bio-research.ai/dr-falk-pharma-and-allianthera-partner-to-develop-and-commercialize-ahr-agonist-for-ulcerative-colitis/ 2025-07-30 https://bio-research.ai/nuvisertib-a-pim1-kinase-inhibitor-receives-orphan-drug-designation-for-myelofibrosis-treatment-in-europe/ 2025-07-30 https://bio-research.ai/newamsterdam-pharma-s-cetp-inhibitor-shows-significant-20-5-reduction-in-p-tau217-in-full-analysis-of-broadway-trial/ 2025-07-30 https://bio-research.ai/vyne-therapeutics-phase-2b-trial-shows-no-meeting-of-primary-endpoints-for-pan-bromodomain-bet-inhibitor-gel-in-vitiligo/ 2025-07-30 https://bio-research.ai/abbvie-s-phase-3-trial-shows-oral-jak-inhibitor-improves-scalp-hair-coverage-at-week-24-in-alopecia-areata/ 2025-07-30 https://bio-research.ai/madrigal-pharmaceuticals-and-cspc-sign-global-license-deal-for-oral-glp-1r-agonist-worth-up-to-2-12b/ 2025-07-30 https://bio-research.ai/viridian-therapeutics-and-kissei-pharmaceutical-partner-for-anti-igf1r-antibodies-in-japan/ 2025-07-30 https://bio-research.ai/us-fda-grants-orphan-drug-designation-to-sanofi-s-anti-gprc5d-mab-for-relapsed-or-refractory-multiple-myeloma/ 2025-07-30 https://bio-research.ai/cardiff-oncology-s-phase-2-trial-shows-49-response-rate-for-30mg-oral-plk1-inhibitor-in-colorectal-cancer/ 2025-07-29 https://bio-research.ai/ltz-therapeutics-and-eli-lilly-enter-strategic-collaboration-to-develop-myeloid-engager-therapeutics/ 2025-07-29 https://bio-research.ai/aclaris-therapeutics-reports-phase-2a-trial-of-dual-itk-jak3-inhibitor-shows-clinically-meaningful-improvements/ 2025-07-29 https://bio-research.ai/artbio-secures-132-million-to-advance-alpha-radioligand-therapy-through-phase-ii-clinical-trials-and-expand-supply-chain/ 2025-07-29 https://bio-research.ai/bausch-health-to-acquire-durect-for-63m-upfront-and-up-to-350m-expanding-hepatology-focus/ 2025-07-29 https://bio-research.ai/eli-lilly-s-phase-3-trial-shows-jaypirca-non-inferior-to-imbruvica-in-cll-sll/ 2025-07-29 https://bio-research.ai/pahr-therapeutics-raises-14m-to-develop-therapies-for-pulmonary-arterial-hypertension/ 2025-07-29 https://bio-research.ai/alphamab-oncology-s-biparatopic-her2-targeting-adc-receives-orphan-drug-designation-from-fda-for-gastric-cancers/ 2025-07-29 https://bio-research.ai/aim-immunotech-inc-phase-2-study-shows-survival-outcomes-in-ampligen-with-imfinzi-for-pancreatic-cancer/ 2025-07-28 https://bio-research.ai/maplight-therapeutics-secures-372-5-million-for-phase-2-trials-of-m1-m4-muscarinic-agonist-in-cns-disorders/ 2025-07-28 https://bio-research.ai/celcuity-inc-s-phase-3-trial-of-pi3k-mtor-inhibitor-shows-76-risk-reduction-in-advanced-breast-cancer/ 2025-07-28 https://bio-research.ai/boehringer-ingelheim-and-re-vana-therapeutics-partner-for-1b-extended-release-eye-therapies/ 2025-07-28 https://bio-research.ai/alfasigma-s-oral-jak1-inhibitor-demonstrates-efficacy-in-phase-3-axial-spondyloarthritis-trial/ 2025-07-28 https://bio-research.ai/velavigo-secures-pre-a-60m-funding-to-advance-multi-specific-ab-and-adc-into-global-clinical-trials/ 2025-07-28 https://bio-research.ai/astrazeneca-s-imfinzi-granted-priority-review-by-fda-for-early-stage-and-locally-advanced-gastric-and-gej-cancers/ 2025-07-28 https://bio-research.ai/stella-pharma-s-phase-ii-trial-achieves-primary-endpoint-for-bnct-in-cutaneous-angiosarcoma/ 2025-07-28 https://bio-research.ai/clarity-pharmaceuticals-raises-203-million-to-fund-targeting-radiopharmaceutical-clinical-trials/ 2025-07-28 https://bio-research.ai/alterity-therapeutics-synuclein-aggregation-inhibitor-slows-disease-progression-and-brain-atrophy-in-phase-2-msa-trial/ 2025-07-28 https://bio-research.ai/gsk-partners-with-hengrui-pharma-in-12b-deal-for-innovative-medicines-starting-with-copd-drug/ 2025-07-27 https://bio-research.ai/kintor-pharmaceutical-s-phase-ii-trial-shows-significant-improvement-in-hair-counts-for-kx-826-tincture/ 2025-07-25 https://bio-research.ai/recognify-life-sciences-phase-2b-trial-of-inidascamine-misses-primary-endpoint-but-shows-numerical-cognitive-gains/ 2025-07-25 https://bio-research.ai/genfleet-therapeutics-receives-fda-fast-track-designation-for-oral-kras-g12d-inhibitor-in-pancreatic-cancer/ 2025-07-25 https://bio-research.ai/memo-therapeutics-bkpyv-antibody-misses-primary-endpoint-but-reduces-viral-load-in-kidney-transplant-trial/ 2025-07-25 https://bio-research.ai/sanofi-s-sarclisa-approved-in-eu-for-transplant-eligible-adults-with-newly-diagnosed-multiple-myeloma/ 2025-07-25 https://bio-research.ai/cascade-pharmaceuticals-oral-fxr-agonist-receives-fda-breakthrough-therapy-designation-for-pbc/ 2025-07-25 https://bio-research.ai/european-commission-approves-cabometyx-for-treating-specific-advanced-neuroendocrine-tumors/ 2025-07-24 https://bio-research.ai/gate-bioscience-and-eli-lilly-partner-to-develop-molecular-gate-therapeutics-in-856m-agreement/ 2025-07-24 https://bio-research.ai/matchpoint-therapeutics-partners-with-novartis-for-inflammatory-disease-inhibitors-with-1b-milestone-potential/ 2025-07-24 https://bio-research.ai/kling-bio-partners-with-sanofi-using-kling-s-proprietary-platform-to-discover-antibodies-for-viral-pathogen/ 2025-07-24 https://bio-research.ai/alexion-s-dual-binding-nanobody-meets-endpoints-in-phase-3-myasthenia-gravis-trial/ 2025-07-24 https://bio-research.ai/dispatch-bio-raises-216-million-to-advance-cancer-treatment-through-clinical-trials-by-2026/ 2025-07-23 https://bio-research.ai/avidity-biosciences-receives-fda-breakthrough-therapy-designation-for-antibody-oligonucleotide-conjugate-in-dmd/ 2025-07-23 https://bio-research.ai/ec-approved-darzalex-s-sc-formulation-for-smouldering-multiple-myeloma/ 2025-07-23 https://bio-research.ai/apnimed-s-phase-3-trial-shows-significant-reduction-in-apnea-hypopnea-index-at-26-weeks/ 2025-07-23 https://bio-research.ai/precision-biosciences-receives-fda-orphan-drug-designation-for-dmd-treatment/ 2025-07-23 https://bio-research.ai/revolution-medicines-kras-g12c-on-inhibitor-receives-fda-breakthrough-therapy-designation/ 2025-07-23 https://bio-research.ai/roche-receives-eu-approval-for-itovebi-combination-to-treat-pik3ca-mutated-advanced-breast-cancer/ 2025-07-23 https://bio-research.ai/abivax-phase-3-trials-show-50-mg-oral-mir-124-enhancer-achieves-remission-in-ulcerative-colitis-at-week-8/ 2025-07-22 https://bio-research.ai/avalyn-pharma-secures-100-million-to-advance-clinical-trials-for-inhaled-pulmonary-fibrosis-treatments/ 2025-07-22 https://bio-research.ai/replimune-receives-fda-complete-response-letter-for-rp1-oncolytic-immunotherapy-with-nivolumab-in-advanced-melanoma/ 2025-07-22 https://bio-research.ai/gesynta-pharma-secures-sek-43-million-for-phase-3-development-of-mpges-1-inhibitor-in-endometriosis/ 2025-07-22 https://bio-research.ai/livzon-pharmaceutical-s-il-17a-f-dual-target-inhibitor-meets-primary-endpoint-in-phase-iii-trial-for-plaque-psoriasis/ 2025-07-22 https://bio-research.ai/fda-grants-orphan-drug-designation-to-kind-pharmaceutical-s-hemoglobin-elevating-agent-for-sickle-cell-disease/ 2025-07-22 https://bio-research.ai/sanofi-to-acquire-vicebio-ltd-for-1-15b-to-enhance-multivalent-vaccine-development/ 2025-07-22 https://bio-research.ai/dualitybio-s-her3-adc-receives-fda-fast-track-designation-for-advanced-nsclc/ 2025-07-22 https://bio-research.ai/sab-bio-announces-175-million-financing-to-support-phase-2b-study-of-human-anti-thymocyte-immunoglobulin-for-type-1-diabetes/ 2025-07-21 https://bio-research.ai/concentra-biosciences-to-acquire-iteos-therapeutics-for-10-047-per-share-upfront-plus-contingent-payments/ 2025-07-21 https://bio-research.ai/promis-neurosciences-anti-amyloid-mab-receives-fda-fast-track-for-alzheimer-s-disease/ 2025-07-21 https://bio-research.ai/alkermes-plc-s-phase-2-study-of-oral-ox2r-agonist-shows-statistically-significant-wakefulness-improvement/ 2025-07-21 https://bio-research.ai/european-commission-approves-nubeqa-with-adt-for-metastatic-hormone-sensitive-prostate-cancer/ 2025-07-21 https://bio-research.ai/cloudbreak-pharma-inc-s-phase-2-trial-of-vegfr-pdgfr-inhibitor-shows-improvements-by-day-28-without-adverse-events/ 2025-07-21 https://bio-research.ai/ribo-life-science-raises-over-200-million-rmb-to-advance-clinical-pipeline-and-enhance-r-d-capabilities/ 2025-07-21 https://bio-research.ai/astrazeneca-s-flaura2-trial-shows-improved-survival-with-combination-therapy-in-egfrm-nsclc/ 2025-07-21 https://bio-research.ai/roche-s-anti-st2-mab-shows-promise-in-phase-iib-copd-trial-misses-primary-endpoint-in-phase-iii/ 2025-07-21 https://bio-research.ai/sun-pharmaceutical-industries-phase-3-trials-show-statistically-significant-acr20-response-in-psoriatic-arthritis/ 2025-07-21 https://bio-research.ai/european-commission-conditionally-approves-ezmekly-for-nf1-pn-in-adults-and-children-based-on-phase-2b-trial/ 2025-07-18 https://bio-research.ai/fda-issues-complete-response-letter-to-genentech-for-columvi-s-second-line-dlbcl-treatment/ 2025-07-18 https://bio-research.ai/imcheck-therapeutics-anti-btn3a-mab-receives-orphan-drug-designation-from-fda-for-treating-aml/ 2025-07-18 https://bio-research.ai/bristol-myers-squibb-s-phase-3-trial-of-reblozyl-in-myelofibrosis-misses-primary-endpoint-but-shows-secondary-benefits/ 2025-07-18 https://bio-research.ai/viatris-inc-reports-phase-3-study-of-pimecrolimus-0-3-for-blepharitis-did-not-achieve-primary-endpoint/ 2025-07-18 https://bio-research.ai/cantargia-s-phase-2-trifour-trial-shows-40-orr-for-anti-il1rap-mab-in-breast-cancer-treatment/ 2025-07-17 https://bio-research.ai/enhertu-and-pertuzumab-receive-breakthrough-therapy-designation-for-her2-positive-breast-cancer-treatment/ 2025-07-17 https://bio-research.ai/i-mab-secures-cldn18-2-rights-with-acquisition-of-bridge-health-biotech-for-up-to-7m/ 2025-07-17 https://bio-research.ai/diamedica-therapeutics-phase-2-trial-of-recombinant-klk1-protein-therapy-shows-blood-pressure-reduction-in-preeclampsia-patients/ 2025-07-17 https://bio-research.ai/rocket-pharmaceuticals-receives-rmat-designation-for-its-gene-therapy-candidate-targeting-pkp2-cardiomyopathy/ 2025-07-17 https://bio-research.ai/trioar-secures-22-5-billion-krw-in-series-b-funding-to-advance-adc-development-and-global-partnerships/ 2025-07-17 https://bio-research.ai/one-biosciences-raises-15m-to-advance-ai-platform-for-tumor-profiling-and-clinical-trial-optimization/ 2025-07-17 https://bio-research.ai/biomed-industries-phase-2-trial-shows-oral-quadruple-receptor-agonist-achieves-13-8-mean-weight-loss-in-obese-adults/ 2025-07-17 https://bio-research.ai/kowa-pharmaceuticals-acquires-a-license-for-ncx470-from-nicox-with-an-upfront-payment-of-7-5-million/ 2025-07-17 https://bio-research.ai/genascence-s-aav-gene-therapy-gnsc-001-for-knee-osteoarthritis-receives-rmat-designation-from-the-fda/ 2025-07-16 https://bio-research.ai/okyo-pharma-limited-s-phase-2-trial-shows-75-of-patients-achieve-80-pain-reduction-with-urcosimod/ 2025-07-16 https://bio-research.ai/onconetix-acquires-ocuvex-giving-ocuvex-shareholders-90-of-combined-company/ 2025-07-16 https://bio-research.ai/alexion-reports-phase-iii-trial-of-anti-amyloid-mab-fails-primary-endpoint-but-improves-subgroup-results/ 2025-07-16 https://bio-research.ai/sanofi-s-intravitreal-gene-therapy-receives-fda-fast-track-for-geographic-atrophy-in-macular-degeneration/ 2025-07-16 https://bio-research.ai/repare-therapeutics-and-debiopharm-international-secure-global-licensing-deal-for-267m-on-pkmyt1-inhibitor/ 2025-07-15 https://bio-research.ai/sino-biopharmaceutical-acquires-lanova-medicines-for-up-to-950-92m/ 2025-07-15 https://bio-research.ai/hengrui-pharma-reports-17-7-mean-weight-loss-in-phase-3-trial-of-dual-glp-1-gip-receptor-agonist/ 2025-07-15 https://bio-research.ai/sellas-life-sciences-phase-2-trial-of-cdk9-inhibitor-shows-50-response-rate-in-relapsed-aml/ 2025-07-15 https://bio-research.ai/hengrui-pharmaceuticals-phase-ii-study-of-glp-1-gip-dual-agonist-shows-improved-glycemic-control-and-weight-loss/ 2025-07-15 https://bio-research.ai/otsuka-pharmaceutical-secures-global-rights-from-cantargia-ab-for-anti-il1rap-antibody-in-usd-33m-deal/ 2025-07-15 https://bio-research.ai/jcr-pharmaceuticals-and-acumen-partner-on-alzheimer-s-therapy-with-up-to-555m-in-milestone-payments/ 2025-07-15 https://bio-research.ai/xenotherapeutics-acquires-essa-pharma-with-xoma-royalty-s-support-for-approximately-1-91-per-share/ 2025-07-14 https://bio-research.ai/boehringer-ingelheim-and-leo-pharma-finalize-global-license-for-spevigo-with-90m-eur-upfront-fee/ 2025-07-14 https://bio-research.ai/illimis-therapeutics-raises-42-million-series-b-to-advance-alzheimer-s-drugs-with-gaia-platform-and-eli-lilly-partnership/ 2025-07-14 https://bio-research.ai/takeda-s-phase-3-trials-of-ox2r-selective-agonist-show-statistically-significant-improvements-for-narcolepsy-type-1/ 2025-07-14 https://bio-research.ai/bayer-s-finerenone-receives-fda-approval-for-heart-failure-treatment-with-lvef-of-40-or-more/ 2025-07-14 https://bio-research.ai/astrazeneca-s-baxhtn-phase-iii-trial-shows-aldosterone-synthase-inhibitor-lowers-systolic-blood-pressure-at-12-weeks/ 2025-07-14 https://bio-research.ai/amylyx-pharmaceuticals-reports-64-reduction-in-post-bariatric-hypoglycemic-events-in-phase-2-trial-of-avexitide/ 2025-07-13 https://bio-research.ai/fda-issues-complete-response-letter-to-ultragenyx-on-ux111-gene-therapy-citing-cmc-concerns/ 2025-07-11 https://bio-research.ai/nuclidium-raises-chf-79-million-to-advance-copper-theranostic-oncology-pipeline-and-expand-network/ 2025-07-10 https://bio-research.ai/eolas-therapeutics-acquires-rights-to-selective-orexin-1-receptor-antagonist-from-astrazeneca-for-phase-ii-trials-in-substance-use-disorders/ 2025-07-10 https://bio-research.ai/bayer-s-lynkuet-receives-world-s-first-regulatory-approval-from-uk-mhra-for-treating-moderate-to-severe-menopause-vasomotor-symptoms/ 2025-07-10 https://bio-research.ai/renasant-bio-launches-with-54-5-million-to-develop-therapies-for-autosomal-dominant-polycystic-kidney-disease/ 2025-07-10 https://bio-research.ai/fda-accepts-merck-s-application-for-doravirine-islatravir-for-virologically-suppressed-hiv-1-infection/ 2025-07-10 https://bio-research.ai/abbvie-and-igi-therapeutics-sign-700m-licensing-deal-for-trispecific-t-cell-engager-development-and-commercialization/ 2025-07-10 https://bio-research.ai/pfizer-and-astellas-phase-3-study-shows-xtandi-plus-leuprolide-improves-survival-in-prostate-cancer/ 2025-07-10 https://bio-research.ai/fda-grants-fast-track-to-trethera-s-dck-inhibitor-tre-515-in-combination-with-radioligand-therapy-for-mcrpc/ 2025-07-09 https://bio-research.ai/coregen-inc-raises-93-39-million-to-advance-src3-ko-regulatory-t-cells-program-for-solid-tumors/ 2025-07-09 https://bio-research.ai/novartis-and-sironax-form-option-agreement-for-175m-brain-delivery-bodule-platform-acquisition/ 2025-07-09 https://bio-research.ai/leo-pharma-reports-significant-week-16-results-in-hand-dermatitis-phase-3b-trial-of-il-13-monoclonal-antibody/ 2025-07-09 https://bio-research.ai/rhythm-pharmaceuticals-phase-2-trial-of-bivamelagon-showed-a-significant-bmi-reduction-of-up-to-9-3/ 2025-07-09 https://bio-research.ai/merck-to-acquire-verona-pharma-for-10b-expanding-reach-of-copd-treatment-ohtuvayre/ 2025-07-09 https://bio-research.ai/actithera-secures-75-5-million-in-series-a-financing-to-advance-fap-targeting-radioligand-candidate/ 2025-07-09 https://bio-research.ai/taiho-pharmaceutical-s-phase-iii-trial-of-oral-hpgds-inhibitor-in-dmd-patients-shows-no-significant-primary-endpoint-difference/ 2025-07-08 https://bio-research.ai/centivax-inc-raises-45-million-to-advance-universal-flu-vaccine-to-phase-i-clinical-trial/ 2025-07-08 https://bio-research.ai/concentra-biosciences-to-acquire-car-t-cell-developer-cargo-therapeutics-for-4-379m-per-share-with-cvr/ 2025-07-08 https://bio-research.ai/prokidney-s-phase-2-regen-007-trial-shows-improved-egfr-decline-in-chronic-kidney-disease-patients/ 2025-07-08 https://bio-research.ai/recursion-pharmaceuticals-acquires-rallybio-s-interest-in-enpp1-inhibitor-program-for-7-5m-upfront/ 2025-07-08 https://bio-research.ai/jcr-pharmaceuticals-and-alexion-sign-agreement-for-just-aav-capsid-technology-with-up-to-825m-in-milestones/ 2025-07-08 https://bio-research.ai/fda-accepts-denali-therapeutics-application-for-enzyme-replacement-therapy-to-treat-hunter-syndrome/ 2025-07-07 https://bio-research.ai/fda-grants-orphan-drug-designation-for-mustang-bio-s-il13ra2-targeted-car-t-therapy-for-astrocytomas-and-glioblastoma/ 2025-07-07 https://bio-research.ai/apogee-therapeutics-phase-2-trial-shows-71-easi-score-reduction-for-anti-il-13-ab-at-week-16-compared-to-placebo/ 2025-07-07 https://bio-research.ai/yiviva-s-phase-2b-study-shows-improved-progression-free-survival-in-liver-cancer-with-botanical-drug/ 2025-07-07 https://bio-research.ai/cogent-biosciences-summit-trial-shows-symptom-improvement-and-tryptase-reduction-in-mastocytosis/ 2025-07-07 https://bio-research.ai/kalvista-pharmaceuticals-receives-u-s-fda-approval-for-ekterly-an-oral-treatment-for-hereditary-angioedema/ 2025-07-07 https://bio-research.ai/nurix-therapeutics-oral-btk-degrader-receives-ema-orphan-drug-designation-for-lymphoplasmacytic-lymphoma/ 2025-07-07 https://bio-research.ai/chugai-pharmaceutical-partners-with-gero-pte-ltd-for-250m-age-related-disease-therapies-development/ 2025-07-07 https://bio-research.ai/j-pharma-raises-470-million-yen-to-support-phase-3-trial-of-lat1-inhibitor-for-biliary-tract-cancer/ 2025-07-07 https://bio-research.ai/bio-thera-solutions-ends-phase-ii-iii-trial-of-bat4406f-for-neuromyelitis-optica-spectrum-disorder-early-due-to-statistically-significant-efficacy-observed-in-interim-results/ 2025-07-07 https://bio-research.ai/abl-bio-and-i-mab-s-phase-1b-trial-of-claudin-18-2-4-1bb-bsab-shows-orr-of-71-and-dcr-of-100-in-gastric-cancer/ 2025-07-07 https://bio-research.ai/imfinzi-becomes-first-and-only-perioperative-immunotherapy-approved-in-the-eu-for-muscle-invasive-bladder-cancer-backed-by-phase-iii-data/ 2025-07-04 https://bio-research.ai/joincare-group-and-brii-biosciences-partner-to-develop-and-commercialize-brii-693-in-greater-china/ 2025-07-04 https://bio-research.ai/alembic-pharmaceuticals-acquires-utility-therapeutics-ltd-to-expand-u-s-portfolio-with-fda-approved-pivya/ 2025-07-03 https://bio-research.ai/sichuan-biokin-pharmaceutical-s-phase-iii-trial-of-egfr-x-her3-bispecific-adc-meets-primary-endpoint-in-carcinoma-study/ 2025-07-03 https://bio-research.ai/mitsubishi-gas-chemical-and-veritas-in-silico-launch-joint-research-on-long-non-coding-rna-asos-and-qbd-based-manufacturing/ 2025-07-03 https://bio-research.ai/brightpath-s-ipsc-derived-car-nkt-cell-therapy-receives-fda-orphan-drug-designation-for-multiple-myeloma/ 2025-07-03 https://bio-research.ai/novartis-phase-iii-gcaptain-study-shows-cosentyx-did-not-meet-sustained-remission-at-week-52/ 2025-07-03 https://bio-research.ai/fda-grants-accelerated-approval-to-zegfrovy-for-nsclc-with-egfr-exon-20-insertion-mutations/ 2025-07-03 https://bio-research.ai/neurizon-therapeutics-and-elanco-animal-health-sign-global-license-agreement-for-als-treatment/ 2025-07-02 https://bio-research.ai/regeneron-s-lynozyfic-receives-fda-accelerated-approval-for-relapsed-or-refractory-multiple-myeloma/ 2025-07-02 https://bio-research.ai/pelthos-therapeutics-secures-50-1m-series-a-from-ligand-and-murchinson-led-group-to-fund-zelsuvmi-launch/ 2025-07-02 https://bio-research.ai/fda-prioritizes-merck-s-winrevair-label-update-based-on-phase-3-zenith-trial-results-for-pulmonary-outcomes/ 2025-07-02 https://bio-research.ai/organon-s-phase-2-trial-of-oral-hsd17b1-inhibitor-for-endometriosis-pain-fails-to-meet-efficacy-endpoint/ 2025-07-02 https://bio-research.ai/bioversys-ag-and-shionogi-co-ltd-partner-on-bv500-ntm-program-with-chf-5-0m-upfront-payment/ 2025-07-02 https://bio-research.ai/unnatural-products-inc-partners-with-argenx-for-oral-macrocyclic-peptide-drugs-with-1-5b-potential-earnings/ 2025-07-01 https://bio-research.ai/syntis-bio-secures-33-million-funding-to-develop-synt-platform-a-synthetic-tissue-lining-approach-for-obesity-and-homocystinuria/ 2025-07-01 https://bio-research.ai/igm-biosciences-acquired-by-concentra-biosciences-at-1-247m-per-share-with-cvr-benefits/ 2025-07-01 https://bio-research.ai/european-commission-grants-conditional-authorization-for-ziihera-in-her2-positive-biliary-tract-cancer/ 2025-07-01 https://bio-research.ai/feliqs-corporation-completes-9-million-series-a-funding-round-for-small-molecule-therapeutics-targeting-oxidized-lipids-in-retinopathy-of-prematurity/ 2025-07-01 https://bio-research.ai/atai-life-sciences-and-beckley-psytech-phase-2b-trial-meets-endpoints-in-depression-with-5-meo-dmt-therapy/ 2025-07-01 https://bio-research.ai/sanofi-invests-25m-in-adagene-inc-for-anti-ctla4-ab-clinical-trials-and-research-collaboration/ 2025-07-01 https://bio-research.ai/apellis-pharmaceuticals-strikes-275m-agreement-with-sobi-for-aspaveli-ex-u-s-royalties/ 2025-07-01 https://bio-research.ai/henlius-and-hanchorbio-establish-licensing-agreement-for-sirp-fc-fusion-protein-hcb101-worth-up-to-202m/ 2025-07-01 https://bio-research.ai/abclon-s-phase-2-trial-of-anti-cd19-car-t-therapy-shows-94-objective-response-and-68-complete-remission-rate/ 2025-07-01 https://bio-research.ai/zai-lab-limited-phase-3-trial-shows-improved-survival-in-gastric-cancer-with-anti-fgfr2b-mab-combo/ 2025-06-30 https://bio-research.ai/abbvie-to-acquire-capstan-therapeutics-in-deal-worth-up-to-2-1b-focusing-on-in-vivo-car-t-tech/ 2025-06-30 https://bio-research.ai/moderna-s-phase-3-trial-shows-26-6-efficacy-of-mrna-1010-vaccine-against-influenza-in-adults-50/ 2025-06-30 https://bio-research.ai/inmune-bio-inc-s-phase-2-trial-of-stnf-inhibitor-in-alzheimer-s-did-not-meet-primary-endpoint-but-showed-subgroup-benefits/ 2025-06-30 https://bio-research.ai/unicycive-therapeutics-receives-fda-complete-response-letter-for-lanthanum-based-phosphate-binding-agent-manufacturing-issues/ 2025-06-30 https://bio-research.ai/pliant-therapeutics-discloses-beacon-ipf-results-as-bexotegrast-development-in-ipf-is-discontinued/ 2025-06-30 https://bio-research.ai/hansa-biopharma-reports-90-patient-5-year-survival-in-kidney-transplant-study-with-antibody-cleaving-enzyme/ 2025-06-30 https://bio-research.ai/pfizer-deepens-ai-collaboration-with-xtalpi-to-leverage-xfep-for-proprietary-chemical-space/ 2025-06-29 https://bio-research.ai/fda-approves-ifn-blocking-mab-for-hlh-and-mas-associated-with-still-s-disease-after-glucocorticoid-failure/ 2025-06-28 https://bio-research.ai/neurocrine-biosciences-phase-3-trial-shows-statistically-significant-post-hoc-results-for-vmat2-inhibitor-in-huntington-s-disease-chorea/ 2025-06-27 https://bio-research.ai/innovent-biologics-receives-approval-for-dual-gcg-glp-1-ra-in-weight-management-for-overweight-adults-in-china/ 2025-06-27 https://bio-research.ai/ucb-s-phase-3-study-of-fenfluramine-for-cdkl5-deficiency-disorder-met-primary-endpoints-with-87-participants/ 2025-06-27 https://bio-research.ai/mabwell-and-calico-enter-exclusive-licensing-deal-for-il-11-therapies-focusing-on-aging-related-disease-indications-excluding-greater-china/ 2025-06-26 https://bio-research.ai/artelo-biosciences-secures-1-425-million-for-clinical-studies-corporate-purposes-and-sol-purchase/ 2025-06-26 https://bio-research.ai/profound-therapeutics-and-novartis-partner-to-advance-cardiovascular-drugs-with-25m-upfront/ 2025-06-26 https://bio-research.ai/phase-3-trial-confirms-opus-genetics-phentolamine-0-75-meets-primary-endpoint-in-improving-dcnva-for-presbyopia/ 2025-06-26 https://bio-research.ai/pfizer-s-hympavzi-achieves-93-abr-reduction-vs-on-demand-therapy-in-hemophilia-a-b-with-inhibitors/ 2025-06-26 https://bio-research.ai/altimmune-reports-phase-2b-trial-results-with-59-1-mash-resolution-at-24-weeks/ 2025-06-26 https://bio-research.ai/percheron-therapeutics-and-hummingbird-bioscience-agree-on-290m-deal-for-anti-vista-antibody-hmbd-002/ 2025-06-26 https://bio-research.ai/alebund-pharmaceuticals-phase-3-study-achieves-primary-endpoint-in-controlling-serum-phosphorus/ 2025-06-26 https://bio-research.ai/vor-bio-partners-with-remegen-to-develop-baff-april-targeting-fusion-protein-with-125m-upfront-and-4b-in-milestones/ 2025-06-25 https://bio-research.ai/assembly-bio-announces-3-2-log-decline-in-hbv-dna-with-400-mg-abi-4334-in-phase-1b-trial-while-gilead-considers-exclusive-license-option/ 2025-06-25 https://bio-research.ai/gilead-sciences-and-kymera-therapeutics-sign-750m-option-agreement-for-cdk2-molecular-glue-degrader/ 2025-06-25 https://bio-research.ai/abion-enters-global-licensing-agreement-for-anti-cldn3-ab-in-1-315b-deal-with-undisclosed-partner/ 2025-06-24 https://bio-research.ai/mindrank-s-phase-2b-trial-shows-ai-designed-oral-glp-1-ra-achieves-8-2-10-3-weight-loss-vs-2-5-with-placebo-at-week-24/ 2025-06-24 https://bio-research.ai/biomarin-s-fviii-delivering-aav-gene-therapy-maintains-fviii-levels-at-5-years-81-3-of-patients-off-prophylaxis/ 2025-06-24 https://bio-research.ai/neuron23-inc-secures-96-5-million-for-phase-2-neulark-trial-of-lrrk2-inhibitor-in-parkinson-s-disease/ 2025-06-24 https://bio-research.ai/nektar-s-pegylated-il-2-sparks-hope-after-meeting-primary-endpoint-in-phase-2-atopic-dermatitis-trial/ 2025-06-24 https://bio-research.ai/bio-thera-solutions-anti-vegfa-mab-reduces-central-retinal-thickness-in-phase-iii-neovascular-amd-trial/ 2025-06-24 https://bio-research.ai/medilink-s-b7h3-targeting-adc-receives-fda-breakthrough-therapy-designation-for-small-cell-lung-cancer/ 2025-06-24 https://bio-research.ai/brightgene-reports-dual-glp-1r-gipr-agonist-reduces-hba1c-and-body-weight-in-phase-2-diabetes-and-obesity-trial/ 2025-06-23 https://bio-research.ai/corxel-pharmaceuticals-reports-phase-2-trial-results-for-oral-glp-1r-agonist-with-up-to-9-7-weight-reduction/ 2025-06-23 https://bio-research.ai/libertas-bio-licenses-oral-jak-syk-inhibitor-to-sanofi-in-a-deal-worth-up-to-545m-for-phase-1-study/ 2025-06-23 https://bio-research.ai/biotheryx-and-incyte-sign-agreement-for-354m-collaboration-on-molecular-glue-degraders-in-oncology/ 2025-06-23 https://bio-research.ai/merck-s-phase-3-hyperion-study-shows-reduced-risk-of-clinical-worsening-in-pah-patients/ 2025-06-23 https://bio-research.ai/compass-pathways-phase-3-trial-shows-comp360-psilocybin-reduces-depression-symptoms-by-3-6-points/ 2025-06-23 https://bio-research.ai/ema-s-chmp-recommends-approval-of-gamma-secretase-inhibitor-for-adults-with-progressing-desmoid-tumors/ 2025-06-23 https://bio-research.ai/enterome-sa-s-phase-1-2-trial-of-eo2463-achieves-60-complete-response-in-non-hodgkin-lymphoma/ 2025-06-23 https://bio-research.ai/harbour-biomed-and-otsuka-pharmaceutical-partner-globally-on-bcmaxcd3-bsab-with-upto-670m-payment/ 2025-06-22 https://bio-research.ai/exelixis-reports-tyrosine-kinase-and-immune-checkpoint-inhibitor-combo-meets-primary-endpoint-in-stellar-303-phase-3-trial/ 2025-06-22 https://bio-research.ai/fda-approves-dupixent-for-bullous-pemphigoid-in-adults-based-on-adept-phase-2-3-trial-results/ 2025-06-20 https://bio-research.ai/fda-approves-harliku-tablets-for-alkaptonuria-to-reduce-urine-homogentisic-acid-in-adult-patients/ 2025-06-19 https://bio-research.ai/hengrui-pharmaceuticals-phase-iii-trial-shows-highly-selective-urat1-inhibitor-outperforming-allopurinol-in-lowering-serum-uric-acid/ 2025-06-19 https://bio-research.ai/polyactiva-receives-25m-funding-for-us-expansion-and-development-of-pa5108-biodegradable-ocular-implant/ 2025-06-18 https://bio-research.ai/zealand-pharma-s-phase-1b-trial-shows-11-6-mean-body-weight-reduction-with-long-acting-glp-1r-glp-2r-dual-agonist/ 2025-06-18 https://bio-research.ai/fda-approves-gilead-sciences-yeztugo-for-hiv-prevention-with-high-efficacy-in-phase-3-trials/ 2025-06-18 https://bio-research.ai/actio-biosciences-secures-66m-for-trials-of-epilepsy-and-charcot-marie-tooth-disease-therapies/ 2025-06-18 https://bio-research.ai/scholar-rock-s-phase-2-embraze-trial-shows-54-9-lean-mass-preservation-with-combined-therapy/ 2025-06-18 https://bio-research.ai/draig-therapeutics-secures-140m-series-a-to-advance-ampa-modulating-dt-101-into-phase-2-for-major-depressive-disorder/ 2025-06-18 https://bio-research.ai/camurus-phase-2b-study-shows-its-somatostatin-analogue-reduces-liver-and-cyst-growth-in-polycystic-liver-disease/ 2025-06-18 https://bio-research.ai/bavarian-nordic-sells-priority-review-voucher-for-160m-nih-to-receive-20-revenue-share/ 2025-06-18 https://bio-research.ai/oncoinvent-asa-s-trial-of-alpha-emitting-radionuclide-therapy-shows-27-8-peritoneal-recurrence-at-18-months/ 2025-06-18 https://bio-research.ai/capricor-therapeutics-allogeneic-cardiosphere-derived-cell-therapy-receives-fda-orphan-drug-designation-for-becker-muscular-dystrophy/ 2025-06-17 https://bio-research.ai/mineralys-therapeutics-phase-2-trial-shows-oral-aldosterone-synthase-inhibitor-25-mg-reduces-systolic-blood-pressure-in-ckd/ 2025-06-17 https://bio-research.ai/immuneering-corporation-s-phase-2a-trial-of-oral-mek-inhibitor-shows-94-overall-survival-in-pancreatic-cancer/ 2025-06-17 https://bio-research.ai/eli-lilly-to-acquire-verve-therapeutics-for-1-3b-in-gene-editing-cardiovascular-expansion/ 2025-06-17 https://bio-research.ai/ventyx-biosciences-phase-2a-trial-of-oral-nlrp3-inflammasome-inhibitor-shows-high-plasma-and-csf-exposure-in-parkinson-s-disease/ 2025-06-17 https://bio-research.ai/ferrer-s-oral-oga-inhibitor-granted-fast-track-designation-by-us-fda-and-undergoing-phase-2-study-for-psp/ 2025-06-17 https://bio-research.ai/fda-approves-csl-s-andembry-for-hereditary-angioedema-following-successful-phase-3-vanguard-trial/ 2025-06-16 https://bio-research.ai/nanocell-therapeutics-completes-financing-to-develop-dual-car-cd19-cd22-in-vivo-car-t-therapy-for-b-cell-malignancies/ 2025-06-16 https://bio-research.ai/abbvie-s-phase-3-verona-trial-of-venclexta-fails-to-improve-overall-survival-in-myelodysplastic-syndrome/ 2025-06-16 https://bio-research.ai/nextcure-partners-with-simcere-zaiming-on-cdh6-binding-adc-potential-payments-up-to-745m/ 2025-06-16 https://bio-research.ai/supernus-pharmaceuticals-to-acquire-sage-therapeutics-for-561m-totaling-795m-with-zurzuvae-focus/ 2025-06-16 https://bio-research.ai/duke-street-bio-s-parp1-inhibitor-receives-fda-fast-track-for-brain-metastases-from-triple-negative-breast-cancer/ 2025-06-16 https://bio-research.ai/celldex-therapeutics-phase-2-trial-shows-77-angioedema-free-and-87-score-improvement-in-csu-treatment/ 2025-06-16 https://bio-research.ai/d-d-pharmatech-s-glp-1-glucagon-dual-agonist-shows-75-8-hepatic-steatosis-reduction-in-phase-2-trial/ 2025-06-16 https://bio-research.ai/roche-to-proceed-with-phase-iii-trial-of-anti-synuclein-antibody-for-early-stage-parkinson-s-disease/ 2025-06-16 https://bio-research.ai/genmab-a-s-reports-87-overall-response-rate-in-epcore-nhl-2-trial-for-diffuse-large-b-cell-lymphoma/ 2025-06-15 https://bio-research.ai/alexion-s-phase-iii-trial-shows-ultomiris-with-92-6-survival-and-17-1-tma-response-in-children/ 2025-06-14 https://bio-research.ai/astrazeneca-and-cspc-partner-for-oral-chronic-disease-drugs-with-potential-5-22b-milestone-payments/ 2025-06-13 https://bio-research.ai/parallel-bio-receives-21-million-to-advance-organoid-based-immune-system-platform-in-drug-discovery/ 2025-06-12 https://bio-research.ai/rebel-medicine-secures-6-million-for-phase-2-trial-of-non-opioid-pain-drug-alevatrix/ 2025-06-12 https://bio-research.ai/johnson-johnson-s-phase-1b-trial-of-oral-menin-inhibitor-shows-a-90-response-rate-in-newly-diagnosed-aml/ 2025-06-12 https://bio-research.ai/vascarta-inc-receives-fda-orphan-drug-designation-for-vasceptor-vas-101-to-treat-sickle-cell-disease/ 2025-06-12 https://bio-research.ai/emd-serono-s-phase-2-study-of-a-tlr7-8-inhibitor-misses-its-primary-endpoint-but-improves-response-rates/ 2025-06-12 https://bio-research.ai/pim1-kinase-inhibitor-shows-clinical-activity-in-phase-1-2-trial-for-relapsed-or-refractory-myelofibrosis/ 2025-06-12 https://bio-research.ai/bharat-biotech-and-gsk-partner-for-phase-3-trials-of-shigella-vaccine-altsonflex1-2-3/ 2025-06-12 https://bio-research.ai/fda-approves-sustained-release-intravesical-mitomycin-for-non-muscle-invasive-bladder-cancer-with-phase-3-trial-showing-response-rates/ 2025-06-12 https://bio-research.ai/biontech-to-acquire-curevac-for-1-25b-enhancing-mrna-capabilities-with-dievini-hopp-biotech-support/ 2025-06-12 https://bio-research.ai/boan-biotech-partners-with-shanghai-pharma-holdings-to-distribute-dulaglutide-biosimilar-in-mainland-china/ 2025-06-12 https://bio-research.ai/mezzion-pharma-secures-20-million-for-phase-3-fuel-2-trial-of-udenafil-in-fontan-circulation/ 2025-06-11 https://bio-research.ai/fda-approves-glecaprevir-pibrentasvir-combi-label-expansion-for-eight-week-hcv-treatment-in-patients-aged-three-and-older/ 2025-06-11 https://bio-research.ai/fda-approves-ros1-tki-for-adults-with-advanced-ros1-positive-non-small-cell-lung-cancer/ 2025-06-11 https://bio-research.ai/johnson-johnson-s-phase-3b-study-demonstrates-il-23-inhibitor-significantly-reduces-joint-damage-in-psoriatic-arthritis-patients-at-week-24/ 2025-06-11 https://bio-research.ai/deep-apple-therapeutics-and-novo-nordisk-partner-on-gpcr-drugs-with-potential-812m-earnings/ 2025-06-11 https://bio-research.ai/splicebio-secures-135-million-to-advance-aav-gene-therapy-delivering-full-length-abca4-for-stargardt-disease/ 2025-06-11 https://bio-research.ai/daewoong-pharmaceutical-and-salipro-biotech-partner-to-develop-next-gen-mrna-drugs-using-salipro-platform/ 2025-06-11 https://bio-research.ai/philochem-licenses-radiopharmaceutical-targeting-acp3-to-rayzebio-in-a-deal-worth-up-to-1-35b-plus-royalties/ 2025-06-10 https://bio-research.ai/antares-therapeutics-raises-177-million-in-series-a-financing-to-develop-precision-medicines-for-cancer/ 2025-06-10 https://bio-research.ai/aribio-and-arcera-finalize-600m-deal-for-oral-pde5-inhibitor-rights-in-latin-america-middle-east-africa-and-cis/ 2025-06-10 https://bio-research.ai/mosanna-therapeutics-secures-80-million-for-mos118-nasal-spray-therapy-for-obstructive-sleep-apnea/ 2025-06-09 https://bio-research.ai/fda-approves-merck-s-enflonsia-for-rsv-prevention-in-newborns-and-infants-during-first-rsv-season/ 2025-06-09 https://bio-research.ai/newamsterdam-pharma-s-phase-3-trial-of-oral-cetp-inhibitor-shows-ldl-c-lowering-efficacy-in-cardiovascular-disease/ 2025-06-09 https://bio-research.ai/merck-s-phase-3-trials-show-oral-pcsk9-inhibitor-significantly-reduces-ldl-cholesterol-in-adults/ 2025-06-09 https://bio-research.ai/samsung-bioepis-and-nipro-corporation-partner-on-biosimilars-for-japanese-market-enhancement/ 2025-06-08 https://bio-research.ai/otsuka-pharmaceutical-s-phase-3-study-shows-april-blocking-antibody-reduces-proteinuria-by-51-2-in-iga-nephropathy/ 2025-06-06 https://bio-research.ai/sino-biopharmaceutical-s-her2-targeted-bispecific-adc-shows-73-1-complete-response-in-stage-ii-iii-her2-positive-breast-cancer-phase-ii-trial/ 2025-06-06 https://bio-research.ai/sichuan-kelun-biotech-to-accelerate-adc-platform-with-250-million-in-new-funding/ 2025-06-06 https://bio-research.ai/zelgen-partners-with-merck-kgaa-for-thyroid-hormone-promotion-in-china-with-payments-up-to-rmb-250-m/ 2025-06-05 https://bio-research.ai/european-commission-approves-low-dose-formulation-of-atropine-for-pediatric-myopia-based-on-phase-3-trial-data/ 2025-06-05 https://bio-research.ai/corcept-s-selective-cortisol-modulator-fails-primary-endpoint-but-shows-survival-benefit-in-als-phase-2-trial/ 2025-06-05 https://bio-research.ai/phase-i-ii-iii-interim-data-show-regenxbio-s-rgx-202-outperforms-natural-history-in-duchenne-muscular-dystrophy-at-9-and-12-months/ 2025-06-05 https://bio-research.ai/cullinan-secures-exclusive-license-from-genrix-bio-for-bispecific-t-cell-engager-with-712m-potential-deal/ 2025-06-05 https://bio-research.ai/moleculin-biotech-s-phase-1b-2-trial-of-annamycin-shows-20-month-median-overall-survival/ 2025-06-04 https://bio-research.ai/oncovita-s-investigational-oncolytic-virus-therapy-receives-fda-orphan-drug-designation-for-pleural-mesothelioma/ 2025-06-04 https://bio-research.ai/vigil-neuroscience-s-phase-2-trial-finds-anti-trem2-antibody-safe-but-ineffective-in-alsp-patients/ 2025-06-04 https://bio-research.ai/vividion-therapeutics-secures-global-rights-from-roche-to-advance-oral-wrn-inhibitor-for-high-msi-cancer-treatment/ 2025-06-04 https://bio-research.ai/european-commission-approves-evrysdi-tablet-for-spinal-muscular-atrophy-therapy/ 2025-06-04 https://bio-research.ai/chimeric-therapeutics-anti-cdh17-car-t-therapy-receives-fast-track-designation-for-neuroendocrine-tumors-trial/ 2025-06-04 https://bio-research.ai/ascletis-pharma-s-phase-iii-trial-for-oral-fasn-inhibitor-shows-efficacy-in-acne-vulgaris-with-480-patients/ 2025-06-03 https://bio-research.ai/fda-approves-bayer-s-nubeqa-for-metastatic-castration-sensitive-prostate-cancer-without-chemotherapy/ 2025-06-03 https://bio-research.ai/johnson-johnson-s-phase-1-trial-of-anti-bcma-gprc5d-cd3-tsab-shows-86-1-response-rate-in-multiple-myeloma/ 2025-06-03 https://bio-research.ai/pheast-therapeutics-anti-cd24-mab-gains-fast-track-designation-from-fda-for-ovarian-cancer-treatment/ 2025-06-03 https://bio-research.ai/european-commission-approves-adcetris-with-chemotherapy-for-advanced-hodgkin-lymphoma-in-adults/ 2025-06-03 https://bio-research.ai/camurus-and-eli-lilly-ink-worldwide-license-deal-for-fluidcrystal-technology-worth-up-to-870-m/ 2025-06-03 https://bio-research.ai/kiora-pharmaceuticals-grants-senju-exclusive-commercialization-option-for-molecular-photoswitch-in-asia/ 2025-06-03 https://bio-research.ai/amylyx-pharmaceuticals-capn2-targeted-aso-receives-fast-track-designation-for-amyotrophic-lateral-sclerosis/ 2025-06-03 https://bio-research.ai/agenus-partners-with-zydus-lifesciences-selling-facilities-for-75m-with-potential-50m-bonus/ 2025-06-03 https://bio-research.ai/immix-biopharma-s-phase-1-2-trial-of-anti-bcma-car-t-therapy-achieves-70-complete-response-rate-in-al-amyloidosis/ 2025-06-03 https://bio-research.ai/kamari-pharma-secures-23-million-to-advance-oral-trpv3-inhibitor-in-phase-1b-trial-for-olmstead-syndrome/ 2025-06-03 https://bio-research.ai/spyglass-pharma-secures-75-million-in-funding-to-support-phase-iii-trials-of-its-multi-year-ophthalmic-drug-delivery-platform/ 2025-06-03 https://bio-research.ai/kura-oncology-and-kyowa-kirin-report-23-remission-rate-in-komet-001-trial-of-oral-menin-inhibitor-in-aml/ 2025-06-03 https://bio-research.ai/amgen-s-phase-3-trial-shows-dll3-cd3-t-cell-engager-reduced-death-risk-by-40-in-lung-cancer-patients/ 2025-06-02 https://bio-research.ai/lyra-therapeutics-phase-3-trial-of-6-months-nasal-implant-shows-statistically-significant-improvements-at-week-24-for-chronic-rhinosinusitis/ 2025-06-02 https://bio-research.ai/regeneron-acquires-rights-to-hansoh-s-dual-glp-1-gip-receptor-agonist-with-an-80m-upfront-and-1-93b-milestone-payments/ 2025-06-02 https://bio-research.ai/trevi-therapeutics-phase-2b-trial-shows-a-statistically-significant-reduction-in-cough-frequency-in-ipf-patients-treated-with-nalbuphine-er/ 2025-06-02 https://bio-research.ai/vera-therapeutics-phase-3-trial-shows-46-reduction-in-proteinuria-for-iga-nephropathy/ 2025-06-02 https://bio-research.ai/biontech-and-bristol-myers-squibb-partner-to-develop-pd-l1-vegf-a-bsab-with-1-5b-upfront-and-7-6b-in-milestones/ 2025-06-02 https://bio-research.ai/moderna-announces-fda-approval-of-mnexspike-covid-19-vaccine-for-older-adults-and-at-risk-groups/ 2025-06-02 https://bio-research.ai/kaken-pharmaceutical-partners-with-twocells-for-stem-cell-therapy-for-cartilage-regeneration-committing-up-to-7b-yen-for-japan-rights/ 2025-06-02 https://bio-research.ai/novartis-reports-significant-improvement-in-radiographic-progression-free-survival-with-pluvicto-trial/ 2025-06-02 https://bio-research.ai/sanofi-to-acquire-blueprint-medicines-for-9-1b-expanding-rare-disease-and-immunology-portfolios/ 2025-06-02 https://bio-research.ai/impact-biotech-s-phase-3-study-shows-73-complete-response-in-low-grade-urothelial-cancer/ 2025-05-31 https://bio-research.ai/regeneron-pharmaceuticals-phase-3-trial-shows-libtayo-reduces-risk-of-recurrence-by-68/ 2025-05-31 https://bio-research.ai/regeneron-and-sanofi-s-phase-3-aerify-1-trial-reduces-copd-exacerbations-by-27-in-former-smokers/ 2025-05-30 https://bio-research.ai/astellas-pharma-licenses-cldn18-2-targeting-adc-from-evopoint-biosciences-with-130m-upfront-and-1-34b-in-milestones/ 2025-05-30 https://bio-research.ai/accuredit-therapeutics-gene-editing-therapy-receives-rmat-designation-from-u-s-fda-for-attr-amyloidosis-study/ 2025-05-29 https://bio-research.ai/genentech-s-96-week-data-show-btk-inhibitor-maintains-no-disability-progression-in-relapsing-ms/ 2025-05-29 https://bio-research.ai/vima-therapeutics-secures-60-million-for-phase-1-trial-of-vim0423-targeting-dystonia/ 2025-05-29 https://bio-research.ai/beam-therapeutics-granted-orphan-drug-designation-for-gene-editing-therapy-targeting-piz-mutation-in-alpha-1-antitrypsin-deficiency/ 2025-05-29 https://bio-research.ai/daiichi-sankyo-and-merck-withdraw-bla-for-her3-targeting-adc-after-lack-of-significant-benefits/ 2025-05-29 https://bio-research.ai/capsida-biotherapeutics-aav-based-gene-therapy-for-stxbp1-encephalopathy-receives-fda-fast-track-designation/ 2025-05-29 https://bio-research.ai/octapharma-s-phase-3-study-of-ivig-shows-improvement-in-cgi-i-scores-for-pediatric-pans-patients/ 2025-05-28 https://bio-research.ai/kyron-bio-raises-5-5-million-to-advance-glycan-engineering-platform-for-biologic-drugs/ 2025-05-28 https://bio-research.ai/proteinqure-inc-secures-11-million-to-support-its-first-clinical-trial-of-pdc-targeting-sort1-in-triple-negative-breast-cancer/ 2025-05-28 https://bio-research.ai/ausperbio-therapeutics-raises-50-million-for-phase-ii-development-of-unconjugated-aso-for-chronic-hepatitis-b/ 2025-05-28 https://bio-research.ai/evommune-reports-30-complete-response-in-phase-2-trial-of-mrgprx2-antagonist-for-chronic-inducible-urticaria/ 2025-05-28 https://bio-research.ai/emd-serono-s-phase-3-trial-shows-csf-1r-inhibitor-achieves-54-response-rate-in-tgct-at-week-25/ 2025-05-28 https://bio-research.ai/gsk-and-spero-s-tebipenem-hbr-phase-3-trial-halted-early-after-meeting-non-inferiority-endpoint-per-idmc-advice/ 2025-05-28 https://bio-research.ai/ono-pharmaceutical-s-phase-2-study-of-oral-btk-inhibitor-shows-67-overall-response-in-lymphoma-treatment/ 2025-05-28 https://bio-research.ai/immutep-limited-s-phase-ii-trial-shows-35-median-tumor-fibrosis-in-soft-tissue-sarcoma/ 2025-05-28 https://bio-research.ai/eddc-s-adc-targeting-n256c5-6-undergoes-phase-1-trials-for-pancreatic-cancer-with-fda-fast-track-designation/ 2025-05-28 https://bio-research.ai/rnatives-inc-raises-eur-2-8-million-for-rna-based-gene-regulation-technology-development/ 2025-05-27 https://bio-research.ai/glycoera-ag-secures-130-million-to-advance-igg4-targeted-protein-degrader-and-initiate-clinical-trials/ 2025-05-27 https://bio-research.ai/abelzeta-pharma-s-anti-cd20-bcma-bi-specific-autologous-car-t-therapy-receives-fda-designation-for-refractory-systemic-lupus-erythematosus-therapy/ 2025-05-27 https://bio-research.ai/ocugen-receives-rare-pediatric-disease-designation-for-aav-based-gene-therapy-in-abca4-associated-retinopathies/ 2025-05-27 https://bio-research.ai/xoma-acquires-bioinvent-s-royalty-rights-for-anti-cd38-mab-for-up-to-30m/ 2025-05-27 https://bio-research.ai/eli-lilly-to-acquire-siteone-therapeutics-with-potential-1b-payout-for-nav1-8-inhibitor-stc-004/ 2025-05-27 https://bio-research.ai/grin-therapeutics-and-angelini-pharma-collaborate-to-develop-radiprodil-and-secure-140-million-funding/ 2025-05-27 https://bio-research.ai/angelini-pharma-partners-with-grin-therapeutics-for-nr2b-negative-allosteric-modulator-with-50m-upfront-and-520m-in-milestones/ 2025-05-27 https://bio-research.ai/iolyx-therapeutics-phase-2-trial-of-ilyx-002-shows-improvement-in-dry-eye-disease-by-day-15/ 2025-05-27 https://bio-research.ai/biogen-and-city-therapeutics-partner-on-rnai-therapies-with-potential-1b-in-milestones-and-royalties/ 2025-05-27 https://bio-research.ai/gilgamesh-pharmaceuticals-phase-2a-trial-of-5-ht2a-receptor-agonist-shows-28-0-point-reduction-in-madrs-scores-at-day-29/ 2025-05-27 https://bio-research.ai/fda-approves-starjemza-injection-a-biosimilar-to-stelara-for-multiple-autoimmune-disorders/ 2025-05-27 https://bio-research.ai/eisai-announces-approval-of-dayvigo-in-china-for-adult-insomnia-treatment/ 2025-05-27 https://bio-research.ai/european-commission-grants-orphan-drug-designation-to-anti-her2-mab-for-gastric-cancer-treatment/ 2025-05-26 https://bio-research.ai/johnson-johnson-phase-i-ii-trial-shows-77-8-response-rate-for-talquetamab-in-multiple-myeloma/ 2025-05-26 https://bio-research.ai/abbisko-therapeutics-fgfr4-inhibitor-receives-breakthrough-therapy-designation-for-liver-cancer-in-china/ 2025-05-26 https://bio-research.ai/fda-accepts-biologics-license-application-for-anti-april-monoclonal-antibody-targeting-iga-nephropathy/ 2025-05-26 https://bio-research.ai/shanghai-allist-s-kras-g12c-inhibitor-approved-in-china-for-krasg12c-mutated-advanced-non-small-cell-lung-cancer/ 2025-05-26 https://bio-research.ai/innovent-biologics-phase-3-results-of-dual-gcg-glp-1-receptor-agonist-published-in-nejm/ 2025-05-26 https://bio-research.ai/prothena-corporation-s-phase-3-trial-of-birtamimab-in-al-amyloidosis-did-not-meet-its-endpoints/ 2025-05-23 https://bio-research.ai/fda-approves-prostacyclin-analog-for-pulmonary-hypertension-amid-patent-lawsuit-challenges/ 2025-05-23 https://bio-research.ai/stella-pharma-phase-ii-trial-shows-14-4-months-progression-free-survival-for-bnct-in-meningioma/ 2025-05-23 https://bio-research.ai/genentech-s-phase-iii-starglo-trial-shows-40-survival-improvement-with-cd20xcd3-t-cell-engager-combo-therapy/ 2025-05-22 https://bio-research.ai/cullinan-therapeutics-reports-35-response-rate-in-phase-2b-trial-of-zipalertinib-for-lung-cancer/ 2025-05-22 https://bio-research.ai/exelixis-reports-63-response-rate-in-stellar-002-trial-with-zanzalintinib-and-nivolumab-combo/ 2025-05-22 https://bio-research.ai/astellas-pharma-and-pfizer-five-year-trial-results-show-xtandi-reduces-death-risk-by-30-in-prostate-cancer/ 2025-05-22 https://bio-research.ai/fda-approves-nucala-as-add-on-treatment-for-adult-copd-patients-with-eosinophilic-phenotype/ 2025-05-22 https://bio-research.ai/gyre-therapeutics-phase-3-trial-shows-oral-p38-kinase-inhibitor-reduces-fibrosis-in-chronic-hepatitis-b-patients/ 2025-05-22 https://bio-research.ai/fda-approves-genentech-s-susvimo-for-diabetic-retinopathy-after-phase-iii-study-results/ 2025-05-22 https://bio-research.ai/fore-biotherapeutics-secures-38m-to-advance-forte-master-protocol-for-braf-v600-mutated-tumors/ 2025-05-22 https://bio-research.ai/annji-pharmaceutical-reports-mar-degrader-improves-physical-and-muscle-function-in-spinal-and-bulbar-muscular-atrophy-over-12-weeks/ 2025-05-22 https://bio-research.ai/step-pharma-s-oral-ctps1-inhibitor-granted-orphan-drug-designation-by-us-fda-for-t-cell-lymphoma-treatment/ 2025-05-22 https://bio-research.ai/sanofi-acquires-vigil-neuroscience-for-470m-adding-trem2-agonist-vg-3927-for-alzheimer-s-to-portfolio/ 2025-05-21 https://bio-research.ai/orionis-biosciences-and-genentech-expand-collaboration-on-molecular-glue-medicines-with-2b-potential-payouts/ 2025-05-21 https://bio-research.ai/merck-kgaa-s-phase-2-study-shows-an-oral-tlr7-8-inhibitor-reduces-lupus-symptoms-by-week-24/ 2025-05-21 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-belite-bio-s-rbp4-modulator-for-stargardt-disease/ 2025-05-21 https://bio-research.ai/repronovo-secures-65-million-to-advance-phase-2-programs-in-reproductive-and-women-s-health/ 2025-05-21 https://bio-research.ai/accrokeutics-phase-2-trial-of-oral-tyk2-jak1-inhibitor-achieves-pasi-75-and-pasi-90-in-plaque-psoriasis-after-12-weeks/ 2025-05-21 https://bio-research.ai/vantai-and-blueprint-medicines-expand-ai-driven-drug-design-deal-worth-up-to-1-67b/ 2025-05-20 https://bio-research.ai/atai-life-sciences-reports-phase-2a-trial-of-mebufotenin-benzoate-shows-antidepressant-effects-lasting-up-to-3-months/ 2025-05-20 https://bio-research.ai/revolka-co-secures-210-million-yen-for-ai-driven-protein-engineering-in-rare-disease-drug-discovery/ 2025-05-20 https://bio-research.ai/pfizer-and-3sbio-ink-global-ex-china-deal-for-pd-1-vegf-bispecific-antibody-with-1-25b-upfront-and-4-8b-in-milestones/ 2025-05-19 https://bio-research.ai/crispr-therapeutics-and-sirius-therapeutics-partner-to-develop-long-acting-factor-xi-sirna-with-a-95m-agreement/ 2025-05-19 https://bio-research.ai/boehringer-ingelheim-s-phase-iii-trials-show-reduced-decline-in-lung-capacity-at-week-52/ 2025-05-19 https://bio-research.ai/bayer-s-jivi-receives-fda-approval-for-pediatric-patients-with-hemophilia-a-aged-7-to-under-12-years/ 2025-05-19 https://bio-research.ai/astrazeneca-s-batura-phase-iiib-trial-shows-airsupra-reduces-severe-asthma-risk-by-47/ 2025-05-19 https://bio-research.ai/repair-biotechnologies-obtains-fda-orphan-drug-designation-for-rep-0003-in-familial-hypercholesterolemia/ 2025-05-19 https://bio-research.ai/apnimed-phase-3-trial-of-ad109-shows-55-6-reduction-in-apnea-hypopnea-index-for-sleep-apnea/ 2025-05-19 https://bio-research.ai/cellcentric-raises-120-million-to-fund-clinical-trials-for-an-oral-p300-cbp-inhibitor-targeting-multiple-myeloma/ 2025-05-19 https://bio-research.ai/ionis-pharmaceuticals-essence-study-shows-liver-directed-apoc3-aso-therapy-reduces-triglycerides-in-phase-3-trial/ 2025-05-19 https://bio-research.ai/savara-inc-phase-3-trial-shows-reduced-surfactant-burden-with-molgramostim-in-pulmonary-alveolar-proteinosis/ 2025-05-19 https://bio-research.ai/hanmi-pharmaceutical-collaborates-with-msd-in-phase-1-trials-of-next-gen-il-2-and-keytruda-combo-for-solid-tumors/ 2025-05-19 https://bio-research.ai/applied-therapeutics-announces-phase-2-3-results-showing-decreased-sorbitol-levels-in-12-months/ 2025-05-18 https://bio-research.ai/sun-pharma-s-led-blu-u-device-approved-by-fda-for-treating-actinic-keratoses/ 2025-05-16 https://bio-research.ai/biomarin-pharmaceutical-to-acquire-inozyme-pharma-for-270m-including-enpp1-enzyme-replacement-phase-3-therapy/ 2025-05-16 https://bio-research.ai/cdk2-4-6-9-inhibitor-approved-in-china-for-hr-her2-breast-cancer-after-prior-endocrine-therapy/ 2025-05-16 https://bio-research.ai/abclon-s-phase-2-trial-of-cd19-car-t-therapy-shows-94-response-rate-and-63-complete-remission-rate/ 2025-05-16 https://bio-research.ai/shanghai-ark-biopharmaceutical-phase-ii-study-shows-anti-fibrotic-agents-improve-fvc-in-idiopathic-pulmonary-fibrosis/ 2025-05-15 https://bio-research.ai/pathos-ai-raises-365-million-to-enhance-ai-enabled-oncology-drug-development-platform/ 2025-05-15 https://bio-research.ai/fda-approves-brekiya-autoinjector-for-treating-acute-migraine-and-cluster-headaches-in-adults/ 2025-05-15 https://bio-research.ai/fda-approves-zynyz-for-advanced-squamous-cell-carcinoma-of-the-anal-canal-with-safety-concerns-noted/ 2025-05-15 https://bio-research.ai/merck-s-phase-3-keynote-b96-trial-meets-endpoints-in-ovarian-cancer-with-keytruda-and-chemotherapy/ 2025-05-15 https://bio-research.ai/rznomics-and-eli-lilly-agree-on-rna-editing-therapeutics-for-hearing-loss-in-1-9b-global-deal/ 2025-05-15 https://bio-research.ai/fda-grants-rmat-designation-to-brainchild-bio-s-b7-h3-car-t-cell-therapy-for-pediatric-brain-tumors-showing-promising-survival-benefits/ 2025-05-14 https://bio-research.ai/fda-approves-merck-s-hif-2-inhibitor-for-pheochromocytoma-paraganglioma-based-on-litespark-015-trial-results/ 2025-05-14 https://bio-research.ai/emrelis-receives-accelerated-fda-approval-for-treating-advanced-non-squamous-nsclc-with-high-c-met-overexpression/ 2025-05-14 https://bio-research.ai/abbvie-and-adarx-pharmaceuticals-partner-to-develop-sirna-therapeutics-with-335m-upfront-payment/ 2025-05-14 https://bio-research.ai/septerna-and-novo-nordisk-partner-on-gpcr-targeted-therapies-with-up-to-2-2b-in-payments/ 2025-05-14 https://bio-research.ai/sernova-biotherapeutics-cell-pouch-bio-hybrid-organ-shows-promise-in-achieving-insulin-independence-for-type-1-diabetes-patients-in-phase-1-2-trial/ 2025-05-14 https://bio-research.ai/gsk-acquires-boston-pharmaceuticals-efimosfermin-alfa-for-1-2b-upfront-plus-800m-in-milestone-payments/ 2025-05-14 https://bio-research.ai/artiva-biotherapeutics-allonk-plus-rituximab-shows-64-complete-response-in-b-cell-non-hodgkin-lymphoma-trial-long-term-results/ 2025-05-13 https://bio-research.ai/somite-ai-raises-47-million-to-advance-deltastem-platform-for-type-1-diabetes-and-blood-disorders/ 2025-05-13 https://bio-research.ai/iteos-therapeutics-ends-anti-tigit-program-with-gsk-after-trial-fails-progression-free-survival-goal/ 2025-05-13 https://bio-research.ai/cytokinetics-maple-hcm-trial-shows-significant-improvement-in-peak-oxygen-uptake-for-cardiac-myosin-inhibitor/ 2025-05-13 https://bio-research.ai/tilt-biotherapeutics-advances-phase-2-trial-for-cytokine-armed-oncolytic-adenovirus-in-ovarian-cancer-with-series-b-funding/ 2025-05-13 https://bio-research.ai/azafaros-raises-132m-to-advance-phase-3-trials-for-nizubaglustat-in-niemann-pick-disease-and-gangliosidoses/ 2025-05-13 https://bio-research.ai/remegen-s-phase-3-trial-of-anti-her2-adc-with-toripalimab-meets-endpoints-for-urothelial-carcinoma/ 2025-05-12 https://bio-research.ai/genentech-s-phase-iii-aphinity-study-shows-17-risk-reduction-in-her2-positive-breast-cancer-treatment/ 2025-05-12 https://bio-research.ai/biodexa-pharmaceuticals-receives-eu-orphan-drug-designation-for-oral-mtor-inhibitor-in-treating-familial-adenomatous-polyposis/ 2025-05-12 https://bio-research.ai/abeona-therapeutics-sells-priority-review-voucher-for-155m-with-support-from-stifel-and-jefferies/ 2025-05-12 https://bio-research.ai/beam-therapeutics-base-editing-gene-therapy-receives-rmat-designation-to-target-alpha-1-antitrypsin-deficiency/ 2025-05-12 https://bio-research.ai/novo-nordisk-s-phase-3-trial-finds-its-long-acting-growth-hormone-therapy-non-inferior-to-norditropin-in-children-with-ns-sga-iss/ 2025-05-12 https://bio-research.ai/madrigal-pharmaceuticals-reports-65-of-mash-cirrhosis-patients-moved-to-lower-risk-after-2-years-on-thr-agonist/ 2025-05-10 https://bio-research.ai/leo-pharma-reports-phase-2b-trial-results-of-il-22ra1-antagonist-showing-significant-easi-score-improvements-in-moderate-to-severe-atopic-dermatitis/ 2025-05-09 https://bio-research.ai/minghui-and-qilu-partner-for-b7-h3-adc-with-1-345b-rmb-deal-in-greater-china/ 2025-05-09 https://bio-research.ai/johnson-johnson-s-oral-il-23r-inhibitor-achieves-up-to-77-skin-clearance-in-phase-3-psoriasis-trial/ 2025-05-09 https://bio-research.ai/eli-lilly-and-purdue-university-expand-collaboration-with-potential-250m-investment-through-2032/ 2025-05-09 https://bio-research.ai/purmx-therapeutics-receives-orphan-drug-designation-from-fda-for-mir-3140-3p-in-mesothelioma-treatment/ 2025-05-09 https://bio-research.ai/astrazeneca-s-phase-iii-trial-shows-improved-disease-free-survival-with-pd-l1-monocloncal-antibody-and-bcg-in-bladder-cancer/ 2025-05-09 https://bio-research.ai/cognition-therapeutics-phase-2-trial-shows-28-6-reduction-in-geographic-atrophy-lesion-growth/ 2025-05-08 https://bio-research.ai/haya-therapeutics-secures-65-million-to-advance-lncrna-targeting-drug-candidate-for-heart-failure-and-expand-platform/ 2025-05-08 https://bio-research.ai/viatris-inc-s-phase-3-trial-of-mr-107a-02-meets-all-endpoints-with-reduced-opioid-use-and-pain-control/ 2025-05-08 https://bio-research.ai/gsk-s-glisten-phase-iii-trial-shows-its-oral-ibat-inhibitor-improves-itch-in-cholestatic-pruritus-over-24-weeks/ 2025-05-08 https://bio-research.ai/dr-falk-pharma-s-phase-3-nuc-5-trial-of-engineered-bile-acid-shows-statistically-significant-improvements-in-liver-health-for-psc-patients/ 2025-05-07 https://bio-research.ai/guselkumab-approved-by-european-commission-for-crohn-s-disease-as-first-dual-acting-il-23-inhibitor/ 2025-05-07 https://bio-research.ai/ashvattha-therapeutics-phase-2-results-show-reduced-anti-vegf-burden-in-wet-amd-and-dme-patients/ 2025-05-07 https://bio-research.ai/viverita-therapeutics-and-boehringer-ingelheim-form-strategic-partnership-to-evaluate-cancer-targets-using-in-vivo-crispr-platform/ 2025-05-07 https://bio-research.ai/altesa-s-vapendavir-achieves-respiratory-symptom-relief-and-faster-recovery-in-phase-2-copd-rhinovirus-study/ 2025-05-07 https://bio-research.ai/marea-therapeutics-phase-2a-trial-shows-anti-angptl4-mab-reduces-remnant-cholesterol-and-triglycerides-by-52/ 2025-05-07 https://bio-research.ai/paq-therapeutics-raises-39-million-for-phase-1-trial-of-selective-kras-degrader-in-kras-g12d-solid-tumors/ 2025-05-07 https://bio-research.ai/atea-pharmaceuticals-reports-oral-ns5b-ns5a-inhibitor-combo-achieves-98-cure-rate-in-hepatitis-c-after-short-8-week-regimen/ 2025-05-07 https://bio-research.ai/grand-pharmaceutical-group-limited-s-phase-ii-trial-of-sepsis-treatment-candidate-shows-significant-improvements-in-sofa-scores/ 2025-05-07 https://bio-research.ai/gilead-sciences-livdelzi-achieves-60-response-in-primary-biliary-cholangitis-trial/ 2025-05-07 https://bio-research.ai/gilead-sciences-phase-3-study-shows-36-maintain-undetectable-hdv-rna-two-years-post-treatment/ 2025-05-07 https://bio-research.ai/daiichi-sankyo-and-astrazeneca-s-phase-3-trial-shows-improved-pathologic-complete-response-with-enhertu-followed-by-thp-in-high-risk-her2-positive-early-breast-cancer/ 2025-05-07 https://bio-research.ai/adcentrx-therapeutics-nectin-4-adc-receives-fda-fast-track-for-squamous-cell-cervical-cancer-treatment/ 2025-05-06 https://bio-research.ai/formosa-and-almac-discovery-sign-global-licensing-agreement-for-bispecific-adc-targeting-egfr-and-ror1-in-cancer-therapy/ 2025-05-06 https://bio-research.ai/astrazeneca-s-calquence-plus-chemoimmunotherapy-approved-in-eu-for-untreated-mantle-cell-lymphoma-adults/ 2025-05-06 https://bio-research.ai/actuate-therapeutics-phase-2-trial-shows-improved-median-overall-survival-in-pancreatic-cancer/ 2025-05-06 https://bio-research.ai/alchemab-partners-with-eli-lilly-in-415m-deal-for-atlx-1282-targeting-als-and-neurodegenerative-diseases/ 2025-05-06 https://bio-research.ai/nuevocor-secures-45m-for-phase-1-2-trial-of-aav-gene-therapy-in-lmna-related-dilated-cardiomyopathy/ 2025-05-06 https://bio-research.ai/innovent-biologics-phase-2-trial-of-anti-vegfr-cr1-fusion-protein-shows-similar-visual-acuity-gains-to-aflibercept/ 2025-05-06 https://bio-research.ai/aldeyra-therapeutics-phase-3-trial-shows-rasp-modulator-reduced-ocular-discomfort-in-dry-eye-disease/ 2025-05-05 https://bio-research.ai/unity-biotechnology-s-phase-2b-trial-of-bcl-xl-inhibitor-10-g-shows-non-inferior-vision-gains-versus-aflibercept-2-mg/ 2025-05-05 https://bio-research.ai/ptc-therapeutics-reports-phase-2-pivot-hd-study-shows-significant-reduction-in-harmful-protein-with-splicing-modifier-therapy/ 2025-05-05 https://bio-research.ai/sylentis-announces-phase-iia-sirna-targeting-nrarp-study-showing-statistically-significant-visual-acuity-improvement-at-42-days/ 2025-05-05 https://bio-research.ai/recursion-s-phase-1b-2-tupelo-trial-reports-43-median-polyp-reduction-in-six-patients/ 2025-05-04 https://bio-research.ai/fda-accepts-novo-nordisk-s-application-for-oral-wegovy-for-weight-management-in-adults/ 2025-05-02 https://bio-research.ai/astrazeneca-s-phase-iii-trials-show-breztri-aerosphere-improves-lung-function-in-4-400-asthma-patients/ 2025-05-02 https://bio-research.ai/an2-therapeutics-phase-3-ebo-301-study-fails-primary-endpoint-for-severe-mac-lung-disease-treatment/ 2025-05-01 https://bio-research.ai/kronos-bio-to-merge-with-concentra-biosciences-for-0-57-per-share-and-contingent-value-rights/ 2025-05-01 https://bio-research.ai/okyo-pharma-receives-fda-fast-track-designation-for-chemr23-agonist-for-the-treatment-of-neuropathic-corneal-pain/ 2025-05-01 https://bio-research.ai/zucara-therapeutics-completes-25m-financing-to-fund-phase-2a-trials-of-sstr2-antagonist-for-type-1-diabetes/ 2025-05-01 https://bio-research.ai/alphamab-oncology-and-cspc-report-phase-ii-iii-trial-of-kn026-in-her2-positive-gastric-cancer-met-primary-endpoint/ 2025-05-01 https://bio-research.ai/dimerix-grants-amicus-u-s-rights-to-ccr2-inhibitor-for-30m-upfront-and-up-to-560m-in-milestones/ 2025-04-30 https://bio-research.ai/gsk-reports-21-reduction-in-copd-exacerbations-with-mepolizumab-in-full-phase-iii-matinee-trial-results/ 2025-04-30 https://bio-research.ai/fda-approves-johnson-johnson-s-imaavy-for-treating-generalized-myasthenia-gravis-in-patients-12-and-older-who-are-anti-achr-or-anti-musk-antibody-positive/ 2025-04-30 https://bio-research.ai/q32-bio-receives-fda-fast-track-designation-for-anti-il-7r-antibody-in-alopecia-areata-treatment/ 2025-04-30 https://bio-research.ai/novartis-to-acquire-regulus-therapeutics-for-up-to-1-7b-with-mir-17-inhibitor-as-main-asset/ 2025-04-30 https://bio-research.ai/addex-therapeutics-signs-option-agreement-with-sinntaxis-for-exclusive-ip-rights-to-mglu5-inhibitors-in-brain-injury-recovery/ 2025-04-30 https://bio-research.ai/creyon-bio-and-eli-lilly-partner-to-develop-rna-targeted-oligonucleotide-therapies-with-potential-1b-milestone-payments/ 2025-04-29 https://bio-research.ai/artios-pharma-s-stella-trial-shows-50-response-rate-with-selective-atr-inhibitor-in-atm-negative-tumors/ 2025-04-29 https://bio-research.ai/fda-approves-zevaskyn-gene-modified-cell-sheet-therapy-for-wounds-in-recessive-dystrophic-epidermolysis-bullosa/ 2025-04-29 https://bio-research.ai/bayer-s-phase-iii-trial-shows-higher-ultra-low-psa-response-rates-with-nubeqa-plus-adt-in-prostate-cancer/ 2025-04-29 https://bio-research.ai/fda-approves-abbvie-s-jak-inhibitor-for-treating-giant-cell-arteritis-after-phase-3-trial-results/ 2025-04-29 https://bio-research.ai/henlius-and-sandoz-ink-301m-deal-for-ipilimumab-biosimilar-hlx13-in-global-markets/ 2025-04-29 https://bio-research.ai/genprex-secures-an-exclusive-patent-license-from-nyu-langone-health-for-a-plasmid-based-gene-therapy-targeting-mesothelioma/ 2025-04-29 https://bio-research.ai/genfit-reports-phase-2-trial-results-of-ipsen-s-ppar-agonist-showing-alp-reduction-in-psc-patients/ 2025-04-29 https://bio-research.ai/astrazeneca-discontinues-capitello-280-phase-iii-trial-due-to-unlikely-endpoint-achievement/ 2025-04-29 https://bio-research.ai/urogen-pharma-s-phase-2b-study-of-ugn-102-shows-median-response-duration-of-24-2-months/ 2025-04-28 https://bio-research.ai/levicept-ltd-s-phase-ii-trial-for-neurotrophin-3-inhibitor-shows-significant-pain-relief-in-osteoarthritis-for-518-participants/ 2025-04-28 https://bio-research.ai/merck-kgaa-to-acquire-springworks-therapeutics-in-a-3-9b-deal-to-expand-rare-tumor-therapies/ 2025-04-28 https://bio-research.ai/akeso-s-bispecific-antibody-ivonescimab-approved-in-china-for-first-line-treatment-of-pd-l1-positive-nsclc-treatment/ 2025-04-26 https://bio-research.ai/pfizer-s-phase-3-trial-shows-32-risk-reduction-with-sasanlimab-in-bladder-cancer/ 2025-04-26 https://bio-research.ai/alx-oncology-s-phase-2-trials-show-evorpacept-and-keytruda-did-not-meet-primary-endpoints/ 2025-04-25 https://bio-research.ai/orion-and-criceto-enter-exclusive-agreement-for-global-parkinson-s-disease-drug-development-and-commercialization/ 2025-04-25 https://bio-research.ai/shionogi-and-apnimed-enter-agreement-for-sulthiame-and-new-drug-development-program-for-sleep-apnea-treatments/ 2025-04-25 https://bio-research.ai/netris-pharma-s-phase-ii-trial-of-netrin-1-antibody-shows-clinical-benefits-in-50-of-advanced-cancer-patients/ 2025-04-25 https://bio-research.ai/vivavision-biotech-s-phase-2-trial-shows-dual-jak1-tyk2-inhibitor-efficacy-comparable-to-prednisolone-acetate/ 2025-04-24 https://bio-research.ai/mosaic-therapeutics-acquires-erk1-2-inhibitor-and-mdm2-antagonist-from-astex-pharmaceuticals-for-oncology-therapies/ 2025-04-24 https://bio-research.ai/granite-bio-ag-secures-100-million-for-development-of-antibodies-targeting-autoimmune-diseases/ 2025-04-24 https://bio-research.ai/dyne-therapeutics-receives-eu-orphan-drug-designation-for-antibody-fragment-oligonucleotide-conjugate-in-duchenne-muscular-dystrophy-trial/ 2025-04-24 https://bio-research.ai/bioxodes-reports-phase-2a-trial-of-therapeutic-protein-based-on-ixodes-ricinus-contact-phase-inhibitor-achieves-key-endpoints-in-intracerebral-hemorrhagic-stroke/ 2025-04-24 https://bio-research.ai/avidicure-launches-with-50-million-seed-financing-to-develop-multifunctional-antibody-targeting-trop2/ 2025-04-24 https://bio-research.ai/qyuns-therapeutics-partners-with-caldera-therapeutics-in-555m-licensing-deal-for-qx030n-development/ 2025-04-24 https://bio-research.ai/hk-inno-n-s-p-cab-class-drug-shows-superior-efficacy-in-gerd-phase-3-trials-meeting-all-endpoints/ 2025-04-24 https://bio-research.ai/repertoire-immune-medicines-and-genentech-collaborate-to-develop-t-cell-targeted-immune-medicines-with-765m-in-funding/ 2025-04-23 https://bio-research.ai/ascletis-pharma-inc-phase-ib-study-of-oral-glp-1r-biased-agonist-shows-6-5-and-4-5-weight-reductions-in-obesity-treatment/ 2025-04-23 https://bio-research.ai/boehringer-ingelheim-and-tessellate-bio-partner-on-oral-treatments-for-alt-dependent-cancers-in-a-500m-deal/ 2025-04-23 https://bio-research.ai/pd-1-vegf-bispecific-antibody-and-chemo-combi-significantly-improves-progression-free-survival-in-sq-nsclc-compared-to-tislelizumab-and-chemo-combi/ 2025-04-23 https://bio-research.ai/bristol-myers-squibb-s-cobenfy-acquired-from-karuna-fails-as-adjunctive-therapy-in-phase-3-arise-trial-for-schizophrenia/ 2025-04-22 https://bio-research.ai/cellphire-therapeutics-study-shows-cryopreserved-platelet-therapy-non-inferior-to-standard-platelets-in-surgery/ 2025-04-22 https://bio-research.ai/fujifilm-diosynth-biotechnologies-wins-3b-contract-with-regeneron-pharmaceuticals-for-u-s-biologics-production/ 2025-04-22 https://bio-research.ai/ferring-pharmaceuticals-phase-3-trial-shows-75-response-rate-in-bladder-cancer-patients-in-japan/ 2025-04-21 https://bio-research.ai/gilead-sciences-phase-3-trial-shows-trodelvy-and-keytruda-combination-improves-progression-free-survival/ 2025-04-21 https://bio-research.ai/ns-pharma-receives-fda-orphan-drug-designation-for-selective-jak1-inhibitor-targeting-eosinophilic-granulomatosis-with-polyangiitis/ 2025-04-21 https://bio-research.ai/tempest-therapeutics-receives-fda-orphan-drug-designation-for-pge2-inhibitor-in-familial-adenomatous-polyposis/ 2025-04-21 https://bio-research.ai/daan-biotherapeutics-and-gc-cell-form-exclusive-agreement-for-a-tumor-antigen-specific-antibody-sequence-for-car-t-and-car-nk-therapy-development/ 2025-04-21 https://bio-research.ai/daiichi-sankyo-and-astrazeneca-s-trial-shows-enhertu-combo-hits-primary-endpoint-paving-way-for-first-line-label-expansion/ 2025-04-21 https://bio-research.ai/ono-pharmaceutical-and-jorna-therapeutics-partner-to-advance-rna-editing-based-therapy-development/ 2025-04-21 https://bio-research.ai/fda-approves-dupixent-for-treating-chronic-spontaneous-urticaria-in-patients-12-and-older/ 2025-04-18 https://bio-research.ai/akeso-s-il-12-il-23-monoclonal-antibody-approved-in-china-for-treating-plaque-psoriasis-in-adults/ 2025-04-18 https://bio-research.ai/earendil-labs-and-sanofi-sign-global-licensing-deal-for-two-tl1a-bispecific-antibodies-worth-125m-upfront/ 2025-04-17 https://bio-research.ai/velavigo-bio-licenses-bispecific-antibody-to-ollin-biosciences-in-440m-global-deal-outside-china/ 2025-04-17 https://bio-research.ai/bighat-biosciences-and-eli-lilly-partner-to-design-antibodies-for-two-programs-using-al-ml-powered-milliner-platform/ 2025-04-17 https://bio-research.ai/palatin-technologies-mc4r-agonist-equals-tirzepatide-in-phase-2-appetite-control-for-obesity/ 2025-04-17 https://bio-research.ai/eli-lilly-s-phase-3-trial-of-an-oral-glp-1r-agonist-shows-a1c-reduction-and-a-16-pound-weight-loss/ 2025-04-17 https://bio-research.ai/akeso-and-innovent-biologics-combine-bispecific-immunotherapy-and-oncolytic-virus-to-combat-crc-liver-metastases/ 2025-04-16 https://bio-research.ai/glycomine-raises-115m-to-advance-mannose-1-phosphate-replacement-therapy-into-phase-2b-trial-for-pmm2-cdg/ 2025-04-16 https://bio-research.ai/fda-approves-expanded-indication-for-isturisa-to-treat-endogenous-hypercortisolemia-in-adults-with-cushing-s-syndrome/ 2025-04-16 https://bio-research.ai/msd-partners-with-cyprumed-gmbh-for-oral-peptide-delivery-technology-in-a-non-exclusive-license-agreement-potentially-worth-493m/ 2025-04-15 https://bio-research.ai/eu-grants-first-full-approval-to-leqembi-as-a-disease-modifying-treatment-for-early-alzheimer-s/ 2025-04-15 https://bio-research.ai/oak-hill-bio-secures-global-rights-to-aso-targeting-ube3a-for-angelman-syndrome-in-agreement-with-roche/ 2025-04-15 https://bio-research.ai/attovia-therapeutics-secures-90-million-for-clinical-studies-of-anti-il31-mabs-and-pipeline-expansion/ 2025-04-15 https://bio-research.ai/metavia-inc-s-phase-1-trial-of-oxyntomodulin-analogue-reports-4-3-body-weight-reduction-at-32-mg-dose-by-day-26/ 2025-04-15 https://bio-research.ai/faron-pharmaceuticals-phase-ii-bexmab-trial-shows-high-response-rate-in-myelodysplastic-syndrome/ 2025-04-15 https://bio-research.ai/sanofi-s-asthma-drug-amlitelimab-fails-to-meet-primary-endpoint-at-highest-dose-level/ 2025-04-15 https://bio-research.ai/bristol-myers-squibb-s-phase-3-odyssey-hcm-trial-for-camzyos-fails-to-meet-dual-primary-endpoints/ 2025-04-14 https://bio-research.ai/synox-therapeutics-receives-fda-fast-track-designation-for-csf-1r-inhibitor-in-treating-tenosynovial-giant-cell-tumours/ 2025-04-14 https://bio-research.ai/the-fda-grants-orphan-drug-designation-to-cellenkos-allogeneic-treg-cell-therapy-for-transfusion-dependent-aplastic-anemia/ 2025-04-14 https://bio-research.ai/verve-therapeutics-phase-1b-trial-shows-69-maximum-ldl-c-reduction-with-verve-102/ 2025-04-14 https://bio-research.ai/pfizer-discontinues-oral-glp-1r-agonist-for-weight-management-after-review-of-clinical-data/ 2025-04-14 https://bio-research.ai/fate-therapeutics-ft819-ipsc-derived-car-t-cell-therapy-receives-fda-rmat-designation/ 2025-04-14 https://bio-research.ai/bridge-biotherapeutics-phase-2-trial-of-autotaxin-inhibitor-shows-no-significant-improvement-in-fvc-at-week-24/ 2025-04-14 https://bio-research.ai/amgen-s-phase-3-trial-of-tarlatamab-dlle-shows-improved-overall-survival-in-small-cell-lung-cancer-meeting-its-primary-endpoint/ 2025-04-11 https://bio-research.ai/verve-therapeutics-verve-102-receives-fda-fast-track-for-hyperlipidemia-targeting-ldl-cholesterol/ 2025-04-11 https://bio-research.ai/fda-approves-vitrakvi-for-ntrk-fusion-positive-solid-tumors-with-60-overall-response-rate/ 2025-04-10 https://bio-research.ai/protagonist-therapeutics-phase-3-trial-shows-84-1-skin-clearance-in-adolescents-with-icotrokinra/ 2025-04-10 https://bio-research.ai/belief-biomed-and-takeda-china-receive-approval-for-fix-aav-gene-therapy-for-hemophilia-b/ 2025-04-10 https://bio-research.ai/alzheon-inc-s-apolloe4-phase-3-trial-fails-primary-endpoint-shows-benefit-in-patients-with-mild-cognitive-impairment/ 2025-04-10 https://bio-research.ai/palatin-technologies-six-month-study-shows-71-achieve-over-30-reduction-in-protein-to-creatinine-ratio/ 2025-04-10 https://bio-research.ai/zhongsheng-suoyuan-nuwacell-raises-235-million-yuan-to-advance-ipsc-derived-cell-therapy-clinical-pipelines/ 2025-04-10 https://bio-research.ai/alterity-therapeutics-iron-chaperone-significantly-slows-disease-progression-in-early-stage-multiple-system-atrophy-in-phase-2-trial/ 2025-04-10 https://bio-research.ai/ractigen-therapeutics-reports-66-7-complete-response-rate-in-p21-sarna-bladder-cancer-trial/ 2025-04-09 https://bio-research.ai/solu-therapeutics-raises-41-million-for-phase-1-trial-of-stx-0712-targeting-ccr2-positive-monocytes/ 2025-04-09 https://bio-research.ai/remegen-announces-phase-3-trial-results-for-telitacicept-showing-mg-adl-reduction-of-5-74-at-week-24/ 2025-04-09 https://bio-research.ai/cartesian-therapeutics-reports-12-month-data-showing-significant-mg-adl-and-qmg-score-reductions/ 2025-04-08 https://bio-research.ai/merida-biosciences-secures-121-million-for-precision-therapeutics-targeting-graves-disease-autoantibodies/ 2025-04-08 https://bio-research.ai/annexon-inc-s-phase-3-trial-shows-c1q-blocking-antibody-significantly-improves-muscle-strength-and-mobility-in-gbs-patients/ 2025-04-08 https://bio-research.ai/kalvista-pharmaceuticals-licenses-plasma-kallikrein-inhibitor-to-kaken-pharmaceutical-for-up-to-24m-for-japan-territory/ 2025-04-08 https://bio-research.ai/johnson-johnson-s-phase-3-study-on-anti-fcrn-mab-shows-improved-mg-adl-and-qmg-scores-with-45-reducing-steroid-use/ 2025-04-08 https://bio-research.ai/daiichi-sankyo-receives-eu-marketing-approval-for-trop2-directed-adc-for-hr-positive-her2-negative-breast-cancer/ 2025-04-08 https://bio-research.ai/rinvoq-approved-in-eu-as-first-oral-janus-kinase-inhibitor-for-treating-giant-cell-arteritis-in-adults/ 2025-04-08 https://bio-research.ai/allogene-therapeutics-receives-fda-fast-track-for-allogeneic-cd19-cd70-dual-car-t-cell-therapy-in-refractory-autoimmune-conditions/ 2025-04-07 https://bio-research.ai/european-commission-approves-subcutaneous-egfr-met-bispecific-antibody-for-advanced-non-small-cell-lung-cancer/ 2025-04-07 https://bio-research.ai/european-commission-approves-j-j-s-subcutaneous-anti-cd38-mab-regimen-for-multiple-myeloma/ 2025-04-07 https://bio-research.ai/rhythm-pharmaceuticals-phase-3-trial-shows-16-5-bmi-reduction-with-mc4r-agonist-in-hypothalamic-obesity/ 2025-04-07 https://bio-research.ai/abl-bio-and-gsk-forge-igf1r-targeting-bbb-platform-deal-for-neurodegenerative-treatments-potentially-worth-gbp-2-14-billion/ 2025-04-07 https://bio-research.ai/beam-therapeutics-reports-piz-mutation-editing-therapy-trial-with-91-m-aat-levels-at-day-28-and-79-mutant-reduction/ 2025-04-05 https://bio-research.ai/raythera-raises-110-million-to-advance-small-molecule-immunology-drugs-into-phase-1-clinical-trials/ 2025-04-04 https://bio-research.ai/johnson-johnson-s-phase-3b-study-demonstrates-tremfya-significantly-improves-acr20-and-inhibits-structural-damage-progression-in-psoriatic-arthritis-by-week-24/ 2025-04-04 https://bio-research.ai/enhertu-receives-eu-approval-for-her2-low-metastatic-breast-cancer-after-positive-phase-iii-trial-results/ 2025-04-04 https://bio-research.ai/arvinas-reports-arv-102-reduces-lrrk2-protein-in-trial-with-healthy-volunteers/ 2025-04-04 https://bio-research.ai/tasman-therapeutics-raises-175-million-to-advance-extended-release-oral-ketamine-into-phase-3-trials/ 2025-04-03 https://bio-research.ai/sangamo-therapeutics-licenses-aav-capsid-for-cns-diseases-to-eli-lilly-for-18m-upfront-and-1-4b-in-milestones/ 2025-04-03 https://bio-research.ai/roche-reports-a-and-tfr1-targeting-bispecific-antibody-reduces-amyloid-plaques-in-alzheimer-s-patients-in-recent-data-release/ 2025-04-03 https://bio-research.ai/neurona-therapeutics-secures-102-million-to-advance-allogeneic-cell-therapy-for-mesial-temporal-lobe-epilepsy-trial/ 2025-04-03 https://bio-research.ai/resvita-bio-s-continuous-protein-therapy-for-netherton-syndrome-receives-orphan-drug-designation-from-the-fda/ 2025-04-03 https://bio-research.ai/atamyo-therapeutics-trial-for-fkrp-gene-therapy-shows-marked-improvements-in-limb-girdle-muscular-dystrophy/ 2025-04-03 https://bio-research.ai/pharmamar-partners-with-merck-kgaa-in-japan-for-transcription-inhibitor-with-22m-upfront-and-potential-31m-milestones/ 2025-04-03 https://bio-research.ai/aldeyra-therapeutics-rasp-modulator-for-dry-eye-disease-receives-complete-response-letter-from-fda/ 2025-04-03 https://bio-research.ai/fda-grants-orphan-drug-designation-to-btk-inhibitor-for-treating-hemolytic-anemia-and-igg4-related-disease/ 2025-04-03 https://bio-research.ai/novartis-eta-receptor-antagonist-receives-fda-accelerated-approval-for-proteinuria-treatment-in-iga-nephropathy-patients/ 2025-04-02 https://bio-research.ai/genentech-s-phase-iii-musette-trial-found-no-additional-benefits-of-a-higher-dose-of-anti-cd20-antibody-over-the-approved-600-mg-dose-for-relapsing-ms/ 2025-04-02 https://bio-research.ai/denali-therapeutics-begins-bla-for-ids-fusion-protein-in-hunter-syndrome/ 2025-04-02 https://bio-research.ai/sanofi-licenses-transcription-factor-tpd-program-from-nurix-therapeutics-targeting-autoimmune-diseases-for-480m-total-payment/ 2025-04-02 https://bio-research.ai/biomarin-pharmaceutical-inc-phase-3-pegasus-trial-shows-pegylated-pegvaliase-significantly-reduces-blood-phe-in-adolescents/ 2025-04-02 https://bio-research.ai/atsena-therapeutics-secures-150-million-to-advance-aav-therapy-for-treating-x-linked-retinoschisis/ 2025-04-02 https://bio-research.ai/medera-reports-improved-heart-function-in-initial-patients-using-an-aav-therapy-delivering-serca2a-for-heart-failure-in-phase-1-2a-trial/ 2025-04-02 https://bio-research.ai/edgewise-therapeutics-phase-2-trial-shows-edg-7500-reduced-outflow-gradients-in-cardiomyopathy-patients/ 2025-04-02 https://bio-research.ai/johnson-johnson-leads-29-billion-krw-series-b-funding-for-korean-tpd-specialist-prazer-therapeutics/ 2025-04-01 https://bio-research.ai/grin-therapeutics-nr2b-negative-allosteric-modulator-designated-as-a-priority-medicine-by-the-european-medicines-agency/ 2025-04-01 https://bio-research.ai/organon-acquires-u-s-rights-for-biogen-s-biosimilar/ 2025-04-01 https://bio-research.ai/cerevance-s-phase-2-trial-of-oral-gpr6-inhibitor-in-parkinson-s-shows-non-significant-motor-improvement/ 2025-04-01 https://bio-research.ai/otsuka-pharmaceutical-submits-bla-to-fda-for-anti-april-antibody-targeting-immunoglobulin-a-nephropathy/ 2025-04-01 https://bio-research.ai/airna-secures-155-million-for-phase-1-2-trial-of-gene-editing-candidate-in-alpha-1-antitrypsin-deficiency/ 2025-04-01 https://bio-research.ai/compass-therapeutics-reports-17-1-response-rate-with-anti-vegf-a-dll4-antibody-in-biliary-tract-cancer-trial/ 2025-04-01 https://bio-research.ai/axsome-therapeutics-phase-3-trial-shows-no-overall-improvement-for-solriamfetol-in-mdd-vs-placebo/ 2025-04-01 https://bio-research.ai/astrazeneca-s-phase-iib-trial-shows-oral-pcsk9-inhibitor-reduced-ldl-cholesterol-by-50-7-over-12-weeks/ 2025-03-31 https://bio-research.ai/genmab-receives-european-commission-approval-for-tissue-factor-targeting-adc-to-treat-recurrent-or-metastatic-cervical-cancer/ 2025-03-31 https://bio-research.ai/launxp-international-acquires-rights-from-apollomics-for-c-met-inhibitor-in-asia/ 2025-03-31 https://bio-research.ai/novo-nordisk-s-stride-trial-semaglutide-1-mg-boosts-walking-distance-by-13-in-type-2-diabetes-patients/ 2025-03-29 https://bio-research.ai/novo-nordisk-s-soul-trial-shows-14-reduction-in-cardiovascular-risk-with-rybelsus-tablets/ 2025-03-29 https://bio-research.ai/fda-approves-qfitlia-the-first-rnai-therapeutic-for-hemophilia-a-or-b-for-patients-aged-12-and-older/ 2025-03-28 https://bio-research.ai/virion-therapeutics-phase-1b-trial-of-vron-0200-shows-t-cell-responses-in-chronic-hbv-patients/ 2025-03-28 https://bio-research.ai/lexicon-licenses-acsl5-inhibitor-to-novo-nordisk-in-1b-deal-with-75m-upfront-and-royalty-provisions/ 2025-03-28 https://bio-research.ai/palatin-technologies-phase-2-trial-shows-33-remission-in-ulcerative-colitis-with-mc1r-agonist/ 2025-03-28 https://bio-research.ai/fda-issues-complete-response-letter-to-milestone-pharmaceuticals-regarding-nda-for-calcium-channel-blocker-nasal-spray/ 2025-03-28 https://bio-research.ai/genfleet-therapeutics-kras-g12c-inhibitor-shows-80-response-rate-in-first-line-nsclc-treatment-in-phase-ii-krocus-study/ 2025-03-28 https://bio-research.ai/merck-s-phase-3-trial-shows-subcutaneous-pembrolizumab-is-noninferior-for-metastatic-lung-cancer/ 2025-03-27 https://bio-research.ai/dermata-therapeutics-once-weekly-topical-acne-treatment-hits-primary-iga-endpoint-in-phase-3-acne-trial/ 2025-03-27 https://bio-research.ai/cytosite-bio-partners-with-lantheus-holdings-to-develop-granzyme-b-targeted-pet-imaging-radiotracer/ 2025-03-27 https://bio-research.ai/vaximm-ag-s-phase-2a-trial-shows-12-response-with-anti-vegfr-2-vaccine-and-pd-l1-inhibitor-in-glioblastoma/ 2025-03-27 https://bio-research.ai/equillium-inc-s-phase-3-equator-study-of-anti-cd6-antibody-shows-no-significant-difference-in-response-rates-at-day-29/ 2025-03-27 https://bio-research.ai/boan-biotech-s-cd228-directed-adc-granted-fda-orphan-drug-designations-for-two-types-of-cancer/ 2025-03-27 https://bio-research.ai/regulus-therapeutics-phase-1b-study-shows-300-mg-of-mir-17-targeting-aso-halts-kidney-growth-in-adpkd-patients/ 2025-03-27 https://bio-research.ai/alzinova-ab-s-phase-1b-trial-of-amyloid-beta-peptide-vaccine-achieves-safety-and-immunogenicity-in-alzheimer-s-study/ 2025-03-27 https://bio-research.ai/alcon-acquires-majority-stake-in-aurion-biotech-to-advance-cell-therapy-for-corneal-edema/ 2025-03-26 https://bio-research.ai/epicrispr-biotechnologies-raises-68m-to-advance-clinical-development-of-one-time-dose-dux4-silencer-for-fshd/ 2025-03-26 https://bio-research.ai/fda-approves-gsk-s-triazaacenaphthylene-antibiotic-for-treating-uncomplicated-urinary-tract-infections-in-females-aged-12-and-older/ 2025-03-26 https://bio-research.ai/bayer-secures-global-rights-from-suzhou-puhe-biopharma-for-prmt5-inhibitor-in-mtap-tumors/ 2025-03-26 https://bio-research.ai/european-commission-approves-extending-slenyto-s-use-to-treat-insomnia-in-children-with-adhd/ 2025-03-26 https://bio-research.ai/filamin-a-modulator-falls-short-of-primary-goals-in-alzheimer-s-phase-3-study/ 2025-03-25 https://bio-research.ai/relmada-therapeutics-secures-exclusive-license-from-trigone-pharma-for-intravesical-gemcitabine-docetaxel-with-3-5m-upfront/ 2025-03-25 https://bio-research.ai/cns-pharmaceuticals-reports-similar-outcomes-for-berubicin-and-lomustine-in-glioblastoma-trial/ 2025-03-25 https://bio-research.ai/character-biosciences-raises-93-million-to-fund-clinical-trials-for-amd-therapies/ 2025-03-25 https://bio-research.ai/kezar-life-sciences-phase-2a-trial-shows-31-response-in-autoimmune-hepatitis-with-immunoproteasome-inhibitor/ 2025-03-25 https://bio-research.ai/alumis-and-kaken-pharmaceutical-partner-to-develop-tyk2-inhibitor-for-dermatology-in-japan-40m-upfront/ 2025-03-25 https://bio-research.ai/mural-oncology-s-phase-3-trial-shows-selective-il-2r-agonist-in-ovarian-cancer-survival-at-10-1-months/ 2025-03-25 https://bio-research.ai/recode-therapeutics-mrna-therapy-granted-orphan-drug-designation-for-cystic-fibrosis/ 2025-03-25 https://bio-research.ai/merck-and-jiangsu-hengrui-ink-1-77b-deal-for-global-rights-to-small-molecule-lp-a-inhibitor-outside-greater-china/ 2025-03-25 https://bio-research.ai/axsome-therapeutics-phase-3-trial-shows-significant-symptom-improvement-with-dopamine-norepinephrine-reuptake-inhibitor-in-adhd/ 2025-03-25 https://bio-research.ai/fda-conducts-priority-review-of-btk-inhibitor-for-secondary-progressive-multiple-sclerosis-treatment/ 2025-03-25 https://bio-research.ai/cg-oncology-s-oncolytic-adenovirus-shows-75-5-complete-response-rate-in-phase-3-hisk-risk-bcg-unresponsive-nmibc-trial/ 2025-03-24 https://bio-research.ai/astrazeneca-s-imfinzi-approved-by-eu-for-limited-stage-small-cell-lung-cancer-post-chemoradiation-therapy/ 2025-03-24 https://bio-research.ai/opthea-limited-s-phase-3-trial-fails-to-meet-primary-endpoint-for-visual-acuity-by-week-52/ 2025-03-24 https://bio-research.ai/augustine-therapeutics-raises-eur-78-million-to-advance-new-hdac6-inhibitor-for-charcot-marie-tooth-disease-trials/ 2025-03-24 https://bio-research.ai/united-laboratories-and-novo-nordisk-partner-with-up-to-1-8b-deal-for-glp-1-gip-and-glucagon-triple-receptor-agonist-development/ 2025-03-24 https://bio-research.ai/abbisko-and-shanghai-allist-collaborate-to-combine-pd-l1-inhibitor-and-kras-g12c-inhibitor-for-nsclc-treatment-options/ 2025-03-24 https://bio-research.ai/syneron-bio-and-astrazeneca-partner-to-develop-macrocyclic-peptides-with-75m-upfront-and-3-4b-in-milestones/ 2025-03-21 https://bio-research.ai/harbour-biomed-and-astrazeneca-partner-globally-to-develop-multi-specific-antibodies-with-105m-investment-and-potential-4-575b-milestones/ 2025-03-21 https://bio-research.ai/johnson-johnson-s-rybrevant-lazcluze-combo-extends-survival-over-one-year-in-first-line-lung-cancer/ 2025-03-21 https://bio-research.ai/ligachem-bio-secures-strategic-stake-and-management-rights-in-iksuda-therapeutics-through-25m-investment-to-boost-adc-pipeline/ 2025-03-21 https://bio-research.ai/fda-approves-alnylam-s-ttr-targeting-rnai-for-treating-cardiomyopathy-in-transthyretin-mediated-amyloidosis-patients/ 2025-03-20 https://bio-research.ai/fda-approves-dual-acting-mab-targeting-il-23-and-cd64-for-crohn-s-disease-offering-subcutaneous-and-intravenous-induction-options/ 2025-03-20 https://bio-research.ai/kintor-pharmaceutical-s-hair-loss-treatment-phase-iii-trial-meets-endpoint-with-significant-hair-count-increase/ 2025-03-20 https://bio-research.ai/fda-grants-orphan-drug-designation-to-bioinvent-s-anti-tnfr2-antibody-for-treating-t-cell-lymphoma/ 2025-03-20 https://bio-research.ai/sanofi-is-acquiring-dren-bio-s-affiliate-for-a-cd20-directed-myeloid-cell-engager-in-a-deal-worth-up-to-1-9-billion/ 2025-03-20 https://bio-research.ai/paratek-pharmaceuticals-to-acquire-optinose-in-a-deal-valued-up-to-330m/ 2025-03-19 https://bio-research.ai/novartis-reports-phase-iii-results-of-aav-therapy-with-a-2-39-point-improvement-in-spinal-muscular-atrophy-trial/ 2025-03-19 https://bio-research.ai/immunovant-inc-phase-3-trial-of-anti-fcrn-antibody-shows-5-6-point-improvement-in-mg-adl-scores/ 2025-03-19 https://bio-research.ai/oxford-biotherapeutics-partners-with-roche-for-new-targets-of-cancer-treatments-earning-up-to-36m-upfront-and-1b-in-milestones/ 2025-03-19 https://bio-research.ai/ampersand-biomedicines-raises-65-million-to-advance-and-body-therapeutics-for-immuno-inflammation/ 2025-03-19 https://bio-research.ai/servier-and-black-diamond-agree-on-780m-deal-for-phase-1-raf-ras-dual-inhibitor-in-solid-tumors/ 2025-03-19 https://bio-research.ai/innovent-biologics-and-hutchmed-s-anti-pd-1-pan-vegf-inhibitor-combi-significantly-improve-pfs-in-advanced-renal-cell-carcinoma/ 2025-03-19 https://bio-research.ai/maat-pharma-s-phase-3-trial-of-microbiome-therapy-shows-62-gastrointestinal-response-rate-by-day-28/ 2025-03-18 https://bio-research.ai/bioclec-launches-to-develop-alzheimer-s-disease-therapies-with-backing-from-sofinnova-partners/ 2025-03-18 https://bio-research.ai/angitia-biopharmaceuticals-recombinant-therapeutic-protein-shows-improved-spinal-fusion-success-in-phase-1-2-trial/ 2025-03-18 https://bio-research.ai/enterobiotix-s-phase-2a-trial-of-gut-microbiome-therapy-in-ibs-c-shows-improvements-across-key-efficacy-assessments-over-placebo/ 2025-03-18 https://bio-research.ai/arbor-biotechnologies-raises-73-9-million-to-support-mrna-based-gene-editing-therapy-phase-1-2-trial-for-primary-hyperoxaluria-type-1/ 2025-03-18 https://bio-research.ai/hanall-biopharma-terminates-license-agreement-with-harbour-biomed-for-its-myasthenia-gravis-antibody-over-trial-delays/ 2025-03-18 https://bio-research.ai/taimed-biologics-phase-2a-study-shows-94-viral-suppression-in-hiv-therapy-with-combination-of-anti-cd4-and-anti-hiv-mabs/ 2025-03-17 https://bio-research.ai/genmab-a-s-phase-1-2-trial-shows-55-6-response-rate-for-fr-targeted-topo1-inhibitor-in-ovarian-cancer/ 2025-03-17 https://bio-research.ai/pep-therapy-gets-fda-orphan-drug-designation-for-peptide-based-pancreatic-cancer-treatment-pep-010/ 2025-03-17 https://bio-research.ai/curevo-vaccine-raises-110-million-to-advance-shingles-vaccine-into-further-trials/ 2025-03-17 https://bio-research.ai/grin-therapeutics-receives-fda-orphan-drug-designation-for-radiprodil-in-grin-related-neurodevelopmental-disorder/ 2025-03-17 https://bio-research.ai/opko-health-and-entera-bio-develop-oral-dual-agonist-glp-1-glucagon-peptide-tablet-for-obesity-with-shared-ownership-and-costs/ 2025-03-17 https://bio-research.ai/scholar-rock-s-anti-myostatin-antibody-in-phase-3-trial-shows-motor-function-improvement-in-sma-patients-aged-2-21/ 2025-03-17 https://bio-research.ai/alexion-s-phase-iii-trial-of-pthr1-agonist-significantly-normalizes-serum-calcium-in-hypoparathyroidism-at-24-weeks/ 2025-03-17 https://bio-research.ai/orca-bio-s-phase-3-results-show-78-survival-free-of-chronic-graft-versus-host-disease-with-regulatory-t-cell-immunotherapy-vs-38-with-conventional-treatment/ 2025-03-17 https://bio-research.ai/astrazeneca-to-acquire-esobiotec-sa-for-up-to-1b-to-enhance-lentivirus-based-in-vivo-cell-therapy-capabilities/ 2025-03-17 https://bio-research.ai/maxion-therapeutics-secures-72-million-to-advance-antibody-therapy-utilizing-cysteine-rich-mini-proteins-for-inflammatory-diseases-into-clinical-trials/ 2025-03-17 https://bio-research.ai/alteogen-and-medimmune-limited-a-uk-subsidiary-of-astrazeneca-sign-exclusive-license-deal-for-hybrozyme-platform-based-human-hyaluronidase-technology-in-astrazeneca-s-cancer-drug-sc-formulations/ 2025-03-15 https://bio-research.ai/korro-bio-s-serpina1-rna-editing-oligo-receives-fda-orphan-drug-designation-for-alpha-1-antitrypsin-deficiency-treatment/ 2025-03-14 https://bio-research.ai/bristol-myers-squibb-receives-approval-from-the-european-commission-to-expand-use-of-car-t-cell-therapy-for-relapsed-or-refractory-follicular-lymphoma/ 2025-03-14 https://bio-research.ai/china-approves-innovent-biologics-sycume-for-treating-thyroid-eye-disease-as-first-igf-1r-antibody-therapy/ 2025-03-14 https://bio-research.ai/accropeutics-secures-12-million-to-fund-phase-ib-trial-for-ripk2-inhibitor-in-ulcerative-colitis/ 2025-03-14 https://bio-research.ai/fda-grants-orphan-drug-designations-to-innorna-s-mrna-drug-for-wilson-disease/ 2025-03-14 https://bio-research.ai/alteogen-enters-exclusive-licensing-agreement-with-medimmune-llc-a-usa-subsidiary-of-astrazeneca-for-subcutaneous-cancer-treatment/ 2025-03-13 https://bio-research.ai/neural-therapeutics-finalizes-series-a-financing-and-receives-approval-to-list-on-canadian-exchange/ 2025-03-13 https://bio-research.ai/amgen-s-phase-3-trial-shows-uplizna-improves-mg-adl-score-by-week-52-in-achr-patients/ 2025-03-13 https://bio-research.ai/insilico-medicine-secures-110-million-to-enhance-drug-pipeline-and-improve-ai-models/ 2025-03-13 https://bio-research.ai/sotio-biotech-exercises-its-option-with-synaffix-to-advance-bispecific-adc-programs/ 2025-03-13 https://bio-research.ai/blue-earth-therapeutics-phase-1-trial-shows-higher-radiation-absorption-in-tumors-with-its-radioligand-therapy/ 2025-03-13 https://bio-research.ai/mallinckrodt-and-endo-merge-to-strengthen-pharmaceutical-portfolio-expanding-treatment-for-rare-and-chronic-diseases/ 2025-03-13 https://bio-research.ai/european-commission-approves-rxulti-for-treating-schizophrenia-in-adolescents-aged-13-and-older/ 2025-03-13 https://bio-research.ai/gsk-s-viiv-healthcare-s-embrace-phase-iib-study-shows-96-efficacy-in-maintaining-suppressed-hiv-levels/ 2025-03-12 https://bio-research.ai/quralis-corporation-s-phase-1-trial-of-kv7-2-7-3-ion-channel-opener-shows-decreased-als-biomarker-in-motor-nerve-excitability-threshold/ 2025-03-12 https://bio-research.ai/seikagaku-receives-fda-complete-response-letter-for-condoliase-therapy-due-to-manufacturing-facility-issues/ 2025-03-12 https://bio-research.ai/zealand-pharma-and-roche-to-co-develop-petrelintide-with-usd-5-6b-in-total-payment/ 2025-03-12 https://bio-research.ai/yoltech-therapeutics-trial-reveals-over-95-serum-ttr-reduction-with-yolt-201-low-dose-administration/ 2025-03-11 https://bio-research.ai/ionis-pharmaceuticals-and-ono-pharmaceutical-sign-280m-deal-for-tmprss6-rnai-development-rights/ 2025-03-11 https://bio-research.ai/european-commission-approves-telomerase-inhibitor-for-anemia-in-lower-risk-myelodysplastic-syndromes/ 2025-03-11 https://bio-research.ai/ose-immunotherapeutics-phase-2-trial-of-neoepitope-based-cancer-vaccine-meets-primary-endpoint-in-107-pancreatic-cancer-patients/ 2025-03-11 https://bio-research.ai/saniona-and-boehringer-ingelheim-extend-ion-channel-research-partnership-for-schizophrenia-treatments/ 2025-03-11 https://bio-research.ai/arvinas-and-pfizer-s-phase-3-trial-shows-significant-pfs-improvement-with-protac-er-degrader-in-esr1m-breast-cancer/ 2025-03-11 https://bio-research.ai/bristol-myers-squibb-to-acquire-2seventy-bio-for-286m-to-boost-abecma-s-multiple-myeloma-potential/ 2025-03-10 https://bio-research.ai/protagonist-therapeutics-reports-63-5-clinical-response-rate-in-phase-2b-trial-of-il-23-receptor-antagonist-peptide/ 2025-03-10 https://bio-research.ai/arrowhead-pharmaceuticals-phase-1-2-trial-of-rnai-therapy-targeting-c3-shows-41-mean-reduction-in-proteinuria/ 2025-03-10 https://bio-research.ai/valo-therapeutics-oy-raises-19-million-for-phase-1b-study-of-its-cancer-immunotherapy-platform/ 2025-03-10 https://bio-research.ai/novo-nordisk-s-redefine-2-trial-shows-significant-15-7-weight-loss-with-cagrisema-over-68-weeks/ 2025-03-10 https://bio-research.ai/mineralys-therapeutics-phase-3-trial-shows-significant-16-9-mmhg-reduction-in-systolic-blood-pressure-at-week-6/ 2025-03-10 https://bio-research.ai/sun-pharmaceutical-to-acquire-checkpoint-therapeutics-for-355m-targeting-squamous-cell-carcinoma-treatment/ 2025-03-09 https://bio-research.ai/amgen-and-kyowa-kirin-s-phase-3-trial-shows-rocatinlimab-s-significant-reduction-in-easi-75-in-atopic-dermatitis/ 2025-03-08 https://bio-research.ai/eli-lilly-s-il-13-inhibitor-ebglyss-shows-50-skin-clearance-in-atopic-dermatitis-over-three-years/ 2025-03-07 https://bio-research.ai/biocon-biologics-phase-3-study-shows-stelara-biosimilar-yesintek-is-equivalent-to-reference-drug-for-chronic-plaque-psoriasis/ 2025-03-07 https://bio-research.ai/astrazeneca-s-phase-iii-trial-shows-imfinzi-with-flot-chemotherapy-significantly-enhances-event-free-survival-in-cancer/ 2025-03-07 https://bio-research.ai/european-commission-approves-opdivo-and-yervoy-for-unresectable-advanced-hepatocellular-carcinoma-for-the-first-line-treatment/ 2025-03-07 https://bio-research.ai/fda-approves-retinal-pigment-epithelial-cell-expressing-cntf-for-macular-telangiectasia-type-2/ 2025-03-06 https://bio-research.ai/tris-pharma-s-phase-3-trial-shows-dual-nop-mop-agonist-significantly-reduces-pain-after-bunionectomy-surgery/ 2025-03-06 https://bio-research.ai/plus-therapeutics-rhenium-186-obisbemeda-receives-fda-orphan-drug-designation-for-treatment-of-leptomeningeal-metastases/ 2025-03-06 https://bio-research.ai/hanall-biopharma-s-anti-fcrn-antibody-receives-orphan-drug-designation-in-japan-for-thyroid-eye-disease/ 2025-03-06 https://bio-research.ai/trimtech-therapeutics-secures-31-million-to-develop-targeted-protein-degraders-for-neurodegenerative-disorders/ 2025-03-06 https://bio-research.ai/itm-isotope-technologies-munich-se-phase-3-trial-shows-23-9-months-median-pfs-with-lu-edotreotide/ 2025-03-06 https://bio-research.ai/jiangsu-nhwa-acquires-10-448-stake-in-neurothree-with-3-5m-investment-for-strategic-collaboration/ 2025-03-06 https://bio-research.ai/encell-s-stem-cell-therapy-receives-orphan-drug-designation-from-us-fda-for-charcot-marie-tooth-disease/ 2025-03-05 https://bio-research.ai/ascentage-pharma-s-bcr-abl-inhibitor-receives-breakthrough-therapy-designation-in-china-for-specific-leukemia-treatment/ 2025-03-05 https://bio-research.ai/fda-approves-neffy-nasal-spray-1-mg-for-anaphylaxis-in-children-aged-4-and-older-following-the-approval-of-2-mg-for-children-and-adults/ 2025-03-05 https://bio-research.ai/laminar-pharma-s-trial-of-membrane-signaling-inhibitor-shows-progression-free-survival-improvement-in-glioblastoma/ 2025-03-05 https://bio-research.ai/irlab-therapeutics-phase-iib-trial-of-pirepemat-shows-no-significant-reduction-in-fall-rate-in-parkinson-s/ 2025-03-05 https://bio-research.ai/jazz-pharmaceuticals-to-acquire-chimerix-for-935m-to-enhance-its-oncology-portfolio/ 2025-03-05 https://bio-research.ai/persica-pharmaceuticals-phase-1b-trial-of-pp353-shows-significant-pain-and-disability-reduction/ 2025-03-05 https://bio-research.ai/fda-accepts-genentech-s-biologics-license-application-for-anti-cd20-mab-to-treat-lupus-nephritis/ 2025-03-04 https://bio-research.ai/cadrenal-therapeutics-partners-with-abbott-to-support-the-tech-lvad-trial-for-the-development-of-vitamin-k-antagonist/ 2025-03-04 https://bio-research.ai/garuda-therapeutics-secures-50-million-funding-to-advance-off-the-shelf-hematopoietic-stem-cell-therapies/ 2025-03-04 https://bio-research.ai/capricor-therapeutics-receives-fda-priority-review-for-allogeneic-cardiosphere-derived-cell-therapy-for-duchenne-muscular-dystrophy-cardiomyopathy/ 2025-03-04 https://bio-research.ai/calcimedica-s-phase-2-trial-shows-62-7-reduction-in-mortality-with-crac-channel-inhibitor-at-day-30-in-covid-19-pneumonia/ 2025-03-04 https://bio-research.ai/osivax-secures-10-million-in-series-b-funding-to-advance-broad-spectrum-influenza-vaccine-candidate-using-self-assembling-nanoparticle-platform-technology/ 2025-03-04 https://bio-research.ai/fda-approves-anti-pd-1-mab-with-chemotherapy-for-first-line-treatment-of-unresectable-metastatic-escc/ 2025-03-04 https://bio-research.ai/avecho-and-sandoz-sign-10-year-agreement-to-develop-and-commercialize-cbd-capsule-for-insomnia-in-australia/ 2025-03-03 https://bio-research.ai/callio-therapeutics-secures-187-million-to-advance-her2-targeted-dual-payload-adc-and-enters-license-with-hummingbird-bioscience/ 2025-03-03 https://bio-research.ai/fda-grants-fast-track-designation-to-new-nav1-8-inhibitor-by-latigo-biotherapeutics-for-treating-acute-pain/ 2025-03-03 https://bio-research.ai/sanofi-returns-full-rights-to-ilt2-receptor-antagonist-to-biond-biologics-during-ongoing-phase-2-trials/ 2025-03-03 https://bio-research.ai/protagonist-and-takeda-s-phase-3-study-shows-hepcidin-mimetic-significantly-reduces-phlebotomy-need-in-polycythemia-vera/ 2025-03-03 https://bio-research.ai/lexicon-pharmaceuticals-phase-2b-study-shows-the-aak1-inhibitor-10-mg-dose-reduces-pain-in-diabetic-neuropathic-pain/ 2025-03-03 https://bio-research.ai/kyorin-and-novartis-sign-global-agreement-for-mrgprx2-antagonist-with-55m-upfront-and-777-5m-in-milestones/ 2025-03-03 https://bio-research.ai/abbvie-and-gubra-agree-to-develop-long-acting-amylin-analog-for-obesity-treatment-with-a-2-3b-total-payment/ 2025-03-03 https://bio-research.ai/genentech-s-phase-iii-study-shows-36-of-ige-mab-xolair-monotherapy-recipients-tolerated-2-000-mg-of-peanut-protein-a-significant-result-compared-to-oral-immuno-therapy-group/ 2025-03-02 https://bio-research.ai/celldex-therapeutics-reports-phase-2-results-of-anti-kit-mab-with-71-complete-response-in-chronic-urticaria-at-week-52/ 2025-03-01 https://bio-research.ai/the-european-medicines-agency-recommends-hsv-vector-delivering-col7a1-for-treating-wounds-in-dystrophic-epidermolysis-bullosa/ 2025-02-28 https://bio-research.ai/novartis-fabhalta-receives-european-recommendation-for-c3-glomerulopathy-after-showing-significant-reduction-in-proteinuria/ 2025-02-28 https://bio-research.ai/vertex-pharmaceuticals-receives-positive-chmp-opinion-to-expand-kaftrio-label-for-cystic-fibrosis-treatment/ 2025-02-28 https://bio-research.ai/magnet-biomedicine-partners-with-eli-lilly-to-develop-molecular-glue-targeting-difficult-to-drug-proteins-with-40m-upfront-and-1-25b-milestones/ 2025-02-28 https://bio-research.ai/regeneron-pharmaceuticals-linvoseltamab-receives-ema-recommendation-for-multiple-myeloma-treatment/ 2025-02-28 https://bio-research.ai/european-medicines-agency-recommends-abbvie-s-upadacitinib-for-giant-cell-arteritis-in-adults/ 2025-02-28 https://bio-research.ai/eisai-licenses-fgfr-inhibitor-to-sciclone-for-cancer-treatment-in-greater-china-with-milestone-payments/ 2025-02-28 https://bio-research.ai/cogent-biosciences-reports-65-improvement-in-symptom-score-at-48-weeks-for-c-kit-inhibitor-trial/ 2025-02-27 https://bio-research.ai/zevra-therapeutics-sells-priority-review-voucher-for-150m/ 2025-02-27 https://bio-research.ai/cassava-sciences-secures-rights-from-yale-university-for-a-filamin-a-modulator-in-treating-neurodevelopmental-disorders/ 2025-02-27 https://bio-research.ai/adicet-bio-receives-fast-track-designation-for-car-t-therapy-targeting-cd20-in-autoimmune-diseases/ 2025-02-27 https://bio-research.ai/leo-pharma-phase-3-trial-meets-its-endpoint-with-its-jak-inhibitor-cream-showing-eczema-severity-improvement/ 2025-02-27 https://bio-research.ai/bluerock-s-ipsc-derived-cell-therapy-receives-fast-track-designation-for-primary-photoreceptor-diseases/ 2025-02-27 https://bio-research.ai/medigene-ag-and-epimab-biotherapeutics-partner-to-co-develop-bispecific-tcr-tces-for-immune-disorders/ 2025-02-27 https://bio-research.ai/yoltech-therapeutics-trial-shows-in-vivo-pcsk9-gene-editing-therapy-reduces-plasma-ldl-c-levels-with-strong-safety-profile/ 2025-02-27 https://bio-research.ai/renovaro-biosciences-and-biosymetrics-to-merge-integrating-ai-for-precision-medicine-in-oncology/ 2025-02-26 https://bio-research.ai/renovaro-inc-secures-15-million-in-equity-for-ai-and-biotechnology-advancements/ 2025-02-26 https://bio-research.ai/enveda-advances-ai-driven-drug-discovery-platform-and-treatment-for-atopic-dermatitis-to-clinical-trials-with-sanofi-investment/ 2025-02-26 https://bio-research.ai/cognition-therapeutics-phase-2-trial-with-its-sigma-2-receptor-modulator-shows-slower-lesion-growth-in-geographic-atrophy-patients/ 2025-02-26 https://bio-research.ai/eikon-therapeutics-raises-350-7-million-to-advance-clinical-portfolio-including-tlr7-8-agonist-for-melanoma/ 2025-02-26 https://bio-research.ai/madrigal-pharmaceuticals-phase-3-trial-shows-rezdiffra-reducing-liver-stiffness-by-6-7-kpa-in-mash-cirrhosis-over-two-years/ 2025-02-26 https://bio-research.ai/fda-accepts-regeneron-s-resubmission-for-odronextamab-targeting-relapsed-refractory-follicular-lymphoma/ 2025-02-26 https://bio-research.ai/alligator-bioscience-s-phase-2-study-of-cd40-mab-shows-a-29-4-24-month-survival-rate-in-metastatic-pancreatic-cancer/ 2025-02-26 https://bio-research.ai/hbm-alpha-therapeutics-partners-for-global-rights-on-crh-mab-potentially-earning-up-to-395m/ 2025-02-26 https://bio-research.ai/emalex-biosciences-phase-3-study-shows-d1-5-receptor-antagonist-significantly-reduces-relapse-rate-in-tourette-syndrome-with-41-9-of-subjects-relapsing/ 2025-02-25 https://bio-research.ai/bridgene-biosciences-and-takeda-in-agreement-to-utilize-chemoproteomics-platform-for-drug-discovery-for-undruggable-targets-in-immunology-and-neurology/ 2025-02-25 https://bio-research.ai/ligand-pharmaceuticals-and-partners-secure-75m-deal-with-castle-creek-for-phase-3-trial-of-d-fi/ 2025-02-25 https://bio-research.ai/fda-accepts-priority-review-for-precigen-s-adenovirus-based-gene-therapy-for-recurrent-respiratory-papillomatosis/ 2025-02-25 https://bio-research.ai/candel-therapeutics-reports-its-oncolytic-virus-therapy-expressing-hsv-tk-extends-survival-to-31-4-months-in-pancreatic-cancer-trial/ 2025-02-25 https://bio-research.ai/eli-lilly-to-acquire-organovo-s-fxr-program-and-advance-fxr314-in-phase-2-trials-for-ibd-treatments/ 2025-02-25 https://bio-research.ai/eupraxia-pharmaceuticals-phase-1b-2a-trial-shows-improved-symptom-scores-in-cohort-6-for-ep-104gi/ 2025-02-25 https://bio-research.ai/merck-s-application-for-keytruda-in-head-and-neck-cancer-receives-fda-priority-review/ 2025-02-25 https://bio-research.ai/hyloris-pharmaceuticals-licenses-5-ht3-antagonist-from-redhill-biopharma-with-60m-potential-milestone-payments/ 2025-02-25 https://bio-research.ai/regeneron-pharmaceuticals-phase-1-2-trial-shows-improved-hearing-in-most-of-12-children-with-dual-aav-vector-gene-therapy-expressing-otoferlin-gene/ 2025-02-24 https://bio-research.ai/auron-therapeutics-receives-fda-fast-track-for-kat2a-b-degrader-in-relapsed-or-refractory-acute-myelogenous-leukemia/ 2025-02-24 https://bio-research.ai/pepgen-s-phase-1-trial-shows-splicing-correction-of-12-3-and-29-1-with-aso-targeting-dmpk-rna-in-early-cohorts-of-patients-with-myotonic-dystrophy-type-1/ 2025-02-24 https://bio-research.ai/axsome-therapeutics-phase-3-trial-shows-cox-2-inhibitor-5-ht-agonist-combi-more-effective-in-migraine-relief-within-2-hours/ 2025-02-24 https://bio-research.ai/ose-immunotherapeutics-phase-2-trial-of-il-7r-mab-antagonist-shows-significant-clinical-remission-in-ulcerative-colitis-after-10-weeks/ 2025-02-24 https://bio-research.ai/summit-therapeutics-and-pfizer-to-test-pd-1-vegf-bsab-with-antibody-drug-conjugates-in-solid-tumors/ 2025-02-24 https://bio-research.ai/takeda-receives-ema-approval-for-2-ml-pre-filled-pen-of-takhzyro-for-hereditary-angioedema/ 2025-02-24 https://bio-research.ai/hengrui-medicine-s-phase-iii-trial-shows-that-cdk4-6-inhibitor-significantly-reduces-the-risk-of-recurrence-in-a-large-breast-cancer-trial/ 2025-02-24 https://bio-research.ai/carlyle-and-sk-capital-partners-to-acquire-bluebird-bio-offering-3-00-per-share-plus-contingent-value/ 2025-02-21 https://bio-research.ai/european-commission-approves-seladelpar-for-primary-biliary-cholangitis-with-biochemical-improvements/ 2025-02-20 https://bio-research.ai/elixirgen-s-exg-34217-receives-orphan-drug-designation-for-telomere-biology-disorders-gene-therapy-trial/ 2025-02-20 https://bio-research.ai/photys-therapeutics-secures-global-rights-to-develop-pht-776-under-agreement-with-polymed-biopharmaceuticals/ 2025-02-20 https://bio-research.ai/sellas-life-sciences-group-phase-2a-shows-67-response-rate-in-non-gcb-dlbcl-with-sls009-and-zanubrutinib/ 2025-02-20 https://bio-research.ai/urogen-pharma-acquires-iconovir-s-oncolytic-virus-in-a-deal-worth-19m-plus-royalties/ 2025-02-20 https://bio-research.ai/japan-approves-epkinly-for-relapsed-or-refractory-follicular-and-large-b-cell-lymphomas/ 2025-02-20 https://bio-research.ai/incyte-and-genesis-therapeutics-form-strategic-collaboration-using-gems-ai-platform-for-drug-discovery/ 2025-02-20 https://bio-research.ai/fibrogen-sells-china-subsidiary-to-astrazeneca-for-160m-retains-u-s-rights-to-roxadustat/ 2025-02-20 https://bio-research.ai/daiichi-sankyo-gains-partial-change-approval-in-japan-for-lixiana-tablets-to-prevent-clots-in-pulmonary-hypertension/ 2025-02-20 https://bio-research.ai/eg-427-raises-27-million-to-fund-phase-1b-2a-study-of-genetic-treatment-for-neurogenic-detrusor-overactivity/ 2025-02-20 https://bio-research.ai/harbour-biomed-and-insilico-medicine-form-collaboration-for-ai-driven-therapeutic-antibodies/ 2025-02-20 https://bio-research.ai/chugai-secures-approval-for-expanded-indication-of-tecentriq-in-unresectable-alveolar-soft-part-sarcoma/ 2025-02-20 https://bio-research.ai/hengrui-medicine-s-phase-i-study-of-nectin4-targeting-adc-shows-50-0-response-rate-in-urothelial-carcinoma/ 2025-02-20 https://bio-research.ai/radiance-biopharma-and-cspc-megalith-partner-for-ror1-targeting-adc-with-up-to-1b-in-commercial-milestones/ 2025-02-19 https://bio-research.ai/perceive-pharma-raises-15-million-series-a-funding-for-neuroprotective-therapies-development/ 2025-02-19 https://bio-research.ai/imunon-s-phase-2-study-of-its-plasmid-vector-based-therapy-shows-a-20-increase-in-il-12-levels-in-the-treatment-of-advanced-ovarian-cancer/ 2025-02-19 https://bio-research.ai/reverb-therapeutics-raises-12-million-to-advance-its-bispecific-antibody-approach-for-il15-delivery-in-cancer-treatments/ 2025-02-19 https://bio-research.ai/boehringer-ingelheim-s-zongertinib-receives-fda-priority-review-for-unresectable-metastatic-nsclc/ 2025-02-19 https://bio-research.ai/epitopea-and-msd-partner-to-identify-shared-non-mutated-antigens-from-non-coding-dna/ 2025-02-19 https://bio-research.ai/ascletis-pharma-reports-6-3-weight-reduction-in-obesity-study-s-cohort-2-after-28-days-with-oral-glp-1r-agonist/ 2025-02-19 https://bio-research.ai/bristol-myers-squibb-s-phase-3-checkmate-816-study-shows-significant-improvement-in-overall-survival-for-lung-cancer/ 2025-02-19 https://bio-research.ai/supernus-pharmaceuticals-phase-2b-study-of-spn-820-shows-no-significant-improvement-in-depression/ 2025-02-18 https://bio-research.ai/biogen-and-stoke-partner-to-develop-aso-targeting-scn1a-gene-for-dravet-syndrome-with-165m-upfront-for-stoke/ 2025-02-18 https://bio-research.ai/ventyx-biosciences-phase-2-trial-of-allosteric-tyk2-inhibitor-shows-dose-dependent-endoscopic-improvements-in-crohn-s-disease/ 2025-02-18 https://bio-research.ai/european-commission-approves-merck-s-hif-2-inhibitor-for-the-treatment-of-von-hippel-lindau-tumors-in-adults/ 2025-02-18 https://bio-research.ai/solid-biosciences-phase-1-2-trial-shows-110-microdystrophin-expression-no-serious-adverse-events/ 2025-02-18 https://bio-research.ai/fda-accepts-priority-review-for-an-il-4-il-13-inhibitor-antibody-application-to-treat-adults-with-bullous-pemphigoid/ 2025-02-18 https://bio-research.ai/kyorin-pharmaceutical-signs-option-agreement-with-cyrano-therapeutics-for-a-phosphodiesterase-inhibitor-in-japan/ 2025-02-18 https://bio-research.ai/the-fda-approves-gsk-s-penmenvy-vaccine-targeting-five-major-serogroups-of-neisseria-meningitidis-for-individuals-aged-10-to-25/ 2025-02-17 https://bio-research.ai/arcus-biosciences-phase-1-1b-trial-shows-9-7-month-median-progression-free-survival-for-hif-2a-inhibitor/ 2025-02-17 https://bio-research.ai/innate-pharma-s-kir3dl2-mab-receives-breakthrough-therapy-designation-from-fda-for-relapsed-or-refractory-s-zary-syndrome/ 2025-02-17 https://bio-research.ai/fda-approves-ono-and-deciphera-s-csf1r-inhibitor-for-advanced-treatment-of-tenosynovial-giant-cell-tumor/ 2025-02-17 https://bio-research.ai/bristol-myers-squibb-s-five-year-trial-of-tyk2-allosteric-inhibitor-shows-nearly-half-of-patients-maintained-a-pasi-90-clinical-response-in-plaque-psoriasis/ 2025-02-16 https://bio-research.ai/astrazeneca-s-phase-iii-trial-shows-imfinzi-with-chemotherapy-reduces-disease-progression-risk-by-42-in-bladder-cancer/ 2025-02-14 https://bio-research.ai/bambusa-therapeutics-secures-90-million-in-series-a-financing-to-advance-long-acting-bispecific-antibody-development/ 2025-02-14 https://bio-research.ai/the-european-commission-approves-the-first-self-amplifying-mrna-covid-19-vaccine-for-individuals-18-and-older/ 2025-02-14 https://bio-research.ai/bayer-s-phase-iii-trials-show-improvement-in-survival-for-nubeqa-in-metastatic-hormone-sensitive-prostate-cancer/ 2025-02-14 https://bio-research.ai/catumaxomab-approved-by-european-commission-for-treating-malignant-ascites-in-adults-with-epcam-positive-carcinomas/ 2025-02-14 https://bio-research.ai/galderma-s-il-31r-alpha-mab-approved-by-european-commission-for-moderate-to-severe-atopic-dermatitis-and-prurigo-nodularis/ 2025-02-14 https://bio-research.ai/junevity-secures-10-million-in-seed-funding-to-advance-reset-platform-and-develop-sirna-therapeutics/ 2025-02-13 https://bio-research.ai/newleos-therapeutics-inc-closes-93-5-million-series-a-financing-to-fund-clinical-trials-for-neurological-disorders-including-generalized-anxiety-disorder/ 2025-02-13 https://bio-research.ai/torrey-pines-investment-and-oost-nl-fund-mair-therapeutics-to-develop-treatments-for-neurodegenerative-disorders/ 2025-02-13 https://bio-research.ai/bristol-myers-squibb-s-phase-3-trial-of-pd-1-lag-3-antibody-fixed-dose-combi-did-not-meet-primary-endpoint-in-stage-iii-iv-melanoma/ 2025-02-13 https://bio-research.ai/elixirgen-therapeutics-receives-rmat-designation-for-its-telomere-enhancing-zscan4-expressing-hsc-therapy-in-a-phase-1-2-trial-for-tbds/ 2025-02-13 https://bio-research.ai/egetis-therapeutics-ab-receives-european-commission-approval-for-emcitate-to-treat-mct8-deficiency/ 2025-02-13 https://bio-research.ai/agios-pharmaceuticals-phase-3-activate-kids-study-of-mitapivat-meets-primary-endpoint-of-hemoglobin-response/ 2025-02-13 https://bio-research.ai/ensoma-receives-rare-pediatric-disease-and-orphan-drug-designations-for-en-374-to-treat-x-cgd/ 2025-02-13 https://bio-research.ai/the-fda-grants-fast-track-designation-to-nkgen-biotech-s-troculeucel-for-moderate-alzheimer-s-disease/ 2025-02-13 https://bio-research.ai/sichuan-kelun-biotech-s-phase-1-2-study-reports-31-response-rate-in-advanced-urothelial-carcinoma/ 2025-02-13 https://bio-research.ai/genentech-announces-fda-approval-of-evrysdi-tablet-for-spinal-muscular-atrophy-sma-in-patients-aged-2-and-older/ 2025-02-13 https://bio-research.ai/oncusp-therapeutics-cusp06-receives-fda-fast-track-for-platinum-resistant-ovarian-cancer-treatment/ 2025-02-13 https://bio-research.ai/catumaxomab-receives-european-commission-approval-for-malignant-ascites-to-be-marketed-by-pharmanovia/ 2025-02-13 https://bio-research.ai/daan-biotherapeutics-enters-exclusive-licensing-agreement-with-ligachem-biosciences-to-advance-adcs-for-solid-tumors/ 2025-02-13 https://bio-research.ai/pulsesight-therapeutics-secures-series-a-funding-for-phase-i-study-of-pst-611-for-dry-age-related-macular-degeneration/ 2025-02-13 https://bio-research.ai/ideaya-biosciences-and-gilead-sciences-collaborate-on-clinical-study-of-ideaya-s-ide397-with-gilead-s-trodelvy/ 2025-02-13 https://bio-research.ai/sanofi-and-johnson-johnson-s-phase-3-study-vaccine-candidate-found-ineffective-at-preventing-e-coli-disease/ 2025-02-13 https://bio-research.ai/astellas-pharma-receives-fda-approval-for-expanded-prescribing-information-for-izervay-in-geographic-atrophy/ 2025-02-12 https://bio-research.ai/telix-pharmaceuticals-receives-uk-regulatory-approval-for-illuccix-a-prostate-cancer-pet-imaging-agent/ 2025-02-12 https://bio-research.ai/opna-bio-s-opn-6602-granted-fda-orphan-drug-designation-for-treatment-of-multiple-myeloma/ 2025-02-12 https://bio-research.ai/tivic-health-systems-acquires-worldwide-rights-to-statera-biopharma-s-tlr5-agonist-entolimod-for-1-5m/ 2025-02-12 https://bio-research.ai/the-u-s-fda-has-approved-pfizer-s-sbla-for-adcetris-with-lenalidomide-and-rituximab-for-treating-relapsed-or-refractory-large-b-cell-lymphoma-in-adults/ 2025-02-12 https://bio-research.ai/terrain-biosciences-raises-9-million-in-seed-funding-to-advance-rna-therapeutics-and-vaccines/ 2025-02-12 https://bio-research.ai/expressionedits-enters-collaboration-and-licensing-agreement-with-boehringer-ingelheim-for-gene-therapy-targets/ 2025-02-12 https://bio-research.ai/anaptysbio-s-phase-2b-renoir-trial-of-pd-1-agonist-for-rheumatoid-arthritis-shows-significant-reduction-in-inflammation-and-joint-swelling/ 2025-02-12 https://bio-research.ai/abbvie-and-xilio-therapeutics-collaborate-to-develop-novel-tumor-activated-antibody-based-immunotherapies-in-a-deal-worth-up-to-2-15-b/ 2025-02-12 https://bio-research.ai/royalty-pharma-to-provide-up-to-250m-in-r-d-funding-to-biogen-for-phase-3-development-of-litifilimab/ 2025-02-12 https://bio-research.ai/abcuro-inc-secures-200-million-for-phase-2-3-trial-of-anti-klrg1-for-inclusion-body-myositis/ 2025-02-12 https://bio-research.ai/simcere-pharmaceutical-group-and-guangzhou-fermion-technology-partner-for-clinical-development-of-sstr4-agonist-for-diabetic-peripheral-neuropathic-pain/ 2025-02-12 https://bio-research.ai/bioxodes-secures-2-7-million-to-advance-biox-101-for-intracerebral-hemorrhage-treatment-in-phase-2a-birch-trial/ 2025-02-12 https://bio-research.ai/moffitt-cancer-center-and-1st-biotherapeutics-form-a-five-year-strategic-alliance-to-evaluate-and-advacne-hpk1-inhibitor/ 2025-02-11 https://bio-research.ai/alloy-therapeutics-and-pfizer-strengthen-longstanding-partnership-to-enhance-antibody-discovery-platform-for-challenging-targets/ 2025-02-11 https://bio-research.ai/the-european-commission-approves-bayer-s-transthyretin-stabilizer-for-treating-transthyretin-amyloidosis-with-cardiomyopathy-in-adults/ 2025-02-11 https://bio-research.ai/spinogenix-phase-2-study-shows-spg601-reduces-high-frequency-gamma-band-activity-in-fragile-x-patients/ 2025-02-11 https://bio-research.ai/the-fda-accepts-regeneron-s-resubmission-for-linvoseltamab-to-treat-relapsed-refractory-multiple-myeloma/ 2025-02-11 https://bio-research.ai/biohaven-receives-fda-acceptance-for-troriluzole-nda-priority-review-granted-for-spinocerebellar-ataxia/ 2025-02-11 https://bio-research.ai/in8bio-s-phase-1-trial-of-inb-100-shows-all-aml-patients-in-complete-remission-with-100-survival-at-one-year/ 2025-02-11 https://bio-research.ai/lipella-pharmaceuticals-inc-phase-2a-trial-of-lp-310-shows-statistically-significant-improvements-and-strong-safety-profile-in-oral-lichen-planus/ 2025-02-11 https://bio-research.ai/ellipses-pharma-secures-global-rights-from-genome-company-to-develop-ep0089-an-immuno-oncology-antibody/ 2025-02-11 https://bio-research.ai/novartis-will-acquire-anthos-therapeutics-and-abelacimab-for-up-to-3-1b-in-total/ 2025-02-11 https://bio-research.ai/pfizer-and-astellas-pharma-s-phase-3-trial-shows-sustained-survival-benefits-of-enfortumab-vedotin-ejfv-plus-pembrolizumab/ 2025-02-10 https://bio-research.ai/boehringer-ingelheim-s-fibroneer-ild-trial-achieves-primary-endpoint-with-fvc-change-at-week-52/ 2025-02-10 https://bio-research.ai/grace-therapeutics-phase-3-trial-shows-19-reduction-in-hypotension-with-gtx-104-in-102-patients/ 2025-02-10 https://bio-research.ai/immix-biopharma-granted-rmat-designation-by-fda-for-car-t-therapy-nxc-201-in-relapsed-al-amyloidosis/ 2025-02-10 https://bio-research.ai/ashvattha-therapeutics-phase-2-data-shows-mgb-reduces-anti-vegf-burden-and-maintains-visual-acuity-in-25-patients/ 2025-02-10 https://bio-research.ai/biodexa-pharmaceuticals-erapa-granted-fast-track-designation-by-fda-for-treating-familial-adenomatous-polyposis/ 2025-02-10 https://bio-research.ai/advancell-and-eli-lilly-expand-collaboration-to-develop-novel-targeted-alpha-therapies-for-cancer-utilizing-pb-212-production-technology/ 2025-02-10 https://bio-research.ai/iview-therapeutics-inc-reports-phase-1-2-trial-of-ivw-1001-shows-significant-improvement-in-dry-eye-symptoms/ 2025-02-10 https://bio-research.ai/bristol-myers-squibb-s-phase-2-transcend-fl-trial-shows-significant-response-rates-in-marginal-zone-lymphoma-cohort/ 2025-02-10 https://bio-research.ai/caliway-biopharmaceuticals-phase-2b-study-for-cbl-514-shows-54-2-participants-with-at-least-20-fat-reduction/ 2025-02-10 https://bio-research.ai/nmpa-s-cde-designates-futuregen-biopharmaceutical-m108-monoclonal-antibody-injection-as-breakthrough-therapy-for-cldn18-2-positive-pancreatic-cancer/ 2025-02-10 https://bio-research.ai/bio-thera-solutions-signs-exclusive-agreement-with-intas-pharmaceuticals-for-simoni-biosimilar-candidate-worth-up-to-164-5m/ 2025-02-10 https://bio-research.ai/hexaell-biotechnologies-raises-200-million-rmb-to-advance-hepacure-bioartificial-liver-research/ 2025-02-08 https://bio-research.ai/acelink-therapeutics-releases-interim-phase-2-data-on-al01211-showing-significant-gl3-reductions-in-fabry-disease-patients/ 2025-02-07 https://bio-research.ai/pliant-therapeutics-pauses-enrollment-and-dosing-in-beacon-ipf-phase-2b-trial-of-v-6-v-1-inhibitor/ 2025-02-07 https://bio-research.ai/the-u-s-fda-approves-a-fixed-dose-combination-of-a-monobactam-antibiotic-and-a-lactamase-inhibitor-to-treat-complicated-intra-abdominal-infections/ 2025-02-07 https://bio-research.ai/lg-ai-research-and-prof-min-kyung-baek-of-seoul-national-university-partner-to-develop-next-gen-ai-for-drug-development/ 2025-02-07 https://bio-research.ai/european-medicines-agency-accepts-marketing-authorization-application-for-bat2506-as-a-biosimilar-to-simponi/ 2025-02-07 https://bio-research.ai/eli-lilly-and-company-reports-over-90-of-omvoh-treated-patients-sustained-clinical-remission-at-two-years/ 2025-02-07 https://bio-research.ai/biothera-inc-s-marketing-authorization-application-for-bat2306-accepted-by-national-medical-products-administration/ 2025-02-07 https://bio-research.ai/novo-nordisk-s-phase-3-trial-shows-74-3-of-children-with-haemophilia-a-had-zero-bleeds-on-weekly-mim8/ 2025-02-07 https://bio-research.ai/olix-pharmaceuticals-signs-usd-630m-global-license-deal-with-eli-lilly-for-olx702a-development/ 2025-02-07 https://bio-research.ai/g2gbio-and-boehringer-ingelheim-sign-agreement-to-develop-long-acting-injectable-therapeutics-using-innolamp-technology/ 2025-02-07 https://bio-research.ai/inflectis-bioscience-sas-completes-phase-2a-trial-of-ifb-088-plus-riluzole-for-bulbar-onset-als/ 2025-02-06 https://bio-research.ai/alumis-inc-and-acelyrin-inc-agree-to-merge-with-a-pro-forma-cash-position-of-approximately-737m/ 2025-02-06 https://bio-research.ai/annexin-pharmaceuticals-ab-phase-2a-study-of-anxv-for-retinal-vein-occlusion-shows-reduction-in-phosphatidylserine/ 2025-02-06 https://bio-research.ai/denali-therapeutics-inc-phase-1-2-trial-shows-significant-biomarker-reductions-in-hunter-syndrome/ 2025-02-06 https://bio-research.ai/sangamo-therapeutics-phase-1-2-staar-study-shows-sustained-alpha-gal-a-activity-and-renal-improvements-in-fabry-disease/ 2025-02-06 https://bio-research.ai/coya-therapeutics-phase-2-study-of-ld-il-2-shows-significant-reductions-in-proinflammatory-markers-in-alzheimer-s-disease-patients/ 2025-02-06 https://bio-research.ai/relmada-therapeutics-acquires-sepranolone-from-asarina-pharma-for-eur-3m-to-enhance-cns-treatment-portfolio/ 2025-02-06 https://bio-research.ai/insmed-incorporated-s-dpp1-inhibitor-granted-fda-priority-review-for-non-cystic-fibrosis-bronchiectasis/ 2025-02-06 https://bio-research.ai/tonix-pharmaceuticals-phase-1-trial-of-tnx-1500-shows-safety-and-antibody-response-blocking-in-healthy-participants/ 2025-02-06 https://bio-research.ai/equillium-and-biocon-phase-2-study-shows-itolizumab-23-3-remission-rate-in-ulcerative-colitis-at-12-weeks/ 2025-02-06 https://bio-research.ai/immuneering-and-regeneron-enter-clinical-supply-agreement-to-evaluate-mek-inhibitor-and-anti-pd-1-mab-in-phase-2a-trial/ 2025-02-06 https://bio-research.ai/henlius-biotech-and-dr-reddy-s-laboratories-sign-131-6m-deal-for-daratumumab-biosimilar-hlx15-commercialization-in-the-us-and-europe/ 2025-02-06 https://bio-research.ai/miist-therapeutics-announces-7m-in-seed-funding-to-advance-ultrasonic-vibration-based-inhaled-medicines-for-smoking-addiction-and-migraine/ 2025-02-05 https://bio-research.ai/qlaris-bio-announces-phase-ii-trial-results-showing-qls-111-reduces-intraocular-pressure-in-glaucoma-patients/ 2025-02-05 https://bio-research.ai/adicet-bio-s-adi-001-granted-fda-fast-track-designation-for-treating-refractory-sle-with-extrarenal-involvement/ 2025-02-05 https://bio-research.ai/gradalis-investigational-immunotherapy-vigil-granted-rmat-designation-by-fda-after-phase-2b-vital-trial/ 2025-02-05 https://bio-research.ai/eyepoint-pharmaceuticals-phase-2-trial-for-duravyu-shows-improved-visual-acuity-by-7-1-letters-at-24-weeks/ 2025-02-05 https://bio-research.ai/algernon-neuroscience-appoints-validcare-as-cro-for-phase-2a-dmt-stroke-trial-starting-in-q3-2025/ 2025-02-05 https://bio-research.ai/klinge-biopharma-enters-exclusive-license-with-lotus-pharmaceutical-for-fyb203-in-asia-pacific-region/ 2025-02-05 https://bio-research.ai/iveena-delivery-systems-inc-completes-3-million-series-b-2-financing-supporting-pediatric-myopia-program/ 2025-02-05 https://bio-research.ai/valneva-se-s-chikungunya-vaccine-ixchiq-receives-uk-marketing-authorization-for-adults-18-and-older/ 2025-02-05 https://bio-research.ai/roche-announces-fda-approval-of-susvimo-for-diabetic-macular-edema-based-on-one-year-phase-iii-results/ 2025-02-04 https://bio-research.ai/siteone-therapeutics-announces-phase-1-trial-results-for-stc-004-showing-increased-pain-tolerance-threshold/ 2025-02-04 https://bio-research.ai/spur-therapeutics-phase-1-2-trial-of-flt201-shows-rapid-and-sustained-improvements-in-gaucher-disease-type-1/ 2025-02-04 https://bio-research.ai/enveric-biosciences-akos-biosciences-licenses-cannabinoid-cox-2-compounds-to-restoration-biologics-for-82m/ 2025-02-04 https://bio-research.ai/auron-therapeutics-announces-27-million-financing-to-initiate-clinical-trial-of-autx-703-for-leukemia-and-cancer/ 2025-02-04 https://bio-research.ai/leo-pharma-s-delta-teen-phase-3-trial-of-anzupgo-shows-significant-improvement-in-che-symptoms-after-16-weeks/ 2025-02-04 https://bio-research.ai/cumberland-pharmaceuticals-inc-phase-2-trial-shows-ifetroban-improves-heart-function-in-duchenne-muscular-dystrophy/ 2025-02-04 https://bio-research.ai/akribion-therapeutics-secures-eur-8-million-for-rna-guided-technology-to-target-hpv-induced-opscc/ 2025-02-04 https://bio-research.ai/mitem-pharma-acquires-rights-to-flisint-from-sanofi-winthrop-industrie/ 2025-02-04 https://bio-research.ai/algiax-pharmaceuticals-phase-2a-trial-of-ap-325-shows-rapid-and-long-lasting-reduction-in-neuropathic-pain/ 2025-02-04 https://bio-research.ai/lactiga-secures-multi-year-multi-m-grant-from-nih-and-niaid-to-advance-lctg-001-for-immunodeficient-patients/ 2025-02-03 https://bio-research.ai/tenaya-therapeutics-receives-8m-grant-from-the-california-institute-for-regenerative-medicine-for-trial-of-tn-401/ 2025-02-03 https://bio-research.ai/advancell-completes-us-112-million-series-c-to-expand-manufacturing-and-accelerate-clinical-development-of-radionuclide-pipelines/ 2025-02-03 https://bio-research.ai/gh-research-plc-s-phase-2b-trial-of-the-ultra-rapid-nasal-antidepressant-gh001-shows-a-significant-reduction-in-depression-scores-by-day-8/ 2025-02-03 https://bio-research.ai/vanda-pharmaceuticals-secures-global-license-agreement-with-anaptysbio-for-il-36r-antagonist-imsidolimab/ 2025-02-03 https://bio-research.ai/aplagon-secures-eur-7-million-investment-to-fund-phase-2a-trial-of-apac-for-peripheral-arterial-occlusive-disease/ 2025-02-03 https://bio-research.ai/invivyd-inc-reports-phase-1-2-trial-of-vyd2311-shows-high-serum-concentrations-and-safety-in-40-subjects/ 2025-02-03 https://bio-research.ai/purple-biotech-ltd-and-icahn-school-of-medicine-partner-to-investigate-immunoregulatory-effects-of-captn-3/ 2025-02-03 https://bio-research.ai/pfizer-s-phase-3-breakwater-trial-of-braftovi-regimen-shows-significant-improvement-in-pfs-for-colorectal-cancer/ 2025-02-03 https://bio-research.ai/chmp-recommends-expanding-marketing-authorisation-for-subcutaneous-rybrevant-to-treat-advanced-egfr-mutated-nsclc/ 2025-02-03 https://bio-research.ai/affibody-has-regained-global-rights-to-anti-il-17a-affibody-after-acelyrin-inc-terminated-its-internal-development/ 2025-02-02 https://bio-research.ai/chmp-recommends-datopotamab-deruxtecan-for-approval-in-eu-for-hr-positive-her2-negative-breast-cancer/ 2025-01-31 https://bio-research.ai/bristol-myers-squibb-receives-ema-recommendation-for-opdivo-plus-yervoy-in-advanced-hepatocellular-carcinoma/ 2025-01-31 https://bio-research.ai/bristol-myers-squibb-s-breyanzi-recommended-for-approval-by-european-medicines-agency-for-follicular-lymphoma/ 2025-01-31 https://bio-research.ai/merck-s-capvaxive-recommended-for-approval-by-chmp-for-prevention-of-invasive-disease-in-europe/ 2025-01-31 https://bio-research.ai/novadip-biosciences-phase-1b-2a-trial-of-nvd003-shows-88-efficacy-in-healing-fractures-for-cpt-patients/ 2025-01-31 https://bio-research.ai/bavarian-nordic-s-chikungunya-vaccine-vimkunya-receives-positive-opinion-from-chmp-for-individuals-12-and-older/ 2025-01-31 https://bio-research.ai/phaxiam-therapeutics-and-technophage-partnered-to-develop-gmp-phage-therapies-for-resistant-bacterial-infections/ 2025-01-30 https://bio-research.ai/the-fda-approves-celltrion-s-avtozma-as-a-biosimilar-to-actemra-for-treating-rheumatoid-arthritis-and-covid-19/ 2025-01-30 https://bio-research.ai/the-us-fda-approves-journavx-a-non-opioid-nav1-8-pain-signal-inhibitor-for-moderate-to-severe-acute-pain-in-adults/ 2025-01-30 https://bio-research.ai/the-fda-approves-symbravo-for-acute-migraine-treatment-showing-rapid-pain-relief-and-lasting-effects/ 2025-01-30 https://bio-research.ai/creative-medical-technology-holdings-phase-1-2-trial-of-celz-201-ddt-reports-no-dose-limiting-toxicities/ 2025-01-30 https://bio-research.ai/orion-corporation-and-invenra-inc-collaborate-to-develop-bispecific-antibody-cancer-therapeutics/ 2025-01-30 https://bio-research.ai/valneva-se-secures-32-8m-contract-with-u-s-department-of-defense-for-japanese-encephalitis-vaccine-ixiaro/ 2025-01-30 https://bio-research.ai/cognition-therapeutics-phase-2-study-shows-zervimesine-improves-symptoms-in-130-dementia-patients/ 2025-01-30 https://bio-research.ai/tectonic-therapeutic-announces-interim-phase-1b-trial-results-of-tx45-reducing-pulmonary-pressure-and-resistance/ 2025-01-30 https://bio-research.ai/os-therapies-to-acquire-listeria-monocytogenes-based-cancer-vaccine-programs-and-ip-from-ayala-pharmaceuticals-for-8m-in-cash-and-shares/ 2025-01-30 https://bio-research.ai/shionogi-phase-2-trial-of-s-337395-shows-88-94-reduction-in-viral-load-at-week-36-in-rsv/ 2025-01-30 https://bio-research.ai/ethris-gmbh-s-phase-1-trial-of-nasal-ifn-mrna-therapy-shows-safety-tolerability-and-dose-dependent-ifn-production/ 2025-01-30 https://bio-research.ai/alterity-therapeutics-phase-2-trial-of-ath434-shows-significant-slowing-of-clinical-progression-and-reducing-of-iron-accumulation-in-early-msa/ 2025-01-30 https://bio-research.ai/bicycle-health-raised-16-5m-in-funding-and-achieved-operating-profitability-in-2024/ 2025-01-29 https://bio-research.ai/ose-immunotherapeutics-and-scienta-lab-partner-to-use-ai-platform-eva-for-precision-immunology-research/ 2025-01-29 https://bio-research.ai/siolta-therapeutics-and-cowellnex-partner-to-develop-live-biotherapeutic-products-for-preventing-necrotizing-enterocolitis-in-infants/ 2025-01-29 https://bio-research.ai/scholar-rock-submits-biologics-license-application-to-fda-for-apitegromab-based-on-phase-3-sapphire-trial-results/ 2025-01-29 https://bio-research.ai/immunitybio-and-beigene-collaborate-on-phase-3-trial-of-pd-1-inhibitor-and-il-15-agonist-for-advanced-lung-cancer/ 2025-01-29 https://bio-research.ai/acellera-therapeutics-and-psivant-therapeutics-form-collaboration-to-enhance-computational-drug-discovery/ 2025-01-29 https://bio-research.ai/imvax-completes-29-million-financing-round-to-support-operations-until-2026-and-announces-phase-2b-trial-results-for-igv-001-expected-in-mid-2025/ 2025-01-29 https://bio-research.ai/regulus-therapeutics-inc-reports-reduction-in-httkv-growth-rate-and-tolerance-in-phase-1b-study-of-farabursen/ 2025-01-29 https://bio-research.ai/tme-pharma-partners-with-aimed-analytics-to-accelerate-ai-driven-drug-discovery-in-cancer-treatment/ 2025-01-29 https://bio-research.ai/vicore-pharma-holding-receives-fda-fast-track-designation-for-buloxibutid-in-idiopathic-pulmonary-fibrosis/ 2025-01-29 https://bio-research.ai/knight-therapeutics-and-helsinn-healthcare-sign-exclusive-agreement-to-distribute-onicit-iv-in-latin-america/ 2025-01-28 https://bio-research.ai/taiho-pharmaceutical-and-cullinan-therapeutics-phase-1-2-trial-of-zipalertinib-for-lung-cancer-meets-primary-endpoint/ 2025-01-28 https://bio-research.ai/tevogen-bio-secures-10m-grant-agreement-with-krhp-llc-for-t-cell-therapeutics-and-ai-initiatives/ 2025-01-28 https://bio-research.ai/march-biosciences-receives-orphan-drug-designation-for-cd5-targeted-car-t-therapy-for-t-cell-lymphoma/ 2025-01-28 https://bio-research.ai/kashiv-biosciences-phase-1-trial-of-kshb002-shows-pharmacokinetic-equivalence-and-similar-safety-to-orencia/ 2025-01-28 https://bio-research.ai/fda-approves-ozempic-for-reducing-risk-of-worsening-kidney-disease-and-cardiovascular-death-in-adults-with-type-2-diabetes/ 2025-01-28 https://bio-research.ai/quibim-closes-50-million-series-a-financing-with-168-growth-in-patient-analysis-and-global-expansion-plans/ 2025-01-28 https://bio-research.ai/beacon-therapeutics-receives-rmat-designation-from-fda-for-laru-zova-to-treat-x-linked-retinitis-pigmentosa/ 2025-01-28 https://bio-research.ai/atalanta-therapeutics-completes-97-million-series-b-financing-to-support-phase-1-trials-for-epilepsy-and-huntington-s-disease/ 2025-01-28 https://bio-research.ai/seed-therapeutics-receives-rare-pediatric-disease-and-orphan-drug-designations-for-cancer-targeting-st-01156/ 2025-01-28 https://bio-research.ai/lutris-pharma-raises-30-million-to-advance-lut014-a-gel-for-mitigating-acneiform-rash-from-cancer-therapies/ 2025-01-28 https://bio-research.ai/beckley-psytech-s-phase-iia-study-of-bpl-003-shows-significant-reductions-in-alcohol-use-over-three-months/ 2025-01-28 https://bio-research.ai/leap-therapeutics-defiance-study-shows-a-35-objective-response-rate-with-sirexatamab-in-colorectal-cancer/ 2025-01-28 https://bio-research.ai/sab-bio-s-phase-1-trial-of-sab-142-shows-no-serum-sickness-or-anti-drug-antibodies-at-target-dose/ 2025-01-28 https://bio-research.ai/saol-therapeutics-drug-application-for-sl1009-to-treat-pyruvate-dehydrogenase-complex-deficiency-accepted-by-fda/ 2025-01-28 https://bio-research.ai/roche-announces-phase-iii-study-results-showing-itovebi-based-regimen-improves-overall-survival-by-57-in-breast-cancer/ 2025-01-28 https://bio-research.ai/itm-isotope-technologies-munich-se-s-phase-3-trial-shows-itm-11-extends-progression-free-survival-in-309-patients/ 2025-01-28 https://bio-research.ai/lantheus-holdings-to-acquire-evergreen-theragnostics-for-250m-plus-752-5m-in-potential-milestone-payments/ 2025-01-28 https://bio-research.ai/commit-biologics-receives-5-5m-in-seed-financing-to-advance-bice-platform-towards-drug-candidate-selection/ 2025-01-28 https://bio-research.ai/enhertu-receives-u-s-approval-for-treating-advanced-breast-cancer-after-progression-on-endocrine-therapies/ 2025-01-28 https://bio-research.ai/oncomatryx-raises-25-million-to-fund-phase-ib-ii-trials-of-omtx705-targeting-fap/ 2025-01-27 https://bio-research.ai/neurocrine-biosciences-and-takeda-revise-agreement-on-osavampator-phase-3-trials-for-major-depressive-disorder/ 2025-01-27 https://bio-research.ai/the-european-commission-has-granted-marketing-authorization-for-amivantamab-and-lazertinib-as-a-first-line-treatment-in-advanced-nsclc-patients/ 2025-01-27 https://bio-research.ai/the-fda-accepts-merck-s-supplemental-drug-application-for-welireg-for-priority-review-in-advanced-ppgl/ 2025-01-27 https://bio-research.ai/akero-therapeutics-phase-2b-symmetry-study-shows-39-significant-reversal-of-cirrhosis-with-efruxifermin-at-week-96/ 2025-01-27 https://bio-research.ai/allakos-inc-s-phase-1-trial-of-ak006-in-chronic-spontaneous-urticaria-fails-to-show-therapeutic-activity-prompting-the-company-to-discontinue-its-development-and-reduce-its-workforce-by-75/ 2025-01-27 https://bio-research.ai/veru-inc-phase-2b-trial-shows-enobosarm-preserved-lean-mass-in-patients-taking-wegovy-for-weight-reduction/ 2025-01-27 https://bio-research.ai/fda-approves-supplemental-biologics-license-application-for-leqembi-allowing-once-every-four-weeks-dosing-for-the-maintenance-dosing/ 2025-01-27 https://bio-research.ai/ab2-bio-and-nippon-shinyaku-enter-agreement-for-u-s-commercialization-of-tadekinig-alfa-for-hyperinflammatory-syndrome/ 2025-01-27 https://bio-research.ai/sarepta-therapeutics-embark-study-part-2-shows-significant-functional-improvements-in-duchenne-muscular-dystrophy/ 2025-01-27 https://bio-research.ai/gsk-and-university-of-oxford-launch-research-collaboration-on-cancer-prevention-vaccines-with-a-50m-commitment/ 2025-01-27 https://bio-research.ai/cstone-pharmaceuticals-partners-with-steincares-to-commercialize-sugemalimab-pd-l1-mab-in-10-latin-american-countries/ 2025-01-26 https://bio-research.ai/china-medical-system-partners-with-hunan-mabgeek-biotechnology-to-co-develop-and-commercialize-mg-k10/ 2025-01-24 https://bio-research.ai/x4-pharmaceuticals-marketing-authorization-application-for-mavorixafor-validated-by-european-medicines-agency-for-whim-syndrome/ 2025-01-24 https://bio-research.ai/merck-and-eisai-s-phase-3-leap-015-trial-shows-significant-improvement-in-progression-free-survival-but-fails-to-meet-the-primary-endpoint-of-overall-survival/ 2025-01-24 https://bio-research.ai/novo-nordisk-s-phase-1b-2a-trial-of-amycretin-shows-safety-profile-in-125-individuals-with-overweight-or-obesity/ 2025-01-24 https://bio-research.ai/zerion-pharma-partners-with-ach-laboratorios-to-enhance-formulation-of-oncology-and-neuroscience-drugs/ 2025-01-23 https://bio-research.ai/cg-pharmaceuticals-phase-1b-study-of-ivaltinostat-with-capecitabine-shows-65-stable-or-no-evidence-of-disease/ 2025-01-23 https://bio-research.ai/zymedi-and-evotec-selected-for-korea-r-d-project-receiving-usd-4-5m-to-develop-dual-specific-antibodies-using-zymedi-s-zma001-and-evotec-s-ai-platform/ 2025-01-23 https://bio-research.ai/exuma-biotech-phase-1-trial-of-her2-targeted-car-t-therapy-shows-no-dose-limiting-toxicities-or-serious-adverse-events-in-12-patients/ 2025-01-23 https://bio-research.ai/sellas-life-sciences-group-phase-3-regal-trial-of-gps-in-aml-to-proceed-following-idmc-interim-analysis/ 2025-01-23 https://bio-research.ai/abbvie-and-neomorph-partner-to-create-novel-molecular-glue-degraders-with-potential-to-earn-up-to-1-64b/ 2025-01-23 https://bio-research.ai/alx-oncology-phase-2-trial-shows-cd47-blocker-evorpacept-improves-response-rates-in-her2-positive-gastric-cancer/ 2025-01-23 https://bio-research.ai/outlook-therapeutics-trial-shows-ons-5010-non-inferior-to-lucentis-at-4-and-12-weeks-in-wet-amd-patients/ 2025-01-23 https://bio-research.ai/fda-grants-rare-pediatric-disease-designation-to-ns-051-ncnp-04-for-treating-duchenne-muscular-dystrophy/ 2025-01-23 https://bio-research.ai/vigil-neuroscience-s-phase-1-trial-of-vg-3927-shows-dose-dependent-reduction-of-strem2-and-high-brain-penetration/ 2025-01-23 https://bio-research.ai/sichuan-kelun-biotech-receives-approval-in-china-for-tagitanlimab-combination-as-first-line-npc-treatment/ 2025-01-23 https://bio-research.ai/genethon-and-eukar-s-form-strategic-partnership-to-lower-gene-therapy-costs-using-advanced-mrna-expression-technology-based-on-c3p3-enzyme/ 2025-01-23 https://bio-research.ai/immvention-therapeutix-and-novo-nordisk-collaborate-on-oral-bach1-inhibitors-for-sickle-cell-disease/ 2025-01-22 https://bio-research.ai/altamira-therapeutics-ltd-partners-with-radiopharmaceutical-company-to-test-rna-delivery-platform-for-cancer-treatment/ 2025-01-22 https://bio-research.ai/valneva-se-s-phase-2-trial-of-chikungunya-vaccine-ixchiq-in-304-children-shows-it-to-be-well-tolerated/ 2025-01-22 https://bio-research.ai/tris-pharma-s-alleviate-1-phase-3-trial-shows-cebranopadol-reduces-pain-intensity-after-abdominoplasty/ 2025-01-22 https://bio-research.ai/artax-biopharma-s-phase-2a-trial-of-ax-158-shows-well-tolerated-safety-and-significant-gene-effects-in-plaque-psoriasis/ 2025-01-22 https://bio-research.ai/conduit-pharmaceuticals-partners-with-agility-life-sciences-to-develop-solid-oral-dosage-form-products/ 2025-01-22 https://bio-research.ai/gi-innovation-and-lanova-medicines-to-develop-combination-therapy-for-metastatic-pancreatic-cancer/ 2025-01-22 https://bio-research.ai/lisata-therapeutics-phase-2-trial-of-certepetide-shows-median-overall-survival-of-12-68-months-in-pancreatic-cancer/ 2025-01-22 https://bio-research.ai/salubris-biotherapeutics-announces-interim-data-from-phase-2-trial-of-jk07-in-heart-failure-at-0-045-mg-kg/ 2025-01-22 https://bio-research.ai/coherus-biosciences-phase-2-trial-data-shows-increased-response-rates-in-advanced-hepatocellular-carcinoma/ 2025-01-22 https://bio-research.ai/eu-approves-sarclisa-for-treating-newly-diagnosed-multiple-myeloma-ineligible-for-stem-cell-transplant/ 2025-01-22 https://bio-research.ai/arctic-therapeutics-raised-26-5-million-in-series-a-financing-to-support-clinical-trials-for-at-001-and-at-004/ 2025-01-22 https://bio-research.ai/vaxcell-bio-acquires-albiotek-to-diversify-anticancer-treatments-and-secure-new-revenue-channels/ 2025-01-21 https://bio-research.ai/arrivent-biopharma-licenses-mrg007-from-lepu-biopharma-for-47m-upfront-and-1-16b-in-milestones/ 2025-01-21 https://bio-research.ai/nacuity-pharmaceuticals-npi-001-receives-fda-fast-track-designation-for-treating-retinitis-pigmentosa/ 2025-01-21 https://bio-research.ai/solid-biosciences-inc-receives-fast-track-designation-for-gene-therapy-candidate-sgt-212-for-friedreich-s-ataxia/ 2025-01-21 https://bio-research.ai/bluejay-therapeutics-brelovitug-receives-fda-breakthrough-therapy-designation-for-chronic-hepatitis-delta/ 2025-01-21 https://bio-research.ai/verrica-pharmaceuticals-reports-vp-315-treatment-for-basal-cell-carcinoma-shows-97-response-rate-in-phase-2-study/ 2025-01-21 https://bio-research.ai/dyne-therapeutics-dyne-101-granted-fda-fast-track-designation-for-myotonic-dystrophy-type-1-treatment/ 2025-01-21 https://bio-research.ai/dermata-therapeutics-and-revance-therapeutics-collaborate-on-phase-2a-trial-for-primary-axillary-hyperhidrosis/ 2025-01-21 https://bio-research.ai/replimune-group-s-biologics-license-application-for-rp1-with-nivolumab-for-advanced-melanoma-accepted-by-fda/ 2025-01-21 https://bio-research.ai/spravato-esketamine-approved-by-us-fda-as-nasal-spray-for-treatment-resistant-depression-in-adults/ 2025-01-21 https://bio-research.ai/saponiqx-partners-with-probius-and-ginkgo-bioworks-to-develop-next-generation-vaccine-adjuvants/ 2025-01-21 https://bio-research.ai/the-european-commission-approved-amivantamab-and-lazertinib-for-first-line-treatment-of-advanced-lung-cancer/ 2025-01-21 https://bio-research.ai/ascletis-pharma-s-asc30-a-small-molecule-oral-glp-1r-agonist-shows-favorable-pharmacokinetics-and-long-half-life-in-obese-patients/ 2025-01-21 https://bio-research.ai/circio-holding-asa-and-4basebio-plc-to-develop-and-test-synthetic-circvec-dna-vectors-in-mouse-models/ 2025-01-21 https://bio-research.ai/hk-inno-n-and-roche-korea-sign-agreement-for-joint-promotion-of-avastin-in-cancer-treatments/ 2025-01-21 https://bio-research.ai/gesynta-pharma-ab-raises-sek-304-million-to-fund-phase-ii-trial-of-vipoglanstat-for-treating-endometriosis/ 2025-01-20 https://bio-research.ai/valneva-se-s-phase-3-trial-of-chikungunya-virus-vaccine-shows-98-3-sero-response-rate-in-adolescents/ 2025-01-20 https://bio-research.ai/shanghai-junshi-biosciences-and-topalliance-partner-with-leo-pharma-to-distribute-toripalimab-in-europe/ 2025-01-20 https://bio-research.ai/formycon-ag-and-klinge-biopharma-received-european-commission-approval-for-fyb203-to-treat-retinal-diseases/ 2025-01-20 https://bio-research.ai/innocare-pharma-and-keymed-biosciences-enter-520m-agreement-with-prolium-bioscience-for-icp-b02-a-cd20-x-cd3-bispecific-antibody/ 2025-01-20 https://bio-research.ai/european-commission-approves-jemperli-combined-with-chemotherapy-for-advanced-or-recurrent-endometrial-cancer/ 2025-01-20 https://bio-research.ai/sumitomo-pharma-partners-with-janssen-to-co-promote-xeplion-and-xeplion-tri-in-japan-for-schizophrenia-treatment/ 2025-01-20 https://bio-research.ai/guangzhou-fermion-and-simcere-collaborate-on-fz002-037-oral-sstr4-agonist-for-pain-treatment-in-greater-china/ 2025-01-19 https://bio-research.ai/datroway-approved-in-the-us-for-metastatic-hormone-receptor-positive-her2-negative-breast-cancer/ 2025-01-18 https://bio-research.ai/the-fda-approves-amgen-s-lumakras-in-combination-with-vectibix-for-metastatic-colorectal-cancer/ 2025-01-17 https://bio-research.ai/novo-nordisk-s-step-up-phase-3b-trial-shows-greater-weight-loss-with-semaglutide-7-2-mg-in-1-407-adults-over-72-weeks/ 2025-01-17 https://bio-research.ai/shanghai-henlius-biotech-and-deep-potential-technology-form-strategic-partnership-for-ai-assisted-drug-development/ 2025-01-17 https://bio-research.ai/innovent-biologics-and-jiangsu-aosaikang-pharmaceutical-s-limertinib-approved-by-china-s-nmpa-for-nsclc/ 2025-01-16 https://bio-research.ai/shionogi-secures-375m-from-barda-u-s-department-of-health-and-human-services-and-amed-to-develop-s-892216/ 2025-01-16 https://bio-research.ai/boehringer-ingelheim-s-three-phase-iii-connex-trials-for-iclepertin-in-schizophrenia-failed-to-improve-cognition-missing-both-primary-and-secondary-endpoints-after-26-weeks/ 2025-01-16 https://bio-research.ai/atara-biotherapeutics-received-complete-response-letter-from-fda-due-to-inspection-issues-at-third-party-manufacturer/ 2025-01-16 https://bio-research.ai/cytiva-and-cellular-origins-collaborate-to-integrate-automated-cell-processing-technologies-and-robotic-manufacturing-systems-for-cell-and-gene-therapy-production/ 2025-01-16 https://bio-research.ai/biothera-inc-and-world-medicine-sign-agreement-for-bat2206-a-biosimilar-to-stelara-distribution-in-turkey/ 2025-01-16 https://bio-research.ai/idorsia-pharmaceuticals-enters-30m-royalty-monetization-agreement-with-r-bridge-healthcare-fund-for-agamree/ 2025-01-16 https://bio-research.ai/outlook-therapeutics-norse-eight-trial-shows-ons-5010-noninferior-to-ranibizumab-at-12-weeks-for-wet-amd/ 2025-01-16 https://bio-research.ai/avacta-therapeutics-clinical-trial-shows-5-out-of-10-salivary-gland-cancer-patients-treated-with-ava6000-experienced-tumor-shrinkage/ 2025-01-16 https://bio-research.ai/innovent-biologics-ibi343-granted-breakthrough-therapy-designation-in-china-for-advanced-pancreatic-cancer/ 2025-01-16 https://bio-research.ai/boehringer-ingelheim-gets-nmpa-acceptance-for-marketing-zongertinib-in-china/ 2025-01-16 https://bio-research.ai/visirose-inc-raises-3-million-in-seed-financing-for-ocular-therapeutic-pv-305-development/ 2025-01-15 https://bio-research.ai/yooyoung-pharmaceutical-and-kangstem-biotech-form-agreement-to-develop-and-market-osca-for-osteoarthritis/ 2025-01-15 https://bio-research.ai/immunitybio-submits-applications-for-anktiva-plus-bcg-for-non-muscle-invasive-bladder-cancer-in-eu-and-uk/ 2025-01-15 https://bio-research.ai/fda-approves-lilly-s-omvoh-mirikizumab-mrkz-for-crohn-s-disease-expanding-its-use-to-the-second-major-type-of-inflammatory-bowel-disease/ 2025-01-15 https://bio-research.ai/handa-therapeutics-acquires-phyrago-dasatinib-tablets-from-nanocopoeia-for-leukemia-treatment/ 2025-01-15 https://bio-research.ai/granata-bio-corporation-announces-15m-series-a-funding-round-to-support-pipeline-and-reproductive-health-assets/ 2025-01-15 https://bio-research.ai/be-biopharma-closes-92m-series-c-financing-to-support-trials-for-hemophilia-b-and-hypophosphatasia/ 2025-01-15 https://bio-research.ai/os-therapies-phase-2b-trial-of-ost-her2-shows-significant-improvements-in-12-month-event-free-survival-in-osteosarcoma/ 2025-01-15 https://bio-research.ai/inflammasome-therapeutics-k8-implant-reduced-ga-lesion-growth-by-66-in-treated-eyes-over-3-months/ 2025-01-15 https://bio-research.ai/johnson-johnson-applies-for-fda-approval-of-tar-200-to-treat-bcg-unresponsive-bladder-cancer-based-on-phase-2b-data/ 2025-01-15 https://bio-research.ai/zai-lab-s-results-from-the-china-subpopulation-of-the-phase-3-shows-tivdak-improved-survival-and-response-rates-in-cervical-cancer/ 2025-01-15 https://bio-research.ai/hinge-bio-closes-series-a-financing-to-support-phase-1-trial-of-hb2198-for-systemic-lupus-erythematosus/ 2025-01-15 https://bio-research.ai/lophora-completes-3-million-raise-to-support-phase-i-trial-of-lph-5-for-cns-conditions-in-2025/ 2025-01-15 https://bio-research.ai/orna-therapeutics-and-shanghai-simnova-biotech-expand-collaboration-to-target-bcma-with-rna-based-therapeutics/ 2025-01-15 https://bio-research.ai/keros-therapeutics-halts-dosing-in-phase-2-trial-of-cibotercept-due-to-pericardial-effusion-events/ 2025-01-15 https://bio-research.ai/immuron-limited-and-monash-university-partner-to-develop-new-drugs-targeting-antimicrobial-resistant-pathogens/ 2025-01-15 https://bio-research.ai/saniona-secures-9-million-in-seed-financing-to-advance-vascular-katp-channel-inhibitor-for-anti-migraine-treatments/ 2025-01-15 https://bio-research.ai/therazyne-inc-and-biorevert-inc-sign-joint-r-d-agreement-to-develop-novel-protein-based-cancer-therapeutics/ 2025-01-14 https://bio-research.ai/keylicon-biosciences-obtains-exclusive-rights-to-self-amplifying-rna-technology-from-boston-university/ 2025-01-14 https://bio-research.ai/acadia-pharmaceuticals-submits-marketing-authorization-application-for-trofinetide-to-treat-rett-syndrome-in-europe/ 2025-01-14 https://bio-research.ai/vistagen-phase-2a-study-of-ph284-nasal-spray-in-cancer-cachexia-shows-higher-mean-hunger-levels-than-placebo/ 2025-01-14 https://bio-research.ai/verastem-oncology-acquires-global-license-from-genfleet-therapeutics-to-develop-and-commercialize-vs-7375/ 2025-01-14 https://bio-research.ai/provectus-biopharmaceuticals-raises-3-million-to-support-visirose-in-advancing-ocular-therapeutics/ 2025-01-14 https://bio-research.ai/hikma-pharmaceuticals-partners-with-emergent-biosolutions-to-sell-kloxxado-naloxone-spray-in-u-s-and-canada/ 2025-01-14 https://bio-research.ai/umoja-biopharma-closes-100-million-series-c-financing-to-advance-cd22-ub-vv400-program-for-oncology-and-autoimmune-clinical-studies/ 2025-01-14 https://bio-research.ai/sling-therapeutics-phase-2b-3-trial-of-linsitinib-in-thyroid-eye-disease-meets-primary-endpoint-with-150mg-dose/ 2025-01-14 https://bio-research.ai/veneno-technologies-and-aska-pharmaceutical-partner-to-develop-new-ion-channel-therapies-using-perisstm/ 2025-01-14 https://bio-research.ai/kyorin-pharmaceutical-signs-option-agreement-with-biodol-therapeutics-for-pain-treatment-candidate-bdt272/ 2025-01-14 https://bio-research.ai/medilink-therapeutics-and-astrazeneca-to-collaborate-on-clinical-study-evaluating-yl201-and-imfinzi-for-solid-tumors/ 2025-01-14 https://bio-research.ai/regenxbio-and-nippon-shinyaku-partner-to-develop-and-commercialize-rgx-121-and-rgx-111-with-110m-upfront/ 2025-01-14 https://bio-research.ai/theravac-biologics-partners-with-perceiv-ai-to-enhance-tv-301-vaccine-trial-for-mild-cognitive-impairment/ 2025-01-13 https://bio-research.ai/immunis-secures-25-million-for-phase-2-trials-of-imm01-stem-targeting-muscle-loss-and-metabolic-dysfunction/ 2025-01-13 https://bio-research.ai/rappta-therapeutics-grants-springworks-therapeutics-exclusive-license-for-rpt04402-in-uterine-cancers/ 2025-01-13 https://bio-research.ai/eisai-and-biogen-s-biologics-license-application-for-subcutaneous-leqembi-accepted-by-fda/ 2025-01-13 https://bio-research.ai/spinogenix-granted-fast-track-designation-for-spg601-in-treating-fragile-x-syndrome-by-u-s-fda/ 2025-01-13 https://bio-research.ai/daiichi-sankyo-pays-glycotope-132-5m-to-settle-all-financial-obligations-and-secure-complete-rights-for-gatipotuzumab-antibody-continuing-adc-development-independently/ 2025-01-13 https://bio-research.ai/roche-licenses-capsid-from-dyno-therapeutics-for-gene-therapy-program-in-227m-agreement/ 2025-01-13 https://bio-research.ai/eli-lilly-to-acquire-scorpion-therapeutics-pi3k-inhibitor-program-stx-478-for-up-to-2-5b/ 2025-01-13 https://bio-research.ai/abbvie-and-simcere-zaiming-enter-1-055b-option-to-license-agreement-to-develop-sim0500-for-multiple-myeloma/ 2025-01-13 https://bio-research.ai/salarius-pharmaceuticals-and-decoy-therapeutics-to-merge-in-7m-deal-combining-key-assets-and-pipelines/ 2025-01-13 https://bio-research.ai/ashvattha-therapeutics-secures-up-to-50-million-funding-to-complete-ongoing-phase-2-and-phase-1-2-trials/ 2025-01-13 https://bio-research.ai/jiangsu-hengrui-pharmaceuticals-phase-2-trial-of-hrs9531-a-glp-1-gip-dual-agonist-shows-22-8-mean-weight-loss-at-36-weeks/ 2025-01-13 https://bio-research.ai/cambium-oncology-partners-with-orient-euro-pharma-receiving-5m-to-accelerate-ant308-clinical-development/ 2025-01-13 https://bio-research.ai/synthego-signs-licensing-agreement-with-astrazeneca-to-manufacture-and-distribute-crispr-enzyme-espot-on/ 2025-01-13 https://bio-research.ai/zhaoke-ophthalmology-grants-aft-pharmaceuticals-exclusive-distribution-rights-for-brimocholtm-pf-in-australia-and-new-zealand/ 2025-01-13 https://bio-research.ai/oric-pharmaceuticals-partners-with-janssen-r-d-to-test-oric-114-with-sc-amivantamab-for-advanced-nsclc/ 2025-01-13 https://bio-research.ai/adaptimmune-therapeutics-lete-cel-granted-fda-breakthrough-therapy-designation-for-treating-mrcls/ 2025-01-13 https://bio-research.ai/x4-pharmaceuticals-and-norgine-sign-exclusive-agreement-for-mavorixafor-commercialization-in-europe-australia-and-new-zealand/ 2025-01-13 https://bio-research.ai/bausch-lomb-corporation-acquires-whitecap-biosciences-llc-adding-therapies-for-glaucoma-and-geographic-atrophy/ 2025-01-13 https://bio-research.ai/regeneron-pharmaceuticals-phase-3-c-post-trial-shows-68-reduction-in-risk-of-recurrence-with-libtayo/ 2025-01-13 https://bio-research.ai/bristol-myers-squibb-exercises-exclusive-license-option-for-arsenalbio-s-ab-4000-series-focused-on-t-cell-therapies/ 2025-01-13 https://bio-research.ai/george-medicines-and-bausch-health-agree-to-commercialize-gmrx2-hypertension-drug-in-canada-mexico-and-more/ 2025-01-13 https://bio-research.ai/johnson-johnson-acquires-intra-cellular-therapies-for-14-6b-securing-rights-to-caplyta-for-schizophrenia-and-bipolar/ 2025-01-13 https://bio-research.ai/vera-therapeutics-enters-exclusive-license-agreement-with-stanford-university-for-vt-109-to-treat-b-cell-mediated-diseases/ 2025-01-13 https://bio-research.ai/klinge-biopharma-partners-with-teva-pharmaceuticals-for-semi-exclusive-commercialization-of-formycon-s-fyb203-in-europe-and-israel/ 2025-01-13 https://bio-research.ai/normunity-secures-75m-to-advance-anti-cancer-therapies-plans-phase-1-trial-for-nrm-823-by-2025/ 2025-01-13 https://bio-research.ai/gsk-acquires-idrx-for-up-to-1-15b-including-1b-upfront-payment-and-150m-contingent-on-regulatory-approval/ 2025-01-13 https://bio-research.ai/tune-therapeutics-completes-175m-financing-to-accelerate-development-of-epigenetic-silencing-drug-for-hbv/ 2025-01-12 https://bio-research.ai/telix-pharmaceuticals-to-acquire-imaginab-s-assets-with-deal-worth-up-to-230m-including-milestone-payments/ 2025-01-12 https://bio-research.ai/biohaven-ltd-and-merus-n-v-announce-research-collaboration-to-co-develop-three-novel-bispecific-adcs/ 2025-01-12 https://bio-research.ai/ouro-medicines-launches-with-120-million-funding-to-develop-therapeutics-for-chronic-immune-mediated-diseases/ 2025-01-10 https://bio-research.ai/rhygaze-raises-86-million-to-develop-gene-therapy-for-optogenetic-vision-restoration/ 2025-01-10 https://bio-research.ai/character-biosciences-and-bausch-lomb-partner-to-develop-amd-treatments-using-ai-driven-platform/ 2025-01-10 https://bio-research.ai/4d-molecular-therapeutics-spectra-trial-shows-4d-150-well-tolerated-with-improved-visual-acuity-in-dme/ 2025-01-10 https://bio-research.ai/harbour-biomed-and-kelun-biotech-license-hbm9378-skb378-to-windward-bio-in-deal-worth-up-to-970m/ 2025-01-10 https://bio-research.ai/zai-lab-and-vertex-pharmaceuticals-form-exclusive-partnership-to-develop-and-commercialize-povetacicept/ 2025-01-10 https://bio-research.ai/absci-corporation-and-owkin-partner-to-accelerate-therapeutic-discovery-using-ai-platforms/ 2025-01-10 https://bio-research.ai/crinetics-pharmaceuticals-phase-2-trial-of-atumelnant-in-cah-shows-significant-biomarker-reductions-without-severe-adverse-events/ 2025-01-10 https://bio-research.ai/mediar-therapeutics-and-eli-lilly-enter-global-licensing-agreement-to-advance-mtx-463-for-idiopathic-pulmonary-fibrosis/ 2025-01-10 https://bio-research.ai/linqmed-secures-1-5-billion-yen-to-support-phase-iii-trial-of-lm001-for-malignant-gliomas-and-new-factory-in-chiba/ 2025-01-10 https://bio-research.ai/pfizer-s-phase-3-crest-trial-shows-significant-improvement-in-event-free-survival-for-nmibc/ 2025-01-10 https://bio-research.ai/city-therapeutics-partners-with-bausch-lomb-to-develop-rnai-based-treatment-for-retinal-diseases/ 2025-01-10 https://bio-research.ai/sciwind-biosciences-grants-verdiva-bio-rights-to-metabolic-disease-therapies-in-2-47b-deal/ 2025-01-10 https://bio-research.ai/bayer-s-phase-iii-quanti-studies-show-gadoquatrane-met-primary-and-secondary-endpoints-in-mri-use/ 2025-01-10 https://bio-research.ai/affibody-regains-rights-to-izokibep-in-asian-countries-after-termination-of-agreement-with-inmagene-biopharmaceuticals/ 2025-01-10 https://bio-research.ai/boehringer-ingelheim-obtains-fourth-license-from-oxford-biotherapeutics-to-develop-novel-antibody-cancer-treatments/ 2025-01-09 https://bio-research.ai/light-horse-therapeutics-and-novartis-collaborate-to-develop-first-in-class-therapeutics-25m-upfront/ 2025-01-09 https://bio-research.ai/light-horse-therapeutics-raises-62-million-in-series-a-financing-led-by-versant-ventures-for-oncology-research/ 2025-01-09 https://bio-research.ai/mountainfield-venture-partners-and-keymed-biosciences-established-timberlyne-therapeutics-with-180-million-financing/ 2025-01-09 https://bio-research.ai/molcure-inc-and-teijin-pharma-limited-enter-agreement-to-develop-innovative-antibody-drugs-for-cns-diseases/ 2025-01-09 https://bio-research.ai/zai-lab-and-medilink-announce-strategic-collaboration-and-worldwide-license-agreement-for-zl-6201/ 2025-01-09 https://bio-research.ai/tenpoint-therapeutics-phase-3-trial-brio-ii-meets-primary-endpoints-with-improvements-in-near-vision/ 2025-01-09 https://bio-research.ai/inmagene-biopharmaceuticals-phase-2a-trial-of-img-007-shows-77-mean-easi-reduction-in-atopic-dermatitis/ 2025-01-09 https://bio-research.ai/synaffix-b-v-licenses-adc-technologies-to-mitsubishi-tanabe-pharma-in-agreement-to-enhance-apac-presence/ 2025-01-09 https://bio-research.ai/boehringer-ingelheim-licenses-adc-technology-from-synaffix-b-v-via-nbe-therapeutics-in-1-3b-deal/ 2025-01-09 https://bio-research.ai/biocytogen-licenses-fully-human-antibodies-to-sotio-biotech-for-adc-candidate-sot109-in-cancer-treatment/ 2025-01-09 https://bio-research.ai/climb-bio-secures-exclusive-license-from-beijing-mabworks-biotech-for-anti-april-antibody-clym116-with-9m-upfront-payment/ 2025-01-09 https://bio-research.ai/thetis-pharmaceuticals-secures-8-975-million-loan-for-phase-1b-trial-of-tp-317-in-ulcerative-colitis-patients/ 2025-01-09 https://bio-research.ai/alchemab-therapeutics-partners-with-lilly-to-develop-novel-antibodies-for-treating-als-using-patients-samples-with-slow-disease-progression/ 2025-01-09 https://bio-research.ai/coave-therapeutics-raises-32-million-to-develop-aligater-delivery-platform-and-advance-gene-therapy-candidates-for-clinical-development/ 2025-01-09 https://bio-research.ai/bayer-s-phase-iii-oasis-4-study-of-elinzanetant-met-the-primary-endpoints-demonstrating-reduced-vasomotor-symptoms-and-improved-quality-of-life/ 2025-01-09 https://bio-research.ai/anacardio-closes-usd-19-million-financing-round-to-complete-phase-1b-2a-study-of-ac01-in-heart-failure/ 2025-01-09 https://bio-research.ai/sanofi-s-sarclisa-sc-meets-co-primary-endpoints-showing-non-inferiority-to-iv-in-phase-3-study-for-r-r-mm/ 2025-01-09 https://bio-research.ai/1cbio-and-alesta-pharmaceuticals-enter-exclusive-worldwide-licensing-agreement-for-oc-1-ale1-in-hypophosphatasia/ 2025-01-08 https://bio-research.ai/samsung-biologics-expands-adc-development-services-in-a-new-collaboration-with-ligachem-biosciences/ 2025-01-08 https://bio-research.ai/alesta-therapeutics-closes-65-million-series-a-to-advance-lead-program-ale1-to-reduce-ppi-levels-for-hypophosphatasia/ 2025-01-08 https://bio-research.ai/alpha-cognition-enters-44m-licensing-agreement-with-china-medical-system-for-zunveyl-in-asia-australia-and-new-zealand/ 2025-01-08 https://bio-research.ai/vividion-therapeutics-a-subsidiary-of-bayer-ag-acquires-tavros-therapeutics-to-enhance-genomics-capabilities/ 2025-01-08 https://bio-research.ai/y-biologics-inc-and-im-biologics-partner-to-develop-new-antibody-drug-candidate-for-autoimmune-diseases/ 2025-01-08 https://bio-research.ai/aspect-biosystems-raises-115-million-to-develop-bioprinted-tissue-therapeutics-and-expand-platform/ 2025-01-08 https://bio-research.ai/anokion-sa-phase-2-trial-shows-kan-101-reduces-symptoms-after-gluten-exposure-in-celiac-disease-patients/ 2025-01-08 https://bio-research.ai/araris-biotech-and-chugai-pharmaceutical-collaborate-to-develop-novel-adcs-with-potential-780m-in-payments/ 2025-01-08 https://bio-research.ai/tenvie-therapeutics-secures-200-million-investment-for-treatments-targeting-inflammation-and-metabolic-dysfunction/ 2025-01-08 https://bio-research.ai/denali-therapeutics-tividenofusp-alfa-receives-fda-breakthrough-therapy-designation-for-hunter-syndrome/ 2025-01-08 https://bio-research.ai/johnson-johnson-therapy-granted-fda-fast-track-designation-for-alzheimer-s-disease-treatment/ 2025-01-08 https://bio-research.ai/lb-pharmaceuticals-inc-phase-2-trial-of-lb-102-shows-significant-reduction-in-panss-score-in-schizophrenia/ 2025-01-08 https://bio-research.ai/moma-therapeutics-secures-global-rights-to-moma-989-in-exclusive-license-from-u-s-based-biopharmaceutical-partner/ 2025-01-08 https://bio-research.ai/mirror-biologics-and-merck-kgaa-partner-for-phase-ii-trial-of-allostim-and-avelumab-in-metastatic-colorectal-cancer/ 2025-01-08 https://bio-research.ai/novo-nordisk-and-valo-health-expand-collaboration-to-develop-treatments-with-valo-s-ai-platform-worth-up-to-4-6b/ 2025-01-08 https://bio-research.ai/marengo-therapeutics-receives-fda-fast-track-designation-for-invikafusp-alfa-in-advanced-colorectal-cancer/ 2025-01-08 https://bio-research.ai/tochigi-cancer-center-and-j-pharma-partner-to-research-lat1-inhibitor-nanvuranlat-in-biliary-tract-cancer/ 2025-01-08 https://bio-research.ai/taimed-biologics-phase-2a-study-of-tmb-365-and-tmb-380-for-hiv-meets-all-primary-endpoints-with-no-virologic-failures/ 2025-01-08 https://bio-research.ai/biocytogen-and-acepodia-form-strategic-partnership-to-develop-dual-payload-bispecific-antibody-drug-conjugate/ 2025-01-07 https://bio-research.ai/hoth-therapeutics-phase-2a-trial-of-ht-001-shows-100-efficacy-in-skin-toxicity-management-without-adverse-effects/ 2025-01-07 https://bio-research.ai/alloy-therapeutics-enters-collaboration-and-license-agreement-with-sanofi-worth-up-to-427-5m/ 2025-01-07 https://bio-research.ai/avenzo-therapeutics-and-duality-biotherapeutics-enter-exclusive-1-2b-license-agreement-for-avzo-1418-db-1418/ 2025-01-07 https://bio-research.ai/actuate-therapeutics-receives-orphan-medicinal-product-designation-from-ema-for-elraglusib-in-pancreatic-cancer/ 2025-01-07 https://bio-research.ai/restem-receives-fda-fast-track-designation-for-restem-l-stem-cell-program-to-treat-polymyositis-and-dermatomyositis-plans-phase-2-3-clinical-trial-in-early-2025/ 2025-01-07 https://bio-research.ai/xylocor-therapeutics-secures-67-5-million-in-series-b-financing-to-fund-phase-2-clinical-trials-of-gene-therapy-product-xc001-targeting-cardiovascular-disease/ 2025-01-07 https://bio-research.ai/hummingbird-bioscience-grants-immunome-exclusive-global-license-to-monoclonal-antibodies/ 2025-01-07 https://bio-research.ai/asher-biotherapeutics-and-astrazeneca-sign-supply-agreement-for-phase-1b-2-study-assessing-etakafusp-alfa-with-rilvegostomig-in-advanced-nsclc/ 2025-01-07 https://bio-research.ai/rezolute-inc-receives-fda-breakthrough-therapy-designation-for-ersodetug-in-treating-hypoglycemia-due-to-congenital-hyperinsulinism/ 2025-01-07 https://bio-research.ai/johnson-johnson-announces-combination-of-rybrevant-and-lazcluze-improves-overall-survival-in-egfr-mutated-nsclc-by-over-one-year-in-phase-3-mariposa-study/ 2025-01-07 https://bio-research.ai/capsida-biotherapeutics-to-receive-40m-from-abbvie-in-neurodegenerative-disease-program-collaboration/ 2025-01-07 https://bio-research.ai/metsera-inc-announces-results-from-phase-2a-trial-of-met-097i-an-ultra-long-acting-glp-1-receptor-agonist-showing-11-3-body-weight-reduction/ 2025-01-07 https://bio-research.ai/aviceda-therapeutics-closes-207-5-million-series-c-financing-to-fund-phase-2b-3-and-planned-pivotal-phase-3-trials-for-avd-104-in-geographic-atrophy/ 2025-01-07 https://bio-research.ai/variant-bio-partners-with-novo-nordisk-in-multi-year-collaboration-for-metabolic-disease-treatments-with-up-to-50m-in-funding-and-shared-financial-benefits/ 2025-01-07 https://bio-research.ai/orna-therapeutics-and-vertex-pharmaceuticals-partner-with-65m-upfront-for-gene-editing-therapies-targeting-sickle-cell-disease-and-thalassemia/ 2025-01-07 https://bio-research.ai/gsk-receives-fda-breakthrough-therapy-designation-for-hs-20093-in-treating-relapsed-or-refractory-osteosarcoma-after-two-prior-lines-of-therapy/ 2025-01-07 https://bio-research.ai/alivexis-raises-5-1m-in-series-d-round-to-advance-modbind-platform-and-accelerate-r-d-programs/ 2025-01-07 https://bio-research.ai/kissei-pharmaceutical-signs-sub-license-agreement-with-tai-tien-pharmaceuticals-to-develop-and-commercialize-tavalisse-in-taiwan/ 2025-01-07 https://bio-research.ai/iqure-pharma-secures-4-million-to-advance-phase-1-clinical-trial-for-iq-007-targeting-epilepsy-and-neurodegenerative-conditions/ 2025-01-07 https://bio-research.ai/alebund-pharmaceuticals-secures-rmb-550-million-in-series-c-financing-to-advance-and-commercialize-renal-disease-therapies/ 2025-01-07 https://bio-research.ai/wuxi-biologics-grants-candid-therapeutics-exclusive-global-rights-to-preclinical-t-cell-engager-in-deal-worth-up-to-925m/ 2025-01-06 https://bio-research.ai/denali-therapeutics-phase-2-3-healey-als-platform-trial-of-dnl343-in-als-does-not-meet-primary-or-key-secondary-endpoints-at-24-weeks-shows-safety-and-tolerance/ 2025-01-06 https://bio-research.ai/pharmaessentia-s-surpass-et-trial-of-besremi-shows-durable-hematologic-responses-and-reduction-in-jak2-v617f-allelic-burden-in-essential-thrombocythemia/ 2025-01-06 https://bio-research.ai/star-therapeutics-receives-fda-fast-track-designation-for-vga039-in-von-willebrand-disease/ 2025-01-06 https://bio-research.ai/technoderma-medicines-phase-2a-trial-shows-tdm-180935-achieves-62-5-percent-viga-ad-improvement-and-significant-m-easi-reduction-in-atopic-dermatitis-patients/ 2025-01-06 https://bio-research.ai/taletrectinib-approved-in-china-for-ros1-positive-nsclc-will-be-marketed-by-innovent-biologics-with-a-u-s-fda-decision-expected-by-june-23-2025/ 2025-01-06 https://bio-research.ai/novo-holdings-participates-in-90-million-series-a-financing-for-orbis-medicines-developing-oral-macrocycle-drugs-using-ngen-platform-with-morten-graugaard-appointed-ceo/ 2025-01-06 https://bio-research.ai/amgen-receives-conditional-marketing-authorization-from-uk-mhra-for-imdylltra-to-treat-extensive-stage-small-cell-lung-cancer-after-at-least-two-prior-therapies/ 2025-01-06 https://bio-research.ai/oculis-holding-ag-reports-phase-2-trial-results-of-ocs-05-for-acute-optic-neuritis-showing-safety-and-significant-improvements-in-retinal-structure-and-visual-function/ 2025-01-06 https://bio-research.ai/hk-inno-n-corporation-partners-with-southern-xp-for-exclusive-distribution-and-sale-of-k-cab-in-australia-and-new-zealand/ 2025-01-06 https://bio-research.ai/jcr-pharmaceuticals-and-modalis-therapeutics-enter-joint-research-agreement-for-pre-clinical-studies-on-novel-gene-therapy-using-bbb-penetration-and-epigenome-modulation-technologies/ 2025-01-06 https://bio-research.ai/china-s-national-medical-products-administration-approves-astellas-pharma-s-vyloy-zolbetuximab-for-first-line-treatment-of-her2-negative-gastric-or-gastroesophageal-junction-adenocarcinoma-with-cldn18-2-positive-tumors/ 2025-01-05 https://bio-research.ai/genkore-secures-10-billion-krw-bridge-investment-from-intervest-and-receives-preferential-listing-benefits-for-its-gene-editing-technology/ 2025-01-03 https://bio-research.ai/eton-pharmaceuticals-acquires-galzin-for-wilson-disease-and-will-commercialize-in-the-u-s-with-european-supply-as-wilzin-with-advice-from-stifel/ 2025-01-03 https://bio-research.ai/gsk-s-mepolizumab-approved-by-china-nmpa-as-add-on-therapy-for-adults-with-chronic-rhinosinusitis-with-nasal-polyps-following-phase-iii-merit-trial/ 2025-01-03 https://bio-research.ai/innovent-biologics-announces-china-s-nmpa-approval-of-second-nda-for-dovbleron-to-treat-adult-patients-with-locally-advanced-or-metastatic-ros1-positive-nsclc/ 2025-01-03 https://bio-research.ai/radius-pharmaceuticals-grants-pharmanovia-exclusive-rights-to-commercialize-abaloparatide-in-asia-pacific-regions/ 2025-01-02 https://bio-research.ai/capricor-therapeutics-completes-bla-submission-for-deramiocel-to-treat-duchenne-muscular-dystrophy-cardiomyopathy-backed-by-phase-2-hope-2-trial-data/ 2025-01-02 https://bio-research.ai/atavistik-bio-and-pfizer-collaborate-to-discover-novel-precision-allosteric-therapeutics-using-amps-platform-with-option-for-licensing-after-research-period/ 2025-01-02 https://bio-research.ai/ibio-in-licenses-anti-myostatin-antibody-ibio-600-from-astralbio-plans-bispecific-antibody-program-for-obesity-and-cardiometabolic-disorders-by-2026/ 2025-01-02 https://bio-research.ai/siga-technologies-antiviral-treatment-tepoxx-approved-in-japan-for-smallpox-mpox-cowpox-and-post-smallpox-vaccination-complications/ 2025-01-02 https://bio-research.ai/neumora-therapeutics-phase-3-koastal-1-study-shows-navacaprant-does-not-significantly-improve-depressive-symptoms-compared-to-placebo-but-notes-efficacy-signal-in-female-participants/ 2025-01-02 https://bio-research.ai/sino-biopharmaceuticals-subsidiary-chia-tai-tianqing-secures-exclusive-eleven-year-agreement-with-ping-an-shionogi-to-market-shionogi-s-naldemedine-in-china-to-benefit-patients-with-opioid-induced-constipation/ 2025-01-02 https://bio-research.ai/zhaoke-ophthalmology-s-phase-iii-trial-of-tab014-for-wet-age-related-macular-degeneration-meets-primary-and-key-secondary-endpoints-showing-improved-visual-acuity-at-week-52-compared-to-lucentis/ 2025-01-02 https://bio-research.ai/shanghai-micurx-pharmaceutical-s-anti-infection-drug-mrx-5-granted-orphan-drug-designation-by-us-fda-for-treatment-of-non-tuberculous-mycobacteria-infections/ 2025-01-01 https://bio-research.ai/innovent-biologics-grants-roche-exclusive-rights-to-ibi3009-for-80m-upfront-potential-1b-in-milestones-in-small-cell-lung-cancer-deal/ 2025-01-01 https://bio-research.ai/xgene-pharmaceutical-s-phase-2b-study-of-xg005-reveals-significant-pain-intensity-reduction-in-bunionectomy-patients/ 2024-12-31 https://bio-research.ai/valo-health-s-phase-2-spectra-study-fails-primary-and-secondary-objectives-company-suspends-development-of-opl-0401-for-diabetic-retinopathy/ 2024-12-31 https://bio-research.ai/galera-therapeutics-acquires-nova-pharmaceuticals-in-a-3m-deal-backed-by-ikarian-capital-and-aims-to-finance-future-clinical-trials-until-2026/ 2024-12-31 https://bio-research.ai/brii-biosciences-acquires-brii-179-intellectual-property-from-vbi-vaccines-for-18m-cancels-future-payment-obligations/ 2024-12-31 https://bio-research.ai/velavigo-secures-50-million-in-pre-a-financing-for-drug-pipeline-development-in-oncology-and-autoimmune-diseases/ 2024-12-31 https://bio-research.ai/pfizer-ends-global-agreement-on-hemophilia-a-gene-therapy-product-sangamo-to-retake-control-by-april-2025/ 2024-12-30 https://bio-research.ai/gubra-teams-up-with-amylyx-pharmaceuticals-for-a-50m-deal-to-develop-potential-novel-long-lasting-glp-1-receptor-antagonist/ 2024-12-30 https://bio-research.ai/lupin-limited-acquires-huminsulin-from-eli-lilly-and-company-in-india-bolstering-its-diabetes-care-portfolio/ 2024-12-30 https://bio-research.ai/radiopharm-theranostics-and-lantheus-forge-2m-co-development-deal-for-oncology-radiopharmaceuticals-in-australia/ 2024-12-30 https://bio-research.ai/orion-and-marinus-end-european-distribution-deal-for-epilepsy-drug-ganaxolone/ 2024-12-30 https://bio-research.ai/immedica-pharma-ab-acquires-marinus-pharmaceuticals-for-151m-gaining-global-rights-to-ztalmy-and-leveraging-expansion-into-north-america/ 2024-12-30 https://bio-research.ai/axsome-therapeutics-accord-2-trial-of-axs-05-shows-delay-in-alzheimer-s-disease-agitation-relapse-advance-2-study-results-non-significant/ 2024-12-30 https://bio-research.ai/chimerix-submits-dordaviprone-application-to-fda-for-recurrent-diffuse-glioma-treatment/ 2024-12-30 https://bio-research.ai/huadong-medicine-and-synerk-pharmatech-partner-to-develop-hypertension-drug-snk-2726-huadong-granted-exclusive-rights-in-greater-china/ 2024-12-30 https://bio-research.ai/european-commission-approves-rybrevant-and-lazcluze-combo-for-first-line-treatment-of-advanced-nsclc-with-egfr-mutations-following-mariposa-study-results/ 2024-12-30 https://bio-research.ai/intrathecal-gene-therapy-oav101-shows-significant-improvements-in-hfmse-scores-in-phase-iii-sma-study/ 2024-12-30 https://bio-research.ai/carsgen-therapeutics-reports-a-significant-improvement-in-pfs-in-phase-ii-trial-of-satricabtagene-autoleucel-infusion-for-advanced-gastric-cancers/ 2024-12-30 https://bio-research.ai/ideaya-biosciences-licenses-dll3-targeting-antibody-drug-shr-4849-to-jiangsu-hengrui-pharmaceuticals-in-deal-worth-up-to-1-045b/ 2024-12-29 https://bio-research.ai/nippon-shinyaku-receives-supplemental-approval-for-uptravi-tablets-in-japan-for-pediatric-pulmonary-arterial-hypertension-treatment/ 2024-12-27 https://bio-research.ai/pdradiopharma-gets-approval-from-japan-s-ministry-for-tauvid-and-donanemab-use-in-alzheimer-s-disease-patients/ 2024-12-27 https://bio-research.ai/eli-lilly-japan-obtain-authorization-for-zepbound-in-japan-for-obesity-treatment-based-on-surmount-j-study-results/ 2024-12-27 https://bio-research.ai/chugai-pharmaceutical-gets-supplementary-approval-for-lunsumio-in-treating-relapsed-follicular-lymphoma-after-two-previous-therapies-in-japan/ 2024-12-27 https://bio-research.ai/daiichi-sankyo-s-datroway-gains-approval-in-japan-for-specific-breast-cancer-treatment-following-tropion-breast01-phase-3-trial-results/ 2024-12-27 https://bio-research.ai/tevimbra-combined-with-chemotherapy-receives-second-fda-approval-for-advanced-gastric-and-gastroesophageal-junction-cancers/ 2024-12-27 https://bio-research.ai/ono-pharmaceutical-gains-supplemental-approval-for-opdivo-in-combined-urothelial-carcinoma-treatment-in-japan-after-successful-phase-3-trial/ 2024-12-27 https://bio-research.ai/japan-approves-supplemental-application-of-vyvdura-in-adults-with-cidp-based-on-adhere-study-results/ 2024-12-27 https://bio-research.ai/takeda-s-hyqvia-gets-approval-in-japan-for-agammaglobulinemia-and-hypogammaglobulinemia/ 2024-12-27 https://bio-research.ai/ausperbio-secures-usd-73-million-in-series-b-funding-round-for-phase-2-development-of-chronic-hepatitis-b-therapy-ahb-137/ 2024-12-26 https://bio-research.ai/hoth-therapeutics-acquires-exclusive-patent-license-from-u-s-department-of-veterans-affairs-and-emory-university-for-innovative-obesity-treatment-technology/ 2024-12-26 https://bio-research.ai/assembly-biosciences-reports-significant-antiviral-activity-in-phase-1b-study-of-abi-4334-for-chronic-hepatitis-b/ 2024-12-26 https://bio-research.ai/johnson-johnson-gains-exclusive-global-license-for-kaken-pharmaceutical-s-stat6-program/ 2024-12-26 https://bio-research.ai/qilu-pharmaceutical-s-phase-i-preliminary-results-demonstrates-anti-tumor-activity-and-tolerance-of-qls32015-in-patients-with-relapsed-refractory-multiple-myeloma/ 2024-12-25 https://bio-research.ai/jcr-pharmaceuticals-jr-441-receives-orphan-drug-designation-from-japan-s-mhlw-for-mucopolysaccharidosis-type-iiia-treatment-following-similar-designations-in-europe-and-us/ 2024-12-25 https://bio-research.ai/achilles-therapeutics-sells-tracerx-nsclc-study-license-and-map-to-astrazeneca-for-12m-astrazeneca-to-sponsor-map/ 2024-12-24 https://bio-research.ai/bio-thera-solutions-partners-with-tabuk-pharmaceutical-to-commercialize-bat2206-in-saudi-arabia-under-astra-industrial-group-s-subsidiary-s-exclusive-distribution-rights/ 2024-12-24 https://bio-research.ai/alfresa-group-invests-in-kortuc-for-clinical-trials-of-cancer-radiosensitizer-securing-exclusive-negotiation-rights-for-distribution-in-japan/ 2024-12-24 https://bio-research.ai/glyconex-licenses-denosumab-biosimilar-spd8-for-development-regulatory-approval-and-commercialization/ 2024-12-24 https://bio-research.ai/daiichi-sankyo-and-astrazeneca-withdrawal-eu-application-for-datopotamab-deruxtecan-continue-development-for-lung-cancer-treatment/ 2024-12-24 https://bio-research.ai/tiumbio-co-concludes-phase-1a-clinical-trial-of-hemophilia-treatment-tu7710-with-high-safety-and-prolonged-half-life/ 2024-12-24 https://bio-research.ai/fda-approves-gemtesa-for-men-with-overactive-bladder-symptoms-already-receiving-benign-prostatic-hyperplasia-therapy/ 2024-12-24 https://bio-research.ai/corxel-pharmaceuticals-acquires-cardiometabolic-drug-cx11-from-vincentage-aims-for-global-phase-2-trials-in-2025/ 2024-12-23 https://bio-research.ai/neutrolis-inc-signs-exclusive-licensing-agreement-with-the-university-of-illinois-chicago-for-the-development-of-dry-eye-disease-treatment/ 2024-12-23 https://bio-research.ai/60-degrees-pharmaceuticals-and-tufts-medical-center-partner-to-develop-and-commercialize-tafenoquine-for-babesiosis-treatment/ 2024-12-23 https://bio-research.ai/ikena-oncology-inmagene-biopharmaceuticals-merge-for-development-of-img-007-with-75m-syndicated-private-placement-raising-175m-for-drug-s-progress/ 2024-12-23 https://bio-research.ai/gemma-biotherapeutics-obtains-34-million-in-seed-funding-for-gene-therapy-programs-and-growth-support/ 2024-12-23 https://bio-research.ai/ec-approves-opdivo-and-yervoy-for-first-line-treatment-of-specific-types-of-colorectal-cancer-based-on-checkmate-8hw-trial-results/ 2024-12-23 https://bio-research.ai/fda-accepts-nuvation-bio-s-nda-for-taletrectinib-sets-target-action-date-for-june-2025/ 2024-12-23 https://bio-research.ai/rapt-therapeutics-and-shanghai-jemincare-pharmaceutical-strike-a-707-5m-deal-for-rpt904-drug-development-rapt-gains-global-rights-excluding-china-and-taiwan/ 2024-12-23 https://bio-research.ai/bristol-myers-squibb-s-phase-3-trials-of-sotyktu-meet-primary-endpoint-in-adults-with-active-psoriatic-arthritis-after-16-weeks-of-treatment/ 2024-12-23 https://bio-research.ai/astrazeneca-s-tagrisso-secures-eu-approval-for-treatment-of-non-small-cell-lung-cancer-based-on-laura-phase-iii-trial-outcomes/ 2024-12-23 https://bio-research.ai/rznomics-inc-secures-20-3-billion-krw-in-pre-ipo-funding-advances-rna-editing-research/ 2024-12-23 https://bio-research.ai/sanofi-and-sk-bioscience-expand-partnership-with-50m-deal-to-co-develop-next-generation-pneumococcal-vaccines-launch-phase-3-trials-for-gbp410/ 2024-12-23 https://bio-research.ai/yoltech-therapeutics-advances-to-dose-expansion-phase-in-yolt-201-clinical-trial-for-attr-amyloidosis-after-showing-over-90-ttr-protein-reduction/ 2024-12-21 https://bio-research.ai/fda-approves-alhemo-a-subcutaneous-injection-for-hemophilia-a-or-b-results-in-reduced-bleeds-in-clinical-trials/ 2024-12-20 https://bio-research.ai/lexicon-pharmaceuticals-discontinues-zynquista-launch-shifts-focus-to-development-of-lx9211-for-diabetic-neuropathic-pain/ 2024-12-20 https://bio-research.ai/fda-approves-eli-lilly-s-zepbound-for-adults-with-obstructive-sleep-apnea-and-obesity-based-on-surmount-osa-phase-3-clinical-trials-results/ 2024-12-20 https://bio-research.ai/fda-approves-vertex-s-alyftrek-for-cystic-fibrosis-treatment-in-patients-6-years-and-older-following-global-phase-3-trial/ 2024-12-20 https://bio-research.ai/grifols-reports-phase-3-clinical-trial-results-of-albutein-in-decompensated-cirrhosis-patients-misses-primary-endpoint-but-notes-other-improvements/ 2024-12-20 https://bio-research.ai/fda-grants-approval-for-rhythm-pharmaceuticals-imcivree-in-treating-obesity-in-children-with-bardet-biedl-syndrome-other-genetic-deficiencies/ 2024-12-20 https://bio-research.ai/innovent-biologics-receives-nmpa-approval-for-dovbleron-in-treating-advanced-ros1-positive-non-small-cell-lung-cancer-following-phase-2-trial-success/ 2024-12-20 https://bio-research.ai/oncodesign-regains-full-control-over-opm-201-parkinson-s-program-from-servier-after-phase-i-trial-seeks-new-partner-for-future-phases/ 2024-12-20 https://bio-research.ai/oncolys-biopharma-grants-taiwan-sales-rights-to-medigen-biotechnology-for-oncolytic-virus-obp-301-with-no-upfront-payment/ 2024-12-20 https://bio-research.ai/novo-nordisk-s-phase-3-redefine-1-trial-reports-significant-weight-loss-with-cagrisema-in-over-3-400-obese-and-overweight-participants/ 2024-12-20 https://bio-research.ai/fresenius-kabi-to-commercialize-samchundang-pharm-s-aflibercept-biosimilar-in-us-and-latin-america-upon-regulatory-approval/ 2024-12-20 https://bio-research.ai/gsk-s-phase-iii-trial-shows-significant-progression-free-survival-increase-with-zejula-and-jemperli-in-advanced-ovarian-cancer-treatment/ 2024-12-20 https://bio-research.ai/sanofi-acquires-rights-to-develop-corxel-s-aficamten-in-china/ 2024-12-20 https://bio-research.ai/hlb-innovation-acquires-verismo-therapeutics-fortifying-presence-in-solid-tumor-field-with-kir-car-technology/ 2024-12-20 https://bio-research.ai/aadi-bioscience-enters-100-million-agreement-to-sell-fyarro-and-related-assets-to-kaken-pharmaceutical/ 2024-12-19 https://bio-research.ai/drug-farm-and-niaid-ink-agreement-for-clinical-trial-of-novel-rosah-drug-df-003-a-highly-selective-alpk1-inhibitor/ 2024-12-19 https://bio-research.ai/epitopea-and-genevant-sciences-enter-partnership-to-develop-mrna-lnp-immunotherapies-genevant-eligible-for-payments-up-to-123-5m/ 2024-12-19 https://bio-research.ai/aadi-bioscience-enters-849m-contract-with-wuxi-biologics-and-hangzhou-dac/ 2024-12-19 https://bio-research.ai/omeros-corporation-s-narsoplimab-meets-primary-endpoint-in-pivotal-ta-tma-trial-plans-to-resubmit-bla-to-fda/ 2024-12-19 https://bio-research.ai/marker-therapeutics-reports-78-measurable-responses-in-phase-1-apollo-study-of-lymphoma-treatment-mt-601/ 2024-12-19 https://bio-research.ai/immix-biopharma-s-nxc-201-normalizes-disease-markers-in-al-amyloidosis-patients-in-nexicart-2-trial-within-30-days/ 2024-12-19 https://bio-research.ai/tolerance-bio-completes-20-2-million-seed-financing-develops-thymus-cell-therapy-platform-for-immune-mediated-diseases/ 2024-12-19 https://bio-research.ai/xentria-secures-exclusive-worldwide-license-from-nyu-for-development-and-commercialization-of-therapeutic-formulation-gl-12/ 2024-12-19 https://bio-research.ai/gilead-sciences-boosts-ownership-in-assembly-bio-to-29-9-with-30-1m-investment-aids-development-of-hepatitis-d-virus-candidate-abi-6250/ 2024-12-19 https://bio-research.ai/hervolution-therapeutics-secures-11-7-million-in-series-a-funding-for-clinical-evaluation-of-herv-targeted-immunotherapies/ 2024-12-19 https://bio-research.ai/merck-s-dor-isl-phase-3-trials-meet-safety-objectives-and-demonstrate-non-inferiority-in-adults-with-hiv-1-infection/ 2024-12-19 https://bio-research.ai/ngm-biopharmaceuticals-licenses-phase-2-ready-fgfr1c-klotho-agonist-to-kdt-ventures-newco-for-608m-in-potential-payments-equity-and-royalties/ 2024-12-19 https://bio-research.ai/afyx-therapeutics-secures-dkk-25-million-funding-to-advance-development-of-clobetasol-patch-and-esketamine-therapy/ 2024-12-19 https://bio-research.ai/palleon-pharmaceuticals-and-shanghai-henlius-biotech-ink-95-3m-deal-to-develop-and-market-e-602-and-hanlikang-for-autoimmune-diseases-in-china/ 2024-12-19 https://bio-research.ai/umecrine-cognition-secures-sek-23-8-million-to-fund-clinical-study-of-golexanolone-in-primary-biliary-cholangitis/ 2024-12-19 https://bio-research.ai/vertex-pharmaceuticals-phase-2-study-of-suzetrigine-shows-no-significant-difference-from-placebo-in-pain-reduction/ 2024-12-19 https://bio-research.ai/certa-therapeutics-acquires-occurx-adding-ocx063-to-pipeline-after-successful-phase-1-trial-seeks-series-b-funding-for-22m-development-plan/ 2024-12-19 https://bio-research.ai/ottimo-pharma-secures-over-140-million-in-series-a-financing-with-pd1-vegfr2-ab/ 2024-12-19 https://bio-research.ai/astellas-pharma-and-sangamo-therapeutics-ink-1-32b-deal-for-potential-neurological-disease-treatments-using-aav-capsid-technology/ 2024-12-19 https://bio-research.ai/bioarctic-pens-100m-upfront-deal-with-bristol-myers-squibb-for-pyroglu-a-antibody-program-with-potential-milestones-up-to-1-25b/ 2024-12-19 https://bio-research.ai/fda-approves-xcovery-s-ensartinib-for-alk-positive-advanced-or-metastatic-nsclc-based-on-phase-iii-exalt3-trial-results/ 2024-12-18 https://bio-research.ai/fda-approves-ryoncil-as-first-msc-therapy-for-sr-agvhd-in-pediatric-patients-phase-3-trial-shows-70-response-rate/ 2024-12-18 https://bio-research.ai/bioage-labs-and-novartis-embark-on-multi-year-research-collaboration-securing-up-to-550m-deal-for-aging-related-drug-targets-discovery/ 2024-12-18 https://bio-research.ai/circio-holding-raises-nok-10-7-million-for-circvec-development-and-cell-therapy-approach-delaying-atlas-convertible-bond-tranche/ 2024-12-18 https://bio-research.ai/abilita-therapeutics-partners-with-orion-corporation-for-the-discovery-of-oncology-and-pain-therapeutics-potential-deal-worth-up-to-785m/ 2024-12-18 https://bio-research.ai/inceptor-bio-and-grit-bio-form-strategic-partnership-for-clinical-development-of-car-t-therapy-ib-t101-in-china/ 2024-12-18 https://bio-research.ai/cognition-therapeutics-phase-2-shimmer-study-demonstrates-safety-and-tolerability-of-ct1812-for-dementia-with-lewy-bodies-patients-over-six-months/ 2024-12-18 https://bio-research.ai/photys-therapeutics-and-novo-nordisk-partner-to-develop-cardiometabolic-disease-therapeutics-deal-worth-up-to-186m/ 2024-12-18 https://bio-research.ai/verastem-oncology-s-ramp-203-phase-1-2-study-reports-no-dose-limiting-toxicities-in-avutometinib-sotorasib-and-defactinib-combination-for-kras-g12c-mutant-nsclc/ 2024-12-18 https://bio-research.ai/cara-and-tvardi-therapeutics-to-merge-and-develop-novel-stat3-inhibitor-treatments/ 2024-12-18 https://bio-research.ai/siteone-therapeutics-secures-100-million-financing-to-advance-sensory-hyperexcitability-disorder-treatments/ 2024-12-18 https://bio-research.ai/merck-and-hansoh-pharma-strike-a-112m-upfront-deal-with-potential-1-9b-in-milestones-for-global-hs-10535-license-agreement/ 2024-12-18 https://bio-research.ai/alk-advances-peanut-allergy-treatment-tablet-to-phase-ii-following-satisfactory-phase-i-ii-safety-results/ 2024-12-18 https://bio-research.ai/european-commission-grants-orphan-medicinal-product-designation-to-agios-pharmaceuticals-mitapivat-for-sickle-cell-disease-treatment/ 2024-12-18 https://bio-research.ai/corestemchemon-s-phase-3-clinical-trial-fails-to-achieve-primary-endpoint-for-neuronata-r-injection-in-als-patients-over-12-months/ 2024-12-18 https://bio-research.ai/fda-grants-orphan-drug-designation-to-medilink-s-yl201-for-small-cell-lung-cancer-treatment/ 2024-12-18 https://bio-research.ai/aurion-biotech-s-phase-1-2-trial-of-aurn001-shows-significant-improvement-in-corneal-edema-treatment-with-no-serious-ocular-adverse-events-reported/ 2024-12-17 https://bio-research.ai/theranexus-and-exeltis-ink-eur-2m-deal-for-tx01-targeting-gaucher-and-niemann-pick-type-c-diseases-with-potential-for-additional-milestone-payments/ 2024-12-17 https://bio-research.ai/fda-approves-celltrion-s-steqeyma-for-adult-and-pediatric-plaque-psoriasis-others-based-on-phase-iii-study-results/ 2024-12-17 https://bio-research.ai/eli-lilly-s-kisunla-approved-in-china-for-early-symptomatic-alzheimer-s-patients-based-on-trailblazer-alz-2-phase-3-clinical-study-results/ 2024-12-17 https://bio-research.ai/hansa-biopharma-s-phase-2-trial-of-imlifidase-shows-improvement-in-gbs-patients-accelerates-return-to-independent-walking-by-six-weeks/ 2024-12-17 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-gilead-s-trodelvy-following-tropics-03-study-results/ 2024-12-17 https://bio-research.ai/silexion-therapeutics-and-evonik-collaborate-on-advanced-sirna-formulation-sil-204-targeting-kras-mutations-in-cancer-treatment/ 2024-12-17 https://bio-research.ai/biomea-fusion-reports-significant-reduction-in-hba1c-in-diabetes-patients-through-26-week-covalent-111-study-using-icovamenib/ 2024-12-17 https://bio-research.ai/milliporesigma-to-acquire-hub-organoids-holding-b-v-solidifying-position-in-cell-culture-portfolio-and-advancing-drug-development/ 2024-12-17 https://bio-research.ai/actuate-therapeutics-reports-increased-survival-rates-in-phase-2-trial-of-elraglusib-with-gnp-in-metastatic-pancreatic-ductal-adenocarcinoma/ 2024-12-17 https://bio-research.ai/fda-fast-tracks-lipocine-s-lpcn-1148-for-sarcopenia-in-patients-with-decompensated-cirrhosis/ 2024-12-17 https://bio-research.ai/gilead-sciences-and-terray-therapeutics-form-strategic-partnership-for-ai-driven-drug-discovery-using-tnova-platform/ 2024-12-17 https://bio-research.ai/sanofi-and-teva-s-phase-2b-relieve-uccd-study-of-duvakitug-meets-primary-endpoints-in-ulcerative-colitis-and-crohn-s-disease-patients/ 2024-12-17 https://bio-research.ai/akamis-bio-partners-with-xuanzhu-biopharma-for-the-licensing-of-oncology-candidate-ng-350a-in-greater-china/ 2024-12-17 https://bio-research.ai/fda-accepts-merck-s-biologics-license-application-for-clesrovimab-long-acting-monoclonal-antibody-for-rsv-disease-prevention-in-infants/ 2024-12-17 https://bio-research.ai/akamis-bio-secures-60-million-in-series-a-prime-financing-and-strategic-partnership-for-ng-350a-clinical-trials-in-advanced-rectal-cancer/ 2024-12-17 https://bio-research.ai/regeneron-s-phase-3-trial-of-eylea-hd-injection-for-retinal-vein-occlusion-related-macular-edema-meets-primary-endpoint/ 2024-12-17 https://bio-research.ai/eyedna-therapeutics-hora-pde6b-therapy-for-inherited-retinal-dystrophy-earns-rare-pediatric-disease-designation-from-us-fda/ 2024-12-17 https://bio-research.ai/orexo-ab-and-abera-bioscience-collaborate-to-develop-intranasal-vaccines-using-amorphox-technology-and-funding-from-cepi/ 2024-12-17 https://bio-research.ai/sk-biopharmaceuticals-and-proen-therapeutics-collaborate-to-develop-radiopharmaceutical-candidates-using-artbody-platform-by-2027/ 2024-12-17 https://bio-research.ai/ucb-s-orchestra-study-of-minzasolmin-fails-to-meet-primary-and-secondary-endpoints-in-early-parkinson-s-disease-trials/ 2024-12-16 https://bio-research.ai/concinnity-genetics-secures-3m-funding-to-advance-gene-control-systems-development-for-cell-and-gene-therapy-market/ 2024-12-16 https://bio-research.ai/scailyte-and-visterra-collaborate-to-use-ai-in-accelerating-development-of-autoimmune-disease-treatments/ 2024-12-16 https://bio-research.ai/nona-biosciences-and-candid-therapeutics-collaborate-on-320m-agreement-for-t-cell-engagers-discovery-in-autoimmune-diseases/ 2024-12-16 https://bio-research.ai/candid-therapeutics-teams-up-with-epimab-biotherapeutics-in-1b-deal-to-develop-t-cell-engager-program-candidates/ 2024-12-16 https://bio-research.ai/innoviva-and-basilea-pharmaceutica-enter-into-4m-agreement-for-commercialization-of-mrsa-treatment-zevtera-in-the-us/ 2024-12-16 https://bio-research.ai/viridian-therapeutics-thrive-2-phase-3-trial-for-veligrotug-meets-all-endpoints-in-chronic-thyroid-eye-disease-with-a-56-proptosis-responder-rate-at-week-15/ 2024-12-16 https://bio-research.ai/foghorn-therapeutics-stops-development-of-leukemia-drug-fhd-286-shifts-focus-to-smarca2-inhibitor-fhd-909/ 2024-12-16 https://bio-research.ai/mochida-pharmaceutical-grants-kuhnil-pharm-exclusive-rights-for-development-and-marketing-of-epadel-in-south-korea/ 2024-12-16 https://bio-research.ai/menarini-and-newamsterdam-report-phase-3-broadway-and-tandem-results-with-obicetrapib-achieving-33-ldl-c-reduction-and-combo-with-ezetimibe-48-6/ 2024-12-16 https://bio-research.ai/edgewise-therapeutics-reports-primary-endpoint-met-with-28-reduction-in-ck-levels-in-phase-2-canyon-trial-for-becker-muscular-dystrophy/ 2024-12-16 https://bio-research.ai/promise-bio-secures-8-3-million-seed-investment-for-computational-platform-development-in-drug-research/ 2024-12-16 https://bio-research.ai/bavarian-nordic-and-serum-institute-of-india-strike-licensing-and-manufacturing-agreement-for-mva-bn-mpox-vaccine/ 2024-12-16 https://bio-research.ai/innovent-biologics-to-handle-commercialization-of-eli-lilly-s-cancer-drug-jaypirca-in-mainland-china-following-new-agreement/ 2024-12-15 https://bio-research.ai/kyorin-secures-global-rights-for-bayer-s-obstructive-sleep-apnea-treatment-bay2925976-in-15m-deal-with-up-to-70m-in-potential-milestones/ 2024-12-13 https://bio-research.ai/abbvie-to-acquire-nimble-therapeutics-for-200m-gaining-oral-peptide-il23r-inhibitor-and-peptide-synthesis-platform/ 2024-12-13 https://bio-research.ai/incyclix-bio-releases-interim-results-from-phase-1-2-trial-of-inx-315-for-cdk4-6-inhibitor-resistant-cancer/ 2024-12-13 https://bio-research.ai/merck-s-welireg-recommended-by-european-medicines-agency-s-chmp-for-conditional-approval-in-treating-vhl-disease-and-rcc-based-on-phase-2-and-3-trial-data/ 2024-12-13 https://bio-research.ai/akeso-s-phase-iii-harmoni-a-study-shows-ivonescimab-reduces-disease-progression-or-death-risk-by-56-in-nsclc-patients/ 2024-12-13 https://bio-research.ai/chmp-recommends-acoramidis-for-marketing-authorization-in-eu-for-attr-cm-treatment/ 2024-12-13 https://bio-research.ai/geron-corporation-s-rytelo-recommended-for-approval-by-ema-s-committee-for-treatment-of-specific-transfusion-dependent-anemia-types/ 2024-12-13 https://bio-research.ai/gilead-sciences-seladelpar-receives-european-medicines-agency-committee-recommendation-for-primary-biliary-cholangitis-treatment-following-fda-endorsement/ 2024-12-13 https://bio-research.ai/dx-vx-licenses-ovm-200-from-oxford-vacmedix-for-development-and-commercialisation-in-asia-oxford-to-receive-milestone-payments-and-royalties/ 2024-12-13 https://bio-research.ai/ea-pharma-strikes-117m-licensing-deal-with-newron-for-schizophrenia-drug-evenamide-in-japan-and-selected-asian-markets/ 2024-12-13 https://bio-research.ai/ema-approves-vabysmo-for-the-treatment-of-various-vision-loss-conditions-following-us-fda-approval-in-july-2024/ 2024-12-13 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-tolebrutinib-for-secondary-progressive-multiple-sclerosis-treatment-based-on-hercules-phase-3-study-results/ 2024-12-13 https://bio-research.ai/chmp-endorses-nemolizumab-for-atopic-dermatitis-and-prurigo-nodularis-treatments-following-successful-phase-iii-trials/ 2024-12-13 https://bio-research.ai/alphamab-oncology-reports-phase-ii-clinical-study-results-for-kn046-axitinib-combination-in-advanced-nsclc-treatment/ 2024-12-13 https://bio-research.ai/remegen-s-phase-iii-study-shows-disitamab-vedotin-improves-progression-free-survival-in-her2-positive-advanced-breast-cancer-patients-with-liver-metastasis/ 2024-12-12 https://bio-research.ai/beigene-lands-150m-global-licensing-deal-with-cspc-for-syh2039-a-mat2a-inhibitor-targeting-mtap-deleted-solid-tumors/ 2024-12-12 https://bio-research.ai/vir-biotechnology-gets-fda-breakthrough-therapy-ema-prime-designation-for-tobevibart-and-elebsiran-in-chronic-hepatitis-delta-treatment/ 2024-12-12 https://bio-research.ai/bicycle-therapeutics-reveals-data-on-zelenectide-pevedotin-efficacy-in-breast-cancer-trials-and-combative-action-in-metastatic-urothelial-and-lung-cancer/ 2024-12-12 https://bio-research.ai/ema-recommends-label-update-for-novo-nordisk-s-ozempic-after-positive-kidney-disease-trial-results/ 2024-12-12 https://bio-research.ai/pfizer-announces-improved-progression-free-survival-in-breast-cancer-patients-with-ibrance-phase-3-patina-trial-results/ 2024-12-12 https://bio-research.ai/turn-therapeutics-secures-75-million-investment-from-gem-global-for-further-healthcare-research/ 2024-12-12 https://bio-research.ai/general-inception-acquires-enable-medicine-to-boost-drug-discovery-by-leveraging-ai-powered-biological-data-platform/ 2024-12-12 https://bio-research.ai/elevation-oncology-licenses-synaffix-s-adc-technology-for-368m-plans-development-of-her3-candidate-eo-1022/ 2024-12-12 https://bio-research.ai/esperion-therapeutics-licenses-nexletol-and-nexlizet-to-neopharm-israel-getting-upfront-and-milestone-payments/ 2024-12-12 https://bio-research.ai/dewpoint-therapeutics-partners-with-concertai-on-phase-1-of-translational-oncology-for-dptx3186-development-raising-287m-and-230m-respectively/ 2024-12-12 https://bio-research.ai/blue-lake-biotechnology-s-blb201-intranasal-vaccine-shows-over-80-reduction-in-symptomatic-rsv-infections-in-phase-1-2a-study/ 2024-12-12 https://bio-research.ai/neurimmune-and-aicura-medical-team-up-to-leverage-ai-for-alzheimer-s-drug-development/ 2024-12-12 https://bio-research.ai/keros-therapeutics-pauses-tropos-phase-2-clinical-trial-of-cibotercept-for-pah-due-to-unanticipated-adverse-events/ 2024-12-12 https://bio-research.ai/neuraxpharm-partners-with-pharmathen-to-develop-and-distribute-long-acting-treatments-for-cns-disorders/ 2024-12-12 https://bio-research.ai/daewoong-pharmaceutical-allies-with-tiolab-therapeutics-daehannupharm-and-dalim-biotech-for-4-week-long-acting-obesity-treatment-eyeing-phase-1-clinical-trials-next-year/ 2024-12-12 https://bio-research.ai/corcept-therapeutics-phase-2-dazals-trial-fails-to-meet-primary-endpoint-observation-of-gastrointestinal-upsets-increase-in-dazucorilant-patients/ 2024-12-11 https://bio-research.ai/okogen-secures-3-3-million-funding-to-aid-completion-of-phase-2b-clinical-program-for-conjunctivitis-treatment-and-development-of-ai-driven-image-based-evaluation-platform/ 2024-12-11 https://bio-research.ai/anaptysbio-halts-investment-in-anb032-after-failing-primary-and-secondary-endpoints-in-atopic-dermatitis-global-trial/ 2024-12-11 https://bio-research.ai/lentiviral-gene-therapy-achieves-zero-annual-bleeding-events-in-hemophilia-a-patients-with-undetectable-to-therapeutic-factor-viii-levels-in-phase-1-trial-of-et3-for-hemophilia-a/ 2024-12-11 https://bio-research.ai/eli-lilly-s-phase-3-ember-3-trial-shows-imlunestrant-improves-progression-free-survival-in-advanced-breast-cancer/ 2024-12-11 https://bio-research.ai/meitheal-pharmaceuticals-lands-exclusive-us-rights-for-antibiotic-xenleta-through-300m-agreement-with-hong-kong-king-friend-industrial-co-and-nabriva-therapeutics/ 2024-12-11 https://bio-research.ai/arrowhead-pharmaceuticals-reports-up-to-90-reduction-in-cfb-protein-with-aro-cfb-in-phase-1-2a-study/ 2024-12-11 https://bio-research.ai/chroma-medicine-merges-with-nvelop-therapeutics-to-form-nchroma-bio-seals-75m-financing-for-crma-1001-lead-program/ 2024-12-11 https://bio-research.ai/polypid-and-immunogenesis-collaborate-to-develop-novel-formulations-targeting-solid-tumors-with-plex-and-sting-technologies/ 2024-12-11 https://bio-research.ai/candel-therapeutics-reports-improved-disease-free-survival-in-phase-3-trial-of-can-2409-for-localized-prostate-cancer/ 2024-12-11 https://bio-research.ai/tc-biopharm-collaborates-with-caredx-for-phase-ii-achieve-trial-assessing-tcb008-in-acute-myeloid-leukemia-patients/ 2024-12-11 https://bio-research.ai/santhera-pharmaceuticals-agamree-receives-approval-from-nmpa-for-duchenne-muscular-dystrophy-treatment-in-china/ 2024-12-11 https://bio-research.ai/fda-grants-fast-track-designation-to-sanofi-s-dual-vaccines-for-individuals-aged-50-and-over-undergoing-phase-1-2-trials/ 2024-12-11 https://bio-research.ai/pharming-group-completes-phase-iii-trial-of-lleniolisib-in-pediatric-apds-patients-plans-for-2025-regulatory-filings/ 2024-12-11 https://bio-research.ai/noema-pharma-secures-chf-130-million-in-series-b-funding-for-ongoing-phase-2-clinical-trials/ 2024-12-11 https://bio-research.ai/tasca-therapeutics-secures-52-million-for-drug-discovery-platform-and-to-advance-cp-383-into-phase-1-2-clinical-trials/ 2024-12-10 https://bio-research.ai/acelyrin-suspends-izokibep-development-for-uveitis-after-failed-phase-2b-3-trial/ 2024-12-10 https://bio-research.ai/moberg-pharma-s-mob-015-fails-to-meet-primary-endpoint-in-phase-3-north-american-study/ 2024-12-10 https://bio-research.ai/cervomed-inc-halts-phase-3-trial-preparations-for-neflamapimod-in-dlb-treatment-following-unmet-endpoints-in-phase-2b/ 2024-12-10 https://bio-research.ai/orthogon-therapeutics-raises-25m-in-funding-to-further-research-on-antivirals-for-bk-virus-in-transplant-patients/ 2024-12-10 https://bio-research.ai/novo-nordisk-invests-in-eikonizo-therapeutics-for-development-of-hdac6-inhibitors-and-ekz-102-first-in-human-clinical-study-slated-for-2025/ 2024-12-10 https://bio-research.ai/newamsterdam-pharma-s-phase-3-trial-finds-obicetrapib-reduces-ldl-c-levels-for-cardiovascular-disease-risk-patients/ 2024-12-10 https://bio-research.ai/gsk-and-relation-ink-45m-upfront-deal-for-fibrotic-and-osteoarthritis-therapies-with-potential-earn-outs-averaging-200m-per-target/ 2024-12-10 https://bio-research.ai/evariste-joins-hands-with-orion-corporation-for-preclinical-research-to-design-therapeutics-using-ai-and-math/ 2024-12-10 https://bio-research.ai/aqemia-secures-38-million-investment-from-cathay-innovation-for-clinical-trials-preparation-and-drug-discovery-platform-enhancement/ 2024-12-10 https://bio-research.ai/ahn-gook-pharmaceuticals-forms-strategic-partnership-with-apitbio-for-new-antibody-based-drug-development/ 2024-12-10 https://bio-research.ai/nona-biosciences-and-kodiak-sciences-collaborate-for-discovery-of-ophthalmic-disease-treatments-using-harbour-mice-technology/ 2024-12-09 https://bio-research.ai/celltrion-s-omlyclo-gets-health-canada-approval-as-first-omalizumab-biosimilar-for-treating-chronic-idiopathic-urticaria-allergic-asthma-chronic-rhinosinusitis-with-nasal-polyps/ 2024-12-09 https://bio-research.ai/cimeio-therapeutics-and-kyowa-kirin-ink-research-collaboration-worth-up-to-300m-for-new-disease-therapies-development/ 2024-12-09 https://bio-research.ai/eli-lilly-s-phase-3-trial-of-pirtobrutinib-shows-46-reduction-in-risk-of-relapse-disease-progression-or-death-in-cll-patients/ 2024-12-09 https://bio-research.ai/gsk-s-dreamm-7-trial-shows-42-reduction-in-death-risk-with-bvd-combination-for-multiple-myeloma-treatment/ 2024-12-09 https://bio-research.ai/tnf-pharmaceuticals-reports-decrease-in-inflammation-biomarkers-in-phase-2a-sarcopenia-trial-of-mymd-1-plans-phase-2b-study-for-2025/ 2024-12-09 https://bio-research.ai/cantex-pharmaceuticals-receives-fda-orphan-drug-designation-for-azeliragon-in-treating-brain-metastasis-from-breast-cancer/ 2024-12-09 https://bio-research.ai/secura-bio-reveals-48-overall-response-rate-in-phase-2-primo-clinical-trial-of-duvelisib-for-t-cell-lymphoma-patients/ 2024-12-09 https://bio-research.ai/johnson-johnson-gains-control-of-mestag-s-novel-target-part-of-multi-year-agreement-with-potential-for-future-payments/ 2024-12-09 https://bio-research.ai/abbvie-s-phase-3-trial-of-tavapadon-shows-statistically-significant-improvements-in-early-parkinson-s-disease-treatment/ 2024-12-09 https://bio-research.ai/kura-oncology-and-kyowa-kirin-announce-high-complete-remission-rate-in-phase-1-aml-trial-of-ziftomenib/ 2024-12-09 https://bio-research.ai/enanta-pharmaceuticals-reports-phase-2-study-results-zelicapavir-shows-antiviral-effect-and-safety-in-treating-respiratory-syncytial-virus/ 2024-12-09 https://bio-research.ai/formycon-and-ms-pharma-ink-deal-to-commercialize-fyb202-biosimilar-in-middle-east-and-north-africa/ 2024-12-09 https://bio-research.ai/citryll-secures-eur-85-million-series-b-for-clinical-development-of-cit-013-phase-2a-trials-for-rheumatoid-arthritis-and-hidradenitis-suppurativa-planned/ 2024-12-09 https://bio-research.ai/vivoryon-therapeutics-phase-2-viva-mind-study-with-varoglutamstat-halts-early-fails-to-meet-primary-and-secondary-endpoints-reports-improved-kidney-function/ 2024-12-09 https://bio-research.ai/fivephusion-secures-exclusive-option-to-acquire-uow-s-next-gen-drug-delivery-platform-resectassist-targeting-4b-pancreatic-cancer-treatment-market/ 2024-12-09 https://bio-research.ai/sanofi-s-phase-3-luna-3-study-reports-65-platelet-response-with-rilzabrutinib-in-chronic-itp-patients/ 2024-12-07 https://bio-research.ai/novo-nordisk-releases-52-week-phase-2-results-on-etavopivat-for-sickle-cell-disease-observes-hemoglobin-increase-at-week-24/ 2024-12-07 https://bio-research.ai/bioage-labs-halts-phase-2-study-of-azelaprag-due-to-liver-transaminitis-set-to-re-evaluate-data-and-progress-nlrp3-inhibitor-program/ 2024-12-06 https://bio-research.ai/indapta-therapeutics-and-sanofi-collaborate-to-evaluate-idp-023-and-sarclisa-combination-for-relapsed-refractory-multiple-myeloma-treatment-in-amended-phase-1-study/ 2024-12-06 https://bio-research.ai/novartis-appulse-pnh-study-shows-fabhalta-improves-hemoglobin-levels-in-pnh-patients-after-24-weeks-of-treatment/ 2024-12-06 https://bio-research.ai/daiichi-sankyo-and-astrazeneca-s-trop2-directed-adc-shows-42-7-response-rate-in-phase-2-and-3-trials-for-egfr-mutated-non-small-cell-lung-cancer/ 2024-12-05 https://bio-research.ai/duality-biologics-and-biontech-s-clinical-trial-reveals-70-4-response-rate-in-sclc-patients-treated-with-bnt324-db-1311/ 2024-12-05 https://bio-research.ai/teva-pharmaceutical-to-sell-shares-of-teva-takeda-pharma-and-subsidiary-to-jki-co-in-pivot-to-growth-strategy-by-2025/ 2024-12-05 https://bio-research.ai/aclaris-therapeutics-enters-940m-deal-with-sino-biopharmaceuticals-and-biosion-for-global-development-of-tslp-antibody-bsi-045b/ 2024-12-05 https://bio-research.ai/medicinova-continues-phase-2b-3-ibudilast-trial-for-als-following-interim-analysis-with-results-expected-in-2026/ 2024-12-05 https://bio-research.ai/fda-grants-fast-track-designation-for-epicentrx-s-adapt-001-for-advanced-refractory-soft-tissue-sarcoma-treatment/ 2024-12-05 https://bio-research.ai/muna-therapeutics-and-gsk-ink-173-5m-deal-to-identify-alzheimer-s-drug-targets-using-mind-map-platform/ 2024-12-05 https://bio-research.ai/medicenna-therapeutics-reports-complete-tumor-regression-in-patients-treated-with-mdna11-and-keytruda-in-phase-1-2-ability-1-study/ 2024-12-05 https://bio-research.ai/pharma-two-b-reveals-pooled-data-analysis-of-phase-2b-and-phase-3-trial-for-p2b001-s-efficacy-in-early-stage-parkinson-s-disease-patients/ 2024-12-05 https://bio-research.ai/protara-therapeutics-reports-results-of-phase-2-trial-on-tara-002-for-high-risk-nmibc-patients-with-no-reported-grade-2-or-greater-adverse-events/ 2024-12-05 https://bio-research.ai/mindmed-s-mm120-odt-receives-uk-mhra-s-innovation-passport-for-treatment-of-generalized-anxiety-disorder/ 2024-12-05 https://bio-research.ai/nuvig-therapeutics-secures-161-million-in-series-b-funding-for-clinical-studies-of-nvg-2089-for-treating-cidp/ 2024-12-05 https://bio-research.ai/cg-oncology-reports-74-5-complete-response-rate-in-phase-3-trial-of-cretostimogene-for-high-risk-bladder-cancer/ 2024-12-05 https://bio-research.ai/gsk-extends-shingrix-commercialization-rights-to-zhifei-in-china-until-2034-exploring-rsv-vaccine-partnership-in-deal-potentially-worth-2-3b/ 2024-12-05 https://bio-research.ai/ariceum-therapeutics-signs-global-supply-agreement-with-eckert-ziegler-for-vital-radionuclides-in-clinical-trials/ 2024-12-05 https://bio-research.ai/fda-approves-astrazeneca-s-imfinzi-for-limited-stage-small-cell-lung-cancer-patients-based-on-adriatic-phase-iii-trial-results/ 2024-12-05 https://bio-research.ai/neurosense-therapeutics-reports-33-slowdown-in-als-progression-and-58-survival-rate-improvement-in-paradigm-study-of-primec/ 2024-12-04 https://bio-research.ai/dewpoint-therapeutics-and-mtpc-set-to-advance-480m-als-research-collaboration-for-tdp-43-modulator-with-potential-to-address-97-of-als-cases/ 2024-12-04 https://bio-research.ai/rgenta-therapeutics-teams-up-with-gsk-in-multi-year-research-alliance-worth-up-to-546m-for-development-of-rna-targeted-therapies/ 2024-12-04 https://bio-research.ai/rondo-therapeutics-and-eli-lilly-collaborate-for-bispecific-antibody-development-against-solid-tumors/ 2024-12-04 https://bio-research.ai/impact-biotech-reports-85-complete-response-in-phase-3-study-of-padeliporfin-vtp-for-low-grade-urothelial-cancer-patients/ 2024-12-04 https://bio-research.ai/theratechnologies-to-pay-ionis-10m-upfront-in-licensing-deal-for-rna-targeted-drugs-olezarsen-and-donidalorsen-with-potential-12-75m-in-future-payouts/ 2024-12-04 https://bio-research.ai/atea-pharmaceuticals-phase-2-study-finds-98-svr12-rate-for-hepatitis-c-treatment-with-bemnifosbuvir-and-ruzasvir/ 2024-12-04 https://bio-research.ai/eli-lilly-s-zepbound-achieves-47-greater-weight-loss-than-wegovy-in-surmount-5-phase-3b-trial/ 2024-12-04 https://bio-research.ai/simcere-pharmaceutical-s-sanbexin-tablets-gain-approval-for-treating-acute-ischemic-stroke-after-successful-phase-iii-clinical-trial/ 2024-12-04 https://bio-research.ai/advanz-pharma-expands-specialty-brand-portfolio-by-acquiring-apac-rights-for-bayer-s-progynova-and-cyclo-progynova-excluding-japan-and-china/ 2024-12-04 https://bio-research.ai/teva-s-phase-3-study-of-ajovy-shows-reduced-monthly-migraine-headache-days-in-pediatric-patients-aged-6-17-years/ 2024-12-04 https://bio-research.ai/antag-therapeutics-secures-80-million-financing-for-clinical-trials-of-at-7687-an-obesity-treatment-under-development/ 2024-12-04 https://bio-research.ai/akeso-highlights-56-9-pfs-in-nsclc-with-cadonilimab-at-2024-aclc/ 2024-12-04 https://bio-research.ai/novavax-sells-czech-manufacturing-facility-to-novo-nordisk-for-200m-agrees-on-asset-transfer-and-upfront-payment-in-2024/ 2024-12-04 https://bio-research.ai/duality-biologics-and-gsk-enter-exclusive-agreement-for-db-1324-commercialization-with-potential-975m-in-milestone-payments/ 2024-12-03 https://bio-research.ai/lisata-therapeutics-licenses-certepetide-to-kuva-labs-to-combine-with-nanomark-for-solid-tumor-detection/ 2024-12-03 https://bio-research.ai/vivavision-biotech-reports-phase-2-trial-of-vvn461-cs-201-shows-reduced-inflammation-and-ocular-pain-post-cataract-surgery-in-91-subjects/ 2024-12-03 https://bio-research.ai/martin-pharmaceuticals-secured-exclusive-rights-to-docarpamine-data-outside-japan-and-china-from-mitsubishi-tanabe-pharma-for-treating-ascites/ 2024-12-03 https://bio-research.ai/exegenesis-bio-receives-fda-orphan-drug-designation-for-its-gene-therapy-exg110-for-fabry-disease-treatment/ 2024-12-03 https://bio-research.ai/unnatural-products-and-bridgebio-pharma-ink-licensing-deal-to-develop-macrocyclic-peptides-utilizing-ai-powered-chemistry-platform/ 2024-12-03 https://bio-research.ai/saol-therapeutics-submits-fda-application-for-sl1009-a-sodium-dichloroacetate-oral-solution-for-rare-pediatric-mitochondrial-disease-pdcd/ 2024-12-03 https://bio-research.ai/transposon-therapeutics-reports-phase-2-results-on-tpn-101-in-als-and-ftd-treatment-study/ 2024-12-03 https://bio-research.ai/maze-therapeutics-secures-115-million-funding-for-development-of-mze829-and-mze782/ 2024-12-03 https://bio-research.ai/restem-receives-orphan-drug-designation-from-fda-for-umbilical-cord-stem-cells-program-aimed-at-treating-polymyositis-and-dermatomyositis/ 2024-12-03 https://bio-research.ai/kinevant-sciences-halts-development-of-namilumab-for-sarcoidosis-following-unsuccessful-phase-2-trial/ 2024-12-03 https://bio-research.ai/fda-fast-tracks-corbus-pharmaceuticals-crb-701-drug-for-relapsed-or-refractory-metastatic-cervical-cancer-treatment/ 2024-12-03 https://bio-research.ai/fda-grants-orphan-drug-designation-to-rezolute-s-ersodetug-for-hypoglycemia-from-tumor-hyperinsulinism/ 2024-12-03 https://bio-research.ai/aptose-biosciences-allies-with-national-cancer-institute-for-tuspetinib-clinical-trials-in-leukemia-treatment/ 2024-12-03 https://bio-research.ai/fda-grants-second-fast-track-designation-to-lantern-pharma-s-lp-184-for-triple-negative-breast-cancer-treatment/ 2024-12-03 https://bio-research.ai/relay-therapeutics-inks-500m-global-licensing-deal-with-elevar-therapeutics-for-development-and-commercialisation-of-lirafugratinib/ 2024-12-03 https://bio-research.ai/gilead-sciences-and-tubulis-enter-465m-agreement-to-develop-antibody-drug-conjugate-for-solid-tumor-treatment/ 2024-12-03 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-merck-s-lung-cancer-drug-sacituzumab-tirumotecan-based-on-phase-2-study-data/ 2024-12-03 https://bio-research.ai/coherus-biosciences-to-sell-udenyca-franchise-to-intas-pharmaceuticals-for-558-4m-with-75m-in-potential-milestones/ 2024-12-03 https://bio-research.ai/takeda-inks-global-licensing-deal-with-keros-for-1-3b-to-advance-elritercept-s-phase-3-trials-on-anemia-and-myelofibrosis/ 2024-12-03 https://bio-research.ai/inventisbio-reports-phase-2-trial-results-d-2570-achieves-75-improvement-in-severe-plaque-psoriasis-patients-by-week-12/ 2024-12-03 https://bio-research.ai/ono-pharmaceutical-and-congruence-therapeutics-announce-agreement-for-novel-drug-discovery-collaboration/ 2024-12-03 https://bio-research.ai/alveogene-s-avg-002-gene-therapy-gets-orphan-drug-designation-from-fda-for-treating-rare-respiratory-syndrome-in-newborns/ 2024-12-03 https://bio-research.ai/ipsen-lands-global-licensing-deal-worth-up-to-610m-with-biomunex-for-the-promising-tce-antibody-bmx-502/ 2024-12-03 https://bio-research.ai/celltrion-and-biome-enter-equity-investment-deal-to-accelerate-development-of-new-microbiome-drug-bm111/ 2024-12-03 https://bio-research.ai/sana-biotechnology-s-sc291-gets-fast-track-designation-from-fda-for-use-in-relapsed-refractory-systemic-lupus-erythematosus/ 2024-12-02 https://bio-research.ai/merus-licenses-us-commercialization-rights-for-zenocutuzumab-to-partner-therapeutics-awaits-fda-review/ 2024-12-02 https://bio-research.ai/kisoji-biotechnology-raises-41-million-to-advance-kj-103-into-clinical-trials-for-solid-tumour-treatment-and-development-of-multi-specific-therapeutic-antibody-drugs/ 2024-12-02 https://bio-research.ai/xoma-acquires-pulmokine-inc-gains-interest-in-seralutinib-with-20m-upfront-payment-potential-25m-milestone-earnings-from-gossamer-bio-and-chiesi-farmaceutici-deal/ 2024-12-02 https://bio-research.ai/biocon-biologics-gets-fda-nod-for-stelara-biosimilar-yesintek-plans-u-s-market-entry-by-2025/ 2024-12-02 https://bio-research.ai/olema-partnered-with-novartis-for-ribociclib-supply-and-raised-250m-to-fund-the-phase-3-opera-02-trial/ 2024-12-02 https://bio-research.ai/china-medical-system-holdings-and-atom-therapeutics-sign-exclusive-agreement-for-commercialization-of-innovative-gout-drug-abp-671/ 2024-12-02 https://bio-research.ai/ptc-therapeutics-and-novartis-sign-1b-upfront-deal-plus-1-9b-in-milestone-potential-for-huntington-s-disease-program/ 2024-12-02 https://bio-research.ai/purple-biotech-reports-phase-2-success-for-cm24-drug-combination-shows-79-reduction-in-death-risk-in-pancreatic-cancer-patients/ 2024-12-02 https://bio-research.ai/stallergenes-greer-s-palforzia-gets-positive-chmp-opinion-for-indication-extension-in-toddlers-with-confirmed-peanut-allergy/ 2024-12-02 https://bio-research.ai/samjin-pharmaceutical-and-apitbio-extend-partnership-to-develop-and-commercialize-innovative-antibody-drug-conjugates-for-solid-tumors/ 2024-12-02 https://bio-research.ai/minghui-pharmaceutical-s-phase-iii-trial-of-mh004-shows-improvement-in-atopic-dermatitis-symptoms/ 2024-11-29 https://bio-research.ai/silo-pharma-and-kymanox-partner-up-for-design-and-testing-of-home-based-ketamine-treatment-implant-sp-26/ 2024-11-29 https://bio-research.ai/hansoh-pharma-s-hs-10374-shows-significant-efficacy-in-phase-ii-clinical-trial-for-plaque-psoriasis/ 2024-11-29 https://bio-research.ai/bio-manguinhos-quantoom-biosciences-and-univercells-ink-mou-to-advance-rna-based-vaccine-development-and-bolster-healthcare-access-in-brazil/ 2024-11-29 https://bio-research.ai/gnt-pharma-reveals-phase-2-and-3-trials-of-stroke-treatment-nelonemdaz-show-improved-disability-outcomes-preps-for-ind-application/ 2024-11-29 https://bio-research.ai/helix-biopharma-to-acquire-laevoroc-s-oral-immune-checkpoint-inhibitor-lr-09-with-16-5-share-exchange/ 2024-11-28 https://bio-research.ai/allink-biotherapeutics-raises-42-million-to-advance-alk201-and-alk202-and-develop-antibody-and-adc-technology-platform/ 2024-11-28 https://bio-research.ai/shanghai-micurx-completes-phase-iii-trial-of-oral-mrx-4-in-cssti-patients-prepares-to-file-nda-in-china/ 2024-11-28 https://bio-research.ai/clarity-pharmaceuticals-cu-sartate-trial-shows-improved-lesion-detection-in-neuroendocrine-tumours/ 2024-11-28 https://bio-research.ai/formosa-pharmaceuticals-and-medvisis-switzerland-clinch-exclusive-licensing-deal-for-post-op-eye-treatment-in-switzerland-liechtenstein/ 2024-11-28 https://bio-research.ai/tennor-therapeutics-inks-a-775m-yuan-deal-with-grand-life-sciences-group-for-the-commercialization-of-tnp-2198-in-mainland-china-hong-kong-and-macau/ 2024-11-28 https://bio-research.ai/dongkoo-bio-pharma-to-supply-five-pharmaceuticals-to-mongolia-at-half-price-under-new-agreement-with-ministry-of-health-and-welfare/ 2024-11-28 https://bio-research.ai/fda-issues-complete-response-letter-for-applied-therapeutics-govorestat-a-treatment-for-classic-galactosemia/ 2024-11-27 https://bio-research.ai/combination-therapy-of-bemusumab-and-anlotinib-approved-for-recurrent-or-metastatic-endometrial-cancer-treatment-from-nmpa/ 2024-11-27 https://bio-research.ai/china-grants-approval-for-varenicline-nasal-spray-offering-a-new-approach-to-dry-eye-treatment/ 2024-11-27 https://bio-research.ai/sichuan-kelun-biotech-biopharmaceutical-gains-approval-for-trop2-directed-adc-sacituzumab-tirumotecan-in-china-for-treating-advanced-triple-negative-breast-cancer/ 2024-11-27 https://bio-research.ai/zjut-and-hisun-pharmaceuticals-form-synthetic-biology-manufacturing-innovation-research-institute-to-bolster-synthetic-biosynthesis-in-china/ 2024-11-27 https://bio-research.ai/ptc-therapeutics-to-sell-fda-granted-priority-review-voucher-for-150m-following-kebilidi-approval/ 2024-11-27 https://bio-research.ai/fda-grants-orphan-drug-designation-to-cervomed-s-neflamapimod-for-treatment-of-frontotemporal-dementia/ 2024-11-27 https://bio-research.ai/lin-bioscience-s-lbs-007-granted-fast-track-designation-by-fda-for-acute-myeloid-leukemia-treatment-in-phase-1-2-trial/ 2024-11-27 https://bio-research.ai/oxford-vacmedix-gets-series-b-investment-from-proven-connect-for-phase-1-trial-of-ovm-200-vaccine-in-cancer-treatment/ 2024-11-27 https://bio-research.ai/idorsia-ltd-in-exclusive-negotiations-for-global-rights-to-aprocitentan-set-to-receive-35m-exclusivity-fee-and-restructure-debt/ 2024-11-27 https://bio-research.ai/fda-approves-aop-health-s-rapiblyk-for-severe-heart-conditions-based-on-results-from-five-clinical-trials/ 2024-11-27 https://bio-research.ai/european-commission-approves-novartis-kisqali-plus-aromatase-inhibitor-for-adjuvant-treatment-in-hormone-receptor-positive-early-breast-cancer-patients-based-on-phase-iii-natalee-trial-data/ 2024-11-27 https://bio-research.ai/european-court-rejects-extension-of-suspension-on-ocaliva-s-revoked-marketing-authorisation-advanz-pharma-seeks-ways-to-maintain-patient-access/ 2024-11-27 https://bio-research.ai/outlook-therapeutics-reports-initial-results-from-norse-eight-clinical-trial-of-ons-5010-in-wet-age-related-macular-degeneration-patients/ 2024-11-27 https://bio-research.ai/european-commission-approves-beigene-s-tevimbra-for-first-line-treatment-of-advanced-esophageal-and-gastric-cancers-based-on-phase-3-studies-results/ 2024-11-27 https://bio-research.ai/faron-pharmaceuticals-reports-80-objective-response-rate-in-phase-2-bexmab-trial-for-mds-patients-who-failed-hma/ 2024-11-27 https://bio-research.ai/rophibio-inks-42m-licensing-out-deal-with-sudair-pharmaceutical-set-to-supply-biosimilar-to-the-middle-east/ 2024-11-27 https://bio-research.ai/ptc-therapeutics-phase-2-cardinals-trial-of-utreloxastat-fails-to-meet-primary-endpoint-in-als-patients/ 2024-11-26 https://bio-research.ai/saniona-partners-with-acadia-pharmaceuticals-to-advance-san711-for-neurological-diseases-with-a-potential-610m-payout/ 2024-11-26 https://bio-research.ai/fda-extends-review-period-for-soleno-therapeutics-dccr-extended-release-tablets-for-prader-willi-syndrome-treatment/ 2024-11-26 https://bio-research.ai/s-biomedics-shares-results-from-phase-1-2a-clinical-trial-of-ted-a9-for-parkinson-s-disease-one-year-post-transplant-data-shows-motor-and-behavioral-improvement-in-6-patients/ 2024-11-26 https://bio-research.ai/35pharma-secures-53-million-in-series-c-financing-to-advance-clinical-studies-of-hs135-and-hs235-for-pulmonary-hypertension-obesity-and-heart-failure/ 2024-11-26 https://bio-research.ai/eisbach-bio-receives-4-75m-from-cprit-for-clinical-development-of-cancer-drug-eis-12656-in-texas/ 2024-11-26 https://bio-research.ai/amgen-s-phase-2-study-results-maritide-leads-to-20-weight-loss-and-decreases-hba1c-levels-by-2-2-points/ 2024-11-26 https://bio-research.ai/theratechnologies-resubmits-sbla-for-tesamorelin-f8-formulation-to-fda-for-hiv-associated-lipodystrophy-treatment-review/ 2024-11-26 https://bio-research.ai/sarepta-therapeutics-signs-825m-global-licensing-agreement-with-arrowhead-pharmaceuticals-for-rare-genetic-diseases-program/ 2024-11-26 https://bio-research.ai/axsome-therapeutics-drug-axs-12-reduces-frequency-of-cataplexy-attacks-in-narcolepsy-patients-in-phase-3-trial/ 2024-11-26 https://bio-research.ai/bio-farma-collaborates-with-gates-foundation-to-produce-nopv2-vaccines-secures-idr-1-4-trillion-export-contract-for-vaccines-against-polio-diphtheria-and-tetanus/ 2024-11-26 https://bio-research.ai/roche-to-acquire-poseida-therapeutics-for-1b-deal-may-rise-to-1-5b-with-addition-of-non-tradeable-cvr/ 2024-11-26 https://bio-research.ai/eisai-biogen-japan-and-ncnp-collaborate-on-apoe-genetic-testing-for-alzheimer-s-disease-treatment-program/ 2024-11-26 https://bio-research.ai/boan-biotech-inks-deal-to-commercialize-denosumab-injection-products-ba6101-and-ba1102-in-brazil-s-31-7b-pharmaceutical-market/ 2024-11-26 https://bio-research.ai/genentech-s-phase-iii-skyscraper-01-study-of-tiragolumab-with-tecentriq-in-high-pd-l1-nsclc-patients-fails-to-meet-overall-survival-endpoint/ 2024-11-25 https://bio-research.ai/empyrean-therapeutics-acquires-first-in-class-tlr-2-antagonist-molecule-ems-312-from-eos-therapeutics-for-accelerated-cancer-drug-development/ 2024-11-25 https://bio-research.ai/alector-inc-s-alzheimer-s-drug-al002-fails-in-phase-2-invoke-2-trial-plans-17-workforce-reduction/ 2024-11-25 https://bio-research.ai/gilead-sciences-acquires-hti-hiv-assets-from-aelix-therapeutics-bolstering-hiv-cure-strategy-amidst-optimistic-clinical-trial-results/ 2024-11-25 https://bio-research.ai/igc-pharma-s-phase-2-trial-reveals-interim-data-on-igc-ad1-for-treating-alzheimer-s-agitation-symptoms-with-favorable-safety-profile/ 2024-11-25 https://bio-research.ai/secretome-therapeutics-secures-20-4-million-funding-for-phase-1-trials-of-stm-01-in-heart-failure-and-dilated-cardiomyopathy-cases/ 2024-11-25 https://bio-research.ai/doron-therapeutics-secures-11-million-financing-for-phase-3-studies-of-motys-in-knee-osteoarthritis-management/ 2024-11-25 https://bio-research.ai/kanglin-biotechnology-raises-20-million-for-clinical-development-of-kl003-gene-therapy-for-beta-thalassemia-and-sickle-cell-disease/ 2024-11-25 https://bio-research.ai/blue-lake-biotechnology-reports-78-lower-risk-of-covid-19-symptoms-with-cvxga-vaccine-in-phase-2a-trial/ 2024-11-25 https://bio-research.ai/cognition-therapeutics-reports-95-reduction-in-cognitive-decline-in-alzheimer-s-patients-with-lower-p-tau217-levels-in-phase-2-shine-study/ 2024-11-25 https://bio-research.ai/astrazeneca-s-truqap-combined-therapy-shows-improved-survival-in-capitello-281-phase-iii-prostate-cancer-trial/ 2024-11-25 https://bio-research.ai/cassava-sciences-rethink-alz-phase-3-trial-unsuccessful-fails-to-demonstrate-cognitive-improvement-in-alzheimer-s-patients/ 2024-11-25 https://bio-research.ai/intellia-therapeutics-obtains-rmat-and-orphan-drug-designations-for-crispr-based-therapy-nexiguran-ziclumeran-in-development-against-hereditary-transthyretin-amyloidosis-with-polyneuropathy/ 2024-11-25 https://bio-research.ai/merck-s-phase-3-zenith-study-meets-primary-endpoint-showing-significant-risk-reduction-in-pulmonary-arterial-hypertension-patients/ 2024-11-25 https://bio-research.ai/adcendo-secures-135-million-in-oversubscribed-series-b-round-for-development-of-first-in-class-adc-programs/ 2024-11-25 https://bio-research.ai/evergreen-therapeutics-partners-with-juxian-pharmaceutical-to-accelerate-drug-development-leveraging-artificial-intelligence-and-clinical-technology/ 2024-11-25 https://bio-research.ai/fda-approves-bridgebio-s-attruby-for-reducing-cardiovascular-complications-in-attr-cm-patients/ 2024-11-22 https://bio-research.ai/orbus-therapeutics-phase-3-stellar-study-finds-combination-of-eflornithine-and-lomustine-improves-survival-in-grade-3-idh-mutant-astrocytoma-patients/ 2024-11-22 https://bio-research.ai/fda-approves-stemcyte-inc-s-license-application-for-regenecyte-cell-therapy-product-derived-from-umbilical-cord-blood/ 2024-11-22 https://bio-research.ai/china-s-national-medical-products-administration-accepts-akeso-s-supplemental-drug-application-for-penpulimab-in-advanced-hepatocellular-carcinoma-treatment/ 2024-11-22 https://bio-research.ai/johnson-johnson-seeks-fda-approval-for-subcutaneous-tremfya-regimen-in-ulcerative-colitis/ 2024-11-22 https://bio-research.ai/merck-s-welireg-approved-in-china-for-treating-von-hippel-lindau-disease-associated-tumors-following-positive-phase-2-trial-results/ 2024-11-22 https://bio-research.ai/otsuka-pharmaceutical-inks-10m-deal-with-ionis-for-global-rights-to-als-treatment-ulefnersen/ 2024-11-22 https://bio-research.ai/rituxan-receives-approval-for-additional-dosage-and-use-in-pediatric-idiopathic-thrombocytopenic-purpura-by-japanese-health-ministry/ 2024-11-22 https://bio-research.ai/japan-expands-approval-of-gsk-s-rsv-vaccine-arexvy-to-include-high-risk-adults-aged-50-59/ 2024-11-22 https://bio-research.ai/nanjing-leads-biolabs-receives-fda-orphan-drug-designation-for-lbl-024-in-neuroendocrine-cancer-treatment/ 2024-11-22 https://bio-research.ai/novartis-secures-1-1b-acquisition-of-san-diego-s-kate-therapeutics-to-expedite-gene-therapy-programs-for-neuromuscular-diseases/ 2024-11-21 https://bio-research.ai/replimune-group-seeks-fda-approval-for-rp1-nivolumab-combination-therapy-for-advanced-melanoma-based-on-ignyte-clinical-trial-results/ 2024-11-21 https://bio-research.ai/vilya-secures-exclusive-license-from-university-of-washington-to-use-rfpeptides-in-drug-discovery-platform-enhancement/ 2024-11-21 https://bio-research.ai/lumos-pharma-inc-unveils-additional-phase-2-trial-results-of-lum-201-in-pediatric-growth-hormone-deficiency-at-european-endocrinology-meeting/ 2024-11-21 https://bio-research.ai/enveda-secures-130-million-in-series-c-funding-for-clinical-trials-receives-fda-clearance-for-anti-inflammatory-agent-env-294/ 2024-11-21 https://bio-research.ai/transposon-therapeutics-acquires-novel-nucleoside-analogs-portfolio-from-primefour-therapeutics-for-synthetic-lethality-based-cancer-treatment/ 2024-11-21 https://bio-research.ai/tearsolutions-completes-3m-series-b-financing-for-advancement-of-lacripep-in-treating-rare-corneal-conditions-and-debt-conversion/ 2024-11-21 https://bio-research.ai/gan-and-lee-pharmaceuticals-phase-iib-study-of-gzr18-reports-17-29-average-weight-loss-in-30-week-trial/ 2024-11-21 https://bio-research.ai/kura-oncology-and-kyowa-kirin-join-forces-to-develop-ziftomenib-with-a-deal-worth-up-to-1-91b/ 2024-11-21 https://bio-research.ai/fda-grants-accelerated-approval-to-ziihera-for-previously-treated-unresectable-or-metastatic-her2-positive-biliary-tract-cancer-based-on-a-52-objective-response-rate-in-the-clinical-trial/ 2024-11-21 https://bio-research.ai/zai-lab-and-pfizer-collaborate-to-commercialize-antibacterial-drug-xacduro-in-mainland-china-targeting-crab-pneumonia-till-2028/ 2024-11-21 https://bio-research.ai/cstone-pharmaceuticals-partners-with-pharmalink-for-commercialization-and-regulatory-activities-of-sugemalimab-in-mena-region-and-south-africa/ 2024-11-21 https://bio-research.ai/gc-biopharma-corp-and-kanaph-therapeutics-sign-conditional-agreement-to-develop-bispecific-antibody-drug-conjugate-for-solid-tumors/ 2024-11-21 https://bio-research.ai/biolinerx-licenses-motixafortide-to-ayrmid-for-10m-upfront-plus-up-to-87m-in-milestones-and-18-23-royalties/ 2024-11-20 https://bio-research.ai/genedit-secures-35-million-in-series-b-investment-round-for-continued-gene-therapy-research/ 2024-11-20 https://bio-research.ai/genprex-acquires-exclusive-license-from-university-of-michigan-for-reqorsa-gene-therapy-in-potential-treatment-for-alk-lung-cancer/ 2024-11-20 https://bio-research.ai/alloy-therapeutics-and-takeda-pharmaceutical-ink-strategic-license-agreement-to-commercialize-ipsc-derived-car-t-and-car-nk-cell-platforms-for-cancer-treatment/ 2024-11-20 https://bio-research.ai/forte-biosciences-receives-53-million-for-clinical-development-of-fb102-results-expected-by-q2-of-2025/ 2024-11-20 https://bio-research.ai/valora-therapeutics-raises-30-million-in-seed-financing-for-further-development-of-ablec-platform-in-oncology-autoimmune-diseases/ 2024-11-20 https://bio-research.ai/flagship-pioneering-brokers-partnership-agreements-between-pfizer-and-montai-therapeutics-for-lung-cancer-treatments/ 2024-11-20 https://bio-research.ai/ocugen-obtains-orphan-drug-designation-from-ema-for-retinopathies-treatment-ocu410st-following-similar-fda-decision/ 2024-11-20 https://bio-research.ai/melt-pharmaceuticals-phase-3-trial-shows-melt-300-outperforms-midazolam-and-placebo-in-over-530-patients-for-cataract-surgery-sedation/ 2024-11-20 https://bio-research.ai/ampersand-biomedicines-to-work-with-pfizer-under-flagship-pfizer-alliance-to-accelerate-cancer-and-obesity-drug-development/ 2024-11-20 https://bio-research.ai/newamsterdam-pharma-reports-phase-3-tandem-trial-results-obicetrapib-and-ezetimibe-combination-significantly-lowers-ldl-c-levels-in-cardiovascular-patients-by-day-84/ 2024-11-20 https://bio-research.ai/sage-therapeutics-phase-2-trial-of-dalzanemdor-sage-718-fails-to-meet-primary-endpoint-in-patients-with-huntington-s-disease/ 2024-11-20 https://bio-research.ai/asahi-kasei-pharma-secures-global-rights-to-chiome-s-anti-cx3cr1-antibody-pfkr-with-potential-payments-of-up-to-24-8b-yen/ 2024-11-20 https://bio-research.ai/fda-grants-orphan-drug-designation-to-innorna-s-mrna-therapy-in015-for-treating-progressive-familial-intrahepatic-cholestasis/ 2024-11-20 https://bio-research.ai/novartis-and-vyriad-ink-strategic-collaboration-to-advance-in-vivo-car-t-cell-therapies-using-lentiviral-vector-platform/ 2024-11-20 https://bio-research.ai/fda-approves-ucb-s-bimzelx-for-adults-with-moderate-to-severe-hidradenitis-suppurativa-based-on-phase-3-study-results/ 2024-11-20 https://bio-research.ai/laekna-and-eli-lilly-partner-to-fast-track-phase-1-clinical-trials-of-obesity-treatment-lae102/ 2024-11-20 https://bio-research.ai/european-commission-approves-pfizer-s-hympavzi-marstacimab-for-treating-severe-hemophilia-a-and-b-in-patients-aged-12-and-above/ 2024-11-20 https://bio-research.ai/amacathera-s-amt-143-phase-1-trial-shows-14-day-sustained-anesthetic-release/ 2024-11-20 https://bio-research.ai/kookmin-bio-raises-3-4-billion-krw-in-series-b-funding-for-microbiome-regulating-drug-development-and-health-food-production-expansion/ 2024-11-20 https://bio-research.ai/sino-biopharmaceuticals-and-lanova-medicines-to-collaborate-on-cancer-treating-antibody-development/ 2024-11-20 https://bio-research.ai/viking-therapeutics-phase-2b-clinical-trial-shows-vk2809-reduces-liver-fat-and-improves-fibrosis-in-nash-patients-over-52-weeks-of-treatment/ 2024-11-19 https://bio-research.ai/ractigen-therapeutics-earns-fda-orphan-drug-designation-for-rag-21-sirna-therapy-for-aggressive-type-of-als/ 2024-11-19 https://bio-research.ai/xbrane-biopharma-ab-and-intas-pharmaceuticals-collaborate-for-global-licensing-of-nivolumab-biosimilar-deal-valued-at-eur-13m-plus-royalties-after-launch/ 2024-11-19 https://bio-research.ai/merck-successfully-completes-phase-3-trial-for-subcutaneous-method-of-pembrolizumab-delivery-in-metastatic-non-small-cell-lung-cancer/ 2024-11-19 https://bio-research.ai/brii-biosciences-reports-phase-2-study-of-elebsiran-33-3-hbv-surface-antigen-seroclearance-achieved-in-combination-with-pegylated-interferon-alpha/ 2024-11-19 https://bio-research.ai/circio-holding-asa-and-certest-biotec-partner-to-test-circvec-dna-lnp-formulations-for-targeted-gene-therapy/ 2024-11-19 https://bio-research.ai/gsk-s-linerixibat-meets-primary-endpoint-in-phase-iii-trial-for-cholestatic-pruritus-treatment-in-pbc-patients-over-24-weeks/ 2024-11-19 https://bio-research.ai/lindis-biotech-pharmanovia-ink-licensing-agreement-for-catumaxomab-therapy-for-malignant-ascites-awaiting-final-approval-from-chmp/ 2024-11-19 https://bio-research.ai/cytokinetics-and-bayer-join-forces-for-exclusive-development-of-cardiomyopathy-treatment-aficamten-in-japan-with-potential-630m-deal/ 2024-11-19 https://bio-research.ai/ucb-and-biogen-report-significant-improvement-in-systemic-lupus-erythematosus-with-dapirolizumab-pegol-in-phase-3-trial/ 2024-11-19 https://bio-research.ai/hansoh-pharma-s-inebilizumab-receives-breakthrough-therapy-designation-from-us-fda-after-global-phase-3-mitigate-trial/ 2024-11-19 https://bio-research.ai/fda-issues-complete-response-letter-to-astellas-over-izervay-s-labelling-issues-not-safety-concerns/ 2024-11-19 https://bio-research.ai/c-ray-therapeutics-secures-100-million-series-a-funding-gears-up-for-advancement-in-radiopharmaceuticals-field/ 2024-11-18 https://bio-research.ai/velavigo-and-avenzo-therapeutics-ink-deal-on-nectin4-trop2-bispecific-adc-development/ 2024-11-18 https://bio-research.ai/johnson-johnson-s-icotrokinra-meets-co-primary-endpoints-in-phase-3-plaque-psoriasis-study-with-74-1-skin-clearance-at-week-24/ 2024-11-18 https://bio-research.ai/aclaris-therapeutics-signs-an-exclusive-global-license-with-biosion-expands-immunology-portfolio-and-boosts-balance-sheet/ 2024-11-18 https://bio-research.ai/alkeus-pharmaceuticals-gildeuretinol-receives-fda-rare-pediatric-disease-and-fast-track-designations-for-stargardt-disease-treatment/ 2024-11-18 https://bio-research.ai/eli-lilly-reports-reduction-in-heart-disease-risk-factor-lp-a-in-phase-2-muvalaplin-trial-over-12-weeks/ 2024-11-18 https://bio-research.ai/ratio-therapeutics-inks-745m-deal-with-novartis-pharma-to-develop-cancer-fighting-radiotherapeutic-drug/ 2024-11-18 https://bio-research.ai/fda-grants-fast-track-designation-to-vaderis-therapeutics-vad044-for-treatment-of-hereditary-hemorrhagic-telangiectasia/ 2024-11-18 https://bio-research.ai/fda-fast-tracks-alentis-therapeutics-ale-p02-for-treatment-of-advanced-cldn1-squamous-cancers/ 2024-11-18 https://bio-research.ai/hcw-biologics-licenses-drug-discovery-platform-molecule-to-wy-biotech-in-7m-deal-retains-development-rights-for-select-regions-post-phase-1-trials/ 2024-11-18 https://bio-research.ai/astrazeneca-s-tagrisso-recommended-for-approval-in-the-eu-for-specific-non-small-cell-lung-cancer-following-laura-phase-iii-trial-results/ 2024-11-18 https://bio-research.ai/abbvie-s-elahere-receives-marketing-authorization-from-european-commission-for-treatment-of-certain-ovarian-fallopian-tube-and-primary-peritoneal-cancers/ 2024-11-18 https://bio-research.ai/tennor-therapeutics-completes-phase-iii-trial-for-rifasutenizol-achieves-higher-eradication-rate-than-current-standard-in-h-pylori-infection-treatment/ 2024-11-18 https://bio-research.ai/impact-therapeutics-raises-250-million-rmb-for-senaparib-commercialization-and-acceleration-of-global-clinical-development/ 2024-11-18 https://bio-research.ai/sustained-90-percent-serum-ttr-reduction-at-12-months-with-nex-z-evidence-of-disease-modification-in-attr-cm-and-attrv-pn-patients/ 2024-11-16 https://bio-research.ai/eli-lilly-s-phase-3-trial-of-tirzepatide-shows-38-reduction-in-heart-failure-risk-in-patients-with-hfpef-and-obesity/ 2024-11-16 https://bio-research.ai/fda-approves-syndax-pharmaceuticals-revuforj-for-treatment-of-relapsed-or-refractory-acute-leukemia-with-a-kmt2a-translocation-in-patients-aged-one-year-and-older/ 2024-11-15 https://bio-research.ai/inventiva-s-phase-2-clinical-trial-shows-lanifibranor-and-empagliflozin-combination-improves-metabolic-dysfunction-associated-steatohepatitis-and-type-2-diabetes-outcomes/ 2024-11-15 https://bio-research.ai/bristol-myers-squibb-s-repotrectinib-gets-recommendation-for-cancer-treatment-approval-by-european-medicines-agency-committee/ 2024-11-15 https://bio-research.ai/genscript-biotech-s-probio-licenses-pd-1-nme-to-lanova-medicines-for-3-3b-merck-co-deal-bolstering-expansion-and-innovation-in-immuno-oncology/ 2024-11-15 https://bio-research.ai/89bio-presents-phase-2b-trial-data-for-pegozafermin-in-advanced-fibrosis-patients/ 2024-11-15 https://bio-research.ai/merck-s-keytruda-garners-positive-opinion-from-chmp-for-first-line-treatment-of-mpm-based-on-ind-227-keynote-483-trial-results/ 2024-11-15 https://bio-research.ai/inflarx-s-gohibic-receives-ema-marketing-authorization-recommendation-for-treatment-of-sars-cov-2-induced-distress-syndrome-following-phase-3-trial-results/ 2024-11-15 https://bio-research.ai/eyenovia-s-phase-3-chaperone-study-for-pediatric-progressive-myopia-fails-to-meet-primary-efficacy-endpoint-plans-for-discontinuation/ 2024-11-15 https://bio-research.ai/numab-and-kaken-pharmaceutical-join-forces-for-nd081-clinical-trials-receiving-chf-13m-upfront-payment-for-ibd-treatment-development/ 2024-11-15 https://bio-research.ai/fda-reviews-dupixent-sbla-for-chronic-spontaneous-urticaria-treatment-in-patients-aged-12-and-up-decision-expected-by-april-2025/ 2024-11-15 https://bio-research.ai/health-canada-approves-knight-therapeutics-jornay-for-adhd-treatment-in-children-aged-6-12/ 2024-11-14 https://bio-research.ai/amgen-reveals-87-reduction-in-disease-flare-risk-in-mitigate-phase-3-trial/ 2024-11-14 https://bio-research.ai/janssen-cilag-s-phase-2-dahlias-study-shows-improved-disease-activity-in-sj-gren-s-patients-after-24-weeks-of-nipocalimab-treatment/ 2024-11-14 https://bio-research.ai/levicept-ltd-s-phase-ii-trial-of-levi-04-shows-significant-differences-to-placebo-in-osteoarthritis-treatment-presented-at-acr-convergence-2024/ 2024-11-14 https://bio-research.ai/immutep-reports-three-fold-increase-in-tumour-hyalinization-in-phase-ii-trial-of-eftilagimod-alpha-with-radiotherapy-and-pembrolizumab-for-sarcoma-patients/ 2024-11-14 https://bio-research.ai/eisai-and-biogen-obtain-ema-committee-recommendation-for-lecanemab-approval-in-alzheimer-s-treatment/ 2024-11-14 https://bio-research.ai/european-medicines-agency-committee-recommends-sarclisa-with-vrd-for-treatment-of-multiple-myeloma-in-adults-ineligible-for-stem-cell-transplant/ 2024-11-14 https://bio-research.ai/orbimed-acquires-neurelis-global-royalties-and-sales-milestones-for-neffy-in-208m-deal/ 2024-11-14 https://bio-research.ai/merck-secures-exclusive-global-license-for-lanova-s-lm-299-invests-588m-upfront-with-potential-for-2-7b-in-milestones/ 2024-11-14 https://bio-research.ai/ac-immune-sa-reports-16-fold-increase-in-antibody-response-in-phase-2-vacsyn-trial-of-aci-7104-056-for-early-parkinson-s-disease/ 2024-11-14 https://bio-research.ai/novoprotein-scientific-inc-and-lumiere-therapeutics-collaboratively-license-encas12ultra-gene-editing-tool-for-global-application-in-t-cells-ipsc-cells-and-more/ 2024-11-14 https://bio-research.ai/gsk-reports-phase-iii-trial-results-blenrep-with-bortezomib-and-dexamethasone-reduces-death-risk-in-multiple-myeloma-patients/ 2024-11-14 https://bio-research.ai/artbio-and-3b-pharmaceuticals-ink-exclusive-worldwide-license-and-research-agreement-for-development-of-novel-peptide-art-in-solid-tumors-treatment/ 2024-11-14 https://bio-research.ai/amplia-therapeutics-partners-with-next-bio-to-test-fak-inhibitors-against-pancreatic-cancer-cells/ 2024-11-14 https://bio-research.ai/tae-life-sciences-partners-with-stella-pharma-to-commercialize-boron-neutron-capture-therapy-in-us-and-europe/ 2024-11-13 https://bio-research.ai/nurexone-biologic-receives-orphan-medicinal-product-designation-by-european-medicines-agency-for-exopten-therapy-in-acute-spinal-cord-injury-treatments/ 2024-11-13 https://bio-research.ai/fda-grants-accelerated-approval-for-ptc-therapeutics-kebilidi-a-gene-therapy-for-aadc-deficiency-directly-administered-to-brain/ 2024-11-13 https://bio-research.ai/eli-lilly-s-phase-3-surmount-1-study-shows-tirzepatide-reduces-risk-of-progression-to-type-2-diabetes-and-sustains-weight-loss-over-three-years/ 2024-11-13 https://bio-research.ai/entero-therapeutics-and-journey-therapeutics-enter-binding-term-sheet-to-merge-with-journey-to-own-99-equity/ 2024-11-13 https://bio-research.ai/stayble-therapeutics-ab-s-sta363-meets-safety-and-tolerability-goals-in-phase-1b-trial-for-lumbar-disc-herniation-treatment/ 2024-11-13 https://bio-research.ai/curium-s-eclipse-phase-3-trial-meets-primary-endpoint-with-lutetium-zadavotide-guraxetan-in-metastatic-prostate-cancer-patients/ 2024-11-13 https://bio-research.ai/aurealis-therapeutics-secures-chf-8-million-for-phase-2-clinical-trials-of-aup-16-for-chronic-wounds-and-development-of-aup-55-for-cancers/ 2024-11-13 https://bio-research.ai/adaptimmune-reports-42-response-in-phase-2-ignyte-eso-trial-of-lete-cel-for-sarcoma-patients/ 2024-11-13 https://bio-research.ai/pulmatrix-and-cullgen-announce-merger-creating-a-nasdaq-listed-company-with-65m-cash-for-clinical-milestones-through-2026/ 2024-11-13 https://bio-research.ai/metsera-inc-secures-215-million-in-series-b-funding-advances-several-therapies-into-clinical-trials/ 2024-11-13 https://bio-research.ai/biorestorative-therapies-reports-preliminary-phase-2-data-on-brtx-100-for-chronic-lumbar-disc-disease-with-reduced-pain-and-increased-function/ 2024-11-13 https://bio-research.ai/trexbio-raises-84-million-in-series-b-funding-to-advance-clinical-trials-of-trb-061-and-expand-pipeline-appoints-new-board-members/ 2024-11-13 https://bio-research.ai/gilead-sciences-presents-phase-3-results-of-lenacapavir-for-hiv-prevention-showing-significant-reduction-in-infections-by-2024/ 2024-11-13 https://bio-research.ai/microbion-corporation-s-phase-2-study-shows-safety-tolerability-and-efficacy-of-pravibismane-in-diabetic-foot-ulcer-infections-over-12-weeks/ 2024-11-13 https://bio-research.ai/biontech-se-to-acquire-biotheus-for-800m-gains-global-rights-to-bnt327-pm8002-for-solid-tumors-treatment/ 2024-11-13 https://bio-research.ai/healx-and-sanofi-collaborate-using-ai-to-identify-novel-therapies-for-rare-diseases-from-discontinued-asset-data/ 2024-11-13 https://bio-research.ai/x4-pharmaceuticals-phase-2-trial-finds-mavorixafor-increases-neutrophil-counts-in-chronic-neutropenia-patients/ 2024-11-13 https://bio-research.ai/nippon-shinyaku-and-atsena-therapeutics-ink-exclusive-licensing-agreement-for-atsn-101-gene-therapy-securing-rights-and-financial-terms-in-us-and-japan/ 2024-11-13 https://bio-research.ai/syros-pharmaceuticals-select-mds-1-phase-3-trial-fails-to-meet-primary-endpoint-discontinued/ 2024-11-12 https://bio-research.ai/insilico-medicine-reports-dose-dependent-improvement-in-idiopathic-pulmonary-fibrosis-patients-using-ism001-055-in-phase-iia-trial/ 2024-11-12 https://bio-research.ai/mycomedica-life-sciences-acquires-global-license-for-enveric-s-evm201-program-with-potential-62m-payout/ 2024-11-12 https://bio-research.ai/caliway-biopharmaceuticals-gains-orphan-drug-designation-for-cbl-514-a-treatment-for-dercum-s-disease-enters-phase-2b-study/ 2024-11-12 https://bio-research.ai/trace-neuroscience-secures-101-million-in-series-a-funding-to-develop-therapies-to-restore-unc13a-for-neurodegenerative-diseases/ 2024-11-12 https://bio-research.ai/fda-issues-complete-response-letter-to-intercept-pharmaceuticals-regarding-ocaliva-s-snda-for-primary-biliary-cholangitis-treatment/ 2024-11-12 https://bio-research.ai/schr-dinger-and-novartis-sign-2-42b-deal-to-advance-drug-candidates-novartis-gains-access-to-advanced-computational-technology/ 2024-11-12 https://bio-research.ai/repare-therapeutics-and-nci-s-ctep-collaborate-to-advance-development-of-anticancer-agent-camonsertib/ 2024-11-12 https://bio-research.ai/vesalius-therapeutics-partners-with-gsk-to-develop-treatments-for-parkinson-s-receives-80m-upfront-and-potential-570m-milestones/ 2024-11-12 https://bio-research.ai/sanofi-secures-exclusive-right-of-first-negotiation-of-zt-01-in-zucara-therapeutics-20-million-series-b-financing/ 2024-11-12 https://bio-research.ai/fda-grants-rare-pediatric-disease-designation-to-actuate-therapeutics-drug-elraglusib-for-ewing-sarcoma-treatment-in-ongoing-phase-1-2-trial/ 2024-11-12 https://bio-research.ai/novo-holdings-co-leads-181-4-million-financing-round-for-alentis-therapeutics-to-start-phase-1-2-trials-for-adcs-targeting-cldn1-tumours/ 2024-11-12 https://bio-research.ai/vittoria-biotherapeutics-secures-25-million-for-phase-1-clinical-trial-of-viper-101-targeting-t-cell-lymphoma/ 2024-11-12 https://bio-research.ai/flare-therapeutics-and-roche-ink-70m-deal-with-possible-1-8b-extra-payouts-to-discover-new-oncology-drugs/ 2024-11-12 https://bio-research.ai/syndax-pharmaceuticals-reports-23-complete-remission-rate-in-phase-2-trial-of-revumenib-for-refractory-mutant-npm1-acute-myeloid-leukemia/ 2024-11-12 https://bio-research.ai/fda-grants-orphan-drug-designation-to-attralus-at-02-for-treating-transthyretin-associated-amyloidosis-in-phase-1-and-2-trials/ 2024-11-12 https://bio-research.ai/gan-lee-pharmaceuticals-phase-1-trial-finds-glp-1-receptor-agonist-gzr18-tablets-lead-to-4-16-weight-reduction-in-two-weeks/ 2024-11-12 https://bio-research.ai/merck-kgaa-and-abbisko-therapeutics-complete-phase-iii-trial-for-pimicotinib-report-54-objective-response-rate-at-week-25/ 2024-11-12 https://bio-research.ai/phase-iii-trial-of-koselugo-by-alexion-astrazeneca-rare-disease-and-msd-research-laboratories-meets-primary-endpoint-in-adults-with-nf1-and-pn/ 2024-11-12 https://bio-research.ai/astrazeneca-and-daiichi-sankyo-resubmit-bla-to-us-fda-for-lung-cancer-treatment-datopotamab-deruxtecan-following-withdrawal-of-prior-application/ 2024-11-12 https://bio-research.ai/apollo-therapeutics-and-china-s-sunshine-lake-pharma-ink-licensing-deal-for-apl-18881-potential-earnings-up-to-938m/ 2024-11-12 https://bio-research.ai/triumvira-immunologics-reports-preliminary-results-from-phase-i-ii-trial-of-tac01-cldn18-2-in-solid-tumors-with-no-dose-limiting-toxicities/ 2024-11-11 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-johnson-johnson-s-nipocalimab-for-sj-gren-s-disease/ 2024-11-11 https://bio-research.ai/adipopharma-secures-funding-for-phase-1-clinical-trials-of-type-2-diabetes-drug-patas-targeting-insulin-resistance-in-the-us/ 2024-11-11 https://bio-research.ai/abbvie-s-phase-2-trials-of-emraclidine-for-schizophrenia-fail-to-meet-primary-endpoint/ 2024-11-11 https://bio-research.ai/gan-lee-pharmaceuticals-phase-2b-clinical-trial-finds-gzr18-effective-in-reducing-body-weight-in-obese-patients-at-week-30/ 2024-11-11 https://bio-research.ai/ideaya-biosciences-secures-exclusive-worldwide-license-for-biocytogen-s-bsadc-program-plans-406-5m-milestone-payments-for-potential-tumor-treatment/ 2024-11-11 https://bio-research.ai/relief-therapeutics-reports-decrease-in-s-aureus-abundance-in-epidermolysis-bullosa-wounds-after-eight-weeks-of-rlf-td011-clinical-trial/ 2024-11-11 https://bio-research.ai/novelty-nobility-secures-23-3-billion-krw-in-series-c-funding-plans-for-kosdaq-application-and-clinical-trial-for-nn3201-in-the-coming-year/ 2024-11-11 https://bio-research.ai/alk-acquires-global-rights-to-ars-pharmaceuticals-nasal-spray-neffy-for-145m-upfront-potential-future-milestones-and-sales-royalties-up-to-320m/ 2024-11-09 https://bio-research.ai/fda-approves-autolus-therapeutics-aucatzyl-for-adult-r-r-b-all-treatment-based-on-felix-clinical-trial-s-resounding-results/ 2024-11-08 https://bio-research.ai/paratek-pharmaceuticals-reports-phase-2b-study-results-of-omadacycline-showing-improved-response-rate-in-patients-with-ntm-pulmonary-disease/ 2024-11-08 https://bio-research.ai/zentek-s-triera-biosciences-secures-1-1m-government-contract-to-test-aptamer-tech-for-h5n1/ 2024-11-08 https://bio-research.ai/kanvas-biosciences-reports-fmt-treatment-triggers-response-in-three-of-15-patient-trials-for-msi-h-refractory-cancers/ 2024-11-08 https://bio-research.ai/janssen-cilag-international-submits-ema-application-for-darzalex-daratumumab-subcutaneous-sc-formulation/ 2024-11-08 https://bio-research.ai/health-canada-approves-moderna-s-mresvia-vaccine-for-active-immunization-against-respiratory-syncytial-virus-in-adults-aged-60-and-above/ 2024-11-08 https://bio-research.ai/alteogen-inks-300m-deal-with-daiichi-sankyo-for-development-and-global-commercialization-of-subcutaneous-cancer-drug-enhanced-with-alt-b4-technology/ 2024-11-08 https://bio-research.ai/allovir-and-kalaris-therapeutics-merge-with-majority-stake-going-to-kalaris/ 2024-11-08 https://bio-research.ai/dizal-submits-drug-application-for-sunvozertinib-to-u-s-fda-for-non-small-cell-lung-cancer-treatment/ 2024-11-08 https://bio-research.ai/astrazeneca-and-amgen-s-tezspire-shows-decreased-nasal-polyps-and-congestion-in-phase-iii-waypoint-trial-on-adults-with-severe-crswnp/ 2024-11-08 https://bio-research.ai/io-biotech-s-phase-2-trial-of-io102-io103-shows-55-response-rate-alongside-keytruda-in-metastatic-nsclc-patients/ 2024-11-07 https://bio-research.ai/imunon-inc-reports-longer-survival-rates-in-ovation-2-study-with-imnn-001-along-with-standard-chemotherapy-for-advanced-ovarian-cancer-patients/ 2024-11-07 https://bio-research.ai/fda-grants-asklepios-biopharmaceutical-s-ab-1003-two-designations-for-limb-girdle-muscular-dystrophy-type-2i-r9-treatment/ 2024-11-07 https://bio-research.ai/arctic-vision-signs-deal-with-santen-pharmaceutical-for-commercialization-of-arvn001-in-china-excluding-taiwan-hong-kong-and-macau/ 2024-11-07 https://bio-research.ai/vaccinex-amgen-merck-and-others-collaborate-on-activmab-technology-for-enhanced-antibody-discovery-and-immunotherapy-development/ 2024-11-07 https://bio-research.ai/mustang-bio-gains-orphan-drug-designation-for-mb-108-in-malignant-glioma-treatment/ 2024-11-07 https://bio-research.ai/impact-biotech-reports-86-complete-response-rate-in-interim-phase-3-results-of-enlighted-study-for-padeliporfin-vtp-therapy-in-utuc-patients/ 2024-11-07 https://bio-research.ai/ascletis-pharma-reports-phase-i-results-of-muscle-preserving-weight-loss-drug-asc47-with-a-half-life-of-21-days/ 2024-11-07 https://bio-research.ai/geron-royalty-pharma-and-pharmakon-advisors-strike-a-375m-deal-for-rytelo-launch-and-phase-3-impactmf-trial-support/ 2024-11-07 https://bio-research.ai/juntendo-university-and-metagen-therapeutics-collaborate-on-fecal-transplant-study-for-parkinson-s-disease-treatment-earning-gaudi-award-2023/ 2024-11-07 https://bio-research.ai/sanofi-launches-retrospective-study-on-cgvhd-treatment-in-collaboration-with-lifen-cemka-and-sfgm-tc/ 2024-11-07 https://bio-research.ai/aditum-bio-leads-biolabs-launch-oblenio-bio-with-614m-option-deal-for-lbl-051-autoimmune-drug-development-and-commercialization/ 2024-11-07 https://bio-research.ai/gho-capital-and-ampersand-capital-set-to-acquire-avid-bioservices-for-1-1b-in-all-cash-deal-pending-approval-in-q1-2025/ 2024-11-06 https://bio-research.ai/fda-grants-orphan-drug-and-rare-pediatric-disease-designations-to-ifetroban-for-duchenne-muscular-dystrophy-related-cardiomyopathy-treatment/ 2024-11-06 https://bio-research.ai/forus-therapeutics-and-pharmaessentia-ink-exclusive-license-agreement-for-besremi-treatment-in-canada/ 2024-11-06 https://bio-research.ai/solascure-partners-with-u-s-army-institute-to-evaluate-aurase-wound-gel-in-combat-conditions/ 2024-11-06 https://bio-research.ai/plus-therapeutics-and-spectronrx-enter-agreement-for-manufacturing-rhenium-obisbemeda-to-enhance-cns-cancer-therapy-supply-chain/ 2024-11-06 https://bio-research.ai/fda-grants-orphan-drug-status-to-leads-biolabs-lbl-034-for-multiple-myeloma-treatment/ 2024-11-06 https://bio-research.ai/tango-therapeutics-announces-tng462-ongoing-phase-1-2-results-advances-tng462-and-tng456-cancer-drugs-halts-enrollment-for-tng908-trial/ 2024-11-06 https://bio-research.ai/minghui-pharmaceutical-s-phase-i-clinical-trial-of-mhb039a-in-relapsed-refractory-solid-tumors-reports-safety-and-20mg-kg-q3w-dosage-in-biomarker-responses/ 2024-11-06 https://bio-research.ai/oxford-vacmedix-secures-3-0m-investment-for-ovm-200-cancer-vaccine-development-plans-for-licensing-discussions-in-south-korea-china-and-india/ 2024-11-06 https://bio-research.ai/european-commission-approves-dupixent-for-eoe-in-children-as-young-as-one-year-following-phase-3-trial-results/ 2024-11-06 https://bio-research.ai/fda-awards-orphan-drug-and-rare-pediatric-disease-designation-to-belief-biomed-s-bbm-d101-for-duchenne-muscular-dystrophy-treatment/ 2024-11-06 https://bio-research.ai/ribomic-reports-interim-results-from-phase-iia-trial-of-umedaptanib-pegol-recording-increased-height-growth-rate-in-pediatric-achondroplasia-patients/ 2024-11-05 https://bio-research.ai/acadia-pharmaceuticals-to-sell-fda-granted-pediatric-disease-review-voucher-for-150m-will-pay-neuren-pharmaceuticals-a-third-of-the-proceeds/ 2024-11-05 https://bio-research.ai/tevogen-bio-partners-with-microsoft-to-expedite-hpv-treatment-development-using-ai-and-cloud-technologies/ 2024-11-05 https://bio-research.ai/arcus-biosciences-reports-36-reduction-in-death-risk-in-arc-10-lung-cancer-study-with-domvanalimab-and-zimberelimab-combination-therapy/ 2024-11-05 https://bio-research.ai/intra-cellular-therapies-inc-reports-63-reduction-in-schizophrenia-patient-relapse-with-lumateperone-treatment/ 2024-11-05 https://bio-research.ai/huons-co-ltd-invests-14-3b-krw-to-acquire-pangen-securing-31-53-stake-and-planning-to-boost-biopharmaceutical-r-d-and-cdmo-business/ 2024-11-05 https://bio-research.ai/advanz-pharma-extends-european-footprint-with-acquisition-of-atarax-and-nootropil-rights-from-ucb/ 2024-11-05 https://bio-research.ai/nxera-pharma-partners-with-antiverse-in-multi-year-ai-driven-antibody-licensing-deal-for-disease-therapies/ 2024-11-05 https://bio-research.ai/858-therapeutics-collaborates-with-openbench-for-discovery-of-small-molecule-inhibitors-using-machine-learning/ 2024-11-04 https://bio-research.ai/crossbridge-bio-secures-10-million-seed-financing-for-development-of-dual-payload-adcs-and-cbb-120-program-for-solid-tumor-treatment/ 2024-11-04 https://bio-research.ai/syndax-pharmaceuticals-secures-350m-in-synthetic-royalty-funding-from-royalty-pharma-for-u-s-net-sales-of-niktimvo/ 2024-11-04 https://bio-research.ai/surrozen-and-tcgfb-partner-in-6m-deal-to-research-antibody-therapeutics-for-idiopathic-pulmonary-fibrosis/ 2024-11-04 https://bio-research.ai/fda-fast-tracks-electra-therapeutics-ela026-for-secondary-hemophagocytic-lymphohistiocytosis-treatment/ 2024-11-04 https://bio-research.ai/fda-accepts-ionis-pharmaceuticals-application-for-donidalorsen-intended-for-preventing-hereditary-angioedema-attacks/ 2024-11-04 https://bio-research.ai/nls-pharmaceutics-and-kadimastem-to-merge-focusing-on-dual-orexin-agonist-platform-and-cell-therapy-program/ 2024-11-04 https://bio-research.ai/bighat-biosciences-licenses-synaffix-s-adc-technology-for-new-pipeline-program-also-gains-access-to-lonza-s-dna-to-ind-offerings/ 2024-11-04 https://bio-research.ai/y-mabs-and-nobelpharma-ink-2m-upfront-deal-for-danyelza-s-development-and-commercialization-in-japan-with-potential-31m-in-future-milestones/ 2024-11-04 https://bio-research.ai/integra-therapeutics-licenses-caszyme-s-cas12l-nucleases-for-40m-euros-in-milestone-payments-to-boost-gene-therapy-efficiency/ 2024-11-04 https://bio-research.ai/viking-therapeutics-unveils-results-from-phase-2-trial-for-obesity-drug-vk2735-showed-dose-dependent-weight-reduction/ 2024-11-04 https://bio-research.ai/mannkind-corporation-concludes-phase-1-study-of-nintedanib-dpi-for-pulmonary-fibrotic-diseases-with-no-adverse-effects-noted/ 2024-11-04 https://bio-research.ai/atossa-therapeutics-reports-19-3-and-26-5-reduction-in-mammographic-breast-density-from-karisma-endoxifen-phase-2-study/ 2024-11-04 https://bio-research.ai/kalvista-pharmaceuticals-inks-up-to-179m-deal-with-dri-healthcare-trust-for-commercialization-of-sebetralstat/ 2024-11-04 https://bio-research.ai/fda-approves-journey-medical-s-emrosi-for-adult-rosacea-treatment-following-successful-phase-3-clinical-trials/ 2024-11-04 https://bio-research.ai/novo-nordisk-secures-exclusive-worldwide-license-for-ascendis-pharma-s-transcon-technology-with-potential-payments-up-to-285m-for-lead-metabolic-program/ 2024-11-04 https://bio-research.ai/biomed-industries-reports-phase-i-trial-results-na-931-causes-5-1-6-8-weight-reduction-in-28-days/ 2024-11-04 https://bio-research.ai/formosa-pharmaceuticals-completes-phase-3-clinical-trial-of-app13007-reporting-reduced-ocular-inflammation-and-pain-in-chinese-cataract-patients/ 2024-11-04 https://bio-research.ai/ose-immunotherapeutics-phase-2-trial-of-lusvertikimab-meets-primary-and-secondary-endpoints-in-ulcerative-colitis-patients/ 2024-11-04 https://bio-research.ai/neurodawn-raises-hundreds-of-millions-rmb-in-series-c-to-expand-cns-treatments/ 2024-11-01 https://bio-research.ai/novo-nordisk-s-essence-trial-reveals-semaglutide-2-4-mg-shows-significant-improvement-in-liver-fibrosis-and-resolving-mash-in-phase-3-trial/ 2024-11-01 https://bio-research.ai/hansoh-pharmaceutical-s-hs-20093-recognized-as-breakthrough-therapy-for-es-sclc-by-china-s-nmpa/ 2024-11-01 https://bio-research.ai/leo-pharma-to-take-over-dovobet-sales-in-japan-after-termination-of-agreement-with-kyowa-kirin/ 2024-11-01 https://bio-research.ai/eisai-and-biogen-submit-biologics-license-application-for-lecanemab-sc-autoinjector-a-treatment-for-alzheimer-s-disease-to-the-fda/ 2024-10-31 https://bio-research.ai/essa-pharma-ends-phase-2-clinical-trial-of-masofaniten-with-enzalutamide-for-prostate-cancer-no-clear-benefit-seen/ 2024-10-31 https://bio-research.ai/bristol-myers-squibb-reports-symptom-reduction-in-schizophrenia-patients-with-cobenfy-in-year-long-phase-3-trials/ 2024-10-31 https://bio-research.ai/nanoscope-therapeutics-phase-2b-restore-trial-reports-sustained-visual-acuity-improvement-with-mco-010-in-retinitis-pigmentosa-patients/ 2024-10-31 https://bio-research.ai/supernus-pharmaceuticals-reports-80-decrease-in-suicidal-ideation-in-phase-2a-clinical-trial-of-spn-820-for-major-depressive-disorder/ 2024-10-31 https://bio-research.ai/biofrontera-inc-reports-65-5-success-in-phase-3-study-of-ameluz-treatment-for-superficial-basal-cell-carcinoma/ 2024-10-31 https://bio-research.ai/ucb-announces-phase-2a-alzheimer-s-drug-bepranemab-fails-primary-endpoint-but-reports-secondary-success-in-slowing-cognitive-decline/ 2024-10-31 https://bio-research.ai/curevo-vaccine-s-phase-2-trial-shows-amezosvatein-and-shingrix-as-effective-shingles-vaccines-with-similar-safety-levels-lower-adverse-reactions-in-higher-dose-of-amezosvatein/ 2024-10-31 https://bio-research.ai/verastem-oncology-completes-nda-submission-for-avutometinib-and-defactinib-combo-in-recurrent-kras-mutant-lgsoc-treatment/ 2024-10-31 https://bio-research.ai/formosa-pharmaceuticals-and-d-vi-farmac-utica-strike-exclusive-licensing-deal-for-post-surgery-eye-medication-app13007-in-portugal/ 2024-10-31 https://bio-research.ai/elektrofi-completes-112-25m-series-c-financing-round-for-the-development-of-commercial-scale-gmp-manufacturing-lines-and-growth-of-portfolio/ 2024-10-31 https://bio-research.ai/recce-pharmaceuticals-reports-positive-phase-ii-clinical-trial-data-for-recce-327-gel-in-treating-acute-bacterial-skin-infections/ 2024-10-31 https://bio-research.ai/abbvie-and-evolveimmune-therapeutics-strike-1-4b-deal-to-develop-oncology-biologics-using-evolve-t-cell-engager-platform/ 2024-10-31 https://bio-research.ai/absci-and-twist-bioscience-join-forces-to-design-ai-generated-therapeutic-for-undisclosed-target/ 2024-10-31 https://bio-research.ai/accenture-ventures-invests-in-ai-driven-biotech-firm-1910-genetics-to-accelerate-drug-discovery-and-enhance-patient-outcomes/ 2024-10-31 https://bio-research.ai/lipocine-inc-enters-agreement-with-spc-korea-for-marketing-and-supply-of-tlando-in-south-korea-anticipates-upfront-payment-and-sales-milestone-rewards/ 2024-10-31 https://bio-research.ai/evommune-secures-115-million-in-series-c-funding-for-further-development-of-mrgprx2-inhibitor-and-fusion-protein-program-targeting-il-18/ 2024-10-31 https://bio-research.ai/boehringer-ingelheim-and-gubra-discontinue-development-of-obesity-treatment-bi-1820237/ 2024-10-31 https://bio-research.ai/abtherx-and-gilead-sciences-expand-agreement-for-new-antibody-discovery-technologies-using-atlas-mice/ 2024-10-31 https://bio-research.ai/aerovate-therapeutics-merges-with-jade-biosciences-in-all-stock-deal-worth-300m-focuses-on-advancing-biologics-portfolio/ 2024-10-31 https://bio-research.ai/mochida-pharmaceutical-and-united-therapeutics-sign-exclusive-distribution-deal-for-tyvaso-dpi-in-japan-a-treatment-for-pah-and-ph-ild/ 2024-10-31 https://bio-research.ai/chugai-pharmaceutical-applies-for-tecentriq-s-additional-indication-for-r-r-enkl-treatment-following-phase-ii-trials/ 2024-10-31 https://bio-research.ai/bpgbio-s-bpm31510t-for-epidermolysis-bullosa-granted-rare-pediatric-disease-designation-by-fda-phase-ii-iii-trials-set-for-2025/ 2024-10-31 https://bio-research.ai/ono-pharmaceutical-forgoes-commercial-rights-to-itolizumab-equillium-and-biocon-press-ahead-with-phase-3-equator-study/ 2024-10-31 https://bio-research.ai/matinas-biopharma-ends-partnership-negotiations-for-antifungal-drug-mat2203-initiates-workforce-reduction-and-seeks-advisor-for-potential-sale/ 2024-10-31 https://bio-research.ai/hutchmed-receives-first-20m-commercial-milestone-payment-from-takeda-following-200m-in-sales-of-fruzaqla-for-metastatic-colorectal-cancer/ 2024-10-31 https://bio-research.ai/anavex-life-sciences-reveals-phase-iib-iii-trial-data-for-blarcamesine-showing-slowdown-of-alzheimer-s-disease-clinical-progression-over-48-weeks/ 2024-10-31 https://bio-research.ai/tme-pharma-receives-2-4m-non-refundable-grant-from-the-german-federal-ministry-of-education-and-research-for-phase-2-brain-cancer-study/ 2024-10-31 https://bio-research.ai/aitia-and-servier-expanding-collaboration-to-discover-new-glioma-treatments-using-digital-twins-and-ai-technology/ 2024-10-30 https://bio-research.ai/fda-grants-fast-track-designation-to-prolong-pharmaceuticals-pp-007-for-acute-ischemic-stroke-as-hemera-1-trial-progresses/ 2024-10-30 https://bio-research.ai/fda-grants-orphan-drug-designation-to-electra-therapeutics-ela026-for-treatment-of-rare-disease-shlh/ 2024-10-30 https://bio-research.ai/blue-earth-therapeutics-secures-76-5m-funding-for-phase-2-studies-of-prostate-cancer-treatments-rhpsma-10-1-isotopes/ 2024-10-30 https://bio-research.ai/remynd-terminates-phase-2a-alzheimer-s-clinical-trial-due-to-off-target-effects-plans-further-study/ 2024-10-30 https://bio-research.ai/leal-therapeutics-secures-45-million-funding-plans-to-initiate-first-in-human-trials-for-als-and-schizophrenia-drugs-in-2025/ 2024-10-30 https://bio-research.ai/capsida-biotherapeutics-gets-fda-orphan-drug-designation-for-cap-002-gene-therapy-for-stxbp1-related-encephalopathy/ 2024-10-30 https://bio-research.ai/axonis-therapeutics-secures-115-million-in-series-a-financing-round-for-neurological-disorder-therapy-axn-027-and-announces-executive-appointments/ 2024-10-30 https://bio-research.ai/synox-therapeutics-increases-series-b-funding-to-92-million-for-phase-3-clinical-trial-of-emactuzumab-in-tgct-treatment-arthur-franken-from-gilde-healthcare-to-join-board/ 2024-10-30 https://bio-research.ai/saol-therapeutics-releases-sl-1002-raise-limb-spasticity-trial-results-statistically-significant-decrease-in-modified-ashworth-score-at-six-months/ 2024-10-30 https://bio-research.ai/fda-reviews-resubmitted-drug-application-from-ptc-therapeutics-for-duchenne-muscular-dystrophy-treatment/ 2024-10-30 https://bio-research.ai/fda-accepts-biologic-license-application-for-hlx14-a-biosimilar-of-prolia-xgeva-backed-by-comparative-studies-and-phase-3-clinical-trial-results/ 2024-10-30 https://bio-research.ai/calcimedica-s-phase-2b-carpo-trial-yields-reduction-in-respiratory-failure-with-auxora-in-acute-pancreatitis-patients/ 2024-10-30 https://bio-research.ai/lexeo-therapeutics-phase-1-2-study-reveals-dose-dependent-apoe2-protein-increase-and-tau-biomarker-improvement-in-alzheimer-s-treatment-lx1001/ 2024-10-30 https://bio-research.ai/sobi-reports-significant-complete-response-rates-with-emapalumab-treatment-for-mas-in-still-s-disease-patients-in-two-studies/ 2024-10-30 https://bio-research.ai/amplia-therapeutics-releases-interim-data-from-phase-2a-accent-trial-of-narmafotinib-in-advanced-pancreatic-cancer-noting-partial-responses-in-six-patients/ 2024-10-30 https://bio-research.ai/biogen-and-neomorph-collaborate-on-1-45b-deal-to-develop-molecular-glue-degraders-for-alzheimer-s-and-rare-neurological-diseases/ 2024-10-29 https://bio-research.ai/spero-therapeutics-suspends-spr720-program-after-phase-2a-study-fails-announces-workforce-reduction-by-39/ 2024-10-29 https://bio-research.ai/cognition-therapeutics-alzheimer-s-drug-ct1812-slows-cognitive-decline-by-up-to-108-in-phase-2-shine-study/ 2024-10-29 https://bio-research.ai/fda-grants-accelerated-approval-to-novartis-s-drug-scemblix-for-chronic-myeloid-leukemia-based-on-asc4first-phase-iii-trial-results/ 2024-10-29 https://bio-research.ai/isomab-ltd-forms-development-agreement-with-catalent-inc-for-ism-001-a-therapeutic-antibody-for-type-2-diabetes-and-peripheral-artery-disease/ 2024-10-29 https://bio-research.ai/sandboxaq-partners-with-university-of-dundee-on-25m-michael-j-fox-foundation-grant-to-advance-parkinson-s-disease-drug-candidates/ 2024-10-29 https://bio-research.ai/biond-biologics-and-merck-kgaa-partner-for-a-phase-1-clinical-trial-to-evaluate-bnd-35-and-cetuximab-combination-in-treating-solid-tumors/ 2024-10-29 https://bio-research.ai/pathos-ai-secures-62m-for-ai-powered-drug-development-platform-plans-2025-clinical-trials-for-p-300-and-p-500-oncology-treatments/ 2024-10-29 https://bio-research.ai/gsk-acquires-tce-cmg1a46-from-chimagen-biosciences-for-300m-upfront-potential-payouts-up-to-550m-pending-success-based-milestones-and-regulatory-clearance/ 2024-10-29 https://bio-research.ai/fda-grants-rmat-designation-to-allogene-s-allo-316-for-advanced-renal-cell-carcinoma-treatment-based-on-traverse-trial-data/ 2024-10-29 https://bio-research.ai/zai-lab-announces-significant-panss-score-reduction-in-phase-3-trial-of-karxt-for-schizophrenia/ 2024-10-29 https://bio-research.ai/abeona-therapeutics-resubmits-biologics-license-application-to-fda-for-gene-therapy-prademagene-zamikeracel-in-recessive-dystrophic-epidermolysis-bullosa-treatment/ 2024-10-29 https://bio-research.ai/invivyd-reports-76-covid-19-risk-reduction-over-12-month-phase-3-trial-of-pemivibart/ 2024-10-29 https://bio-research.ai/quris-ai-acquires-kidney-on-chip-technology-of-nortis-plans-to-integrate-chip-tech-with-bio-ai-platform-for-advance-drug-testing/ 2024-10-29 https://bio-research.ai/glycomimetics-phase-2-trial-of-uproleselan-shows-no-significant-improvement-in-survival-for-older-acute-myeloid-leukemia-patients/ 2024-10-29 https://bio-research.ai/ryvu-therapeutics-and-ncage-therapeutics-collaborate-to-enhance-adc-platform-with-trap-cage-tech-for-oncology-treatments/ 2024-10-29 https://bio-research.ai/gemvax-kael-s-phase-2a-trial-of-gv1001-shows-decrease-in-disease-progression-in-progressive-supranuclear-palsy-patients/ 2024-10-29 https://bio-research.ai/coya-therapeutics-reports-phase-2-trial-results-of-ld-il-2-in-alzheimer-s-patients-regulatory-t-cell-populations-increase-csf-soluble-a-42-levels-improve-with-four-week-regimen/ 2024-10-29 https://bio-research.ai/glycomimetics-enters-acquisition-deal-with-crescent-biopharma-to-focus-on-oncology-therapeutics-development/ 2024-10-29 https://bio-research.ai/innovent-biologics-conducts-phase-2-study-of-picankibart-in-plaque-psoriasis-patients-showcases-significant-skin-clearance-post-16-week-treatment/ 2024-10-29 https://bio-research.ai/dr-falk-pharma-acquires-kynos-therapeutics-and-its-key-investigational-asset-kns366-for-undisclosed-financial-terms/ 2024-10-29 https://bio-research.ai/jw-pharmaceutical-collaborates-with-tempus-ai-to-expedite-oncology-drug-development-using-real-world-data-and-organoid-models/ 2024-10-29 https://bio-research.ai/fda-grants-fast-track-designation-to-healx-s-drug-candidate-hlx-1502-for-neurofibromatosis-type-1-treatment/ 2024-10-28 https://bio-research.ai/vaxxas-awarded-nih-license-for-rsv-vaccine-set-to-advance-needle-free-room-temperature-stable-rsv-vaccine-for-clinical-studies/ 2024-10-28 https://bio-research.ai/sparrow-pharmaceuticals-completes-phase-2-trial-of-clofutriben-for-endogenous-cushing-s-syndrome-plans-for-further-development/ 2024-10-28 https://bio-research.ai/eyepoint-pharmaceuticals-reports-16-week-phase-2-results-of-duravyu-trial-for-diabetic-macular-edema-patients/ 2024-10-28 https://bio-research.ai/novartis-and-monte-rosa-reach-2-25b-deal-for-global-rights-on-vav1-mgds-including-phase-1-drug-mrt-6160/ 2024-10-28 https://bio-research.ai/abbvie-to-acquire-aliada-therapeutics-for-1-4b-plans-to-advance-phase-1-alzheimer-s-drug-alia-1758-and-neurological-disorder-treatments/ 2024-10-28 https://bio-research.ai/johnson-johnson-s-phase-3-study-shows-higher-remission-rates-in-crohn-s-disease-with-tremfya-treatment-at-48-weeks/ 2024-10-28 https://bio-research.ai/odyssey-therapeutics-and-terray-therapeutics-team-up-to-discover-small-molecule-medicines-for-autoimmune-diseases/ 2024-10-28 https://bio-research.ai/eli-lilly-reports-majority-of-patients-maintain-remission-in-phase-3-studies-of-mirikizumab-for-bowel-diseases/ 2024-10-28 https://bio-research.ai/sanofi-invests-in-resalis-therapeutics-for-development-and-trials-of-obesity-therapy-res-010/ 2024-10-28 https://bio-research.ai/astrazeneca-s-fasenra-gets-european-union-approval-as-supplementary-treatment-for-adult-egpa-patients-following-mandara-phase-iii-trial-results/ 2024-10-28 https://bio-research.ai/vianautis-bio-and-eli-lilly-enter-strategic-collaboration-leveraging-polynaut-platform-to-develop-genetic-medicines/ 2024-10-28 https://bio-research.ai/gc-biopharma-and-novelty-nobility-partner-to-develop-antibody-based-treatment-for-geographic-atrophy/ 2024-10-28 https://bio-research.ai/corxel-pharmaceuticals-and-lenz-therapeutics-phase-3-trial-hits-primary-endpoints-for-lnz100-in-presbyopia-patients/ 2024-10-27 https://bio-research.ai/biogen-announces-phase-2-ignaz-study-results-showing-felzartamab-reduced-proteinuria-in-iga-nephropathy-patients-over-18-months/ 2024-10-26 https://bio-research.ai/celldex-therapeutics-met-all-primary-and-secondary-endpoints-in-phase-2-trial-of-barzolvolimab-for-chronic-inducible-urticaria-plans-phase-3-in-2025/ 2024-10-26 https://bio-research.ai/leo-pharma-reports-safety-and-92-9-efficacy-in-atopic-dermatitis-treatment-with-adbry-in-five-year-extension-study/ 2024-10-25 https://bio-research.ai/johnson-johnson-s-phase-3b-spectrem-study-results-show-tremfya-clearing-skin-in-patients-with-moderate-plaque-psoriasis-failing-topical-treatments/ 2024-10-25 https://bio-research.ai/dermavant-sciences-48-week-adoring-3-study-results-show-51-9-of-patients-achieve-complete-disease-clearance-using-vtama-cream-1-for-atopic-dermatitis/ 2024-10-25 https://bio-research.ai/fda-grants-orphan-drug-designation-to-modalis-therapeutics-mdl-101-for-congenital-muscular-dystrophy-type-1a-treatment/ 2024-10-25 https://bio-research.ai/aspa-therapeutics-canaspire-gene-therapy-trial-for-canavan-disease-leads-to-lower-naa-levels-and-improved-motor-skills-in-participants/ 2024-10-25 https://bio-research.ai/belief-biomed-gets-advanced-therapy-medicinal-product-designation-from-european-medicines-agency-for-hemophilia-b-gene-therapy/ 2024-10-25 https://bio-research.ai/agomab-therapeutics-secures-89-million-in-series-d-financing-for-development-of-fibrosis-focused-drugs/ 2024-10-25 https://bio-research.ai/eli-lilly-s-phase-3b-adapt-study-reveals-ebglyss-reduces-symptoms-in-atopic-dermatitis-patients-previously-treated-with-dupilumab/ 2024-10-25 https://bio-research.ai/senhwa-biosciences-silmitasertib-gains-fda-orphan-drug-status-for-neuroblastoma-treatment-proceeds-to-phase-i-ii-trial/ 2024-10-25 https://bio-research.ai/dash-bio-secures-6-5m-in-seed-financing-led-by-freestyle-capital-for-automation-in-drug-development/ 2024-10-24 https://bio-research.ai/3sbio-subsidiary-acquires-commercialization-rights-for-oral-paclitaxel-from-haihe-biopharma-s-nomaixi-overseeing-phase-iii-clinical-trials-and-product-development/ 2024-10-24 https://bio-research.ai/tyra-biosciences-reports-54-5-partial-response-rate-in-phase-1-study-of-tyra-300-for-fgfr3-muc-patients/ 2024-10-24 https://bio-research.ai/lyell-immunopharma-to-acquire-immpact-bio-for-30m-and-37-5m-shares-expanding-car-t-cell-therapies-portfolio/ 2024-10-24 https://bio-research.ai/coeptis-therapeutics-expands-license-agreement-with-deverra-for-allogeneic-nk-cell-technology-includes-provisions-for-pandemic-related-diseases/ 2024-10-24 https://bio-research.ai/abbvie-and-gedeon-richter-enter-25m-agreement-for-neuropsychiatric-treatment-development-abbvie-retains-global-rights/ 2024-10-24 https://bio-research.ai/dyno-therapeutics-and-roche-join-forces-to-develop-aav-vectors-for-neurological-gene-therapies-dyno-to-get-50m-upfront-plus-1b-in-milestones/ 2024-10-24 https://bio-research.ai/omeros-zaltenibart-receives-fda-rare-pediatric-disease-designation-for-c3g-and-preps-for-phase-3-trials/ 2024-10-24 https://bio-research.ai/marinus-pharmaceuticals-halts-ganaxolone-development-after-phase-3-trial-misses-primary-endpoint-in-tsc-seizures-initiates-cost-cutting-measures/ 2024-10-24 https://bio-research.ai/quantro-therapeutics-partners-with-dr-zuber-s-team-at-imp-to-study-cancer-targets-leveraging-11m-funding-from-boehringer-ingelheim-venture-fund-and-evotec/ 2024-10-24 https://bio-research.ai/ntc-partners-with-chinoin-productos-farmac-uticos-for-licensing-and-distribution-of-colonoscopy-preparation-drug-ntc015-in-mexico-and-latin-america/ 2024-10-24 https://bio-research.ai/bayer-and-dewpoint-therapeutics-enter-exclusive-licensing-agreement-worth-424m-for-dilated-cardiomyopathy-treatment-program/ 2024-10-24 https://bio-research.ai/intellia-therapeutics-reports-reduction-in-hae-attack-rates-in-phase-2-study-of-ntla-2002-chooses-50-mg-dosage-for-phase-3-trials/ 2024-10-24 https://bio-research.ai/regeneron-sanofi-report-dupixent-reduced-itch-hive-activity-in-chronic-spontaneous-urticaria-study/ 2024-10-24 https://bio-research.ai/fda-grants-fast-track-designation-to-shionogi-co-ube-corporation-s-rsv-drug-candidate-s-337395/ 2024-10-24 https://bio-research.ai/monopar-therapeutics-acquires-exclusive-global-license-to-alxn-1840-from-alexion-set-to-take-charge-of-future-development-and-commercialization-activities/ 2024-10-24 https://bio-research.ai/hope-medicine-reports-positive-phase-2-study-results-of-hmi-115-in-endometriosis-associated-pain-reduction/ 2024-10-23 https://bio-research.ai/alkeus-pharmaceuticals-reports-reduced-growth-of-ga-lesions-in-amd-patients-treated-with-gildeuretinol/ 2024-10-23 https://bio-research.ai/merck-acquires-modifi-biosciences-for-30m-upfront-with-potential-milestone-payments-up-to-1-3b-for-advancing-cancer-therapeutics/ 2024-10-23 https://bio-research.ai/march-biosciences-secures-28-4-million-in-series-a-financing-for-phase-2-development-of-mb-105-car-t-therapy-for-t-cell-lymphoma/ 2024-10-23 https://bio-research.ai/nimmune-acquires-omilancor-development-and-commercialization-rights-in-asia-after-lianbio-wind-down/ 2024-10-23 https://bio-research.ai/intocell-and-abl-bio-sign-technology-transfer-agreement-for-ohpas-nexatecan-in-pursuit-of-advanced-adcs-development/ 2024-10-23 https://bio-research.ai/alpha-9-oncology-attains-175-million-funding-for-clinical-trials-and-expansion-of-research-development-capabilities/ 2024-10-23 https://bio-research.ai/double-point-ventures-to-acquire-lumos-pharma-for-38m-with-contingent-value-right-conditions/ 2024-10-23 https://bio-research.ai/ikarovec-secures-additional-5m-seed-funding-for-preclinical-studies-of-ikc159v-a-gene-therapy-for-geographic-atrophy/ 2024-10-23 https://bio-research.ai/zhaoke-ophthalmology-reveals-phase-iii-trial-results-of-nvk002-for-myopia-control-in-children-and-adolescents-in-china/ 2024-10-23 https://bio-research.ai/duhn-therapeutics-and-om-pharma-in-exclusive-license-agreement-advance-lipid-based-cancer-immunotherapy-dhn198-with-116-5m-in-milestones/ 2024-10-23 https://bio-research.ai/european-commission-approves-darzalex-in-combination-with-bortezomib-lenalidomide-and-dexamethasone-for-specific-multiple-myeloma-patients-based-on-perseus-study-data/ 2024-10-23 https://bio-research.ai/evotec-earns-50m-from-bristol-myers-squibb-as-strategic-partnership-expands-beyond-oncology-with-novel-drug-discovery-efforts/ 2024-10-23 https://bio-research.ai/calluna-pharma-completes-phase-1-clinical-study-of-cal101-with-favorable-safety-profile-on-57-subjects/ 2024-10-23 https://bio-research.ai/pfizer-s-rsv-vaccine-abrysvo-receives-fda-approval-for-preventing-lrtd-in-high-risk-adults-and-pregnant-individuals/ 2024-10-22 https://bio-research.ai/alto-neuroscience-s-alto-100-fails-to-meet-primary-endpoint-in-phase-2b-major-depressive-disorder-study-but-exhibits-consistent-safety-profile/ 2024-10-22 https://bio-research.ai/ocuphire-pharma-acquires-opus-genetics-in-all-stock-deal-forges-leading-gene-therapy-firm-for-inherited-retinal-diseases/ 2024-10-22 https://bio-research.ai/remedy-pharmaceuticals-receives-fda-orphan-drug-designation-for-cirara-in-acute-ischemic-stroke-treatment/ 2024-10-22 https://bio-research.ai/be-biopharma-closes-82-million-financing-to-advance-be-101-program-for-hemophilia-b-treatment-into-clinics-and-progress-be-102-for-hypophosphatasia/ 2024-10-22 https://bio-research.ai/hansoh-pharma-s-phase-iii-trial-of-ameile-with-chemotherapy-halves-disease-progression-risk-in-advanced-nsclc-patients/ 2024-10-22 https://bio-research.ai/tersera-therapeutics-acquires-global-rights-to-margenza-from-macrogenics-for-40m-with-additional-35m-in-potential-milestones/ 2024-10-22 https://bio-research.ai/siga-technologies-licenses-vanderbilt-university-s-monoclonal-antibodies-for-orthopoxviruses-treatment-funded-by-department-of-defense-for-phase-1-trials/ 2024-10-22 https://bio-research.ai/passkey-therapeutics-attains-20-million-for-development-of-synergistic-multifunctional-therapeutics-and-locksmith-platform/ 2024-10-22 https://bio-research.ai/avencell-therapeutics-rakes-in-112-million-for-car-t-cell-therapy-platform-and-clinical-trials-for-aml-treatments/ 2024-10-22 https://bio-research.ai/minghui-pharmaceutical-reports-safety-and-efficacy-of-mhb018a-in-phase-ib-ii-clinical-trial-for-thyroid-eye-disease/ 2024-10-22 https://bio-research.ai/shandong-luoxin-pharmaceutical-secures-marketing-approval-for-tegoprazan-as-adjunct-therapy-in-helicobacter-pylori-eradication-from-china-s-national-medical-products-administration/ 2024-10-22 https://bio-research.ai/otsuka-pharmaceutical-s-phase-3-trial-of-sibeprenlimab-achieves-primary-endpoint-in-iga-nephropathy-treatment-after-nine-months/ 2024-10-22 https://bio-research.ai/redhill-biopharma-and-duke-university-collaborate-for-in-vivo-studies-of-opaganib-as-countermeasure-for-phosgene-inhalation/ 2024-10-22 https://bio-research.ai/molecular-partners-and-orano-med-revise-agreement-set-to-jointly-develop-four-radio-darpin-programs-for-cancer-treatment/ 2024-10-22 https://bio-research.ai/fda-issues-complete-response-letter-to-camurus-for-cam2029-due-to-manufacturing-concerns/ 2024-10-22 https://bio-research.ai/aft-pharmaceuticals-collaborates-with-european-partners-for-phase-iii-trial-of-undisclosed-drug-targeting-market-set-to-reach-7b-by-2033/ 2024-10-22 https://bio-research.ai/samsung-biologics-secures-1-24b-contract-manufacturing-deal-with-unnamed-asian-pharmaceutical-firm-till-2037/ 2024-10-21 https://bio-research.ai/annexon-reports-phase-2-study-results-for-anx007-in-treating-dry-age-related-macular-degeneration-shows-preservation-of-central-photoreceptor-cells/ 2024-10-21 https://bio-research.ai/innovent-biologics-phase-2-trial-finds-the-drug-ibi302-as-effective-as-aflibercept-in-treating-neovascular-age-related-macular-degeneration/ 2024-10-21 https://bio-research.ai/editas-medicine-and-genevant-sciences-collaborate-on-238m-deal-to-develop-in-vivo-gene-editing-treatments/ 2024-10-21 https://bio-research.ai/bright-minds-biosciences-teams-up-with-firefly-neuroscience-for-eeg-data-analysis-in-phase-2-clinical-trial-of-bmb-101-targeting-epilepsy/ 2024-10-21 https://bio-research.ai/mitsubishi-tanabe-pharma-america-presents-phase-3b-study-results-of-radicava-ors-for-als-at-2024-consortium-meeting/ 2024-10-21 https://bio-research.ai/fda-accepts-lenz-therapeutics-application-for-presbyopia-treatment-lnz100-sets-pdufa-date-for-august-2025/ 2024-10-21 https://bio-research.ai/papillon-therapeutics-receives-second-fda-rare-pediatric-disease-designation-for-ppl-002-in-danon-disease-treatment/ 2024-10-21 https://bio-research.ai/fda-to-review-elevar-therapeutics-rivoceranib-application-for-unresectable-hepatocellular-carcinoma-treatment-by-march-2025/ 2024-10-21 https://bio-research.ai/regenxbio-reports-97-reduction-in-treatment-burden-in-phase-ii-study-of-abbv-rgx-314-for-wet-amd/ 2024-10-21 https://bio-research.ai/perseus-proteomics-and-ube-corporation-team-up-for-research-into-antibody-drug-conjugates-eyeing-long-term-business-expansion/ 2024-10-21 https://bio-research.ai/gsk-invests-50m-in-ai-driven-research-partnership-with-university-of-cambridge-to-accelerate-r-d-in-immune-related-diseases/ 2024-10-21 https://bio-research.ai/avacta-therapeutics-and-tempus-ai-join-to-analyze-tumor-data-and-enhance-pre-cision-platform-for-cancer-indications/ 2024-10-21 https://bio-research.ai/novo-nordisk-reports-reduction-in-cardiovascular-events-in-type-2-diabetes-patients-using-semaglutide-in-soul-trial/ 2024-10-21 https://bio-research.ai/seaport-therapeutics-secures-225-million-for-clinical-trials-and-glyph-platform-development/ 2024-10-21 https://bio-research.ai/angelini-pharma-secures-exclusive-global-development-option-for-cureverse-s-cv-01-could-pay-up-to-360m/ 2024-10-21 https://bio-research.ai/gilead-sciences-and-merck-s-phase-2-study-reports-48-week-viral-suppression-with-islatravir-and-lenacapavir-for-hiv-treatment/ 2024-10-19 https://bio-research.ai/vyloy-becomes-the-first-fda-approved-cldn18-2-targeted-therapy-for-advanced-gastric-and-gej-cancer/ 2024-10-18 https://bio-research.ai/arcutis-biotherapeutics-zoryve-receives-canadian-approval-for-seborrheic-dermatitis-treatment-based-on-phase-3-study-outcomes/ 2024-10-18 https://bio-research.ai/lanova-secured-42-million-in-series-c1-funding-which-will-push-the-clinical-development-of-its-pipeline-including-lm-299/ 2024-10-18 https://bio-research.ai/chmp-recommends-novartis-s-kisqali-for-high-risk-early-breast-cancer-based-on-phase-iii-natalee-trial-results/ 2024-10-18 https://bio-research.ai/chmp-re-evaluates-decision-on-renewal-of-translarna-s-conditional-marketing-authorization-for-treating-nmdmd-european-commission-review-pending/ 2024-10-18 https://bio-research.ai/chmp-issues-positive-opinion-on-alhemo-a-prophylactic-treatment-for-haemophilia-a-or-b-from-novo-nordisk-based-on-phase-3-trials/ 2024-10-18 https://bio-research.ai/merck-s-phase-2b-3-trial-reveals-clesrovimab-reduces-rsv-associated-illness-and-hospitalization-rates-by-84-and-90-respectively/ 2024-10-17 https://bio-research.ai/supernus-pharmaceuticals-reports-reduced-depressive-symptoms-in-phase-2a-spn-820-clinical-study/ 2024-10-17 https://bio-research.ai/spyglass-pharma-s-intraocular-lens-drug-delivery-platform-leads-to-43-7-reduction-in-mean-iop-in-glaucoma-patients-at-18-month-study-follow-up/ 2024-10-17 https://bio-research.ai/avadel-pharmaceuticals-secures-fda-approval-for-supplemental-application-of-lumryz-in-narcolepsy-patients-aged-seven-and-older/ 2024-10-17 https://bio-research.ai/agenebio-s-hope4mci-phase-2b-study-finds-agb101-reduces-clinical-decline-by-40-in-non-apoe-4-alzheimer-s-patients/ 2024-10-17 https://bio-research.ai/ema-denies-conditional-marketing-authorization-for-ab-science-s-masitinib-in-als-treatment/ 2024-10-17 https://bio-research.ai/clearb-therapeutics-inks-deal-with-adjuvance-technologies-plans-to-use-novel-adjuvant-tql-1055-in-hepatitis-b-cure-development/ 2024-10-17 https://bio-research.ai/eterna-therapeutics-and-factor-bioscience-partner-to-advance-ipsc-based-cell-therapy-for-oncology-and-rare-diseases/ 2024-10-17 https://bio-research.ai/noema-pharma-ag-s-phase-2a-trial-of-noe-105-in-tourette-syndrome-patients-hits-primary-and-key-secondary-endpoints-with-57-improvement-reported/ 2024-10-17 https://bio-research.ai/xenetic-biosciences-and-tokyo-medical-university-collaborate-for-systemic-dnase-program-targeting-ewing-sarcoma-in-landmark-agreement/ 2024-10-17 https://bio-research.ai/fda-approves-abbvie-s-vyalev-for-treatment-of-motor-fluctuations-in-advanced-parkinson-s-disease-patients-phase-3-study-results/ 2024-10-17 https://bio-research.ai/marinus-pharmaceuticals-phase-3-raise-trial-shows-iv-ganaxolone-reduces-seizures-quicker-in-rse-patients-but-fails-some-primary-endpoints/ 2024-10-17 https://bio-research.ai/innovent-biologics-phase-2-trial-of-picankibart-achieves-primary-and-secondary-endpoints-in-chinese-ulcerative-colitis-patients/ 2024-10-17 https://bio-research.ai/lexicon-pharmaceuticals-licenses-sotagliflozin-to-viatris-for-25m-upfront-payment-retains-rights-in-us-and-europe/ 2024-10-16 https://bio-research.ai/athos-therapeutics-announces-phase-1-clinical-trial-results-of-ath-063-for-inflammatory-bowel-disease-treatment-increase-in-regulatory-t-cells-observed/ 2024-10-16 https://bio-research.ai/sanofi-s-flublok-flu-vaccine-shows-no-increased-risk-for-pregnancy-related-issues-according-to-fda-updated-label-data-from-a-large-safety-study/ 2024-10-16 https://bio-research.ai/akeso-biopharma-s-compassion-16-study-reveals-50-reduction-in-risk-of-death-with-cadonilimab-in-cervical-cancer-treatment/ 2024-10-16 https://bio-research.ai/matica-bio-partners-with-mongoose-bio-to-develop-lentivirus-for-tcr-t-cancer-treatments-in-key-texas-biotech-move/ 2024-10-16 https://bio-research.ai/ability-biologics-teams-up-with-mila-quebec-artificial-intelligence-institute-to-develop-safer-more-efficient-antibody-therapeutics/ 2024-10-16 https://bio-research.ai/wave-life-sciences-reports-rna-editing-in-phase-1b-2a-trial-of-wve-006-for-alpha-1-antitrypsin-deficiency/ 2024-10-16 https://bio-research.ai/theriva-biologics-vcn-01-for-retinoblastoma-treatment-receives-orphan-medicinal-product-designation-from-the-european-commission/ 2024-10-16 https://bio-research.ai/orasis-pharmaceuticals-licenses-presbyopia-treatment-to-optus-for-18m-paving-way-for-qlosi-s-launch-in-south-korea-by-2026/ 2024-10-16 https://bio-research.ai/astria-therapeutics-secures-orphan-medicinal-product-designation-for-navenibart-in-the-eu-and-us-following-phase-1b-2-results/ 2024-10-16 https://bio-research.ai/expres2ion-announces-term-sheet-to-license-malaria-vaccine-product-lines-in-development-to-serum-institute-of-india-assured-to-reach-millions-at-risk/ 2024-10-16 https://bio-research.ai/merck-s-stride-8-trial-reveals-capvaxive-s-immunogenicity-for-21-pneumococcal-strains-comparable-immune-responses-and-decreased-adverse-events-in-adults-with-chronic-conditions/ 2024-10-16 https://bio-research.ai/fda-accepts-gsk-s-gepotidacin-application-for-urinary-tract-infections-based-on-eagle-2-and-eagle-3-trial-results/ 2024-10-16 https://bio-research.ai/neurogastrx-s-drug-ng101-reduces-nausea-by-40-and-vomiting-by-56-in-glp-1-agonist-study/ 2024-10-16 https://bio-research.ai/bioversys-completes-phase-2-clinical-trial-for-antibiotic-bv100-lowers-mortality-rates-in-vabp-collaborates-further-with-gsk-on-bv200-and-bv500-development/ 2024-10-16 https://bio-research.ai/hutchmed-reports-efficacy-of-tagrisso-and-orpathys-combination-in-phase-ii-trial-for-egfr-mutated-lung-cancer/ 2024-10-16 https://bio-research.ai/nuclera-secure-57-million-for-expansion-of-eprotein-discovery-system-in-us-and-europe/ 2024-10-16 https://bio-research.ai/tennor-therapeutics-secures-over-300-million-rmb-in-series-e-funding-for-development-of-treatments-for-h-pylori-infection-and-prosthetic-joint-infections/ 2024-10-16 https://bio-research.ai/valbiotis-reports-significant-reduction-in-systolic-blood-pressure-with-totum-854-in-3-month-insight-study/ 2024-10-15 https://bio-research.ai/beacon-therapeutics-phase-2-skyline-trial-shows-57-response-rate-and-safety-of-agtc-501-in-x-linked-retinitis-pigmentosa-patients/ 2024-10-15 https://bio-research.ai/synedgen-and-barda-enter-119m-deal-for-miist305-development-to-combat-gi-ars-17m-granted-for-initial-proof-of-concept-studies/ 2024-10-15 https://bio-research.ai/fda-grants-fast-track-designation-to-lantern-pharma-s-lp-184-for-glioblastoma-treatment-phase-1a-clinical-trial-underway/ 2024-10-15 https://bio-research.ai/revopsis-therapeutics-receives-1-8m-sbir-grant-from-national-eye-institute-aims-for-human-trials-of-ro-104-by-2025/ 2024-10-15 https://bio-research.ai/thryv-therapeutics-shares-top-line-results-from-lqt-1213-clinical-study-on-clqts-types-2-and-3-shows-qtcf-interval-reduction-after-two-day-dosing/ 2024-10-15 https://bio-research.ai/fda-grants-rare-pediatric-disease-designation-to-papillon-therapeutics-for-friedreich-s-ataxia-therapy-ppl-001/ 2024-10-15 https://bio-research.ai/molecure-s-a-licenses-selective-ykl-40-inhibitor-program-to-ocean-biomedical-inc-for-32m-with-joint-oversight-on-research-and-commercialization-process/ 2024-10-15 https://bio-research.ai/ripple-therapeutics-and-glaukos-corporation-enter-evaluation-and-licensing-agreement-for-sustained-release-implants-development-in-glaucoma-treatment/ 2024-10-15 https://bio-research.ai/amgen-s-phase-3-mint-trial-meets-primary-endpoint-evaluating-uplizna-in-treating-generalized-myasthenia-gravis-at-week-26/ 2024-10-15 https://bio-research.ai/tolerance-bio-secures-17-2-million-seed-financing-to-advance-immune-tolerance-therapies-using-ipsc-technologies/ 2024-10-15 https://bio-research.ai/fda-grants-orphan-drug-designation-to-immuneering-s-imm-1-104-for-pancreatic-cancer-treatment/ 2024-10-15 https://bio-research.ai/johnson-johnson-s-phase-2-3-trial-shows-sustained-control-of-generalized-myasthenia-gravis-with-nipocalimab-over-24-weeks/ 2024-10-15 https://bio-research.ai/sellas-life-sciences-earns-rare-pediatric-disease-designation-for-galinpepimut-s-in-pediatric-acute-myeloid-leukemia-treatment-from-fda/ 2024-10-15 https://bio-research.ai/triana-biomedicines-partners-with-pfizer-on-1-5b-deal-for-molecular-glue-degraders-discovery-and-development/ 2024-10-15 https://bio-research.ai/jazz-pharmaceuticals-reports-improved-survival-in-phase-3-trial-of-zepzelca-and-atezolizumab-for-es-sclc-patients/ 2024-10-15 https://bio-research.ai/invios-gmbh-secures-8-2-million-funding-advances-inv441-and-inv501-anti-cancer-programs-with-dana-farber-cancer-institute/ 2024-10-15 https://bio-research.ai/topas-therapeutics-announces-phase-2a-trial-results-tpm502-safe-and-efficacious-in-celiac-disease-patients/ 2024-10-15 https://bio-research.ai/lg-and-hanmi-pharmaceutical-invest-5m-in-medic-life-sciences-for-cancer-drug-discovery-and-biomarker-technology-enhancement/ 2024-10-14 https://bio-research.ai/medic-life-sciences-and-hanmi-pharmaceutical-collaborate-to-identify-cancer-biomarkers-for-clinical-trials/ 2024-10-14 https://bio-research.ai/exelixis-and-merck-ink-clinical-development-collaboration-for-phase-3-trials-of-zanzalintinib-in-head-neck-cancers-and-renal-cell-carcinoma/ 2024-10-14 https://bio-research.ai/jasper-therapeutics-spotlight-study-reports-response-in-14-of-15-patients-using-briquilimab-for-cold-urticaria-and-symptomatic-dermographism/ 2024-10-14 https://bio-research.ai/gsk-s-phase-iii-trials-for-depemokimab-meet-primary-endpoints-at-52-weeks-in-treatment-of-crswnp/ 2024-10-14 https://bio-research.ai/lundbeck-to-acquire-longboard-pharmaceuticals-for-2-5b-enhancing-neuro-rare-disease-portfolio-with-late-stage-asset-bexicaserin/ 2024-10-14 https://bio-research.ai/eli-lilly-s-phase-3-study-shows-more-crohn-s-disease-patients-achieve-histologic-response-with-mirikizumab-than-ustekinumab-at-week-52/ 2024-10-14 https://bio-research.ai/inventiva-nets-348-million-in-equity-financing-to-advance-phase-3-trial-of-lanifibranor-sees-changes-in-key-leadership-positions/ 2024-10-14 https://bio-research.ai/shanghai-junshi-biosciences-gains-approval-for-ongericimab-injection-for-primary-hypercholesterolemia-treatment-following-phase-3-clinical-trials/ 2024-10-12 https://bio-research.ai/benitec-biopharma-reports-interim-data-from-bb-301-phase-1b-2a-study-showing-improvement-in-swallowing-function-in-two-opmd-patients/ 2024-10-12 https://bio-research.ai/fda-approves-pfizer-s-therapy-hympavzi-for-hemophilia-a-and-b-demonstrating-reduced-bleeding-frequency-in-basis-trial/ 2024-10-11 https://bio-research.ai/dong-a-st-s-imuldosa-secures-fda-approval-as-second-approved-biosimilar-after-sivextro-in-2014/ 2024-10-11 https://bio-research.ai/perspective-therapeutics-unveils-initial-phase-1-2a-results-of-pb-vmt01-with-no-reported-dose-limiting-toxicities-in-melanoma-research-society-study/ 2024-10-11 https://bio-research.ai/fda-advisory-committee-supports-approval-of-stealth-biotherapeutics-elamipretide-for-barth-syndrome-treatment/ 2024-10-11 https://bio-research.ai/cantargia-s-drug-candidate-can10-blocks-il-1-and-il-36-signaling-in-phase-1-clinical-trial-with-68-participants/ 2024-10-11 https://bio-research.ai/janssen-biotech-to-use-xtalpi-s-ai-software-xtalfold-for-drug-discovery-under-new-licensing-agreement/ 2024-10-10 https://bio-research.ai/fda-approves-genentech-s-itovebi-for-hormone-receptor-positive-breast-cancer-with-pik3ca-mutation-following-phase-iii-trial-results/ 2024-10-10 https://bio-research.ai/allakos-inc-reports-77-bioavailability-in-phase-1-study-of-ak006-with-no-severe-side-effects-observed/ 2024-10-10 https://bio-research.ai/eli-lilly-and-keybioscience-expand-collaboration-on-dacra-obesity-treatment-deal-includes-1-4b-in-milestone-payments-and-royalties-on-sales/ 2024-10-10 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-volixibat-for-cholestatic-pruritus-in-primary-biliary-cholangitis-patients-based-on-phase-2b-study-results/ 2024-10-10 https://bio-research.ai/johnson-johnson-s-tremfya-shows-high-endoscopic-remission-rates-in-phase-3-crohn-s-disease-and-ulcerative-colitis-studies/ 2024-10-10 https://bio-research.ai/vico-therapeutics-reports-interim-data-from-phase-1-2a-trial-of-vo659-showing-mean-reduction-in-mutant-htt-protein-in-huntington-s-disease-patients/ 2024-10-10 https://bio-research.ai/booster-therapeutics-initiates-its-journey-with-15-million-financing-for-developing-proteasome-activator-medicines/ 2024-10-10 https://bio-research.ai/tempest-therapeutics-and-roche-partner-for-phase-3-trial-of-cancer-drug-amezalpat-in-combination-with-atezolizumab-and-bevacizumab/ 2024-10-10 https://bio-research.ai/pfizer-s-talzenna-in-combination-with-xtandi-improves-survival-in-metastatic-prostate-cancer-study/ 2024-10-10 https://bio-research.ai/immatics-n-v-reports-54-objective-response-rate-from-phase-1b-trials-on-actengine-ima203-plans-phase-3-for-2024/ 2024-10-10 https://bio-research.ai/ono-pharmaceutical-licenses-ligachem-s-antibody-drug-conjugate-lcb97-for-700m-partners-for-future-adc-development/ 2024-10-10 https://bio-research.ai/janssen-cilag-applies-to-european-medicines-agency-for-darzalex-indication-extension-based-on-phase-3-cepheus-study-data/ 2024-10-10 https://bio-research.ai/arda-therapeutics-raises-43-million-in-series-a-financing-round-for-cell-depletion-therapies-development-appoints-scott-turner-as-chief-scientific-officer/ 2024-10-09 https://bio-research.ai/vanqua-bio-s-phase-1-trials-show-vq-101-activates-gcase-enzyme-by-over-75-in-healthy-volunteers/ 2024-10-09 https://bio-research.ai/nona-biosciences-and-overt-bio-join-forces-to-develop-advanced-cell-therapies-for-solid-tumors-using-hcab-harbour-mice-and-nonacarfx-platforms/ 2024-10-09 https://bio-research.ai/sonnet-biotherapeutics-and-alkem-laboratories-ink-2m-licensing-agreement-for-dpn-treatment-son-080-in-india-sharing-clinical-trials-data-for-further-collaborations/ 2024-10-09 https://bio-research.ai/fda-accepts-bayer-s-application-for-elinzanetant-based-on-phase-iii-studies-for-treating-menopausal-vasomotor-symptoms/ 2024-10-09 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-biogen-s-felzartamab-for-kidney-transplant-rejection-treatment/ 2024-10-09 https://bio-research.ai/a-head-bio-ag-raises-funds-for-preclinical-to-clinical-drug-development-link-former-minister-and-founding-member-join-supervisory-board/ 2024-10-09 https://bio-research.ai/european-commission-authorizes-novavax-s-updated-nuvaxovid-covid-19-vaccine-for-individuals-aged-12-and-older-based-on-clinical-trial-data/ 2024-10-09 https://bio-research.ai/boehringer-ingelheim-and-circle-pharma-ink-607m-deal-for-cancer-trials-using-mxmotm-platform/ 2024-10-09 https://bio-research.ai/innocare-pharma-s-icp-488-achieves-primary-endpoint-in-phase-ii-clinical-study-for-moderate-to-severe-plaque-psoriasis/ 2024-10-09 https://bio-research.ai/fda-grants-orphan-drug-designation-to-namodenoson-of-can-fite-biopharma-for-pancreatic-cancer-treatment/ 2024-10-09 https://bio-research.ai/bio-thera-and-gedeon-richter-ink-110m-exclusive-deal-for-bat2206-targeting-eu-and-uk-markets/ 2024-10-09 https://bio-research.ai/clearside-biomedical-s-odyssey-phase-2b-trial-of-cls-ax-shows-stable-visual-acuity-in-67-participants-over-six-months/ 2024-10-09 https://bio-research.ai/viking-therapeutics-phase-1b-clinical-trial-reveals-vk0214-s-safety-and-reductions-in-plasma-vlcfa-and-lipid-levels-in-x-ald-patients/ 2024-10-09 https://bio-research.ai/alnylam-pharmaceuticals-submits-snda-to-fda-for-vutrisiran-following-phase-3-helios-b-study-in-treatment-of-attr-amyloidosis-with-cardiomyopathy/ 2024-10-09 https://bio-research.ai/viatris-phase-3-trial-of-effexor-for-generalized-anxiety-disorder-in-japanese-adults-meets-primary-objective-and-seven-secondary-endpoints/ 2024-10-09 https://bio-research.ai/purespring-therapeutics-secures-80m-in-series-b-funding-round-to-advance-kidney-disease-focused-gene-therapies-and-initiate-phase-i-ii-clinical-trial/ 2024-10-09 https://bio-research.ai/fda-issues-complete-response-letter-for-zealand-pharma-s-dasiglucagon-due-to-manufacturing-inspection-timing/ 2024-10-09 https://bio-research.ai/aurigene-oncology-limited-reports-successful-phase-1-trial-of-drl-1801-in-refractory-multiple-myeloma-patients-approval-received-for-phase-2/ 2024-10-08 https://bio-research.ai/insmed-incorporated-presents-phase-3-trial-data-of-brensocatib-demonstrating-reduced-lung-function-decline-in-non-cystic-fibrosis-bronchiectasis-patients-at-chest-2024/ 2024-10-08 https://bio-research.ai/city-therapeutics-secures-135-million-in-series-a-funding-plans-rna-interference-based-medicine-advancement/ 2024-10-08 https://bio-research.ai/tonix-pharmaceuticals-collaborates-with-x-chem-for-accelerated-development-of-34m-tnx-4200-program-using-ai-and-ml-technology/ 2024-10-08 https://bio-research.ai/orasis-pharmaceuticals-completes-78-million-financing-to-launch-qlosi-a-corrective-eye-drop-for-presbyopia-in-adults/ 2024-10-08 https://bio-research.ai/biogen-reveals-devote-study-results-high-dose-regimen-of-nusinersen-shows-motor-function-improvements-in-spinal-muscular-atrophy-patients/ 2024-10-08 https://bio-research.ai/mink-therapeutics-and-autonomous-therapeutics-collaborate-for-a-novel-therapy-aimed-at-treatment-resistant-metastatic-solid-tumors/ 2024-10-08 https://bio-research.ai/mestag-therapeutics-partners-with-msd-for-1-9b-collaboration-on-inflammatory-disease-therapies-using-novel-fibroblast-technology/ 2024-10-08 https://bio-research.ai/merck-s-phase-3-keynote-689-trial-for-keytruda-meets-primary-endpoint-in-advanced-head-and-neck-squamous-cell-carcinoma-treatment/ 2024-10-08 https://bio-research.ai/bayer-partners-with-moma-therapeutics-for-small-molecule-oncology-program-access-to-proprietary-knomatic-platform-granted/ 2024-10-08 https://bio-research.ai/gsk-s-phase-iii-trial-of-arexvy-shows-67-4-efficacy-against-severe-rsv-lrtd-in-adults-aged-60-and-above/ 2024-10-08 https://bio-research.ai/aviadobio-and-astellas-pharma-sign-2-18b-deal-to-develop-and-commercialize-gene-therapy-avb-101-for-frontotemporal-dementia/ 2024-10-08 https://bio-research.ai/sage-therapeutics-phase-2-alzheimer-s-study-of-dalzanemdor-fails-to-show-significant-difference-halts-development/ 2024-10-08 https://bio-research.ai/boehringer-ingelheim-s-survodutide-gets-fda-breakthrough-therapy-designation-for-mash-treatment-phase-iii-clinical-trials-underway/ 2024-10-08 https://bio-research.ai/sk-bioscience-invests-usd-3m-in-finabio-to-leverage-proprietary-crm197-technology-for-improved-vaccine-efficacy/ 2024-10-08 https://bio-research.ai/medilink-therapeutics-and-amgen-collaborate-for-clinical-trial-of-yl201-and-imdelltra-in-extensive-stage-small-cell-lung-cancer-treatment/ 2024-10-07 https://bio-research.ai/ultragenyx-gains-fda-breakthrough-therapy-designation-for-setrusumab-in-reducing-osteogenesis-imperfecta-fracture-risk-study-reveals/ 2024-10-07 https://bio-research.ai/galecto-shifts-focus-to-cancer-and-liver-disease-with-acquisition-of-brm-1420-from-bridge-medicines-issues-shares-in-agreement/ 2024-10-07 https://bio-research.ai/judo-bio-garners-100-million-financing-appoints-new-ceo-and-progresses-with-ligand-sirna-conjugate-clinical-trials/ 2024-10-07 https://bio-research.ai/rege-nephro-raises-22-5-billion-yen-in-series-b-funding-for-phase-ii-trials-of-rn-014-and-preclinical-trials-of-rn-032/ 2024-10-07 https://bio-research.ai/biomed-industries-achieves-6-8-weight-reduction-with-na-931-quadruple-receptor-agonist-in-phase-1-obesity-trial/ 2024-10-07 https://bio-research.ai/bpgbio-collaborates-with-oxford-s-centre-for-medicine-discovery-to-advance-drug-development-for-oncology-and-cns-conditions/ 2024-10-07 https://bio-research.ai/scholar-rock-s-apitegromab-meets-primary-endpoint-in-phase-3-sapphire-trial-for-spinal-muscular-atrophy-plans-submission-for-us-and-eu-approval-in-q1-2025/ 2024-10-07 https://bio-research.ai/orchard-therapeutics-and-er-kim-ink-exclusive-distribution-agreement-for-libmeldy-gene-therapy-in-turkey-russia-ukraine-and-cis/ 2024-10-07 https://bio-research.ai/astrazeneca-and-cspc-pharmaceutical-ink-100m-upfront-payment-deal-for-ys2302018-with-potential-1-92b-in-future-milestones-and-royalties/ 2024-10-07 https://bio-research.ai/avillion-achieves-primary-endpoint-in-phase-iiib-trial-of-astrazeneca-s-airsupra-for-asthma-shows-lowered-risk-of-severe-exacerbations/ 2024-10-07 https://bio-research.ai/biodexa-pharmaceuticals-phase-1-study-reports-survival-rates-of-12-13-months-with-mtx110-treatment-for-recurrent-glioblastoma/ 2024-10-04 https://bio-research.ai/health-canada-approves-use-of-telix-s-illuccix-for-patient-selection-in-psma-targeted-radionuclide-therapy-for-metastatic-prostate-cancer/ 2024-10-04 https://bio-research.ai/daiichi-sankyo-seeks-approval-in-japan-for-enhertu-first-her2-directed-therapy-based-on-destiny-breast06-phase-3-trial/ 2024-10-04 https://bio-research.ai/recordati-acquires-global-rights-to-sanofi-s-enjaymo-for-825m-securing-a-foothold-in-rare-b-cell-disorder-treatment-sector/ 2024-10-04 https://bio-research.ai/sirnaomics-secures-hk-58-9-million-investment-from-biotech-leader-dr-poon-hung-fai-to-accelerate-rnai-therapeutics-development/ 2024-10-04 https://bio-research.ai/amyris-partners-with-biomap-c-and-ibmsc-for-12-3m-agreement-to-boost-us-pharma-manufacturing-and-address-drug-shortages/ 2024-10-03 https://bio-research.ai/fda-approves-bristol-myers-squibb-s-opdivo-for-resectable-non-small-cell-lung-cancer-based-on-phase-3-trial-results/ 2024-10-03 https://bio-research.ai/ultragenyx-pharmaceutical-s-ux701-phase-1-2-3-trial-shows-clinical-activity-in-15-patients-six-stop-standard-treatment/ 2024-10-03 https://bio-research.ai/integrated-biosciences-secures-17-2-million-seed-funding-to-boost-synthetic-biology-and-ai-platform-advances-small-molecule-portfolio/ 2024-10-03 https://bio-research.ai/halozyme-therapeutics-and-argenx-expand-collaboration-for-enhanze-technology-with-30m-upfront-payment-and-potential-of-up-to-85m-per-target/ 2024-10-03 https://bio-research.ai/teva-and-mabxience-initiate-new-global-licensing-agreement-for-anti-pd-1-oncology-biosimilar-development-and-manufacturing/ 2024-10-03 https://bio-research.ai/gigagen-scores-135-2m-barda-contract-for-botulinum-neurotoxins-therapy-development/ 2024-10-03 https://bio-research.ai/resolution-therapeutics-secures-63-5-million-series-b-funding-for-development-of-rtx001-prepares-for-phase-i-ii-emerald-study/ 2024-10-03 https://bio-research.ai/eton-pharmaceuticals-acquires-rights-to-increlex-from-ipsen-s-a-reinforcing-focus-on-ultra-rare-conditions/ 2024-10-03 https://bio-research.ai/aldeyra-therapeutics-resubmits-reproxalap-drug-application-to-fda-following-completion-of-dry-eye-symptom-trial/ 2024-10-03 https://bio-research.ai/enara-bio-secures-32-5-million-in-series-b-funding-led-by-pfizer-ventures-and-m-ventures-for-tcr-based-immunotherapies/ 2024-10-03 https://bio-research.ai/mithradote-bio-secures-1-million-seed-funding-and-partners-with-taho-pharma-and-haorui-pharmatech-for-m-101-s-development-a-self-administered-antidote-against-drink-spiking/ 2024-10-02 https://bio-research.ai/astrazeneca-and-arcus-biosciences-collaborate-for-a-second-time-to-conduct-study-on-ccrcc-treatment-using-casdatifan-and-volrustomig-gilead-gets-option-to-join-later/ 2024-10-02 https://bio-research.ai/johnson-johnson-s-erleada-shows-23-percent-reduction-in-death-risk-at-24-months-compared-to-enzalutamide-in-large-mcspc-study/ 2024-10-02 https://bio-research.ai/pds-biotechnology-reports-36-month-survival-rate-of-84-4-in-phase-2-immunocerv-trial-investigating-versamune-hpv-for-advanced-cervical-cancer/ 2024-10-02 https://bio-research.ai/gilead-sciences-partners-with-six-generic-drugmakers-including-dr-reddy-s-emcure-eva-pharma-ferozsons-hetero-and-mylan-to-distribute-hiv-drug-lenacapavir-in-low-income-countries/ 2024-10-02 https://bio-research.ai/biotest-ag-and-kedrion-biopharma-ink-1b-deal-for-commercialization-and-distribution-of-yimmugo-in-the-us-market/ 2024-10-02 https://bio-research.ai/european-commission-approves-vevizye-for-moderate-to-severe-dry-eye-disease-clinical-studies-observe-effects-within-four-weeks/ 2024-10-02 https://bio-research.ai/novaliq-enters-agreement-with-laboratoires-th-a-to-commercialise-in-europe-middle-east-and-north-africa/ 2024-10-02 https://bio-research.ai/loqus23-therapeutics-secures-35-million-for-clinical-trials-on-a-drug-to-target-dna-instability-in-huntington-s-disease/ 2024-10-02 https://bio-research.ai/triveni-bio-inc-secures-115-million-in-series-b-funding-to-advance-clinical-trials-and-broaden-pipeline/ 2024-10-02 https://bio-research.ai/volastra-therapeutics-vls-1488-receives-fda-fast-track-designation-for-treating-platinum-resistant-ovarian-cancer-early-phase-studies-inbound/ 2024-10-02 https://bio-research.ai/scandinavian-biopharma-completes-phase-iib-trial-of-etvax-reports-over-80-efficacy-against-etec-in-gambian-children/ 2024-10-02 https://bio-research.ai/abl-bio-and-msd-partner-for-phase-1b-2-trial-of-abl103-combined-with-keytruda-targeting-b7-h4-and-4-1bb-in-advanced-solid-tumors/ 2024-10-02 https://bio-research.ai/kailera-therapeutics-secures-400-million-in-series-a-financing-for-obesity-therapies-appoints-former-gilead-ceo-to-board/ 2024-10-01 https://bio-research.ai/aytu-biopharma-and-lupin-pharma-collaborate-to-bring-adhd-dissolving-tablets-to-canada-enters-1-1b-market/ 2024-10-01 https://bio-research.ai/papillon-therapeutics-garners-orphan-drug-designation-from-fda-for-ppl-002-a-gene-modified-therapy-for-danon-disease/ 2024-10-01 https://bio-research.ai/thryv-therapeutics-receives-fda-orphan-drug-designation-for-lqt-1213-in-treatment-of-long-qt-syndrome/ 2024-10-01 https://bio-research.ai/myrtelle-inc-s-phase-1-2-trial-for-gene-therapy-raav-oligo001-aspa-indicates-over-80-decrease-in-canavan-disease-biomarkers/ 2024-10-01 https://bio-research.ai/vaxess-technologies-secures-national-institute-grant-raises-12m-to-test-mimix-transdermal-patch-for-glp-1-ra-therapies-in-type-2-diabetics/ 2024-10-01 https://bio-research.ai/biomarin-and-camp4-therapeutics-ink-deal-to-develop-regrna-targeting-therapeutics-with-upfront-payment-and-potential-milestones/ 2024-10-01 https://bio-research.ai/sun-pharma-and-philogen-ink-global-licensing-deal-for-anti-cancer-immunotherapy-fibromun-split-post-commercialization-profits-45-55/ 2024-10-01 https://bio-research.ai/pdradiopharma-and-curium-partner-to-develop-and-commercialize-prostate-cancer-targeting-radiopharmaceuticals-in-japan/ 2024-10-01 https://bio-research.ai/amneal-pharmaceuticals-and-metsera-team-up-for-obesity-drug-development-pledging-150m-200m-for-new-manufacturing-units-in-india/ 2024-10-01 https://bio-research.ai/fda-grants-fast-track-designation-to-ionis-pharmaceuticals-zilganersen-for-alexander-disease-treatment/ 2024-10-01 https://bio-research.ai/sagimet-biosciences-receives-fda-breakthrough-therapy-designation-for-denifanstat-in-steatohepatitis-treatment-following-successful-phase-2b-trial/ 2024-10-01 https://bio-research.ai/nxera-pharma-japan-partners-with-shionogi-for-distribution-and-sales-of-insomnia-drug-quviviq-in-japan-following-termination-of-mochida-deal/ 2024-10-01 https://bio-research.ai/cartherics-secures-funding-beyond-au-15m-target-to-commence-clinical-trials-for-ovarian-cancer-cell-therapy-product-cth-401/ 2024-10-01 https://bio-research.ai/gritstone-bio-s-phase-2-trial-of-granite-immunotherapy-shows-21-relative-risk-reduction-in-colorectal-cancer-38-in-specific-subgroup/ 2024-09-30 https://bio-research.ai/cytokinetics-reports-68-hemodynamic-response-in-phase-3-clinical-trial-of-aficamten-for-obstructive-hypertrophic-cardiomyopathy-patients/ 2024-09-30 https://bio-research.ai/rivus-pharmaceuticals-hu6-results-in-significant-weight-loss-in-phase-2a-obesity-related-heart-failure-trial/ 2024-09-30 https://bio-research.ai/windtree-therapeutics-reports-phase-2b-clinical-results-of-istaroxime-showing-improved-systolic-blood-pressure-in-heart-failure-patients/ 2024-09-30 https://bio-research.ai/celaid-therapeutics-receives-19m-grant-from-amed-for-development-of-pediatric-hematopoietic-stem-cell-therapy/ 2024-09-30 https://bio-research.ai/fda-approves-formycon-and-fresenius-kabi-s-biosimilar-fyb202-for-treatment-of-crohn-s-disease-and-other-conditions/ 2024-09-30 https://bio-research.ai/aktis-oncology-raises-175-million-in-series-b-financing-to-advance-nectin-4-targeted-radiopharmaceuticals/ 2024-09-30 https://bio-research.ai/nanoscope-therapeutics-secures-catch-technology-license-from-max-planck-innovation-to-advance-gene-therapy-for-vision-restoration/ 2024-09-30 https://bio-research.ai/prime-medicine-and-bristol-myers-squibb-ink-deal-to-develop-next-gen-t-cell-therapies-prime-to-receive-110m-plus-potential-3-5b-in-milestones/ 2024-09-30 https://bio-research.ai/valerio-therapeutics-acquires-emglev-therapeutics-forms-valour-bio-to-develop-single-domain-antibodies/ 2024-09-30 https://bio-research.ai/genentech-and-regor-pharmaceuticals-ink-850m-deal-for-next-generation-cdk-inhibitors-development-in-breast-cancer-treatment/ 2024-09-30 https://bio-research.ai/alphamab-oncology-subsidiary-licenses-anti-her2-bispecific-adc-to-jmt-bio-for-3-08b-rmb-with-double-digit-royalties-on-net-sales/ 2024-09-30 https://bio-research.ai/bridgebio-pharma-s-post-hoc-analysis-of-phase-3-study-reveals-reduction-in-mortality-and-hospitalizations-with-acoramidis-treatment/ 2024-09-27 https://bio-research.ai/johnson-johnson-s-phase-1b-trimm-2-study-reveals-82-percent-response-rate-in-multiple-myeloma-patients-treated-with-talvey-and-darzalex-faspro-combination/ 2024-09-27 https://bio-research.ai/bayer-and-bluerock-therapeutics-report-24-month-data-from-phase-1-trial-of-bemdaneprocel-for-parkinson-s-disease/ 2024-09-27 https://bio-research.ai/ucb-s-two-year-phase-3-clinical-data-for-bimzelx-indicates-sustained-response-in-severe-hidradenitis-suppurativa-patients/ 2024-09-27 https://bio-research.ai/regeneron-pharmaceuticals-sanofi-get-approval-for-dupixent-in-adult-copd-treatment-after-successful-phase-3-trials-in-china/ 2024-09-27 https://bio-research.ai/iaso-biotherapeutics-phase-2-study-reports-equivalent-efficacy-of-eque-cel-in-treating-multiple-myeloma-with-or-without-renal-impairment/ 2024-09-27 https://bio-research.ai/fda-authorizes-cobenfy-for-treating-adult-schizophrenia-based-on-emergent-program-data/ 2024-09-26 https://bio-research.ai/crinetics-pharmaceuticals-submits-fda-application-for-paltusotine-based-on-18-clinical-trials-data-for-treatment-of-acromegaly-and-carcinoid-syndrome/ 2024-09-26 https://bio-research.ai/858-therapeutics-raises-50-million-in-series-b-funding-to-advance-development-of-etx-19477-for-advanced-solid-tumor-treatment/ 2024-09-26 https://bio-research.ai/repair-biotechnologies-and-genevant-sciences-enter-agreement-for-atherosclerosis-treatment-could-fetch-up-to-107m/ 2024-09-26 https://bio-research.ai/abbvie-s-phase-3-tempo-1-trial-of-tavapadon-for-early-stage-parkinson-s-disease-meets-primary-endpoint-with-significant-reduction-in-mds-updrs-score/ 2024-09-26 https://bio-research.ai/evaxion-biotech-and-merck-co-sign-a-option-agreement-worth-up-to-1-2b-for-preclinical-vaccine-candidates-evx-b2-and-evx-b3/ 2024-09-26 https://bio-research.ai/biocon-and-tabuk-pharmaceutical-team-up-to-commercialize-glp-1-products-for-diabetes-and-weight-management-in-the-middle-east/ 2024-09-26 https://bio-research.ai/enanta-pharmaceuticals-phase-2a-trial-of-edp-323-shows-reduction-in-viral-load-and-clinical-symptoms-in-rsv-infected-adults/ 2024-09-26 https://bio-research.ai/biogen-ends-collaboration-with-sage-therapeutics-on-sage-324-program-after-negative-phase-2-trial-results/ 2024-09-26 https://bio-research.ai/evotec-and-novo-nordisk-join-forces-for-stem-cell-based-therapy-development-novo-gains-exclusive-rights-to-use-outcomes/ 2024-09-26 https://bio-research.ai/genentech-reports-phase-iii-regency-study-results-gazyva-with-standard-therapy-improves-renal-response-in-lupus-nephritis-patients/ 2024-09-25 https://bio-research.ai/leo-pharma-s-delta-force-trial-reveals-delgocitinib-cream-s-superior-efficacy-over-oral-alitretinoin-in-severe-chronic-hand-eczema/ 2024-09-25 https://bio-research.ai/celldex-therapeutics-reports-71-complete-response-in-csu-patients-with-barzolvolimab-in-52-week-study-at-eadv-congress-2024/ 2024-09-25 https://bio-research.ai/union-therapeutics-orismilast-achieves-statistically-significant-iga0-1-responses-in-phase-2b-atopic-dermatitis-study-but-fails-to-meet-primary-easi-endpoint/ 2024-09-25 https://bio-research.ai/gen-pharmaceuticals-phase-2-trial-shows-gn-037-cream-reduces-psoriasis-symptoms-in-190-patients/ 2024-09-25 https://bio-research.ai/intrabio-receives-fda-approval-for-aqneursa-to-treat-niemann-pick-disease-type-c-following-clinical-trial/ 2024-09-25 https://bio-research.ai/windtree-therapeutics-phase-2b-seismic-study-reveals-istaroxime-increase-in-systolic-blood-pressure-in-cardiogenic-shock-patients/ 2024-09-25 https://bio-research.ai/elixirgen-therapeutics-initiates-phase-1-2-trial-of-exg-34217-for-telomere-biology-disorders-at-cincinnati-children-s-hospital-medical-center/ 2024-09-25 https://bio-research.ai/orion-corporation-and-aitia-partner-for-10m-per-drug-target-cancer-discovery-melding-digital-twins-and-ai-with-pre-clinical-data/ 2024-09-25 https://bio-research.ai/bayer-askbio-and-belief-biomed-collaborate-to-explore-liver-targeted-gene-therapies-using-bbm-s-next-gen-capsid-technology/ 2024-09-25 https://bio-research.ai/abbvie-reports-efficacy-of-upadacitinib-in-phase-3-atopic-dermatitis-trials-over-16-weeks/ 2024-09-25 https://bio-research.ai/kyowa-kirin-reports-phase-3-trial-success-of-rocatinlimab-for-atopic-dermatitis/ 2024-09-25 https://bio-research.ai/merck-s-keyform-007-trial-fails-to-meet-primary-endpoint-in-metastatic-colorectal-cancer-treatment/ 2024-09-25 https://bio-research.ai/genespire-secures-46-6-million-in-series-b-funding-for-phase-i-ii-trials-of-pediatric-gene-therapy-gene202-for-methylmalonic-acidemia/ 2024-09-25 https://bio-research.ai/arcutis-biotherapeutics-phase-3-trials-show-zoryve-cream-0-15-consistently-treats-atopic-dermatitis-symptoms-across-racial-ethnic-and-skin-type-subgroups/ 2024-09-25 https://bio-research.ai/european-commission-approves-toripalimab-for-treatment-of-two-cancer-types-based-on-jupiter-02-and-jupiter-06-studies-results/ 2024-09-24 https://bio-research.ai/coegin-pharma-and-scandinavian-biolabs-to-develop-hair-growth-products-using-fol005-set-to-launch-in-2025/ 2024-09-24 https://bio-research.ai/fzata-inc-receives-7m-ug3-uh3-grant-from-nih-national-institute-of-neurological-disorders-and-stroke-for-development-of-fz006-in-collaboration-with-university-of-maryland-baltimore/ 2024-09-24 https://bio-research.ai/pharmaand-and-tolmar-ink-exclusive-deal-for-us-promotion-of-rubraca-in-treatment-of-metastatic-prostate-cancer/ 2024-09-24 https://bio-research.ai/silexion-therapeutics-reports-56-response-rate-in-phase-2-loder-trial-for-advanced-pancreatic-cancer-ups-to-67-for-resectable-tumors/ 2024-09-24 https://bio-research.ai/niams-awards-2-03m-to-resvita-bio-for-phase-ii-sbir-project-advancing-novel-treatment-rvb-003-for-netherton-syndrome/ 2024-09-24 https://bio-research.ai/nona-biosciences-partners-with-alkyon-therapeutics-to-accelerate-oncology-drug-development-using-patented-harbour-mice-platform/ 2024-09-24 https://bio-research.ai/aurinia-pharmaceuticals-gets-approval-for-lupus-nephritis-treatment-lupkynis-in-japan-expects-10-million-from-otsuka-pharmaceutical-collaboration-deal/ 2024-09-24 https://bio-research.ai/wave-life-sciences-reports-positive-interim-phase-2-data-for-wve-n531-in-duchenne-muscular-dystrophy-trial/ 2024-09-24 https://bio-research.ai/metsera-reports-phase-1-trial-results-of-met-097-an-ultra-long-acting-glp-1-receptor-agonist-for-obesity-shows-weight-loss-and-monthly-dosing/ 2024-09-24 https://bio-research.ai/generate-biomedicines-and-novartis-to-develop-protein-therapeutics-via-ai-platform-with-65m-upfront-payment-and-potential-1b-milestone-payments/ 2024-09-24 https://bio-research.ai/ribo-ribocure-and-pheiron-collaborate-to-integrate-ai-in-rna-based-drug-development-for-cardiometabolic-diseases/ 2024-09-24 https://bio-research.ai/japanese-ministry-of-health-approves-hutchmed-s-fruzaqla-for-metastatic-colorectal-cancer-following-fresco-2-trial-results/ 2024-09-24 https://bio-research.ai/dydo-pharma-gets-approval-to-commercialize-firdapse-in-japan-for-treatment-of-lambert-eaton-myasthenic-syndrome/ 2024-09-24 https://bio-research.ai/eli-lilly-s-alzheimer-s-treatment-kisunla-receives-approval-from-japanese-health-ministry-following-trailblazer-alz-2-study/ 2024-09-24 https://bio-research.ai/lift-biosciences-secures-10-million-for-clinical-trials-of-cancer-killing-cell-therapy-via-its-n-lift-platform/ 2024-09-24 https://bio-research.ai/ucb-and-biogen-s-phase-3-trial-of-dapirolizumab-pegol-achieves-primary-endpoint-in-systemic-lupus-erythematosus-treatment-second-phase-3-study-initiated/ 2024-09-24 https://bio-research.ai/verimmune-secures-4-5-million-in-funding-for-cancer-immunotherapy-veri-101-development-and-board-expansion/ 2024-09-23 https://bio-research.ai/oryzon-genomics-reports-positive-phase-iib-trial-data-for-vafidemstat-in-borderline-personality-disorder-patients/ 2024-09-23 https://bio-research.ai/elevar-therapeutics-resubmits-fda-application-for-rivoceranib-and-camrelizumab-combination-in-unresectable-hepatocellular-carcinoma-treatment-following-manufacturing-issues/ 2024-09-23 https://bio-research.ai/yoltech-therapeutics-earns-orphan-drug-and-rare-pediatric-disease-designations-for-ph1-therapy-yolt-203-kicks-off-clinical-trials/ 2024-09-23 https://bio-research.ai/european-commission-approves-kayfanda-for-treating-cholestatic-pruritus-in-alagille-syndrome-patients-based-on-assert-trial-data/ 2024-09-23 https://bio-research.ai/context-therapeutics-acquires-exclusive-rights-to-ba3362-from-bioatla-in-deal-worth-up-to-133-5m/ 2024-09-23 https://bio-research.ai/biohaven-s-troriluzole-demonstrates-50-70-disease-progression-delay-in-3-year-spinocerebellar-ataxia-study/ 2024-09-23 https://bio-research.ai/sanofi-invests-27m-in-ventyx-biosciences-with-rights-to-negotiate-on-vtx3232-neuroinflammation-treatment-program/ 2024-09-23 https://bio-research.ai/nicox-sa-and-glaukos-corporation-enter-exclusive-agreement-for-global-licensing-of-ncx-1728-post-ind-process-completion/ 2024-09-23 https://bio-research.ai/vicebio-obtains-100-million-in-series-b-funding-for-development-of-multivalent-respiratory-virus-vaccines-and-initiates-phase-i-clinical-trial-with-vxb-241/ 2024-09-23 https://bio-research.ai/teva-pharmaceuticals-reports-significant-improvement-in-schizophrenia-symptoms-in-phase-3-solaris-trial-of-tev-749/ 2024-09-21 https://bio-research.ai/fda-grants-third-approval-to-sarclisa-in-combination-with-vrd-for-specific-multiple-myeloma-patients-after-positive-imroz-phase-3-trial-results/ 2024-09-20 https://bio-research.ai/fda-approves-zevra-therapeutics-miplyffa-for-niemann-pick-disease-type-c-treatment-initiates-amplifyassist-patient-support-program/ 2024-09-20 https://bio-research.ai/fda-approves-flumist-the-only-self-administered-influenza-vaccine-in-the-us-for-at-home-use/ 2024-09-20 https://bio-research.ai/novo-nordisk-s-phase-2a-trial-shows-monlunabant-leads-to-significant-weight-loss-but-higher-doses-offer-little-extra-benefit/ 2024-09-20 https://bio-research.ai/european-commission-conditionally-approves-iqirvo-for-primary-biliary-cholangitis-based-on-phase-iii-elative-trial-data/ 2024-09-20 https://bio-research.ai/samsung-bioepis-and-biogen-receive-chmp-endorsement-for-opuviz-a-biosimilar-to-eylea-after-positive-phase-3-trial-results-for-retinal-disorders-treatment/ 2024-09-20 https://bio-research.ai/sanofi-s-phase-3-hercules-study-on-tolebrutinib-delays-progression-of-disability-in-nrspms-patients-reports-increased-improvement-compared-to-placebo/ 2024-09-20 https://bio-research.ai/apellis-pharmaceuticals-pegcetacoplan-denied-marketing-authorization-by-european-medicines-agency-for-age-related-macular-degeneration-treatment/ 2024-09-20 https://bio-research.ai/amplia-therapeutics-gets-fast-track-designation-by-us-fda-for-pancreatic-cancer-drug-narmafotinib-under-accent-trial/ 2024-09-19 https://bio-research.ai/fda-approves-johnson-johnson-s-drug-rybrevant-for-use-in-combination-with-chemotherapy-for-non-small-cell-lung-cancer-treatment/ 2024-09-19 https://bio-research.ai/chmp-recommends-label-update-for-wegovy-reflecting-improved-heart-failure-symptoms-and-physical-function-in-obesity-related-hfpef-patients-based-on-step-trials/ 2024-09-19 https://bio-research.ai/european-commission-approves-bavarian-nordic-s-mva-bn-vaccine-for-adolescents-clinical-trials-upcoming-for-children-aged-2-12/ 2024-09-19 https://bio-research.ai/aligos-therapeutics-reports-significant-reduction-in-liver-fat-in-phase-2a-study-of-alg-055009-on-metabolic-dysfunction-associated-steatohepatitis-patients/ 2024-09-19 https://bio-research.ai/fda-grants-rare-pediatric-disease-and-orphan-drug-designations-to-longboard-pharmaceuticals-bexicaserin-for-dravet-syndrome-treatment/ 2024-09-19 https://bio-research.ai/fda-rejects-vanda-pharmaceuticals-application-for-gastroparesis-medication-asks-for-further-studies/ 2024-09-19 https://bio-research.ai/tiziana-life-sciences-secures-4m-nih-grant-for-alzheimer-s-research-prepares-for-first-in-human-clinical-trials-for-nasal-anti-cd3-treatment/ 2024-09-19 https://bio-research.ai/oncolytics-biotech-s-phase-2-study-shows-over-half-of-patients-alive-at-end-of-trial-with-pelareorep-based-therapy-for-advanced-or-metastatic-breast-cancer/ 2024-09-19 https://bio-research.ai/edgewise-therapeutics-reports-phase-1-and-2-trials-results-for-edg-7500-relates-reduction-in-hypertrophic-cardiomyopathy-symptoms/ 2024-09-19 https://bio-research.ai/basilea-pharmaceutica-bags-initial-29m-from-barda-under-multi-year-agreement-for-antifungal-and-antibacterial-development/ 2024-09-19 https://bio-research.ai/laekna-inc-shares-end-of-study-results-for-phase-ib-clinical-trial-of-lae002-in-advanced-breast-cancer-begins-phase-iii-trial-affirm-205/ 2024-09-19 https://bio-research.ai/genentech-s-phase-iii-trial-of-xofluza-shows-significant-reduction-in-influenza-transmission-in-households/ 2024-09-18 https://bio-research.ai/transcenta-holding-s-cancer-treatment-transtar102-reports-median-progression-free-survival-of-14-2-months-in-cldn18-2-expressing-patients-presented-at-esmo-congress-2024/ 2024-09-18 https://bio-research.ai/insilico-medicine-reports-phase-iia-trial-success-of-ai-generated-drug-ism001-055-for-treating-idiopathic-pulmonary-fibrosis/ 2024-09-18 https://bio-research.ai/glycomine-s-glm101-gets-fda-fast-track-designation-advances-to-phase-2-clinical-trials-for-pmm2-cdg-treatment/ 2024-09-18 https://bio-research.ai/novo-nordisk-and-nanovation-therapeutics-partner-for-600m-deal-to-develop-genetic-medicines-for-rare-diseases-using-lipid-nanoparticles-technology/ 2024-09-18 https://bio-research.ai/organon-to-acquire-dermavant-sciences-for-175m-upfront-regulatory-and-commercial-milestones-worth-up-to-1-025b-and-future-tiered-royalties-on-net-sales/ 2024-09-18 https://bio-research.ai/gsk-s-phase-3-trial-finds-co-administration-of-arexvy-and-shingrix-in-adults-over-50-as-tolerable-and-effective-as-separate-administration/ 2024-09-18 https://bio-research.ai/bristol-myers-squibb-s-phase-3-daybreak-trial-shows-decrease-in-brain-volume-loss-with-five-years-of-zeposia-treatment-in-multiple-sclerosis-patients/ 2024-09-18 https://bio-research.ai/fda-awards-breakthrough-therapy-designation-to-anges-inc-s-collategene-for-combating-peripheral-arterial-disease/ 2024-09-18 https://bio-research.ai/fda-approves-merck-s-keytruda-for-use-with-chemotherapy-in-first-line-treatment-of-advanced-malignant-pleural-mesothelioma-following-phase-3-trial-results/ 2024-09-18 https://bio-research.ai/purple-biotech-s-phase-2-study-on-cm24-therapy-for-pancreatic-ductal-adenocarcinoma-presented-at-cancer-research-conference/ 2024-09-18 https://bio-research.ai/fda-approves-astrazeneca-s-fasenra-for-egpa-treatment-based-on-mandara-phase-iii-trial-results/ 2024-09-18 https://bio-research.ai/fda-grants-fast-track-designation-to-imcheck-therapeutics-ict01-for-treatment-of-acute-myeloid-leukemia-in-older-or-unfit-patients/ 2024-09-18 https://bio-research.ai/brenus-pharma-bags-25-million-in-series-a-financing-for-clinical-trials-of-stc-1010-cancer-vaccine-targeting-metastatic-colorectal-cancer/ 2024-09-18 https://bio-research.ai/capricor-therapeutics-and-nippon-shinyaku-ink-750m-deal-for-duchenne-muscular-dystrophy-treatment-s-european-commercialization/ 2024-09-17 https://bio-research.ai/fda-approves-kisqali-in-combination-with-an-aromatase-inhibitor-for-adjuvant-treatment-of-early-stage-breast-cancer-following-phase-iii-natalee-trial-results/ 2024-09-17 https://bio-research.ai/epicentrx-teams-up-with-qut-tri-for-1-6m-cdmrp-award-to-advance-rrx-001-development-as-neuroprotective-agent/ 2024-09-17 https://bio-research.ai/unravel-biosciences-partners-with-the-jackson-laboratory-to-expedite-drug-discovery-for-alternating-hemiplegia-of-childhood-using-bionav-platform/ 2024-09-17 https://bio-research.ai/rakovina-therapeutics-and-variational-ai-collaborate-to-develop-cancer-therapies-using-dna-damage-response-tech-and-enki-ai-platform/ 2024-09-17 https://bio-research.ai/fda-grants-orphan-drug-designation-to-papillon-therapeutics-for-ppl-001-a-friedreich-s-ataxia-treatment/ 2024-09-17 https://bio-research.ai/fda-grants-orphan-drug-designation-to-camp4-s-cmp-cps-001-for-urea-cycle-disorders-treatment-phase-1-clinical-trial-underway/ 2024-09-17 https://bio-research.ai/ripple-therapeutics-partners-with-abbvie-on-311-8m-deal-for-glaucoma-treatment-rtc-620-development/ 2024-09-17 https://bio-research.ai/inmune-bio-inc-reports-strong-correlation-in-phase-ii-alzheimer-s-disease-trial-data-analysis/ 2024-09-17 https://bio-research.ai/atsena-therapeutics-receives-orphan-drug-designation-from-fda-for-atsn-201-gene-therapy-to-treat-x-linked-retinoschisis-begins-phase-i-ii-clinical-trial/ 2024-09-17 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-bridgebio-pharma-s-infigratinib-for-achondroplasia-in-children-results-from-propel-2-clinical-trial/ 2024-09-17 https://bio-research.ai/nura-bio-secures-over-140-million-in-series-a-financing-and-prepares-for-phase-1b-2-trial-of-nb-4746-in-2025/ 2024-09-17 https://bio-research.ai/asieris-pharmaceuticals-presents-phase-iii-clinical-trial-results-for-cevira-showing-higher-regression-rate-in-apl-1702-group-than-placebo/ 2024-09-17 https://bio-research.ai/daiichi-sankyo-and-merck-s-phase-3-herthena-lung02-trial-meets-primary-endpoint-in-egfr-mutated-non-small-cell-lung-cancer-treatment/ 2024-09-17 https://bio-research.ai/korro-bio-inks-530m-deal-with-novo-nordisk-to-develop-genetic-medicines-using-its-opera-platform/ 2024-09-16 https://bio-research.ai/vivtex-to-apply-ai-tech-for-optimized-oral-formulation-of-equillium-s-eq302-under-new-agreement/ 2024-09-16 https://bio-research.ai/somite-therapeutics-obtains-fda-orphan-and-rare-pediatric-disease-designations-for-duchenne-muscular-dystrophy-drug-smt-m01/ 2024-09-16 https://bio-research.ai/ipsen-reports-77-and-62-reduction-in-disease-progression-or-mortality-in-pnets-and-epnets-patients-with-cabometyx-in-cabinet-phase-iii-trial/ 2024-09-16 https://bio-research.ai/bioatla-reports-32-overall-response-rate-in-phase-2-clinical-trial-of-ozuriftamab-vedotin-for-head-and-neck-cancer-patients/ 2024-09-16 https://bio-research.ai/fda-grants-rmat-designation-to-poseida-therapeutics-p-bcma-allo1-in-phase-1-1b-development-for-relapsed-refractory-multiple-myeloma-treatment/ 2024-09-16 https://bio-research.ai/jazz-pharmaceuticals-reports-84-response-rate-in-phase-2-trial-of-zanidatamab-for-advanced-gastroesophageal-adenocarcinoma/ 2024-09-16 https://bio-research.ai/tharimmune-secures-exclusive-licensing-deal-with-intract-pharma-for-development-of-oral-anti-tnf-infliximab/ 2024-09-16 https://bio-research.ai/astrazeneca-s-himalaya-phase-iii-trial-reports-24-decrease-in-death-risk-from-hepatocellular-carcinoma-with-imfinzi-and-imjudo-treatment/ 2024-09-16 https://bio-research.ai/boehringer-ingelheim-s-fibroneer-ipf-trial-achieves-primary-goal-with-nerandomilast-in-phase-iii-studies-for-treating-idiopathic-pulmonary-fibrosis/ 2024-09-16 https://bio-research.ai/bayer-s-aranote-trial-shows-46-reduced-risk-of-progression-or-death-in-mhspc-patients-with-darolutamide-and-adt-treatment/ 2024-09-16 https://bio-research.ai/evaxion-biotech-s-phase-2-trial-of-evx-01-reports-69-overall-response-rate-tumor-reduction-in-94-patients/ 2024-09-16 https://bio-research.ai/ascendis-pharma-a-s-reports-positive-topline-data-from-approach-trial-of-transcon-cnp-for-achondroplasia-plans-fda-submission-in-2025/ 2024-09-16 https://bio-research.ai/novartis-reports-kisqali-reduces-recurrence-risk-by-28-5-in-phase-iii-natalee-trial-for-early-stage-breast-cancer-patients/ 2024-09-16 https://bio-research.ai/debiopharm-and-whitelab-genomics-partner-to-explore-ai-potential-in-enhancing-non-viral-oncology-vectors-delivery/ 2024-09-13 https://bio-research.ai/csl-and-arcturus-therapeutics-receive-japanese-approval-for-self-amplifying-mrna-covid-19-vaccine-targeting-omicron-subvariant/ 2024-09-13 https://bio-research.ai/curevac-reveals-phase-1-cvgbm-cancer-vaccine-study-results-showing-t-cell-responses-in-77-of-evaluable-patients-post-chemo-radiation-therapy/ 2024-09-13 https://bio-research.ai/onl-therapeutics-raises-65m-for-further-development-of-onl1204-ophthalmic-solution-enters-phase-2-trials-for-geographic-atrophy-treatment/ 2024-09-13 https://bio-research.ai/vico-therapeutics-reports-28-reduction-in-csf-mutant-htt-in-phase-1-2a-trial-of-vo659-for-huntington-s-disease/ 2024-09-13 https://bio-research.ai/gsk-s-blenrep-combined-with-bortezomib-and-dexamethasone-for-relapsed-or-refractory-multiple-myeloma-receives-breakthrough-therapy-designation-in-china-following-dreamm-7-trial-results/ 2024-09-13 https://bio-research.ai/atea-pharmaceuticals-phase-3-sunrise-3-trial-fails-primary-goal-bemnifosbuvir-does-not-significantly-reduce-covid-19-hospitalization-or-death-rate/ 2024-09-13 https://bio-research.ai/marengo-therapeutics-and-gilead-sciences-collaborate-on-clinical-study-for-metastatic-breast-cancer-treatment/ 2024-09-13 https://bio-research.ai/senhwa-biosciences-silmitasertib-receives-rare-pediatric-disease-designation-by-fda-for-neuroblastoma-treatment/ 2024-09-13 https://bio-research.ai/vironexis-emerges-from-stealth-with-26m-seed-funding-to-unveil-groundbreaking-aav-delivered-cancer-immunotherapy-platform/ 2024-09-12 https://bio-research.ai/nona-biosciences-and-umoja-biopharma-partner-to-develop-new-car-t-cell-therapies-using-hcab-and-vivovec-technologies/ 2024-09-12 https://bio-research.ai/fda-approves-genentech-s-tecentriq-hybreza-a-subcutaneous-anti-pd-l-1-cancer-therapy-reducing-treatment-time-and-demonstrating-comparable-effectiveness/ 2024-09-12 https://bio-research.ai/neurocrine-biosciences-halts-development-of-luvadaxistat-after-phase-2-clinical-study-fails-to-meet-primary-endpoint-in-treating-schizophrenia/ 2024-09-12 https://bio-research.ai/navamedic-and-alex-therapeutics-partner-to-launch-medication-management-app-for-parkinson-s-patients-in-nordic-countries/ 2024-09-12 https://bio-research.ai/china-s-nmpa-approves-keymed-biosciences-drug-stapokibart-for-moderate-to-severe-atopic-dermatitis-treatment-based-on-phase-iii-trial-results/ 2024-09-12 https://bio-research.ai/janssen-cilag-international-nv-submits-application-to-european-medicines-agency-for-nipocalimab-a-treatment-for-myasthenia-gravis-following-phase-3-vivacity-mg3-study-results/ 2024-09-12 https://bio-research.ai/kazia-therapeutics-acquires-rights-for-pi3k-inhibitor-drug-therapies-from-qimr-berghofer-medical-research-institute/ 2024-09-12 https://bio-research.ai/gilead-sciences-phase-3-trial-shows-lenacapavir-reduces-hiv-infections-by-96/ 2024-09-12 https://bio-research.ai/oncternal-therapeutics-halts-clinical-trials-for-onct-534-due-to-insignificant-patient-improvements-and-high-dose-toxicity/ 2024-09-12 https://bio-research.ai/encell-and-lucy-biotech-sign-usd-19-5m-licensing-agreement-for-stem-cell-therapy-en001-development-in-asia/ 2024-09-12 https://bio-research.ai/curevac-advances-to-phase-3-trials-for-seasonal-influenza-mrna-vaccine-after-demonstrating-immune-responses-in-phase-2/ 2024-09-12 https://bio-research.ai/f2g-secures-100-million-for-late-stage-development-of-antifungal-therapy-olorofim-a-candidate-for-invasive-aspergillosis-treatment/ 2024-09-12 https://bio-research.ai/oncopeptides-ab-and-scbio-inc-sign-15-30m-deal-for-pepaxti-commercialization-in-south-korea-until-2032/ 2024-09-12 https://bio-research.ai/aura-biosciences-completes-phase-2-trial-of-au-011-with-80-tumor-control-and-90-visual-acuity-preservation-in-early-stage-choroidal-melanoma/ 2024-09-12 https://bio-research.ai/organon-china-strikes-12m-license-agreement-with-baopharma-and-centergene-for-exclusive-rights-to-potential-first-long-acting-fertility-drug-sj02/ 2024-09-12 https://bio-research.ai/fulcrum-therapeutics-stops-phase-3-reach-trial-for-fshd-drug-losmapimod-after-failing-to-meet-primary-and-secondary-endpoints/ 2024-09-12 https://bio-research.ai/innovent-biologics-mazdutide-showed-improved-glycemic-control-and-weight-reduction-in-phase-3-trials-for-type-2-diabetes/ 2024-09-12 https://bio-research.ai/sanofi-lands-exclusive-licensing-deal-with-radiomedix-and-orano-med-for-100m-upfront-and-up-to-220m-sales-milestones-for-alphamedix-s-commercialization-and-production/ 2024-09-12 https://bio-research.ai/onconic-therapeutics-enters-central-and-south-american-pharmaceutical-market-through-license-agreement-with-mexico-s-laboratorios-sanfer-for-gastroesophageal-reflux-drug-jakyubo/ 2024-09-12 https://bio-research.ai/fda-grants-ascendis-pharma-orphan-drug-exclusivity-for-yorvipath-in-hypoparathyroidism-treatment/ 2024-09-11 https://bio-research.ai/fda-approves-johnson-johnson-s-tremfya-for-treatment-of-active-ulcerative-colitis-in-adults-based-on-quasar-study-data/ 2024-09-11 https://bio-research.ai/safi-biotherapeutics-secures-5m-seed-funding-to-boost-clinical-trials-of-manufactured-red-blood-cell-transfusion-product/ 2024-09-11 https://bio-research.ai/contraline-secures-exclusive-licensing-agreement-with-population-council-for-potential-male-contraceptive-nes-t/ 2024-09-11 https://bio-research.ai/skyhawk-therapeutics-presents-phase-1-data-for-sky-0515-reports-72-htt-mrna-reduction-in-healthy-volunteers-trial/ 2024-09-11 https://bio-research.ai/briacell-therapeutics-reports-15-6-months-median-overall-survival-in-phase-2-breast-cancer-trial-with-bria-imt-and-immune-check-point-inhibitor/ 2024-09-11 https://bio-research.ai/fda-grants-orphan-drug-designation-to-actuate-therapeutics-for-elraglusib-in-treating-soft-tissue-sarcoma-and-other-cancers/ 2024-09-11 https://bio-research.ai/tff-pharmaceuticals-partners-with-emory-university-and-barda-to-explore-tff-technology-with-mrna-based-antiviral-for-influenza-and-sars-cov-2-treatment/ 2024-09-11 https://bio-research.ai/ilc-therapeutics-secures-2-5m-for-pre-clinical-development-of-alfacyte-and-dermacyte-appoints-new-leadership/ 2024-09-11 https://bio-research.ai/merck-s-phase-3-trial-shows-gardasil-9-vaccine-reduces-hpv-infection-incidence-in-japanese-males-aged-16-to-26/ 2024-09-11 https://bio-research.ai/eupraxia-pharmaceuticals-advances-in-resolve-phase-1b-2a-trial-reports-safety-and-symptom-reduction-for-ep-104gi-in-eosinophilic-esophagitis/ 2024-09-11 https://bio-research.ai/bharat-biotech-partners-with-alopexx-to-co-develop-and-commercialize-anti-microbial-vaccine-av0328-in-india-and-lower-income-countries/ 2024-09-11 https://bio-research.ai/gsk-s-phase-ii-trial-for-herpes-vaccine-candidate-gsk3943104-fails-to-meet-primary-efficacy-objective-not-proceeding-to-phase-iii/ 2024-09-11 https://bio-research.ai/fda-grants-orphan-drug-designation-to-agios-pharmaceuticals-pk-activator-tebapivat-for-treatment-of-myelodysplastic-syndromes/ 2024-09-11 https://bio-research.ai/regeneron-and-sanofi-s-phase-3-trial-for-dupixent-meets-primary-and-secondary-endpoints-in-uncontrolled-csu-patients-showing-50-reduction-in-itch-and-urticaria-activity-scores/ 2024-09-11 https://bio-research.ai/regeneron-and-sanofi-s-dupixent-trial-meets-primary-and-key-secondary-endpoints-in-adults-with-bullous-pemphigoid-five-times-more-patients-achieve-sustained-remission/ 2024-09-11 https://bio-research.ai/bridgebio-pharma-reports-increased-cortisol-production-in-phase-1-2-adventure-study-on-bbp-631-for-cah-treatment-seeks-partnerships-for-future-development/ 2024-09-10 https://bio-research.ai/fda-grants-rmat-designation-to-bridgebio-pharma-s-bbp-812-for-canavan-disease-alongside-orphan-drug-rpdd-and-fast-track-designations/ 2024-09-10 https://bio-research.ai/neurona-therapeutics-receives-3-8m-grant-from-cirm-for-neural-cell-therapy-development-boosting-total-investment-to-18-5m/ 2024-09-10 https://bio-research.ai/altimmune-s-phase-2-trial-of-pemvidutide-shows-21-9-lean-loss-ratio-28-3-reduction-in-vat-at-week-48-in-mash-treatment/ 2024-09-10 https://bio-research.ai/eli-lilly-s-phase-3-trial-shows-efsitora-alfa-achieves-non-inferior-a1c-reduction-at-week-26-compared-to-insulin-degludec-in-type-1-diabetes/ 2024-09-10 https://bio-research.ai/novo-nordisk-and-kallyope-collaborate-for-obesity-treatment-kallyope-receives-upfront-fee-and-potential-royalties-on-global-sales/ 2024-09-10 https://bio-research.ai/beyondspring-s-dublin-3-study-shows-improved-survival-rates-with-plinabulin-docetaxel-combo-for-advanced-non-small-cell-lung-cancer/ 2024-09-10 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-arrowhead-s-plozasiran-for-familial-chylomicronemia-syndrome/ 2024-09-10 https://bio-research.ai/cardiatec-procures-6-5m-seed-funding-to-augment-platform-and-drug-targets-utilizing-human-data-to-understand-cardiovascular-disease-biology/ 2024-09-10 https://bio-research.ai/carisma-therapeutics-and-moderna-expand-partnership-to-develop-autoimmune-disease-therapies-retaining-rights-and-sharing-development-responsibilities/ 2024-09-10 https://bio-research.ai/gilead-sciences-and-genesis-therapeutics-join-forces-for-35m-collaboration-to-develop-novel-therapies-using-ai-platform-gems/ 2024-09-10 https://bio-research.ai/lexicon-pharmaceuticals-phase-3-trial-shows-sotagliflozin-enhances-glucose-monitoring-parameters-in-type-2-diabetes-patients/ 2024-09-10 https://bio-research.ai/phoremost-secures-an-additional-12-million-in-series-b-financing-for-the-advancement-of-oncology-and-inflammatory-disease-programmes/ 2024-09-10 https://bio-research.ai/maia-biotechnology-s-phase-2-trial-for-thio-extends-survival-follow-up-to-12-months-in-advanced-non-small-cell-lung-cancer-patients/ 2024-09-10 https://bio-research.ai/bayer-s-finearts-hf-trial-data-reveals-24-reduced-diabetes-risk-and-minimized-cardiovascular-events-with-finerenone-in-heart-failure-patients/ 2024-09-10 https://bio-research.ai/viridian-therapeutics-phase-3-trial-for-veligrotug-meets-key-endpoints-in-thyroid-eye-disease-treatment-plans-for-biologics-license-application-in-2025/ 2024-09-10 https://bio-research.ai/innovent-biologics-reports-49-1-response-rate-in-phase-2-trial-of-dupert-for-advanced-non-small-cell-lung-cancer/ 2024-09-10 https://bio-research.ai/santhera-pharmaceuticals-signs-exclusive-agreement-with-genesis-pharma-for-agamree-distribution-in-central-and-eastern-europe/ 2024-09-10 https://bio-research.ai/osivax-inks-license-option-agreement-with-km-biologics-for-development-and-sales-of-universal-flu-vaccine-candidates-in-japan/ 2024-09-10 https://bio-research.ai/hanall-biopharma-reports-77-reduction-in-blood-antibody-levels-in-phase-2a-batoclimab-trial-for-graves-disease-patients-unresponsive-to-atd/ 2024-09-10 https://bio-research.ai/bambusa-therapeutics-secures-15m-in-series-seed-financing-for-advancing-bispecific-antibodies-to-phase-i-clinical-studies/ 2024-09-09 https://bio-research.ai/daiichi-sankyo-and-astrazeneca-s-datopotamab-deruxtecan-improves-overall-survival-by-2-3-months-in-tropion-lung01-phase-iii-trial-for-nonsquamous-non-small-cell-lung-cancer/ 2024-09-09 https://bio-research.ai/aisa-pharma-s-aisa-021-receives-fda-orphan-drug-designation-for-systemic-sclerosis-treatment-phase-2-study-in-progress/ 2024-09-09 https://bio-research.ai/grin-therapeutics-phase-1b-trial-of-radiprodil-shows-86-median-reduction-in-seizure-frequency-with-71-of-patients-experiencing-more-than-a-50-decrease/ 2024-09-09 https://bio-research.ai/immunitybio-s-quilt-3-055-trial-results-show-median-overall-survival-of-over-14-months-for-advanced-non-small-cell-lung-cancer-patients-treated-with-anktiva-and-checkpoint-inhibitors/ 2024-09-09 https://bio-research.ai/immunovant-inc-reports-phase-2a-trial-results-showing-76-response-rate-and-56-atd-free-response-rate-for-batoclimab-in-graves-disease-patients-uncontrolled-on-antithyroid-drugs/ 2024-09-09 https://bio-research.ai/fda-grants-cartesian-therapeutics-descartes-08-rare-pediatric-disease-designation-for-juvenile-dermatomyositis-treatment/ 2024-09-09 https://bio-research.ai/kissei-pharmaceutical-and-reborna-biosciences-sign-research-collaboration-agreement-for-rna-targeting-small-molecule-drug-discovery-in-genetic-rare-diseases/ 2024-09-09 https://bio-research.ai/epsilogen-completes-12-5-million-series-b-expansion-financing-for-phase-ib-trial-of-mov18-ige-targeting-platinum-resistant-ovarian-cancer/ 2024-09-09 https://bio-research.ai/ultimovacs-announces-uv1-phase-ii-trial-data-showing-secondary-endpoint-benefits-in-mesothelioma-despite-not-meeting-primary-progression-free-survival-target/ 2024-09-09 https://bio-research.ai/hutchmed-s-flowers-study-shows-osimertinib-combined-with-savolitinib-yields-deeper-responses-in-egfrm-met-aberrant-advanced-non-small-cell-lung-cancer-patients-compared-to-osimertinib-monotherapy/ 2024-09-08 https://bio-research.ai/janssen-cilag-s-phase-3-mariposa-study-shows-combination-of-rybrevant-and-lazertinib-results-in-61-survival-at-3-years-in-advanced-non-small-cell-lung-cancer-patients-with-egfr-mutations/ 2024-09-08 https://bio-research.ai/astrazeneca-s-phase-iii-trial-of-datopotamab-deruxtecan-shows-43-reduction-in-disease-progression-or-death-in-trop2-qcs-biomarker-positive-non-small-cell-lung-cancer-patients/ 2024-09-08 https://bio-research.ai/summit-therapeutics-phase-iii-harmoni-2-trial-in-lung-cancer-shows-ivonescimab-with-median-pfs-of-11-14-months-compared-to-5-82-months-for-pembrolizumab/ 2024-09-08 https://bio-research.ai/longboard-pharmaceuticals-interim-results-show-bexicaserin-achieves-57-7-median-seizure-reduction-over-9-months-in-ongoing-52-week-pacific-study-evaluating-developmental-and-epileptic-encephalopathies/ 2024-09-08 https://bio-research.ai/daiichi-sankyo-and-merck-s-ideate-lung01-phase-2-trial-shows-54-8-and-26-1-objective-response-rates-in-pretreated-small-cell-lung-cancer-for-12-mg-kg-and-8-mg-kg-cohorts-respectively/ 2024-09-07 https://bio-research.ai/sun-pharma-and-moebius-medical-s-mm-ii-receives-fda-fast-track-designation-for-osteoarthritis-knee-pain-treatment-planning-phase-3-clinical-trials/ 2024-09-06 https://bio-research.ai/fda-grants-rare-pediatric-disease-designation-to-ns-050-ncnp-03-for-treatment-of-duchenne-muscular-dystrophy-targeting-exon-50-skipping/ 2024-09-06 https://bio-research.ai/orsobio-closes-67-million-series-b-financing-for-mitochondrial-protonophore-portfolio-targeting-obesity-and-associated-disorders/ 2024-09-06 https://bio-research.ai/gsk-s-phase-iii-matinee-trial-of-nucala-shows-statistically-significant-reduction-in-annualized-rate-of-moderate-severe-copd-exacerbations/ 2024-09-06 https://bio-research.ai/ji-xing-pharmaceuticals-phase-3-trial-of-etripamil-nasal-spray-in-500-psvt-patients-in-china-shows-statistically-significant-conversion-to-normal-sinus-rhythm-without-serious-adverse-events/ 2024-09-06 https://bio-research.ai/fda-grants-full-approval-to-travere-therapeutics-filspari-for-slowing-kidney-function-decline-in-adults-with-primary-iga-nephropathy-based-on-protect-study-results/ 2024-09-05 https://bio-research.ai/pleopharma-s-phase-2b-study-of-pp-01-meets-primary-endpoint-in-cannabis-withdrawal-syndrome-with-234-participants-showing-significant-symptom-reduction-across-22-us-centers/ 2024-09-05 https://bio-research.ai/hdax-therapeutics-announces-us-3-2-million-seed-round-led-by-seedfolio-facit-and-tiap-to-advance-preclinical-development-of-hdac6-targeting-therapeutics-for-neurological-and-cardiometabolic-diseases/ 2024-09-05 https://bio-research.ai/evotec-se-and-x-chem-enter-collaboration-to-accelerate-early-stage-drug-discovery-combining-screening-platforms-with-dna-encoded-library-technology/ 2024-09-05 https://bio-research.ai/abdera-therapeutics-abd-147-receives-fda-orphan-drug-designation-for-treatment-of-neuroendocrine-carcinoma-with-clinical-trials-starting-in-2024/ 2024-09-05 https://bio-research.ai/lisata-therapeutics-receives-fda-orphan-drug-designation-for-certepetide-to-treat-cholangiocarcinoma/ 2024-09-05 https://bio-research.ai/voyager-therapeutics-licenses-novel-capsid-to-novartis-ag-for-gene-therapy-program-with-15m-upfront-and-up-to-305m-in-milestone-payments-and-royalties/ 2024-09-05 https://bio-research.ai/eli-lilly-and-company-s-phase-3-trials-show-once-weekly-insulin-efsitora-alfa-non-inferior-to-daily-glargine-and-degludec-in-reducing-a1c-for-type-2-diabetes-over-52-and-78-weeks/ 2024-09-05 https://bio-research.ai/fda-grants-fast-track-designation-to-perspective-therapeutics-for-pb-vmt01-in-unresectable-or-metastatic-melanoma-with-mc1r-tumor-expression/ 2024-09-05 https://bio-research.ai/nerviano-medical-sciences-and-blue-owl-capital-agree-on-monetization-of-over-80m-in-potential-future-braftovi-royalties/ 2024-09-05 https://bio-research.ai/vivet-therapeutics-vtx-806-receives-european-orphan-drug-designation-for-ctx-and-shows-metabolic-normalization-and-enzyme-upregulation-in-pre-clinical-mouse-models-with-plans-for-us-fda-submission-in-2024/ 2024-09-05 https://bio-research.ai/tippingpoint-biosciences-announces-pre-seed-investment-to-develop-treatments-for-diffuse-intrinsic-pontine-glioma-utilizing-disease-specific-dna-packaging-in-cancer-cells/ 2024-09-04 https://bio-research.ai/pharmaessentia-licenses-besremi-to-forus-therapeutics-for-canadian-market-with-potential-107m-milestone-payments-and-double-digit-royalties/ 2024-09-04 https://bio-research.ai/mid-atlantic-biotherapeutics-and-accelero-biostructures-announce-research-collaboration-to-identify-novel-usp30-inhibitors-for-neurological-disorders-using-abs-onestepsm-platform-for-drug-discovery/ 2024-09-04 https://bio-research.ai/beiersdorf-and-macro-biologics-partner-to-develop-biodegradable-antimicrobial-peptides-leveraging-macro-biologics-amicidins-for-beiersdorf-s-skin-care-and-healthcare-products-with-a-focus-on-innovation-and-sustainable-solutions/ 2024-09-04 https://bio-research.ai/mitsubishi-tanabe-pharma-america-and-nobias-therapeutics-collaborate-to-use-ai-technology-for-advancing-drug-discovery-in-autism-spectrum-disorder/ 2024-09-04 https://bio-research.ai/feldan-therapeutics-closes-us-21-million-series-b-round-to-advance-phase-1-2a-study-for-fld-103-and-support-preclinical-development/ 2024-09-04 https://bio-research.ai/haya-therapeutics-enters-multi-year-agreement-with-eli-lilly-to-leverage-rna-guided-platform-could-earn-up-to-1b-in-milestone-payments-plus-royalties/ 2024-09-04 https://bio-research.ai/yoltech-therapeutics-granted-fda-rare-pediatric-disease-designation-for-yolt-203-gene-editing-therapy-treating-primary-hyperoxaluria-type-1/ 2024-09-04 https://bio-research.ai/biogen-inc-phase-2-3-devote-study-higher-dose-nusinersen-regimen-shows-statistically-significant-motor-function-improvement-in-infants-with-sma/ 2024-09-04 https://bio-research.ai/jnana-therapeutics-phase-1-2-trial-of-jnt-517-shows-60-reduction-in-blood-phenylalanine-levels-in-pku-patients/ 2024-09-04 https://bio-research.ai/arsenal-biosciences-closes-325-million-series-c-financing-round-to-support-t-cell-therapy-development-for-solid-tumors-including-clinical-trial-of-ab-2100-for-clear-cell-renal-cell-carcinoma-with-fda-fast-track-designation/ 2024-09-04 https://bio-research.ai/dion-foundation-finances-us-expansion-of-atamyo-therapeutics-clinical-trial-for-ata-200-in-limb-girdle-muscular-dystrophy-type-2c-r5-children/ 2024-09-04 https://bio-research.ai/lilly-and-eva-pharma-collaborate-to-expand-baricitinib-manufacturing-for-immunological-diseases-across-49-african-countries-aiming-to-reach-20-000-people-by-2030-under-lilly-s-30x30-initiative/ 2024-09-04 https://bio-research.ai/roche-announces-48-week-phase-ii-data-showing-fenebrutinib-maintains-low-disease-activity-and-no-disability-progression-in-relapsing-multiple-sclerosis-patients/ 2024-09-04 https://bio-research.ai/epimab-biotherapeutics-and-vignette-bio-enter-license-agreement-for-emb-06-with-60m-upfront-potential-575m-milestones-and-royalties-on-net-sales/ 2024-09-04 https://bio-research.ai/innovent-biologics-receives-fda-fast-track-designation-for-ibi363-in-melanoma-patients-after-immunotherapy-failure/ 2024-09-04 https://bio-research.ai/caribou-biosciences-receives-fda-fast-track-for-cb-010-in-lupus-and-cb-012-in-acute-myeloid-leukemia/ 2024-09-03 https://bio-research.ai/organon-k-k-s-phase-iii-trial-of-og-8276a-achieves-primary-endpoint-in-treating-dysmenorrhea-in-211-japanese-women/ 2024-09-03 https://bio-research.ai/royalty-pharma-and-ascendis-pharma-enter-150m-synthetic-royalty-funding-agreement-based-on-us-sales-of-yorvipath-to-support-development-and-commercialization-of-endocrine-rare-disease-products/ 2024-09-03 https://bio-research.ai/acepodia-enters-strategic-clinical-collaboration-with-pfizer-ignite-to-advance-cell-therapies-in-oncology-and-autoimmune-diseases/ 2024-09-03 https://bio-research.ai/acurastem-secures-4m-grant-from-the-california-institute-for-regenerative-medicine-for-unc13a-gene-therapeutic-program-targeting-als-and-ftd-using-ineurorx-technology-platform/ 2024-09-03 https://bio-research.ai/fda-grants-fast-track-designation-to-arthrosi-therapeutics-ar882-for-treating-visible-tophi-in-gout-patients/ 2024-09-03 https://bio-research.ai/athira-pharma-s-phase-2-3-lift-ad-trial-of-fosgonimeton-in-alzheimer-s-disease-did-not-meet-primary-and-key-secondary-endpoints-at-26-weeks-but-showed-biomarker-changes-consistent-with-hgf-modulation/ 2024-09-03 https://bio-research.ai/avenzo-therapeutics-announces-clinical-study-collaboration-and-supply-agreement-with-gilead-sciences-to-assess-avzo-021-and-trodelvy-combination-therapy-for-hr-her2-breast-cancer/ 2024-09-03 https://bio-research.ai/circle-pharma-completes-90-million-series-d-financing-to-support-development-of-cid-078-and-mxmo-macrocycle-platform/ 2024-09-03 https://bio-research.ai/remedy-pharmaceuticals-phase-3-trial-shows-cirara-improves-ambulation-in-lhi-patients-significant-results-for-lesion-volume-125-ml/ 2024-09-03 https://bio-research.ai/somite-therapeutics-announces-4-8m-extension-of-pre-seed-round-to-advance-ai-driven-cell-replacement-therapies-and-clinical-programs/ 2024-09-03 https://bio-research.ai/primrose-bio-and-explorna-therapeutics-announce-strategic-partnership-to-enhance-mrna-medicines-through-co-developed-rna-polymerases-and-capping-compounds/ 2024-09-03 https://bio-research.ai/regenxbio-announces-85-median-reduction-in-heparan-sulfate-d2s6-in-phase-i-ii-iii-trial-of-rgx-121-for-mps-ii-with-results-sustained-for-up-to-two-years/ 2024-09-03 https://bio-research.ai/obsidian-therapeutics-granted-rmat-designation-for-obx-115-in-treating-unresectable-or-metastatic-melanoma-resistant-to-immune-checkpoint-inhibitor-therapy/ 2024-09-03 https://bio-research.ai/prilenia-therapeutics-submits-marketing-authorisation-application-for-pridopidine-to-treat-huntington-s-disease/ 2024-09-03 https://bio-research.ai/caribou-biosciences-gets-fda-fast-track-designations-for-cb-010-and-cb-012-in-lupus-and-acute-myeloid-leukemia-trials/ 2024-09-03 https://bio-research.ai/vaxcyte-s-phase-1-2-study-of-vax-31-in-adults-aged-50-and-older-shows-robust-immune-responses-and-safety-for-all-31-serotypes-at-all-doses-tested/ 2024-09-03 https://bio-research.ai/praxis-precision-medicines-phase-2-embold-study-of-relutrigine-shows-46-placebo-adjusted-monthly-motor-seizure-reduction-and-75-reduction-in-median-seizure-rate-in-scn2a-and-scn8a-patients/ 2024-09-03 https://bio-research.ai/recursion-announces-phase-2-sycamore-trial-results-for-rec-994-showing-safety-and-tolerability-at-200mg-and-400mg-doses-with-secondary-mri-endpoints-indicating-trend-towards-reduced-lesion-volume-and-hemosiderin-ring-size/ 2024-09-03 https://bio-research.ai/rigel-pharmaceuticals-and-kissei-pharmaceutical-expand-agreement-to-develop-and-commercialize-rezlidhia-in-japan-korea-and-taiwan-with-up-to-162-5m-in-total-payments/ 2024-09-03 https://bio-research.ai/unicycive-therapeutics-submits-fda-application-for-oxylanthanum-carbonate-to-treat-hyperphosphatemia-in-chronic-kidney-disease-patients-on-dialysis/ 2024-09-03 https://bio-research.ai/dyne-therapeutics-phase-1-2-deliver-trial-of-dyne-251-shows-high-levels-of-dystrophin-expression-and-functional-improvements-in-dmd-patients-amenable-to-exon-51-skipping-with-registrational-cohorts-planned/ 2024-09-03 https://bio-research.ai/simcere-pharmaceuticals-sanbexin-sublingual-tablets-granted-fda-breakthrough-therapy-designation-for-treating-acute-ischemic-stroke/ 2024-09-03 https://bio-research.ai/cereno-scientific-s-cs1-granted-orphan-medicinal-product-designation-by-european-commission-for-pulmonary-arterial-hypertension/ 2024-09-03 https://bio-research.ai/kalvista-pharmaceuticals-nda-for-sebetralstat-accepted-by-fda-with-pdufa-date-set-for-june-17-2025/ 2024-09-03 https://bio-research.ai/european-commission-revokes-conditional-marketing-authorisation-for-ocaliva-in-europe-for-second-line-treatment-of-primary-biliary-cholangitis-following-ema-reassessment/ 2024-09-03 https://bio-research.ai/skyline-therapeutics-receives-fda-orphan-drug-designation-for-gene-therapy-skg1108-targeting-retinitis-pigmentosa/ 2024-09-02 https://bio-research.ai/simcere-zaiming-and-shenzhen-targetrx-inc-partner-on-tgrx-326-with-20m-deal-giving-simcere-zaiming-exclusive-rights-in-mainland-china-for-alk-ros1-positive-non-small-cell-lung-cancer-treatment/ 2024-09-02 https://bio-research.ai/arrowhead-pharmaceuticals-phase-3-palisade-study-shows-80-reduction-in-triglycerides-and-83-reduced-risk-of-acute-pancreatitis-in-patients-with-familial-chylomicronemia-syndrome/ 2024-09-02 https://bio-research.ai/sanofi-s-phase-3-hercules-study-shows-tolebrutinib-delays-confirmed-disability-progression-in-nrspms-while-gemini-1-and-2-studies-show-no-significant-reduction-in-relapse-rate-for-rms-compared-to-teriflunomide/ 2024-09-02 https://bio-research.ai/bayer-s-phase-iii-trial-shows-kerendia-achieves-16-reduction-in-cardiovascular-death-and-heart-failure-events-in-patients-with-heart-failure-and-lvef-40/ 2024-09-01 https://bio-research.ai/thinkcyte-completes-series-c-funding-round-raising-15-million-for-global-expansion-of-visionsort-product/ 2024-08-31 https://bio-research.ai/novavax-covid-19-vaccine-nvx-cov2705-receives-emergency-use-authorization-from-u-s-fda-for-individuals-aged-12-and-older/ 2024-08-30 https://bio-research.ai/aptose-biosciences-inc-receives-10m-through-facility-agreement-with-hanmi-pharmaceutical-co-ltd-for-development-of-tuspetinib-as-frontline-treatment-for-newly-diagnosed-acute-myeloid-leukemia-patients/ 2024-08-30 https://bio-research.ai/bridgebio-pharma-announces-phase-3-trial-results-showing-acoramidis-increased-ttr-levels-and-reduced-cardiovascular-events-and-hospitalizations-at-month-30-in-transthyretin-amyloid-cardiomyopathy/ 2024-08-30 https://bio-research.ai/hutchmed-withdraws-supplemental-nda-in-china-for-fruquintinib-and-paclitaxel-combination-to-treat-advanced-gastric-or-gastroesophageal-junction-adenocarcinoma/ 2024-08-30 https://bio-research.ai/jacobio-pharma-grants-china-rights-of-kras-g12c-inhibitor-glecirasib-and-shp2-inhibitor-jab-3312-to-shanghai-allist-pharmaceuticals-in-a-deal-worth-rmb200-m-with-potential-rmb700-m-in-milestone-payments/ 2024-08-30 https://bio-research.ai/revolka-ltd-secures-250-million-jpy-in-series-a-extension-funding-and-launches-drug-discovery-program-for-rare-diseases/ 2024-08-29 https://bio-research.ai/fda-approves-supplemental-biologics-license-application-for-acam2000-to-include-prevention-of-mpox-in-high-risk-individuals/ 2024-08-29 https://bio-research.ai/nucana-discontinues-nutide-323-study-after-initial-analysis-suggests-nuc-3373-combination-unlikely-to-achieve-primary-objective/ 2024-08-29 https://bio-research.ai/lexaria-bioscience-corp-reports-zero-adverse-events-in-second-glp-1-human-pilot-study-with-dehydratech-processed-rybelsus-capsules-compared-to-mild-adverse-events-in-6-out-of-9-participants-with-commercially-available-tablets/ 2024-08-29 https://bio-research.ai/noetik-secures-40-million-to-expand-spatial-omics-atlas-enhance-crispr-perturb-map-platform-and-scale-multi-modal-cancer-foundation-models/ 2024-08-29 https://bio-research.ai/johnson-johnson-submits-biologics-license-application-to-fda-for-nipocalimab-as-treatment-for-generalized-myasthenia-gravis-based-on-phase-3-vivacity-mg3-study-results/ 2024-08-29 https://bio-research.ai/nuvectis-pharma-receives-fda-orphan-drug-designation-for-nxp800-for-treatment-of-arid1a-deficient-ovarian-fallopian-tube-and-primary-peritoneal-cancers/ 2024-08-29 https://bio-research.ai/merck-discontinues-keytruda-trials-keynote-867-and-keynote-630-due-to-lack-of-improvement-and-primary-endpoint-not-met/ 2024-08-29 https://bio-research.ai/gsk-s-arexvy-vaccine-approved-by-european-commission-for-preventing-rsv-in-adults-aged-50-59-with-medical-conditions-after-phase-iii-trial-results/ 2024-08-29 https://bio-research.ai/cancervax-and-flashpoint-therapeutics-enter-research-agreement-on-cancervax-s-universal-cancer-treatment-platform-using-nanomedicine-technology/ 2024-08-29 https://bio-research.ai/biocon-biologics-ltd-announces-settlement-with-janssen-and-johnson-johnson-for-biosimilar-bmab-1200-commercialization-in-europe-uk-canada-and-japan/ 2024-08-29 https://bio-research.ai/geovax-labs-inc-secure-up-to-45m-from-barda-for-phase-2b-trial-of-geo-cm04s1-covid-19-vaccine-as-part-of-hhs-s-project-nextgen/ 2024-08-28 https://bio-research.ai/eydisbio-receives-2-6m-phase-2-sbir-grant-from-nih-s-nhlbi-to-advance-tak1-inhibitors-for-systemic-sclerosis/ 2024-08-28 https://bio-research.ai/innovate-uk-invests-10m-in-innovation-projects-with-1-5m-awarded-to-mestag-therapeutics-to-advance-bispecific-antibody-mst-0300-for-cancer-treatment/ 2024-08-28 https://bio-research.ai/unravel-biosciences-and-csnk2a1-foundation-expand-collaboration-to-personalize-treatments-for-okur-chung-neurodevelopmental-syndrome-using-ai-platforms-and-nasal-swabs/ 2024-08-28 https://bio-research.ai/life-molecular-imaging-s-18f-pi-2620-injection-granted-fda-fast-track-designation-for-clinical-development-in-alzheimer-s-disease-progressive-supranuclear-palsy-and-corticobasal-degeneration/ 2024-08-28 https://bio-research.ai/arcutis-biotherapeutics-long-term-study-shows-roflumilast-cream-0-05-maintains-or-improves-efficacy-for-atopic-dermatitis-in-children-aged-2-5-with-71-9-achieving-75-improvement-in-easi-after-56-weeks/ 2024-08-28 https://bio-research.ai/flagship-pioneering-and-quotient-therapeutics-to-explore-somatic-mutations-in-cardiovascular-and-renal-diseases-using-quotient-s-somatic-genomics-platform-under-partnership-with-pfizer/ 2024-08-28 https://bio-research.ai/egetis-therapeutics-ab-reports-post-hoc-analyses-from-triac-trial-i-showing-caregiver-reported-outcomes-in-40-patients-with-mct8-deficiency-treated-with-tiratricol/ 2024-08-28 https://bio-research.ai/destiny-pharma-receives-us-fda-qidp-designation-for-xf-73-dermal-gel-to-treat-or-prevent-staphylococcal-infections-in-burn-wounds/ 2024-08-28 https://bio-research.ai/bayer-and-nextrna-therapeutics-enter-547m-partnership-to-develop-small-molecule-therapeutics-targeting-lncrnas-in-oncology/ 2024-08-28 https://bio-research.ai/neurocrine-biosciences-phase-2-trial-of-nbi-1117568-in-schizophrenia-shows-7-5-point-improvement-in-panss-total-score-at-week-6/ 2024-08-28 https://bio-research.ai/springworks-therapeutics-nda-for-mirdametinib-to-treat-nf1-associated-plexiform-neurofibromas-accepted-by-fda-with-european-medicines-agency-also-validating-application/ 2024-08-28 https://bio-research.ai/novartis-phase-iii-study-shows-leqvio-reduces-ldl-c-in-low-to-moderate-risk-ascvd-patients-compared-to-placebo-and-ezetimibe/ 2024-08-28 https://bio-research.ai/chugai-pharmaceutical-transfers-secondary-hyperparathyroidism-drug-oxarol-for-injection-to-ltl-pharma-with-marketing-authorization-effective-october-1-2024-and-sales-transfer-by-january-1-2025/ 2024-08-28 https://bio-research.ai/astellas-pharma-receives-european-commission-authorization-for-padcev-and-keytruda-combination-as-first-line-treatment-for-urothelial-cancer-based-on-phase-3-ev-302-trial-results/ 2024-08-28 https://bio-research.ai/navigator-medicines-secures-100m-series-a-financing-to-advance-the-clinical-development-of-nav-240-bispecific-antibody/ 2024-08-27 https://bio-research.ai/navigator-medicines-secures-in-licensing-deal-for-nav-240-bispecific-antibody-from-imbiologics/ 2024-08-27 https://bio-research.ai/cosciens-biopharma-inc-s-phase-3-aezs-130-p02-detect-trial-shows-macimorelin-stimulates-growth-hormone-but-fails-primary-efficacy-endpoint-due-to-high-false-positive-rate-in-comparator-tests/ 2024-08-27 https://bio-research.ai/camp4-therapeutics-receives-fda-rare-pediatric-disease-designation-for-cmp-cps-001-targeting-urea-cycle-disorders/ 2024-08-27 https://bio-research.ai/fda-accepts-soleno-therapeutics-drug-application-for-dccr-for-treating-prader-willi-syndrome-with-a-pdufa-target-action-date-of-december-27-2024/ 2024-08-27 https://bio-research.ai/ensysce-biosciences-receives-14m-nih-and-national-institute-on-drug-abuse-grant-for-pf614-mpar-phase-1b-clinical-trial-addressing-opioid-crisis-total-federal-support-now-40m/ 2024-08-27 https://bio-research.ai/gc-cell-and-dewcell-biotherapeutics-partner-to-develop-and-commercialize-high-quality-artificial-platelets-leveraging-stem-cell-based-technology-and-advanced-biopharmaceutical-solutions/ 2024-08-27 https://bio-research.ai/yoltech-therapeutics-and-salubris-pharmaceuticals-enter-licensing-agreement-worth-rmb-1-035b-for-yolt-101-development-and-commercialization-in-mainland-china/ 2024-08-27 https://bio-research.ai/invivyd-announces-180-day-data-from-phase-3-trial-of-pemivibart-showing-84-relative-risk-reduction-in-symptomatic-covid-19-and-no-hospitalizations-or-deaths-in-immunocompetent-participants/ 2024-08-27 https://bio-research.ai/advanz-pharma-and-enzene-biosciences-announce-strategic-partnership-for-commercialization-of-biosimilar-to-enhance-access-to-affordable-life-saving-therapies-in-europe/ 2024-08-27 https://bio-research.ai/faron-pharmaceuticals-receives-fda-fast-track-designation-for-bexmarilimab-in-combination-with-azacitidine-for-relapsed-or-refractory-myelodysplastic-syndrome/ 2024-08-27 https://bio-research.ai/european-commission-approves-extension-for-rybrevant-in-combination-with-chemotherapy-for-advanced-nsclc-with-egfr-mutations-after-prior-egfr-tki-therapy-failure/ 2024-08-27 https://bio-research.ai/basilea-pharmaceutica-ltd-extends-cresemba-s-use-to-pediatric-patients-and-receives-chf-10-million-milestone-payment-from-pfizer/ 2024-08-27 https://bio-research.ai/roche-announces-european-commission-approval-of-piasky-for-pnh-based-on-phase-iii-studies-offering-monthly-subcutaneous-self-administration-option/ 2024-08-27 https://bio-research.ai/jw-therapeutics-supplemental-biological-license-application-for-carteyva-approved-in-china-for-treating-relapsed-or-refractory-mantle-cell-lymphoma/ 2024-08-27 https://bio-research.ai/avanzanite-bioscience-receives-european-commission-marketing-authorization-for-akantior-to-treat-acanthamoeba-keratitis-following-successful-phase-iii-odak-trial-results/ 2024-08-27 https://bio-research.ai/european-commission-approves-eurneffy-for-emergency-treatment-of-severe-allergic-reactions-in-adults-and-children/ 2024-08-26 https://bio-research.ai/actinogen-medical-s-phase-2a-trial-of-xanamem-shows-50-higher-remission-rate-in-depression-at-week-10-compared-to-placebo/ 2024-08-26 https://bio-research.ai/dewpoint-therapeutics-and-biospective-receive-second-target-als-foundation-grant-for-in-vivo-development-of-condensate-modifying-drugs-targeting-tdp-43-condensatopathy-in-als/ 2024-08-26 https://bio-research.ai/bridgebio-pharma-collaborates-with-yale-school-of-medicine-to-enhance-early-detection-of-attr-cm-using-ai-based-screening-tools/ 2024-08-26 https://bio-research.ai/immorna-biotherapeutics-receives-grant-from-bill-melinda-gates-foundation-for-jcxh-108-rsv-vaccine-clinical-development-with-commitment-to-supply-low-income-regions-if-approved/ 2024-08-26 https://bio-research.ai/tonix-pharmaceuticals-and-bilthoven-biologicals-collaborate-to-advance-tnx-801-mpox-vaccine-candidate-in-the-manufacturing-processes/ 2024-08-26 https://bio-research.ai/beigene-receives-fda-fast-track-designation-for-bgb-16673-in-adult-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-after-two-prior-lines-of-therapy/ 2024-08-26 https://bio-research.ai/regeneron-pharmaceuticals-receives-european-commission-approval-for-ordspono-in-relapsed-or-refractory-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma/ 2024-08-26 https://bio-research.ai/gi-innovation-and-msd-sign-clinical-trial-agreement-to-evaluate-gi-102-and-keytruda-in-patients-with-immunotherapy-resistant-liver-cancer-melanoma-and-renal-cell-carcinoma/ 2024-08-26 https://bio-research.ai/cessatech-and-proveca-enter-agreement-for-worldwide-commercialization-of-ct001-with-upfront-payment-and-double-digit-royalties-while-exploring-ct002-program-for-pediatric-needs/ 2024-08-26 https://bio-research.ai/european-commission-approves-akantior-for-treatment-of-acanthamoeba-keratitis-in-patients-aged-12-and-older/ 2024-08-26 https://bio-research.ai/celltrion-receives-european-commission-approval-for-steqeyma-ustekinumab-biosimilar-to-treat-chronic-inflammatory-diseases-based-on-phase-iii-study-in-plaque-psoriasis-demonstrating-similarity-to-stelara/ 2024-08-26 https://bio-research.ai/pharmaust-limited-s-study-on-als-shows-monepantel-at-10-mg-kg-daily-improved-survival-by-80-3-and-slowed-disease-progression/ 2024-08-25 https://bio-research.ai/invenra-s-antibody-inv724-for-neuroblastoma-receives-rare-pediatric-disease-and-orphan-drug-designations-from-fda/ 2024-08-23 https://bio-research.ai/european-commission-approves-erdafitinib-as-monotherapy-for-unresectable-or-metastatic-urothelial-carcinoma-with-fgfr3-genetic-alterations-based-on-thor-phase-3-study-results/ 2024-08-23 https://bio-research.ai/arthrosi-therapeutics-announces-data-from-phase-2-program-showing-83-of-patients-achieved-serum-urate-levels-below-5-mg-dl-with-ar882-in-gout-treatment/ 2024-08-23 https://bio-research.ai/genfleet-therapeutics-receives-approval-for-dupert-in-treating-advanced-non-small-cell-lung-cancer-with-kras-g12c-mutation-after-prior-therapy/ 2024-08-23 https://bio-research.ai/anges-inc-terminates-exclusive-distribution-license-agreements-in-japan-and-the-united-states-with-mitsubishi-tanabe-pharma-for-hgf-gene-therapy-product-collategene/ 2024-08-23 https://bio-research.ai/moderna-s-mrna-vaccine-mresvia-granted-marketing-authorization-by-european-commission-for-rsv-in-adults-aged-60-years-and-older-based-on-phase-3-conquerrsv-trial-involving-37000-adults/ 2024-08-23 https://bio-research.ai/viatris-phase-2-study-shows-2-mg-and-4-mg-doses-of-cenerimod-are-safe-and-well-tolerated-with-reversible-decrease-in-lymphocyte-counts-and-improvement-in-disease-activity-for-systemic-lupus-erythematosus-in-japanese-patients/ 2024-08-23 https://bio-research.ai/moderna-receives-fda-approval-for-spikevax-2024-2025-formula-for-ages-12-and-up-and-emergency-use-authorization-for-ages-6-months-to-11-years/ 2024-08-22 https://bio-research.ai/tevogen-bio-holdings-inc-enters-6-0-million-series-c-preferred-stock-investment-agreement-with-the-patel-family-llp-to-support-t-cell-therapies-development/ 2024-08-22 https://bio-research.ai/pfizer-and-biontech-announce-fda-approval-and-emergency-use-authorization-for-omicron-adapted-covid-19-vaccine-for-various-age-groups/ 2024-08-22 https://bio-research.ai/abata-therapeutics-granted-fda-fast-track-designation-for-aba-101-to-treat-progressive-multiple-sclerosis/ 2024-08-22 https://bio-research.ai/fda-grants-orphan-drug-designation-to-ractigen-therapeutics-sarna-product-rag-18-for-duchenne-muscular-dystrophy/ 2024-08-22 https://bio-research.ai/oblique-therapeutics-enters-research-collaboration-agreement-with-eli-lilly-and-company-to-generate-antibodies-using-abiprot-technology-aiming-to-accelerate-innovative-treatments-development/ 2024-08-22 https://bio-research.ai/cognition-therapeutics-sequel-study-of-ct1812-in-16-adults-with-mild-to-moderate-alzheimer-s-disease-shows-eeg-measured-brain-wave-improvements-and-reports-no-severe-adverse-events/ 2024-08-22 https://bio-research.ai/ractigen-therapeutics-receives-fda-rare-pediatric-disease-designation-for-rag-18-in-treating-duchenne-muscular-dystrophy/ 2024-08-22 https://bio-research.ai/eisai-and-biogen-s-lecanemab-granted-marketing-authorization-by-mhra-for-alzheimer-s-treatment-based-on-phase-3-clinical-trial-data/ 2024-08-22 https://bio-research.ai/bridge-biotherapeutics-and-hitgen-enter-joint-research-agreement-to-develop-novel-cancer-therapeutics-leveraging-dna-encoded-library-technology/ 2024-08-22 https://bio-research.ai/rafael-holdings-and-cyclo-therapeutics-enter-definitive-merger-agreement-to-develop-trappsol-cyclo-for-niemann-pick-disease-type-c1/ 2024-08-22 https://bio-research.ai/liquidia-corporation-files-lawsuit-challenging-fda-s-3-year-exclusivity-decision-for-tyvaso-dpi-delaying-yutrepia-approval-until-may-2025/ 2024-08-22 https://bio-research.ai/henlius-trastuzumab-biosimilar-hlx02-receives-approval-from-health-canada-for-treatment-of-early-and-metastatic-cancers-under-trade-name-adheroza/ 2024-08-22 https://bio-research.ai/ck-life-sciences-announces-fda-fast-track-designation-for-wex-pharmaceuticals-halneuron-in-treating-chemotherapy-induced-neuropathic-pain/ 2024-08-22 https://bio-research.ai/clarity-pharmaceuticals-cu-sar-bispsma-granted-fda-fast-track-designation-for-pet-imaging-of-psma-positive-prostate-cancer-lesions-as-phase-iii-trials-are-underway/ 2024-08-22 https://bio-research.ai/photonpharma-completes-2-5-million-seed-financing-for-phase-i-clinical-trial-of-innocell-for-advanced-ovarian-cancer-treatment/ 2024-08-21 https://bio-research.ai/virogin-biotech-s-vg201-phase-i-trial-on-hsv-1-oncolytic-virus-shows-partial-response-in-3-patients-and-stable-disease-in-8-with-no-severe-adverse-events/ 2024-08-21 https://bio-research.ai/retension-pharmaceuticals-secures-10-4-million-in-series-a-funding-to-advance-phase-2-clinical-study-for-rtn-001-in-hypertension-patients/ 2024-08-21 https://bio-research.ai/innovent-biologics-nmpa-approval-of-dupert-for-advanced-nsclc-with-kras-g12c-mutation-based-on-phase-2-study-showing-49-1-orr-and-90-5-dcr/ 2024-08-21 https://bio-research.ai/pharmazz-signs-agreement-with-sun-pharmaceutical-industries-limited-for-15m-investment-in-phase-3-trial-of-sovateltide-for-acute-cerebral-ischemic-stroke-and-expands-marketing-rights-to-emerging-market-countries/ 2024-08-21 https://bio-research.ai/timber-pharmaceuticals-phase-3-trial-of-tmb-001-for-moderate-to-severe-congenital-ichthyosis-fails-to-meet-endpoints-with-no-statistically-significant-difference-observed/ 2024-08-21 https://bio-research.ai/tokyo-medical-and-dental-university-and-celaid-therapeutics-sign-joint-research-agreement-for-novel-gene-modified-cell-therapies-using-human-bone-marrow-hscs-for-inborn-errors-of-immunity/ 2024-08-21 https://bio-research.ai/newish-technology-beijing-announces-phase-i-trial-results-of-nwrd08-with-hpv16-negativity-and-benign-hsil-outcome-in-first-subject-within-12-weeks/ 2024-08-21 https://bio-research.ai/egetis-therapeutics-reports-tiratricol-treatment-in-mct8-deficiency-linked-to-three-times-lower-risk-of-mortality-from-international-real-world-study-on-228-patients-across-173-sites-in-48-countries/ 2024-08-21 https://bio-research.ai/annexin-pharmaceuticals-phase-2a-trial-of-anxv-in-retinal-vein-occlusion-shows-12-of-14-patients-with-improvement-or-stable-disease/ 2024-08-21 https://bio-research.ai/vandria-sa-secures-30-7m-in-series-a-financing-to-support-first-in-man-phase-1-study-and-three-parallel-phase-1b-2a-efficacy-studies-of-vna-318-in-2025/ 2024-08-21 https://bio-research.ai/innovo-therapeutics-inc-announces-phase-2-trial-results-showing-safety-and-significant-scar-reduction-with-inv-001-in-77-korean-patients-following-thyroidectomy/ 2024-08-20 https://bio-research.ai/fda-issues-complete-response-letter-for-regeneron-s-linvoseltamab-application-in-relapsed-refractory-multiple-myeloma-due-to-findings-at-third-party-manufacturer-facility-awaiting-reinspection/ 2024-08-20 https://bio-research.ai/dr-reddy-s-laboratories-aurigene-pharmaceutical-and-kainomyx-sign-mou-for-affordable-anti-malarial-drug-development/ 2024-08-20 https://bio-research.ai/pathalys-pharma-secures-105-million-funding-to-finalize-phase-3-trials-and-prepare-nda-filing-for-eskd-treatment-upacicalcet/ 2024-08-20 https://bio-research.ai/life-molecular-imaging-and-pharmalogic-holdings-corp-partner-to-distribute-fda-approved-neuraceq-from-denver-site-for-improved-access-to-beta-amyloid-pet-imaging-in-brain/ 2024-08-20 https://bio-research.ai/talus-bioscience-raises-11-2m-to-advance-therapeutic-programs-targeting-brachyury-driven-cancers-and-a-transcription-factor-in-prostate-cancer-expanding-marmot-platform-for-transcription-factor-modulation/ 2024-08-20 https://bio-research.ai/opus-genetics-receives-rare-pediatric-disease-designation-from-fda-for-opgx-lca5-gene-therapy-for-leber-congenital-amaurosis/ 2024-08-20 https://bio-research.ai/organon-expands-agreement-with-eli-lilly-for-22-5m-to-distribute-and-promote-emgality-in-canada-colombia-israel-south-korea-kuwait-mexico-qatar-saudi-arabia-taiwan-turkey-and-uae/ 2024-08-20 https://bio-research.ai/fda-approves-johnson-johnson-s-rybrevant-plus-lazcluze-for-first-line-treatment-of-egfr-mutated-nsclc-following-phase-3-study-showing-significant-clinical-benefits-over-osimertinib/ 2024-08-20 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-for-gsk5764227-targeting-small-cell-lung-cancer-by-gsk-after-progression-on-chemotherapy/ 2024-08-20 https://bio-research.ai/shanghai-henlius-biotech-and-convalife-pharmaceuticals-partner-for-exclusive-commercialization-of-neratinib-in-china-and-other-regions/ 2024-08-20 https://bio-research.ai/astrazeneca-s-fasenra-receives-approval-in-china-for-maintenance-treatment-of-severe-eosinophilic-asthma-based-on-miracle-phase-iii-trial-results-showing-significant-reduction-in-asthma-exacerbation-rate/ 2024-08-20 https://bio-research.ai/eli-lilly-and-company-reports-tirzepatide-phase-3-study-results-with-22-9-average-weight-loss-and-reduced-progression-to-type-2-diabetes/ 2024-08-20 https://bio-research.ai/bergenbio-collaborates-with-tempus-to-enhance-bemcentinib-development-for-first-line-nsclc-patients-with-stk11-mutations-using-real-world-data/ 2024-08-20 https://bio-research.ai/adcendo-and-multitude-sign-licensing-agreement-for-adce-t02-targeting-tissue-factor-with-multitude-receiving-over-1b-in-payments-and-royalties-phase-i-study-set-to-begin-in-q4-2024/ 2024-08-20 https://bio-research.ai/astellas-pharma-s-padcev-approved-in-china-for-advanced-urothelial-cancer-following-prior-chemotherapy-and-pd-1-pd-l1-inhibitor-treatment-based-on-data-from-ev-301-and-ev-203-trials/ 2024-08-20 https://bio-research.ai/genovis-divests-antibody-business-to-leinco-technologies-to-focus-on-core-enzyme-business/ 2024-08-19 https://bio-research.ai/realta-life-sciences-receives-fda-orphan-drug-and-fast-track-designation-for-rls-0071-to-treat-hospitalized-patients-with-steroid-refractory-acute-graft-versus-host-disease/ 2024-08-19 https://bio-research.ai/arthrosi-therapeutics-ar882-receives-fda-fast-track-designation-for-treating-clinically-visible-tophi-in-gout-patients/ 2024-08-19 https://bio-research.ai/visiox-pharmaceuticals-enters-definitive-merger-agreement-with-ocuvex-therapeutics-to-accelerate-commercialization-and-enhance-eye-care-portfolio/ 2024-08-19 https://bio-research.ai/mindbio-therapeutics-corp-phase-2a-trial-of-lsd-microdose-mb22001-shows-62-8-reduction-in-depressive-symptoms-three-months-post-treatment/ 2024-08-19 https://bio-research.ai/sonnet-biotherapeutics-enters-into-master-clinical-collaboration-agreement-with-sarcoma-oncology-center-to-advance-son-1210-development-for-metastatic-pancreatic-cancer/ 2024-08-19 https://bio-research.ai/european-medicines-agency-validates-type-ii-variation-application-for-enhertu-in-her2-low-or-ultralow-breast-cancer-based-on-destiny-breast06-trial-results-showing-improved-progression-free-survival/ 2024-08-19 https://bio-research.ai/bristol-myers-squibb-application-to-expand-breyanzi-indication-validated-by-ema-for-adults-with-relapsed-or-refractory-follicular-lymphoma-based-on-phase-2-transcend-fl-study-data/ 2024-08-19 https://bio-research.ai/canbridge-pharmaceuticals-pivotal-trial-of-can103-shows-significant-reductions-in-spleen-volume-for-gaucher-disease-at-nine-months/ 2024-08-19 https://bio-research.ai/fda-grants-tentative-approval-for-liquidia-s-yutrepia-inhalation-powder-to-treat-pah-and-ph-ild-pending-tyvaso-dpi-s-regulatory-exclusivity-expiration-and-liquidia-s-challenge/ 2024-08-19 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-enhertu-for-treatment-of-certain-types-of-advanced-breast-cancer-based-on-destiny-breast06-phase-3-trial-data/ 2024-08-19 https://bio-research.ai/fda-grants-orphan-drug-designation-to-phanes-therapeutics-pt217-for-neuroendocrine-carcinoma/ 2024-08-16 https://bio-research.ai/scisparc-signs-exclusive-patent-license-agreement-with-polyrizon-for-sci-160-program-in-pain-treatment-with-scisparc-to-receive-polyrizon-securities-worth-3m-potential-milestone-fees-of-3m-and-royalties/ 2024-08-16 https://bio-research.ai/pfizer-and-biontech-phase-3-trial-of-combination-mrna-vaccine-meets-immunogenicity-objective-for-influenza-a-and-covid-19-but-not-for-influenza-b/ 2024-08-16 https://bio-research.ai/astrazeneca-s-imfinzi-combined-with-chemotherapy-approved-by-fda-for-resectable-early-stage-nsclc-without-egfr-mutations-or-alk-rearrangements-based-on-aegean-trial-data/ 2024-08-16 https://bio-research.ai/immuron-limited-secures-3-5m-from-u-s-department-of-defense-for-research-agreement-with-naval-medical-research-command-and-walter-reed-army-institute-of-research-to-enhance-travelan-for-military-relevant-diarrheal-pathogens/ 2024-08-16 https://bio-research.ai/imbiologics-signs-deal-with-hangzhou-zhongmei-huadong-pharmaceutical-for-imb-101-regional-rights-in-315-5m-agreement-including-8m-upfront-and-additional-royalties-continues-collaboration-with-navigator-medicines/ 2024-08-16 https://bio-research.ai/fda-accepts-priority-review-for-nda-for-vimseltinib-by-deciphera-pharmaceuticals-for-tenosynovial-giant-cell-tumor-with-target-action-date-february-17-2025-based-on-phase-3-motion-study-results-showing-objective-response-rate/ 2024-08-16 https://bio-research.ai/nuntius-therapeutics-enters-collaboration-agreement-with-taiho-pharmaceutical-to-develop-novel-mrna-cancer-immunotherapies-utilizing-peptide-dendrimer-and-lipid-based-nanocarriers/ 2024-08-15 https://bio-research.ai/incyte-s-phase-3-inmind-trial-meets-primary-endpoint-in-patients-with-relapsed-or-refractory-follicular-lymphoma-evaluating-tafasitamab-combined-with-lenalidomide-and-rituximab/ 2024-08-15 https://bio-research.ai/fda-approves-pediatric-indication-for-vericel-s-nexobrid-in-eschar-removal-for-deep-partial-thickness-and-full-thickness-burns-based-on-phase-3-trial-and-additional-pediatric-data/ 2024-08-15 https://bio-research.ai/enplusone-biosciences-and-wyss-institute-receive-up-to-27m-from-arpa-h-for-rna-therapeutic-development-targeting-cancer-and-infectious-diseases-using-ezrna-platform-and-dna-nanotechnology-for-drug-delivery/ 2024-08-15 https://bio-research.ai/pathos-ai-licenses-prt811-from-prelude-therapeutics-raises-40m-to-develop-p-500-following-promising-phase-1-trial-results-in-high-grade-glioma-and-uveal-melanoma/ 2024-08-15 https://bio-research.ai/dermbiont-s-phase-2a-study-shows-clinical-response-in-7-subjects-with-basal-cell-carcinoma-treated-with-sm-020-1-gel/ 2024-08-15 https://bio-research.ai/niaid-s-palm-007-trial-of-siga-technologies-tecovirimat-in-monkeypox-patients-shows-safety-but-does-not-meet-primary-endpoint-for-lesion-resolution-improvement/ 2024-08-15 https://bio-research.ai/aarvik-therapeutics-and-arrivent-biopharma-announce-exclusive-license-agreement-for-novel-adc-molecule/ 2024-08-15 https://bio-research.ai/abata-therapeutics-receives-equity-investment-from-bristol-myers-squibb-to-advance-treg-cell-therapy-products-for-progressive-multiple-sclerosis-and-type-1-diabetes/ 2024-08-15 https://bio-research.ai/nanoform-finland-plc-enters-pre-clinical-development-agreement-with-plasma-derived-therapies-business-unit-of-takeda-pharmaceuticals-to-develop-nano-formulations-of-biologics-for-rare-conditions/ 2024-08-15 https://bio-research.ai/fda-approves-niktimvo-for-treatment-of-chronic-graft-versus-host-disease-in-patients-after-failure-of-at-least-two-prior-therapies/ 2024-08-14 https://bio-research.ai/turnstone-biologics-phase-1-starling-trial-of-tidal-01-in-metastatic-microsatellite-stable-colorectal-cancer-shows-25-overall-response-rate-and-50-disease-control-rate/ 2024-08-14 https://bio-research.ai/gilead-sciences-livdelzi-receives-fda-accelerated-approval-for-primary-biliary-cholangitis-in-adults-with-inadequate-response-to-or-intolerance-of-udca-based-on-phase-3-response-study-data/ 2024-08-14 https://bio-research.ai/accutar-biotechnology-receives-fast-track-designation-for-ac699-to-treat-advanced-or-metastatic-breast-cancer-after-progression-on-endocrine-based-therapy/ 2024-08-14 https://bio-research.ai/veralox-therapeutics-vlx-1005-receives-european-medicines-agency-orphan-drug-designation-for-platelet-activating-anti-pf4-disorders-progresses-to-phase-2-trials/ 2024-08-14 https://bio-research.ai/vaccinex-s-phase-1b-2-trial-of-pepinemab-shows-significant-difference-in-fdg-pet-signals-in-medial-temporal-cortex-after-12-months-in-alzheimer-s-disease-patients-with-mci/ 2024-08-14 https://bio-research.ai/verrica-pharmaceuticals-phase-2-trial-of-vp-315-for-basal-cell-carcinoma-shows-51-of-lesions-achieving-complete-histological-clearance-and-86-overall-tumor-size-reduction/ 2024-08-14 https://bio-research.ai/atsena-therapeutics-receives-rare-pediatric-disease-designation-from-fda-for-atsn-201-gene-therapy-for-x-linked-retinoschisis/ 2024-08-14 https://bio-research.ai/kiromic-biopharma-s-deltacel-granted-fda-fast-track-designation-for-treating-metastatic-non-small-cell-lung-cancer-as-phase-1-deltacel-01-study-shows-favorable-safety-profile/ 2024-08-14 https://bio-research.ai/viracta-therapeutics-phase-2-trial-of-nana-val-shows-33-overall-response-rate-in-ebv-positive-ptcl/ 2024-08-14 https://bio-research.ai/astrazeneca-s-imfinzi-and-lynparza-approved-in-eu-for-treating-advanced-or-recurrent-endometrial-cancer-with-differing-mismatch-repair-statuses/ 2024-08-14 https://bio-research.ai/bavarian-nordic-s-chikungunya-vaccine-receives-fda-acceptance-and-priority-review-with-an-expected-completion-date-in-february-2025/ 2024-08-13 https://bio-research.ai/acelyrin-phase-3-trial-of-izokibep-in-hidradenitis-suppurativa-meets-primary-endpoint-of-hiscr75-at-12-weeks-shifts-focus-to-lonigutamab-for-thyroid-eye-disease-with-phase-3-trials-planned-by-q1-2025/ 2024-08-13 https://bio-research.ai/dalim-biotech-acquires-90-of-lysotech-shares-through-capital-increase-to-enhance-new-drug-development-efforts/ 2024-08-13 https://bio-research.ai/lynk-pharmaceuticals-phase-1b-trial-of-lnk01004-shows-safety-and-tolerability-in-adults-with-mild-to-moderate-atopic-dermatitis-with-significant-efficacy-in-the-1-0-dose-group/ 2024-08-13 https://bio-research.ai/rivus-pharmaceuticals-phase-2a-humain-trial-of-hu6-for-hfpef-meets-primary-endpoint-of-weight-reduction-results-to-be-presented-in-2024/ 2024-08-13 https://bio-research.ai/insignis-therapeutics-announces-fda-fast-track-designation-for-investigational-drug-in-001-a-needle-free-epinephrine-delivery-system-utilizing-a-sublingual-spray/ 2024-08-13 https://bio-research.ai/adial-pharmaceuticals-enters-collaboration-with-boudicca-dx-to-advance-regulatory-strategy-for-companion-diagnostic-genetic-test-for-ad04-in-alcohol-use-disorder/ 2024-08-13 https://bio-research.ai/apollomics-inc-s-phase-2-sparta-trial-of-vebreltinib-shows-43-objective-response-rate-in-non-cns-met-fusion-solid-tumors/ 2024-08-13 https://bio-research.ai/atai-life-sciences-phase-1b-trial-of-vls-01-shows-short-psychedelic-experiences-and-good-tolerability-with-mild-to-moderate-adverse-events/ 2024-08-13 https://bio-research.ai/galderma-announces-fda-approval-of-nemluvio-for-treating-prurigo-nodularis-based-on-phase-iii-olympia-clinical-trials-showing-improvements-in-itch-and-skin-nodules/ 2024-08-13 https://bio-research.ai/proto-axiom-secures-20-million-in-series-b-funding-to-support-australia-s-biotech-sector-and-increase-ip-retention/ 2024-08-13 https://bio-research.ai/kyverna-therapeutics-receives-fda-designation-for-kyv-101-in-treating-progressive-myasthenia-gravis/ 2024-08-12 https://bio-research.ai/astria-therapeutics-partners-with-ypsomed-to-develop-autoinjector-for-hereditary-angioedema-treatment/ 2024-08-12 https://bio-research.ai/mabwell-s-adc-9mw2821-receives-breakthrough-therapy-designation-in-china-for-advanced-or-metastatic-urothelial-carcinoma-after-other-treatments-have-failed/ 2024-08-12 https://bio-research.ai/actinogen-medical-s-phase-2a-xanacidd-trial-shows-xanamem-provides-significant-benefits-for-depression-but-does-not-meet-primary-endpoint-for-attention-and-working-memory/ 2024-08-12 https://bio-research.ai/kano-therapeutics-secures-5-million-seed-round-to-advance-ssdna-production-for-gene-insertions-and-drug-development/ 2024-08-12 https://bio-research.ai/lenz-therapeutics-submits-drug-application-to-fda-for-lnz100-ophthalmic-solution-for-presbyopia-treatment-backed-by-phase-3-clarity-study-results-showing-significant-improvements-in-near-vision-without-serious-adverse-events/ 2024-08-12 https://bio-research.ai/wave-life-sciences-wve-n531-receives-fda-designation-for-treating-duchenne-muscular-dystrophy-with-exon-53-skipping-dystrophin-data-expected-in-q3-2024/ 2024-08-12 https://bio-research.ai/crown-laboratories-to-acquire-revance-therapeutics-for-924m-in-cash-at-6-66-per-share-an-89-premium/ 2024-08-12 https://bio-research.ai/absci-corporation-and-memorial-sloan-kettering-cancer-center-to-co-develop-novel-cancer-therapeutics-using-absci-s-ai-drug-creation-platform/ 2024-08-12 https://bio-research.ai/tonix-pharmaceuticals-phase-3-resilient-study-shows-statistically-significant-improvement-in-fibromyalgia-with-tnx-102-sl-meeting-primary-endpoint-and-all-six-key-secondary-endpoints/ 2024-08-12 https://bio-research.ai/locus-biosciences-phase-2-eliminate-trial-shows-safety-and-high-drug-exposure-for-lbp-ec01-in-treating-e-coli-urinary-tract-infections/ 2024-08-12 https://bio-research.ai/scpharmaceuticals-inc-receives-fda-approval-to-expand-furoscix-indication-for-nyha-class-iv-chronic-heart-failure-patients/ 2024-08-12 https://bio-research.ai/pfizer-s-phase-3-monet-trial-substudy-b-evaluates-abrysvo-vaccine-in-203-immunocompromised-adults-showing-strong-neutralizing-responses-against-rsv-a-and-rsv-b/ 2024-08-12 https://bio-research.ai/halda-therapeutics-raises-126-million-to-advance-riptac-candidates-into-clinical-trials-for-metastatic-prostate-cancer-and-breast-cancer/ 2024-08-12 https://bio-research.ai/lykos-therapeutics-receives-fda-complete-response-letter-for-nda-for-midomafetamine-capsules-for-ptsd-treatment-requests-additional-phase-3-trial/ 2024-08-09 https://bio-research.ai/visen-pharmaceuticals-phase-3-pathway-china-trial-reveals-77-6-of-participants-receiving-palopegteriparatide-achieved-normal-serum-calcium-levels/ 2024-08-09 https://bio-research.ai/chimeric-therapeutics-collaborates-with-cell-therapies-pty-ltd-to-manufacture-car-t-assets-in-australia-and-expand-clinical-trials-in-progress/ 2024-08-09 https://bio-research.ai/avidity-biosciences-phase-1-2-trial-of-del-zota-reveals-25-increase-in-dystrophin-production-for-dmd44-mutations/ 2024-08-09 https://bio-research.ai/ono-pharmaceutical-and-bristol-myers-squibb-submit-application-for-opdivo-and-yervoy-combination-therapy-for-unresectable-hepatocellular-carcinoma-in-japan/ 2024-08-09 https://bio-research.ai/neuren-pharmaceuticals-reports-positive-phase-2-trial-results-for-nnz-2591-in-treating-angelman-syndrome/ 2024-08-09 https://bio-research.ai/an2-therapeutics-discontinues-ebo-301-study-after-phase-2-results-to-refocus-on-boron-chemistry-platform/ 2024-08-08 https://bio-research.ai/actio-biosciences-receives-orphan-drug-and-rare-pediatric-disease-designations-for-abs-0871-in-trpv4-charcot-marie-tooth-disease-subtype-2c-treatment/ 2024-08-08 https://bio-research.ai/humanetics-and-us-department-of-defense-partner-in-3m-deal-to-advance-radiation-countermeasure-drug-bio-300-development/ 2024-08-08 https://bio-research.ai/recursion-and-exscientia-merge-to-form-end-to-end-drug-discovery-platform-projecting-200m-in-24-month-milestone-payments-and-total-revenue-of-over-20b/ 2024-08-08 https://bio-research.ai/suzhou-zelgen-biopharmaceuticals-zg006-gains-orphan-drug-designation-by-fda-for-small-cell-lung-cancer-treatment/ 2024-08-08 https://bio-research.ai/fda-approves-citius-pharmaceuticals-lymphir-for-treatment-of-relapsed-or-refractory-cutaneous-t-cell-lymphoma-following-phase-3-study-results/ 2024-08-08 https://bio-research.ai/conduit-pharmaceuticals-secures-exclusive-license-with-astrazeneca-for-azd1656-azd5658-and-azd5904-astrazeneca-receives-equity-and-revenue-share-in-return/ 2024-08-08 https://bio-research.ai/guangzhou-lupeng-pharmaceutical-grants-hansoh-pharmaceutical-rights-to-lp-168-in-deal-worth-729m-rmb/ 2024-08-08 https://bio-research.ai/coegin-pharma-secures-exclusive-rights-to-university-of-bradford-s-pigmentation-peptide-technology-with-plans-for-cosmetic-product-launch-by-2026/ 2024-08-08 https://bio-research.ai/apellis-pharmaceuticals-and-sobi-s-phase-3-trial-of-pegcetacoplan-achieves-68-proteinuria-reduction-in-rare-kidney-disease-patients/ 2024-08-08 https://bio-research.ai/aldeyra-therapeutics-reproxalap-achieves-primary-endpoint-in-phase-3-dry-eye-disease-trial-preparing-for-fda-resubmission-in-2024/ 2024-08-08 https://bio-research.ai/sanofi-reports-reduced-disease-progression-in-multiple-myeloma-patients-with-sarclisa-from-gmmg-hd7-phase-3-study/ 2024-08-08 https://bio-research.ai/wuxi-biologics-and-medigene-ag-form-strategic-partnership-for-tcr-guided-t-cell-engager-research-on-difficult-to-treat-tumors/ 2024-08-08 https://bio-research.ai/fda-grants-accelerated-approval-for-novartis-fabhalta-in-reducing-proteinuria-in-igan-patients-based-on-interim-applause-igan-study-results/ 2024-08-08 https://bio-research.ai/purdue-pharma-s-zurnai-auto-injector-gets-fda-approval-for-emergency-opioid-overdose-treatment-in-adults-children-over-12-years/ 2024-08-07 https://bio-research.ai/johnson-johnson-s-unity-study-shows-nipocalimab-facilitates-live-births-in-54-of-cases-at-risk-of-eos-hdfn-without-need-for-intrauterine-transfusion/ 2024-08-07 https://bio-research.ai/amneal-pharmaceuticals-receives-fda-approval-for-crexont-for-parkinson-s-disease-treatment-commercial-launch-expected-in-september-2024/ 2024-08-07 https://bio-research.ai/apotex-acquires-exclusive-distribution-and-marketing-rights-for-formosa-pharmaceuticals-postoperative-eyedrop-app13007-in-canada/ 2024-08-07 https://bio-research.ai/fda-grants-rmat-designation-to-neurogene-s-ngn-401-for-rett-syndrome-treatment-with-interim-data-expected-in-late-2024-and-2025/ 2024-08-07 https://bio-research.ai/formosa-pharmaceuticals-and-eyenovia-collaborate-to-co-develop-clobetasol-propionate-suspension-for-acute-dry-eye-disease-sharing-development-costs-and-profits/ 2024-08-07 https://bio-research.ai/quantro-therapeutics-secures-1-7m-research-grant-from-austrian-research-promotion-agency-for-transcriptomic-platform-advancements/ 2024-08-07 https://bio-research.ai/idrx-inc-secures-120-million-financing-to-back-strategist-1-study-of-oral-kit-inhibitor-idrx-42-for-gist-treatment/ 2024-08-07 https://bio-research.ai/chugai-secures-exclusive-license-from-roche-for-anti-tl1a-antibody-rg6631-development-and-marketing-in-japan/ 2024-08-07 https://bio-research.ai/pharmacosmos-a-s-to-acquire-g1-therapeutics-for-405m-expanding-access-to-oncology-drug-cosela/ 2024-08-07 https://bio-research.ai/european-commission-approves-takeda-s-adzynma-for-treating-cttp-after-successful-phase-3-trial-results/ 2024-08-07 https://bio-research.ai/sumitomo-pharma-and-poxel-sa-release-post-marketing-study-results-for-twymeeg-in-type-2-diabetics-with-renal-impairment/ 2024-08-07 https://bio-research.ai/fda-approves-servier-s-idh-inhibitor-voranigo-for-grade-2-astrocytoma-or-oligodendroglioma-treatment-post-surgery-based-on-phase-3-study-results/ 2024-08-06 https://bio-research.ai/neurotherapia-secures-12-3m-in-series-b-financing-for-alzheimer-s-treatment-development-adam-hoffman-to-join-board-as-observer/ 2024-08-06 https://bio-research.ai/shinobi-therapeutics-gets-59m-grant-from-amed-raises-total-funding-to-119m-with-yosemite-mitsubishi-ufj-capital-investments-partners-with-panasonic-anocca-for-cancer-therapy-development/ 2024-08-06 https://bio-research.ai/exelixis-snda-for-cabozantinib-use-in-treating-advanced-neuroendocrine-tumors-accepted-by-us-fda-decision-due-by-april-2025/ 2024-08-06 https://bio-research.ai/sellas-life-sciences-drug-sls009-receives-orphan-drug-designation-from-ema-for-treatment-of-peripheral-t-cell-lymphomas/ 2024-08-06 https://bio-research.ai/sangamo-and-genentech-ink-1-9b-deal-to-develop-genomic-medicines-for-neurodegenerative-diseases/ 2024-08-06 https://bio-research.ai/tff-pharmaceuticals-advances-with-phase-2-trial-on-tacrolimus-inhalation-powder-for-lung-transplant-rejection-prevention-in-13-patients/ 2024-08-06 https://bio-research.ai/neurobo-pharmaceuticals-dong-a-st-and-immunoforge-to-collaborate-on-long-lasting-version-of-obesity-drug-da-1726/ 2024-08-06 https://bio-research.ai/eisai-and-seed-collaborate-on-development-of-molecular-glue-degraders-possible-1-5b-payout-and-24m-in-series-a-3-financing-for-seed/ 2024-08-06 https://bio-research.ai/seres-therapeutics-sells-vowst-business-to-nestl-health-science-for-175m-with-additional-275m-pending-on-sales-targets-and-75m-due-in-2025-based-on-transition-obligations/ 2024-08-06 https://bio-research.ai/daiichi-sankyo-and-merck-expand-global-partnership-for-mk-6070-deal-includes-upfront-payment-of-170m/ 2024-08-06 https://bio-research.ai/george-medicines-submits-fda-application-for-hypertension-drug-gmrx2-after-successful-phase-iii-trials/ 2024-08-06 https://bio-research.ai/elevation-oncology-reports-42-8-orr-in-phase-1-trial-of-eo-3021-for-certain-gastric-and-gej-cancer-subsets/ 2024-08-06 https://bio-research.ai/release-therapeutics-secures-chf-3-3-million-in-seed-funding-after-reversing-mld-symptoms-in-preclinical-trials-plans-for-series-a-fundraise-and-ind-application/ 2024-08-06 https://bio-research.ai/levicept-reports-results-from-phase-ii-trial-of-levi-04-for-osteoarthritis-significant-analgesia-provided-for-over-510-participants/ 2024-08-06 https://bio-research.ai/leon-nanodrugs-gmbh-secures-series-d-financing-led-by-lbbw-venture-capital-for-portfolio-expansion-in-cell-gene-therapy-industry/ 2024-08-06 https://bio-research.ai/santen-pharmaceutical-and-cloudbreak-pharma-enter-91m-licensing-agreement-for-pterygium-treatment-cbt-001-in-asia/ 2024-08-05 https://bio-research.ai/ultimovacs-phase-ii-focus-trial-with-uv1-and-pembrolizumab-fails-to-improve-survival-in-head-and-neck-cancer-patients/ 2024-08-05 https://bio-research.ai/lupin-limited-concludes-phase-3-trial-for-lubt010-confirming-therapeutic-equivalence-with-lucentis-for-wet-amd-treatment/ 2024-08-05 https://bio-research.ai/genor-biopharma-secures-global-licensing-for-gb261-with-trc-2004-expects-upfront-payment-equity-participation-and-up-to-443m-in-milestones/ 2024-08-05 https://bio-research.ai/mbx-biosciences-secures-63-5-million-in-funding-for-phase-2-trials-of-mbx-2109-and-advancement-of-early-stage-pipeline-programs/ 2024-08-05 https://bio-research.ai/lantern-pharma-s-phase-2-clinical-trial-for-lp-300-shows-86-patient-benefit-in-never-smokers-with-advanced-nsclc/ 2024-08-05 https://bio-research.ai/mediwound-s-nexobrid-sees-94-9-adult-and-100-children-complete-debridement-in-next-protocol-trial/ 2024-08-05 https://bio-research.ai/fda-deems-phase-3-sierra-trial-inadequate-for-actinium-pharmaceuticals-iomab-b-bla-filing-calls-for-additional-clinical-trial/ 2024-08-05 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-for-attralus-cardiac-amyloidosis-imaging-agent-i-evuzamitide/ 2024-08-05 https://bio-research.ai/genmab-to-continue-development-of-acasunlimab-solo-as-biontech-opts-out-despite-promising-results/ 2024-08-05 https://bio-research.ai/bayer-s-finearts-hf-study-meets-primary-goal-with-kerendia-in-heart-failure-patients-with-40-or-higher-left-ventricular-ejection-fraction/ 2024-08-05 https://bio-research.ai/fda-advisory-committee-votes-in-favor-of-zevra-therapeutics-arimoclomol-for-niemann-pick-disease-type-c-treatment/ 2024-08-02 https://bio-research.ai/amylyx-pharmaceuticals-amx0035-receives-orphan-drug-designation-from-european-commission-for-wolfram-syndrome-treatment/ 2024-08-02 https://bio-research.ai/maiji-biotech-raises-200-million-rmb-in-series-b-financing-round-plans-to-advance-mg-k10-drug-to-phase-iii-clinical-trials/ 2024-08-02 https://bio-research.ai/winhealth-acquires-kyowa-kirin-china-and-secures-commercialization-and-manufacturing-rights-for-key-drugs-in-china/ 2024-08-02 https://bio-research.ai/perseus-proteomics-yamagata-university-osaka-metropolitan-university-and-tokyo-university-of-agriculture-and-technology-collaborate-for-new-antibody-development-and-production/ 2024-08-02 https://bio-research.ai/zelgen-biopharmaceuticals-jicaxitinib-hydrochloride-tablets-delay-decline-of-forced-vital-capacity-in-phase-ii-idiopathic-pulmonary-fibrosis-trial/ 2024-08-02 https://bio-research.ai/bridgene-biosciences-and-galapagos-nv-extend-collaboration-target-159m-deal-value-for-oral-smarca2-small-molecule-protac-development/ 2024-08-01 https://bio-research.ai/vir-biotechnology-finalizes-exclusive-global-licensing-agreement-with-sanofi-for-clinical-stage-tumor-therapies-sar446309-sar446329-and-sar446368/ 2024-08-01 https://bio-research.ai/adaptimmune-therapeutics-gets-accelerated-fda-approval-for-engineered-cell-therapy-tecelra-for-adults-with-mage-a4-synovial-sarcoma-following-prior-chemotherapy/ 2024-08-01 https://bio-research.ai/fda-awards-orphan-drug-designation-to-cellectis-clls52-for-treatment-of-b-cell-acute-lymphoblastic-leukemia-under-balli-01-clinical-trial/ 2024-08-01 https://bio-research.ai/fda-expands-approval-for-gsk-s-jemperli-in-combination-with-chemotherapy-for-advanced-or-recurrent-endometrial-cancer-patients/ 2024-08-01 https://bio-research.ai/outpace-bio-secures-144-million-in-series-b-funding-round-led-by-ra-capital-to-advance-t-cell-product-candidates-including-lead-program-opb-101/ 2024-08-01 https://bio-research.ai/elevar-therapeutics-granted-orphan-medicinal-product-designation-by-ema-for-rivoceranib-and-camrelizumab-in-uhcc-treatment/ 2024-08-01 https://bio-research.ai/neurosense-therapeutics-reports-12-month-iron-biomarker-data-from-phase-iib-als-study-of-primec/ 2024-08-01 https://bio-research.ai/fda-grants-fast-track-designation-to-corvus-pharmaceuticals-drug-soquelitinib-for-relapsed-ptcl-treatment/ 2024-08-01 https://bio-research.ai/adverum-biotechnologies-ixo-vec-gets-fda-s-rmat-designation-for-the-treatment-of-wet-age-related-macular-degeneration/ 2024-08-01 https://bio-research.ai/agios-pharmaceuticals-phase-3-activate-kidst-study-of-mitapivat-in-pk-deficiency-fails-primary-endpoint-28-1-reach-transfusion-reduction-response/ 2024-08-01 https://bio-research.ai/healx-secures-47-million-funding-for-phase-2-trial-of-nf1-treatment-hlx-1502-after-fda-clearance/ 2024-08-01 https://bio-research.ai/xbrane-biopharma-regains-full-rights-to-biib801-after-biogen-terminates-8m-agreement-company-accelerates-out-licensing-amid-fda-approval-delay/ 2024-08-01 https://bio-research.ai/passage-bio-out-licenses-three-pediatric-disease-programs-to-gemma-biotherapeutics-for-20m-with-potential-114m-in-milestones-and-future-royalties/ 2024-08-01 https://bio-research.ai/bayer-submits-fda-application-for-elinzanetant-based-on-favorable-phase-iii-study-findings-for-vasomotor-symptoms-in-menopause/ 2024-08-01 https://bio-research.ai/ono-pharmaceutical-and-monash-university-strike-new-r-d-deal-on-antibody-development-for-autoimmune-and-inflammatory-diseases/ 2024-08-01 https://bio-research.ai/regenxbio-reports-interim-safety-and-efficacy-data-of-rgx-202-in-phase-i-ii-affinity-duchenne-trial-for-duchenne-muscular-dystrophy-patients-aged-1-11-years/ 2024-08-01 https://bio-research.ai/eli-lilly-s-summit-trial-finds-tirzepatide-injection-reduces-heart-failure-outcomes-and-body-weight-by-15-7-in-adults/ 2024-08-01 https://bio-research.ai/otsuka-pharma-to-acquire-jnana-therapeutics-for-800m-making-it-a-subsidiary-and-adding-jnt-517-to-their-pipeline/ 2024-08-01 https://bio-research.ai/valneva-secures-exclusive-license-for-limmatech-s-phase-2-shigella-vaccine-s4v-with-10m-upfront-payment-and-additional-milestones/ 2024-08-01 https://bio-research.ai/instil-bio-and-immuneonco-strike-deal-for-development-and-sales-rights-of-imm2510-and-imm27m-potential-payments-to-exceed-2b/ 2024-08-01 https://bio-research.ai/innovent-biologics-second-new-drug-application-for-diabetes-treatment-mazdutide-accepted-by-china-s-nmpa/ 2024-08-01 https://bio-research.ai/immuneering-corporation-receives-fda-fast-track-designation-for-imm-1-104-set-for-phase-2a-trial-in-pancreatic-cancer-treatment/ 2024-07-31 https://bio-research.ai/alx-oncology-s-phase-2-aspen-06-trial-of-evorpacept-shows-improved-response-in-her2-positive-advanced-gastric-cancer-patients/ 2024-07-31 https://bio-research.ai/vaccinex-reports-safe-and-tolerable-alzheimer-s-treatment-in-early-stage-signal-ad-trial-of-pepinemab-with-increased-fdg-pet-signal/ 2024-07-31 https://bio-research.ai/abcellera-and-eli-lilly-expand-antibody-discovery-partnership-receive-payments-for-research-and-potential-milestones/ 2024-07-31 https://bio-research.ai/fda-grants-rare-pediatric-drug-designation-to-theriva-biologics-vcn-01-for-retinoblastoma-treatment/ 2024-07-31 https://bio-research.ai/achieve-life-sciences-cytisinicline-receives-fda-breakthrough-therapy-designation-for-treating-e-cigarette-or-vaping-addiction-after-phase-2-orca-v1-clinical-trial-results/ 2024-07-31 https://bio-research.ai/airna-secures-60-million-funding-to-advance-aatd-treatment-into-clinical-trials/ 2024-07-31 https://bio-research.ai/sanbio-receives-conditional-approval-for-akuugo-a-stem-cell-product-targeting-chronic-motor-paralysis-following-phase-2-clinical-trials/ 2024-07-31 https://bio-research.ai/ideaya-biosciences-signs-licensing-deal-with-biocytogen-pharmaceuticals-for-bsadc-program-compensation-scheme-could-reach-406-5m/ 2024-07-31 https://bio-research.ai/chugai-pharmaceutical-obtains-exclusive-licensing-from-roche-for-promising-breast-cancer-drug-inavolisib-in-japan/ 2024-07-31 https://bio-research.ai/eisai-and-biogen-report-lecanemab-reduced-cognitive-decline-in-early-alzheimer-s-patients-by-0-95-over-three-years-in-aaic-2024-findings/ 2024-07-31 https://bio-research.ai/genexys-biomed-secures-320k-grant-from-national-institutes-of-health-for-non-viral-gene-therapy-research-on-cystic-fibrosis/ 2024-07-30 https://bio-research.ai/shenzhen-synthetica-secures-funding-to-propel-oncolytic-bacterial-pipelines-into-clinical-trials/ 2024-07-30 https://bio-research.ai/zymedi-s-zma001-gets-orphan-drug-status-from-us-fda-for-treatment-of-pulmonary-arterial-hypertension/ 2024-07-30 https://bio-research.ai/fibrogen-to-discontinue-pamrevlumab-r-d-following-phase-2-3-trial-failure-in-pancreatic-cancer-plans-75-u-s-job-cuts/ 2024-07-30 https://bio-research.ai/fda-approves-darzalex-faspro-in-combination-therapy-for-autologous-stem-cell-transplant-eligible-multiple-myeloma-patients/ 2024-07-30 https://bio-research.ai/pepgen-inc-provides-clinical-data-from-phase-2-trial-of-pgn-edo51-indicates-increase-in-dystrophin-production-in-dmd-patients/ 2024-07-30 https://bio-research.ai/pinetree-therapeutics-raises-17-million-for-abreptor-platform-furthers-development-of-cancer-treatments-under-exclusive-astrazeneca-license-agreement/ 2024-07-30 https://bio-research.ai/yamo-pharmaceuticals-phase-2-trial-shows-significant-improvement-in-autism-spectrum-disorder-symptoms-with-l1-79/ 2024-07-30 https://bio-research.ai/imunon-reports-hazard-ratio-of-0-74-from-phase-2-ovation-2-study-on-il-12-immunotherapy-with-chemotherapy-for-advanced-ovarian-cancer/ 2024-07-30 https://bio-research.ai/eyenovia-and-sgn-nanopharma-collaborate-to-develop-3b-market-potential-dry-eye-treatment-using-mnp-and-optejet-technologies/ 2024-07-30 https://bio-research.ai/atyr-pharma-and-stanford-medicine-partner-to-explore-anti-nrp2-antibodies-in-glioblastoma-treatment-terms-undisclosed/ 2024-07-30 https://bio-research.ai/neurobo-pharmaceuticals-licenses-out-nb-01-to-mthera-pharma-for-painful-diabetic-neuropathy-treatment-research-and-possible-phase-3-trials/ 2024-07-30 https://bio-research.ai/ptc-therapeutics-submits-nda-for-sepiapterin-in-phenylketonuria-treatment-following-phase-3-aphenity-trial-results/ 2024-07-30 https://bio-research.ai/fda-approves-stallergenes-greer-s-palforzia-for-oral-use-in-toddlers-with-confirmed-peanut-allergy/ 2024-07-30 https://bio-research.ai/kiora-pharmaceuticals-kio-301-receives-orphan-medicinal-product-designation-from-european-medicines-agency-plans-multi-center-study/ 2024-07-30 https://bio-research.ai/cns-pharmaceuticals-acquires-exclusive-license-for-tpi-287-from-cortice-biosciences-aims-to-conduct-gbm-study-in-2025/ 2024-07-30 https://bio-research.ai/biontech-reports-phase-2-clinical-trial-data-showing-improved-response-rate-with-bnt111-and-cemiplimab-for-advanced-unresectable-melanoma/ 2024-07-30 https://bio-research.ai/european-commission-approves-roche-s-vabysmo-for-retinal-vein-occlusion-treatment-based-on-phase-iii-studies-data/ 2024-07-30 https://bio-research.ai/vivozon-partners-with-icure-to-develop-transdermal-patch-formulation-of-opiranserin-for-non-surgical-treatment-needs/ 2024-07-30 https://bio-research.ai/fda-approves-amneal-pharmaceuticals-preservative-free-potassium-phosphates-iv-infusion-bag-for-hypophosphatemia-correction/ 2024-07-29 https://bio-research.ai/clearside-biomedical-reports-phase-3-clinical-trial-results-of-arcatus-for-uveitic-macular-edema-treatment-in-china/ 2024-07-29 https://bio-research.ai/fda-grants-priority-review-for-scemblix-in-treatment-of-newly-diagnosed-philadelphia-chromosome-positive-chronic-myeloid-leukemia-based-on-asc4first-study/ 2024-07-29 https://bio-research.ai/fda-grants-orphan-drug-designation-to-verastem-oncology-s-avutometinib-and-defactinib-for-pancreatic-cancer-treatment/ 2024-07-29 https://bio-research.ai/celldex-therapeutics-inc-reports-phase-2-clinical-trial-results-of-barzolvolimab-for-treating-chronic-inducible-urticaria-advances-to-phase-3/ 2024-07-29 https://bio-research.ai/boehringer-ingelheim-acquires-nerio-therapeutics-for-up-to-1-3b-focusing-on-immuno-oncology-advancement/ 2024-07-29 https://bio-research.ai/fda-approves-alpha-cognition-s-zunveyl-for-mild-to-moderate-alzheimer-s-disease-with-studies-reporting-minimal-side-effects/ 2024-07-29 https://bio-research.ai/newamsterdam-pharma-s-brooklyn-phase-3-trial-of-obicetrapib-reduces-ldl-c-levels-in-cardiovascular-disease-patients-at-days-84-and-365/ 2024-07-29 https://bio-research.ai/arcutis-biotherapeutics-and-kowa-pharmaceuticals-america-sign-co-promotion-deal-for-zoryve-cream-and-foam-arcutis-to-handle-manufacturing-and-retain-all-revenues/ 2024-07-29 https://bio-research.ai/ventyx-biosciences-phase-2-trial-of-vtx958-in-crohn-s-disease-fails-primary-endpoint-achieves-secondary-endpoint/ 2024-07-29 https://bio-research.ai/gsk-and-flagship-pioneering-commit-150m-to-develop-novel-drugs-promising-up-to-720m-for-each-acquired-program-in-respiratory-and-immunology-field/ 2024-07-29 https://bio-research.ai/cipher-pharmaceuticals-buys-natroba-from-parapro-for-89-5m-plans-to-expand-global-sales/ 2024-07-29 https://bio-research.ai/cognition-therapeutics-reports-cognitive-improvement-in-neurodegenerative-disorder-patients-after-six-months-of-ct1812-treatment-in-phase-2-study/ 2024-07-29 https://bio-research.ai/collegium-to-purchase-ironshore-therapeutics-for-525m-gaining-adhd-treatment-jornay-pm-financed-by-a-646m-loan-from-pharmakon-advisors/ 2024-07-29 https://bio-research.ai/alzinova-ab-s-phase-1b-trials-reveal-safety-and-immune-response-of-alz-101-in-early-stage-alzheimer-s-patients/ 2024-07-29 https://bio-research.ai/anavex-life-sciences-reports-phase-iib-iii-study-blarcamesine-slows-cognitive-decline-in-early-stage-alzheimer-s-patients-without-neurological-damage/ 2024-07-28 https://bio-research.ai/shanghai-luoqi-biopharmaceutical-technology-secures-rmb-200-million-in-series-b2-funding-for-phase-ii-clinical-research-of-two-inhalation-antibody-drugs/ 2024-07-26 https://bio-research.ai/astellas-pharma-seeks-approval-of-zolbetuximab-for-gastric-adenocarcinoma-treatment-based-on-phase-3-trial-outcomes/ 2024-07-26 https://bio-research.ai/janssen-cilag-s-yuvanci-a-single-tablet-combination-therapy-for-pulmonary-arterial-hypertension-recommended-for-marketing-authorisation-by-european-medicines-agency/ 2024-07-26 https://bio-research.ai/rybrevant-and-chemotherapy-combination-recommended-for-use-in-advanced-non-small-cell-lung-cancer-by-the-european-medicines-agency-s-committee/ 2024-07-26 https://bio-research.ai/revir-therapeutics-secures-30-million-in-a-series-a-funding-to-further-develop-ai-driven-drug-discovery-platform-and-rna-based-genetic-therapies-for-neurological-disorders/ 2024-07-26 https://bio-research.ai/cel-sci-reports-no-bias-in-phase-3-multikine-study-with-73-five-year-survival-for-head-and-neck-cancer-patients/ 2024-07-26 https://bio-research.ai/promis-neurosciences-reports-favorable-safety-profile-in-phase-1a-trial-of-alzheimer-s-drug-pmn310/ 2024-07-26 https://bio-research.ai/sun-pharmaceutical-s-leqselvi-approved-by-fda-for-severe-alopecia-areata-based-on-phase-3-clinical-trial-results/ 2024-07-26 https://bio-research.ai/merck-s-keytruda-and-padcev-combo-recommended-for-unresectable-or-metastatic-urothelial-carcinoma-by-ema-s-chmp-based-on-phase-3-results/ 2024-07-26 https://bio-research.ai/european-commission-grants-approval-for-cstone-s-lung-cancer-drug-sugemalimab-based-on-gemstone-302-phase-3-trial-results/ 2024-07-26 https://bio-research.ai/european-medicines-agency-declines-marketing-approval-for-eisai-s-alzheimer-s-drug-lecanemab/ 2024-07-26 https://bio-research.ai/european-commission-approves-abbvie-s-skyrizi-for-ulcerative-colitis-in-adults-based-on-phase-3-trial-data/ 2024-07-26 https://bio-research.ai/calliditas-therapeutics-phase-2b-trial-shows-statistically-significant-improvement-in-alp-with-setanaxib-in-pbc-patients/ 2024-07-26 https://bio-research.ai/confo-therapeutics-secures-60-million-euros-in-series-b-funding-for-progression-towards-ind-approval-and-gpcr-focused-drug-development/ 2024-07-26 https://bio-research.ai/innovent-biologics-partners-with-wecomput-to-advance-ai-for-drug-discovery-using-nvidia-s-bionemo/ 2024-07-26 https://bio-research.ai/fda-fast-tracks-tonix-pharmaceuticals-fibromyalgia-drug-tonmya-following-significant-phase-3-clinical-trial-results/ 2024-07-25 https://bio-research.ai/fda-considers-checkpoint-therapeutics-resubmitted-bla-for-cosibelimab-in-treating-advanced-cutaneous-squamous-cell-carcinoma/ 2024-07-25 https://bio-research.ai/fda-accepts-scpharmaceuticals-inc-s-supplemental-application-for-extended-use-of-furoscix-in-chronic-kidney-disease-patients-with-fluid-overload-edema/ 2024-07-25 https://bio-research.ai/immunome-to-develop-cancer-therapies-in-exclusive-worldwide-licensing-deal-with-nectin-therapeutics/ 2024-07-25 https://bio-research.ai/chemomab-therapeutics-reports-phase-2-triumph-of-cm-101-in-psc-patients-advancement-to-phase-3-expected-in-2025/ 2024-07-25 https://bio-research.ai/fda-grants-fast-track-designation-to-ac-immune-s-alzheimer-s-therapy-jnj-2056-targeting-pathogenic-tau-protein-phase-2b-retain-study-begins/ 2024-07-25 https://bio-research.ai/ipsen-inks-461m-deal-with-day-one-biopharmaceuticals-for-tovorafenib-to-treat-pediatric-low-grade-glioma-outside-u-s/ 2024-07-25 https://bio-research.ai/galderma-s-phase-iii-trials-show-significant-improvements-with-nemolizumab-in-moderate-to-severe-atopic-dermatitis-patients/ 2024-07-25 https://bio-research.ai/cartherics-enters-agreement-with-uniquest-and-the-university-of-sydney-for-development-and-commercialization-of-ipsc-derived-cardiomyocytes/ 2024-07-25 https://bio-research.ai/sk-bioscience-invests-2m-in-sunflower-therapeutics-via-safe-agreement-to-improve-vaccine-production-and-optimize-cost-efficiency/ 2024-07-25 https://bio-research.ai/lindus-health-to-support-pila-pharma-with-clinical-research-services-for-phase-2a-study-pp-ct03-targeting-obesity-and-type-2-diabetes-treatment/ 2024-07-24 https://bio-research.ai/elixirgen-scientific-and-mitsubishi-tanabe-pharma-america-collaborate-on-drug-discovery-using-ipsc-derived-neurons-and-glial-cells/ 2024-07-24 https://bio-research.ai/fda-grants-rare-pediatric-disease-designation-to-consynance-s-drug-csti-500-for-prader-willi-syndrome-treatment-in-children-and-adolescents/ 2024-07-24 https://bio-research.ai/biomarin-receives-fda-approval-to-use-brineura-for-all-ages-in-cln2-disease-after-phase-2-trial-success/ 2024-07-24 https://bio-research.ai/os-therapies-releases-phase-1-data-for-ost-her2-in-her2-expressing-solid-tumors-targets-osteosarcoma-approval/ 2024-07-24 https://bio-research.ai/m8-pharmaceuticals-an-acino-company-partners-with-lg-chem-to-market-diabetes-and-osteoarthritis-treatments-in-latin-america/ 2024-07-24 https://bio-research.ai/sonnet-biotherapeutics-reports-positive-phase-1b-trial-results-for-son-080-in-treating-chemotherapy-induced-peripheral-neuropathy/ 2024-07-24 https://bio-research.ai/catalyst-pharmaceuticals-licenses-dmd-drug-agamree-to-kye-pharmaceuticals-for-canadian-market-with-upfront-payment-and-future-royalties/ 2024-07-24 https://bio-research.ai/pfizer-reports-phase-3-affine-study-results-giroctocogene-fitelparvovec-reduces-bleeding-rate-in-adult-hemophilia-a-patients/ 2024-07-24 https://bio-research.ai/transposon-therapeutics-phase-2-trial-drug-tpn-101-shows-50-reduction-in-als-patients-vital-capacity-decline/ 2024-07-24 https://bio-research.ai/palvella-therapeutics-and-pieris-pharmaceuticals-merge-to-form-a-clinical-stage-biopharmaceutical-company-with-80-5m-cash-focusing-on-rare-genetic-skin-diseases-treatment-development/ 2024-07-24 https://bio-research.ai/fda-grants-fast-track-designation-to-tiziana-life-sciences-intranasal-foralumab-for-na-spms-treatment-and-expands-access-for-additional-patients/ 2024-07-24 https://bio-research.ai/sage-therapeutics-and-biogen-halt-development-of-sage-324-for-essential-tremor-after-phase-2-trial-shows-no-significant-impact/ 2024-07-24 https://bio-research.ai/vigil-neuroscience-releases-interim-phase-1-trial-data-of-vg-3927-showing-safety-tolerability-and-significant-impact-on-alzheimer-s-disease-biomarker/ 2024-07-24 https://bio-research.ai/ose-immunotherapeutics-reports-significant-efficacy-in-phase-2-lusvertikimab-trial-for-ulcerative-colitis-at-10-week-mark/ 2024-07-24 https://bio-research.ai/gilead-sciences-reports-superior-hiv-prevention-with-lenacapavir-in-phase-3-trial-compared-to-truvada/ 2024-07-24 https://bio-research.ai/nuvation-bio-reports-fda-orphan-drug-designation-for-taletrectinib/ 2024-07-23 https://bio-research.ai/astrazeneca-pays-pinetree-therapeutics-45m-upfront-for-exclusive-global-rights-to-preclinical-egfr-degrader-total-deal-valued-over-500m/ 2024-07-23 https://bio-research.ai/evofem-biosciences-pharma-1-sign-licensing-deal-for-hormone-free-contraceptive-phexxi-in-middle-east-targeting-185-1m-market-by-2030/ 2024-07-23 https://bio-research.ai/mendus-ab-teams-up-with-institut-bergoni-to-test-ilixadencel-in-regomune-trial-for-soft-tissue-sarcomas-slated-for-completion-in-2024/ 2024-07-23 https://bio-research.ai/affyimmune-s-aic100-receives-rmat-designation-from-fda-for-treatment-of-recurrent-anaplastic-thyroid-cancer/ 2024-07-23 https://bio-research.ai/cellectar-biosciences-achieves-56-4-major-response-rate-surpassing-20-primary-endpoint-in-pivotal-waldenstrom-s-macroglobulinemia-study/ 2024-07-23 https://bio-research.ai/eyenovia-and-senju-pharmaceutical-collaborate-to-develop-novel-drug-device-combo-for-chronic-dry-eye-disease-hoping-for-fda-approval-and-phase-3-studies-by-2026/ 2024-07-23 https://bio-research.ai/jaguar-health-s-phase-3-ontarget-study-of-crofelemer-fails-primary-endpoint-shows-efficacy-in-breast-and-respiratory-cancer-subgroups/ 2024-07-23 https://bio-research.ai/bioatla-receives-fda-fast-track-designation-for-ozuriftamab-vedotin-in-metastatic-scchn-patients-post-platinum-based-chemotherapy-and-anti-pd-1-l1-therapy/ 2024-07-23 https://bio-research.ai/merck-s-phase-2b-3-trial-of-clesrovimab-meets-primary-endpoints-for-preventing-rsv-infections-in-infants/ 2024-07-23 https://bio-research.ai/cytoki-pharma-s-phase-1-study-finds-a-lipidated-il-22-ck-0045-affects-body-weight-cholesterol-and-blood-sugar-levels/ 2024-07-23 https://bio-research.ai/pharma-two-b-merges-with-hepion-pharmaceuticals-issuing-2-9m-non-convertible-notes-and-aiming-for-2026-parkinson-s-disease-drug-approval/ 2024-07-22 https://bio-research.ai/johnson-johnson-seeks-fda-approval-for-spravato-as-standalone-treatment-for-treatment-resistant-depression-following-trd4005-study-results/ 2024-07-22 https://bio-research.ai/gan-lee-pharmaceuticals-gzr18-injection-leads-to-significant-weight-changes-in-obesity-trial-in-china/ 2024-07-22 https://bio-research.ai/ionis-pharmaceuticals-phase-1-2-study-of-ion582-shows-97-participants-with-improved-angelman-syndrome-symptoms/ 2024-07-22 https://bio-research.ai/fda-approves-samsung-bioepis-s-biosimilar-drug-epysqli-for-treatment-of-pnh-and-ahus-patients-demonstrating-similarity-to-soliris/ 2024-07-22 https://bio-research.ai/gr-nenthal-group-acquires-valinor-pharma-for-250m-expands-portfolio-with-movantik-brand/ 2024-07-22 https://bio-research.ai/valneva-and-cepi-expand-partnership-secure-41-3m-from-horizon-europe-programme-for-clinical-trials-of-first-chikungunya-vaccine-ixchiq/ 2024-07-22 https://bio-research.ai/certa-therapeutics-ft011-receives-orphan-drug-status-for-treating-systemic-sclerosis-from-the-fda-and-ema-plans-for-phase-iib-trial-underway/ 2024-07-22 https://bio-research.ai/astellas-pharma-airm-universal-cells-and-osaka-university-join-forces-to-develop-stem-cell-therapy-for-intervertebral-disc-degenerative-disease/ 2024-07-22 https://bio-research.ai/innovent-biologics-phase-3-trial-of-mazdutide-meets-primary-and-key-secondary-endpoints-for-type-2-diabetes-in-chinese-adults/ 2024-07-22 https://bio-research.ai/gc-cell-and-lukas-biomedical-enter-strategic-partnership-to-enhance-autologous-t-cell-therapy-share-clinical-trial-data-and-expand-patient-access/ 2024-07-21 https://bio-research.ai/innorna-earns-fda-s-rare-pediatric-and-orphan-drug-designations-for-investigational-therapy-in022-in-classic-homocystinuria-treatment/ 2024-07-19 https://bio-research.ai/bristol-myers-squibb-s-opdivo-and-yervoy-treatment-for-hepatocellular-carcinoma-validated-by-ema-for-review-based-on-checkmate-9dw-trial-results/ 2024-07-19 https://bio-research.ai/ema-accepts-marketing-authorisation-application-for-gsk-s-blenrep-for-relapsed-or-refractory-multiple-myeloma-treatment-based-on-dreamm-7-and-dreamm-8-trial-results/ 2024-07-19 https://bio-research.ai/ono-pharmaceutical-submits-marketing-authorization-application-to-ema-for-cancer-therapy-vimseltinib-after-motion-phase-3-study-results/ 2024-07-19 https://bio-research.ai/meitheal-pharmaceuticals-acquires-north-american-rights-for-contepo-from-nabriva-therapeutics-gearing-towards-antibiotic-development/ 2024-07-18 https://bio-research.ai/abliva-ab-s-falcon-study-continues-with-kl1333-for-primary-mitochondrial-disease-market-advancement-expected-in-2024/ 2024-07-18 https://bio-research.ai/me-therapeutics-and-nanovation-therapeutics-collaborate-on-mrna-based-drug-trials-using-lnp-technologies-under-a-new-material-transfer-agreement/ 2024-07-18 https://bio-research.ai/alkeus-pharmaceuticals-shares-interim-tease-3-study-data-at-the-42nd-american-society-of-retina-specialists-meeting/ 2024-07-18 https://bio-research.ai/aveo-oncology-s-phase-3-trial-of-tinivo-2-fails-primary-endpoint-in-advanced-rcc-provides-efficacy-at-standard-monotherapy-dose/ 2024-07-18 https://bio-research.ai/lupin-limited-to-market-huons-co-ltd-s-cyclosporine-ophthalmic-nanoemulsion-in-mexico-for-treating-dry-eye-syndrome-and-corneal-ulcers/ 2024-07-18 https://bio-research.ai/teva-pharmaceutical-s-phase-3-space-study-finds-ajovy-effective-in-preventing-episodic-migraine-in-children-and-adolescents-over-12-weeks/ 2024-07-18 https://bio-research.ai/haystack-oncology-and-lisata-therapeutics-collaborate-to-utilize-mrd-technology-in-certepetide-study-for-metastatic-pancreatic-cancer/ 2024-07-18 https://bio-research.ai/fda-approves-phathom-pharmaceuticals-voquezna-for-non-erosive-gerd-in-adults-based-on-phalcon-nerd-301-study-results/ 2024-07-18 https://bio-research.ai/paratek-pharmaceuticals-announces-phase-3-results-omadacycline-meets-all-fda-endpoints-in-cabp-treatment-similar-adverse-effects-as-moxifloxacin/ 2024-07-18 https://bio-research.ai/exscientia-acquires-full-control-of-cdk7-inhibitor-programme-from-gt-apeiron-for-20m-and-royalty-commitments/ 2024-07-18 https://bio-research.ai/marinus-pharmaceuticals-gets-chinese-approval-for-ganaxolone-oral-suspension-to-treat-epileptic-seizures-in-cdd-patients-following-phase-3-trial-results/ 2024-07-18 https://bio-research.ai/ono-pharmaceutical-receives-additional-approval-for-opdivo-in-combination-therapy-for-advanced-urothelial-carcinoma-in-south-korea/ 2024-07-18 https://bio-research.ai/biosenic-completes-post-hoc-analysis-of-phase-2-clinical-trial-of-arsenic-trioxide-reports-75-overall-response-rate-in-cgvhd-treatment/ 2024-07-18 https://bio-research.ai/vivoryon-therapeutics-reports-beneficial-effect-on-kidney-function-in-diabetes-patients-with-varoglutamstat-phase-2b-study-results/ 2024-07-18 https://bio-research.ai/fda-grants-second-fast-track-designation-to-diamyd-medical-for-type-1-diabetes-treatment-in-pediatric-patients-with-hla-dr3-dq2-genotype/ 2024-07-18 https://bio-research.ai/everest-medicines-drug-nefecon-gets-full-approval-application-acceptance-by-china-s-national-medical-products-administration/ 2024-07-18 https://bio-research.ai/shanghai-junshi-biosciences-seeks-approval-for-toripalimab-and-bevacizumab-combination-as-a-first-line-treatment-for-advanced-hcc-based-on-hepatorch-study-results/ 2024-07-17 https://bio-research.ai/opko-health-secures-250m-non-dilutive-note-purchase-deal-with-healthcare-royalty-backed-by-pfizer-s-payments-for-ngenla-treatment/ 2024-07-17 https://bio-research.ai/cytomed-therapeutics-acquires-cellsafe-international-assets-for-490k-aiming-to-expand-therapeutic-use-of-cord-blood-units/ 2024-07-17 https://bio-research.ai/genentech-s-vabysmo-maintains-vision-improvements-in-80-of-dme-patients-for-four-years-in-rhone-x-study/ 2024-07-17 https://bio-research.ai/atara-biotherapeutics-tabelecleucel-receives-fda-priority-review-for-epstein-barr-virus-post-transplant-lymphoproliferative-disease-treatment/ 2024-07-17 https://bio-research.ai/bioinvent-and-msd-international-to-evaluate-bi-1607-with-ipilimumab-and-keytruda-in-phase-2-metastatic-melanoma-study/ 2024-07-17 https://bio-research.ai/adverum-biotechnologies-reports-76-of-patients-injection-free-at-26-week-interim-luna-phase-2-trial-analysis-of-ixo-vec-for-wet-age-related-macular-degeneration/ 2024-07-17 https://bio-research.ai/4d-molecular-therapeutics-reports-89-reduction-in-injection-rate-in-phase-2-prism-trial-for-wet-amd-at-3e10-vg-eye-dose/ 2024-07-17 https://bio-research.ai/genentech-s-phase-i-clinical-trial-of-ct-996-reveals-6-1-placebo-adjusted-weight-loss-in-obese-participants-within-four-weeks/ 2024-07-17 https://bio-research.ai/bayer-s-phase-iii-aranote-trial-of-nubeqa-with-adt-meets-primary-endpoint-in-metastatic-hormone-sensitive-prostate-cancer/ 2024-07-17 https://bio-research.ai/sk-biopharmaceuticals-secures-rights-to-full-life-technologies-cancer-targeting-radiopharmaceutical-fl-091-in-a-deal-worth-571-5m/ 2024-07-17 https://bio-research.ai/alterity-therapeutics-reports-43-of-msa-patients-improved-in-daily-activities-in-ath434-202-phase-2-trial/ 2024-07-17 https://bio-research.ai/fda-issues-complete-response-letter-to-orexo-ab-for-ox124-nda-requests-additional-human-factors-study-and-technical-manufacturing-data/ 2024-07-16 https://bio-research.ai/aclaris-therapeutics-sells-future-olumiant-royalties-and-milestones-to-omers-for-up-to-31-5m/ 2024-07-16 https://bio-research.ai/fda-grants-orphan-drug-designation-to-mabwell-s-adc-compound-7mw3711-for-small-cell-lung-cancer-treatment/ 2024-07-16 https://bio-research.ai/sionna-therapeutics-to-develop-and-commercialize-abbvie-s-phase-2-compounds-abbv-2222-and-abbv-3067-and-phase-1-abbv-2851-in-cystic-fibrosis-deal/ 2024-07-16 https://bio-research.ai/sotio-biotech-and-biocytogen-partner-on-bispecific-antibodies-development-with-325-5m-deal-for-solid-tumor-adcs/ 2024-07-16 https://bio-research.ai/evommune-reports-evo756-mrgprx2-receptor-antagonist-tolerated-in-phase-1-trial-set-for-phase-2-in-urticaria-patients/ 2024-07-16 https://bio-research.ai/orum-therapeutics-licenses-tpd-technology-to-vertex-pharmaceuticals-in-deal-worth-up-to-945m-for-gene-editing-agents/ 2024-07-16 https://bio-research.ai/senju-pharmaceutical-completes-phase-iii-trials-of-sjp-0132-for-dry-eye-disease-with-primary-endpoints-met/ 2024-07-16 https://bio-research.ai/eisai-and-sato-pharmaceutical-ink-licensing-deal-for-antifungal-agent-fosravuconazole-in-asia-oceania-with-upfront-payment-milestones-and-royalties/ 2024-07-16 https://bio-research.ai/kyverna-therapeutics-receives-rmat-designation-from-fda-for-kyv-101-in-stiff-person-syndrome-treatment-trials/ 2024-07-15 https://bio-research.ai/ferring-pharmaceuticals-and-seikagaku-report-phase-3-data-on-si-6603-for-radicular-leg-pain-showing-improvement-at-week-13-without-serious-adverse-events/ 2024-07-15 https://bio-research.ai/enveric-biosciences-and-aries-science-technology-ink-licensing-deal-with-up-to-61m-in-milestones-for-radiation-dermatitis-treatment-through-akos-biosciences/ 2024-07-15 https://bio-research.ai/fda-grants-fast-track-designation-to-rabi-767-for-acute-pancreatitis-treatment-arrivo-bioventures-initiates-phase-2a-trial/ 2024-07-15 https://bio-research.ai/lantheus-bolsters-alzheimer-s-diagnostics-with-acquisition-of-meilleur-technologies-and-phase-3-nav-4694-agent-backed-by-advisors-chestnut-partners-and-legal-teams-goodwin-procter-foley-hoag/ 2024-07-15 https://bio-research.ai/gc-cell-and-checkpoint-therapeutics-to-explore-synergistic-cancer-treatments-with-cosibelimab-and-immuncell-lc/ 2024-07-15 https://bio-research.ai/lexeo-therapeutics-reports-interim-clinical-trial-data-of-lx2006-with-11-4-reduction-in-lvmi-at-12-months-for-friedreich-ataxia-cardiomyopathy/ 2024-07-15 https://bio-research.ai/sensorion-reports-new-positive-secondary-endpoints-of-sens-401-in-phase-2a-trial-for-hearing-loss-treatment-after-cochlear-implantation/ 2024-07-15 https://bio-research.ai/camurus-reports-acroinnova-2-phase-3-study-results-of-octreotide-sc-depot-in-acromegaly-showing-safety-and-improved-treatment-response-over-52-weeks/ 2024-07-15 https://bio-research.ai/everest-medicines-reports-phase-3-trial-of-velsipity-achieves-significant-improvements-in-ulcerative-colitis-at-week-40-in-asia/ 2024-07-15 https://bio-research.ai/fda-grants-fast-track-designation-to-oricell-s-oricar-017-for-relapsed-refractory-multiple-myeloma-as-phase-i-trials-proceed/ 2024-07-15 https://bio-research.ai/nona-biosciences-collaborates-with-alaya-bio-to-develop-car-t-cell-therapies-using-hcab-harbour-mice-platform-and-polymeric-delivery-technology/ 2024-07-14 https://bio-research.ai/mabwell-s-adc-9mw2821-receives-fast-track-designation-from-fda-for-nectin-4-positive-triple-negative-breast-cancer/ 2024-07-12 https://bio-research.ai/abbvie-seeks-fda-and-ema-approval-for-upadacitinib-in-giant-cell-arteritis-treatment-after-phase-3-trial-results/ 2024-07-12 https://bio-research.ai/health-canada-approves-tagrisso-in-combination-with-chemotherapy-for-first-line-treatment-of-certain-advanced-nsclc-types-after-flaura2-trial-results/ 2024-07-12 https://bio-research.ai/fda-issues-complete-response-letter-to-medrx-for-mrx-5lbt-lidocaine-patch-company-and-dwti-evaluating-feedback/ 2024-07-12 https://bio-research.ai/biodexa-pharmaceuticals-reports-phase-2-erapa-trial-results-with-17-median-polyp-reduction-in-fap-patients/ 2024-07-11 https://bio-research.ai/innorna-s-mrna-candidate-in016-receives-rare-pediatric-disease-designation-for-pfic-treatment-from-fda/ 2024-07-11 https://bio-research.ai/immutep-limited-reports-phase-iib-tacti-003-trial-results-for-eftilagimod-alfa-with-pembrolizumab-showing-35-5-response-rate-in-hnscc/ 2024-07-11 https://bio-research.ai/tiba-biotech-partners-with-barda-for-0-75m-ez-baa-contract-to-develop-rnai-based-influenza-therapeutics-under-hhs-s-fastx-program/ 2024-07-11 https://bio-research.ai/arc-therapies-inc-secures-ccr4-car-t-cell-therapy-license-from-national-cancer-center-and-university-of-pennsylvania-for-cancer-r-d-initiative/ 2024-07-11 https://bio-research.ai/abeona-therapeutics-partners-with-beacon-therapeutics-to-explore-aav204-capsid-for-ophthalmology-gene-therapy-programs/ 2024-07-11 https://bio-research.ai/ino-3107-receives-innovation-passport-designation-from-u-k-s-ilap-for-treatment-of-recurrent-respiratory-papillomatosis/ 2024-07-11 https://bio-research.ai/fda-grants-fast-track-designation-for-askbio-and-bayer-s-ab-1005-gene-therapy-in-parkinson-s-disease-uk-mhra-awards-innovation-passport-phase-ib-trial-meets-primary-safety-objective/ 2024-07-11 https://bio-research.ai/ipsen-inks-exclusive-1-03b-deal-with-foreseen-biotechnology-for-global-rights-to-tumor-targeting-fs001-antibody-drug-conjugate/ 2024-07-11 https://bio-research.ai/bioarctic-ab-partner-eisai-gains-hong-kong-approval-for-alzheimer-s-treatment-leqembi-based-on-phase-3-study-results/ 2024-07-11 https://bio-research.ai/ausperbio-gets-breakthrough-therapy-designation-from-china-s-national-medical-products-administration-for-chb-drug-ahb-137-based-on-early-trials/ 2024-07-10 https://bio-research.ai/fda-issues-complete-response-letter-to-novo-nordisk-for-basal-insulin-icodec-application-citing-manufacturing-type-1-diabetes-concerns/ 2024-07-10 https://bio-research.ai/spine-biopharma-inks-155m-deal-with-ensol-biosciences-for-sb-01-rights-expansion-into-osteoarthritis-fibrotic-diseases-and-oncology/ 2024-07-10 https://bio-research.ai/xylocor-therapeutics-secures-global-license-for-smartwise-s-extroducer-catheter-system-in-130m-deal-for-cardiovascular-gene-therapy/ 2024-07-10 https://bio-research.ai/cosette-pharmaceuticals-acquires-ambien-brands-from-sanofi-us-in-a-deal-to-bolster-global-availability-with-a-39m-sales-backdrop/ 2024-07-10 https://bio-research.ai/kazia-therapeutics-reports-phase-ii-iii-trial-results-of-paxalisib-with-3-8-month-increase-in-overall-survival-for-glioblastoma-patients/ 2024-07-10 https://bio-research.ai/longeveron-inc-s-lomecel-b-receives-fda-rmat-designation-following-phase-2a-clear-mind-trial-in-mild-alzheimer-s-disease/ 2024-07-10 https://bio-research.ai/context-therapeutics-acquires-ct-95-from-link-immunotherapeutics-for-phase-1-solid-tumor-trial-with-fda-ind-clearance/ 2024-07-10 https://bio-research.ai/okyo-pharma-limited-reports-68-improvement-in-dry-eye-disease-symptoms-in-phase-2-trial-of-ok-101/ 2024-07-10 https://bio-research.ai/evotec-se-partners-with-pfizer-in-multi-year-research-collaboration-for-metabolic-and-infectious-diseases/ 2024-07-10 https://bio-research.ai/adocia-regains-biochaperone-combo-rights-as-tonghua-dongbao-exits-diabetes-partnership-maintains-biochaperone-lispro-phase-3-trials-cooperation/ 2024-07-10 https://bio-research.ai/amylyx-pharmaceuticals-acquires-avexitide-from-eiger-biopharmaceuticals-for-phase-3-program-in-post-bariatric-hypoglycemia/ 2024-07-10 https://bio-research.ai/skyhawk-therapeutics-reports-72-htt-mrna-reduction-in-phase-1-trial-of-sky-0515-for-huntington-s-disease/ 2024-07-10 https://bio-research.ai/pendopharm-secures-exclusive-deal-with-ascendis-pharma-to-distribute-transcon-pth-in-canada/ 2024-07-09 https://bio-research.ai/fda-approves-zoryve-cream-0-15-for-mild-to-moderate-atopic-dermatitis-in-adults-and-children-aged-6-and-older/ 2024-07-09 https://bio-research.ai/celon-pharma-s-a-reports-phase-2-trial-results-of-cpl-36-with-improvement-in-schizophrenia-panss-scores-at-4-weeks/ 2024-07-09 https://bio-research.ai/discgenics-reports-phase-i-ii-trial-results-of-idct-with-significant-improvements-in-lumbar-disc-disease-patients-up-to-2-years/ 2024-07-09 https://bio-research.ai/fda-fast-track-designation-granted-to-obsidian-therapeutics-obx-115-for-treatment-of-advanced-melanoma/ 2024-07-09 https://bio-research.ai/prelude-therapeutics-partners-with-merck-to-evaluate-prt3789-and-keytruda-in-phase-2-trial-for-smarca4-mutated-cancers/ 2024-07-09 https://bio-research.ai/uniqure-reports-80-slowing-of-disease-progression-in-phase-i-ii-trial-of-amt-130-for-huntington-s-disease-at-24-months/ 2024-07-09 https://bio-research.ai/s-biomedics-reports-phase-i-iia-trial-one-year-follow-up-for-ted-a9-in-parkinson-s-disease-showing-motor-function-improvement-and-increased-dopamine-transporters/ 2024-07-09 https://bio-research.ai/harrow-partners-with-apexus-to-offer-ophthalmic-products-including-iheezo-through-the-340b-prime-vendor-program/ 2024-07-09 https://bio-research.ai/ionctura-partners-with-etop-ibcsg-foundation-and-gsk-for-phase-ii-nsclc-trial-of-roginolisib-with-dostarlimab-and-docetaxel/ 2024-07-09 https://bio-research.ai/taiho-pharmaceutical-exercises-option-for-arcus-biosciences-quemliclustat-in-japan-and-asia-bolstering-global-phase-3-pancreatic-cancer-study/ 2024-07-08 https://bio-research.ai/moderna-and-mitsubishi-tanabe-pharma-join-forces-to-co-promote-mrna-vaccine-portfolio-in-japan-until-2029/ 2024-07-08 https://bio-research.ai/hillevax-inc-reports-that-hil-214-vaccine-candidate-fails-to-meet-primary-and-secondary-efficacy-endpoints-in-nest-in1-infant-trial/ 2024-07-08 https://bio-research.ai/rs-biotherapeutics-partners-with-university-of-colorado-for-rsbt-001-trials-targeting-lung-diseases-and-chemical-threats/ 2024-07-08 https://bio-research.ai/sirnaomics-ltd-reports-no-serious-adverse-events-in-second-cohort-of-phase-i-trial-for-stp122g-after-140-days/ 2024-07-08 https://bio-research.ai/ligand-pharmaceuticals-to-acquire-apeiron-biologics-for-100m-gaining-qarziba-royalties-with-potential-28m-in-milestone-payments-and-4m-investment-in-invios-holding-ag/ 2024-07-08 https://bio-research.ai/tuhura-biosciences-secures-exclusive-rights-for-kineta-s-kva12123-with-an-initial-5m-payment-and-additional-shareholder-investment/ 2024-07-08 https://bio-research.ai/ideaya-biosciences-reports-39-orr-from-phase-2-trial-of-ide397-in-mtap-deletion-cancers-with-94-dcr/ 2024-07-08 https://bio-research.ai/eli-lilly-to-acquire-morphic-holding-for-3-2b-to-expand-immunology-pipeline-with-oral-integrin-therapies/ 2024-07-08 https://bio-research.ai/oxolife-reports-phase-2-trial-results-of-oxo-001-with-increased-ongoing-pregnancy-and-live-birth-rates-in-ivf-icsi/ 2024-07-08 https://bio-research.ai/innorna-secures-fda-rare-pediatric-disease-designation-for-in022-targeting-classic-homocystinuria-treatment/ 2024-07-08 https://bio-research.ai/celon-pharma-s-a-reports-phase-ii-success-of-cpl-36-with-significant-improvement-in-panss-scores-for-schizophrenia-treatment/ 2024-07-05 https://bio-research.ai/fda-grants-fast-track-designation-to-hinova-pharmaceuticals-hp518-for-ar-triple-negative-breast-cancer-treatment/ 2024-07-05 https://bio-research.ai/china-nmpa-approves-xpovio-for-new-indication-of-adult-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-based-on-search-study-results/ 2024-07-05 https://bio-research.ai/iaso-biotechnology-secures-global-commercial-rights-to-fucaso-in-strategic-deal-with-innovent-biologics-gaining-an-18-investment-stake/ 2024-07-05 https://bio-research.ai/eu-approves-astrazeneca-s-tagrisso-with-chemotherapy-for-first-line-treatment-of-egfr-mutated-advanced-non-small-cell-lung-cancer-following-flaura2-phase-iii-trial-results/ 2024-07-05 https://bio-research.ai/luye-pharma-group-s-mimeixin-approved-by-china-s-national-medical-products-administration-for-severe-pain-management-in-adults-requiring-opioid-treatment/ 2024-07-04 https://bio-research.ai/hutchmed-s-application-for-tazemetostat-in-relapsed-or-refractory-follicular-lymphoma-accepted-for-priority-review-by-china-national-medical-products-administration/ 2024-07-04 https://bio-research.ai/impact-biotech-s-enlighted-phase-3-trial-of-padeliporfin-vtp-reports-77-complete-response-rate-in-low-grade-upper-tract-urothelial-cancer-patients-during-induction-treatment-phase/ 2024-07-04 https://bio-research.ai/european-medicines-agency-validates-marketing-authorization-application-for-nidlegy-a-melanoma-treatment-by-philogen-and-sun-pharmaceutical-industries-currently-in-phase-iii-and-ii-trials/ 2024-07-04 https://bio-research.ai/genentech-s-phase-ii-iii-skyscraper-06-trial-of-tiragolumab-with-tecentriq-and-chemotherapy-fails-to-meet-endpoints-in-non-small-cell-lung-cancer-with-hazard-ratios-of-1-27-for-progression-free-survival-and-1-33-for-overall-survival/ 2024-07-04 https://bio-research.ai/hutchmed-s-tazemetostat-nda-accepted-by-china-nmpa-for-relapsed-or-refractory-follicular-lymphoma/ 2024-07-04 https://bio-research.ai/navidea-biopharmaceuticals-halts-nav3-33-trial-as-tc-99m-tilmanocept-fails-to-predict-anti-tnf-therapy-response-in-rheumatoid-arthritis-with-less-than-70-accuracy/ 2024-07-03 https://bio-research.ai/geneseeq-technology-partners-with-jiangsu-vcare-pharmatech-to-co-develop-companion-diagnostic-kit-for-vc004-marking-a-leap-in-ntrk-fusion-positive-cancer-treatment-in-china/ 2024-07-03 https://bio-research.ai/intelgenx-corp-completes-phase-2a-buena-study-of-montelukast-buccal-film-in-alzheimer-s-significant-cognition-improvement-at-30-mg-doses-twice-daily/ 2024-07-03 https://bio-research.ai/gsk-secures-exclusive-rights-to-mrna-influenza-and-covid-19-vaccines-in-new-licensing-deal-with-curevac-worth-upfront-400m-and-up-to-1-05b-in-milestones-plus-royalties/ 2024-07-03 https://bio-research.ai/enimmune-corp-reports-99-21-efficacy-in-phase-iii-trial-of-envax-a71-vaccine-for-ev71-with-fda-approval-in-taiwan-and-plans-for-southeast-asian-neonatal-market-entry/ 2024-07-03 https://bio-research.ai/cstone-pharmaceuticals-entrusts-jiangsu-hengrui-pharmaceuticals-exclusive-promotion-of-ayvakit-in-china-with-upfront-payment-of-35m-rmb/ 2024-07-03 https://bio-research.ai/european-commission-approves-dupixent-for-adults-with-uncontrolled-chronic-obstructive-pulmonary-disease-based-on-phase-3-trial-results/ 2024-07-03 https://bio-research.ai/pentixapharm-ag-acquires-glycotope-gmbh-s-target-discovery-business-to-enhance-radiopharmaceutical-development-pipeline-ahead-of-frankfurt-stock-exchange-listing/ 2024-07-03 https://bio-research.ai/full-life-technologies-radiopharmaceutical-ac-fl-020-granted-fast-track-designation-by-fda-for-metastatic-castration-resistant-prostate-cancer-treatment/ 2024-07-02 https://bio-research.ai/gyre-therapeutics-receives-china-s-national-medical-products-administration-approval-for-avatrombopag-maleate-tablets-to-treat-thrombocytopenia-in-chronic-liver-disease/ 2024-07-02 https://bio-research.ai/fda-approves-kisunla-for-treatment-of-early-symptomatic-alzheimer-s-disease-with-evidence-of-reduced-cognitive-and-functional-decline-over-18-months/ 2024-07-02 https://bio-research.ai/leniobio-and-touchlight-partner-to-enhance-rapid-vaccine-production-using-alice-and-dbdna-technologies-under-cepi-funded-project/ 2024-07-02 https://bio-research.ai/biodexa-pharmaceuticals-reports-phase-1-clinical-data-of-mtx110-with-a-median-overall-survival-of-16-5-months-in-diffuse-midline-glioma-treatment/ 2024-07-02 https://bio-research.ai/fda-accepts-vertex-pharmaceuticals-cystic-fibrosis-treatment-vanzacaftor-tezacaftor-deutivacaftor-application-for-review-with-a-pdufa-target-date-set-for-january-2025/ 2024-07-02 https://bio-research.ai/alvotech-reports-avt03-biosimilar-meets-primary-endpoints-in-clinical-study-against-reference-biologic-denosumab-in-532-postmenopausal-women-with-osteoporosis/ 2024-07-02 https://bio-research.ai/annovis-bio-inc-announces-phase-iii-trial-results-for-buntanetap-with-statistical-improvements-in-cognition-and-mds-updrs-scores-in-parkinson-s-disease-patients/ 2024-07-02 https://bio-research.ai/johnson-johnson-reports-phase-3-cartitude-4-study-results-showing-carvykti-improves-overall-survival-in-relapsed-or-lenalidomide-refractory-multiple-myeloma/ 2024-07-02 https://bio-research.ai/cartesian-therapeutics-phase-2b-trial-of-descartes-08-meets-primary-endpoint-in-generalized-myasthenia-gravis-with-71-of-patients-showing-improvement-at-month-3/ 2024-07-02 https://bio-research.ai/ipsen-expands-collaboration-with-exelixis-on-cabometyx-eyes-eu-marketing-authorization-following-successful-cabinet-trial-for-pnets-and-epnets/ 2024-07-02 https://bio-research.ai/mission-therapeutics-secures-5-2m-from-the-michael-j-fox-foundation-and-parkinson-s-uk-for-mtx325-phase-i-trials-in-parkinson-s-disease/ 2024-07-02 https://bio-research.ai/innovent-biologics-reports-phase-1-clinical-trial-results-of-ibi343-with-36-7-orr-and-93-3-dcr-in-advanced-gastric-and-gastroesophageal-junction-adenocarcinoma/ 2024-07-01 https://bio-research.ai/ubix-therapeutics-licenses-preclinical-androgen-receptor-degrader-ubx-103-to-yuhan-in-deal-up-to-105m-plus-royalties/ 2024-07-01 https://bio-research.ai/merck-acquires-exclusive-rights-to-develop-and-commercialize-orion-s-opevesostat-in-potential-1-63b-deal-for-prostate-cancer-treatment/ 2024-07-01 https://bio-research.ai/tracon-pharmaceuticals-ends-envafolimab-development-after-pivotal-trial-misses-primary-endpoint-with-5-response-rate/ 2024-07-01 https://bio-research.ai/longboard-pharmaceuticals-receives-breakthrough-therapy-designation-for-bexicaserin-targeting-seizures-in-developmental-and-epileptic-encephalopathies-and-plans-phase-3-program/ 2024-07-01 https://bio-research.ai/humacyte-receives-fda-s-regenerative-medicine-advanced-therapy-designation-for-acellular-tissue-engineered-vessel-in-peripheral-artery-disease-treatment-and-clearance-for-investigational-new-drug-application/ 2024-07-01 https://bio-research.ai/tonix-pharmaceuticals-secures-up-to-34m-from-dtra-for-development-of-tnx-4200-antiviral-agent-to-support-u-s-military-medical-preparedness/ 2024-07-01 https://bio-research.ai/neurosense-therapeutics-reports-primec-slows-als-progression-by-36-and-improves-12-month-survival-rates-by-43-in-phase-2b-study/ 2024-07-01 https://bio-research.ai/uniqure-n-v-sells-lexington-gene-therapy-facility-to-genezen-for-25m-including-preferred-stock-and-convertible-note-to-streamline-hemgenix-production-and-cut-annual-expenses-by-40m/ 2024-07-01 https://bio-research.ai/european-commission-authorizes-valneva-s-ixchiq-vaccine-for-chikungunya-virus-prevention-in-adults/ 2024-07-01 https://bio-research.ai/samsung-bioepis-gains-fda-approval-for-biosimilar-pyzchiva-to-treat-plaque-psoriasis-psoriatic-arthritis-crohn-s-disease-and-ulcerative-colitis-with-commercial-launch-scheduled-for-february-2025/ 2024-07-01 https://bio-research.ai/european-medicines-agency-s-chmp-recommends-approval-of-piasky-for-paroxysmal-nocturnal-haemoglobinuria-treatment-with-monthly-subcutaneous-administration/ 2024-06-28 https://bio-research.ai/johnson-johnson-s-phase-3-vivacity-mg3-study-demonstrates-efficacy-of-nipocalimab-in-improving-mg-adl-scores-in-generalized-myasthenia-gravis-over-24-weeks/ 2024-06-28 https://bio-research.ai/ema-s-chmp-endorses-marketing-authorization-expansion-for-imcivree-in-childhood-obesity-linked-to-rare-genetic-disorders/ 2024-06-28 https://bio-research.ai/rocket-pharmaceuticals-receives-fda-request-for-more-information-on-kresladi-gene-therapy-for-lad-i-after-phase-1-2-study-shows-survival-and-reduced-infections/ 2024-06-28 https://bio-research.ai/ema-s-chmp-issues-negative-opinion-on-ab-science-sa-s-masitinib-for-als-company-to-seek-re-examination/ 2024-06-28 https://bio-research.ai/iovance-biotherapeutics-submits-marketing-authorization-application-to-european-medicines-agency-for-lifileucel-in-advanced-melanoma-treatment-after-anti-pd1-therapy-based-on-c-144-01-trial-results/ 2024-06-28 https://bio-research.ai/chmp-recommends-approval-of-winrevair-for-treatment-of-adult-pah-patients-to-improve-exercise-capacity-based-on-phase-3-trial-data/ 2024-06-28 https://bio-research.ai/esperion-sells-bempedoic-acid-royalty-rights-in-europe-to-omers-for-304-7m-retains-potential-300m-in-milestones-as-debt-with-oberland-capital-is-cleared/ 2024-06-28 https://bio-research.ai/european-medicines-agency-committee-endorses-epcoritamab-for-conditional-marketing-authorization-in-relapsed-or-refractory-follicular-lymphoma-based-on-epcore-nhl-1-trial-results/ 2024-06-28 https://bio-research.ai/abbisko-therapeutics-reports-50-orr-for-irpagratinib-and-atezolizumab-in-phase-ii-trial-in-fgf19-advanced-hcc/ 2024-06-28 https://bio-research.ai/eisai-s-phase-3-reflect-trial-analysis-reveals-median-overall-survival-rates-in-uhcc-with-lenvima-as-first-line-therapy/ 2024-06-27 https://bio-research.ai/kazia-therapeutics-reports-phase-2-study-results-of-paxalisib-on-diffuse-midline-glioma-survival-rates/ 2024-06-27 https://bio-research.ai/innovent-biologics-reports-phase-3-glory-1-study-results-of-mazdutide-showing-weight-reduction-and-reduced-liver-fat-in-overweight-or-obese-adults-in-china/ 2024-06-27 https://bio-research.ai/bayer-collaborates-with-rad-ai-to-enhance-hospital-efficiency-through-calantic-digital-solutions-integration/ 2024-06-27 https://bio-research.ai/chroma-medicine-secures-exclusive-license-for-charm-epigenetic-editing-technology-from-whitehead-institute-to-further-gene-regulation-therapeutics/ 2024-06-27 https://bio-research.ai/abbvie-acquires-celsius-therapeutics-for-250m-in-cash-to-advance-cel383-an-anti-trem1-antibody-for-inflammatory-bowel-disease/ 2024-06-27 https://bio-research.ai/recode-therapeutics-receives-fda-orphan-drug-designation-for-rct1100-in-primary-ciliary-dyskinesia-related-to-dnai1-gene-mutations/ 2024-06-27 https://bio-research.ai/purple-biotech-ltd-reports-phase-2-trial-interim-data-indicating-improved-survival-outcomes-with-cm24-nivolumab-and-chemotherapy-in-patients-with-low-baseline-mpo-levels/ 2024-06-27 https://bio-research.ai/calcimedica-inc-reports-phase-2b-carpo-trial-of-auxora-achieves-primary-objective-in-acute-pancreatitis-and-sirs-reduces-median-time-to-solid-food-tolerance-and-severe-organ-failure/ 2024-06-27 https://bio-research.ai/lantheus-holdings-acquires-global-rights-to-life-molecular-imaging-s-prostate-and-breast-cancer-targeting-agents-lu-dota-rm2-and-ga-dota-rm2-for-35m-with-future-milestones-and-royalties/ 2024-06-27 https://bio-research.ai/medivir-ab-reports-24-response-rate-and-10-8-months-median-time-to-progression-in-phase-1b-2a-trial-of-fostroxacitabine-bralpamide-with-lenvima-for-second-line-hcc-patients/ 2024-06-27 https://bio-research.ai/x4-pharmaceuticals-reports-phase-2-trial-results-for-mavorixafor-in-chronic-neutropenia-with-increases-in-absolute-neutrophil-count-at-six-months/ 2024-06-27 https://bio-research.ai/sanofi-invests-40m-in-vigil-neuroscience-for-phase-1-trem2-agonist-program-targeting-alzheimer-s-with-exclusive-negotiation-rights/ 2024-06-27 https://bio-research.ai/harbour-biomed-resubmits-batoclimab-application-to-china-s-nmpa-including-phase-iii-data-for-myasthenia-gravis-treatment/ 2024-06-27 https://bio-research.ai/fda-approves-genmab-s-epkinly-for-adults-with-relapsed-or-refractory-follicular-lymphoma-after-two-or-more-therapies-contingent-on-further-trials/ 2024-06-27 https://bio-research.ai/verona-pharma-s-ohtuvayre-approved-by-us-fda-for-chronic-obstructive-pulmonary-disease-maintenance-treatment-based-on-phase-3-enhance-trial-results/ 2024-06-26 https://bio-research.ai/vogenx-announces-study-results-mizagliflozin-meets-primary-and-secondary-endpoints-in-post-bariatric-hypoglycemia-treatment-trial/ 2024-06-26 https://bio-research.ai/agile-therapeutics-to-merge-with-insud-pharma-s-us-subsidiary-exeltis-in-45m-deal-conditional-on-agile-shareholder-approval-and-accompanied-by-warrant-cash-out-and-corium-agreement-amendments/ 2024-06-26 https://bio-research.ai/fda-grants-fast-track-designation-for-vir-biotechnology-s-ind-of-tobevibart-and-elebsiran-combination-in-chronic-hepatitis-delta-treatment/ 2024-06-26 https://bio-research.ai/savara-inc-reports-molgramostim-achieves-primary-endpoint-in-phase-3-impala-2-trial-for-apap-at-weeks-24-and-48-with-high-completion-rate-and-sgrq-score-improvement/ 2024-06-26 https://bio-research.ai/lyell-immunopharma-reports-phase-1-trial-results-of-lyl797-with-a-40-objective-response-rate-in-triple-negative-breast-cancer/ 2024-06-26 https://bio-research.ai/alligator-bioscience-reports-median-overall-survival-of-14-9-months-in-phase-2-optimize-1-study-of-mitazalimab-with-mfolfirinox-for-metastatic-pancreatic-cancer/ 2024-06-26 https://bio-research.ai/genexine-merges-with-epd-biotherapeutics-at-a-1-1-111-ratio-to-boost-drug-development-and-clinical-trial-capabilities/ 2024-06-26 https://bio-research.ai/sanofi-s-phase-2-study-of-riliprubart-reports-one-year-follow-up-results-for-chronic-inflammatory-demyelinating-polyneuropathy-treatment-with-improvements-in-participant-reported-fatigue-and-quality-of-life/ 2024-06-25 https://bio-research.ai/shanghai-junshi-biosciences-toripalimab-in-combination-with-paclitaxel-receives-nmpa-approval-for-first-line-treatment-of-recurrent-or-metastatic-triple-negative-breast-cancer-based-on-phase-iii-torchlight-study-results/ 2024-06-25 https://bio-research.ai/excellthera-inc-s-um171-cell-therapy-application-accepted-for-accelerated-assessment-by-european-medicines-agency-for-adults-with-hematological-malignancies-requiring-stem-cell-transplant-without-suitable-donor/ 2024-06-25 https://bio-research.ai/eli-lilly-and-openai-join-forces-to-combat-antimicrobial-resistance-using-generative-ai-with-lilly-investing-100m-in-the-amr-action-fund/ 2024-06-25 https://bio-research.ai/abbvie-receives-complete-response-letter-from-fda-for-abbv-951-due-to-third-party-manufacturing-issues-not-safety-or-efficacy-concerns/ 2024-06-25 https://bio-research.ai/fda-grants-fast-track-designation-to-carisma-therapeutics-ct-0525-for-her2-high-expressing-solid-tumor-treatment-phase-1-data-expected-by-end-of-2024/ 2024-06-25 https://bio-research.ai/wave-life-sciences-reports-46-reduction-in-mutant-huntingtin-protein-in-phase-1b-2a-select-hd-trial-for-wve-003/ 2024-06-25 https://bio-research.ai/european-commission-approves-roche-s-ocrevus-for-subcutaneous-administration-in-multiple-sclerosis-treatment-based-on-phase-iii-ocarina-ii-trial-data/ 2024-06-25 https://bio-research.ai/jcr-pharmaceuticals-takes-back-full-commercialization-rights-to-jr-141-from-takeda-pharmaceutical-following-mutual-termination-of-collaboration/ 2024-06-25 https://bio-research.ai/astrazeneca-s-phase-iii-niagara-trial-shows-imfinzi-with-chemotherapy-improves-event-free-and-overall-survival-in-muscle-invasive-bladder-cancer/ 2024-06-25 https://bio-research.ai/astrazeneca-s-tagrisso-approved-in-japan-for-first-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer-after-extending-median-progression-free-survival-in-phase-iii-trial/ 2024-06-25 https://bio-research.ai/alebund-pharmaceuticals-receives-breakthrough-therapy-designation-from-nmpa-for-ap306-in-hyperphosphatemia-treatment-for-ckd-patients/ 2024-06-25 https://bio-research.ai/innovent-biologics-reports-phase-3-trial-results-of-mazdutide-with-liver-fat-reduction-in-overweight-or-obese-chinese-adults/ 2024-06-25 https://bio-research.ai/novo-nordisk-s-flow-phase-3b-trial-of-semaglutide-shows-a-24-reduction-in-kidney-disease-events-in-type-2-diabetes-patients/ 2024-06-24 https://bio-research.ai/medicure-inc-acquires-p5p-analogues-ip-from-canam-bioresearch-with-terms-including-1-35m-in-milestone-payments-and-10-of-net-proceeds-up-to-20m/ 2024-06-24 https://bio-research.ai/ascendis-pharma-a-s-reports-phase-2-accomplish-trial-results-of-transcon-cnp-in-children-with-achondroplasia-showing-improvements-in-well-being-and-physical-functioning-at-100-g-kg-week-dose-after-one-year/ 2024-06-24 https://bio-research.ai/iliad-biotechnologies-and-emmes-group-gear-up-for-phase-iii-trials-of-bpze1-pertussis-vaccine-with-pending-definitive-agreement/ 2024-06-24 https://bio-research.ai/navamedic-asa-and-orion-corporation-strike-exclusive-license-and-supply-deal-for-parkinson-s-disease-treatment-flexilev-in-27-european-countries/ 2024-06-24 https://bio-research.ai/biodexa-pharmaceuticals-plc-reports-phase-2-trial-results-of-erapa-with-75-non-progression-rate-in-fap-and-plans-for-phase-3-study/ 2024-06-24 https://bio-research.ai/evommune-secures-exclusive-worldwide-rights-for-aprilbio-s-evo301-aiming-to-tackle-inflammation-with-planned-phase-2-trial/ 2024-06-24 https://bio-research.ai/allecra-therapeutics-teams-up-with-acino-to-commercialize-novel-antibiotic-exblifep-in-gulf-cooperation-council-countries-and-south-africa/ 2024-06-24 https://bio-research.ai/rani-therapeutics-and-progen-co-ltd-partner-to-co-develop-and-commercialize-oral-obesity-treatment-rt-114-with-50-50-global-profit-and-cost-sharing-preclinical-phase-set-for-2025/ 2024-06-24 https://bio-research.ai/biontech-se-and-duality-biologics-bnt324-db-1311-receives-fda-fast-track-designation-for-phase-1-2-trial-in-advanced-prostate-cancer/ 2024-06-24 https://bio-research.ai/alnylam-pharmaceuticals-reports-phase-3-helios-b-study-of-vutrisiran-meets-primary-endpoint-in-attr-amyloidosis-with-cardiomyopathy/ 2024-06-24 https://bio-research.ai/g1-therapeutics-phase-3-preserve-2-trial-of-trilaciclib-for-metastatic-triple-negative-breast-cancer-fails-to-meet-primary-endpoint-with-median-survival-of-17-4-months/ 2024-06-24 https://bio-research.ai/regulus-therapeutics-inc-reports-statistically-significant-changes-in-urinary-biomarkers-and-kidney-volume-reductions-in-phase-1b-mad-study-of-rgls8429-for-adpkd/ 2024-06-24 https://bio-research.ai/altimmune-inc-reports-weight-loss-and-cardiovascular-improvements-in-48-week-phase-2-momentum-clinical-trial-of-pemvidutide/ 2024-06-23 https://bio-research.ai/novo-nordisk-s-phase-3-frontier2-trial-data-shows-mim8-reduces-annualized-bleeding-rate-in-haemophilia-a-patients/ 2024-06-23 https://bio-research.ai/takeda-s-phase-2b-study-of-mezagitamab-in-primary-immune-thrombocytopenia-meets-primary-safety-endpoint-platelet-counts-sustained-through-week-16/ 2024-06-22 https://bio-research.ai/mannkind-corporation-reports-afrezza-meets-primary-endpoint-in-inhale-3-phase-4-trial-for-type-1-diabetes-with-30-of-participants-achieving-hba1c-under-7/ 2024-06-22 https://bio-research.ai/vertex-pharmaceuticals-reports-phase-1-2-trial-data-for-vx-880-shows-islet-cell-engraftment-in-12-type-1-diabetes-patients-with-some-achieving-insulin-independence-and-no-severe-hypoglycemic-events/ 2024-06-21 https://bio-research.ai/eli-lilly-s-tirzepatide-reduces-obstructive-sleep-apnea-severity-by-up-to-62-8-in-surmount-osa-phase-3-trial/ 2024-06-21 https://bio-research.ai/lexicon-pharmaceuticals-resubmits-fda-drug-application-for-sotagliflozin-as-insulin-adjunct-in-type-1-diabetes-patients-with-chronic-kidney-disease/ 2024-06-21 https://bio-research.ai/sun-pharma-strikes-non-exclusive-patent-deal-with-takeda-for-voltapraz-commercialization-in-india/ 2024-06-21 https://bio-research.ai/hightide-therapeutics-reports-phase-2-clinical-study-results-of-htd1801-indicating-dose-dependent-improvements-in-glycemic-parameters-for-t2dm-patients-after-12-weeks/ 2024-06-21 https://bio-research.ai/ema-validates-bristol-myers-squibb-s-application-for-opdivo-subcutaneous-formulation-based-on-checkmate-67t-phase-3-trial-results-in-advanced-or-metastatic-renal-cell-carcinoma/ 2024-06-21 https://bio-research.ai/sanofi-reports-phase-3-interim-results-for-altuviiio-in-severe-hemophilia-a/ 2024-06-21 https://bio-research.ai/fda-accepts-neurotech-pharmaceuticals-bla-for-nt-501-targeting-mactel-with-december-17-2024-review-completion-date/ 2024-06-20 https://bio-research.ai/johnson-johnson-seeks-fda-approval-for-tremfya-in-treating-moderately-to-severely-active-crohn-s-disease-based-on-phase-3-trial-results/ 2024-06-20 https://bio-research.ai/lantheus-holdings-secures-strategic-agreement-with-radiopharm-theranostics-for-a-7-5m-investment-and-additional-a-7-5m-option-acquiring-rights-to-trop2-targeting-nanobody-and-lrrc15-targeting-mab-for-a-3m-up-front/ 2024-06-20 https://bio-research.ai/fda-grants-traditional-approval-for-ambulatory-duchenne-muscular-dystrophy-patients-and-accelerated-approval-with-further-trial-requirement-for-non-ambulatory-patients-for-sarepta-therapeutics-elevidys/ 2024-06-20 https://bio-research.ai/johnson-johnson-s-phase-3-graviti-trial-of-tremfya-meets-primary-endpoints-in-crohn-s-disease-at-week-12/ 2024-06-20 https://bio-research.ai/silence-therapeutics-phase-2-study-of-zerlasiran-achieves-90-reduction-in-lp-a-levels-in-atherosclerotic-cardiovascular-disease-patients-at-48-weeks/ 2024-06-20 https://bio-research.ai/clearmind-medicine-inc-seals-exclusive-licensing-pact-with-yissum-research-of-hebrew-university-for-ptsd-treatment-compounds/ 2024-06-20 https://bio-research.ai/coya-therapeutics-expands-research-on-t-cell-derived-exosomes-under-new-agreement-with-houston-methodist-research-institute/ 2024-06-20 https://bio-research.ai/aphaia-pharma-announces-phase-2-trial-success-of-aphd-012-in-improving-glucose-tolerance-for-prediabetes/ 2024-06-20 https://bio-research.ai/gilead-sciences-reports-100-efficacy-of-lenacapavir-in-phase-3-purpose-1-trial-for-hiv-prevention-in-cisgender-women/ 2024-06-20 https://bio-research.ai/jazz-pharmaceuticals-phase-2b-trial-of-suvecaltamide-fails-to-reach-primary-endpoint-in-essential-tremor-treatment/ 2024-06-20 https://bio-research.ai/tempest-therapeutics-reports-phase-1b-2-trial-results-of-amezalpat-in-combination-with-atezolizumab-and-bevacizumab-in-unresectable-or-metastatic-hepatocellular-carcinoma-with-a-median-overall-survival-of-21-months/ 2024-06-20 https://bio-research.ai/ptc-therapeutics-announces-phase-2-pivot-hd-study-interim-results-of-ptc518-with-mutant-huntingtin-protein-reduction-and-motor-symptom-progression-slowdown-in-huntington-s-disease-at-12-months/ 2024-06-20 https://bio-research.ai/alligator-bioscience-reports-phase-2-optimize-1-trial-results-of-mitazalimab-and-mfolfirinox-in-metastatic-pancreatic-cancer-with-40-4-orr/ 2024-06-20 https://bio-research.ai/astrazeneca-s-truqap-gains-eu-approval-for-estrogen-receptor-positive-her2-negative-advanced-breast-cancer-in-combination-with-faslodex-after-capitello-291-trial-results/ 2024-06-20 https://bio-research.ai/glioblastoma-foundation-acquires-oncology-drug-lisavanbulin-from-basilea-pharmaceutica-with-commitment-to-continue-development-and-patient-access-program/ 2024-06-20 https://bio-research.ai/cmtrf-and-revir-therapeutics-team-up-to-develop-new-treatment-for-cmt1a-using-groundbreaking-small-molecule-splice-modulators/ 2024-06-19 https://bio-research.ai/aurion-biotech-receives-fda-breakthrough-therapy-and-regenerative-medicine-advanced-therapy-designations-for-aurn001-cell-therapy-in-corneal-edema/ 2024-06-19 https://bio-research.ai/golidocitinib-approved-by-china-s-national-medical-products-administration-for-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma-after-demonstrating-44-3-objective-response-rate-in-jackpot8b-study/ 2024-06-19 https://bio-research.ai/macomics-ltd-and-prof-andrea-alimonti-s-lab-at-institute-of-oncology-research-ior-collaborate-to-harness-in-vivo-prostate-cancer-models-for-advancing-macrophage-targeted-therapies-in-precision-oncology/ 2024-06-19 https://bio-research.ai/european-commission-authorizes-sobi-s-altuvoct-for-haemophilia-a-treatment-following-phase-3-study-results-showing-significant-bleed-protection-and-improved-patient-health/ 2024-06-19 https://bio-research.ai/fda-approves-abbvie-s-skyrizi-for-adults-with-moderately-to-severely-active-ulcerative-colitis-based-on-phase-3-trial-results/ 2024-06-18 https://bio-research.ai/neurona-therapeutics-receives-rmat-designation-from-fda-for-nrtx-1001-for-drug-resistant-mesial-temporal-lobe-epilepsy/ 2024-06-18 https://bio-research.ai/acadia-pharmaceuticals-presents-interim-data-from-lotus-study-of-daybue-in-rett-syndrome-at-annual-scientific-meeting/ 2024-06-18 https://bio-research.ai/xbiotech-phase-1-2-study-shows-natrunix-associated-with-reduced-adverse-events-and-hospitalizations-in-advanced-pancreatic-cancer/ 2024-06-18 https://bio-research.ai/day-one-biopharmaceuticals-licenses-mtx-13-now-day301-from-mabcare-therapeutics-with-upfront-55m-and-up-to-1-152b-in-milestones-for-global-rights-excluding-greater-china/ 2024-06-18 https://bio-research.ai/taysha-gene-therapies-reports-two-adult-patients-with-sustained-clinical-outcomes-in-reveal-phase-1-2-trials-of-tsha-102-in-rett-syndrome-with-no-serious-adverse-events/ 2024-06-18 https://bio-research.ai/intra-cellular-therapies-reports-lumateperone-achieves-primary-endpoint-in-study-502-for-major-depressive-disorder-adjunctive-treatment-with-14-7-point-madrs-score-reduction/ 2024-06-18 https://bio-research.ai/takeda-s-phase-3-advance-cidp-3-trial-demonstrates-hyqvia-s-safety-and-tolerability-with-low-relapse-rate-over-33-months-for-cidp-treatment/ 2024-06-18 https://bio-research.ai/ionis-pharmaceuticals-grants-otsuka-exclusive-asia-pacific-rights-to-donidalorsen-in-20m-deal-with-additional-milestones-and-tiered-royalties/ 2024-06-18 https://bio-research.ai/ascidian-therapeutics-partners-with-roche-on-rna-exon-editing-for-neurological-diseases-in-deal-worth-up-to-1-8b-plus-royalties/ 2024-06-18 https://bio-research.ai/astrazeneca-s-phase-iii-trial-of-truqap-with-paclitaxel-fails-to-meet-primary-overall-survival-endpoints-in-triple-negative-breast-cancer/ 2024-06-18 https://bio-research.ai/shanghai-junshi-biosciences-toripalimab-approved-by-nmpa-for-first-line-treatment-of-extensive-stage-small-cell-lung-cancer-in-combination-with-etoposide-and-platinum/ 2024-06-18 https://bio-research.ai/alvotech-and-advanz-pharma-strike-deal-for-commercialization-rights-of-biosimilars-avt06-and-avt29-in-europe/ 2024-06-18 https://bio-research.ai/fda-approves-merck-s-capvaxive-for-adults-to-prevent-invasive-pneumococcal-disease-and-pneumonia-caused-by-s-pneumoniae-serotypes-following-priority-review-based-on-phase-3-studies/ 2024-06-17 https://bio-research.ai/spinethera-and-mayo-clinic-form-know-how-agreement-to-develop-long-acting-injectables-for-substance-abuse-disorders-with-joint-leadership/ 2024-06-17 https://bio-research.ai/company-s-management-board-announces-phase-ii-trial-results-of-cpl-409116-in-rheumatoid-arthritis-patients-with-dose-dependent-improvement-in-das28-crp-scores/ 2024-06-17 https://bio-research.ai/northwest-biotherapeutics-acquires-exclusive-license-from-roswell-park-for-dr-pawel-kalinski-s-phase-2-dendritic-cell-technologies-with-2-3m-in-milestone-payments-and-up-to-4-royalties/ 2024-06-17 https://bio-research.ai/kira-pharmaceuticals-reports-phase-2-study-outcomes-of-kp104-in-complement-inhibitor-na-ve-paroxysmal-nocturnal-hemoglobinuria-patients-with-sustained-hemoglobin-and-ldh-level-control-for-65-weeks/ 2024-06-17 https://bio-research.ai/aerovate-therapeutics-halts-phase-3-trial-of-av-101-after-phase-2b-study-fails-to-improve-pulmonary-vascular-resistance-in-pulmonary-arterial-hypertension/ 2024-06-17 https://bio-research.ai/mirum-pharmaceuticals-reports-outstanding-positive-interim-phase-2b-results-of-volixibat-with-a-2-32-point-reduction-in-pruritus-on-adult-itchro-scale-in-primary-biliary-cholangitis-patients/ 2024-06-17 https://bio-research.ai/marinus-pharmaceuticals-phase-3-raise-trial-of-intravenous-ganaxolone-in-refractory-status-epilepticus-shows-80-cessation-rate-within-30-minutes-versus-13-with-placebo/ 2024-06-17 https://bio-research.ai/takeda-s-phase-3-trials-of-soticlestat-fail-to-meet-primary-endpoint-in-refractory-dravet-syndrome-and-lennox-gastaut-syndrome/ 2024-06-17 https://bio-research.ai/astrazeneca-s-phase-iii-echo-trial-of-calquence-with-bendamustine-and-rituximab-extends-progression-free-survival-in-untreated-mantle-cell-lymphoma-patients-to-66-4-months/ 2024-06-16 https://bio-research.ai/nurix-therapeutics-reports-69-2-objective-response-rate-for-nx-5948-in-phase-1a-b-trial-in-adults-with-relapsed-or-refractory-b-cell-malignancies/ 2024-06-16 https://bio-research.ai/roche-s-phase-iii-starglo-study-reports-columvi-with-gemox-chemotherapy-extends-survival-in-r-r-dlbcl-with-41-reduction-in-death-risk/ 2024-06-15 https://bio-research.ai/agios-pharmaceuticals-presents-phase-3-energize-study-results-of-mitapivat-showing-increased-hemoglobin-response-in-non-transfusion-dependent-thalassemia/ 2024-06-15 https://bio-research.ai/sumitomo-pharma-america-reports-phase-1-2-study-results-of-dsp-5336-in-acute-leukemia-with-57-response-rate-in-npm1-or-kmt2a-altered-patients/ 2024-06-14 https://bio-research.ai/actinium-pharmaceuticals-reports-phase-3-sierra-trial-results-iomab-b-leads-to-median-overall-survival-of-5-49-months-in-tp53-mutated-acute-myeloid-leukemia-patients/ 2024-06-14 https://bio-research.ai/cogent-biosciences-reports-bezuclastinib-reduces-mast-cell-burden-by-over-90-in-summit-trial-for-systemic-mastocytosis/ 2024-06-14 https://bio-research.ai/wugen-inc-reports-phase-2-clinical-trial-results-for-wu-cart-007-showing-a-73-complete-remission-rate-in-t-cell-acute-lymphoblastic-leukemia-lymphoma/ 2024-06-14 https://bio-research.ai/takeda-secures-option-for-exclusive-rights-to-ascentage-pharma-s-olverembatinib-outside-asia-and-russia-with-100m-deal-and-potential-add-ons/ 2024-06-14 https://bio-research.ai/bio-path-holdings-reports-interim-phase-2-results-of-prexigebersen-with-decitabine-and-venetoclax-in-aml-treatment-75-remission-in-newly-diagnosed-cohort/ 2024-06-14 https://bio-research.ai/editas-medicine-reports-safety-and-efficacy-data-from-ruby-trial-of-renizgamglogene-autogedtemcel-in-18-scd-patients-with-no-vaso-occlusive-events-and-improved-hemoglobin-levels/ 2024-06-14 https://bio-research.ai/pfizer-reports-phase-2-magnetismm-3-study-results-of-elrexfio-with-24-6-month-median-overall-survival-in-relapsed-or-refractory-multiple-myeloma/ 2024-06-14 https://bio-research.ai/fda-grants-accelerated-approval-to-augtyro-for-treatment-of-ntrk-gene-fusion-positive-solid-tumors-in-adults-and-children-over-12-based-on-trident-1-trial-results/ 2024-06-13 https://bio-research.ai/beigene-to-retake-control-of-brukinsa-sales-in-middle-east-and-africa-as-partnership-with-newbridge-pharmaceuticals-concludes/ 2024-06-13 https://bio-research.ai/urogen-pharma-reports-82-3-12-month-response-rate-in-phase-3-envision-trial-of-ugn-102-for-low-grade-intermediate-risk-non-muscle-invasive-bladder-cancer/ 2024-06-13 https://bio-research.ai/abbvie-secures-global-rights-to-futuregen-biopharmaceutical-s-fg-m701-in-a-1-71b-licensing-deal-for-ibd-therapy-development/ 2024-06-13 https://bio-research.ai/cardiol-therapeutics-inc-reports-phase-ii-maveric-pilot-study-results-of-cardiolrx-in-recurrent-pericarditis-with-reduced-pain-and-inflammation-in-89-of-patients-heading-to-phase-iii-trial/ 2024-06-13 https://bio-research.ai/fda-extends-exclusivity-for-collegium-pharmaceutical-s-nucynta-franchise-until-2027-with-serious-risks-associated-with-opioid-use-highlighted/ 2024-06-13 https://bio-research.ai/xencor-to-regain-exclusive-rights-to-plamotamab-as-janssen-biotech-terminates-collaboration-while-retaining-rights-to-other-bispecific-antibodies-with-potential-for-additional-milestone-payments-and-royalties/ 2024-06-13 https://bio-research.ai/moderna-s-mrna-1283-meets-primary-efficacy-endpoint-in-phase-3-trial-with-comparable-safety-to-spikevax-in-participants-12-years-and-older/ 2024-06-13 https://bio-research.ai/jumpcode-genomics-and-takara-bio-usa-resolve-patent-dispute-and-form-partnership-to-advance-crispr-based-ngs-library-clean-up-technologies/ 2024-06-13 https://bio-research.ai/innovent-biologics-ibi343-granted-fda-fast-track-designation-for-advanced-pancreatic-ductal-adenocarcinoma-treatment-following-therapy-failure/ 2024-06-13 https://bio-research.ai/pfizer-s-phase-3-ciffreo-study-of-fordadistrogene-movaparvovec-fails-to-meet-primary-and-secondary-endpoints-in-dmd-trial/ 2024-06-12 https://bio-research.ai/flagship-pioneering-and-profound-therapeutics-partner-with-pfizer-on-profoundry-platform-for-obesity-treatment-research-in-strategic-collaboration/ 2024-06-12 https://bio-research.ai/cara-therapeutics-ends-phase-2-3-study-of-oral-difelikefalin-in-notalgia-paresthetica-as-drug-fails-to-meet-primary-endpoint-in-itch-severity-measurement/ 2024-06-12 https://bio-research.ai/fda-approves-astrazeneca-s-farxiga-for-type-2-diabetes-in-children-aged-10-and-above-following-t2now-phase-iii-trial-results/ 2024-06-12 https://bio-research.ai/quoin-pharmaceuticals-partners-with-university-college-cork-to-develop-topical-rapamycin-formulations-using-dissolvable-microneedles-technology-for-rare-diseases-without-upfront-fees-or-royalties/ 2024-06-12 https://bio-research.ai/sibylla-biotech-partners-with-md-anderson-cancer-center-to-develop-cancer-therapies-using-ppi-fit-technology-under-new-strategic-collaboration-agreement/ 2024-06-12 https://bio-research.ai/ochre-bio-signs-multi-year-data-licence-agreement-with-gsk-for-up-to-37-5m-to-enhance-liver-disease-research-using-human-liver-data-and-computational-biology/ 2024-06-12 https://bio-research.ai/avidity-biosciences-announces-phase-1-2-fortitude-trial-results-of-del-brax-showing-over-50-reduction-in-dux4-regulated-genes-in-fshd/ 2024-06-12 https://bio-research.ai/scancell-holdings-inks-deal-with-major-biotech-for-exclusive-evaluation-of-anti-glycan-antibody-securing-1m-payment-and-licensing-option/ 2024-06-12 https://bio-research.ai/belite-bio-s-tinlarebant-shows-reduced-growth-of-atrophic-lesions-in-phase-2-trial-for-stargardt-disease-and-dry-amd-phase-3-trials-underway/ 2024-06-12 https://bio-research.ai/shanghai-junshi-biosciences-reports-phase-iii-hepatorch-trial-meets-primary-endpoints-of-pfs-and-os-in-first-line-treatment-of-advanced-hepatocellular-carcinoma-with-toripalimab-plus-bevacizumab/ 2024-06-11 https://bio-research.ai/ultragenyx-pharmaceutical-and-mereo-biopharma-report-phase-2-orbit-study-results-of-setrusumab-with-67-reduction-in-annualized-fracture-rate-and-increased-bone-mineral-density/ 2024-06-11 https://bio-research.ai/60-degrees-pharmaceuticals-receives-orphan-drug-designation-for-tafenoquine-in-acute-babesiosis-treatment-prepares-for-clinical-trial-with-tufts-medical-center/ 2024-06-11 https://bio-research.ai/annovis-bio-inc-reports-phase-ii-iii-trial-results-of-buntanetap-showing-decreased-adas-cog11-scores-in-alzheimer-s-disease-patients-without-aria-incidents/ 2024-06-11 https://bio-research.ai/gardp-and-bugworks-research-partner-to-co-develop-new-antibiotic-bwc0977-with-20m-support-against-multidrug-resistant-bacteria/ 2024-06-11 https://bio-research.ai/fda-issues-complete-response-letter-to-mitsubishi-tanabe-pharma-for-nd0612-application-in-parkinson-s-disease-treatment/ 2024-06-11 https://bio-research.ai/kangpu-biopharmaceuticals-releases-phase-2a-clinical-trial-results-of-kpg-818-in-sle-patients-showing-improvements-in-sledai-2k-and-clasi-scores-over-12-weeks/ 2024-06-11 https://bio-research.ai/sage-therapeutics-reports-phase-2-surveyor-study-results-of-dalzanemdor-in-huntington-s-disease-indicating-significant-cognitive-impairment-and-good-tolerance-in-40-participants/ 2024-06-11 https://bio-research.ai/alvotech-and-stada-bolster-strategic-alliance-with-new-deal-on-avt03-biosimilar-for-prolia-xgeva-as-they-prepare-for-uzpruvo-launch-in-europe/ 2024-06-11 https://bio-research.ai/gannex-pharma-reports-68-2-reduction-in-liver-fat-among-mash-patients-after-12-week-asc41-treatment-in-phase-ii-trial/ 2024-06-11 https://bio-research.ai/panbela-therapeutics-reports-phase-iia-trial-of-eflornithine-shows-safety-and-reduced-dna-damage-in-gastric-premalignant-conditions-after-24-months/ 2024-06-10 https://bio-research.ai/sellas-life-sciences-completes-phase-2a-trial-enrollment-for-sls009-reports-29-6-response-rate-in-r-r-aml-patients-with-higher-rates-in-specific-cohorts/ 2024-06-10 https://bio-research.ai/actinium-pharmaceuticals-reports-phase-3-sierra-trial-results-iomab-b-achieves-primary-endpoint-in-bone-marrow-transplant-for-acute-myeloid-leukemia-patients-showing-higher-median-overall-survival-in-tp53-mutant-subset/ 2024-06-10 https://bio-research.ai/shattuck-labs-receives-fda-orphan-drug-designation-for-sl-172154-in-acute-myeloid-leukemia-treatment-presents-phase-1b-trial-data-at-european-hematology-association-congress/ 2024-06-10 https://bio-research.ai/oculis-holding-ag-reports-phase-2b-relief-trial-results-of-licaminlimab-indicating-statistical-improvements-in-dry-eye-disease-at-day-43/ 2024-06-10 https://bio-research.ai/moderna-reports-phase-3-trial-of-mrna-1083-meets-primary-endpoints-shows-higher-immune-responses-in-adults-over-50/ 2024-06-10 https://bio-research.ai/kissei-pharmaceutical-licenses-linzagolix-to-jw-pharmaceutical-corporation-for-development-and-commercialization-in-korea/ 2024-06-10 https://bio-research.ai/fda-grants-priority-review-to-astrazeneca-s-snda-for-tagrisso-in-treating-adults-with-unresectable-stage-iii-egfr-mutated-nsclc-post-crt-based-on-laura-phase-iii-trial-results/ 2024-06-10 https://bio-research.ai/4d-molecular-therapeutics-reports-phase-2-prism-clinical-trial-results-for-4d-150-showing-stable-visual-acuity-and-reduced-central-subfield-thickness-in-severe-wet-amd/ 2024-06-08 https://bio-research.ai/eli-lilly-s-synergy-nash-phase-2-trial-of-tirzepatide-meets-primary-endpoint-in-metabolic-dysfunction-associated-steatohepatitis-with-stage-2-or-3-fibrosis/ 2024-06-08 https://bio-research.ai/akero-therapeutics-reports-phase-2b-harmony-study-results-96-week-efx-treatment-shows-higher-fibrosis-improvement-rates-in-mash-with-fibrosis-stage-2-or-3/ 2024-06-08 https://bio-research.ai/scg-cell-therapy-pte-ltd-reports-33-objective-response-rate-in-scg101-t-cell-therapy-trial-for-hbv-related-hepatocellular-carcinoma/ 2024-06-07 https://bio-research.ai/international-isotopes-and-alpha-nuclide-enter-strategic-alliance-to-distribute-and-produce-nuclear-medicine-products-in-china/ 2024-06-07 https://bio-research.ai/chromadex-corp-receives-orphan-drug-and-rare-pediatric-disease-designations-from-fda-for-nrc-aimed-at-ataxia-telangiectasia-treatment-and-plans-ind-filing-to-start-human-clinical-trials-with-guidance-from-dr-vilhelm-bohr/ 2024-06-07 https://bio-research.ai/ipsen-and-marengo-therapeutics-enhance-oncology-research-with-tristar-platform-for-cold-tumor-t-cell-activation-deal-includes-up-to-1-2b-in-milestones-plus-royalties/ 2024-06-07 https://bio-research.ai/brii-biosciences-reports-phase-2-trial-results-of-brii-179-in-combination-with-brii-835-and-added-to-peg-ifn-showing-immune-response-and-hbsag-loss-in-chronic-hbv-patients/ 2024-06-07 https://bio-research.ai/boehringer-ingelheim-s-phase-ii-trial-of-survodutide-demonstrates-improvement-in-fibrosis-in-64-5-of-adults-with-mash-compared-to-placebo-after-48-weeks/ 2024-06-07 https://bio-research.ai/fda-approves-geron-s-rytelo-for-certain-myelodysplastic-syndromes-after-positive-phase-3-trial-results/ 2024-06-06 https://bio-research.ai/barinthus-biotherapeutics-plc-reports-significant-hbsag-reduction-in-im-prove-ii-trial-for-chronic-hepatitis-b-treatment/ 2024-06-06 https://bio-research.ai/cg-oncology-reports-phase-2-trial-results-of-cretostimogene-plus-pembrolizumab-in-nmibc-with-54-complete-response-rate-at-24-months/ 2024-06-06 https://bio-research.ai/cycle-pharmaceuticals-proposes-to-acquire-vanda-pharmaceuticals-for-466m-offering-a-98-premium-over-pre-offer-share-price-and-outbidding-future-pak-llc/ 2024-06-06 https://bio-research.ai/abbvie-s-phase-2-piccolo-trial-of-mirvetuximab-soravtansine-achieves-primary-endpoint-with-51-9-response-rate-in-platinum-sensitive-ovarian-cancer/ 2024-06-06 https://bio-research.ai/gsk-acquires-elsie-biotechnologies-for-up-to-50m-to-boost-oligonucleotide-therapeutic-development-programs/ 2024-06-06 https://bio-research.ai/madrigal-pharmaceuticals-reports-phase-3-maestro-nash-trial-results-for-rezdiffra-with-improvement-in-fibrosis-and-liver-health-over-three-years/ 2024-06-06 https://bio-research.ai/4d-molecular-therapeutics-reports-interim-clinical-data-from-aerow-trial-indicating-lung-function-improvement-in-cystic-fibrosis-patients-plans-phase-2-with-1e15-vg-dose-in-second-half-of-2024/ 2024-06-06 https://bio-research.ai/niaid-commits-1-4m-for-second-year-of-pluri-inc-contract-to-advance-plx-r18-cell-therapy-for-h-ars-complications/ 2024-06-06 https://bio-research.ai/agomab-therapeutics-receives-fda-orphan-drug-designation-for-agmb-447-in-phase-1-trial-for-idiopathic-pulmonary-fibrosis-treatment/ 2024-06-06 https://bio-research.ai/kalvista-pharmaceuticals-reports-phase-3-konfident-trial-results-of-sebetralstat-with-median-treatment-time-of-38-minutes-in-us-subgroup/ 2024-06-06 https://bio-research.ai/replimune-group-reports-a-33-6-overall-response-rate-in-ignyte-clinical-trial-for-rp1-and-nivolumab-combination-in-anti-pd1-failed-melanoma/ 2024-06-06 https://bio-research.ai/sagimet-biosciences-reports-denifanstat-achieves-significant-results-in-phase-2b-trial-for-liver-fibrosis-without-worsening-mash/ 2024-06-06 https://bio-research.ai/alphamab-oncology-and-arrivent-biopharma-sign-collaboration-for-novel-adcs-with-potential-615-5m-deal-and-tiered-royalties/ 2024-06-06 https://bio-research.ai/bluejay-therapeutics-phase-2-study-of-bjt-778-reports-100-virologic-response-at-week-28-in-chronic-hepatitis-d-patients/ 2024-06-05 https://bio-research.ai/harmony-biosciences-phase-2-study-data-indicates-pitolisant-reduced-excessive-daytime-sleepiness-and-fatigue-in-adults-with-myotonic-dystrophy-type-1/ 2024-06-05 https://bio-research.ai/lupin-limited-expands-respiratory-and-gastro-intestinal-portfolio-through-acquisition-of-aarane-and-nalcrom-brands-from-sanofi/ 2024-06-05 https://bio-research.ai/i-mab-and-bristol-myers-squibb-partner-to-evaluate-givastomig-in-phase-1-study-with-nivolumab-for-gastric-and-esophageal-cancer-treatment/ 2024-06-05 https://bio-research.ai/ipsen-s-elative-phase-iii-trial-of-elafibranor-in-primary-biliary-cholangitis-shows-70-of-patients-achieved-progression-slowing-endpoint-after-78-weeks/ 2024-06-05 https://bio-research.ai/vir-biotechnology-reports-phase-2-solstice-trial-outcomes-showing-up-to-100-viral-suppression-and-64-alt-normalization-in-chronic-hepatitis-delta-treatment-with-tobevibart-and-elebsiran/ 2024-06-05 https://bio-research.ai/adicet-bio-receives-fda-fast-track-designation-for-adi-001-in-relapsed-refractory-lupus-nephritis-gears-up-for-phase-1-study/ 2024-06-05 https://bio-research.ai/atea-pharmaceuticals-reports-97-svr12-rate-in-phase-2-hcv-study-with-bemnifosbuvir-and-ruzasvir/ 2024-06-05 https://bio-research.ai/arbutus-biopharma-corporation-reports-phase-2a-trial-outcomes-for-imdusiran-with-ifn-and-nucleos-t-ide-therapy-showing-undetectable-hbsag-in-chronic-hepatitis-b-patients-after-48-weeks/ 2024-06-05 https://bio-research.ai/gilead-sciences-phase-3-assure-study-of-seladelpar-presents-two-year-improvements-in-cholestasis-markers-and-pruritus-reduction-in-pbc-patients-at-european-association-for-the-study-of-the-liver-congress-2024/ 2024-06-05 https://bio-research.ai/bluesphere-bio-and-national-cancer-institute-enter-crada-to-develop-tcr-therapy-for-rare-recurrent-respiratory-papillomatosis/ 2024-06-04 https://bio-research.ai/hightide-therapeutics-presents-phase-2a-study-results-of-htd1801-for-metabolic-dysfunction-associated-steatohepatitis-and-type-2-diabetes-at-european-association-for-the-study-of-the-liver-congress/ 2024-06-04 https://bio-research.ai/excellthera-s-um171-cell-therapy-receives-who-inn-listing-and-additional-fda-orphan-drug-designation-for-enhanced-cell-engraftment-in-stem-cell-transplants/ 2024-06-04 https://bio-research.ai/fda-grants-fast-track-designation-to-lunresertib-and-camonsertib-combo-for-certain-ovarian-and-endometrial-cancers/ 2024-06-04 https://bio-research.ai/be-biopharma-receives-fda-orphan-drug-designation-for-be-101-for-hemophilia-b-treatment-phase-1-2-study-become-9-set-for-second-half-of-2024/ 2024-06-04 https://bio-research.ai/abbvie-secures-u-s-approval-for-rinvoq-to-treat-pediatric-patients-with-active-polyarticular-juvenile-idiopathic-arthritis-and-psoriatic-arthritis-after-inadequate-response-to-tnf-blockers/ 2024-06-04 https://bio-research.ai/bristol-myers-squibb-reports-phase-3-trial-of-opdivo-combined-with-yervoy-extends-overall-survival-to-23-7-months-in-unresectable-hepatocellular-carcinoma-compared-to-20-6-months-with-alternative-treatments/ 2024-06-04 https://bio-research.ai/equillium-inc-reports-phase-2-trial-results-of-eq101-for-alopecia-areata-with-20-of-subjects-achieving-significant-salt-score-reduction-after-24-weeks/ 2024-06-04 https://bio-research.ai/glycomimetics-phase-3-study-of-uproleselan-shows-median-overall-survival-of-31-2-months-in-refractory-aml-patients-compared-to-10-1-months-in-placebo-group/ 2024-06-04 https://bio-research.ai/annexon-inc-phase-3-trial-of-anx005-in-guillain-barr-syndrome-patients-shows-2-4-fold-improvement-on-gbs-disability-scale-at-week-8/ 2024-06-04 https://bio-research.ai/spruce-biosciences-partners-with-hmnc-brain-health-to-develop-tildacerfont-and-cortibon-for-major-depressive-disorder-treatment-with-potential-milestone-payments-and-royalties/ 2024-06-04 https://bio-research.ai/janssen-cilag-international-nv-reports-phase-3-cartitude-4-study-results-showing-ciltacabtagene-autoleucel-improves-progression-free-survival-in-lenalidomide-refractory-multiple-myeloma-after-one-prior-therapy/ 2024-06-03 https://bio-research.ai/janssen-cilag-international-nv-reports-phase-3-perseus-study-outcomes-with-88-percent-of-multiple-myeloma-patients-achieving-complete-response-and-maia-study-shows-7-5-years-median-overall-survival/ 2024-06-03 https://bio-research.ai/ladrx-regains-control-of-aldoxorubicin-as-agreement-with-nantcell-and-immunitybio-ends-xoma-revises-deal-to-receive-synthetic-royalties-and-a-percentage-of-future-licensing-transactions/ 2024-06-03 https://bio-research.ai/sanofi-s-sarclisa-combination-reduces-risk-of-multiple-myeloma-disease-progression-or-death-by-40-in-phase-3-trial/ 2024-06-03 https://bio-research.ai/bristol-myers-squibb-reports-three-year-data-from-breyanzi-phase-3-transform-study-showing-improved-event-free-and-progression-free-survival-in-large-b-cell-lymphoma/ 2024-06-03 https://bio-research.ai/fibrogen-and-regeneron-collaborate-to-assess-cancer-antibodies-in-combination-with-anti-pd-1-therapy-libtayo-in-phase-1-trials-for-solid-tumors/ 2024-06-03 https://bio-research.ai/stryker-to-acquire-artelon-enhancing-soft-tissue-fixation-portfolio-for-foot-ankle-and-sports-medicine-procedures/ 2024-06-03 https://bio-research.ai/aurobac-therapeutics-partners-with-boehringer-ingelheim-biom-rieux-and-evotec-for-atx101-development-in-septic-shock-treatment/ 2024-06-03 https://bio-research.ai/arrowhead-pharmaceuticals-announces-phase-3-results-for-plozasiran-with-reductions-in-triglycerides-and-apoc3-at-month-10-lower-incidence-of-acute-pancreatitis-in-fcs-treatment/ 2024-06-03 https://bio-research.ai/moderna-and-merck-report-phase-2b-study-results-mrna-4157-with-keytruda-reduces-risk-of-melanoma-recurrence-or-death-by-49/ 2024-06-03 https://bio-research.ai/medicenna-therapeutics-corp-reports-phase-2b-trial-results-of-bizaxofusp-improving-median-overall-survival-to-13-5-months-in-recurrent-glioblastoma-patients/ 2024-06-03 https://bio-research.ai/uniqure-s-gene-therapy-amt-130-for-huntington-s-disease-receives-rmat-designation-from-u-s-fda-based-on-interim-phase-i-ii-clinical-data/ 2024-06-03 https://bio-research.ai/treos-bio-limited-reports-phase-2-oberto-301-study-results-polypepi1018-with-atezolizumab-yields-median-overall-survival-of-12-8-months-in-mss-mcrc/ 2024-06-03 https://bio-research.ai/takeda-reports-phase-2b-trial-results-of-tak-861-demonstrating-improvements-in-sleep-latency-and-cataplexy-frequency-in-narcolepsy-type-1-over-8-weeks/ 2024-06-03 https://bio-research.ai/bayer-ag-partners-with-samsung-electronics-america-to-launch-an-observational-study-on-sleep-disturbances-during-menopause-using-wearable-technology/ 2024-06-03 https://bio-research.ai/agios-pharmaceuticals-announces-phase-3-energize-t-study-of-mitapivat-meets-primary-endpoint-in-adults-with-transfusion-dependent-alpha-or-beta-thalassemia/ 2024-06-03 https://bio-research.ai/ideaya-biosciences-reports-phase-2-trial-results-of-darovasertib-in-uveal-melanoma-with-75-eye-preservation-rate-and-67-showing-significant-tumor-shrinkage/ 2024-06-03 https://bio-research.ai/deciphera-pharmaceuticals-reports-phase-3-study-of-vimseltinib-meets-primary-endpoint-with-40-orr-in-treating-tenosynovial-giant-cell-tumor/ 2024-06-03 https://bio-research.ai/eli-lilly-and-quralis-forge-exclusive-license-agreement-for-als-and-ftd-therapy-qrl-204-with-45m-upfront-payment-up-to-577m-in-milestones-and-royalties/ 2024-06-03 https://bio-research.ai/genome-company-enters-426m-licensing-deal-with-debiopharm-for-cancer-targeting-adc-gena-111-with-milestone-payments-and-global-development-rights/ 2024-06-03 https://bio-research.ai/immutep-and-msd-collaborate-to-conduct-phase-iii-trial-of-eftilagimod-alfa-and-keytruda-in-first-line-treatment-of-metastatic-non-small-cell-lung-cancer/ 2024-06-02 https://bio-research.ai/gsk-s-dreamm-8-phase-iii-trial-demonstrates-blenrep-combination-extends-progression-free-survival-in-relapsed-or-refractory-multiple-myeloma/ 2024-06-02 https://bio-research.ai/takeda-s-recombinant-adamts13-recommended-by-ema-s-chmp-for-adamts13-deficiency-treatment-in-cttp-patients-awaits-european-commission-decision/ 2024-05-31 https://bio-research.ai/novartis-phase-iii-asc4first-trial-reveals-scemblix-achieves-higher-mmr-rates-than-standard-of-care-tyrosine-kinase-inhibitors-in-chronic-myeloid-leukemia/ 2024-05-31 https://bio-research.ai/fda-sets-pdufa-date-for-iterum-therapeutics-resubmitted-nda-of-oral-sulopenem-after-reassure-trial-results-in-uncomplicated-urinary-tract-infections/ 2024-05-31 https://bio-research.ai/chmp-recommends-approval-of-risankizumab-for-adults-with-moderately-to-severely-active-ulcerative-colitis-based-on-phase-3-trial-results/ 2024-05-31 https://bio-research.ai/ionis-pharmaceuticals-reports-phase-3-oasis-hae-and-oasisplus-studies-show-reduction-in-monthly-attack-rates-for-hereditary-angioedema-with-donidalorsen/ 2024-05-31 https://bio-research.ai/european-commission-approves-biogen-s-qalsody-for-treatment-of-als-with-sod1-gene-mutation/ 2024-05-30 https://bio-research.ai/adaptimmune-and-galapagos-partner-to-evaluate-mage-a4-tcr-therapy-uza-cel-in-head-neck-cancer-using-a-decentralized-manufacturing-platform/ 2024-05-30 https://bio-research.ai/elevar-therapeutics-reports-phase-3-cares-310-study-results-camrelizumab-and-rivoceranib-combination-extends-median-overall-survival-to-23-8-months-in-unresectable-hepatocellular-carcinoma-compared-to-15-2-months-with-sorafenib/ 2024-05-30 https://bio-research.ai/xeris-biopharma-holdings-reveals-phase-2-trial-results-for-xp-8121-indicating-normalized-tsh-t4-levels-with-45-reduced-dosage-compared-to-oral-levothyroxine/ 2024-05-30 https://bio-research.ai/fda-grants-orphan-drug-designation-to-candel-therapeutics-can-3110-for-recurrent-high-grade-glioma-treatment-phase-1b-trials-to-assess-multiple-dose-safety-with-findings-to-be-revealed-at-2024-asco-annual-meeting/ 2024-05-30 https://bio-research.ai/bayer-ag-and-bluerock-therapeutics-report-fda-rmat-designation-for-bemdaneprocel-in-parkinson-s-disease-with-phase-i-trial-indicating-tolerance-and-cellular-survival-in-the-brain/ 2024-05-30 https://bio-research.ai/anocca-ab-collaborates-with-shinobi-therapeutics-to-develop-allogeneic-tcr-engineered-ips-t-cell-therapies-for-solid-tumors/ 2024-05-30 https://bio-research.ai/teva-pharmaceuticals-announces-fda-approval-of-austedo-xr-for-treatment-of-tardive-dyskinesia-and-huntington-s-disease-chorea-in-adults/ 2024-05-29 https://bio-research.ai/vbi-vaccines-inc-reports-interim-phase-2b-trial-results-for-vbi-1901-in-recurrent-glioblastoma-with-43-disease-control-rate/ 2024-05-29 https://bio-research.ai/huidagene-therapeutics-licenses-high-fidelity-cas12-crispr-nuclease-to-synthego-corporation-for-research-and-therapeutic-applications/ 2024-05-29 https://bio-research.ai/fda-approves-tris-pharma-s-onyda-xr-as-first-liquid-adhd-medication-for-pediatric-patients/ 2024-05-29 https://bio-research.ai/johnson-johnson-s-phase-3-trial-of-seltorexant-achieves-primary-and-secondary-endpoints-for-major-depressive-disorder-with-insomnia/ 2024-05-29 https://bio-research.ai/boan-biotech-s-denosumab-injection-boluojia-approved-by-china-s-national-medical-products-administration-for-treatment-of-unresectable-giant-cell-tumor-of-bone/ 2024-05-29 https://bio-research.ai/jaguar-health-expands-out-licensing-agreement-with-magdalena-biosciences-for-botanical-drug-candidate-development-in-potential-schizophrenia-market-projected-to-grow-to-8-06b-by-2030/ 2024-05-29 https://bio-research.ai/fda-grants-priority-review-to-merck-s-sbla-for-keytruda-combined-with-chemotherapy-in-unresectable-advanced-or-metastatic-malignant-pleural-mesothelioma/ 2024-05-29 https://bio-research.ai/fda-grants-priority-review-to-zanidatamab-for-her2-positive-biliary-tract-cancer-based-on-phase-2b-trial-results-pdufa-date-set-for-november-2024/ 2024-05-29 https://bio-research.ai/european-commission-approves-bristol-myers-squibb-s-opdivo-with-cisplatin-and-gemcitabine-for-first-line-treatment-of-adult-patients-with-unresectable-or-metastatic-urothelial-carcinoma-based-on-checkmate-901-trial-results/ 2024-05-29 https://bio-research.ai/foundation-medicine-and-pmv-pharmaceuticals-collaborate-on-foundationone-cdx-for-rezatapopt-companion-diagnostic-in-tp53-y220c-mutant-solid-tumors/ 2024-05-29 https://bio-research.ai/merck-to-acquire-eyebio-for-up-to-3b-advancing-restoret-for-diabetic-macular-edema-and-age-related-macular-degeneration-with-pivotal-study-slated-for-h2-2024/ 2024-05-29 https://bio-research.ai/astrazeneca-s-phase-i-trial-of-azd0780-reports-52-ldl-c-level-reduction-in-hypercholesterolemia-patients-with-well-tolerated-safety-profile/ 2024-05-29 https://bio-research.ai/cellectar-biosciences-and-city-of-hope-partner-to-evaluate-iopofosine-i-131-in-treating-mycosis-fungoides-in-investigator-sponsored-trial/ 2024-05-29 https://bio-research.ai/rocket-pharmaceuticals-secures-orphan-medicinal-product-designation-from-european-commission-for-rp-a601-in-arrhythmogenic-cardiomyopathy-treatment/ 2024-05-29 https://bio-research.ai/fda-grants-fast-track-designation-to-afm24-and-atezolizumab-combination-for-advanced-metastatic-nsclc-without-egfr-mutations-after-standard-therapy-progression/ 2024-05-29 https://bio-research.ai/alentis-therapeutics-receives-fda-orphan-drug-designation-for-lixudebart-in-idiopathic-pulmonary-fibrosis-treatment-reports-completion-of-ind-enabling-studies-and-progresses-with-clinical-trials/ 2024-05-29 https://bio-research.ai/fda-grants-priority-review-to-genentech-s-inavolisib-with-palbociclib-and-fulvestrant-for-treating-pik3ca-mutated-hr-positive-her2-negative-advanced-breast-cancer-with-a-decision-date-of-november-27-2024/ 2024-05-28 https://bio-research.ai/iliad-biotechnologies-phase-2b-trial-of-bpze1-pertussis-vaccine-shows-mucosal-immunity-and-safe-co-administration-with-tdap-in-366-school-age-children/ 2024-05-28 https://bio-research.ai/corcept-therapeutics-phase-3-grace-trial-of-relacorilant-achieves-primary-endpoint-with-significant-blood-pressure-control-in-cushing-s-syndrome-patients/ 2024-05-28 https://bio-research.ai/bristol-myers-squibb-exercises-option-for-neurodegenerative-therapy-prx019-from-prothena-with-potential-milestones-worth-up-to-697-5m/ 2024-05-28 https://bio-research.ai/fda-grants-fast-track-designation-to-av-001-for-ards-treatment-developed-by-vasomune-therapeutics-in-partnership-with-anges-inc/ 2024-05-28 https://bio-research.ai/european-commission-authorizes-lytenava-for-treatment-of-wet-age-related-macular-degeneration-in-the-eu/ 2024-05-28 https://bio-research.ai/vera-therapeutics-atacicept-receives-fda-breakthrough-therapy-designation-for-iga-nephropathy-as-phase-2b-origin-trial-meets-primary-and-key-secondary-endpoints/ 2024-05-28 https://bio-research.ai/johnson-johnson-to-acquire-numab-therapeutics-subsidiary-yellow-jersey-therapeutics-for-1-25b-securing-global-rights-to-phase-2-ready-antibody-nm26-for-atopic-dermatitis/ 2024-05-28 https://bio-research.ai/hanall-biopharma-secures-exclusive-rights-to-turn-biotechnologies-era-technology-for-ophthalmic-and-otic-disease-treatments-in-a-deal-worth-up-to-300m/ 2024-05-28 https://bio-research.ai/merus-n-v-reports-67-response-rate-in-phase-1-2-trial-of-petosemtamab-with-pembrolizumab-for-first-line-head-and-neck-cancer/ 2024-05-28 https://bio-research.ai/insmed-incorporated-s-brensocatib-meets-primary-endpoint-in-phase-3-aspen-study-for-bronchiectasis-with-reduced-rate-of-pulmonary-exacerbations/ 2024-05-28 https://bio-research.ai/merck-s-keynote-522-phase-3-trial-meets-overall-survival-endpoint-in-high-risk-early-stage-triple-negative-breast-cancer-with-keytruda-and-chemotherapy/ 2024-05-28 https://bio-research.ai/agios-pharmaceuticals-to-sell-vorasidenib-royalty-rights-to-royalty-pharma-for-905m-upfront-and-retains-milestone-and-limited-sales-royalties-in-deal-with-servier/ 2024-05-28 https://bio-research.ai/arrowhead-pharmaceuticals-reports-phase-2b-muir-study-outcomes-with-plozasiran-reducing-triglycerides-and-cholesterol-levels-at-week-24/ 2024-05-28 https://bio-research.ai/asahi-kasei-corporation-announces-sek-11-164b-bid-for-calliditas-therapeutics/ 2024-05-28 https://bio-research.ai/innovent-biologics-reports-picankibart-reaches-90-improvement-in-psoriasis-severity-score-in-phase-3-trial-in-china/ 2024-05-28 https://bio-research.ai/ns-pharma-reports-phase-3-trial-of-viltolarsen-in-duchenne-muscular-dystrophy-fails-to-meet-primary-endpoint/ 2024-05-27 https://bio-research.ai/cstone-pharmaceuticals-strikes-a-deal-with-ewopharma-to-launch-sugemalimab-in-central-eastern-europe-and-switzerland-for-up-to-51-3m/ 2024-05-27 https://bio-research.ai/astrazeneca-and-daiichi-sankyo-s-phase-iii-tropion-lung01-trial-of-datopotamab-deruxtecan-meets-progression-free-survival-endpoint-in-nonsquamous-nsclc-overall-survival-improvement-not-statistically-significant/ 2024-05-27 https://bio-research.ai/medilink-therapeutics-and-biontech-forge-1-8b-adc-partnership-with-exclusive-global-licensing-rights-and-potential-royalties/ 2024-05-27 https://bio-research.ai/alebund-pharmaceuticals-reports-phase-2-study-results-of-ap306-with-reduction-in-serum-phosphate-levels-in-hemodialysis-patients/ 2024-05-27 https://bio-research.ai/human-immunology-biosciences-announces-phase-2-trial-results-of-felzartamab-with-82-resolution-of-amr-in-kidney-transplant-recipients-at-24-weeks/ 2024-05-25 https://bio-research.ai/novartis-phase-iii-align-study-reports-a-36-1-reduction-in-proteinuria-with-atrasentan-in-iga-nephropathy-patients/ 2024-05-25 https://bio-research.ai/novartis-phase-iii-appear-c3g-study-of-fabhalta-demonstrates-reduction-in-proteinuria-and-improved-kidney-function-in-c3g-patients/ 2024-05-25 https://bio-research.ai/briacell-therapeutics-corp-reports-phase-2-study-results-of-bria-imt-with-median-progression-free-survival-of-4-1-months-and-9-5-overall-response-rate-in-advanced-metastatic-breast-cancer/ 2024-05-24 https://bio-research.ai/sobi-and-apellis-pharmaceuticals-report-one-year-phase-2-noble-study-results-of-pegcetacoplan-with-55-complete-c3c-clearance-in-c3-glomerulopathy-and-immune-complex-membranoproliferative-glomerulonephritis-post-transplant/ 2024-05-24 https://bio-research.ai/cg-oncology-reports-phase-2-core-001-trial-results-of-cretostimogene-and-pembrolizumab-for-high-risk-bladder-cancer-54-complete-response-rate-over-21-months-median-duration-of-response-100-progression-free-survival-at-24-months/ 2024-05-24 https://bio-research.ai/verastem-oncology-initiates-rolling-submission-of-drug-application-to-fda-for-avutometinib-and-defactinib-in-recurrent-low-grade-serous-ovarian-cancer-treatment/ 2024-05-24 https://bio-research.ai/european-commission-approves-celltrion-s-omlyclo-an-omalizumab-biosimilar-based-on-phase-iii-trial-results-showing-comparable-efficacy-and-safety-to-xolair/ 2024-05-24 https://bio-research.ai/fosun-pharma-releases-phase-2-trial-results-for-fs-1502-in-her2-high-expressing-gastric-cancer-with-26-1-experiencing-high-grade-adverse-events/ 2024-05-24 https://bio-research.ai/oricell-therapeutics-reports-phase-i-oricar-017-study-results-with-100-overall-response-rate-in-relapsed-refractory-multiple-myeloma-patients/ 2024-05-24 https://bio-research.ai/transcenta-holding-limited-reports-median-progression-free-survival-of-12-6-months-in-phase-i-iia-trial-of-osemitamab-plus-nivolumab-and-capox-for-g-gej-cancer-with-high-or-medium-cldn18-2-expression/ 2024-05-24 https://bio-research.ai/zealand-pharma-reports-dapiglutide-leads-to-2-9-and-4-3-weight-loss-in-dream-trial-participants-at-4-and-6-mg-doses-compared-to-2-2-with-placebo/ 2024-05-23 https://bio-research.ai/orna-therapeutics-acquires-renagade-therapeutics-appoints-amit-munshi-as-ceo-and-boosts-rna-based-therapy-development-with-100m-series-a-and-221m-series-b-by-orna-alongside-renagade-s-300m-series-a-financing/ 2024-05-23 https://bio-research.ai/providence-therapeutics-and-ontario-institute-for-cancer-research-partner-to-develop-mrna-cancer-therapies-with-priority-access-for-canadian-patients/ 2024-05-23 https://bio-research.ai/theriva-biologics-receives-fast-track-designation-from-fda-for-vcn-01-in-combination-with-chemotherapy-for-metastatic-pancreatic-adenocarcinoma-virage-phase-2b-trial-underway/ 2024-05-23 https://bio-research.ai/icell-gene-therapeutics-clinical-trial-results-for-bcma-cd19-ccar-t-cell-therapy-in-13-systemic-lupus-erythematosus-patients-indicate-remission-up-to-46-months-and-autoantibody-negative-status-in-12-participants/ 2024-05-23 https://bio-research.ai/european-medicines-agency-reviews-camurus-s-market-authorisation-application-for-octreotide-sc-depot-in-acromegaly-treatment-based-on-seven-clinical-trials-data/ 2024-05-23 https://bio-research.ai/spybiotech-and-the-university-of-oxford-partner-to-initiate-phase-i-trial-for-epstein-barr-virus-vaccine-using-spyvlp-platform-with-support-from-oxford-science-enterprises-and-google-ventures-after-raising-32-5m-in-series-a-funding/ 2024-05-23 https://bio-research.ai/delsitech-strikes-a-deal-with-unidentified-global-pharma-for-long-acting-injectable-using-silica-matrix-tech-scoring-9m-upfront-and-potential-200m-in-milestones-plus-sales-royalties/ 2024-05-23 https://bio-research.ai/nona-biosciences-licenses-monoclonal-antibodies-to-astrazeneca-in-a-potential-594m-oncology-treatment-deal/ 2024-05-23 https://bio-research.ai/sanofi-s-phase-2-study-of-rilzabrutinib-demonstrates-a-36-and-25-risk-reduction-in-asthma-control-events-at-different-doses/ 2024-05-22 https://bio-research.ai/exavir-therapeutics-inks-licensing-deal-with-viiv-healthcare-to-develop-ultra-long-acting-hiv-drugs-with-upfront-and-milestone-payments-plus-royalties/ 2024-05-22 https://bio-research.ai/biogen-to-acquire-human-immunology-biosciences-for-1-15b-with-additional-650m-milestone-based-agreements-advancing-felzartamab-in-rare-disease-treatments/ 2024-05-22 https://bio-research.ai/cartesian-therapeutics-descartes-08-receives-rmat-designation-from-fda-for-myasthenia-gravis-treatment-and-progresses-to-phase-2b-trial-with-topline-data-expected-by-mid-2024/ 2024-05-22 https://bio-research.ai/ose-immunotherapeutics-and-boehringer-ingelheim-expand-partnership-with-13-5m-upfront-maintaining-previously-agreed-upon-potential-1-1b-milestones-in-anti-sirp-cancer-and-cardio-renal-metabolic-programs/ 2024-05-22 https://bio-research.ai/achilles-therapeutics-and-arcturus-therapeutics-collaborate-to-develop-personalized-cancer-vaccines-in-pre-clinical-ind-enabling-studies-targeting-clonal-neoantigens/ 2024-05-22 https://bio-research.ai/g1-therapeutics-and-deimos-biosciences-strike-global-licensing-deal-for-lerociclib-granting-jupiter-bioventures-exclusive-rights-for-non-asia-pacific-markets-with-equity-and-royalty-terms/ 2024-05-22 https://bio-research.ai/active-biotech-secures-exclusive-rights-from-wistar-institute-for-tasquinimod-in-multiple-myeloma-therapy-agreeing-to-low-single-digit-royalties-on-sales-and-partnership-income/ 2024-05-22 https://bio-research.ai/citius-pharmaceuticals-reports-phase-3-trial-of-mino-lok-meets-primary-endpoint-with-significant-difference-in-catheter-failure-events/ 2024-05-21 https://bio-research.ai/fda-grants-fast-track-designation-to-ractigen-therapeutics-rag-01-for-treatment-of-non-muscle-invasive-bladder-cancer/ 2024-05-21 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-larsucosterol-for-severe-alcohol-associated-hepatitis-based-on-phase-2b-ahfirm-trial-results-ahead-of-phase-3-clinical-trial/ 2024-05-21 https://bio-research.ai/johnson-johnson-announces-phase-3-results-for-tremfya-in-crohn-s-disease-reporting-superior-efficacy-to-placebo-and-ustekinumab-in-galaxi-studies/ 2024-05-21 https://bio-research.ai/eupraxia-pharmaceuticals-phase-1b-2a-resolve-trial-of-ep-104gi-shows-sustained-symptom-improvement-and-eosinophil-count-reduction-in-eosinophilic-esophagitis-over-24-weeks/ 2024-05-21 https://bio-research.ai/rezolute-inc-reports-phase-2-study-of-rz402-achieves-primary-endpoints-in-diabetic-macular-edema-with-significant-cst-reduction-and-comparable-safety-to-placebo/ 2024-05-21 https://bio-research.ai/eli-lilly-s-phase-3-vivid-1-study-shows-50-of-crohn-s-disease-patients-achieve-endoscopic-response-with-mirikizumab-at-52-weeks/ 2024-05-21 https://bio-research.ai/aktis-oncology-and-eli-lilly-collaborate-on-new-tumor-targeting-radiopharmaceuticals-with-a-60m-upfront-payment-and-up-to-1-1b-in-milestone-potential-plus-royalties/ 2024-05-21 https://bio-research.ai/alvotech-and-dr-reddy-s-laboratories-strike-a-deal-for-avt03-biosimilar-with-exclusive-rights-in-the-u-s-and-semi-exclusive-rights-in-europe-and-uk/ 2024-05-21 https://bio-research.ai/jacobio-pharma-s-nda-for-kras-g12c-inhibitor-glecirasib-accepted-by-china-s-cde-for-priority-review-in-nsclc-patients-with-kras-g12c-mutation-after-phase-ii-trial-results-show-47-9-objective-response-rate/ 2024-05-21 https://bio-research.ai/contera-pharma-s-phase-iib-trial-of-jm-010-fails-to-meet-primary-endpoint-in-parkinson-s-disease-dyskinesia-study/ 2024-05-21 https://bio-research.ai/gsk-s-phase-iii-clinical-trials-of-depemokimab-demonstrate-reduced-severe-asthma-exacerbations-over-52-weeks/ 2024-05-21 https://bio-research.ai/glenmark-pharmaceuticals-inks-exclusive-deal-with-beigene-to-market-tislelizumab-and-zanubrutinib-cancer-therapies-in-india/ 2024-05-21 https://bio-research.ai/biocon-biologics-secures-us-fda-approval-for-biosimilar-aflibercept-yesafili-for-ophthalmologic-conditions-with-plans-for-canadian-launch-by-july-2025/ 2024-05-21 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-genentech-s-inavolisib-for-advanced-breast-cancer-treatment-following-phase-iii-inavo120-trial-results-showing-doubled-progression-free-survival/ 2024-05-20 https://bio-research.ai/cantex-pharmaceuticals-granted-fda-orphan-drug-designation-for-azeliragon-in-pancreatic-cancer-treatment-expands-previous-glioblastoma-designation/ 2024-05-20 https://bio-research.ai/aprinoia-therapeutics-apn-1607-receives-fast-track-designation-from-fda-for-the-diagnosis-of-progressive-supranuclear-palsy-and-advances-to-phase-3-trial-in-alzheimer-s-diagnosis-in-china/ 2024-05-20 https://bio-research.ai/dana-farber-cancer-institute-and-effector-therapeutics-partner-for-zotatifin-trial-in-er-endometrial-and-low-grade-serous-ovarian-cancers-led-by-dr-panagiotis-konstantinopoulos/ 2024-05-20 https://bio-research.ai/taimed-grants-orient-europharma-exclusive-license-for-trogarzo-in-taiwan-enhancing-hiv-treatment-reach/ 2024-05-20 https://bio-research.ai/vicore-pharma-holding-ab-reports-phase-2a-air-trial-results-with-216-ml-increase-in-fvc-for-buloxibutid-in-idiopathic-pulmonary-fibrosis-treatment/ 2024-05-20 https://bio-research.ai/arecor-therapeutics-reports-phase-i-trial-success-with-at278-achieving-primary-and-secondary-endpoints-in-type-2-diabetes/ 2024-05-20 https://bio-research.ai/european-commission-requests-re-evaluation-of-translarna-following-chmp-s-negative-opinion-while-ptc-therapeutics-suspends-2024-revenue-guidance-due-to-authorization-uncertainties/ 2024-05-20 https://bio-research.ai/esperion-and-otsuka-pharmaceutical-report-phase-3-trial-success-with-bempedoic-acid-showing-reduction-in-ldl-c-levels-in-hypercholesterolemia-patients-in-japan/ 2024-05-20 https://bio-research.ai/gilead-sciences-reports-seladelpar-improves-markers-of-cholestasis-in-70-of-pbc-patients-in-assure-study/ 2024-05-18 https://bio-research.ai/ferring-pharmaceuticals-beyond-trial-shows-1-3-more-oocytes-retrieved-with-follitropin-delta-in-first-ivf-icsi-cycles-using-gnrh-agonist-protocol-compared-to-antagonist-protocol/ 2024-05-17 https://bio-research.ai/fda-grants-accelerated-approval-to-amgen-s-imdelltra-for-treating-extensive-stage-small-cell-lung-cancer-after-platinum-based-chemotherapy-failure-based-on-dellphi-301-trial-results/ 2024-05-16 https://bio-research.ai/bayer-reports-phase-iii-trials-of-elinzanetant-reduce-severity-of-menopausal-symptoms-and-improve-sleep-seeking-marketing-authorizations/ 2024-05-16 https://bio-research.ai/pharmaust-limited-granted-orphan-drug-designation-by-us-fda-for-monepantel-in-motor-neurone-disease-amyotrophic-lateral-sclerosis-treatment/ 2024-05-16 https://bio-research.ai/erasca-inks-deals-with-joyo-pharmatech-and-medshine-discovery-for-preclinical-ras-programs-eras-0015-and-eras-4001-with-up-to-336-5m-in-milestone-payments-and-royalties/ 2024-05-16 https://bio-research.ai/nuvalent-s-nvl-655-receives-breakthrough-therapy-designation-from-fda-for-alk-positive-non-small-cell-lung-cancer-after-two-prior-alk-inhibitor-treatments/ 2024-05-16 https://bio-research.ai/johnson-johnson-to-acquire-proteologix-for-850m-with-additional-milestones-bolstering-immunotherapy-pipeline-with-px128-and-px130-for-ad-and-asthma/ 2024-05-16 https://bio-research.ai/totus-medicines-teams-up-with-eli-lilly-on-small-molecule-candidates-leveraging-omnidel-platform-in-milestone-based-deal/ 2024-05-16 https://bio-research.ai/ionis-pharmaceuticals-and-biogen-halt-development-of-biib105-in-phase-1-2-alspire-study-due-to-lack-of-neurofilament-light-chain-reduction-in-als/ 2024-05-16 https://bio-research.ai/arvinas-inc-and-pfizer-inc-report-phase-1b-trial-results-of-vepdegestrant-with-palbociclib-in-er-her2-advanced-breast-cancer-showing-63-clinical-benefit-rate-41-9-overall-response-rate-and-median-progression-free-survival-of-11-2-months/ 2024-05-16 https://bio-research.ai/sol-gel-technologies-strikes-a-deal-with-shenzhen-beimei-pharmaceutical-for-twyneo-commercialization-in-asia-and-israel-with-up-to-15m-in-payments/ 2024-05-16 https://bio-research.ai/ionis-pharmaceuticals-announces-ion582-safe-and-well-tolerated-in-halos-phase-1-2a-study-for-angelman-syndrome-plans-pivotal-trial-after-observed-improvements-in-cognitive-and-motor-functions/ 2024-05-16 https://bio-research.ai/astrazeneca-s-phase-iii-supernova-trial-of-sipavibart-shows-reduced-symptomatic-covid-19-in-immunocompromised-patients-with-a-relative-risk-reduction-for-sars-cov-2-infections-without-the-f456l-mutation/ 2024-05-16 https://bio-research.ai/genentech-s-phase-ib-trial-of-ct-388-achieves-18-8-mean-placebo-adjusted-weight-loss-in-obesity-and-type-2-diabetes-treatment-over-24-weeks/ 2024-05-15 https://bio-research.ai/barda-partners-with-mapp-biopharmaceutical-to-advance-mbp091-monoclonal-antibody-for-marburg-virus-securing-fda-ind-submissions-and-aiming-for-bla-approval/ 2024-05-15 https://bio-research.ai/bristol-myers-squibb-receives-accelerated-fda-approval-for-breyanzi-in-adult-patients-with-relapsed-or-refractory-follicular-lymphoma-after-two-or-more-lines-of-systemic-therapy-based-on-transcend-fl-trial-results/ 2024-05-15 https://bio-research.ai/galapagos-nv-partners-with-blood-centers-of-america-for-decentralized-manufacturing-of-car-t-cell-therapies-to-enhance-u-s-clinical-programs-in-hemato-oncology/ 2024-05-15 https://bio-research.ai/vanda-pharmaceuticals-reports-phase-iii-study-results-of-tradipitant-with-significant-reduction-in-vomiting-during-motion-sickness/ 2024-05-15 https://bio-research.ai/aulos-bioscience-partners-with-merck-kgaa-s-ares-trading-s-a-to-evaluate-au-007-in-combination-with-bavencio-and-aldesleukin-in-a-phase-2-cancer-study/ 2024-05-15 https://bio-research.ai/insphero-ag-secures-exclusive-global-rights-to-commercialize-genome-biologics-3d-cardiac-organoid-platform-enhancing-preclinical-model-accuracy-for-heart-diseases/ 2024-05-15 https://bio-research.ai/ms-pharma-secures-exclusive-rights-for-fyb203-aflibercept-with-klinge-biopharma-for-mena-region-launch-localizes-production-in-saudi-arabia-biosimilars-site/ 2024-05-15 https://bio-research.ai/olema-pharmaceuticals-reports-interim-results-from-phase-1b-2-study-of-palazestrant-with-ribociclib-showing-85-clinical-benefit-rate-in-er-her2-metastatic-breast-cancer/ 2024-05-15 https://bio-research.ai/medincell-phase-3-trial-of-f14-in-post-total-knee-replacement-does-not-meet-primary-endpoint-shows-improved-knee-motion-and-reduced-swelling-in-a-specific-patient-sub-group/ 2024-05-14 https://bio-research.ai/moffitt-cancer-center-and-fulgent-pharma-forge-strategic-partnership-to-accelerate-personalized-cancer-therapy-development-using-nanoencapsulation-technology-and-genomics-platforms/ 2024-05-14 https://bio-research.ai/curis-inc-reports-expanded-clinical-trial-data-for-emavusertib-in-relapsed-refractory-acute-myeloid-leukemia-with-observed-objective-responses-in-flt3-and-u2af1-sf3b1-mutation-cohorts/ 2024-05-14 https://bio-research.ai/nykode-therapeutics-asa-joins-forces-with-msd-to-launch-phase-2-trial-of-vb10-16-and-keytruda-in-hpv16-positive-cervical-cancer/ 2024-05-14 https://bio-research.ai/pliant-therapeutics-reports-bexotegrast-reduces-lung-collagen-improves-fvc-in-12-week-phase-2-trial-for-ipf/ 2024-05-14 https://bio-research.ai/enveric-biosciences-to-out-license-novel-psilocin-prodrugs-to-mindbio-therapeutics-with-potential-deals-up-to-66-5m-plus-royalties/ 2024-05-14 https://bio-research.ai/fda-issues-complete-response-letter-to-dynavax-for-heplisav-b-supplemental-application-due-to-insufficient-data-from-compromised-phase-1-study-in-hemodialysis-patients/ 2024-05-14 https://bio-research.ai/shionogi-s-phase-3-scorpio-hr-study-of-ensitrelvir-fails-primary-endpoint-in-non-hospitalized-covid-19-patients-despite-reduced-viral-rna-levels/ 2024-05-13 https://bio-research.ai/ascendis-pharma-a-s-reveals-2-year-phase-3-pathway-trial-results-with-transcon-pth-improving-renal-function-in-chronic-hypoparathyroidism/ 2024-05-13 https://bio-research.ai/outlook-therapeutics-seeks-mhra-authorization-for-ons-5010-lytenava-to-treat-wet-age-related-macular-degeneration-following-european-medicines-agency-committee-opinion/ 2024-05-13 https://bio-research.ai/abbvie-and-gilgamesh-pharmaceuticals-partner-to-develop-novel-neuroplastogens-for-psychiatric-disorders-with-potential-deal-worth-up-to-1-95b-plus-65m-upfront-and-tiered-royalties/ 2024-05-13 https://bio-research.ai/reneo-pharmaceuticals-and-onkure-announce-all-stock-merger-to-form-onkure-therapeutics-with-65m-pipe-financing-and-120m-cash-resources-projected-to-last-until-q4-2026/ 2024-05-13 https://bio-research.ai/merus-n-v-receives-fda-breakthrough-therapy-designation-for-petosemtamab-in-hnscc-after-platinum-based-chemotherapy-and-anti-pd-1-pd-l1-antibody-treatment-failure/ 2024-05-13 https://bio-research.ai/bridgebio-pharma-s-phase-3-attribute-cm-study-of-acoramidis-reports-reduction-in-all-cause-mortality-and-improved-health-related-quality-of-life-in-attr-cm-patients/ 2024-05-13 https://bio-research.ai/aldevron-and-acuitas-therapeutics-partner-to-enhance-mrna-lipid-nanoparticle-encapsulation-services/ 2024-05-13 https://bio-research.ai/scandion-oncology-reports-phase-ib-trial-results-of-sco-101-with-chemotherapy-for-advanced-pancreatic-cancer-maximal-tolerated-dose-6-7-response-rate-and-median-survival-data/ 2024-05-13 https://bio-research.ai/tiziana-life-sciences-seeks-fda-orphan-drug-designation-for-foralumab-to-treat-secondary-progressive-multiple-sclerosis/ 2024-05-13 https://bio-research.ai/fulcrum-therapeutics-and-sanofi-forge-1-055b-deal-on-losmapimod-for-fshd-sharing-global-development-costs-and-splitting-commercial-rights/ 2024-05-13 https://bio-research.ai/takeda-obtains-exclusive-option-for-ac-immune-s-alzheimer-s-therapy-aci-24-060-with-potential-deal-value-up-to-2-1b-and-double-digit-royalties-upon-commercialization/ 2024-05-13 https://bio-research.ai/valneva-se-reports-phase-3-trial-of-ixchiq-vaccine-demonstrates-sustained-immune-response-in-adolescents-six-months-after-chikungunya-vaccination/ 2024-05-13 https://bio-research.ai/immix-biopharma-reports-92-response-rate-in-phase-1b-2a-study-of-nxc-201-in-relapsed-refractory-al-amyloidosis/ 2024-05-10 https://bio-research.ai/fda-grants-breakthrough-therapy-designation-to-novartis-scemblix-for-treatment-of-chronic-phase-philadelphia-chromosome-positive-chronic-myeloid-leukemia/ 2024-05-10 https://bio-research.ai/shionogi-secures-exclusive-worldwide-rights-to-maze-therapeutics-mze001-in-150m-deal-for-pompe-disease-therapy/ 2024-05-10 https://bio-research.ai/fda-delays-review-of-moderna-s-mrna-1345-rsv-vaccine-bla-until-end-of-may-2024-due-to-administrative-constraints-safety-efficacy-and-quality-unaffected-ahead-of-cdc-acip-meeting/ 2024-05-10 https://bio-research.ai/sanofi-seals-co-exclusive-deal-with-novavax-for-covid-19-vaccine-commercialization-and-flu-covid-combo-vaccine-development-with-500m-upfront-and-up-to-700m-milestone-payments/ 2024-05-10 https://bio-research.ai/anaptysbio-revises-royalty-deal-with-sagard-healthcare-for-jemperli-securing-50m-upfront-and-up-to-25-on-sales-over-1b/ 2024-05-09 https://bio-research.ai/fate-therapeutics-treats-first-patient-with-lupus-in-phase-1-study-of-ft819-observes-sustained-cd19-b-cell-depletion-over-30-days-in-separate-trial/ 2024-05-09 https://bio-research.ai/calico-life-sciences-and-broad-institute-extend-aging-and-neurodegeneration-research-partnership-until-2029-with-ongoing-and-new-clinical-trials/ 2024-05-09 https://bio-research.ai/novo-nordisk-joins-forces-with-metaphore-biotechnologies-and-flagship-pioneering-in-a-600m-deal-to-develop-new-obesity-therapeutics-using-the-mimic-platform/ 2024-05-09 https://bio-research.ai/arecor-therapeutics-and-medtronic-diabetes-partner-to-develop-thermostable-insulin-for-implantable-pumps/ 2024-05-09 https://bio-research.ai/merck-s-phase-3-keynote-b21-trial-of-keytruda-with-chemotherapy-in-high-risk-endometrial-cancer-does-not-meet-primary-endpoint-of-disease-free-survival/ 2024-05-09 https://bio-research.ai/innovent-biologics-reports-phase-3-clinical-trial-results-of-mazdutide-in-chinese-type-2-diabetes-patients-showing-improved-hba1c-and-body-weight-reduction-over-28-weeks/ 2024-05-09 https://bio-research.ai/tiumbio-co-ltd-reports-phase-2a-trial-success-of-merigolix-for-endometriosis-associated-pain-with-primary-endpoint-achievement-in-reducing-dysmenorrhea-scores-across-three-dosage-groups/ 2024-05-08 https://bio-research.ai/cytomx-therapeutics-reports-phase-1a-study-results-of-cx-904-with-favorable-safety-profile-and-partial-responses-in-pancreatic-cancer-patients/ 2024-05-08 https://bio-research.ai/phanes-therapeutics-and-roche-collaborate-to-evaluate-pt217-and-atezolizumab-combo-in-small-cell-lung-cancer-and-neuroendocrine-carcinoma-clinical-study/ 2024-05-08 https://bio-research.ai/maxwell-biosciences-and-usamriid-partner-for-second-crada-to-evaluate-claromer-technology-in-treating-infectious-diseases/ 2024-05-08 https://bio-research.ai/anixa-biosciences-and-cleveland-clinic-collaborate-on-innovative-cancer-vaccines-targeting-retired-proteins-with-royalties-deal-in-place/ 2024-05-08 https://bio-research.ai/coherus-biosciences-and-cancer-research-institute-partner-in-iproc-platform-study-to-combine-anti-pd-1-antibody-with-etbr-inhibitor-for-platinum-resistant-ovarian-cancer-treatment/ 2024-05-08 https://bio-research.ai/cytokinetics-reports-phase-1-study-results-of-ck-586-showing-safety-and-linear-pharmacokinetics-in-healthy-participants-plans-phase-2-trial-in-hfpef-for-q4-2024/ 2024-05-08 https://bio-research.ai/avidity-biosciences-receives-fda-breakthrough-therapy-designation-for-the-treatment-of-myotonic-dystrophy-type-1/ 2024-05-08 https://bio-research.ai/teva-pharmaceuticals-and-medincell-announce-phase-3-solaris-trial-results-of-tev-749-showing-significant-reductions-in-panss-scores-for-schizophrenia-treatment-after-8-weeks/ 2024-05-08 https://bio-research.ai/arbor-biotechnologies-acquires-serendipity-biosciences-to-expand-genomic-medicine-portfolio-with-enhanced-gene-editing-technologies/ 2024-05-08 https://bio-research.ai/iecure-s-ecur-506-receives-fda-fast-track-designation-for-treatment-of-neonatal-onset-ornithine-transcarbamylase-deficiency-and-commences-phase-1-2-otc-hope-study/ 2024-05-07 https://bio-research.ai/sciwind-biosciences-partners-with-hk-inno-n-to-bring-ecnoglutide-to-south-korea-in-a-deal-worth-up-to-56m-with-double-digit-royalties/ 2024-05-07 https://bio-research.ai/cytomx-and-merck-enter-clinical-trial-collaboration-to-assess-cx-801-with-keytruda-in-treating-advanced-metastatic-solid-tumors/ 2024-05-07 https://bio-research.ai/fda-grants-priority-review-for-stealth-biotherapeutics-elamipretide-nda-for-barth-syndrome-treatment-with-january-2025-decision-date/ 2024-05-07 https://bio-research.ai/leo-pharma-s-phase-3-trial-of-enstilar-meets-primary-and-secondary-endpoints-in-604-chinese-patients-with-stable-plaque-psoriasis/ 2024-05-07 https://bio-research.ai/neurosense-therapeutics-ltd-announces-phase-2b-paradigm-trial-results-showing-43-slower-als-progression-rate-with-primec-treatment-over-6-months/ 2024-05-07 https://bio-research.ai/impact-biotech-s-phase-3-enlighted-study-shows-a-67-complete-response-rate-in-upper-tract-urothelial-cancer-with-padeliporfin-vtp-treatment/ 2024-05-07 https://bio-research.ai/allergy-therapeutics-phase-iii-trial-of-grass-mata-mpl-reports-20-3-reduction-in-combined-symptom-medication-score-for-allergic-rhinoconjunctivitis/ 2024-05-07 https://bio-research.ai/gsk-joins-bioversys-series-c-extension-with-chf-44-9m-investment-to-boost-clinical-development-of-tuberculosis-drug-alpibectir-in-collaboration-with-pasteur-institute-lille-and-university-of-lille/ 2024-05-07 https://bio-research.ai/coave-therapeutics-reports-phase-i-ii-study-results-for-hora-pde6b-in-retinitis-pigmentosa-with-24-month-follow-up-showing-stabilized-visual-acuity-and-visual-field-in-treated-eyes/ 2024-05-07 https://bio-research.ai/santen-pharmaceutical-and-mitsubishi-tanabe-pharma-to-collaborate-on-sales-promotion-for-alesion-eyelid-cream-following-successful-phase-iii-trials-for-allergic-conjunctivitis/ 2024-05-07 https://bio-research.ai/inmagene-biopharmaceuticals-reports-interim-phase-2a-trial-data-of-img-007-for-atopic-dermatitis-indicating-improved-skin-symptoms-without-serious-adverse-events/ 2024-05-06 https://bio-research.ai/gossamer-bio-and-chiesi-group-forge-partnership-to-advance-seralutinib-in-pulmonary-hypertension-with-up-to-486m-in-milestone-payments/ 2024-05-06 https://bio-research.ai/ferring-pharmaceuticals-reveals-adstiladrin-phase-3-study-results-with-80-overall-survival-rate-at-60-months-for-bcg-unresponsive-bladder-cancer/ 2024-05-06 https://bio-research.ai/nrx-pharmaceuticals-trial-of-nrx-101-shows-a-76-reduction-in-akathisia-symptoms-over-42-days-compared-to-lurasidone-in-patients-with-suicidal-bipolar-depression/ 2024-05-06 https://bio-research.ai/biocytogen-pharmaceuticals-and-biocopy-ag-partner-to-advance-cancer-therapy-leveraging-human-tcr-mimic-antibodies-from-rentcr-mimic-mice-for-novel-treatments/ 2024-05-06 https://bio-research.ai/lyra-therapeutics-phase-3-trial-of-lyr-210-fails-to-meet-primary-endpoint-in-chronic-rhinosinusitis-at-24-weeks/ 2024-05-06 https://bio-research.ai/xeris-biopharma-signs-exclusive-worldwide-collaboration-with-beta-bionics-for-dual-hormone-pump-development-using-xerisol-glucagon-technology/ 2024-05-06 https://bio-research.ai/eyepoint-pharmaceuticals-phase-2-pavia-trial-of-duravyu-for-non-proliferative-diabetic-retinopathy-does-not-meet-primary-endpoint-plans-phase-3-trials-for-wet-amd/ 2024-05-06 https://bio-research.ai/adc-therapeutics-sa-reports-high-response-rate-in-phase-2-trial-of-zynlonta-for-relapsed-refractory-marginal-zone-lymphoma-with-13-complete-responses-out-of-15-patients/ 2024-05-06 https://bio-research.ai/calliditas-therapeutics-reports-phase-2-trial-results-of-setanaxib-with-pembrolizumab-for-squamous-cell-carcinoma-progression-free-and-overall-survival-improved-no-significant-tumor-size-reduction-in-55-patients/ 2024-05-06 https://bio-research.ai/lantern-pharma-and-oregon-therapeutics-team-up-for-ai-driven-development-of-cancer-drug-xce853-focusing-on-precision-biomarker-identification-and-clinical-strategy/ 2024-05-06 https://bio-research.ai/simcere-pharmaceutical-s-phase-iii-trial-of-deunoxavir-marboxil-tablets-achieves-primary-endpoint-with-26-543-improvement-in-median-time-to-symptom-remission-for-influenza-a-and-b/ 2024-05-06 https://bio-research.ai/boehringer-ingelheim-s-phase-i-iia-hornbill-study-of-bi-764524-shows-safety-and-foveal-avascular-zone-stabilization-at-week-16-in-diabetic-macular-ischemia-treatment/ 2024-05-06 https://bio-research.ai/urogen-pharma-ltd-reports-atlas-trial-results-with-ugn-102-for-low-grade-intermediate-risk-non-muscle-invasive-bladder-cancer-showing-12-month-response-rates-after-treatment/ 2024-05-04 https://bio-research.ai/janssen-cilag-international-nv-reports-100-percent-biochemical-recurrence-free-rate-at-24-months-in-phase-2-apa-rp-study-of-apalutamide-with-androgen-deprivation-therapy-after-radical-prostatectomy/ 2024-05-03 https://bio-research.ai/cg-oncology-reports-75-2-complete-response-rate-in-phase-3-bond-003-study-of-cretostimogene-monotherapy-for-high-risk-non-muscle-invasive-bladder-cancer-unresponsive-to-bcg/ 2024-05-03 https://bio-research.ai/aeon-biopharma-s-phase-2-trial-of-abp-450-fails-to-meet-primary-endpoint-in-chronic-migraine-prevention-with-no-significant-reduction-in-monthly-migraine-days/ 2024-05-03 https://bio-research.ai/immutep-reports-phase-ii-trial-data-indicating-eftilagimod-alpha-with-radiotherapy-and-anti-pd-1-therapy-well-tolerated-in-soft-tissue-sarcoma-with-near-complete-pathological-responses-in-4-out-of-6-patients/ 2024-05-02 https://bio-research.ai/allarity-therapeutics-halts-phase-2-trial-of-stenoparib-in-ovarian-cancer-plans-analysis-for-fda-trial-focus/ 2024-05-02 https://bio-research.ai/amolyt-pharma-s-eneboparatide-granted-fast-track-designation-by-fda-in-phase-3-trial-for-hypoparathyroidism-treatment/ 2024-05-02 https://bio-research.ai/fda-grants-rmat-designation-to-taysha-gene-therapies-tsha-102-in-phase-1-2-trials-for-rett-syndrome/ 2024-05-02 https://bio-research.ai/ascelia-pharma-ab-s-orviglance-meets-primary-endpoint-in-sparkle-phase-3-study-for-liver-mri-contrast-agent-set-for-fda-application-submission-by-mid-2025/ 2024-05-02 https://bio-research.ai/novartis-to-acquire-mariana-oncology-for-1b-upfront-plus-750m-in-milestones-bolstering-radioligand-cancer-therapy-portfolio-with-mc-339-for-small-cell-lung-cancer/ 2024-05-02 https://bio-research.ai/novo-nordisk-acquires-alkermes-athlone-facility-for-91m-with-subcontracting-arrangement-until-end-of-2025-ensuring-ongoing-royalty-revenues-and-future-cost-savings/ 2024-05-02 https://bio-research.ai/astrazeneca-s-phase-iii-echo-trial-of-calquence-improves-progression-free-survival-in-previously-untreated-mantle-cell-lymphoma/ 2024-05-02 https://bio-research.ai/everest-medicines-nefecon-approved-by-hong-kong-for-adult-primary-iga-nephropathy-treatment-after-positive-phase-3-trial-results/ 2024-05-02 https://bio-research.ai/biocardia-reports-cardiamp-cell-therapy-bcda-02-trial-results-with-107-second-increase-in-exercise-tolerance-and-82-reduction-in-angina-episodes-for-chronic-myocardial-ischemia-patients/ 2024-05-01 https://bio-research.ai/janssen-seeks-ema-approval-for-tremfya-in-ulcerative-colitis-and-crohn-s-disease-following-phase-3-trial-successes/ 2024-05-01 https://bio-research.ai/boehringer-ingelheim-gains-fda-approval-for-high-concentration-citrate-free-cyltezo-formulation-in-chronic-inflammatory-diseases/ 2024-05-01 https://bio-research.ai/sellas-life-sciences-reports-up-to-100-overall-response-rate-in-phase-2a-trial-of-sls009-for-r-r-aml-patients-with-asxl1-mutations/ 2024-05-01 https://bio-research.ai/astellas-pharma-and-poseida-therapeutics-embark-on-a-600m-collaboration-through-xyphos-biosciences-to-advance-convertiblecar-cell-therapies-for-solid-tumors/ 2024-05-01 https://bio-research.ai/atsena-therapeutics-reports-on-phase-i-ii-lighthouse-study-of-atsn-201-for-x-linked-retinoschisis-with-two-out-of-three-patients-showing-extensive-resolution-of-schisis-and-no-serious-adverse-events/ 2024-05-01 https://bio-research.ai/merck-s-phase-3-keynote-811-trial-of-keytruda-meets-dual-primary-endpoint-in-overall-survival-for-first-line-treatment-of-her2-positive-advanced-gastric-or-gej-adenocarcinoma/ 2024-05-01 https://bio-research.ai/editas-medicine-and-bristol-myers-squibb-extend-t-cell-therapy-collaboration-through-2028-with-provisions-for-milestones-and-royalties/ 2024-05-01 https://bio-research.ai/jacobio-pharma-reports-phase-ii-results-of-glecirasib-showing-47-9-objective-response-rate-in-second-line-nsclc-patients-with-86-3-disease-control-rate-and-median-progression-free-survival-of-8-2-months/ 2024-05-01 https://bio-research.ai/harmony-biosciences-acquires-epygenix-therapeutics-for-up-to-680m-to-expand-cns-portfolio-and-advance-epx-100-in-pivotal-trials-for-dravet-and-lennox-gastaut-syndromes/ 2024-04-30 https://bio-research.ai/fda-approves-ingrezza-sprinkle-that-can-be-sprinkled-on-soft-food-for-adults-with-tardive-dyskinesia-and-chorea-associated-with-huntington-s-disease/ 2024-04-30 https://bio-research.ai/alnylam-pharmaceuticals-and-medison-pharma-expand-collaboration-to-accelerate-global-access-to-rnai-therapies-in-latam-apac-and-other-international-markets/ 2024-04-30 https://bio-research.ai/xoma-invests-22m-in-dar-bioscience-s-women-s-health-portfolio-with-royalty-stake-in-xaciato-ovaprene-and-sildenafil-cream/ 2024-04-30 https://bio-research.ai/nrx-pharmaceuticals-reports-phase-2b-3-trial-results-of-nrx-101-for-suicidal-bipolar-depression-with-33-reduction-in-suicidality-and-plans-for-a-300-person-trial/ 2024-04-30 https://bio-research.ai/newron-pharmaceuticals-reports-phase-ii-iii-trial-success-of-evenamide-in-schizophrenia-with-primary-endpoint-met-and-favorable-safety-profile/ 2024-04-30 https://bio-research.ai/bayer-and-evotec-enhance-strategic-alliance-to-advance-precision-treatments-for-cardiovascular-diseases-using-stem-cell-disease-modelling/ 2024-04-30 https://bio-research.ai/fda-approves-tivdak-for-recurrent-or-metastatic-cervical-cancer-based-on-phase-3-trial-results-showing-median-overall-survival-benefit/ 2024-04-30 https://bio-research.ai/annovis-bio-reports-phase-ii-iii-trial-results-of-buntanetap-with-cognitive-improvements-in-alzheimer-s-patients-and-reduction-in-plasma-tau-levels/ 2024-04-29 https://bio-research.ai/immix-biopharma-s-nxc-201-receives-orphan-drug-designation-from-european-commission-for-multiple-myeloma-treatment-with-market-exclusivity-benefits/ 2024-04-29 https://bio-research.ai/pantherx-rare-to-distribute-x4-pharmaceuticals-fda-approved-xolremdi-for-whim-syndrome-treatment/ 2024-04-29 https://bio-research.ai/fda-grants-orphan-drug-exclusivity-to-octapharma-usa-for-wilate-in-von-willebrand-disease-prophylaxis-and-management/ 2024-04-29 https://bio-research.ai/bavarian-nordic-a-s-begins-fda-rolling-submission-for-chikv-vlp-vaccine-candidate-to-prevent-chikungunya-virus-in-individuals-aged-12-and-older/ 2024-04-29 https://bio-research.ai/soleno-therapeutics-receives-fda-breakthrough-therapy-designation-for-diazoxide-choline-in-the-treatment-of-prader-willi-syndrome/ 2024-04-29 https://bio-research.ai/repertoire-immune-medicines-and-bristol-myers-squibb-announce-strategic-collaboration-on-tolerizing-vaccines-for-autoimmune-diseases-with-potential-1-8b-in-milestones-plus-royalties/ 2024-04-29 https://bio-research.ai/fda-approves-aquestive-therapeutics-libervant-buccal-film-for-seizure-cluster-treatment-in-children-aged-2-to-5-and-sees-increased-prescriptions-for-diazepam-rectal-gel/ 2024-04-29 https://bio-research.ai/deciphera-pharmaceuticals-acquired-by-ono-pharmaceutical-for-2-4b-in-cash-deal-involving-tender-offer-and-merger-to-bolster-oncology-portfolio/ 2024-04-29 https://bio-research.ai/fda-approves-xolremdi-for-whim-syndrome-in-patients-12-and-older-based-on-phase-3-trial-data/ 2024-04-29 https://bio-research.ai/astrazeneca-s-truqap-with-faslodex-receives-chmp-recommendation-for-eu-approval-in-advanced-breast-cancer-treatment-based-on-capitello-291-phase-iii-trial-results/ 2024-04-29 https://bio-research.ai/amgen-to-submit-marketing-authorization-application-for-teprotumumab-in-thyroid-eye-disease-to-the-european-medicines-agency/ 2024-04-26 https://bio-research.ai/european-commission-approves-kalydeco-for-treatment-of-cystic-fibrosis-in-infants-over-1-month-old-with-specific-cftr-mutations/ 2024-04-26 https://bio-research.ai/biodexa-pharmaceuticals-enters-global-licensing-deal-with-emtora-biosciences-for-phase-3-erapa-in-familial-adenomatous-polyposis-secures-17m-grant-and-potential-for-41-5m-in-sales-milestones/ 2024-04-26 https://bio-research.ai/fda-approves-bausch-lomb-s-lumify-preservative-free-eye-drops-for-ocular-redness-with-brimonidine-tartrate-slated-for-early-2025-release/ 2024-04-26 https://bio-research.ai/european-medicines-agency-committee-recommends-approval-of-takeda-s-fruquintinib-for-treatment-of-metastatic-colorectal-cancer-based-on-phase-3-trial-results/ 2024-04-26 https://bio-research.ai/chmp-of-the-european-medicines-agency-recommends-approval-of-sobi-s-efanesoctocog-alfa-for-haemophilia-a-treatment/ 2024-04-26 https://bio-research.ai/fda-approves-pfizer-s-beqvez-for-adults-with-hemophilia-b-who-meet-specific-criteria-based-on-benegene-2-study-results-and-introduces-warranty-program/ 2024-04-26 https://bio-research.ai/chmp-issues-positive-opinion-on-idorsia-ltd-s-jeraygo-aprocitentan-for-treatment-of-resistant-hypertension-in-adults/ 2024-04-26 https://bio-research.ai/chmp-recommends-approval-of-opdivo-of-bms-in-combination-with-cisplatin-and-gemcitabine-for-unresectable-or-metastatic-urothelial-carcinoma-following-checkmate-901-trial-results/ 2024-04-26 https://bio-research.ai/chmp-issues-positive-opinion-on-biogen-s-tofidence-a-biosimilar-to-roactemra-based-on-analytical-non-clinical-and-clinical-study-outcomes-for-arthritis-and-covid-19-treatment/ 2024-04-25 https://bio-research.ai/apollomics-announces-chinese-nmpa-approval-of-vebreltinib-for-treatment-of-certain-gliomas-with-c-met-alteration-based-on-fugen-study-results-expanding-the-use-of-vebreltinib/ 2024-04-25 https://bio-research.ai/vistagen-reports-phase-2a-pilot-study-results-of-ph15-nasal-spray-improving-reaction-times-in-sleep-deprived-individuals/ 2024-04-25 https://bio-research.ai/abbvie-s-phase-3b-4-study-shows-rinvoq-achieves-greater-skin-clearance-and-reduces-itch-than-dupixent-in-moderate-to-severe-atopic-dermatitis-by-week-16/ 2024-04-25 https://bio-research.ai/compass-therapeutics-secures-fda-fast-track-designation-for-ctx-009-and-paclitaxel-combination-in-phase-2-study-for-advanced-biliary-tract-cancer-treatment/ 2024-04-25 https://bio-research.ai/caliway-biopharmaceuticals-reports-phase-2-clinical-study-results-of-cbl-514-with-over-50-of-participants-experiencing-cellulite-severity-improvement-after-12-weeks/ 2024-04-25 https://bio-research.ai/ono-pharmaceutical-and-prism-biolab-enter-collaboration-to-develop-oncology-drugs-using-pepmetics-technology-with-exclusive-rights-and-milestone-based-payments/ 2024-04-25 https://bio-research.ai/eyenovia-announces-phase-iv-study-results-of-mydcombi-achieving-67-dilation-at-30-minutes-and-86-at-60-minutes/ 2024-04-25 https://bio-research.ai/regeneron-pharmaceuticals-teams-up-with-mammoth-biosciences-for-in-vivo-crispr-gene-editing-therapies-with-up-to-370m-milestones-plus-royalties-per-target/ 2024-04-25 https://bio-research.ai/medivir-ab-s-miv-711-receives-rare-pediatric-disease-designation-and-orphan-drug-designation-from-fda-for-treatment-of-legg-calv-perthes-disease/ 2024-04-25 https://bio-research.ai/abbisko-therapeutics-granted-fda-orphan-drug-designation-for-irpagratinib-in-hepatocellular-carcinoma-treatment/ 2024-04-25 https://bio-research.ai/cidara-therapeutics-divests-antifungal-drug-rezafungin-to-mundipharma-in-a-deal-shifting-clinical-trial-and-regulatory-responsibilities-and-projecting-128m-in-cost-savings/ 2024-04-24 https://bio-research.ai/junshi-biosciences-application-for-toripalimab-in-nasopharyngeal-carcinoma-treatment-accepted-by-hong-kong-s-drug-office-following-results-from-jupiter-02-and-polaris-02-studies/ 2024-04-24 https://bio-research.ai/immutep-limited-reports-26-9-overall-response-rate-in-phase-iib-tacti-003-trial-of-eftilagimod-alpha-and-keytruda-for-pd-l1-negative-head-and-neck-cancer/ 2024-04-24 https://bio-research.ai/ascendis-pharma-receives-marketing-authorization-from-uk-s-mhra-for-yorvipath-in-the-treatment-of-chronic-hypoparathyroidism/ 2024-04-24 https://bio-research.ai/european-commission-grants-conditional-marketing-authorization-for-travere-s-filspari-in-adult-patients-with-iga-nephropathy/ 2024-04-24 https://bio-research.ai/fda-accepts-for-priority-review-gsk-s-supplemental-biologics-license-application-for-jemperli-in-combination-with-chemotherapy-for-advanced-or-recurrent-endometrial-cancer/ 2024-04-24 https://bio-research.ai/alvotech-confirms-avt05-biosimilar-clinically-equivalent-to-simponi-in-rheumatoid-arthritis-study-with-no-meaningful-safety-differences-through-week-24/ 2024-04-24 https://bio-research.ai/novartis-and-medicines-for-malaria-venture-report-phase-ii-iii-calina-study-results-for-coartem-in-infants-under-5-kg-with-malaria/ 2024-04-24 https://bio-research.ai/tetra-pharm-technologies-and-glysious-collaborate-to-enhance-transdermal-drug-delivery-for-endocannabinoid-system-treatments-aim-to-file-joint-patent/ 2024-04-24 https://bio-research.ai/calliditas-therapeutics-ab-reports-consistent-treatment-response-in-phase-3-nefigard-open-label-extension-study-for-igan-patients/ 2024-04-24 https://bio-research.ai/european-commission-approves-astellas-pharma-s-xtandi-extension-for-high-risk-non-metastatic-hormone-sensitive-prostate-cancer/ 2024-04-24 https://bio-research.ai/medicure-inc-receives-fast-track-designation-from-fda-for-mc-1-in-pnpo-deficiency-seizures-launches-phase-3-trial/ 2024-04-23 https://bio-research.ai/fda-grants-day-one-accelerated-approval-for-tovorafenib-in-pediatric-low-grade-glioma-patients-with-braf-alterations-following-firefly-1-trial-results/ 2024-04-23 https://bio-research.ai/fda-approves-novartis-lutathera-for-treatment-of-pediatric-patients-aged-12-and-older-with-sstr-positive-gep-nets-based-on-netter-p-trial-results/ 2024-04-23 https://bio-research.ai/palisade-bio-and-strand-life-sciences-forge-strategic-partnership-to-personalize-ulcerative-colitis-treatment-using-bioinformatics-and-machine-learning/ 2024-04-23 https://bio-research.ai/edgewise-therapeutics-drug-sevasemten-receives-orphan-drug-designation-from-ema-for-becker-and-duchenne-muscular-dystrophies-treatment/ 2024-04-23 https://bio-research.ai/tharimmune-secures-exclusive-licensing-deal-with-washington-university-for-development-of-antibodies-targeting-her2-in-solid-tumors/ 2024-04-23 https://bio-research.ai/neurocrine-biosciences-reports-nbi-1065845-achieves-primary-endpoint-in-phase-2-savitri-study-for-major-depressive-disorder/ 2024-04-23 https://bio-research.ai/vertex-pharmaceuticals-licenses-treefrog-therapeutics-c-stem-technology-in-a-deal-potentially-worth-over-780m-to-advance-cell-therapies-for-type-1-diabetes/ 2024-04-23 https://bio-research.ai/european-commission-approves-beigene-s-tislelizumab-for-three-types-of-non-small-cell-lung-cancer-treatments-based-on-phase-3-study-outcomes/ 2024-04-23 https://bio-research.ai/incyte-to-acquire-escient-pharmaceuticals-for-750m-plus-net-cash-gains-mrgpr-antagonist-assets-ep262-and-ep547-with-potential-launches-by-2029/ 2024-04-23 https://bio-research.ai/eu-approves-voydeya-as-add-on-treatment-for-adults-with-paroxysmal-nocturnal-haemoglobinuria-based-on-alexion-s-alpha-phase-iii-trial-results/ 2024-04-23 https://bio-research.ai/sanofi-s-phase-3-luna-3-study-of-rilzabrutinib-achieves-primary-endpoint-in-immune-thrombocytopenia-trial/ 2024-04-23 https://bio-research.ai/health-canada-grants-priority-review-to-acadia-pharmaceuticals-submission-of-trofinetide-for-rett-syndrome-treatment-based-on-phase-3-study-results/ 2024-04-23 https://bio-research.ai/fda-approves-immunitybio-s-anktiva-in-combination-with-bcg-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-treatment-with-62-complete-response-rate-in-clinical-trial/ 2024-04-22 https://bio-research.ai/boehringer-ingelheim-and-ochre-bio-strike-1b-deal-to-advance-liver-disease-treatments-with-focus-on-cirrhosis-and-metabolic-dysfunction-associated-steatohepatitis/ 2024-04-22 https://bio-research.ai/corcept-therapeutics-reports-phase-3-grace-trial-results-for-relacorilant-with-statistically-significant-improvements-in-cushing-s-syndrome-symptoms-over-22-weeks/ 2024-04-22 https://bio-research.ai/abeona-therapeutics-inc-receives-fda-request-for-additional-cmc-information-for-bla-of-prademagene-zamikeracel-in-treating-recessive-dystrophic-epidermolysis-bullosa/ 2024-04-22 https://bio-research.ai/european-commission-grants-authorization-to-pfizer-s-emblaveo-for-treating-specific-infections-in-adults-based-on-phase-3-trial-results/ 2024-04-22 https://bio-research.ai/aslan-pharmaceuticals-reports-statistical-significance-in-phase-2-study-of-eblasakimab-for-adult-atopic-dermatitis-with-16-week-eczema-area-severity-index-score-improvement/ 2024-04-22 https://bio-research.ai/neurosense-therapeutics-partners-with-genetika-to-enhance-alzheimer-s-drug-development-through-in-vitro-neuronal-plasticity-assessment-technology-in-phase-2-clinical-trial/ 2024-04-22 https://bio-research.ai/kura-oncology-s-ziftomenib-granted-fda-breakthrough-therapy-designation-for-relapsed-refractory-npm1-mutant-acute-myeloid-leukemia-with-plans-for-registration-directed-trial-completion-by-mid-2024/ 2024-04-22 https://bio-research.ai/lexeo-therapeutics-in-licenses-lx2006-gene-therapy-candidate-from-cornell-university-for-friedreich-ataxia-cardiomyopathy-treatment-gains-access-to-ongoing-weill-cornell-medicine-phase-1a-trial-data/ 2024-04-22 https://bio-research.ai/european-commission-approves-type-ii-variation-for-carvykti-in-adult-relapsed-and-refractory-multiple-myeloma-after-at-least-one-prior-therapy-based-on-phase-3-cartitude-4-study-results/ 2024-04-22 https://bio-research.ai/bristol-myers-squibb-secures-exclusive-access-to-cellares-cell-shuttle-platform-in-a-380m-car-t-cell-therapy-manufacturing-deal/ 2024-04-22 https://bio-research.ai/european-commission-approves-bimzelx-for-treatment-of-moderate-to-severe-hidradenitis-suppurativa-after-phase-3-trials-show-improvement-in-symptoms/ 2024-04-22 https://bio-research.ai/ipsen-and-skyhawk-therapeutics-forge-1-8b-deal-for-rare-neurological-disease-rna-modulators-development/ 2024-04-22 https://bio-research.ai/bioarctic-and-eisai-explore-alzheimer-s-treatment-potential-with-ban2802-under-new-research-agreement-incorporating-braintransporter-technology/ 2024-04-20 https://bio-research.ai/sunshine-biopharma-subsidiary-nora-pharma-secures-health-canada-approval-for-biosimilar-niopeg-to-prevent-infection-in-chemotherapy-patients-with-non-myeloid-cancers/ 2024-04-19 https://bio-research.ai/simcere-zaiming-s-sim0500-granted-fda-fast-track-designation-for-treatment-of-advanced-multiple-myeloma/ 2024-04-19 https://bio-research.ai/alvotech-partners-with-strategic-ally-to-expand-u-s-availability-of-fda-approved-adalimumab-ryvk-alongside-teva-s-ongoing-simlandi-marketing/ 2024-04-19 https://bio-research.ai/fda-approves-genentech-s-alecensa-for-adjuvant-treatment-of-alk-positive-early-stage-nsclc-following-surgery-based-on-phase-iii-alina-study/ 2024-04-18 https://bio-research.ai/fda-approves-subcutaneous-administration-of-takeda-s-entyvio-for-crohn-s-disease-maintenance-therapy-after-successful-intravenous-induction/ 2024-04-18 https://bio-research.ai/barinthus-biotherapeutics-reports-phase-1b-2-trial-results-of-vtp-200-with-60-hpv-clearance-and-67-lesion-clearance-rates-in-cervical-lesions-trial/ 2024-04-18 https://bio-research.ai/abvc-biopharma-s-aibtl-biopharma-acquires-tt-life-for-8-33m-in-a-share-swap-deal-to-bolster-synergy-across-global-development-and-precision-medicine-operations/ 2024-04-18 https://bio-research.ai/immutep-limited-partners-with-chdr-for-phase-i-clinical-trial-of-autoimmune-therapy-imp761-using-novel-klh-challenge-model/ 2024-04-18 https://bio-research.ai/moleculin-biotech-s-annamycin-receives-orphan-drug-designation-from-european-medicines-agency-for-acute-myeloid-leukemia-treatment/ 2024-04-18 https://bio-research.ai/abbvie-s-phase-3-select-gca-study-shows-upadacitinib-with-steroid-taper-led-to-sustained-remission-in-46-of-giant-cell-arteritis-patients/ 2024-04-18 https://bio-research.ai/fda-grants-fast-track-designation-to-askbio-for-ab-1002-gene-therapy-program-in-phase-ii-trial-for-congestive-heart-failure-treatment/ 2024-04-18 https://bio-research.ai/benitec-biopharma-reports-interim-clinical-trial-results-of-bb-301-in-phase-1b-2a-study-for-opmd-showing-swallowing-function-improvements-in-first-subject-treated/ 2024-04-18 https://bio-research.ai/cerevel-therapeutics-phase-3-tempo-3-trial-of-tavapadon-meets-primary-endpoint-with-increased-on-time-without-troublesome-dyskinesia-over-27-weeks/ 2024-04-18 https://bio-research.ai/gsk-s-phase-iii-trial-data-shows-shingrix-vaccine-79-7-effective-after-six-to-11-years-in-adults-aged-50-and-over/ 2024-04-17 https://bio-research.ai/clearmind-medicine-inc-secures-exclusive-global-rights-through-licensing-deal-with-yissum-to-develop-psychedelic-compounds-for-addiction-and-mental-disorders/ 2024-04-17 https://bio-research.ai/abvc-biopharma-and-oncox-enter-licensing-deal-worth-up-to-13-75m-for-maitake-mushroom-extract-drug-blex-404-in-non-small-cell-lung-cancer-treatment/ 2024-04-17 https://bio-research.ai/igm-biosciences-and-sanofi-amend-terms-of-worldwide-collaboration-cutting-potential-targets-in-half-for-igm-agonist-antibodies-potential-milestones-up-to-1-065b-per-target/ 2024-04-17 https://bio-research.ai/ventus-therapeutics-reports-phase-1-trial-of-vent-02-shows-safety-and-100-inhibition-of-il-1-in-participants/ 2024-04-17 https://bio-research.ai/jacobio-pharma-s-kras-g12c-inhibitor-glecirasib-receives-orphan-drug-designation-from-fda-for-pancreatic-cancer-with-reported-objective-response-and-disease-control-rates-in-asco-gi-symposium-study-prepares-for-nda-submission-after-phase-i-ii-trials/ 2024-04-17 https://bio-research.ai/bivictrix-therapeutics-plc-receives-orphan-drug-designation-from-fda-for-bvx001-in-acute-myeloid-leukaemia-treatment-and-advances-towards-ind-submission-with-regulatory-meeting-completion/ 2024-04-17 https://bio-research.ai/sage-therapeutics-reports-phase-2-precedent-study-of-dalzanemdor-fails-to-meet-primary-endpoint-in-parkinson-s-disease-cognitive-impairment-trial/ 2024-04-17 https://bio-research.ai/gsk-s-phase-iii-trial-of-gepotidacin-reveals-92-6-microbiological-success-rate-in-treating-uncomplicated-urogenital-gonorrhoea/ 2024-04-17 https://bio-research.ai/eli-lilly-s-tirzepatide-reduces-apnea-hypopnea-index-in-phase-3-trials-for-adults-with-obstructive-sleep-apnea-and-obesity/ 2024-04-17 https://bio-research.ai/sanofi-s-frexalimab-associated-with-reduced-disease-activity-in-a-48-week-phase-2-trial-for-relapsing-multiple-sclerosis-with-96-of-high-dose-patients-showing-no-new-gd-t1-lesions-and-an-annual-relapse-rate-of-0-04/ 2024-04-17 https://bio-research.ai/essential-pharma-acquires-alzheimer-s-drug-reminyl-from-janssen-pharmaceutica-expanding-cns-portfolio-in-eea-thailand-south-korea-and-beyond/ 2024-04-17 https://bio-research.ai/novartis-reports-six-year-kesimpta-treatment-sustains-efficacy-in-relapsing-multiple-sclerosis-and-shows-safety-in-alithios-study/ 2024-04-17 https://bio-research.ai/genentech-s-phase-iii-ocarina-ii-study-of-ocrevus-ocrelizumab-reports-97-suppression-of-clinical-relapses-and-brain-lesions-in-multiple-sclerosis-over-48-weeks/ 2024-04-16 https://bio-research.ai/kumquat-biosciences-and-takeda-partner-on-immuno-oncology-inhibitor-deal-includes-130m-initial-payment-and-potential-for-over-1-2b-in-milestones-plus-royalties/ 2024-04-16 https://bio-research.ai/fda-approves-alvotech-and-teva-pharmaceuticals-selarsdi-a-biosimilar-to-stelara-for-plaque-psoriasis-and-active-psoriatic-arthritis-in-adults-and-pediatric-patients/ 2024-04-16 https://bio-research.ai/medincell-and-abbvie-strike-strategic-co-development-and-licensing-deal-for-six-long-acting-injectable-therapies-with-35m-upfront-payment-and-potential-milestones-up-to-1-9b/ 2024-04-16 https://bio-research.ai/jaguar-health-inks-exclusive-5-year-deal-with-venture-life-group-to-commercialize-fda-approved-gelclair-for-oral-mucositis-in-the-u-s-market/ 2024-04-16 https://bio-research.ai/lexeo-therapeutics-lx2006-receives-fast-track-designation-from-fda-for-friedreich-s-ataxia-cardiomyopathy-treatment-in-sunrise-fa-trial/ 2024-04-16 https://bio-research.ai/igc-pharma-reports-phase-2-trial-results-of-igc-ad1-with-significant-reduction-in-alzheimer-s-patient-agitation-using-cmai/ 2024-04-16 https://bio-research.ai/astrazeneca-s-phase-iii-topaz-1-trial-shows-imfinzi-with-chemotherapy-extends-overall-survival-in-advanced-biliary-tract-cancer/ 2024-04-16 https://bio-research.ai/ever-pharma-secures-eu-approval-for-eribulin-in-the-treatment-of-advanced-or-metastatic-breast-cancer-and-unresectable-liposarcoma/ 2024-04-16 https://bio-research.ai/fda-reviews-gsk-s-biologics-license-application-for-meningococcal-abcwy-vaccine-candidate-with-decision-date-set-for-14-february-2025/ 2024-04-16 https://bio-research.ai/intra-cellular-therapies-reports-lumateperone-meets-primary-endpoint-in-phase-3-mdd-trial-with-a-reduction-in-madrs-total-score-at-week-6/ 2024-04-16 https://bio-research.ai/curevac-and-md-anderson-partner-to-develop-mrna-cancer-vaccines-with-co-development-and-licensing-terms-granting-curevac-exclusive-rights-for-late-stage-trials-and-commercialization/ 2024-04-16 https://bio-research.ai/mrm-health-nv-reports-phase-2a-trial-results-of-mh002-with-a-46-clinical-remission-rate-in-pouchitis-patients/ 2024-04-16 https://bio-research.ai/telix-announces-fda-fast-track-designation-for-tlx101-cdx-imaging-agent-for-glioma-characterization-in-pet-scans/ 2024-04-16 https://bio-research.ai/edgewise-therapeutics-reports-two-year-arch-trial-results-of-sevasemten-in-becker-muscular-dystrophy-with-stable-nsaa-scores-and-reduced-muscle-damage-biomarkers/ 2024-04-15 https://bio-research.ai/norgine-b-v-submits-marketing-authorization-applications-for-eflornithine-in-australia-switzerland-and-the-united-kingdom-for-high-risk-neuroblastoma-treatment-through-project-orbis-following-us-fda-approval/ 2024-04-15 https://bio-research.ai/novartis-phase-iii-applause-igan-study-interim-analysis-reveals-iptacopan-reduces-proteinuria-by-38-3-in-iga-nephropathy-patients-compared-to-placebo/ 2024-04-15 https://bio-research.ai/pulmocide-s-opelconazole-shows-high-tolerance-in-lung-transplant-patients-small-sample-size-limits-comparative-efficacy-results-in-phase-2-opera-s-study/ 2024-04-15 https://bio-research.ai/organovo-holdings-reports-phase-2-study-results-of-fxr314-for-steatohepatitis-showing-significant-reduction-in-liver-fat-content/ 2024-04-15 https://bio-research.ai/soligenix-s-marvax-receives-orphan-drug-designation-from-fda-for-marburg-virus-vaccine-with-market-exclusivity-rights-upon-approval/ 2024-04-15 https://bio-research.ai/chugai-pharmaceutical-reports-phase-iii-nihonbashi-study-of-vabysmo-for-angioid-streaks-meets-primary-endpoint-and-exhibits-safety-profile-consistent-with-prior-trials/ 2024-04-15 https://bio-research.ai/genentech-s-columvi-combination-therapy-meets-overall-survival-endpoint-in-phase-iii-starglo-study-of-dlbcl-patients/ 2024-04-14 https://bio-research.ai/atogepant-shows-long-term-efficacy-in-migraine-prevention-70-of-patients-see-significant-reduction-over-48-weeks/ 2024-04-12 https://bio-research.ai/agenus-reports-phase-1-trial-results-for-bot-bal-therapy-in-metastatic-colorectal-cancer-with-a-23-response-rate-and-21-2-month-median-survival/ 2024-04-12 https://bio-research.ai/harmony-biosciences-enters-exclusive-license-agreement-with-bioprojet-for-narcolepsy-drug-tpm-1116-committing-up-to-393m-in-payments-and-mid-teens-percentage-royalties/ 2024-04-11 https://bio-research.ai/fda-grants-orphan-drug-designation-to-candel-therapeutics-can-2409-for-pancreatic-cancer-treatment-following-phase-2-trial-results-showing-improved-median-overall-survival-rates/ 2024-04-11 https://bio-research.ai/mei-pharma-reports-phase-1b-study-results-of-me-344-with-bevacizumab-in-metastatic-colorectal-cancer-opts-for-different-me-344-formulation-development/ 2024-04-11 https://bio-research.ai/teva-pharmaceuticals-reports-phase-3-study-results-of-ajovy-in-reducing-migraine-days-in-adult-chinese-patients/ 2024-04-11 https://bio-research.ai/soligenix-receives-orphan-drug-designation-from-fda-for-suvax-a-vaccine-aimed-at-preventing-sudan-ebolavirus-infection/ 2024-04-11 https://bio-research.ai/european-commission-grants-orphan-medicinal-product-designation-to-zatolmilast-for-fragile-x-syndrome-treatment/ 2024-04-11 https://bio-research.ai/allay-therapeutics-reports-phase-2b-clinical-study-results-of-atx101-for-post-surgical-pain-relief-in-knee-replacement-surgery/ 2024-04-11 https://bio-research.ai/fda-grants-fast-track-designation-to-puretech-health-s-lyt-200-for-recurrent-metastatic-head-and-neck-squamous-cell-carcinoma-treatment-with-anti-pd1-therapy/ 2024-04-11 https://bio-research.ai/fda-approves-astrazeneca-s-fasenra-for-children-aged-6-to-11-with-severe-eosinophilic-asthma-based-on-tate-phase-iii-trial-results/ 2024-04-11 https://bio-research.ai/simcere-zaiming-s-sim0500-receives-fast-track-designation-by-fda-and-nmpa-for-treatment-of-relapsed-or-refractory-multiple-myeloma/ 2024-04-11 https://bio-research.ai/eliem-therapeutics-acquires-tenet-medicines-to-advance-tnt119-supported-by-120-million-private-placement/ 2024-04-11 https://bio-research.ai/arvinas-and-novartis-seal-exclusive-license-deal-for-arv-766-with-arvinas-potentially-receiving-over-1-16b-including-upfront-and-milestone-payments/ 2024-04-11 https://bio-research.ai/lipocine-inc-reports-phase-2-trial-results-of-lpcn-2401-with-improvements-in-body-composition-in-obese-men/ 2024-04-11 https://bio-research.ai/century-therapeutics-acquires-clade-therapeutics-for-35m-upfront-plus-milestones-secures-60m-in-private-placement-with-bain-capital-life-sciences-and-others-to-bolster-pipeline-through-2026/ 2024-04-11 https://bio-research.ai/alpine-immune-sciences-reports-clinical-data-for-povetacicept-in-iga-nephropathy-with-reduced-proteinuria-and-stabilized-renal-function-at-36-weeks/ 2024-04-10 https://bio-research.ai/vertex-pharmaceuticals-to-acquire-alpine-immune-sciences-for-65-per-share-in-4-9b-deal-focused-on-povetacicept-s-potential-in-iga-nephropathy/ 2024-04-10 https://bio-research.ai/amylyx-pharmaceuticals-releases-interim-phase-2-helios-trial-data-of-amx0035-for-wolfram-syndrome-showing-effects-on-diabetes-progression-visual-decline-and-disease-burden/ 2024-04-10 https://bio-research.ai/fda-grants-fast-track-designation-to-adrenomed-ag-s-enibarcimab-for-septic-shock-treatment-phase-iib-iii-trial-preparation-underway/ 2024-04-10 https://bio-research.ai/aim-immunotech-reports-interim-data-from-ovarian-cancer-study-with-ampligen-and-keytruda-showing-a-45-objective-response-rate-and-7-8-month-median-progression-free-survival/ 2024-04-10 https://bio-research.ai/bioprojet-acquires-exclusive-global-license-from-teijin-pharma-to-develop-and-commercialize-new-narcolepsy-treatment-with-upfront-payment-of-30m-and-potential-milestones-of-up-to-400m-plus-royalties/ 2024-04-10 https://bio-research.ai/epiendo-pharmaceuticals-reports-completion-of-phase-2a-clinical-trial-for-ep395-in-copd-patients-with-safety-and-inflammatory-biomarker-impact-assessed/ 2024-04-10 https://bio-research.ai/ema-grants-priority-medicines-prime-scheme-designation-to-hookipa-s-hb-200-for-oropharyngeal-squamous-cell-carcinoma-opscc-treatment/ 2024-04-10 https://bio-research.ai/ginkgo-bioworks-and-novo-nordisk-forge-five-year-strategic-partnership-to-innovate-diabetes-and-obesity-drug-manufacturing-processes/ 2024-04-10 https://bio-research.ai/moonlake-immunotherapeutics-partners-with-komodo-health-in-a-three-year-deal-to-advance-nanobody-therapy-for-inflammatory-diseases-targeting-over-10b-market-by-2035/ 2024-04-10 https://bio-research.ai/medicenna-therapeutics-corp-reports-ability-1-study-results-for-mdna11-in-patients-with-advanced-solid-tumors-at-aacr-annual-meeting-2024/ 2024-04-09 https://bio-research.ai/alx-oncology-holdings-inc-reports-phase-1-2-trial-results-of-evorpacept-with-rituximab-and-lenalidomide-in-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma/ 2024-04-09 https://bio-research.ai/rapt-therapeutics-reports-phase-2-trial-results-for-tivumecirnon-with-pembrolizumab-in-advanced-head-and-neck-cancer-patients/ 2024-04-09 https://bio-research.ai/atossa-therapeutics-reports-phase-2-evangeline-trial-results-for-z-endoxifen-in-er-her2-breast-cancer-with-observed-ki-67-level-reductions-and-lesion-size-decrease-despite-side-effects/ 2024-04-09 https://bio-research.ai/obsidian-therapeutics-reports-obx-115-trial-results-in-advanced-melanoma-patients-with-50-response-rate-at-the-american-association-for-cancer-research-annual-meeting/ 2024-04-09 https://bio-research.ai/denovo-biopharma-announces-phase-2b-trial-results-of-db104-in-treatment-resistant-depression-achieving-primary-endpoint/ 2024-04-09 https://bio-research.ai/ys-biopharma-co-ltd-announces-phase-3-clinical-trial-interim-results-of-pika-rabies-vaccine/ 2024-04-09 https://bio-research.ai/lisata-therapeutics-receives-fda-orphan-drug-designation-for-lsta1-in-osteosarcoma-treatment-after-rare-pediatric-disease-designation-highlighting-cendr-platform-technology-in-drug-development/ 2024-04-09 https://bio-research.ai/madrigal-pharmaceuticals-releases-rezdiffra-for-adult-noncirrhotic-nash-treatment-with-fda-accelerated-approval-based-on-phase-3-maestro-nash-trial-results/ 2024-04-09 https://bio-research.ai/pfizer-reports-phase-3-monet-clinical-trial-results-for-abrysvo-in-adults-at-risk-for-severe-rsv-associated-disease-indicating-safety-and-immunogenicity/ 2024-04-09 https://bio-research.ai/syros-pharmaceuticals-tamibarotene-earns-fda-fast-track-designation-for-aml-treatment-in-combination-with-azacitidine-and-venetoclax-based-on-select-aml-1-phase-2-trial/ 2024-04-09 https://bio-research.ai/nurix-therapeutics-and-sanofi-expand-collaboration-to-develop-oral-stat6-degrader-for-type-2-inflammation-with-the-goal-of-nominating-a-development-candidate-in-the-first-year-of-the-extended-term/ 2024-04-09 https://bio-research.ai/essential-pharma-expands-into-clinical-stage-assets-with-acquisition-of-renaissance-pharma-and-collaborative-development-of-neuroblastoma-immunotherapy-hu14-18k322a/ 2024-04-09 https://bio-research.ai/fda-grants-fast-track-designation-to-phanes-therapeutics-pt217-for-extensive-stage-small-cell-lung-cancer-treatment-and-orphan-drug-designation-phase-i-skybridge-trial-underway/ 2024-04-08 https://bio-research.ai/bristol-myers-squibb-announces-phase-1-2-krystal-1-study-results-for-krazati-and-cetuximab-in-krasg-c-mutated-colorectal-cancer-showing-objective-response-and-survival-rates/ 2024-04-08 https://bio-research.ai/stealth-biotherapeutics-drug-application-for-elamipretide-in-barth-syndrome-treatment-accepted-by-u-s-fda-phase-3-trial-data-under-review/ 2024-04-08 https://bio-research.ai/fda-approves-viiv-healthcare-s-dovato-for-hiv-1-treatment-in-adolescents-aged-12-and-older/ 2024-04-08 https://bio-research.ai/fda-issues-complete-response-letter-to-supernus-pharmaceuticals-for-spn-830-device-targeting-motor-fluctuations-in-parkinson-s-disease-patients-requiring-further-product-quality-data/ 2024-04-08 https://bio-research.ai/vernalis-and-c4x-discovery-partner-in-drug-discovery-collaboration-for-immuno-inflammatory-diseases-targeting-undisclosed-protein/ 2024-04-08 https://bio-research.ai/clover-biopharmaceuticals-releases-phase-i-trial-results-for-scb-1019-showing-6-4-11-8-fold-increased-rsv-antibody-titers/ 2024-04-08 https://bio-research.ai/bridgebio-pharma-reports-attribute-cm-phase-3-trial-results-of-acoramidis-indicating-stabilization-or-improvement-in-cardiac-structure-and-function/ 2024-04-07 https://bio-research.ai/ionis-pharmaceuticals-phase-3-balance-study-results-of-olezarsen-for-treating-familial-chylomicronemia-syndrome-shows-reduction-in-fasting-triglycerides-and-acute-pancreatitis-instances/ 2024-04-07 https://bio-research.ai/alnylam-pharmaceuticals-reports-phase-2-kardia-2-study-results-of-zilebesiran-in-patients-with-inadequately-controlled-hypertension/ 2024-04-07 https://bio-research.ai/novartis-reports-ldl-c-reductions-in-ascvd-patients-with-leqvio-in-v-initiate-trial-compared-to-usual-care/ 2024-04-06 https://bio-research.ai/ocular-therapeutix-reports-phase-2-trial-results-of-paxtrava-implant-in-glaucoma-patients-indicating-24-30-reductions-in-intraocular-pressure-over-six-months/ 2024-04-06 https://bio-research.ai/fda-grants-accelerated-approval-to-daiichi-sankyo-and-astrazeneca-s-enhertu-for-treatment-of-unresectable-or-metastatic-her2-positive-solid-tumors-with-boxed-warnings/ 2024-04-06 https://bio-research.ai/merck-acquires-university-at-buffalo-spinoff-abceutics-for-up-to-208m-to-advance-antibody-drug-conjugate-technology-with-milestone-driven-deal-terms/ 2024-04-05 https://bio-research.ai/fda-approves-carvykti-for-treatment-of-relapsed-or-refractory-multiple-myeloma-after-one-prior-therapy-based-on-phase-3-cartitude-4-study-results/ 2024-04-05 https://bio-research.ai/cytokinetics-reports-48-week-aficamten-data-from-forest-hcm-with-clinical-efficacy-endpoints-nyha-class-and-cardiac-biomarkers-improvement-in-hcm-patients/ 2024-04-05 https://bio-research.ai/astrazeneca-s-phase-iii-adriatic-trial-of-imfinzi-improves-overall-survival-and-progression-free-survival-in-limited-stage-small-cell-lung-cancer-after-concurrent-chemoradiotherapy/ 2024-04-05 https://bio-research.ai/teva-pharmaceuticals-and-mabxience-forge-global-licensing-deal-for-oncology-biosimilar-amidst-expansion-efforts/ 2024-04-04 https://bio-research.ai/candel-therapeutics-reports-positive-interim-survival-data-from-phase-2-trial-of-can-2409-with-valacyclovir-in-pancreatic-cancer/ 2024-04-04 https://bio-research.ai/effector-therapeutics-reports-phase-2-kickstart-trial-results-of-tomivosertib-with-pembrolizumab-in-non-small-cell-lung-cancer-without-meeting-progression-free-survival-threshold/ 2024-04-04 https://bio-research.ai/acumen-pharmaceuticals-partners-with-lonza-for-phase-2-trial-manufacturing-of-alzheimer-s-treatment-sabirnetug-using-scalable-bioreactor-technology/ 2024-04-04 https://bio-research.ai/odyssey-therapeutics-and-janssen-pharmaceutica-collaborate-to-develop-ai-driven-small-molecule-medicines-with-potential-milestone-payments-and-royalties/ 2024-04-04 https://bio-research.ai/mina-therapeutics-and-nippon-shinyaku-forge-research-collaboration-to-develop-rnaa-therapeutics-for-rare-neurodegenerative-diseases-with-licensing-and-commercialization-options/ 2024-04-04 https://bio-research.ai/caris-life-sciences-and-merck-kgaa-forge-1-4b-deal-to-develop-antibody-drug-conjugates-for-cancer-with-milestones-and-royalties/ 2024-04-04 https://bio-research.ai/basilea-pharmaceutica-ltd-s-zevtera-approved-by-fda-for-staphylococcus-aureus-bloodstream-infections-and-cabp-receives-usd-112-million-in-federal-funding-for-development/ 2024-04-04 https://bio-research.ai/curevac-and-gsk-release-interim-phase-2-data-showing-increased-antibody-titers-from-influenza-vaccine-candidate-in-clinical-trial-with-adults/ 2024-04-04 https://bio-research.ai/amylyx-pharmaceuticals-to-discontinue-marketing-authorizations-for-als-treatment-relyvrio-albrioza-after-phase-3-trial-results/ 2024-04-04 https://bio-research.ai/arca-biopharma-and-oruka-therapeutics-to-merge-in-an-all-stock-deal-with-oruka-securing-275m-for-chronic-skin-disease-biologics-trials/ 2024-04-03 https://bio-research.ai/kintara-therapeutics-merges-with-tuhura-biosciences-in-an-all-stock-deal-forming-a-new-entity-trading-as-hura-with-31m-in-subscribed-financing/ 2024-04-03 https://bio-research.ai/genmab-a-s-to-acquire-profoundbio-inc-for-1-8b-gaining-rights-to-next-generation-adcs-and-expanding-clinical-trials-portfolio/ 2024-04-03 https://bio-research.ai/european-commission-expands-approval-for-bristol-myers-squibb-s-reblozyl-for-first-line-treatment-of-adult-patients-with-transfusion-dependent-anemia-due-to-lower-risk-myelodysplastic-syndromes/ 2024-04-02 https://bio-research.ai/fda-approves-vanda-s-fanapt-for-acute-treatment-of-manic-or-mixed-episodes-in-bipolar-i-disorder-adults/ 2024-04-02 https://bio-research.ai/fibrogen-reports-phase-1-study-results-of-fg-3246-in-metastatic-castration-resistant-prostate-cancer-with-median-radiographic-progression-free-survival-and-psa50-response-rates/ 2024-04-02 https://bio-research.ai/myrtelle-inc-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-raav-olig001-aspa-in-canavan-disease-treatment/ 2024-04-02 https://bio-research.ai/jazz-pharmaceuticals-submits-biologics-license-application-to-fda-for-zanidatamab-based-on-phase-2b-herizon-btc-01-trial-results-in-her2-positive-biliary-tract-cancer/ 2024-04-02 https://bio-research.ai/kiromic-biopharma-reports-stage-4-metastatic-non-small-cell-lung-cancer-patient-achieves-tumor-stabilization-in-deltacel-01-phase-1-trial/ 2024-04-02 https://bio-research.ai/european-medicines-agency-accepts-autolus-therapeutics-marketing-authorization-application-for-obe-cel-a-car-t-cell-therapy-for-relapsed-refractory-adult-b-cell-acute-lymphoblastic-leukemia/ 2024-04-02 https://bio-research.ai/ginkgo-bioworks-acquires-modulus-therapeutics-cell-therapy-platform-to-enhance-car-therapies-for-solid-tumors-and-autoimmune-diseases/ 2024-04-02 https://bio-research.ai/roivant-and-priovant-therapeutics-release-phase-2-neptune-study-results-of-brepocitinib-in-non-anterior-non-infectious-uveitis-and-announce-share-repurchase-program/ 2024-04-02 https://bio-research.ai/ipsen-and-sutro-biopharma-ink-exclusive-global-licensing-deal-for-stro-003-adc-targeting-ror1-with-up-to-900m-in-potential-payments/ 2024-04-02 https://bio-research.ai/astrazeneca-and-daiichi-sankyo-s-biologics-license-application-for-datopotamab-deruxtecan-accepted-in-the-us-for-treatment-of-hormone-receptor-positive-her2-negative-breast-cancer-after-prior-therapy/ 2024-04-02 https://bio-research.ai/nurix-therapeutics-secures-15m-extension-fee-from-gilead-sciences-for-continued-e3-ligase-targeted-drug-discovery-collaboration-with-up-to-1-7b-in-potential-milestones-and-profit-sharing-options/ 2024-04-02 https://bio-research.ai/innovent-biologics-and-hutchmed-announce-nmpa-priority-review-for-sintilimab-and-fruquintinib-combination-therapy-nda-in-advanced-endometrial-cancer/ 2024-04-02 https://bio-research.ai/biomea-fusion-inc-reports-initial-response-data-from-type-1-diabetes-patients-in-phase-ii-covalent-112-study-with-bmf-219-and-beta-cell-function-improvement/ 2024-04-01 https://bio-research.ai/gritstone-bio-reports-preliminary-phase-2-study-results-of-granite-in-metastatic-microsatellite-stable-colorectal-cancer-indicating-progression-free-survival-benefit-and-alignment-with-circulating-tumor-dna-analysis/ 2024-04-01 https://bio-research.ai/surrozen-inc-reports-phase-1a-trial-results-of-szn-043-for-liver-function-begins-phase-1b-trial-for-alcohol-associated-hepatitis/ 2024-04-01 https://bio-research.ai/teva-pharmaceutical-partners-with-launch-therapeutics-and-secures-up-to-150m-from-abingworth-for-tev-248-asthma-inhaler-clinical-trials/ 2024-04-01 https://bio-research.ai/equillium-reports-phase-1b-equalise-study-results-of-itolizumab-in-lupus-nephritis-patients-indicating-urine-protein-creatinine-ratio-reduction/ 2024-04-01 https://bio-research.ai/incyte-partners-with-china-medical-system-holdings-for-development-and-commercialization-of-jak1-inhibitor-povorcitinib-in-asia/ 2024-04-01 https://bio-research.ai/solid-biosciences-receives-rare-pediatric-disease-designation-from-the-fda-for-duchenne-muscular-dystrophyl-of-sgt-003/ 2024-04-01 https://bio-research.ai/fda-approves-alexion-s-voydeya-as-add-on-therapy-for-adults-with-paroxysmal-nocturnal-haemoglobinuria-based-on-alpha-phase-iii-trial-results/ 2024-04-01 https://bio-research.ai/cellenkos-and-icahn-school-of-medicine-at-mount-sinai-partner-to-research-ck0804-treg-cell-therapy-in-myelofibrosis-treatment-under-dr-ronald-hoffman-s-leadership/ 2024-04-01 https://bio-research.ai/astellas-pharma-inc-announces-fda-acceptance-of-snda-for-izervay-to-include-2-year-data-in-prescribing-information-for-geographic-atrophy-treatment/ 2024-04-01 https://bio-research.ai/eisai-and-biogen-submit-supplemental-application-to-fda-for-monthly-iv-maintenance-dosing-of-lecanemab-irmb-for-early-alzheimer-s-disease-treatment-based-on-phase-2-and-clarity-ad-study-data/ 2024-04-01 https://bio-research.ai/biostar-pharma-receives-fda-orphan-drug-designation-for-utidelone-injectable-in-breast-cancer-brain-metastasis-treatment-following-phase-ii-trial-results/ 2024-03-29 https://bio-research.ai/alebund-pharmaceuticals-receives-orphan-drug-designation-from-fda-for-ap303-in-treatment-of-autosomal-dominant-polycystic-kidney-disease/ 2024-03-29 https://bio-research.ai/asahi-kasei-pharma-expands-doptelet-distribution-in-japan-for-idiopathic-thrombocytopenic-purpura-through-exclusive-rights-deal-with-sobi-japan/ 2024-03-29 https://bio-research.ai/eisai-co-ltd-sells-merislon-and-myonal-rights-to-kaken-pharmaceutical-co-ltd-for-3-8b-yen-with-plans-for-marketing-and-manufacturing-transfer-by-march-2025/ 2024-03-29 https://bio-research.ai/health-canada-approves-paladin-labs-wakix-for-excessive-daytime-sleepiness-and-cataplexy-in-pediatric-narcolepsy-patients-aged-6-and-older/ 2024-03-28 https://bio-research.ai/bridge-biotherapeutics-collaborates-with-emory-university-s-dr-jessica-m-konen-to-enhance-lung-cancer-treatment-with-bbt-877-and-anti-pd-1-therapy-combination/ 2024-03-28 https://bio-research.ai/ironwood-pharmaceuticals-reports-phase-ii-stargaze-trial-results-of-apraglutide-in-steroid-refractory-gastrointestinal-acute-graft-versus-host-disease-patients/ 2024-03-28 https://bio-research.ai/lupin-limited-secures-us-fda-approval-for-generic-eslicarbazepine-acetate-tablets-to-treat-partial-onset-seizures/ 2024-03-28 https://bio-research.ai/fda-extends-review-period-for-applied-therapeutics-nda-for-govorestat-in-classic-galactosemia-to-november-28-2024/ 2024-03-28 https://bio-research.ai/biodexa-pharmaceuticals-reports-phase-1-trial-results-of-mtx110-for-diffuse-midline-glioma-and-recurrent-glioblastoma-using-convection-enhanced-delivery-technology/ 2024-03-28 https://bio-research.ai/ptc-therapeutics-submits-mma-to-ema-for-sepiapterin-for-phenylketonuria-treatment-based-on-phase-3-aphenity-trial-results-showing-reduction-in-blood-phenylalanine-levels/ 2024-03-28 https://bio-research.ai/fda-approves-gilead-sciences-vemlidy-for-chronic-hepatitis-b-in-children-over-six-years-based-on-phase-2-trial-results/ 2024-03-28 https://bio-research.ai/lipocine-inc-reports-phase-2-study-results-of-lpcn-1148-for-cirrhosis-management-indicating-increased-skeletal-muscle-index-and-reduced-overt-hepatic-encephalopathy-events/ 2024-03-28 https://bio-research.ai/genfleet-therapeutics-partners-with-beigene-switzerland-for-phase-ib-ii-trial-of-gfh009-combination-with-brukinsa-in-dlbcl-treatment-across-china/ 2024-03-28 https://bio-research.ai/european-commission-approves-merck-s-keytruda-with-chemotherapy-as-neoadjuvant-treatment-then-continued-as-monotherapy-as-adjuvant-treatment-for-resectable-non-small-cell-lung-cancer-based-on-phase-3-trial-results/ 2024-03-28 https://bio-research.ai/gilead-sciences-inks-exclusive-license-deal-with-xilio-therapeutics-for-phase-1-tumor-activated-il-12-program-xtx301-with-up-to-647-5m-in-potential-payments-and-tiered-royalties/ 2024-03-28 https://bio-research.ai/fda-approves-vafseo-tablets-for-anemia-in-chronic-kidney-disease-patients-on-dialysis/ 2024-03-27 https://bio-research.ai/avalo-therapeutics-acquires-phase-2-ready-avtx-009-from-almatabio-in-a-185m-deal-with-financing-from-commodore-capital-tcgx-bvf-partners-deep-track-capital-orbimed-petrichor-and-ra-capital-management/ 2024-03-27 https://bio-research.ai/pyxis-oncology-sells-beovu-royalty-rights-to-novartis-for-8m-to-continue-development-of-promising-lead-adc-asset-pyx-201/ 2024-03-27 https://bio-research.ai/european-medicines-agency-grants-prime-status-to-89bio-s-pegozafermin-for-mash-treatment-phase-2b-enliven-trial-supports-efficacy-and-safety-in-fibrosis-stages-phase-3-trials-underway/ 2024-03-27 https://bio-research.ai/japan-approves-astrazeneca-and-sanofi-s-beyfortus-for-rsv-prophylaxis-in-infants-and-children-based-on-results-from-late-stage-clinical-trials/ 2024-03-27 https://bio-research.ai/astrazeneca-s-truqap-with-faslodex-approved-in-japan-for-treatment-of-breast-cancer-with-specific-biomarkers-after-phase-iii-trial-results-show-reduced-disease-progression-risk/ 2024-03-27 https://bio-research.ai/heidelberg-pharma-ag-receives-fda-orphan-drug-designation-for-hdp-101-in-multiple-myeloma-treatment/ 2024-03-27 https://bio-research.ai/beckley-psytech-ltd-reports-phase-iia-clinical-study-results-for-bpl-003-in-treatment-resistant-depression-indicating-antidepressant-response-and-remission-rates-after-a-single-intranasal-dose/ 2024-03-26 https://bio-research.ai/fda-grants-priority-review-for-syndax-pharmaceuticals-nda-for-revumenib-as-a-treatment-for-relapsed-or-refractory-kmt2a-rearranged-acute-leukemia/ 2024-03-26 https://bio-research.ai/fda-approves-merck-s-winrevair-for-treatment-of-pulmonary-arterial-hypertension-to-increase-exercise-capacity-and-improve-who-functional-class/ 2024-03-26 https://bio-research.ai/zevra-therapeutics-releases-phase-2-data-on-kp1077-for-treating-idiopathic-hypersomnia-indicating-symptoms-improvement-and-informs-phase-3-study-design/ 2024-03-26 https://bio-research.ai/johnson-johnson-s-nipocalimab-receives-fda-fast-track-designation-for-fnait-treatment-ongoing-phase-3-trials-assess-effectiveness-in-fnait-and-hdfn/ 2024-03-26 https://bio-research.ai/nanoscope-therapeutics-reports-phase-2b-restore-trial-of-mco-010-meets-primary-endpoint-for-retinitis-pigmentosa-with-statistically-significant-visual-acuity-improvement-at-week-52/ 2024-03-26 https://bio-research.ai/fda-approves-medexus-s-sbla-for-ixinity-in-pediatric-patients-under-12-with-hemophilia-b-based-on-phase-3-4-study-results/ 2024-03-26 https://bio-research.ai/japan-approves-adzynma-for-treatment-of-congenital-thrombotic-thrombocytopenic-purpura-in-individuals-12-and-older/ 2024-03-26 https://bio-research.ai/astellas-vyloy-approved-in-japan-for-cldn18-2-positive-gastric-cancer-treatment-based-on-phase-3-spotlight-and-glow-trial-results/ 2024-03-26 https://bio-research.ai/viking-therapeutics-reports-phase-1-clinical-trial-results-of-vk2735-with-observed-weight-loss-and-plans-for-phase-2-obesity-treatment-trial/ 2024-03-26 https://bio-research.ai/moderna-reports-phase-3-trial-results-for-mrna-1283-demonstrating-higher-immune-response-than-licensed-vaccine-mrna-1273-222-especially-in-participants-over-65-years-old/ 2024-03-26 https://bio-research.ai/praxis-precision-medicines-reports-phase-2a-study-results-of-prax-628-for-epilepsy-with-complete-response-in-45-mg-cohort-and-high-response-rate-in-15-mg-cohort-ahead-of-planned-efficacy-study-in-focal-onset-epilepsy/ 2024-03-26 https://bio-research.ai/japan-approves-vyvgart-for-adult-primary-immune-thrombocytopenia-following-positive-phase-3-trial-results/ 2024-03-26 https://bio-research.ai/bluejay-therapeutics-bjt-778-receives-priority-medicine-designation-from-european-medicines-agency-for-chronic-hepatitis-delta-virus-treatment/ 2024-03-25 https://bio-research.ai/moleculin-biotech-reports-60-crc-rate-in-phase-1b-2-trial-of-annamycin-and-cytarabine-in-second-line-aml-patients-without-cardiotoxicity-plans-for-end-of-phase-2-meeting-with-fda/ 2024-03-25 https://bio-research.ai/astria-therapeutics-announces-alpha-star-phase-1b-2-clinical-trial-results-of-star-0215-in-hereditary-angioedema-patients-with-reduced-attack-rates-and-plans-for-phase-3-trial/ 2024-03-25 https://bio-research.ai/fda-approves-alexion-s-ultomiris-for-adult-patients-with-anti-aqp4-antibody-positive-neuromyelitis-optica-spectrum-disorder-following-champion-nmosd-phase-iii-trial-results/ 2024-03-25 https://bio-research.ai/tonix-pharmaceuticals-receives-rare-pediatric-disease-designation-from-fda-for-tnx-2900-to-treat-prader-willi-syndrome/ 2024-03-25 https://bio-research.ai/sobi-s-ava-ped-301-study-shows-avatrombopag-meets-primary-endpoint-in-pediatric-itp-patients/ 2024-03-25 https://bio-research.ai/verge-genomics-partners-with-ferrer-to-co-develop-and-explore-commercialization-of-als-drug-vrg50635-in-europe-and-other-regions/ 2024-03-25 https://bio-research.ai/axsome-therapeutics-phase-3-trial-of-axs-12-reduces-cataplexy-attacks-in-narcolepsy-patients/ 2024-03-25 https://bio-research.ai/fda-grants-orphan-drug-designation-to-advicenne-s-adv7103-for-cystinuria-treatment-expanding-on-previous-renal-tubular-acidosis-indication/ 2024-03-25 https://bio-research.ai/nuvation-bio-acquires-anheart-therapeutics-in-all-stock-agreement-gains-next-gen-cancer-inhibitors-taletrectinib-and-safusidenib-with-shareholders-to-own-33-of-merged-entity/ 2024-03-25 https://bio-research.ai/fda-issues-complete-response-letters-for-regeneron-s-odronextamab-biologics-license-application-cites-further-trial-enrollment-needs/ 2024-03-25 https://bio-research.ai/novo-nordisk-to-acquire-cardior-pharmaceuticals-in-a-deal-up-to-1-025b-advancing-phase-2-rna-targeting-heart-failure-treatment-cdr132l/ 2024-03-25 https://bio-research.ai/biocytogen-pharmaceuticals-and-abl-bio-inc-partner-to-develop-new-bispecific-antibody-drug-conjugates-using-renlite-mice-platform/ 2024-03-25 https://bio-research.ai/astellas-pharma-announced-that-the-chmp-recommended-approval-of-xtandi-for-treatment-of-high-risk-biochemical-recurrent-non-metastatic-hormone-sensitive-prostate-cancer-based-on-phase-3-embark-trial-results/ 2024-03-25 https://bio-research.ai/aribio-secures-up-to-770m-deal-with-undisclosed-chinese-licensee-for-alzheimer-s-drug-ar1001/ 2024-03-24 https://bio-research.ai/fda-approves-johnson-johnson-s-opsynvi-for-adult-patients-with-pulmonary-arterial-hypertension-after-demonstrating-improvement-in-pulmonary-vascular-resistance-in-a-due-study/ 2024-03-22 https://bio-research.ai/pharmazz-inc-and-dr-reddy-s-laboratories-to-commercialize-hypovolemic-shock-drug-lyfaquin-in-india-and-nepal-under-new-licensing-agreement-with-royalties-and-upfront-payments/ 2024-03-22 https://bio-research.ai/fda-grants-full-approval-for-abbvie-s-elahere-in-fr-positive-platinum-resistant-ovarian-cancer-following-up-to-three-prior-therapies-based-on-mirasol-phase-3-trial-results-showing-reduced-risk-of-cancer-progression-and-overall-survival-benefit/ 2024-03-22 https://bio-research.ai/fda-approves-expanded-labeling-for-esperion-s-drugs-nexletol-and-nexlizet-based-on-clear-outcomes-trial-results-for-broader-patient-use-in-ldl-c-and-cardiovascular-risk-reduction/ 2024-03-22 https://bio-research.ai/novartis-iptacopan-recommended-by-ema-s-chmp-for-adult-pnh-patients-following-apply-pnh-and-appoint-pnh-clinical-trials/ 2024-03-22 https://bio-research.ai/chmp-issues-positive-opinion-on-outlook-therapeutics-ons-5010-lytenava-for-wet-amd-treatment-in-eu/ 2024-03-22 https://bio-research.ai/okyo-pharma-limited-s-phase-2-trial-of-ok-101-shows-reductions-in-ocular-pain-and-improvements-in-tear-film-break-up-time-in-patients-with-inflammatory-dry-eye-disease/ 2024-03-22 https://bio-research.ai/chmp-recommends-marketing-authorization-for-ucb-s-bimzelx-bimekizumab-for-adults-with-moderate-to-severe-hidradenitis-suppurativa-based-on-phase-3-study-data/ 2024-03-22 https://bio-research.ai/ono-pharmaceutical-partners-with-university-of-oxford-for-drug-discovery-in-neuroscience-secures-global-commercialization-rights/ 2024-03-22 https://bio-research.ai/european-medicines-agency-s-chmp-recommends-marketing-authorization-for-novo-nordisk-s-awiqli-for-diabetes-treatment-following-onwards-phase-3a-clinical-trial-results/ 2024-03-21 https://bio-research.ai/fda-grants-orphan-drug-designation-to-biostar-pharma-s-utd2-for-gastric-cancer-treatment-with-tax-incentives-and-exclusive-marketing-rights/ 2024-03-21 https://bio-research.ai/kazia-therapeutics-signs-20-5m-deal-with-sovargen-for-paxalisib-development-in-rare-cns-disorders/ 2024-03-21 https://bio-research.ai/otsuka-reports-interim-phase-2b-c-trial-data-of-quabodepistat-in-combination-therapy-for-pulmonary-tb/ 2024-03-21 https://bio-research.ai/fda-grants-orphan-drug-designation-to-hi-bio-s-felzartamab-for-treatment-of-antibody-mediated-rejection-in-kidney-transplant-recipients/ 2024-03-21 https://bio-research.ai/oscotec-inc-receives-orphan-drug-designation-from-fda-for-syk-inhibitor-cevidoplenib-in-immune-thrombocytopenia-treatment/ 2024-03-21 https://bio-research.ai/blue-lake-biotechnology-reports-initial-phase-1-2a-clinical-trial-data-for-blb201-rsv-vaccine-in-children-aged-18-59-months/ 2024-03-21 https://bio-research.ai/fda-grants-rare-pediatric-disease-designation-to-lisata-therapeutics-lsta1-for-treatment-of-osteosarcoma-in-youth-offers-priority-voucher-upon-approval/ 2024-03-21 https://bio-research.ai/scandion-oncology-releases-interim-phase-2-corist-trial-data-showing-progression-free-survival-and-clinical-benefit-in-metastatic-colorectal-cancer-patients/ 2024-03-21 https://bio-research.ai/merck-s-keylynk-006-phase-3-trial-of-keytruda-and-lynparza-fails-to-meet-primary-endpoints-in-metastatic-nonsquamous-non-small-cell-lung-cancer/ 2024-03-21 https://bio-research.ai/sosei-heptares-regains-full-rights-to-gpr35-agonist-htl0027477-for-ibd-as-gsk-ends-partnership-without-financial-terms-disclosure/ 2024-03-21 https://bio-research.ai/fda-grants-fast-track-designation-to-phanes-therapeutics-pt886-for-metastatic-pancreatic-adenocarcinoma-treatment/ 2024-03-21 https://bio-research.ai/european-commission-grants-approval-to-abecma-for-advanced-multiple-myeloma-following-successful-phase-3-trial/ 2024-03-20 https://bio-research.ai/m8-pharmaceuticals-inks-exclusive-deal-with-serb-for-voraxaze-marketing-in-latin-america-to-combat-cancer-patient-toxicity/ 2024-03-20 https://bio-research.ai/nls-pharmaceutics-acquires-worldwide-rights-to-aexon-labs-orexin-receptor-agonists-in-bid-to-tackle-neurological-disorders/ 2024-03-20 https://bio-research.ai/tevogen-bio-reports-tvgn-489-immunotherapy-retains-activity-against-jn-1-strain-of-sars-cov-2/ 2024-03-20 https://bio-research.ai/idorsia-s-new-hypertension-drug-tryvio-gains-fda-approval-poised-for-2024-u-s-launch-with-special-distribution-program/ 2024-03-20 https://bio-research.ai/china-s-nmpa-accepts-simcere-zaiming-s-application-for-ovarian-cancer-drug-suvemcitug-after-positive-phase-iii-results/ 2024-03-20 https://bio-research.ai/fda-grants-orphan-drug-designation-to-cabaletta-bio-s-cd19-car-t-cell-therapy-for-systemic-sclerosis-treatment-in-reset-clinical-trial-program/ 2024-03-20 https://bio-research.ai/gensight-biologics-reports-four-year-results-from-reflect-phase-iii-clinical-trial-of-lumevoq-for-treatment-of-leber-hereditary-optic-neuropathy/ 2024-03-20 https://bio-research.ai/singapore-grants-approval-for-everest-medicines-nefegan-to-treat-iga-nephropathy-following-successful-phase-3-trial-results/ 2024-03-19 https://bio-research.ai/ptc-therapeutics-seeks-fda-approval-for-aav2-based-upstaza-delivering-ddc-gene-in-aadc-deficiency/ 2024-03-19 https://bio-research.ai/bayer-reports-phase-iii-oasis-3-study-results-of-elinzanetant-showing-significant-reduction-in-menopausal-vasomotor-symptoms/ 2024-03-19 https://bio-research.ai/seelos-therapeutics-reports-phase-2-3-healey-als-trial-results-for-sls-005-in-als-patients-showing-no-statistical-significance-in-primary-endpoints/ 2024-03-19 https://bio-research.ai/fda-grants-accelerated-snda-approval-to-takeda-s-iclusig-for-new-ph-all-treatment-in-combination-with-chemotherapy-bolstered-by-phallcon-study-results/ 2024-03-19 https://bio-research.ai/health-canada-approves-csl-vifor-s-ferinject-for-iron-deficiency-anemia-and-heart-failure-patients-launch-expected-in-late-2024/ 2024-03-19 https://bio-research.ai/forge-biologics-fbx-101-for-krabbe-disease-granted-innovation-passport-by-mhra-reports-progress-in-reklaim-trial-and-secures-multiple-regulatory-designations/ 2024-03-19 https://bio-research.ai/crinetics-pharmaceuticals-reports-paltusotine-reaches-primary-and-secondary-endpoints-in-pathfndr-2-phase-3-study/ 2024-03-19 https://bio-research.ai/boehringer-ingelheim-s-spevigo-granted-fda-approval-for-generalized-pustular-psoriasis-treatment-in-adults-and-pediatric-patients/ 2024-03-19 https://bio-research.ai/astrazeneca-acquires-fusion-pharmaceuticals-for-2-4b-enhancing-cancer-treatment-arsenal-with-radioconjugates/ 2024-03-19 https://bio-research.ai/sun-pharma-s-winlevi-cream-gains-australian-approval-for-acne-treatment-in-patients-12-and-up/ 2024-03-19 https://bio-research.ai/innovent-biologics-phase-2-clinical-study-of-efdamrofusp-alfa-meets-primary-endpoint-in-namd-treatment-trial/ 2024-03-19 https://bio-research.ai/fda-approves-orchard-therapeutics-innovative-gene-therapy-lenmeldy-to-combat-rare-genetic-disorder-metachromatic-leukodystrophy-in-children/ 2024-03-18 https://bio-research.ai/pmv-pharmaceuticals-reports-phase-1-results-of-rezatapopt-in-tp53-y220c-mutant-advanced-ovarian-cancer-patients/ 2024-03-18 https://bio-research.ai/fda-sets-review-deadline-for-citius-pharma-s-lymphir-in-cutaneous-t-cell-lymphoma-after-previous-crl/ 2024-03-18 https://bio-research.ai/perspective-therapeutics-partners-with-bristol-myers-squibb-for-phase-1-2a-safety-and-efficacy-trial-of-alpha-particle-therapy-pb-vmt01-in-combination-with-nivolumab-for-melanoma-treatment/ 2024-03-18 https://bio-research.ai/fda-sets-pdufa-goal-date-of-november-4-2024-for-journey-medical-s-rosacea-candidate-dfd-29-after-positive-phase-3-results/ 2024-03-18 https://bio-research.ai/phase-iii-trials-of-asieris-pharmaceuticals-cevira-show-increased-hsil-response-and-high-risk-hpv-clearance-rates-prepares-for-regulatory-submission-in-china/ 2024-03-18 https://bio-research.ai/aska-pharmaceutical-joins-forces-with-red-arrow-therapeutics-to-develop-ph-sensing-drug-delivery-nanotech-based-preeclampsia-treatment/ 2024-03-18 https://bio-research.ai/faron-pharmaceuticals-reports-phase-1-2-bexmab-study-results-for-hr-mds-patients-after-failed-hypomethylating-agent-therapies/ 2024-03-18 https://bio-research.ai/fennec-pharmaceuticals-inks-40m-deal-with-norgine-for-eu-and-u-k-commercialization-of-pedmarqsi-with-potential-210m-milestones-and-sales-royalties/ 2024-03-17 https://bio-research.ai/fda-approves-xhance-as-first-and-only-medication-indicated-for-treatment-of-adults-with-chronic-rhinosinusitis-without-nasal-polyps/ 2024-03-15 https://bio-research.ai/jasper-therapeutics-reports-full-donor-engraftment-and-blood-count-recovery-in-all-six-phase-1b-2a-trial-patients-treated-with-briquilimab/ 2024-03-15 https://bio-research.ai/union-therapeutics-a-s-reports-positive-results-of-osiris-phase-2-study-on-orismilast-in-treating-hidradenitis-suppurativa/ 2024-03-15 https://bio-research.ai/merck-s-keytruda-in-combination-with-chemoradiotherapy-improves-overall-survival-in-phase-3-trial-for-high-risk-locally-advanced-cervical-cancer/ 2024-03-15 https://bio-research.ai/biotheus-inc-and-hansoh-pharma-ink-deal-for-global-license-of-pm1080-hs-20117-adc-with-upfront-and-milestones-worth-up-to-5b-rmb/ 2024-03-15 https://bio-research.ai/fda-approves-rezdiffra-for-nash-with-liver-fibrosis-based-on-results-from-the-phase-3-maestro-nash-trial-awaits-confirmation-from-ongoing-studies/ 2024-03-14 https://bio-research.ai/fda-grants-accelerated-approval-to-bristol-myers-squibb-s-car-t-cell-therapy-breyanzi-for-cll-and-sll-amid-continued-clinical-trials/ 2024-03-14 https://bio-research.ai/aquestive-therapeutics-reports-phase-3-results-of-anaphylm-epinephrine-sublingual-film-showing-comparable-pharmacokinetic-endpoints-to-autoinjectors/ 2024-03-14 https://bio-research.ai/fda-approves-beigene-s-tevimbra-for-advanced-esophageal-cancer-following-based-on-the-rationale-302-trial-which-met-its-primary-endpoint/ 2024-03-14 https://bio-research.ai/ocuterra-therapeutics-fails-to-meet-its-primary-or-key-secondary-efficacy-endpoints-in-phase-2-trial-results-of-ott166-for-diabetic-retinopathy/ 2024-03-14 https://bio-research.ai/immuneering-corporation-reports-phase-1-results-of-imm-1-104-in-advanced-ras-mutant-solid-tumors-showing-drug-tolerance-and-target-lesion-regression/ 2024-03-14 https://bio-research.ai/ono-pharmaceutical-and-sibylla-biotech-team-up-to-develop-new-drugs-for-neurological-disorders-with-potential-milestone-payments-up-to-three-digit-m-dollars-using-ppi-fit-technology/ 2024-03-14 https://bio-research.ai/first-wave-biopharma-acquires-immunogenx-in-all-stock-deal-worth-104m-secures-us-and-canada-commercial-rights-for-celiac-disease-biotherapeutic-latiglutenase/ 2024-03-14 https://bio-research.ai/anocca-ab-licenses-emendobio-s-omni-a4-gene-editing-technology-to-enhance-tcr-t-cell-therapy-manufacturing-for-solid-cancer-treatment/ 2024-03-14 https://bio-research.ai/astrazeneca-acquires-amolyt-pharma-for-up-to-1-05b-including-800m-upfront-and-250m-milestone-payments-with-eneboparatide-in-phase-3-trials/ 2024-03-14 https://bio-research.ai/fda-approves-mirum-s-livmarli-for-cholestatic-pruritus-in-pfic-patients-aged-five-and-up-with-plans-to-expand-treatment-to-younger-children/ 2024-03-13 https://bio-research.ai/probiogen-and-mapp-biopharmaceuticals-announce-collaboration-to-develop-afucosylated-antibody-cell-line-using-glymaxx-technology-against-marburg-virus/ 2024-03-13 https://bio-research.ai/almirall-acquires-global-rights-to-eloxx-s-zkn-013-for-rare-dermatological-diseases-in-deal-worth-up-to-473m-plus-royalties/ 2024-03-13 https://bio-research.ai/switzerland-approves-bavarian-nordic-s-jynneos-vaccine-for-smallpox-and-mpox/ 2024-03-13 https://bio-research.ai/takeda-releases-phase-2-clinical-trial-results-for-mezagitamab-in-primary-immune-thrombocytopenia-patients/ 2024-03-13 https://bio-research.ai/ricoh-enhances-drug-discovery-capabilities-through-crispr-cas9-patent-agreement-with-ers-genomics-post-elixirgen-scientific-acquisition/ 2024-03-13 https://bio-research.ai/silence-therapeutics-reports-90-median-reduction-in-lp-a-levels-at-36-weeks-in-phase-2-alpacar-360-study-of-zerlasiran/ 2024-03-13 https://bio-research.ai/novartis-acquires-ifm-due-for-90m-upfront-with-potential-milestone-payments-of-up-to-745m-totaling-835m-in-sting-antagonist-program-deal/ 2024-03-13 https://bio-research.ai/ionis-pharmaceuticals-reports-phase-2-study-results-of-ion224-in-mash-showing-significant-liver-histological-improvement/ 2024-03-13 https://bio-research.ai/eu-commission-approves-pfizer-s-prevenar-20-vaccine-broadening-protection-against-pneumococcal-disease-in-youth/ 2024-03-13 https://bio-research.ai/crinetics-pharmaceuticals-releases-phase-2-study-results-on-paltusotine-for-carcinoid-syndrome-with-plans-for-phase-3-trial-initiation/ 2024-03-12 https://bio-research.ai/allogene-therapeutics-and-arbor-biotechnologies-ink-licensing-deal-for-crispr-tech-in-allocar-t-autoimmune-therapy-development/ 2024-03-12 https://bio-research.ai/mc2-therapeutics-licenses-wynzora-cream-to-hyphens-pharma-for-asean-market-with-2-5m-euro-deal-including-milestones-and-royalties/ 2024-03-12 https://bio-research.ai/regulus-therapeutics-inc-reports-dose-response-in-phase-1b-study-of-rgls8429-for-adpkd-and-discusses-accelerated-approval-pathway-with-fda/ 2024-03-12 https://bio-research.ai/pfizer-announces-positive-phase-3-results-for-adcetris-combination-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/ 2024-03-12 https://bio-research.ai/ideaya-biosciences-and-merck-collaborate-on-clinical-trial-for-endometrial-cancer-with-parg-inhibitor-ide161-and-keytruda-combo/ 2024-03-12 https://bio-research.ai/johnson-johnson-seeks-fda-approval-for-tremfya-in-ulcerative-colitis-following-promising-phase-3-trial-results/ 2024-03-11 https://bio-research.ai/acadia-pharmaceuticals-phase-3-advance-2-trial-of-pimavanserin-for-schizophrenia-symptoms-fails-to-meet-primary-endpoint/ 2024-03-11 https://bio-research.ai/abcellera-partners-with-biogen-to-advance-brain-delivery-of-biotherapeutics-deal-includes-upfront-payment-and-potential-milestone-and-royalty-rewards/ 2024-03-11 https://bio-research.ai/affibody-and-acelyrin-report-izokibep-phase-2b-3-trial-success-for-psoriatic-arthritis/ 2024-03-11 https://bio-research.ai/biokin-s-systimmune-and-bristol-myers-squibb-ink-800m-deal-for-joint-development-and-global-commercialization-of-cancer-drug-bl-b01d1/ 2024-03-11 https://bio-research.ai/boehringer-ingelheim-partners-with-sosei-heptares-to-develop-novel-schizophrenia-treatment-totaling-up-to-755-m/ 2024-03-11 https://bio-research.ai/sanofi-reports-phase-2b-stream-ad-study-results-of-amlitelimab-for-atopic-dermatitis-showing-sustained-symptom-improvement/ 2024-03-11 https://bio-research.ai/incyte-reports-phase-2-clinical-trial-results-for-povorcitinib-in-adult-prurigo-nodularis-patients-showing-significant-improvement-in-itch-severity/ 2024-03-10 https://bio-research.ai/johnson-johnson-reports-sustained-efficacy-of-jnj-2113-for-psoriasis-in-phase-2b-frontier-2-trial-extension/ 2024-03-09 https://bio-research.ai/stemson-therapeutics-strikes-exclusive-deal-with-aderans-for-global-rights-to-hair-regeneration-cell-therapy-technology/ 2024-03-08 https://bio-research.ai/ucb-announces-48-week-post-hoc-analyses-from-be-heard-studies-of-bimekizumab-in-moderate-to-severe-hidradenitis-suppurativa/ 2024-03-08 https://bio-research.ai/mind-medicine-reports-phase-2b-clinical-trial-data-on-mm120-for-generalized-anxiety-disorder/ 2024-03-08 https://bio-research.ai/amylyx-pharmaceuticals-reports-phoenix-study-of-amx0035-fails-to-meet-primary-and-secondary-endpoints-in-als-treatment-trial/ 2024-03-08 https://bio-research.ai/alligator-bioscience-ab-and-aptevo-therapeutics-report-interim-phase-1-results-for-alg-apv-527-in-solid-tumors-treatment-with-stable-disease-in-two-breast-cancer-patients/ 2024-03-07 https://bio-research.ai/alphyn-phase-2a-trial-of-zabalafin-hydrogel-achieves-safety-and-efficacy-endpoints-in-atopic-dermatitis-treatment/ 2024-03-07 https://bio-research.ai/solid-biosciences-and-armatus-bio-strike-deal-for-fshd-treatment-licensing-of-aav-slb101-capsid/ 2024-03-07 https://bio-research.ai/mustang-bio-releases-phase-1-clinical-data-of-mb-101-car-t-cell-therapy-for-recurrent-high-grade-gliomas/ 2024-03-07 https://bio-research.ai/immuron-s-travelan-shows-efficacy-in-preventing-severe-travelers-diarrhea-by-66-7-compared-to-placebo-in-phase-2-trial/ 2024-03-07 https://bio-research.ai/gsk-s-dreamm-8-phase-iii-trial-of-blenrep-combo-meets-primary-endpoint-in-multiple-myeloma/ 2024-03-07 https://bio-research.ai/nodthera-s-nt-0796-shows-reduction-in-neuroinflammatory-biomarkers-for-parkinson-s-patients-in-study/ 2024-03-07 https://bio-research.ai/gabather-ab-reports-phase-ib-study-results-of-gt-002-for-schizophrenia-treatment-showing-safety-tolerability-and-target-engagement-in-the-brain/ 2024-03-07 https://bio-research.ai/gilead-sciences-partners-with-merus-in-1-6b-cancer-therapy-deal-pioneering-trispecific-antibody-research/ 2024-03-06 https://bio-research.ai/viiv-healthcare-s-latitude-phase-iii-trial-shows-long-acting-injectable-monthly-cabenuva-maintains-hiv-suppression-better-than-oral-therapy/ 2024-03-06 https://bio-research.ai/interim-data-shows-biogen-s-spinraza-influences-neurofilament-levels-in-sma-patients-post-zolgensma-treatment/ 2024-03-06 https://bio-research.ai/biomx-announces-m-a-deal-with-adaptive-phage-therapeutics-forming-a-phage-therapy-innovator-with-two-phase-2-candidates/ 2024-03-06 https://bio-research.ai/phase-i-trial-of-bluerock-therapeutics-bemdaneprocel-shows-sustained-engraftment-f-dopa-increase-and-motor-improvement-in-parkinson-s/ 2024-03-06 https://bio-research.ai/ono-pharmaceutical-gains-global-rights-to-develop-nxi-101-in-licensing-deal-with-nex-i-inc/ 2024-03-06 https://bio-research.ai/immutep-s-eftilagimod-alpha-and-paclitaxel-show-safety-and-tolerability-in-phase-ii-iii-breast-cancer-trial-preliminary-data/ 2024-03-05 https://bio-research.ai/inmune-bio-reports-statistically-significantly-increased-alpha-waves-in-ad-patients-with-xpro1595/ 2024-03-05 https://bio-research.ai/promising-early-results-for-bioinvent-s-bi-1206-antibody-in-phase-1-trial-with-rituximab-for-refractory-indolent-non-hodgkin-lymphoma/ 2024-03-05 https://bio-research.ai/alnylam-s-zilebesiran-shows-promise-in-kardia-2-study-for-hypertension-control-with-biannual-dosing/ 2024-03-05 https://bio-research.ai/regenxbio-s-phase-i-ii-trial-shows-positive-interim-results-for-duchenne-muscular-dystrophy-gene-therapy-rgx-202/ 2024-03-05 https://bio-research.ai/exonate-s-exn407-eye-drops-show-early-success-in-treating-retinal-disease-in-patients-with-diabetes-phase-ib-iia-trials-reveal-safety-and-efficacy/ 2024-03-05 https://bio-research.ai/fibrocor-therapeutics-partners-with-mcquade-center-to-advance-fib918-for-alport-syndrome/ 2024-03-05 https://bio-research.ai/novo-nordisk-s-semaglutide-shows-groundbreaking-success-in-slowing-ckd-progression-in-type-2-diabetics/ 2024-03-05 https://bio-research.ai/cellectar-biosciences-phase-1-trial-of-clr-131-reports-complete-remission-rate-of-64-in-head-and-neck-cancer/ 2024-03-04 https://bio-research.ai/c4-therapeutics-partners-with-merck-kgaa-in-a-16m-upfront-deal-eyeing-up-to-740m-in-milestones-for-cancer-focused-protein-degrader-collaboration/ 2024-03-04 https://bio-research.ai/brightpath-biotherapeutics-reports-phase-1-trial-results-of-bp2201-for-head-and-neck-cancer-showing-safety-and-disease-control/ 2024-03-04 https://bio-research.ai/akero-therapeutics-phase-2b-trial-of-efruxifermin-reports-endpoint-met-in-mash-treatment-with-50mg-dose-after-96-weeks/ 2024-03-04 https://bio-research.ai/vivoryon-therapeutics-reports-phase-2b-trial-of-pq912-varoglutamstat-misses-primary-and-key-secondary-endpoints-in-alzheimer-s-disease-study/ 2024-03-04 https://bio-research.ai/bridgebio-pharma-inks-deal-with-bayer-to-advance-acoramidis-in-europe-with-310m-milestone-payments-and-royalty-structure/ 2024-03-04 https://bio-research.ai/kinnate-biopharma-inc-strikes-31m-deal-with-pierre-fabre-laboratories-for-global-rights-to-exarafenib-and-pan-raf-assets-for-solid-tumors/ 2024-03-01 https://bio-research.ai/regimmune-s-phase-2b-trial-of-rgi-2001-reports-reduced-agvhd-rates-after-allohct/ 2024-03-01 https://bio-research.ai/stemcell-technologies-acquires-all-sqz-biotechnologies-assets-gains-over-400-patents-and-clinical-rights-to-cellpore-transfection-system/ 2024-02-29 https://bio-research.ai/clene-nanomedicine-reports-phase-2-trial-results-of-cnm-au8-in-relapsing-multiple-sclerosis-focusing-on-visual-and-cognitive-function-improvements/ 2024-02-29 https://bio-research.ai/1910-genetics-and-microsoft-forge-five-year-alliance-to-accelerate-ai-driven-drug-discovery-with-azure-quantum-elements/ 2024-02-29 https://bio-research.ai/pfizer-s-phase-3-trial-of-abrysvo-vaccine-reports-positive-topline-results-in-preventing-rsv-lrtd-in-adults-over-60/ 2024-02-29 https://bio-research.ai/bristol-myers-squibb-reports-phase-3-daybreak-trial-results-of-zeposia-in-relapsing-multiple-sclerosis-in-long-term-extension-study/ 2024-02-29 https://bio-research.ai/ironwood-pharmaceuticals-phase-3-trial-of-apraglutide-meets-primary-endpoint-in-short-bowel-syndrome-with-intestinal-failure-patients-reducing-weekly-parenteral-support-volume-at-week-24/ 2024-02-29 https://bio-research.ai/arcutis-biotherapeutics-inks-25m-deal-with-sato-pharmaceutical-for-japanese-rights-to-topical-roflumilast-with-up-to-40m-milestones-plus-royalties/ 2024-02-28 https://bio-research.ai/palatin-s-pl9643-fails-to-meet-co-primary-and-secondary-endpoints-in-unadjusted-analysis-finds-success-in-symptom-relief-with-adjusted-itt-approach-for-dry-eye/ 2024-02-28 https://bio-research.ai/abbvie-secures-global-rights-to-ose-immunotherapeutics-monoclonal-antibody-ose-230-in-a-713m-deal-for-chronic-inflammation-therapy/ 2024-02-28 https://bio-research.ai/viatris-partners-with-idorsia-in-350m-deal-for-exclusive-rights-to-phase-3-drugs-selatogrel-and-cenerimod/ 2024-02-28 https://bio-research.ai/amneal-pharmaceuticals-secures-exclusive-licensing-agreement-with-zambon-biotech-sa-to-commercialize-parkinson-s-disease-treatment-rytary-in-europe/ 2024-02-27 https://bio-research.ai/viking-therapeutics-phase-2-trial-of-vk2735-achieves-endpoints-in-obesity-and-metabolic-disorder-treatment/ 2024-02-27 https://bio-research.ai/purple-biotech-s-phase-1-2-trial-of-nt219-in-head-and-neck-cancer-reports-well-tolerated-safety-profile-and-disease-control-rate/ 2024-02-27 https://bio-research.ai/nona-biosciences-partners-with-boostimmune-to-develop-new-adc-therapies-using-harbour-mice-h2l2-platform/ 2024-02-26 https://bio-research.ai/fibrogen-reclaims-roxadustat-rights-from-astrazeneca-collaboration-in-u-s-and-selected-territories-continues-partnership-in-leading-chinese-market/ 2024-02-26 https://bio-research.ai/janux-therapeutics-reports-phase-1a-trial-results-for-janx007-in-metastatic-castration-resistant-prostate-cancer/ 2024-02-26 https://bio-research.ai/ose-immunotherapeutics-reports-phase-1-2-trial-results-for-ose-279-in-advanced-solid-tumors/ 2024-02-26 https://bio-research.ai/ars-pharmaceuticals-phase-2-trial-of-neffy-reports-efficacy-in-chronic-spontaneous-urticaria/ 2024-02-26 https://bio-research.ai/ibio-divests-pd-1-agonist-program-to-otsuka-for-1m-upfront-with-potential-52-5m-milestone-payments/ 2024-02-26 https://bio-research.ai/max-biopharma-and-metaba-llc-partner-to-advance-metabolomic-research-on-oxysterol-drug-candidates-for-nash-and-ipf/ 2024-02-26 https://bio-research.ai/glaxosmithkline-s-phase-3-trial-of-gepotidacin-meets-primary-endpoint-in-urogenital-gonorrhoea-treatment-evaluation/ 2024-02-26 https://bio-research.ai/boehringer-ingelheim-s-phase-2-trial-of-survodutide-reports-endpoint-met-in-mash-after-48-weeks-treatment/ 2024-02-26 https://bio-research.ai/celldex-therapeutics-phase-2-trial-of-barzolvolimab-meets-endpoints-in-csu-disease-activity-reduction/ 2024-02-24 https://bio-research.ai/biodexa-pharmaceuticals-phase-1-trial-of-mtx110-reports-median-survival-of-16-5-months-in-diffuse-midline-glioma-patients/ 2024-02-23 https://bio-research.ai/silence-therapeutics-secures-10m-from-astrazeneca-after-launching-phase-1-trial-under-multi-target-sirna-therapeutics-collaboration/ 2024-02-23 https://bio-research.ai/invion-forms-strategic-collaboration-with-dr-inb-for-photosoft-photodynamic-therapy-in-hpv-indication-under-terms-allowing-extended-rights-retention-and-supply-responsibilities/ 2024-02-22 https://bio-research.ai/tentarix-biotherapeutics-and-abbvie-ink-strategic-collaboration-for-multifunctional-biologic-candidate-development-targeting-oncology-and-immunology-areas/ 2024-02-22 https://bio-research.ai/tarsus-pharmaceuticals-phase-2a-trial-of-tp-05-demonstrates-tick-mortality-increase-in-lyme-disease-treatment/ 2024-02-22 https://bio-research.ai/cogent-biosciences-reports-positive-phase-2-trial-results-of-bezuclastinib-for-systemic-mastocytosis/ 2024-02-22 https://bio-research.ai/blueprint-medicines-corporation-licenses-us-rights-for-gavreto-to-rigel-pharmaceuticals-in-117-5-m-deal-for-ret-kinase-targeting-cancer-treatment/ 2024-02-22 https://bio-research.ai/immunocore-holdings-and-bristol-myers-squibb-company-collaborate-on-phase-3-clinical-trial-for-imc-f106c-in-cutaneous-melanoma-treatment/ 2024-02-22 https://bio-research.ai/synact-pharma-reports-phase-2b-trial-of-ap1189-reveals-efficacy-endpoints-met-in-rheumatoid-arthritis-patients-with-elevated-baseline-crp/ 2024-02-22 https://bio-research.ai/cymabay-therapeutics-phase-3-trial-of-seladelpar-yields-significant-efficacy-in-primary-biliary-cholangitis-endpoints/ 2024-02-21 https://bio-research.ai/neurosense-therapeutics-reports-phase-2b-trial-results-of-primec-in-als-indicating-reduced-risk-of-disease-complications-and-slower-progression/ 2024-02-21 https://bio-research.ai/viiv-healthcare-s-phase-3-interim-data-of-cabenuva-reveals-efficacy-for-hiv-patients-facing-treatment-adherence-challenges/ 2024-02-21 https://bio-research.ai/ono-pharmaceutical-and-epsilon-molecular-engineering-enter-strategic-collaboration-for-development-of-humanized-vhh-antibody-candidates/ 2024-02-21 https://bio-research.ai/immvirx-and-innovent-biologics-sign-strategic-collaboration-to-conduct-phase-1-trials-of-oncolytic-virus-ivx037-in-combination-with-sintilimab-for-ovarian-colorectal-and-gastric-cancer/ 2024-02-21 https://bio-research.ai/hox-therapeutics-enters-strategic-collaboration-with-vernalis-for-oncology-drug-candidate-development/ 2024-02-20 https://bio-research.ai/teva-pharmaceutical-s-first-in-human-trials-of-tev-574-engages-tl1a-and-maintains-safety-in-asthma-informs-continued-ibd-and-asthma-research/ 2024-02-20 https://bio-research.ai/tharimmune-reports-phase-1-trial-findings-for-transmucosal-th104-in-pruritus-assessing-safety-and-bioavailability/ 2024-02-20 https://bio-research.ai/innovent-biologics-phase-3-trial-of-ibi311-meets-primary-endpoint-in-thyroid-eye-disease-treatment-at-week-24/ 2024-02-20 https://bio-research.ai/astrazeneca-s-tagrisso-phase-3-trial-shows-improved-pfs-in-stage-iii-egfr-mutated-nsclc-following-crt/ 2024-02-19 https://bio-research.ai/novo-nordisk-licenses-il-21-blocker-nn-8828-to-almirall-for-global-development-and-commercialization-under-phase-2-in-immune-inflammatory-dermatological-disease-treatment/ 2024-02-19 https://bio-research.ai/inveniai-and-ono-pharmaceuticals-sign-strategic-collaboration-for-development-of-therapeutic-targets-in-multiple-disease-indications/ 2024-02-19 https://bio-research.ai/gilead-sciences-and-biocytogen-pharmaceuticals-enter-strategic-collaboration-for-antibody-therapeutics-using-renmice-platform/ 2024-02-19 https://bio-research.ai/everest-medicines-ends-strategic-collaboration-and-license-agreement-with-providence-therapeutics-for-mrna-treatment/ 2024-02-19 https://bio-research.ai/xoma-corporation-acquires-kinnate-biopharma-in-merger-deal-involving-fgfr-inhibitor-kin-3248-and-additional-oncology-programs/ 2024-02-16 https://bio-research.ai/kelonia-therapeutics-enters-strategic-collaboration-with-and-xyphos-biosciences-for-oncology-car-t-therapy-candidate-for-875-m/ 2024-02-16 https://bio-research.ai/corcept-therapeutics-phase-4-trial-of-korlym-identifies-hypercortisolism-in-24-of-cushing-s-syndrome-patients/ 2024-02-15 https://bio-research.ai/harrow-and-apotex-sign-license-agreement-granting-canadian-rights-to-market-verkazia-for-vernal-keratoconjunctivitis-and-4-more-ophthalmic-drugs/ 2024-02-15 https://bio-research.ai/tonix-pharmaceuticals-phase-3-trial-of-tonmya-achieves-primary-endpoint-in-fibromyalgia-with-reductions-in-pain-and-improvements-in-sleep-and-fatigue/ 2024-02-15 https://bio-research.ai/csl-behring-and-abionyx-pharma-s-csl112-fails-to-meet-endpoint-in-phase-3-ami-trial/ 2024-02-15 https://bio-research.ai/applied-therapeutics-reports-phase-3-trial-results-of-at-007-in-sord-deficiency-showing-reduced-sorbitol-levels-and-improved-patient-reported-outcomes/ 2024-02-15 https://bio-research.ai/recode-therapeutics-and-intellia-therapeutics-sign-strategic-collaboration-to-advance-gene-editing-therapy-candidate-for-cystic-fibrosis/ 2024-02-15 https://bio-research.ai/clarity-pharmaceuticals-phase-1-2-trial-of-64cu-sar-bispsma-demonstrates-lesion-detection-in-prostate-cancer-recurrence/ 2024-02-15 https://bio-research.ai/replicate-bioscience-s-rbi-4000-rna-vaccine-meets-who-threshold-for-rabies-protection-in-phase-1-trial-initial-results/ 2024-02-14 https://bio-research.ai/biotest-s-phase-3-trial-of-bt524-for-fibrinogen-deficiency-meets-primary-endpoint-with-reduced-intraoperative-blood-loss/ 2024-02-14 https://bio-research.ai/numab-therapeutics-enters-strategic-collaboration-with-ono-pharmaceuticals-for-preclinical-cancer-therapy-nm49-targeting-il-4-13-and-il-31/ 2024-02-14 https://bio-research.ai/vbi-vaccines-and-brii-biosciences-sign-phase-2-licensing-agreement-for-hepatitis-b-vaccine-brii-179-and-glioblastoma-treatment-vbi-1901-with-33-million-in-potential-payments/ 2024-02-14 https://bio-research.ai/kalvista-pharmaceuticals-phase-3-trial-of-sebetralstat-demonstrates-significantly-reduced-time-to-hae-symptom-relief/ 2024-02-13 https://bio-research.ai/bristol-myers-squibb-company-signs-strategic-collaboration-and-license-agreement-with-vantai-for-ai-designed-molecular-glue-candidate-development-and-potential-674-million-milestone-payments/ 2024-02-13 https://bio-research.ai/ono-pharmaceutical-and-shattuck-labs-engage-in-strategic-collaboration-for-fusion-protein-drug-candidate-development-in-immunology-for-227-m/ 2024-02-13 https://bio-research.ai/otsuka-pharmaceutical-phase-3-trial-of-avp-786-misses-primary-endpoint-in-agitation-associated-with-dementia-due-to-alzheimer-s-disease/ 2024-02-13 https://bio-research.ai/repare-therapeutics-regains-rights-to-atr-inhibitor-camonsertib-from-roche-following-termination-of-license-agreement-for-solid-tumor-indications/ 2024-02-12 https://bio-research.ai/gilead-sciences-acquires-cymabay-therapeutics-for-4-3-b-to-secure-rights-to-phase-3-drug-seladelpar-in-primary-biliary-cholangitis-treatment/ 2024-02-12 https://bio-research.ai/larimar-therapeutics-reports-phase-2-trial-results-for-cti-1601-in-treating-friedreich-s-ataxia/ 2024-02-12 https://bio-research.ai/sylentis-phase-3-trial-of-syl1001-v-tivanisiran-for-dry-eye-disease-in-sj-gren-s-syndrome-misses-primary-endpoint/ 2024-02-09 https://bio-research.ai/vicore-pharma-holding-licenses-ipf-drug-c21-to-nippon-shinyaku-under-285-million-deal-for-japanese-market-development-rights/ 2024-02-09 https://bio-research.ai/chugai-pharmaceutical-s-phase-1-trial-of-mosunetuzumab-achieves-primary-endpoint-in-follicular-lymphoma-cohort/ 2024-02-09 https://bio-research.ai/takeda-pharmaceutical-s-phase-2b-trial-of-tak-861-reports-significant-improvement-in-narcolepsy-type-1-wakefulness-measures/ 2024-02-08 https://bio-research.ai/adverum-biotechnologies-phase-2-trial-of-advm-022-displays-visual-acuity-and-anatomic-maintenance-in-wet-amd/ 2024-02-08 https://bio-research.ai/beacon-therapeutics-holdings-reports-phase-2-trial-results-for-agtc-501-in-x-linked-retinitis-pigmentosa-indicating-improved-retinal-sensitivity/ 2024-02-08 https://bio-research.ai/nicox-and-kowa-company-sign-license-agreement-for-ophthalmic-drug-ncx-470-development-and-commercialization-in-japan-with-up-to-30-5-million-deal-value/ 2024-02-08 https://bio-research.ai/telix-pharmaceuticals-acquires-qsam-biosciences-to-expand-oncology-portfolio-with-samarium-153-dotmp-for-bone-cancer-treatment/ 2024-02-08 https://bio-research.ai/johnson-johnson-and-protagonist-therapeutics-report-phase-2b-trial-results-for-jnj-2113-in-psoriasis-with-significant-dose-response-at-week-16/ 2024-02-07 https://bio-research.ai/janssen-pharmaceuticals-signs-option-and-asset-purchase-agreement-with-arkuda-therapeutics-for-exclusive-rights-to-lysosomal-function-enhancers-portfolio/ 2024-02-07 https://bio-research.ai/legochem-biosciences-and-samsung-biologics-enter-strategic-collaboration-for-preclinical-adc-candidate-targeting-solid-tumors-with-ind-submission-planned-by-first-half-of-2025/ 2024-02-07 https://bio-research.ai/regenxbio-s-phase-1-2-3-trial-of-rgx-121-reports-86-median-reduction-in-csf-biomarker-d2s6-for-mps-ii-at-16-weeks/ 2024-02-07 https://bio-research.ai/cassava-sciences-reports-no-decline-in-cognition-score-in-mild-alzheimer-s-disease-who-received-simufilam-continuously-for-24-months-in-phase-2-trial/ 2024-02-07 https://bio-research.ai/bridgebio-pharma-licenses-infigratinib-to-kyowa-kirin-for-development-and-commercialization-in-japan-with-terms-including-100-million-upfront-payment-and-milestone-based-royalties/ 2024-02-07 https://bio-research.ai/redx-pharma-collaborates-with-jazz-pharmaceuticals-in-potential-880-million-licensing-deal-for-kras-inhibitor-oncology-program-targeting-colorectal-pancreatic-and-lung-cancer/ 2024-02-07 https://bio-research.ai/manhattan-biosolutions-enters-strategic-collaboration-with-nascent-biotech-for-phase-2-development-of-pritumumab-containing-adc-in-oncology-indications/ 2024-02-06 https://bio-research.ai/vertex-pharmaceuticals-phase-3-trials-of-vanza-triple-meets-primary-endpoint-matches-trikafta-in-cystic-fibrosis-lung-function-improvement/ 2024-02-05 https://bio-research.ai/gsk-s-phase-3-trial-of-blenrep-in-multiple-myeloma-indicates-extended-progression-free-survival-over-daratumumab-combination/ 2024-02-05 https://bio-research.ai/novartis-signs-agreement-to-acquire-morphosys-for-eur-2-7-billion-securing-ownership-of-phase-3-bet-protein-inhibitor-pelabresib-and-tulmimetostat/ 2024-02-05 https://bio-research.ai/sangamo-therapeutics-phase-1-2-trial-of-st-920-exhibits-sustained-gal-a-activity-in-fabry-disease/ 2024-02-05 https://bio-research.ai/johnson-johnson-s-phase-3-trial-of-nipocalimab-reaches-primary-endpoints-in-gmg-and-sjd-studies/ 2024-02-05 https://bio-research.ai/immunitybio-s-phase-2-3-trial-of-anktiva-assesses-cr-incidence-and-survival-in-bladder-cancer/ 2024-02-05 https://bio-research.ai/novo-holdings-signs-agreement-to-acquire-catalent-for-16-5-b-with-plans-to-divest-select-sites-to-novo-nordisk-post-merger/ 2024-02-05 https://bio-research.ai/pliant-therapeutics-phase-2a-trial-of-bexotegrast-reports-safety-and-dosing-effects-in-psc-treatment-evaluation/ 2024-02-04 https://bio-research.ai/4d-molecular-therapeutics-reports-phase-2-trial-results-of-4d-150-in-wet-amd-indicating-reduced-annualized-anti-vegf-injection-rates-and-tolerable-safety-profile/ 2024-02-03 https://bio-research.ai/hutchmed-announces-inmagene-s-exercise-of-licensing-options-for-immunological-drug-candidates-img-007-and-img-004/ 2024-02-02 https://bio-research.ai/bridgebio-s-acoramidis-shows-positive-outcomes-in-japan-phase-iii-trial-for-attr-cm/ 2024-02-02 https://bio-research.ai/roche-s-phase-3-trial-of-vabysmo-reveals-sustained-retinal-fluid-dryness-in-crvo-and-brvo-treatment/ 2024-02-01 https://bio-research.ai/iasobio-reports-case-of-ct103a-in-treating-refractory-autoimmune-necrotizing-myopathy-with-improved-motor-function-and-biomarkers/ 2024-02-01 https://bio-research.ai/neurimmune-regains-global-rights-to-alzheimer-s-disease-treatment-aducanumab-from-biogen-and-continues-development-of-subcutaneous-formulation/ 2024-01-31 https://bio-research.ai/microsoft-and-almirall-sign-strategic-collaboration-for-ai-and-analytics-in-skin-disease-drug-development/ 2024-01-31 https://bio-research.ai/scandion-oncology-s-phase-2a-trial-of-sco-101-reports-median-pfs-and-cbr-outcomes-in-crc/ 2024-01-31 https://bio-research.ai/ionis-pharmaceuticals-acquires-exclusive-worldwide-license-of-vect-horus-vectrans-for-cns-targeted-rna-therapies/ 2024-01-30 https://bio-research.ai/phase-3-trial-of-iterum-therapeutics-sulopenem-shows-non-inferiority-to-augmentin-in-treating-uncomplicated-urinary-tract-infections-with-consistent-safety-profile/ 2024-01-30 https://bio-research.ai/kura-oncology-reports-phase-1-trial-results-of-ziftomenib-showing-100-complete-remission-in-newly-diagnosed-npm1-mutated-and-kmt2a-rearranged-aml/ 2024-01-30 https://bio-research.ai/jnana-therapeutics-phase-1b-trial-of-jnt-517-reports-blood-phenylalanine-significant-51-reduction-in-pku-treatment-p-0-0019/ 2024-01-30 https://bio-research.ai/tectonic-therapeutic-merges-with-avrobio-in-deal-targeting-phase-1-fusion-protein-tx45-for-pulmonary-hypertension/ 2024-01-30 https://bio-research.ai/alzinova-reports-phase-1b-trial-of-alz-101-vaccine-indicates-safety-and-tolerability-in-alzheimer-s-disease-without-marked-biomarker-or-cognitive-change/ 2024-01-30 https://bio-research.ai/gilead-sciences-and-arcus-biosciences-amend-strategic-collaboration-to-advance-domvanalimab-in-phase-3-for-lung-and-gastrointestinal-cancer-treatments/ 2024-01-29 https://bio-research.ai/nanoviricides-reports-no-adverse-events-in-phase-1a-1b-trial-of-nv-387-for-covid-19/ 2024-01-29 https://bio-research.ai/acurx-pharmaceuticals-phase-2-trial-of-ibezapolstat-reports-100-extended-clinical-cure-in-cdi-over-three-month-observation-period/ 2024-01-29 https://bio-research.ai/sarepta-therapeutics-reports-increased-dystrophin-expression-in-phase-2-trial-of-srp-5051-for-duchenne-muscular-dystrophy/ 2024-01-29 https://bio-research.ai/forge-biologics-releases-phase-1b-study-results-of-fbx-101-indicating-safety-and-efficacy-in-krabbe-disease-post-gene-therapy-administration/ 2024-01-29 https://bio-research.ai/alligator-bioscience-s-phase-2-trial-of-mitazalimab-achieves-40-4-objective-response-rate-in-pancreatic-cancer/ 2024-01-29 https://bio-research.ai/armgo-pharma-s-phase-1b-trial-of-arm210-shows-improvements-in-fatigue-and-muscle-strength-in-ryanodine-receptor-1-related-myopathies/ 2024-01-29 https://bio-research.ai/alvotech-s-pharmacokinetic-study-of-avt03-meets-primary-endpoints-in-comparison-to-prolia-in-healthy-adult-subjects/ 2024-01-29 https://bio-research.ai/starpharma-s-phase-4-trial-of-viraleze-shows-80-reduction-of-sars-cov-2-viral-load-in-participants-aged-65-and-over-in-covid-19/ 2024-01-29 https://bio-research.ai/boan-biotech-forges-exclusive-licensing-pact-with-joincare-pharmaceutical-for-phase-2-monoclonal-antibody-ba2101-in-chinese-mainland-for-respiratory-diseases/ 2024-01-29 https://bio-research.ai/bristol-myers-squibb-s-phase-3-trial-shows-comparable-efficacy-of-subcutaneous-nivolumab-to-intravenous-nivolumab-in-renal-cell-carcinoma/ 2024-01-27 https://bio-research.ai/merck-s-phase-3-trial-of-keytruda-as-adjuvant-therapy-demonstrates-superior-overall-survival-in-renal-cell-carcinoma/ 2024-01-27 https://bio-research.ai/orion-corporation-s-phase-2-trial-of-odm-208-shows-significant-decrease-in-psa-levels-in-metastatic-castration-resistant-prostate-cancer/ 2024-01-26 https://bio-research.ai/renalys-pharma-secures-exclusive-regional-rights-with-travere-therapeutics-for-sparsentan-development-in-asian-territory/ 2024-01-25 https://bio-research.ai/knight-therapeutics-secures-exclusive-rights-for-ipx203-in-canada-and-latin-america-through-license-agreement-with-amneal-pharmaceuticals/ 2024-01-25 https://bio-research.ai/vera-therapeutics-phase-2b-ole-trial-of-vt-001-reveals-significant-reductions-in-serum-galactose-deficient-iga1-levels-and-hematuria-percentages-at-week-72-in-iga-nephropathy/ 2024-01-25 https://bio-research.ai/lava-therapeutics-and-merck-enter-strategic-collaboration-to-evaluate-keytruda-with-lava-1207-for-metastatic-castration-resistant-prostate-cancer/ 2024-01-25 https://bio-research.ai/glenmark-pharmaceuticals-secures-license-agreement-for-envafolimab-a-pd-l1-inhibitor-monoclonal-antibody-with-jiangsu-alphamab-biopharmaceuticals/ 2024-01-25 https://bio-research.ai/moleculin-biotech-s-phase-1b-2-trial-of-mb-106-annamycin-demonstrates-significant-complete-response-rates-in-soft-tissue-sarcoma-and-acute-myeloid-leukemia/ 2024-01-24 https://bio-research.ai/capricor-therapeutics-signs-strategic-collaboration-with-national-institutes-of-health-for-development-of-stealthx-vaccine-for-covid-19/ 2024-01-24 https://bio-research.ai/kyowa-kirin-completes-acquisition-of-orchard-therapeutics-forging-strategic-alliance-in-stem-cell-therapy-advancements/ 2024-01-24 https://bio-research.ai/leo-pharma-s-phase-3-trial-of-delgocitinib-shows-superior-reduction-in-hand-eczema-severity-index-score-for-chronic-hand-eczema/ 2024-01-24 https://bio-research.ai/hangzhou-sciwind-biosciences-phase-1-trial-of-xw004-demonstrates-significant-body-weight-reduction-in-type-2-diabetes-and-obesity/ 2024-01-23 https://bio-research.ai/pepromene-bio-s-phase-1-study-of-pmb-ct01-shows-complete-remission-in-b-cell-acute-lymphoblastic-leukemia-in-first-patient-treated/ 2024-01-23 https://bio-research.ai/eli-lilly-s-phase-1-2-trial-of-ak-otof-shows-pharmacologic-hearing-restoration-in-hearing-loss/ 2024-01-23 https://bio-research.ai/genentech-partners-with-genedit-for-autoimmune-drug-development-with-644-m/ 2024-01-23 https://bio-research.ai/spimaco-secures-exclusive-rights-with-recbio-for-phase-3-hpv-9-vaccine-rec603-in-15-middle-east-and-north-african-countries-including-saudi-arabia/ 2024-01-23 https://bio-research.ai/sanofi-acquires-inhibrx-for-1-7-billion-gains-rights-to-inbrx-101-in-alpha-1-antitrypsin-deficiency-aatd/ 2024-01-23 https://bio-research.ai/sagimet-biosciences-phase-2b-trial-of-asc40-demonstrates-positive-results-on-primary-and-secondary-endpoints-in-nash-patients/ 2024-01-23 https://bio-research.ai/bristol-myers-squibb-s-phase-3-follow-up-study-results-of-opdivo-plus-yervoy-shows-sustained-efficacy-in-renal-cell-carcinoma/ 2024-01-22 https://bio-research.ai/bristol-myers-squibb-s-phase-3-follow-up-results-of-opdivo-plus-cabometyx-reveals-significant-progression-free-survival-and-overall-survival-benefits-in-renal-cell-carcinoma-patients/ 2024-01-22 https://bio-research.ai/ionis-pharmaceuticals-phase-3-trial-of-donidalorsen-shows-reduction-in-rate-of-angioedema-attacks-in-hereditary-angioedema/ 2024-01-22 https://bio-research.ai/gilead-sciences-phase-3-study-of-trodelvy-in-non-small-cell-lung-cancer-did-not-meet-primary-endpoint-of-overall-survival/ 2024-01-22 https://bio-research.ai/sandoz-to-acquire-coherus-biosciences-cimerli-franchise-for-170-million-gains-exclusive-worldwide-ophthalmology-rights/ 2024-01-22 https://bio-research.ai/bristol-myers-squibb-s-phase-3-trial-of-opdivo-shows-significant-improvement-in-progression-free-survival-in-metastatic-colorectal-cancer/ 2024-01-20 https://bio-research.ai/novartis-pharma-s-phase-3-trial-of-lutathera-shows-reduced-risk-of-disease-progression-or-death-in-gastroenteropancreatic-neuroendocrine-tumors/ 2024-01-19 https://bio-research.ai/astrazeneca-s-phase-3-trial-of-imfinzi-shows-statistically-significant-improvement-in-progression-free-survival-in-patients-with-hepatocellular-carcinoma/ 2024-01-19 https://bio-research.ai/askgene-pharma-s-phase-1b-2-trial-of-askb589-shows-good-safety-and-anti-tumor-activities-in-gastricor-gastroesophageal-junction-adenocarcinoma/ 2024-01-18 https://bio-research.ai/golden-biotechnology-s-phase-3-trial-of-hocena-shows-improved-overall-survival-of-14-1-months-in-pancreatic-cancer-with-combination-therapy/ 2024-01-18 https://bio-research.ai/coherus-biosciences-phase-2-trial-of-casdozokitug-shows-38-overall-response-rate-and-8-1-months-median-progression-free-survival-in-hepatocellular-carcinoma/ 2024-01-18 https://bio-research.ai/verity-pharmaceuticals-secures-270-m-tlando-license-agreement-with-lipocine/ 2024-01-18 https://bio-research.ai/sun-pharma-to-acquire-taro-pharmaceutical-industries-for-us-3-5-billion-marks-entry-into-generic-dermatology-products-with-us-43-00-per-share-deal/ 2024-01-18 https://bio-research.ai/bpgbio-s-phase-2a-trial-of-bpm31510-shows-doubled-progression-free-survival-in-pancreatic-cancer/ 2024-01-17 https://bio-research.ai/lee-s-pharmaceutical-to-develop-and-commercialize-istaroxime-in-greater-china-under-windtree-therapeutics-license-agreement/ 2024-01-17 https://bio-research.ai/urogen-pharma-secures-exclusive-rights-for-ugn-103-a-phase-3-intravesical-mitomycin-based-formulation-in-collaboration-with-medac/ 2024-01-17 https://bio-research.ai/acurx-pharmaceuticals-phase-2b-trial-of-acx-362e-reveals-higher-fecal-c-difficile-eradication-compared-to-vancomycin-and-preservation-of-key-gut-bacterial-species-for-clostridioides-difficile-infection/ 2024-01-17 https://bio-research.ai/galderma-s-phase-3-trial-of-relabotulinumtoxina-shows-significant-improvement-in-frown-lines-and-crow-s-feet/ 2024-01-17 https://bio-research.ai/medivir-s-phase-1b-2a-trial-of-fostroxacitabine-bralpamide-demonstrates-an-orr-of-25-and-a-disease-control-rate-at-18-weeks-of-5-1-months-in-hepatocellular-carcinoma-when-combined-with-lenvima/ 2024-01-17 https://bio-research.ai/imugene-s-phase-1-trial-of-vaxinia-shows-positive-interim-results-in-solid-tumor-treatment/ 2024-01-17 https://bio-research.ai/leap-therapeutics-s-phase-2-trial-of-dkn-01-shows-objective-response-rates-of-30-in-second-line-microsatellite-stable-crc-patients/ 2024-01-16 https://bio-research.ai/adagene-s-phase-1b-2-study-of-adg126-shows-best-in-class-safety-profile-in-colorectal-cancer/ 2024-01-16 https://bio-research.ai/genevant-sciences-and-tome-biosciences-sign-114-3-million-collaboration-for-development-of-in-vivo-gene-editing-treatment/ 2024-01-16 https://bio-research.ai/allakos-s-phase-2b-trial-of-lirentelimab-shows-no-significant-difference-in-uas7-for-atopic-dermatitis-and-chronic-spontaneous-urticaria/ 2024-01-16 https://bio-research.ai/regenxbio-and-abbvie-s-phase-2-trial-of-abbv-rgx-314-shows-positive-results-in-vision-improvement-for-wet-age-related-macular-degeneration/ 2024-01-16 https://bio-research.ai/aviceda-therapeutics-phase-2-3-trial-of-avd-104-shows-positive-safety-and-efficacy-outcomes-in-geographic-atrophy/ 2024-01-16 https://bio-research.ai/accurus-biosciences-and-immpact-bio-ink-exclusive-worldwide-rights-deal-for-cldn18-2-monoclonal-antibody-in-solid-tumors/ 2024-01-16 https://bio-research.ai/theralase-technologies-phase-2-trial-of-ruvidar-shows-a-complete-response-rate-of-54-at-6-months-in-non-muscle-invasive-bladder-cancer/ 2024-01-15 https://bio-research.ai/hope-medicine-s-phase-1b-trial-of-hmi-115-shows-positive-efficacy-in-androgenetic-alopecia/ 2024-01-15 https://bio-research.ai/basilea-pharmaceutica-secures-antibiotics-candidate-license-from-spexis-with-2-3m/ 2024-01-15 https://bio-research.ai/arcutis-biotherapeutics-phase-3-trial-of-zoryve-demonstrates-significant-improvement-in-atopic-dermatitis-with-roflumilast-cream-0-15/ 2024-01-14 https://bio-research.ai/arcutis-biotherapeutics-has-released-further-findings-from-the-subgroup-analysis-of-the-phase-3-trial-for-zoryve-in-the-treatment-of-seborrheic-dermatitis/ 2024-01-14 https://bio-research.ai/simcere-pharmaceutical-group-secures-global-rights-for-the-parkinson-s-disease-drug-candidate-in-strategic-collaboration-deal-with-stanford-university/ 2024-01-13 https://bio-research.ai/bioinvent-terminates-license-agreement-with-exelixis-for-immuno-oncology-antibodies/ 2024-01-12 https://bio-research.ai/biogen-terminates-license-collaboration-agreement-allowing-acorda-to-assume-commercialization-of-fampyra-for-multiple-sclerosis-outside-the-united-states/ 2024-01-11 https://bio-research.ai/ji-xing-pharmaceuticals-shanghai-secures-global-development-rights-for-biib131-in-acute-ischemic-stroke-agreement-from-biogen/ 2024-01-11 https://bio-research.ai/sermonix-pharmaceuticals-signs-exclusive-collaboration-and-license-agreement-with-henlius-biopharmaceuticals-for-lasofoxifene-in-china-potentially-reaching-58m-milestone-payment/ 2024-01-11 https://bio-research.ai/ferrer-internacional-s-phase-3-trial-of-fab122-in-amyotrophic-lateral-sclerosis-fails-to-show-significant-benefit-over-placebo-in-disease-progression/ 2024-01-10 https://bio-research.ai/vyne-therapeutics-phase-1b-trial-of-vyn201-shows-biological-activity-and-positive-effect-on-key-biomarkers-in-nonsegmental-vitiligo/ 2024-01-10 https://bio-research.ai/amgen-secures-exclusive-global-rights-for-tepezza-subcutaneous-formulation-in-xeris-pharmaceuticals-collaboration/ 2024-01-10 https://bio-research.ai/aclaris-therapeutics-phase-2b-trial-of-ati-1777-shows-significant-improvement-in-easi-score-for-atopic-dermatitis/ 2024-01-10 https://bio-research.ai/maruho-secures-exclusive-license-for-phase-3-clinical-development-of-b244-in-japan-for-atopic-dermatitis/ 2024-01-10 https://bio-research.ai/menarini-group-secures-exclusive-rights-for-commercialization-of-cefepime-taniborbactam-with-venatorx-pharmaceuticals-for-pyelonephritis/ 2024-01-09 https://bio-research.ai/ngm-biopharmaceuticals-phase-1-trial-of-ngm707-shows-partial-and-complete-responses-in-patients-with-advanced-or-metastatic-solid-tumor-malignancy/ 2024-01-09 https://bio-research.ai/precision-medicine-group-steps-to-305-million-license-agreement-after-collaboration-with-tg-therapeutics-for-azercabtagene-zapreleucel-development/ 2024-01-09 https://bio-research.ai/perspective-therapeutics-and-lantheus-holdings-unveil-strategic-collaboration-for-pb212-vmt-net-in-neuroendocrine-tumors/ 2024-01-09 https://bio-research.ai/chiesi-farmaceutici-collaborates-with-oak-hill-bio-for-the-development-of-neonatal-therapy-ohb-607/ 2024-01-09 https://bio-research.ai/gsk-secures-access-to-aiolos-bio-s-monoclonal-antibody-aio-001-for-respiratory-diseases-with-a-1-4-billion-merger-acquisition-deal/ 2024-01-09 https://bio-research.ai/innovent-biologics-phase-3-trial-of-ibi362-shows-superiority-in-weight-loss-in-overweight-and-obese-individuals/ 2024-01-09 https://bio-research.ai/orano-med-and-molecular-partners-sign-co-development-agreement-for-radio-darpin-targeting-dll3-in-small-cell-lung-cancer/ 2024-01-08 https://bio-research.ai/novartis-secures-full-rights-to-caly-002-for-celiac-disease-and-autoimmune-indications-in-425-million-acquisition-from-calypso-biotech/ 2024-01-08 https://bio-research.ai/radiance-therapeutics-secures-worldwide-exclusive-license-option-for-biocytogen-s-bsadc-candidate/ 2024-01-08 https://bio-research.ai/abbvie-s-phase-2-trial-of-abt-981-shows-higher-response-rates-in-achieving-hs-clinical-response-in-adults-with-moderate-to-severe-hidradenitis-suppurativa/ 2024-01-08 https://bio-research.ai/immunome-secures-exclusive-global-license-for-zentalis-adc-zpc-21-with-310-million-potential-payment/ 2024-01-08 https://bio-research.ai/johnson-johnson-signs-acquisition-agreement-for-ambrx-biopharma-gaining-access-to-adc-technology-and-arx517-for-prostate-cancer-treatment/ 2024-01-08 https://bio-research.ai/servier-and-aitia-enter-strategic-collaboration-to-identify-patients-most-likely-to-respond-positively-to-lrrk2i-in-parkinson-s-disease/ 2024-01-08 https://bio-research.ai/merck-acquires-harpoon-therapeutics-for-680-million-gains-access-to-promising-oncology-drug-hpn328-targeting-dll3/ 2024-01-08 https://bio-research.ai/nerviano-medical-sciences-and-iktos-forge-strategic-collaboration-for-ai-based-small-molecule-candidate-development/ 2024-01-08 https://bio-research.ai/orion-biotechnology-glykos-finland-ink-adc-collaboration-deal-for-oncology-candidates/ 2024-01-08 https://bio-research.ai/hillevax-secures-exclusive-license-for-norovirus-vaccine-hil-216-outside-greater-china-in-270-5-million-deal-with-chengdu-kanghua-biological-products/ 2024-01-08 https://bio-research.ai/evotec-and-bristol-myers-squibb-extend-strategic-collaboration-with-25-million-expansion-for-neurodegenerative-drug-development/ 2024-01-08 https://bio-research.ai/novartis-pharma-s-phase-3-trial-of-scemblix-shows-superior-mmr-rates-at-week-48-vs-standard-of-care-tkis-in-chronic-myeloid-leukemia/ 2024-01-08 https://bio-research.ai/curevo-s-phase-2-trial-of-crv-101-demonstrates-100-0-vaccine-response-rate-in-shingles/ 2024-01-07 https://bio-research.ai/praxis-precision-medicines-strikes-15m-upfront-deal-with-tenacia-biotechnology-for-essential-tremor-drug-ulixacaltamide-in-greater-china-with-milestones-up-to-264m/ 2024-01-05 https://bio-research.ai/stayble-therapeutics-phase-2b-trial-of-sta363-for-chronic-disc-related-back-pain-did-not-achieve-primary-objective/ 2024-01-05 https://bio-research.ai/tilt-biotherapeutics-regains-exclusive-rights-to-tilt-123-clinical-development-in-china-as-biotheus-terminates-license-agreement/ 2024-01-05 https://bio-research.ai/jiangsu-simcere-pharmaceutical-s-phase-3-trial-of-bd0801-met-primary-endpoint-in-ovarian-cancer-fallopian-tube-cancer-and-peritoneal-cancer-patients/ 2024-01-05 https://bio-research.ai/boehringer-ingelheim-signs-license-agreement-for-novel-fibro-inflammatory-diseases-treatment-with-kyowa-kirin-for-up-to-410-million/ 2024-01-05 https://bio-research.ai/theravance-biopharma-s-phase-4-study-of-yupelri-reveals-no-significant-difference-from-spiriva-handihaler-in-copd/ 2024-01-05 https://bio-research.ai/debiopharm-enters-strategic-collaboration-with-repare-therapeutics-for-evaluation-of-combination-of-lunresertib-and-debio0123-in-solid-tumor-clinical-study/ 2024-01-05 https://bio-research.ai/the-menarini-group-to-develop-and-commercialize-insilico-s-kat6a-inhibitor-securing-global-rights-in-over-500-million-licensing-deal/ 2024-01-04 https://bio-research.ai/roche-secures-strategic-collaboration-and-license-agreement-with-moma-therapeutics-for-atpase-target-drug-candidate-in-oncology-with-potential-milestone-payments-exceeding-2-billion/ 2024-01-04 https://bio-research.ai/boehringer-ingelheim-and-3t-biosciences-forge-538-5-million-oncology-collaboration-for-t-cell-based-therapy/ 2024-01-04 https://bio-research.ai/inovio-pharmaceuticals-enters-strategic-collaboration-with-coherus-biosciences-to-advance-ino-3112-for-hpv-related-cancers/ 2024-01-04 https://bio-research.ai/soligenix-s-phase-2a-trial-of-sgx302-demonstrates-positive-outcomes-in-treating-psoriasis/ 2024-01-04 https://bio-research.ai/rhythm-pharmaceuticals-secures-global-rights-for-lb54640-in-285-license-deal-with-lg-chem/ 2024-01-04 https://bio-research.ai/glycomimetics-s-phase-1a-trial-of-gmi-1687-shows-safety-and-pk-pd-results-in-sickle-cell-disease/ 2024-01-04 https://bio-research.ai/abbvie-signs-strategic-collaboration-and-license-agreement-with-umoja-biopharma-for-in-situ-generated-car-t-cell-therapy-development/ 2024-01-04 https://bio-research.ai/vicore-pharma-ab-s-phase-2a-trial-of-digital-therapy-almee-shows-a-2-7-point-improvement-in-anxiety-symptoms-in-anxiety-with-pulmonary-fibrosis/ 2024-01-04 https://bio-research.ai/evotec-ag-and-owkin-sign-strategic-collaboration-for-a-i-powered-drug-candidate-in-oncology-immunology-and-inflammation/ 2024-01-04 https://bio-research.ai/omega-therapeutics-and-novo-nordisk-seal-strategic-collaboration-for-mrna-obesity-therapy/ 2024-01-04 https://bio-research.ai/gpn-vaccines-phase-1-safety-trial-of-gamma-pn-shows-met-primary-endpoint/ 2024-01-04 https://bio-research.ai/galapagos-nv-signs-727-million-collaboration-and-license-agreement-with-bridgene-biosciences-for-exclusive-development-of-oncology-small-molecule-drug/ 2024-01-03 https://bio-research.ai/sanofi-and-scribe-therapeutics-expand-strategic-collaboration-to-develop-crispr-based-candidate-for-potentially-curative-genetic-diseases/ 2024-01-03 https://bio-research.ai/roche-ltd-signs-1-042-billion-licensing-deal-with-remix-therapeutics-for-exclusive-small-molecule-rna-processing-reprogramming-candidate/ 2024-01-03 https://bio-research.ai/janssen-to-advance-oncology-treatment-with-elektrofi-in-155-million-strategic-collaboration/ 2024-01-03 https://bio-research.ai/agios-pharmaceuticals-inc-s-phase-3-trial-of-pyrukynd-shows-significant-hemoglobin-response-in-thalassemia-participants/ 2024-01-03 https://bio-research.ai/dyne-therapeutics-inc-s-phase-1-2-trial-of-dyne-101-shows-dose-dependent-splicing-correction-and-functional-improvement-in-myotonic-dystrophy-type-1/ 2024-01-03 https://bio-research.ai/4d-molecular-therapeutics-and-arbor-biotechnologies-collaborate-for-ai-driven-development-of-aav-delivered-crispr-cas-based-als-therapy/ 2024-01-03 https://bio-research.ai/daiichi-sankyo-ameneds-collaboration-for-nilemdo-and-nustendi-worth-125-million-with-esperion-for-cardiovascular-disease/ 2024-01-03 https://bio-research.ai/boehringer-ingelheim-and-ribo-life-science-co-ltd-strike-strategic-collaboration-for-developing-rnai-candidate-for-liver-diseases/ 2024-01-03 https://bio-research.ai/alvotech-s-phase-3-trial-of-avt06-shows-therapeutic-equivalence-to-eylea-in-neovascular-age-related-macular-degeneration/ 2024-01-03 https://bio-research.ai/atai-life-sciences-n-v-s-phase-1-trial-of-emp-01-shows-positive-topline-results-for-mental-health-disorders/ 2024-01-02 https://bio-research.ai/roche-signs-strategic-collaboration-and-license-agreement-with-medilink-for-yl211-potentially-worth-1-billion/ 2024-01-02 https://bio-research.ai/longboard-pharmaceuticals-phase-1b-2a-trial-of-lp352-reveals-effective-reduction-in-motor-seizure-frequency-in-encephalopathies/ 2024-01-02 https://bio-research.ai/anavex-life-sciences-corp-s-phase-2-3-trial-of-anavex2-73-shows-improvement-on-the-key-co-primary-endpoint-rsbq-after-12-weeks-of-treatment-for-rett-syndrome/ 2024-01-02 https://bio-research.ai/novartis-signs-strategic-collaboration-and-license-agreement-with-voyager-therapeutics-inc-for-huntington-s-disease-gene-therapy-candidate-worth-up-to-1-3-billion/ 2024-01-02 https://bio-research.ai/ascletis-pharmaceuticals-phase-2-trial-of-asc41-shows-substantial-reductions-in-liver-fat-content-in-nash-and-hyperlipidemia/ 2024-01-02 https://bio-research.ai/clover-biopharmaceuticals-aus-phase-1-trial-of-scb-219m-shows-100-platelet-count-maintenance-75-x-109-l-post-chemotherapy-in-thrombocytopenia/ 2023-12-29 https://bio-research.ai/briacell-therapeutics-phase-3-trial-of-bria-imt-shows-71-intracranial-objective-response-rate-in-metastatic-breast-cancer/ 2023-12-28 https://bio-research.ai/astellas-pharma-secures-1-737-billion-deal-with-elpiscience-biopharma-for-cancer-treatment-es019-including-37-million-upfront-payment/ 2023-12-28 https://bio-research.ai/innovent-biologics-signs-strategic-collaboration-deal-with-xuanzhu-biopharma-for-phase-1b-clinical-study-of-bispecific-adc-km-501-in-combination-therapy-trial/ 2023-12-28 https://bio-research.ai/cytokinetics-phase-3-trial-of-aficamten-shows-positive-results-with-improved-exercise-capacity-in-obstructive-hypertrophic-cardiomyopathy/ 2023-12-27 https://bio-research.ai/innovent-biologics-and-sanegenebio-enter-strategic-collaboration-for-development-of-sgb-3908-therapeutic-for-hypertension-treatment/ 2023-12-27 https://bio-research.ai/atreca-secures-12-5-million-oncology-deal-with-immunome-for-apn-497444-and-other-antibody-related-assets-and-materials/ 2023-12-26 https://bio-research.ai/bristol-myers-squibb-acquires-rayzebio-inc-for-4-10-billion-gains-rights-to-ryz101-225ac-dotatate-for-gastroenteropancreatic-neuroendocrine-tumors-and-expands-radiopharmaceutical-portfolio/ 2023-12-26 https://bio-research.ai/lianbio-signs-license-agreement-with-janssen-for-nbtxr3-head-and-neck-cancer-radioenhancer-with-25-million-upfront-payment-and-up-to-5-million-in-milestone-payments/ 2023-12-26 https://bio-research.ai/astrazeneca-signs-1-2bn-acquisition-deal-with-gracell-biotechnologies-for-innovative-car-t-therapy-gc012f-targeting-multiple-myeloma-and-autoimmune-diseases/ 2023-12-26 https://bio-research.ai/concentra-biosciences-acquires-theseus-pharmaceuticals-for-the-349-an-egfr-inhibitor-for-nsclc-in-a-deal-valued-4-05-per-share/ 2023-12-22 https://bio-research.ai/bristol-myers-squibb-acquires-karuna-therapeutics-for-14-0-billion-gains-access-to-karxt-targeting-schizophrenia-and-alzheimer-s-disease-psychosis/ 2023-12-22 https://bio-research.ai/juniper-pharmaceuticals-gains-exclusive-rights-for-ensitrelvir-in-singapore-in-licensing-agreement-with-shionogi-for-covid-19-treatment/ 2023-12-22 https://bio-research.ai/mendus-s-phase-2-trial-of-ilixadencel-shows-no-significant-survival-difference-in-metastatic-renal-cell-carcinoma/ 2023-12-22 https://bio-research.ai/biocon-biologics-partners-with-sandoz-for-the-distribution-of-adalimumab-in-japan-with-exclusive-rights/ 2023-12-22 https://bio-research.ai/peptidream-enters-strategic-collaboration-with-linqmed-for-rights-to-develop-and-commercialize-cu-atsm-for-malignant-brain-tumors-in-japan/ 2023-12-22 https://bio-research.ai/astellas-pharma-completes-175-million-acquisition-of-propella-therapeutics-gains-exclusive-rights-to-prostate-cancer-drug-prl-02/ 2023-12-22 https://bio-research.ai/galecto-s-phase-2-trial-of-gb2064-shows-successful-assessment-of-safety-and-tolerability-in-myelofibrosis/ 2023-12-21 https://bio-research.ai/jazz-pharmaceuticals-phase-2-trial-of-jzp150-shows-no-significant-difference-in-total-ptsd-symptom-severity-compared-to-placebo/ 2023-12-21 https://bio-research.ai/janssen-signs-415-million-license-agreement-with-meiragtx-holdings-for-xlrp-gene-therapy-drug-bota-vec/ 2023-12-21 https://bio-research.ai/sanofi-halts-phase-3-tusamitamab-ravtansine-trial-for-non-small-cell-lung-cancer-over-primary-endpoint-miss/ 2023-12-21 https://bio-research.ai/cstone-pharmaceuticals-returns-the-right-to-develop-and-commercialize-tibsovo-for-aml-and-other-indications-in-greater-china-and-singapore-to-servier-with-50-million/ 2023-12-21 https://bio-research.ai/immunovant-s-phase-2-trial-of-batoclimab-shows-meaningful-reduction-in-igg-levels-and-normalization-of-t3-and-t4-hormone-levels-in-graves-disease/ 2023-12-20 https://bio-research.ai/immunoscape-signs-strategic-collaboration-with-mink-therapeutics-to-advance-novel-tcr-therapy-for-targeted-cancer-treatment/ 2023-12-20 https://bio-research.ai/dare-bioscience-s-phase-1-trial-of-dare-pdm1-shows-statistically-significant-decrease-in-pelvic-vaginal-and-lower-back-pain-scores-in-dysmenorrhea/ 2023-12-20 https://bio-research.ai/tonix-pharmaceuticals-holding-s-phase-3-trial-of-tnx-102-sl-shows-statistically-significant-and-clinically-meaningful-results-in-improving-fibromyalgia-symptoms/ 2023-12-20 https://bio-research.ai/gsk-enters-potential-1-7-billion-deal-with-hansoh-bio-for-exclusive-worldwide-rights-to-hs-20093-an-antibody-drug-conjugate-targeting-b7-h3/ 2023-12-20 https://bio-research.ai/passage-bio-s-phase-1-2-trial-of-pbft02-shows-supraphysiologic-cerebrospinal-fluid-progranulin-levels-in-frontotemporal-dementia/ 2023-12-20 https://bio-research.ai/absci-corporation-and-precisionlife-enter-strategic-collaboration-to-develop-ai-enabled-biotherapeutics-for-multiple-targets-and-indications/ 2023-12-20 https://bio-research.ai/jcr-pharmaceuticals-and-alexion-sign-strategic-collaboration-and-license-agreement-for-novel-oligonucleotide-candidate-allowing-nomination-of-pre-clinical-development-targets/ 2023-12-20 https://bio-research.ai/argenx-reports-disappointing-phase-3-results-for-vyvgart-hytrulo-in-pemphigus-shifts-focus-to-severe-autoimmune-indications-for-efgartigimod-development/ 2023-12-20 https://bio-research.ai/aldeyra-therapeutics-phase-2-trial-of-adx-629-reveals-significant-improvement-in-atopic-dermatitis-outcomes/ 2023-12-19 https://bio-research.ai/neoleukin-therapeutics-announces-closing-of-merger-with-neurogene-inc-for-ngn-401-in-rett-syndrome-treatment/ 2023-12-19 https://bio-research.ai/knight-therapeutics-signs-license-agreement-with-supernus-pharmaceuticals-for-exclusive-rights-to-commercialize-qelbree-viloxazine-for-adhd-patients-in-canada/ 2023-12-19 https://bio-research.ai/gilead-sciences-signs-848-million-agreement-with-compugen-for-monoclonal-antibody-com503-gaining-global-development-and-commercialization-rights/ 2023-12-19 https://bio-research.ai/sanofi-triggers-1-35-billion-potential-milestone-payments-by-exercising-license-option-for-innate-pharma-s-iph6101-sar-579-in-solid-tumor-treatment-under-strategic-collaboration-license-agreement/ 2023-12-19 https://bio-research.ai/tff-pharmaceuticals-ongoing-phase-2-trial-of-tff-vori-shows-positive-results-in-invasive-pulmonary-aspergillosis/ 2023-12-19 https://bio-research.ai/ono-pharmaceuticals-signs-strategic-collaboration-deal-with-evqlv-inc-for-exclusive-global-rights-to-ai-powered-antibody-candidate/ 2023-12-19 https://bio-research.ai/medivir-s-phase-1b-2a-trial-of-miv-818-shows-improved-durable-clinical-benefit-in-hepatocellular-carcinoma/ 2023-12-19 https://bio-research.ai/starpharma-s-phase-2-trial-of-dep-docetaxel-shows-disease-control-in-advanced-gastro-esophageal-cancer-and-reduction-in-tumor-lesions-in-advanced-metastatic-solid-tumors/ 2023-12-19 https://bio-research.ai/otsuka-signs-licensing-deal-with-ionis-pharmaceuticals-for-hae-therapy-secures-exclusive-marketing-rights-in-europe-with-upfront-payment-of-usd-65-million/ 2023-12-19 https://bio-research.ai/glaxosmithkline-s-phase-3-trial-of-jemperli-zejula-combination-shows-significant-benefit-in-pfs-for-advanced-endometrial-cancer/ 2023-12-18 https://bio-research.ai/organon-co-signs-exclusive-distribution-and-promotion-deal-with-eli-lilly-for-emgality-in-europe-commits-to-50-million-usd-upfront-payment/ 2023-12-18 https://bio-research.ai/replay-bio-secures-license-agreement-with-miltenyi-biotec-for-exclusive-development-of-off-the-shelf-prame-tcr-nk-cell-therapy-targeting-solid-tumors-and-hematological-malignancies/ 2023-12-18 https://bio-research.ai/biocytogen-pharmaceuticals-enters-license-agreement-with-ona-therapeutics-for-renmice-derived-antibody-drug-conjugates-featuring-milestone-payments-and-single-digit-royalties/ 2023-12-18 https://bio-research.ai/invivyd-s-phase-3-trial-of-vyd222-shows-high-serum-virus-neutralizing-antibody-titer-levels-in-immunocompromised-participants-for-prevention-of-symptomatic-covid-19/ 2023-12-18 https://bio-research.ai/sensorion-s-phase-2a-trial-of-sens-401-shows-preliminary-safety-data-in-hearing-disorders-induced-by-cisplatin/ 2023-12-18 https://bio-research.ai/saniona-and-boehringer-ingelheim-amend-ongoing-collaboration-for-cns-ion-channel-target-drug-candidates-in-schizophrenia-treatment-with-research-funding/ 2023-12-18 https://bio-research.ai/cansino-biologics-partners-with-spimaco-to-bring-menhycia-vaccine-for-meningococcal-disease-to-saudi-arabia-and-key-mena-markets/ 2023-12-18 https://bio-research.ai/genequantum-healthcare-partners-with-biomap-in-strategic-collaboration-for-development-of-novel-adc-candidate-utilizing-proprietary-conjugation-technology-platforms/ 2023-12-17 https://bio-research.ai/alebund-pharmaceuticals-releases-positive-phase-2-results-for-ap306-in-hyperphosphatemia-patients-on-hemodialysis/ 2023-12-15 https://bio-research.ai/akeso-s-phase-1b-trial-of-ak117-shows-48-1-complete-remission-rate-in-patients-with-myelodysplastic-syndrome-acute-myeloid-leukemia-and-hematological-tumors/ 2023-12-14 https://bio-research.ai/nona-biosciences-inks-1-103-billion-pfizer-deal-for-msln-targeted-antibody-drug-conjugate-hbm9033-in-solid-tumors/ 2023-12-14 https://bio-research.ai/aerpio-pharmaceuticals-s-phase-2-trial-of-fyarro-shows-overall-response-rate-and-stable-disease-in-solid-tumors-with-tsc1-or-tsc2-inactivating-alterations/ 2023-12-14 https://bio-research.ai/kira-pharmaceuticals-phase-2-trial-of-kp104-shows-successful-achievement-of-endpoints-in-paroxysmal-nocturnal-hemoglobinuria/ 2023-12-14 https://bio-research.ai/reneo-pharmaceuticals-phase-2b-trial-of-ren001-shows-results-for-mitochondrial-myopathies-and-long-chain-fatty-acid-oxidation-disorder/ 2023-12-14 https://bio-research.ai/teva-pharmaceutical-industries-signs-license-agreement-with-biolojic-design-ltd-for-development-and-commercialization-of-bd9-featuring-subsequent-milestone-payments-and-tiered-royalties/ 2023-12-14 https://bio-research.ai/nerviano-medical-sciences-signs-license-agreement-with-italfarmaco-for-novel-peptide-drug-conjugate-in-oncology-allowing-italfarmaco-to-use-nms-s-proprietary-technology/ 2023-12-14 https://bio-research.ai/moderna-and-merck-s-phase-2b-trial-of-mrna-4157-v940-shows-improvement-in-survival-for-stage-iii-iv-melanoma/ 2023-12-14 https://bio-research.ai/shattuck-labs-phase-1a-b-trial-of-sl-172154-shows-significant-efficacy-in-higher-risk-nyelodysplastic-syndromes-and-relapsed-refractory-acute-ayeloid-leukemia/ 2023-12-13 https://bio-research.ai/vertex-pharmaceuticals-phase-2-trial-of-vx-548-shows-statistically-significant-reduction-in-pain-intensity-for-diabetic-peripheral-neuropathy/ 2023-12-13 https://bio-research.ai/black-diamond-therapeutics-phase-1-trial-of-bdtx-1535-shows-positive-results-in-patients-with-recurrent-glioblastoma/ 2023-12-13 https://bio-research.ai/astrazeneca-acquires-icosavax-in-1-1bn-agreement-for-vlp-vaccine-platform-against-respiratory-viruses/ 2023-12-12 https://bio-research.ai/connect-biopharma-s-phase-2b-trial-of-cbp-201-demonstrates-significant-improvement-in-lung-function-in-patients-with-moderate-to-severe-asthma/ 2023-12-12 https://bio-research.ai/mendus-s-phase-2-trial-of-dcp-001-demonstrates-positive-results-in-acute-myeloid-leukemia-patients/ 2023-12-12 https://bio-research.ai/novartis-s-phase-3-trial-of-fabhalta-shows-comparable-hemoglobin-levels-in-paroxysmal-nocturnal-hemoglobinuria-patients-at-48-weeks/ 2023-12-11 https://bio-research.ai/morphosys-s-phase-3-trial-of-cpi-0610-shows-positive-results-in-myelofibrosis-patients/ 2023-12-11 https://bio-research.ai/astrazeneca-s-phase-3-trial-of-danicopan-demonstrates-positive-results-for-paroxysmal-nocturnal-haemoglobinuria/ 2023-12-11 https://bio-research.ai/regeneron-pharmaceuticals-phase-1-2-trial-of-linvoseltamab-shows-high-response-rates-in-relapsed-refractory-multiple-myeloma-patients/ 2023-12-07 https://bio-research.ai/actelion-licenses-ponvory-to-vanda-pharmaceuticals-for-exclusive-distribution-of-multiple-sclerosis-drug-in-the-u-s-and-canada/ 2023-12-07 https://bio-research.ai/sanofi-s-phase-3-trial-of-sarclisa-shows-significant-improvement-in-progression-free-survival-in-multiple-myeloma-patients-with-transplant-ineligible-status/ 2023-12-07 https://bio-research.ai/pharvaris-s-phase-2-trial-of-phvs416-demonstrates-significant-reduction-in-monthly-attack-rate-in-hereditary-angioedema-patients/ 2023-12-06 https://bio-research.ai/abbvie-acquires-cerevel-and-its-neuroscience-pipeline-in-8-7b-deal-to-revolutionize-psychiatry/ 2023-12-06 https://bio-research.ai/dermavant-sciences-phase-4-trial-of-vtama-shows-strong-efficacy-in-treating-head-and-neck-plaque-psoriasis/ 2023-12-06 https://bio-research.ai/sentynl-therapeutics-enters-into-4-5-million-license-agreement-with-cyprium-therapeutics-for-menkes-disease-drug-cutx-101/ 2023-12-06 https://bio-research.ai/kedrion-and-kamada-amend-u-s-distribution-deal-for-kedrab-rabies-prophylaxis-antibody/ 2023-12-06 https://bio-research.ai/neurosense-therapeutics-phase-2b-trial-of-primec-reveals-positive-clinical-efficacy-endpoints-in-amyotrophic-lateral-sclerosis-patients/ 2023-12-05 https://bio-research.ai/roche-ltd-acquires-carmot-therapeutics-in-2-7-billion-deal-for-obesity-and-diabetes-pipeline-including-ct-868-dual-glp-1-gip-receptor-agonist/ 2023-12-04 https://bio-research.ai/abbvie-s-10-billion-acquisition-of-immunogen-expanding-abbvie-s-oncology-franchise-and-unleashing-potential/ 2023-11-30 https://bio-research.ai/alzinova-s-phase-1b-study-of-alz-101-reveals-positive-results-in-alzheimer-s-disease/ 2023-11-29 https://bio-research.ai/exonate-s-phase-1b-2a-study-of-exn407-shows-positive-results-in-diabetic-retinopathy-and-diabetic-macular-oedema/ 2023-11-28 https://bio-research.ai/argenx-s-phase-3-trial-of-vyvgart-hytrulo-in-immune-thrombocytopenia-shows-no-significant-platelet-count-response/ 2023-11-28 https://bio-research.ai/glaxosmithkline-s-phase-3-trial-of-blenrep-shows-significant-progression-free-survival-in-multiple-myeloma-patients/ 2023-11-27 https://bio-research.ai/springworks-therapeutics-phase-2b-trial-of-mirdametinib-shows-significant-response-rate-in-neurofibromatosis-type-1-associated-plexiform-neurofibromas-patients/ 2023-11-16 https://bio-research.ai/ipsen-s-phase-3-trial-of-elafibranor-shows-significant-alp-reduction-in-patients-with-primary-biliary-cholangitis/ 2023-11-13 https://bio-research.ai/imbria-pharmaceuticals-phase-2-trial-of-ninerafaxstat-shows-tolerability-and-safety-in-patients-with-cardiac-ischemia-stable-angina-and-chronic-stable-angina/ 2023-11-12 https://bio-research.ai/ionis-pharmaceuticals-reports-positive-phase-2-open-label-expansion-study-results-for-donidalorsen-in-hereditary-angioedema-study/ 2023-11-09 https://bio-research.ai/takeda-pharmaceutical-reports-promising-phase-2b-results-for-tak-279-in-psoriatic-arthritis-patients-significant-acr-20-response-at-week-12/ 2023-11-07 https://bio-research.ai/karyopharm-therapeutics-selinexor-releases-phase-3-trials-for-endometrial-cancer/ 2023-11-06 https://bio-research.ai/kodiak-sciences-publishes-phase-3-data-for-ksi-301-in-non-proliferative-diabetic-retinopathy-macular-edema-following-retinal-vein-occlusion-and-wet-age-related-macular-degeneration/ 2023-11-06 https://bio-research.ai/celldex-therapeutics-barzolvolimab-disappoints-in-phase-2-trial-for-chronic-spontaneous-urticaria/ 2023-11-06 https://bio-research.ai/celldex-therapeutics-announces-positive-phase-1b-results-for-barzolvolimab-in-prurigo-nodularis-treatment/ 2023-11-05 https://bio-research.ai/sarepta-therapeutics-elevidys-shows-promise-in-phase-3-study-for-duchenne-muscular-dystrophy/ 2023-10-30 https://bio-research.ai/galderma-research-and-development-releases-phase-3-data-on-nemolizumab-in-prurigo-nodularis-and-atopic-dermatitis/ 2023-10-11 https://bio-research.ai/inventiva-and-hepalys-pharma-enter-deal-for-nash-drug-lanifibranor-with-upfront-10m-payment-and-over-231m-in-milestones-in-japan-and-south-korea/ 2023-09-20 https://bio-research.ai/kezar-life-sciences-zetomipzomib-license-deal-with-everest-medicines-132-5-m-for-the-future-of-lupus-treatment/ 2023-09-20 https://bio-research.ai/vir-biotechnology-s-influenza-drug-vir-2482-fails-phase-2-trials-in-symptomatic-influenza-a-study/ 2023-07-20 https://bio-research.ai/halozyme-reports-significant-reduction-in-risk-of-relapse-in-cidp-patients-treated-with-vyvgart-hytrulo/ 2023-07-17 https://bio-research.ai/calliditas-therapeutics-setanaxib-shows-early-signs-of-efficacy-in-phase-2-scchn-trial/ 2023-07-13 https://bio-research.ai/incyte-s-ruxolitinib-cream-demonstrates-positive-results-in-treating-atopic-dermatitis-in-phase-3-study-for-children/ 2023-07-11 https://bio-research.ai/janssen-s-jnj-2113-shows-significant-efficacy-in-phase-2b-trial-for-plaque-psoriasis/ 2023-07-04 https://bio-research.ai/roivant-sciences-reports-positive-phase-2b-results-for-rvt-3101-in-moderate-to-severe-ulcerative-colitis/ 2023-06-22 https://bio-research.ai/genequantum-healthcare-strikes-20m-upfront-deal-with-pyramid-biosciences-for-trop2-adc-gq1010-with-milestones-up-to-1b-as-tyligand-biosciences-eyes-xdc-drug-expansion/ 2023-04-18 https://bio-research.ai/unity-s-ubx1325-maintains-anti-vegf-treatment-free-intervals-in-wet-amd-patients/ 2023-03-27 https://bio-research.ai/lantheus-acquires-exclusive-rights-to-point-biopharma-s-pnt2002-and-pnt2003-with-totalling-up-to-2-115b/ 2022-11-14 https://bio-research.ai/puma-biotechnology-licenses-alisertib-from-takeda-with-totalling-up-to-294-3m-for-cancer-treatments/ 2022-09-20 https://bio-research.ai/otsuka-partners-with-aurinia-for-exclusive-rights-to-voclosporin-in-lupus-nephritis-ln-for-up-to-100-million/ 2020-12-17 https://bio-research.ai/merck-partners-with-aligos-therapeutics-on-oligonucleotide-technology-for-nash-with-deal-up-to-458m-in-milestones/ 2020-12-07 https://bio-research.ai/novo-nordisk-acquires-corvidia-therapeutics-for-725m-upfront-with-up-to-2-1b-in-milestones-focused-on-cardiovascular-drug-ziltivekimab/ 2020-06-11 https://bio-research.ai/morphosys-and-incyte-strike-up-to-2b-deal-for-the-global-development-and-commercialization-of-tafasitamab/ 2020-01-13 https://bio-research.ai/chimerix-secures-exclusive-global-rights-to-cx-01-from-cantex-for-acute-myeloid-leukemia-treatment-in-30m-deal-plus-10m-shares-and-up-to-587-5m-in-milestones/ 2019-07-31 https://bio-research.ai/astrazeneca-snaps-up-ardea-biosciences-for-1-26b-to-secure-gout-drug-lesinurad-in-multi-country-deal/ 2012-04-23 https://bio-research.ai/pfizer-secures-exclusive-option-to-license-lpath-s-isonep-in-deal-worth-up-to-511-5m-for-wet-amd-treatment/ 2010-12-20 https://bio-research.ai/bristol-myers-squibb-forges-40m-global-alliance-with-allergan-for-phase-ii-neuropathic-pain-treatment-agn-209323-with-milestone-payments-up-to-373m/ 2010-03-03 https://bio-research.ai/amgen-and-kyowa-hakko-ink-100m-licensing-deal-for-anti-ccr4-antibody-kw-0761-with-up-to-420m-in-milestones/ 2008-03-06 https://bio-research.ai/johnson-johnson-to-acquire-scios-inc-for-2-4b-net-of-cash-expanding-heart-failure-treatment-options-with-natrecor-acquisition/ 2003-02-10